

Update tot 28-05-2020

1. Remdesivir. Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
2. Favipiravir. Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
3. **HIV medicine disappoints: Lopinavir/ritonavir has no benefits in critically ill COVID-19 patients.** Deutsche Apotheker Zeitung. 2020;160(14).
4. **Hirsutism, Amphetamines, COVID-19 Viral Shedding, Hand-Foot-and-Mouth Disease.** American family physician. 2020;101(10):589.
5. **Science in the time of coronavirus.** Nature Methods. 2020;17(4):355.
6. **Cytokine Storm Drugs Move from CAR T to COVID-19.** Cancer discovery. 2020.
7. **Biggest COVID-19 trial tests repurposed drugs first.** Nat Biotechnol. 2020;38(5):510.
<http://dx.doi.org/10.1038/s41587-020-0528-x>.
8. **Coronavirus drugs trials must get bigger and more collaborative.** Nature. 2020;581(7807):120.
<http://dx.doi.org/10.1038/d41586-020-01391-9>.
9. **Do not discontinue ACE inhibitors and sartans!: RAS inhibitors could even protect hypertensive patients against severe COVID-19 progressions.** Deutsche Apotheker Zeitung. 2020;60(17).
10. **Fatal Pulmonary Thromboembolism in SARS-CoV-2-Infection.** Cardiovascular Pathology. 2020;48.
11. **The utility of fecal calprotectin in the era of COVID-19 pandemic.** Gastroenterology. 2020.
12. **Preliminary Estimate of Excess Mortality During the COVID-19 Outbreak - New York City, March 11-May 2, 2020.** MMWR Morbidity and mortality weekly report. 2020;69(19):603-5.
13. **EMA advice on the use of NSAIDs for Covid-19.** Drug Ther Bull. 2020;58(5):69-.
14. **Reply to Letter to the Editor: "COVID-19: is the ACE2 just a foe?".** Abassi ZA, Skorecki K, Heyman SN, Kinaneh S, Armary Z. American journal of physiology Lung cellular and molecular physiology. 2020;318(5):L1031.
15. **Coronavirus 2019 and health systems affected by protracted conflict: the case of Syria.** Abbara A, Rayes D, Fahham O, Alhiraki OA, Khalil M, Alomar A, et al. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020.
16. **The mutual effects of COVID-19 and obesity.** Abbas AM, Fathy SK, Fawzy AT, Salem AS, Shawky MS. Obesity Medicine. 2020;19.
17. **Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings.** Abbasi-Oshaghi E, Mirzaei F, Farahani F, Khodadadi I, Tayebinia H. International journal of surgery (London, England). 2020.
18. **Comment on "Antipsoriatic treatments during COVID-19 outbreak".** Abdelmaksoud A, Goldust M, Vestita M. Dermatologic Therapy. 2020.
19. **Systemic Isotretinoin Therapy In The Era Of COVID19.** Abdelmaksoud A, Vestita M, El-Amawy HS, Ayhan

E, An İ, Öztürk M, et al. *Dermatologic Therapy*. 2020.

20. **In search for effective and safe drugs against SARS-CoV-2: Part II| The role of selected salts and organometallics of copper, zinc, selenium, and iodine food supplements.** Abdel-Mottaleb MS, Abdel-Mottaleb Y. 2020.

21. **Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19 ?** Abeygunasekera A, Jayasinghe S. *Medical hypotheses*. 2020:109843.

22. **Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review.** Aoughdir M, Kirwin T, Abdul Khader A, Wang B. *Viruses*. 2020;12(5).

23. **Clinical Course, Imaging Features, and Outcomes of COVID-19 in Kidney Transplant Recipients.** Abrishami A, Samavat S, Behnam B, Arab-Ahmadi M, Nafar M, Sanei Taheri M. *European Urology*. 2020.

24. **SARS-CoV-2 (CoVID-19) and chronic myeloid leukemia (CML): A case report and review of Abl kinase involvement in viral infection.** Abruzzese E, Luciano L, D'Agostino F, Trawinska MM, Pane F, de Fabritiis P. *Mediterranean Journal of Hematology and Infectious Diseases*. 2020;12(1).

25. **Sacubitril/valsartan in COVID-19 patients: the need for trials.** Acanfora D, Ciccone MM, Scicchitano P, Acanfora C, Casucci G. *European heart journal Cardiovascular pharmacotherapy*. 2020.

26. **Myth Busters: Dietary Supplements and COVID-19.** Adams KK, Baker WL, Sobieraj DM. *The Annals of pharmacotherapy*. 2020:1060028020928052.

27. **Cracking the code to the 2019 novel coronavirus (COVID-19): Lessons from the eye.** Adams N. *Eye Reports*. 2020;6(1):S1-S6.

28. **Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus.** Adeoye AO, Oso BJ, Olaoye IF, Tijjani H, Adebayo AI. *Journal of biomolecular structure & dynamics*. 2020:1-14.

29. **Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.** Aggarwal G, Henry BM, Aggarwal S, Bangalore S. *The American journal of cardiology*. 2020. <http://dx.doi.org/10.1016/j.amjcard.2020.04.054>.

30. **Cardiac patient care during a pandemic: how to reorganise a heart failure unit at the time of COVID-19.** Agostoni P, Mapelli M, Conte E, Baggiano A, Assanelli E, Apostolo A, et al. *European Journal of Preventive Cardiology*. 2020.

31. **Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities.** Ahmad I, Alam M, Saadi R, Mahmud S, Saadi E. *medRxiv*. 2020:2020.05.18.20066902.

32. **First Covid-19 maternal mortality in the UK associated with thrombotic complications.** Ahmed I, Azhar A, Eltaweel N, Tan BK. *British journal of haematology*. 2020.

33. **Reply to Rheumatologists' perspective on coronavirus disease 19: is heparin the dark horse for COVID-19?** Ahmed S, Anirvan P. *Clinical rheumatology*. 2020.

34. **Cutaneous lesions in a patient with COVID-19: are they related?** Ahouach B, Harant S, Ullmer A, Martres P, Bégon E, Blum L, et al. *British Journal of Dermatology*. 2020.

35. **Coronavirus disease 2019 (SARS-CoV-2) and colonization of ocular tissues and secretions: a**

- systematic review.** Aiello F, Gallo Afflitto G, Mancino R, Li JPO, Cesareo M, Giannini C, et al. *Eye (London, England)*. 2020;1-6.
36. **Implications for cancer care in Iran during COVID-19 pandemic.** Akbarzadeh MA, Hosseini MS. *Radiotherapy and Oncology*. 2020;148:211-2.
37. **Asthma, Biologics, Corticosteroids, and COVID-19.** Akenroye AT, Wood R, Keet C. *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology*. 2020.
38. **Pharmacological options in treating SARS-CoV-2 infection/COVID-19.** Ákos F, István L, Marianna J, Mariann B, Tamás V, György K, et al. *Orvosi Hetilap*. 2020;161(17):685-8.
39. **The human coronavirus disease covid-19: Its origin, characteristics, and insights into potential drugs and its mechanisms.** Alanagreh L, Alzoughool F, Atoum M. *Pathogens*. 2020;9(5).
40. **Do COVID-19 patients admitted to the ICU require anti-Pneumocystis jirovecii prophylaxis?** Alanio A, Voicu S, Delliere s, Megarbane B, Bretagne S. *medRxiv*. 2020:2020.05.18.20105296.
41. **COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?** Alany RG. *Pharmaceutical development and technology*. 2020;25(6):649. <http://dx.doi.org/10.1080/10837450.2020.1764670>.
42. **Tocilizumab for the Treatment of Severe COVID-19.** Alattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K, Daghfal JN, et al. *Journal of medical virology*. 2020.
43. **Tocilizumab for the treatment of severe coronavirus disease 2019.** Alattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K, Daghfal JN, et al. *Journal of Medical Virology*. 2020.
44. **Incidental Findings Suggestive of COVID-19 in Asymptomatic Patients Undergoing Nuclear Medicine Procedures in a High-Prevalence Region.** Albano D, Bertagna F, Bertoli M, Bosio G, Lucchini S, Motta F, et al. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2020;61(5):632-6.
45. **A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection.** Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. *Kidney international*. 2020. <http://dx.doi.org/10.1016/j.kint.2020.04.030>.
46. **Guillain-Barré syndrome related to COVID-19 infection.** Alberti P, Beretta S, Piatti M, Karantzoulis A, Piatti ML, Santoro P, et al. *Neurology: Neuroimmunology and NeuroInflammation*. 2020;7(4).
47. **An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19.** Alexander GC, Stoller KB, Haffajee RL, Saloner B. *Annals of internal medicine*. 2020.
48. **Guidelines for dental care provision during the COVID-19 pandemic.** Alharbi A, Alharbi S, Alqaidi S. *Saudi Dental Journal*. 2020;32(4):181-6.
49. **Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19).** Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. *Intensive Care Medicine*. 2020;46(5):854-87.
50. **SARS-CoV-2 and the Hidden Carriers - Sewage, Feline, and Blood Transfusion.** Ali M, Zaid M, Saqib MAN, Ahmed H, Afzal MS. *Journal of medical virology*. 2020.
51. **SARS-CoV-2 and the Hidden Carriers – Sewage, Feline, and Blood Transfusion.** Ali M, Zaid M, Saqib MAN, Ahmed H, Afzal MS. *Journal of Medical Virology*. 2020.

52. **Social media as a recruitment platform for a nationwide online survey of COVID-19 knowledge, beliefs, and practices in the United States: methodology and feasibility analysis.** Ali SH, Foreman J, Capasso A, Jones AM, Tozan Y, DiClemente RJ. BMC medical research methodology. 2020;20(1):116. <http://dx.doi.org/10.1186/s12874-020-01011-0>.
53. **Hyperglycemia management in the critically ill patient with COVID-19.** Al-Jaghbeer MJ, Lansang MC. Cleveland Clinic journal of medicine. 2020.
54. **Cardiovascular disease in the literature: A selection of recent original research papers.** AlJaroudi WA, Hage FG. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2020.
55. **Interleukin-6 Receptor Antagonist Therapy to Treat SARS-CoV-2 Driven Inflammatory Syndrome in a Renal Transplant Recipient.** Allam SR, Dao A, Madhrira MM, Antiporta PB, Nair RR, Guiteau JJ, et al. Transplant infectious disease : an official journal of the Transplantation Society. 2020:e13326.
56. **Are Italy and Iran really suffering from COVID-19 epidemic? A controversial study.** Al-Najjar H, Al-Rousan N. European review for medical and pharmacological sciences. 2020;24(8):4519-22.
57. **Integrative considerations during the COVID-19 pandemic.** Alschuler L, Weil A, Horwitz R, Stamets P, Chiasson AM, Crocker R, et al. Explore (New York, NY). 2020.
58. **Novel coronavirus (2019-NCov): Disease briefings.** Al-Tameemi K, Kabakli R. Asian Journal of Pharmaceutical and Clinical Research. 2020;13(5):22-7.
59. **Additional challenges faced by cancer patients in Gaza due to COVID-19.** AlWaheidi S, Sullivan R, Davies EA. ecanermedicalscience. 2020;14.
60. **A serological assay to detect SARS-CoV-2 seroconversion in humans.** Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. Nature Medicine. 2020.
61. **COVID-19 pandemic: an overview of epidemiology, parthenogenesis, diagnostics and potential vaccines and therapeutics.** Amawi H, Abu Deiab GI, A.A AA, Dua K, Tambuwala MM. Therapeutic delivery. 2020.
62. **COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics.** Amawi H, Abu Deiab GI, Aa AA, Dua K, Tambuwala MM. Therapeutic delivery. 2020. <http://dx.doi.org/10.4155/tde-2020-0035>.
63. **COVID-19 in Patients with Myasthenia Gravis.** Anand P, Slama MCC, Kaku M, Ong C, Cervantes-Arslanian AM, Zhou L, et al. Muscle & nerve. 2020.
64. **In vitro data of current therapies for SARS-CoV-2.** Anastasiou IA, Eleftheriadou I, Tentolouris A, Tsilingiris D, Tentolouris N. Curr Med Chem. 2020. <http://dx.doi.org/10.2174/0929867327666200513075430>.
65. **Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?** Andersson U, Ottestad W, Tracey KJ. Molecular medicine (Cambridge, Mass). 2020;26(1):42.
66. **Chilblains in children in the setting of COVID-19 pandemic.** Andina D, Noguera-Morel L, Bascuas-Arribas M, Gaitero-Tristán J, Alonso-Cadenas JA, Escalada-Pellitero S, et al. Pediatric dermatology. 2020.
67. **Importance of the imaging techniques in the management of COVID-19infected patients.** Andrés L, Péter H, Anita K, Szilvia K, Tamás M, Zsolt S, et al. Orvosi Hetilap. 2020;161(17):672-7.
68. **The coronavirus-induced COVID-19 pandemic: Previous experiences and scientific evidences at the end of March, 2020.** Andrés V, Tamás F, Andrés F. Orvosi Hetilap. 2020;161(17):644-51.

69. **Herbal medicine for treatment of children diagnosed with COVID-19: A review of guidelines.** Ang L, Lee HW, Kim A, Lee JA, Zhang J, Lee MS. *Complementary therapies in clinical practice.* 2020;39:101174.
70. **Unravelling potential severe psychiatric repercussions on healthcare professionals during the COVID-19 crisis.** Anmella G, Fico G, Roca A, Gómez M, Vázquez M, Murru A, et al. *Journal of affective disorders.* 2020.
71. **Making waves: Coronavirus detection, presence and persistence in the water environment: State of the art and knowledge needs for public health.** Annalaura C, Federigi I, Dasheng L, Julian RT, Marco V. *Water Research.* 2020;179.
72. **Chloroquine and hydroxychloroquine for COVID-19: A word of caution.** Annangi S. *Respirology.* 2020.
73. **Counter-regulatory 'Renin-Angiotensin' System-based Candidate Drugs to Treat COVID-19 Diseases in SARS-CoV-2-infected patients.** Annweiler C, Cao Z, Wu Y, Faucon E, Mouhat S, Kovacic H, et al. *Infectious disorders drug targets.* 2020. <http://dx.doi.org/10.2174/1871526520666200518073329>.
74. **Does communicable diseases (including COVID-19) may increase global poverty risk? A cloud on the horizon.** Anser MK, Yousaf Z, Khan MA, Nassani AA, Alotaibi SM, Qazi Abro MM, et al. *Environmental Research.* 2020;187.
75. **Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?** Antinori S, Bonazzetti C, Gubertini G, Capetti A, Pagani C, Morena V, et al. *Autoimmunity reviews.* 2020:102564.
76. **NKG2A and COVID-19: another brick in the wall.** Antonioli L, Fornai M, Pellegrini C, Blandizzi C. *Cellular & molecular immunology.* 2020.
77. **Clinical Outcomes in COVID-19 Patients Treated with Tocilizumab: An Individual Patient Data Systematic Review.** Antwi-Amoabeng D, Kanji Z, Ford B, Beutler BD, Riddle MS, Siddiqui F. *J Med Virol.* 2020. <http://dx.doi.org/10.1002/jmv.26038>.
78. **COVID-19: a novel coronavirus and a novel challenge for critical care.** Arabi YM, Murthy S, Webb S. *Intensive Care Medicine.* 2020;46(5):833-6.
79. **Proposal for a vaccine for COVID-19 with inhibited virus and zinc.** Araneda JAB. 2020.
80. **Characteristics and Outcomes of 21 Critically Ill Patients with COVID-19 in Washington State.** Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. *JAMA - Journal of the American Medical Association.* 2020;323(16):1612-4.
81. **Endocrinology in the time of COVID-19: Management of adrenal insufficiency.** Arlt W, Baldeweg SE, Pearce SHS, Simpson HL. *European journal of endocrinology.* 2020.
82. **Water, climate change, and COVID-19: prioritising those in water-stressed settings.** Armitage R, Nellums LB. *The Lancet Planetary Health.* 2020;4(5):e175.
83. **The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response.** Arnaldez FI, O'Day SJ, Drake CG, Fox BA, Fu B, Urba WJ, et al. *Journal for immunotherapy of cancer.* 2020;8(1).
84. **Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.** Arshad U, Pertinez H, Box H, Tatham L, Rajoli RK, Curley P, et al. *Clin Pharmacol Ther.* 2020. <http://dx.doi.org/10.1002/cpt.1909>.

85. **Seizures associated with coronavirus infections.** Asadi-Pooya AA. *Seizure*. 2020;79:49-52.
86. **Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence.** Asensio E, Acunzo R, Uribe W, Saad EB, Saenz LC. *Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing*. 2020. <http://dx.doi.org/10.1007/s10840-020-00765-3>.
87. **A Marker of Systemic Inflammation or Direct Cardiac Injury: Should Cardiac Troponin Levels be Monitored in COVID-19 Patients?** Atallah B, Mallah SI, AbdelWareth L, AlMahmeed W, Fonarow GC. *European heart journal Quality of care & clinical outcomes*. 2020.
88. **An Invited Commentary on 'Evidence Based Management Guideline for the COVID-19 pandemic-Review article'.** Atogebania JW, Chen H. *International Journal of Surgery*. 2020;78:106-7.
89. **Management of patients with COPD during the COVID-19 pandemic.** Attaway A. *Cleveland Clinic journal of medicine*. 2020.
90. **COVID-19 and ischemic stroke: Should we systematically look for lupus anticoagulant and antiphospholipid antibodies?** Aubignat M, Godefroy O. *Revue Neurologique*. 2020.
91. **Evidence that high temperatures and intermediate relative humidity might favor the spread of COVID-19 in tropical climate: A case study for the most affected Brazilian cities.** Auler AC, Cássaro FAM, da Silva VO, Pires LF. *Science of the Total Environment*. 2020;729.
92. **Sustainable health promotion for the seniors during COVID-19 outbreak: a lesson from Tokyo.** Aung MN, Yuasa M, Koyanagi Y, Aung TNN, Moolphate S, Matsumoto H, et al. *Journal of infection in developing countries*. 2020;14(4):328-31.
93. **Could individuals from countries using bcg vaccination be resistant to sars-cov-2 induced infections?** Ayanoglu İ C, İpekoğlu EM, Yazar V, Yılmaz İ C, Gürsel İ, Gürsel M. *Turkish Journal of Immunology*. 2020;8(1):29-36.
94. **Correspondence: Importance of validated serum biochemistry and hemogram parameters for rapid diagnosis and prevent false negative results during COVID-19 pandemic.** Aydemir D, Ulusu NN. *Biotechnology and Applied Biochemistry*. 2020.
95. **TMPRSS2 inhibitors, Bromhexine, Aprotinin, Camostat and Nafamostat as potential treatments for COVID-19.** Azimi A. 2020.
96. **Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.** Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggem MC, et al. *Allergy*. 2020.
97. **Pandemic preparedness of community pharmacies for COVID-19.** Bahlol M, Dewey RS. *Research in social & administrative pharmacy : RSAP*. 2020.
98. **Clinical Analysis of 25 Novel Coronavirus Infections in Children.** Bai K, Liu W, Liu C, Fu Y, Hu J, Qin Y, et al. *The Pediatric infectious disease journal*. 2020. <http://dx.doi.org/10.1097/INF.0000000000002740>.
99. **Analysis of the first cluster of cases in a family of COVID-19 in Gansu Province.** Bai SL, Wang JY, Zhou YQ, Yu DS, Gao XM, Li LL, et al. *Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]*. 2020;54(5):491-3.
100. **Managing the supportive care needs of those affected by COVID-19.** Bajwah S, Wilcock A, Towers R, Costantini M, Bausewein C, Simon ST, et al. *European Respiratory Journal*. 2020;55(4).

101. **Information Sharing in the School Setting During a Public Health Emergency.** Baker C, Galemore CA, Lowrey KM. *NASN school nurse* (Print). 2020:1942602x20925031. <http://dx.doi.org/10.1177/1942602X20925031>.
102. **Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab.** Balasubramanian S, Nagendran TM, Ramachandran B, Ramanan AV. *Indian pediatrics*. 2020.
103. **European Task Force on Contact Dermatitis statement on coronavirus 19 disease (COVID-19) outbreak and the risk of adverse cutaneous reactions.** Balato A, Ayala F, Bruze M, Crepy MN, Gonçalo M, Duus Johansen J, et al. *Journal of the European Academy of Dermatology and Venereology*. 2020.
104. **Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?** Baldelli S, Corbellino M, Clementi E, Cattaneo D, Gervasoni C. *The Journal of antimicrobial chemotherapy*. 2020. <http://dx.doi.org/10.1093/jac/dkaa190>.
105. **Occurrence of SARS-CoV-2 during mycophenolate mofetil treatment for pemphigus.** Balestri R, Rech G, Girardelli CR. *Journal of the European Academy of Dermatology and Venereology*. 2020.
106. **Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials.** Balevic SJ, Hornik CP, Green TP, Clowse MEB, Gonzalez D, Maharaj AR, et al. *The Journal of rheumatology*. 2020.
107. **Covid-19 pandemic: A new chapter in the history of infectious diseases.** Balkhair AA. *Oman Medical Journal*. 2020;35(2).
108. **Anti-vaccine movement could undermine efforts to end coronavirus pandemic, researchers warn.** Ball P. *Nature*. 2020.
109. **The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.** Ballout RA, Sviridov D, Bukrinsky MI, Remaley AT. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2020.
110. **Non-lesional status epilepticus in a patient with coronavirus disease 2019.** Balloy G, Mahé PJ, Leclair-Visonneau L, Péréon Y, Derkinderen P, Magot A, et al. *Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology*. 2020.
111. **Selection of viral variants during persistent infection of insectivorous bat cells with Middle East respiratory syndrome coronavirus.** Banerjee A, Subudhi S, Rapin N, Lew J, Jain R, Falzarano D, et al. *Scientific reports*. 2020;10(1):7257.
112. **Continue ACE inhibitors/ ARB'S till further evidence in Coronavirus disease 2019 (COVID-19).** Bansal S, Agstam S, Gupta A, Gupta P, Isser HS. *Indian heart journal*. 2020.
113. **Application of Reyaning Mixture in evaluating combining disease with syndrome of human coronavirus pneumonia with pestilence attacking lung syndrome.** Bao L, Shi YJ, Geng ZH, Sun J, Zhao RH, Du CQ, et al. *Zhongguo Zhongyao Zazhi*. 2020;45(7):1465-72.
114. **Does lockdown reduce air pollution? Evidence from 44 cities in northern China.** Bao R, Zhang A. *Science of the Total Environment*. 2020;731.
115. **Therapeutic effect of Compound Qinlan Oral Liquid on treating combining disease with syndrome of human coronavirus pneumonia with pestilence attacking lung syndrome.** Bao YY, Shi YJ, Guo SS, Geng ZH, Bao L, Sun J, et al. *Zhongguo Zhongyao Zazhi*. 2020;45(7):1473-80.

116. **The diagnostic value of rapid anti IgM and IgG detecting tests in the identification of patients with SARS CoV-2 virus infection.** Barna V, Katalin K, Eszter O, Dóra S, Zoltán P, Béla M. *Orvosi Hetilap*. 2020;161(20):807-12.
117. **The COVID-19 Pandemic and Rapid Implementation of Adolescent and Young Adult Telemedicine: Challenges and Opportunities for Innovation.** Barney A, Buckelew S, Mesheriakova V, Raymond-Flesch M. *The Journal of adolescent health : official publication of the Society for Adolescent Medicine*. 2020.
118. **CONVALESCENT PLASMA TO TREAT CORONAVIRUS DISEASE 2019 (COVID-19): CONSIDERATIONS FOR CLINICAL TRIAL DESIGN.** Barone P, DeSimone RA. *Transfusion*. 2020.
119. **Persistence of viral RNA in stool samples from patients recovering from covid-19.** Barth RE, De Regt MJA. *BMJ (Clinical research ed)*. 2020;369:m1724.
120. **Management of Cancer Surgery Cases During the COVID-19 Pandemic: Considerations.** Bartlett DL, Howe JR, Chang G, Crago A, Hogg M, Karakousis G, et al. *Annals of Surgical Oncology*. 2020;27(6):1717-20.
121. **A Proposed Plan for Prenatal Care to Minimize Risks of COVID-19 to Patients and Providers: Focus on Hypertensive Disorders of Pregnancy.** Barton JR, Saade GR, Sibai BM. *American journal of perinatology*. 2020.
122. **Hypothesized behavioral host manipulation by SARS-CoV2/COVID-19 infection.** Barton MC, Bennett KV, Cook JR, Gallup GG, Platek SM. *Medical Hypotheses*. 2020;141.
123. **COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.** Barzegar M, Mirmosayyeb O, Nehzat N, Sarrafi R, Khorvash F, Maghzi AH, et al. *Neurology(R) neuroimmunology & neuroinflammation*. 2020;7(4).
124. **Correlation between environmental pollution indicators and COVID-19 pandemic: A brief study in Californian context.** Bashir MF, Bilal BM, Komal B. *Environmental research*. 2020:109652.
125. **Truncated human Angiotensin Converting Enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.** Basit A, Ali T, Rehman SU. *Journal of biomolecular structure & dynamics*. 2020:1-17.
126. **Covid-19 and co-morbidities: a role for Dipeptidyl Peptidase 4 (DPP4) in disease severity?** Bassendine MF, Bridge SH, McCaughan GW, Gorrell MD. *Journal of diabetes*. 2020.
127. **Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP).** Bassetti M, Giacobbe DR, Aliberti S, Barisione E, Centanni S, De Rosa FG, et al. *Clinical Microbiology and Infection*. 2020.
128. **Non-communicable disease management in vulnerable patients during Covid-19.** Basu S. *Indian journal of medical ethics*. 2020(2):103-5.
129. **COVID-19 in Piau : Initial scenario and perspectives for coping.** Batista FMA, Mascarenhas MDM, Marinelli NP, Albuquerque LPA, Rodrigues MTP, Vieira MADCES, et al. *Revista da Sociedade Brasileira de Medicina Tropical*. 2020;53.
130. **Emerging therapies for COVID-19 pneumonia.** Battaglini D, Robba C, Ball L, Cruz FF, Silva PL, Pelosi P, et al. *Expert opinion on investigational drugs*. 2020.
131. **No deleterious effect of lockdown due to COVID-19 pandemic on glycaemic control, measured by glucose monitoring, in adults with type 1 diabetes.** Beato-V bora PI. *Diabetes technology & therapeutics*. 2020.

132. **SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate.** Becerra-Flores M, Cardozo T. *International journal of clinical practice*. 2020.
133. **Rapid detection of SARS-CoV-2 by low volume real-time single tube reverse transcription recombinase polymerase amplification using an exo probe with an internally linked quencher (exo-IQ).** Behrmann O, Bachmann I, Spiegel M, Schramm M, El Wahed AA, Dobler G, et al. *Clinical chemistry*. 2020.
134. **Remdesivir for the Treatment of Covid-19 — Preliminary Report.** Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. *New England Journal of Medicine*. 2020.
135. **Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy.** Belen-Apak FB, Sarıalioğlu F. *Journal of thrombosis and thrombolysis*. 2020.
136. **Artificial intelligence to codify lung CT in Covid-19 patients.** Belfiore MP, Urraro F, Grassi R, Giacobbe G, Patelli G, Cappabianca S, et al. *La Radiologia medica*. 2020;125(5):500-4.
137. **Acute limb ischemia in patients with COVID-19 pneumonia.** Bellostà R, Luzzani L, Natalini G, Pegorer MA, Attisani L, Cossu LG, et al. *Journal of Vascular Surgery*. 2020.
138. **Improvement of SARS-CoV2 symptoms following Guselkumab injection in a psoriatic patient.** Benhadou F, Del Marmol V. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2020.
139. **Respiratory advice for the non-respiratory physician in the time of COVID-19.** Bennett J, Munavvar M, Walker P, Phillips G. *Clinical medicine (London, England)*. 2020.
140. **Hand sanitisers amid CoViD-19: A critical review of alcohol-based products on the market and formulation approaches to respond to increasing demand.** Berardi A, Perinelli DR, Merchant HA, Bisharat L, Basheti IA, Bonacucina G, et al. *International journal of pharmaceutics*. 2020:119431.
141. **Global epidemiology, pathogenesis, immune response, diagnosis, treatment, economic and psychological impact, challenges, and future prevention of COVID-19: A scoping review.** Berhe B, Legese H, Degefa H, Adhanom G, Gebrewahd A, Mardu F, et al. *medRxiv*. 2020:2020.04.02.20051052.
142. **Imatinib might constitute a treatment option for lung involvement in COVID-19: Comment to: "The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease" by Dennis McGonagle, et al., Autoimmunity Reviews, <https://doi.org/10.1016/j.autrev.2020.102537>.** Bernal-Bello D, Jaenes-Barrios B, Morales-Ortega A, Ruiz-Giardin JM, García-Bermúdez V, Frutos-Pérez B, et al. *Autoimmunity reviews*. 2020:102565.
143. **Identification of bioactive molecules from Tea plant as SARS-CoV-2 main protease inhibitors.** Bhardwaj VK, Singh R, Sharma J, Rajendran V, Purohit R, Kumar S. *J Biomol Struct Dyn*. 2020:1-13. <http://dx.doi.org/10.1080/07391102.2020.1766572>.
144. **COVID-19 Pandemic-Induced Panic Disorder.** Bhatia MS, Goyal S, Singh A, Daral A. *The primary care companion for CNS disorders*. 2020;22(3).
145. **COVID-19 related home confinement in adults: weight gain risks and opportunities.** Bhutani S, Cooper JA. *Obesity (Silver Spring, Md)*. 2020. <http://dx.doi.org/10.1002/oby.22904>.
146. **Prediction of severe illness due to COVID-19 based on an analysis of initial Fibrinogen to Albumin Ratio and Platelet count.** Bi X, Su Z, Yan H, Du J, Wang J, Chen L, et al. *Platelets*. 2020:1-6.
147. **Discovery of intervention effect of Chinese herbal formulas on COVID-19 pulmonary fibrosis treated**

by VEGFR and FGFR inhibitors. Bian YQ, Ma J, Ren Y, Zhang YL, Qiao YJ. Zhongguo Zhongyao Zazhi. 2020;45(7):1481-7.

148. **An opinion of the Heart Rhythm Section of the Polish Cardiac Society on safety of using antiviral and anti-inflammatory drugs prolonging QT interval in patients with COVID-19.** Biernacka EK, Kosior DA, Ziencuk-Krajka A, Miszczak-Knecht M, Kempa M, Przybylski A. Kardiologia polska. 2020.

149. **Psychopharmacology of COVID-19.** Bilbul M, Papparone P, Kim AM, Mutalik S, Ernst CL. Psychosomatics. 2020. <http://dx.doi.org/10.1016/j.psym.2020.05.006>.

150. **Expression of the SARS-CoV-2 Entry Proteins, ACE2 and TMPRSS2, in Cells of the Olfactory Epithelium: Identification of Cell Types and Trends with Age.** Bilinska K, Jakubowska P, C.S VONB, Butowt R. ACS chemical neuroscience. 2020.

151. **Gastrointestinal effects of an attempt to "disinfect" from COVID-19.** Binder L, Högenauer C, Langner C. Histopathology. 2020.

152. **Parenteral fish oil emulsions in critically ill COVID-19 emulsions.** Bistran BR. JPEN Journal of parenteral and enteral nutrition. 2020.

153. **Emergence of Novel Coronavirus and COVID-19: whether to stay or die out?** Biswas A, Bhattacharjee U, Chakrabarti AK, Tewari DN, Banu H, Dutta S. Critical Reviews in Microbiology. 2020;46(2):182-93.

154. **COVID-19 in patients with HIV: clinical case series.** Blanco JL, Ambrosioni J, Garcia F, Martinez E, Soriano A, Mallolas J, et al. The lancet HIV. 2020;7(5):e314-e6. [http://dx.doi.org/10.1016/S2352-3018\(20\)30111-9](http://dx.doi.org/10.1016/S2352-3018(20)30111-9). Epub 2020 Apr 15.

155. **Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.** Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Cell. 2020.

156. **Acute Respiratory Distress Syndrome in a Preterm Pregnant Patient With Coronavirus Disease 2019 (COVID-19).** Blauvelt CA, Chiu C, Donovan AL, Prah M, Shimotake TK, George RB, et al. Obstetrics and gynecology. 2020.

157. **Focus on Middle East respiratory syndrome coronavirus (MERS-CoV).** Bleibtreu A, Bertine M, Bertin C, Houhou-Fidouh N, Visseaux B. Medecine et Maladies Infectieuses. 2020;50(3):243-51.

158. **A Call to Action: Novel Ways that Hepatologists Can Contribute to Patient Care During the COVID-19 Pandemic.** Bloom PP. Dig Dis Sci. 2020;65(6):1557-8. <http://dx.doi.org/10.1007/s10620-020-06251-0>.

159. **Liver Biochemistries in Hospitalized Patients With COVID-19.** Bloom PP, Meyerowitz EA, Reinus Z, Daidone M, Gustafson J, Kim AY, et al. Hepatology (Baltimore, Md). 2020. <http://dx.doi.org/10.1002/hep.31326>.

160. **Natural antiviral compound silvestrol modulates human monocyte-derived macrophages and dendritic cells.** Blum L, Geisslinger G, Parnham MJ, Grünweller A, Schiffmann S. Journal of cellular and molecular medicine. 2020.

161. **Effective Use of Angiotensin II in Coronavirus Disease 19-Associated Mixed Shock State: A Case Report.** Bobeck KA, Holtzclaw AW, Brown TE, Clark PA. A and A Practice. 2020.

162. **COVID-19 Pandemic: Impact on psychiatric care in the United States.** Bojdani E, Rajagopalan A, Chen A, Gearin P, Olcott W, Shankar V, et al. Psychiatry Research. 2020;289.

163. **Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.** Bojkova D, Klann K, Koch B,

Widera M, Krause D, Ciesek S, et al. Nature. 2020.

164. **COVID-19 is a Real Headache!** Bolay H, Gül A, Baykan B. Headache. 2020.

165. **The Equitable Distribution of COVID-19 Therapeutics and Vaccines.** Bollyky TJ, Gostin LO, Hamburg MA. JAMA. 2020.

166. **Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes.** Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Cytokine and Growth Factor Reviews. 2020.

167. **Laboratory predictors of death from coronavirus disease 2019 (COVID-19) in the area of Valcamonica, Italy.** Bonetti G, Manelli F, Patroni A, Bettinardi A, Borrelli G, Fiordalisi G, et al. Clinical Chemistry and Laboratory Medicine. 2020.

168. **Glycaemic Control Among People with Type 1 Diabetes During Lockdown for the SARS-CoV-2 Outbreak in Italy.** Bonora BM, Boscari F, Avogaro A, Bruttomesso D, Fadini GP. Diabetes Therapy. 2020.

169. **Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation.** Bonow RO, Hernandez AF, Turakhia M. JAMA Cardiology. 2020.

170. **Rapid and sensitive detection of SARS-CoV-2 RNA using the Simplex™ COVID-19 direct assay.** Bordi L, Piralla A, Lalle E, Giardina F, Colavita F, Tallarita M, et al. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2020;128:104416.

171. **State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2.** Borgio JF, Alsuwat HS, Al Otaibi WM, Ibrahim AM, Almandil NB, Al Asoom LI, et al. Archives of medical science : AMS. 2020;16(3):508-18. <http://dx.doi.org/10.5114/aoms.2020.94567>. eCollection 2020.

172. **Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia.** Bou Khalil R. Medical Hypotheses. 2020;142.

173. **Pathologies cardiovasculaires et Covid-19 : particularités chez les personnes âgées.** Boureau AS, de Decker L, Berrut G, Hanon O. Geriatrie et psychologie neuropsychiatrie du vieillissement. 2020.

174. **Administration of end-of-life drugs by family caregivers during covid-19 pandemic.** Bowers B, Pollock K, Barclay S. The BMJ. 2020;369.

175. **COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine.** Bozzalla Cassione E, Zanframundo G, Biglia A, Codullo V, Montecuccio C, Cavagna L. Annals of the rheumatic diseases. 2020.

176. **Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.** Brandstetter S, Roth S, Harner S, Buntrock-Döpke H, Toncheva A, Borchers N, et al. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2020.

177. **Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry.** Brenner EJ, Ungaro RC, Geary RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al. Gastroenterology. 2020.

178. **Is Alcohol in Hand Sanitizers Absorbed Through the Skin or Lungs? Implications for Disulfiram Treatment.** Brewer C, Streeb E. Alcohol and alcoholism (Oxford, Oxfordshire). 2020.

179. **The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human Receptor.** Brielle ES, Schneidman-Duhovny D, Linial M. Viruses. 2020;12(5).

180. **The Malnutritional Status of the Host as a Virulence Factor for New Coronavirus SARS-CoV-2.** Briguglio M, Pregliasco FE, Lombardi G, Perazzo P, Banfi G. *Frontiers in Medicine*. 2020;7.
181. **Off-target ACE2 ligands: possible therapeutic option for CoVid-19?** Brogi S, Calderone V. *British Journal of Clinical Pharmacology*. 2020.
182. **Air care: an 'aerography' of breath, buildings and bugs in the cystic fibrosis clinic.** Brown N, Buse C, Lewis A, Martin D, Nettleton S. *Sociology of health & illness*. 2020.
183. **Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS): Protocol for a Pragmatic, Open Label, Active Comparator Trial.** Brown SM, Peltan ID, Webb B, Kumar N, Starr N, Grissom C, et al. *Annals of the American Thoracic Society*. 2020.
<http://dx.doi.org/10.1513/AnnalsATS.202004-309SD>.
184. **Impact of COVID-19 and Future Emerging Viruses on Hematopoietic Cell Transplantation and Other Cellular Therapies.** Broxmeyer HE, Parker GC. *Stem cells and development*. 2020;29(10):625-6.
<http://dx.doi.org/10.1089/scd.2020.0064>. Epub 2020 Apr 3.
185. **Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho.** Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. *Journal of clinical microbiology*. 2020.
186. **The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities.** Buja LM, Wolf D, Zhao B, Akkanti B, McDonald M, Lelenwa L, et al. *Cardiovascular Pathology*. 2020;48.
187. **COVID-19 challenging cell biology.** Bullerdiek J. *Protoplasma*. 2020;257(3):619-20.
188. **Epidemiology of bacteria and viruses in the respiratory tract of humans and domestic pigs.** Bunke J, Receveur K, Christin Oeser A, Gutschmann I, Schubert S, Podschun R, et al. *APMIS*. 2020.
189. **Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients.** Burbelo PD, Riedo FX, Morishima C, Rawlings S, Smith D, Das S, et al. *The Journal of infectious diseases*. 2020.
190. **Ozone disinfectants like soclean CPAP sanitizer can be used to sterilize cloth and n95 masks in the protection against COVID-19.** Burkhart CG. *Open Dermatology Journal*. 2020;14(1):14-5.
191. **A survey of psoriasis patients on biologics during COVID-19: a single centre experience.** Burlando M, Carmisciano L, Cozzani E, Parodi A. *The Journal of dermatological treatment*. 2020:1-3.
192. **Rational Vaccine Design in the Time of COVID-19.** Burton DR, Walker LM. *Cell host & microbe*. 2020;27(5):695-8.
193. **Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them.** Burton MJ, Clarkson JE, Goulao B, Glenny A-M, McBain AJ, Schilder AGM, et al. *Cochrane Database of Systematic Reviews*. 2020(5).
194. **COVID-19: guidance for infection prevention and control in nuclear medicine.** Buscombe JR, Notghi A, Croasdale J, Pandit M, O'Brien J, Graham R, et al. *Nuclear medicine communications*. 2020;41(6):499-504.
195. **[Brug af hydroxychloroquin til COVID-19].** Bygbjerg IC. *Ugeskrift for laeger*. 2020;182(20).

196. **Developing a vaccine for covid-19.** Caddy S. *BMJ (Clinical research ed)*. 2020;369:m1790.
197. **Severe Acute Respiratory Syndrome–Coronavirus-2 Infection and Patients With Lung Cancer: The Potential Role of Interleukin-17 Target Therapy.** Cafarotti S. *Journal of Thoracic Oncology*. 2020.
198. **Coding potential and sequence conservation of SARS-CoV-2 and related animal viruses.** Cagliani R, Forni D, Clerici M, Sironi M. *Infection, Genetics and Evolution*. 2020;83.
199. **Hydroxychloroquine in the treatment of COVID-19: how to use it waiting for conclusive scientific evidence.** Cairoli E, Espinosa G. *Medicina clinica*. 2020.
200. **Cytokine storm and the prospects for immunotherapy with COVID-19.** Calabrese LH. *Cleveland Clinic journal of medicine*. 2020.
201. **Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections.** Calder PC, Carr AC, Gombart AF, Eggersdorfer M. *Nutrients*. 2020;12(4).
202. **Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review).** Calina D, Docea AO, Petrakis D, Egorov AM, Ishmukhametov AA, Gabibov AG, et al. *International journal of molecular medicine*. 2020.
203. **Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter's and Gitelman's syndrome patients.** Calò LA, Bertoldi G, Davis PA. *Pharmacological research*. 2020;158.
204. **Inborn errors of immunity and coronavirus pandemic.** Camcioğlu Y. *Turkish Journal of Immunology*. 2020;8(1):13-20.
205. **section signrefers to: Camdessanche JP, Morel J,Pozzetto B, Paul S. COVID-19 may induce Guillain-Barre syndrome.COVID-19 and Guillain-Barre syndrome : response section sign.** Camdessanche JP, Morel J, Pozzetto B, Paul S, Tholance Y, Botelho-Nevers E. *Rev Neurol (Paris)*. 2020. <http://dx.doi.org/10.1016/j.neurol.2020.05.003>.
206. **The impact of MicroRNAs (miRNAs) on the genotype of coronaviruses.** Canatan D, De Sanctis V. *Acta bio-medica : Atenei Parmensis*. 2020;91(2):195-8. <http://dx.doi.org/10.23750/abm.v91i2.9534>.
207. **The tug-of-war between coagulopathy and anticoagulant agents in patients with COVID-19.** Canonico ME, Siciliano R, Scudiero F, Sanna GD, Parodi G. *European heart journal Cardiovascular pharmacotherapy*. 2020.
208. **Clinical analysis of ten pregnant women with COVID-19 in Wuhan, China: A retrospective study.** Cao D, Yin H, Chen J, Tang F, Peng M, Li R, et al. *International Journal of Infectious Diseases*. 2020;95:294-300.
209. **The clinical characteristic of eight patients of COVID-19 with positive RT-PCR test after discharge.** Cao H, Ruan L, Liu J, Liao W. *Journal of medical virology*. 2020.
210. **Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells.** Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, et al. *Cell*. 2020.
211. **SARS-CoV-2 & Covid-19: Key-Roles of the 'Renin-Angiotensin' System / Vitamin D Impacting Drug and Vaccine Developments.** Cao Z, Wu Y, Faucon E, Sabatier JM. *Infectious disorders drug targets*. 2020.
212. **Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?** Caocci G, La Nasa G. *Annals of Hematology*. 2020.
213. **Maternal and neonatal consequences of coronavirus COVID-19 infection during pregnancy: a scoping**

review. Caparros-Gonzalez RA. Revista espanola de salud publica. 2020;94.

214. **Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia.** Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani MP, et al. European journal of internal medicine. 2020. <http://dx.doi.org/10.1016/j.ejim.2020.05.009>.

215. **Liver injury in critically ill patients with COVID-19: A case series.** Cardoso FS, Pereira R, Germano N. Critical Care. 2020;24(1).

216. **Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients.** Carlucci P, Ahuja T, Petrilli CM, Rajagopalan H, Jones S, Rahimian J. medRxiv. 2020.

217. **SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab.** Caroppo F, Biolo G, Belloni Fortina A. Journal of the European Academy of Dermatology and Venereology : JEADV. 2020.

218. **COVID-19 and biologics for psoriasis: a high-epidemic area experience - Bergamo, Lombardy, Italy.** Carugno A, Gambini DM, Raponi F, Vezzoli P, Locatelli AGC, Di Mercurio M, et al. Journal of the American Academy of Dermatology. 2020.

219. **Optical techniques for fast screening – Towards prevention of the coronavirus COVID-19 outbreak.** Carvalho LFDCESD, Nogueira MS. Photodiagnosis and Photodynamic Therapy. 2020;30.

220. **Venous thrombotic risk related to SARS-CoV-2 : prevalence, recommendations and perspectives.** Casini A, Fontana P, Glauser F, Robert-Ebadi H, Righini M, Blondon M. Revue medicale suisse. 2020;16(692):951-4.

221. **Asymptomatic COVID-19 positive patient suspected on FDG-PET/CT.** Castanheira J, Mascarenhas Gaivão A, Mairos Teixeira S, Pereira PJ, Costa DC. Nuclear medicine communications. 2020;41(6):598-9.

222. **Does lopinavir really inhibit SARS-CoV-2?** Cattaneo D, Cattaneo D, Gervasoni C, Corbellino M, Galli M, Riva A, et al. Pharmacological research. 2020;158:104898. <http://dx.doi.org/10.1016/j.phrs.2020.104898>.

223. **Tobacco smoking and COVID-19 pandemic: old and new issues. A summary of the evidence from the scientific literature.** Cattaruzza MS, Zagà V, Gallus S, D'Argenio P, Gorini G. Acta bio-medica : Atenei Parmensis. 2020;91(2):106-12.

224. **Rational hand hygiene during the coronavirus 2019 (COVID-19) pandemic.** Cavanagh G, Wambier CG. Journal of the American Academy of Dermatology. 2020;82(6):e211.

225. **Peribronchial Consolidation with Surrounding Ground-Glass Opacity in COVID-19 Pneumonia: 3D Reconstruction of a Chest Computed Tomography.** Cellina M, Orsi MA. The American journal of tropical medicine and hygiene. 2020.

226. **Hyperglycemia and the worse prognosis of COVID-19. Why a fast blood glucose control should be mandatory.** Ceriello A. Diabetes Research and Clinical Practice. 2020;163.

227. **Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era.** Ceriello A, Standl E, Catrinou D, Itzhak B, Lalic NM, Rahelic D, et al. Diabetes care. 2020.

228. **Coincidence of COVID-19 Infection and Smell: Taste Perception Disorders.** Cetinkaya EA. The Journal of craniofacial surgery. 2020.

229. **Hydroxychloroquine in COVID-19: A systematic review and meta-analysis.** Chacko J, Brar G, Premkumar R. medRxiv. 2020:2020.05.14.20101774.

230. **Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis.** Chai P, Yu J, Ge S, Jia R, Fan X. *Journal of hematology & oncology*. 2020;13(1):43.
231. **Consider TLR5 for new therapeutic development against COVID-19.** Chakraborty C, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Agoramoorthy G. *Journal of medical virology*. 2020.
232. **CD4 deficiency causes poliomyelitis and axonal blebbing in murine coronavirus induced neuroinflammation.** Chakravarty D, Saadi F, Kundu S, Bose A, Khan R, Dine K, et al. *Journal of virology*. 2020.
233. **Weakness and elevated creatinine kinase as the initial presentation of coronavirus disease 2019 (COVID-19).** Chan KH, Farouji I, Abu Hanoud A, Slim J. *American Journal of Emergency Medicine*. 2020.
234. **Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)-Associated Interstitial Lung Disease During the COVID-19 Pandemic.** Chang HL, Chen YH, Yang CJ. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2020.
235. **Prophylactic Treatment Protocol against the Severity of COVID-19 Using Melatonin.** Charaa N, Chahed M, Ghedira H, Daghfous R. Available at SSRN 3601861. 2020.
236. **The 2019 novel coronavirus disease (Covid-19) pandemic: A review of the current evidence.** Chatterjee P, Nagi N, Agarwal A, Das B, Banerjee S, Sarkar S, et al. *Indian Journal of Medical Research, Supplement*. 2020;151(2):147-59.
237. **Interactions of recommended COVID-19 drugs with commonly used psychotropics.** Chatterjee SS, Malathesh BC, Das S, Singh OP. *Asian journal of psychiatry*. 2020;52:102173. <http://dx.doi.org/10.1016/j.ajp.2020.102173>.
238. **Systematic review of important viral diseases in africa in light of the 'one health' concept.** Chauhan RP, Dessie ZG, Noreddin A, El Zowalaty ME. *Pathogens*. 2020;9(4).
239. **COVID-19: Challenges and opportunities for dermatology response.** Chawla S. *The Journal of dermatological treatment*. 2020;31(4):326. <http://dx.doi.org/10.1080/09546634.2020.1751040>. Epub 2020 Apr 14.
240. **Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus.** Chee YJ, Ng SJH, Yeoh E. *Diabetes Research and Clinical Practice*. 2020;164.
241. **The effects of COVID-19 pandemic on the provision of urgent surgery: A perspective from the USA.** Cheeyandira A. *Journal of Surgical Case Reports*. 2020;2020(4):1-2.
242. **Photosensitizing potential of tailored magnetite hybrid nanoparticles functionalized with levan and zinc (II) phthalocyanine.** Chelminiak-Dudkiewicz D, Rybczynski P, Smolarkiewicz-Wyczachowski A, Mlynarczyk DT, Wegrzynowska-Drzymalska K, Ilnicka A, et al. *Appl Surf Sci*. 2020:146602-.
243. **Biosafety in the preparation and processing of cytology specimens with potential coronavirus (COVID-19) infection: Perspectives from Taiwan.** Chen CC, Chi CY. *Cancer Cytopathology*. 2020;128(5):309-16.
244. **Containing COVID-19 Among 627,386 Persons in Contact With the Diamond Princess Cruise Ship Passengers Who Disembarked in Taiwan: Big Data Analytics.** Chen CM, Jyan HW, Chien SC, Jen HH, Hsu CY, Lee PC, et al. *Journal of medical Internet research*. 2020;22(5):e19540.
245. **Donor heart selection during the COVID-19 pandemic: A case study.** Chen CY, Chen SF, Hollander SA, Rosenthal D, Maeda K, Burgart A, et al. *Journal of Heart and Lung Transplantation*. 2020;39(5):497-8.

246. **Can Chest CT Features Distinguish Patients With Negative From Those With Positive Initial RT-PCR Results for Coronavirus Disease (COVID-19)?** Chen D, Jiang X, Hong Y, Wen Z, Wei S, Peng G, et al. *AJR American journal of roentgenology*. 2020;1-5.
247. **Reconstructing and forecasting the COVID-19 epidemic in the United States using a 5-parameter logistic growth model.** Chen DG, Chen X, Chen JK. *Global health research and policy*. 2020;5:25. <http://dx.doi.org/10.1186/s41256-020-00152-5>. eCollection 2020.
248. **Clinical and imaging features of COVID-19.** Chen H, Ai L, Lu H, Li H. *Radiology of Infectious Diseases*. 2020.
249. **A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19.** Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. *Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences*. 2020;49(2):215-9.
250. **Demonstration and mitigation of aerosol and particle dispersion during mastoidectomy relevant to the COVID-19 era.** Chen JX, Workman AD, Chari DA, Jung DH, Kozin E, Lee DJ, et al. *Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology*. 2020.
251. **Ocular manifestations and clinical characteristics of 535 cases of COVID-19 in Wuhan, China: a cross-sectional study.** Chen L, Deng C, Chen X, Zhang X, Chen B, Yu H, et al. *Acta Ophthalmologica*. 2020.
252. **Pulmonary contusion mimicking COVID-19: A case report.** Chen LR, Chen ZX, Liu YC, Peng L, Zhang Y, Xu Q, et al. *World journal of clinical cases*. 2020;8(8):1554-60.
253. **Clinical Characteristics of Re-hospitalized Patients with COVID-19 in China.** Chen M, An W, Xia F, Yang P, Li K, Zhou Q, et al. *J Med Virol*. 2020. <http://dx.doi.org/10.1002/jmv.26002>.
254. **Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China.** Chen R, Sang L, Jiang M, Yang Z, Jia N, Fu W, et al. *The Journal of allergy and clinical immunology*. 2020.
255. **A potential treatment of COVID-19 with TGF-beta blockade.** Chen W. *International journal of biological sciences*. 2020;16(11):1954-5. <http://dx.doi.org/10.7150/ijbs.46891>. eCollection 2020.
256. **A potential treatment of COVID-19 with TGF-β blockade.** Chen W. *International journal of biological sciences*. 2020;16(11):1954-5.
257. **Plasma CRP level is positively associated with the severity of COVID-19.** Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. *Annals of clinical microbiology and antimicrobials*. 2020;19(1):18.
258. **Pregnant women complicated with COVID-19: a clinical analysis of 3 cases.** Chen X, Li Y, Wang J, Cai H, Cao H, Sheng J. *Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences*. 2020;49(2):240-4.
259. **Diagnosis and treatment recommendation for pediatric COVID-19 (the second edition).** Chen Z, Fu J, Shu Q, Wang W, Chen Y, Hua C, et al. *Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences*. 2020;49(2):139-46.
260. **COVID-19 with rheumatic diseases: a report of 5 cases.** Cheng C, Li C, Zhao T, Yue J, Yang F, Yan Y, et al. *Clinical rheumatology*. 2020.

261. **Coronavirus disease 2019 in renal transplant recipients: report of two cases.** Cheng DR, Wen JQ, Liu ZZ, Lv TF, Chen JS. *Transplant infectious disease : an official journal of the Transplantation Society.* 2020:e13329.
262. **Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.** Cheong DHJ, Daniel Tan WS, Fred Wong WS, Tran T. *Pharmacological research.* 2020:104901.
263. **Is the oncologic patient more susceptible to covid19 but perhaps less likely to undergo severe infection-related complications due to fewer cytokines storm as a consequent of the associated immunodeficiency?** Cherri S, Noventa S, Zaniboni A. *Medical Hypotheses.* 2020;141.
264. **COVID-19 and the role of chronic inflammation in patients with obesity.** Chiappetta S, Sharma AM, Bottino V, Stier C. *International Journal of Obesity.* 2020.
265. **Alcohol and COVID-19.** Chick J. *Alcohol and alcoholism (Oxford, Oxfordshire).* 2020.
266. **Prevention of Infection and Disruption of the Pathogen Transfer Chain in Elective Surgery.** Chisari E, Krueger CA, Barnes CL, Van Onsem S, Walter WL, Parvizi J. *Journal of Arthroplasty.* 2020.
267. **COVID-19 transmission and blood transfusion: A case report.** Cho HJ, Koo JW, Roh SK, Kim YK, Suh JS, Moon JH, et al. *Journal of Infection and Public Health.* 2020.
268. **Angiotension-converting enzyme inhibitors and angiotensin-receptor blockers are not associated with increased risk of SARS-CoV-2 infection.** Chodick G, Nutman A, Yiekutiel N, Shalev V. *Journal of travel medicine.* 2020.
269. **Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19.** Chong VH, Chong PL, Metussin D, Asli R, Momin RN, Mani BI, et al. *J Med Virol.* 2020. <http://dx.doi.org/10.1002/jmv.26004>.
270. **QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin.** Chorin E, Wadhvani L, Magnani S, Dai M, Shulman E, Nadeau-Routhier C, et al. *Heart Rhythm.* 2020. <http://dx.doi.org/10.1016/j.hrthm.2020.05.014>.
271. **Plasma concentration and safety of lopinavir/ritonavir in patients with Covid-19: a retrospective cohort study.** Chouchana L, Boujaafar S, Gana I, Preta L-H, Regard L, Legendre P, et al. *medRxiv.* 2020:2020.05.18.20105650.
272. **In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.** Choudhury A, Mukherjee S. *Journal of medical virology.* 2020.
273. **Endocrinology in the time of COVID-19: Management of Hyponatraemia and Diabetes Insipidus.** Christ Crain M, Hoorn EJ, Sherlock M, Thompson CJ, Wass JAH. *European journal of endocrinology.* 2020.
274. **Beneficial effect of corticosteroids in severe COVID-19 pneumonia: a propensity score matching analysis.** Chroboczek T, Lacoste M, Wackenheim C, Challan-Belval T, Amar B, Boisson T, et al. *medRxiv.* 2020:2020.05.08.20094755.
275. **Letter to editor regarding Ogen Y 2020 paper: "Assessing nitrogen dioxide (NO2) levels as a contributing factor to coronavirus (COVID-19) fatality".** Chudnovsky AA. *The Science of the total environment.* 2020:139236.
276. **COVID-19 Infection and Circulating ACE2 Levels: Protective Role in Women and Children.** Ciaglia E, Vecchione C, Puca AA. *Frontiers in pediatrics.* 2020;8.

277. **Pharmacological (or Synthetic) and Nutritional Agonists of PPAR- γ as Candidates for Cytokine Storm Modulation in COVID-19 Disease.** Ciavarella C, Motta I, Valente S, Pasquinelli G. *Molecules (Basel, Switzerland)*. 2020;25(9).
278. **Drug repurposing against COVID-19: focus on anticancer agents.** Ciliberto G, Mancini R, Paggi MG. *Journal of experimental & clinical cancer research* : CR. 2020;39(1):86. <http://dx.doi.org/10.1186/s13046-020-01590-2>.
279. **The puzzle of sharing bio-molecular targets between coronaviruses and mediators of the cardiovascular system in humans: Looking for plausible hypotheses.** Ciulla MM. *Medical Hypotheses*. 2020;141.
280. **Intravenous Thrombolysis for Stroke in a COVID-19 Positive Filipino Patient, a Case Report.** Co COC, Yu JRT, Laxamana LC, David-Ona DIA. *Journal of Clinical Neuroscience*. 2020.
281. **The race is on for antibodies that stop the new coronavirus.** Cohen J. *Science*. 2020;368(6491):564-5. <http://dx.doi.org/10.1126/science.368.6491.564>.
282. **COVID-19 shot protects monkeys.** Cohen J. *Science*. 2020;368(6490):456-7.
283. **Combination prevention for COVID-19.** Cohen MS, Corey L. *Science (New York, NY)*. 2020;368(6491):551.
284. **COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?** Colafrancesco S, Alessandri C, Conti F, Priori R. *Autoimmunity reviews*. 2020:102573.
285. **Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE).** Colaneri M, Bogliolo L, Valsecchi P, Sacchi P, Zuccaro V, Brandolino F, et al. *Microorganisms*. 2020;8(5). <http://dx.doi.org/10.3390/microorganisms8050695>.
286. **SARS-CoV-2 Isolation From Ocular Secretions of a Patient With COVID-19 in Italy With Prolonged Viral RNA Detection.** Colavita F, Lapa D, Carletti F, Lalle E, Bordi L, Marsella P, et al. *Annals of internal medicine*. 2020.
287. **Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): An Unprecedented Partnership for Unprecedented Times.** Collins FS, Stoffels P. *JAMA*. 2020.
288. **Lockdown for CoViD-2019 in Milan: What are the effects on air quality?** Collivignarelli MC, Abbà A, Bertanza G, Pedrazzani R, Ricciardi P, Carnevale Miino M. *The Science of the total environment*. 2020;732:139280.
289. **Allergen Immunotherapy in the era of SARS-CoV-2.** Compalati E, Erlewyn-Lajeunesse M, Ali FR, Ojeda Fernández P, Garcia Nuñez I, Frati F, et al. *Journal of investigational allergology & clinical immunology*. 2020:0.
290. **Neurotropic mechanisms in COVID-19 and their potential influence on neuropsychological outcomes in children.** Condie LO. *Child neuropsychology : a journal on normal and abnormal development in childhood and adolescence*. 2020:1-20.
291. **Biologic therapy for psoriasis during the COVID-19 outbreak: the choice is to weigh risks and benefits.** Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I. *Dermatologic Therapy*. 2020.
292. **Coagulopathy of COVID-19 and antiphospholipid antibodies.** Connell NT, Battinelli EM, Connors JM. *Journal of thrombosis and haemostasis* : JTH. 2020.
293. **Evolution of COVID-19 infection in 4 psoriatic patients treated with biological drugs.** Conti A, Lasagni C, Bigi L, Pellacani G. *Journal of the European Academy of Dermatology and Venereology* : JEADV. 2020.
294. **COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic**

- antirheumatic drugs.** Conticini E, Bargagli E, Bardelli M, Rana GD, Baldi C, Cameli P, et al. *Annals of the rheumatic diseases.* 2020.
295. **Critical Illness in Patients with COVID-19: Mounting an Effective Clinical and Research Response.** Cook DJ, Marshall JC, Fowler RA. *JAMA - Journal of the American Medical Association.* 2020;323(16):1559-60.
296. **Favipiravir, an antiviral for COVID-19?** Coomes EA, Haghbayan H. *The Journal of antimicrobial chemotherapy.* 2020. <http://dx.doi.org/10.1093/jac/dkaa171>.
297. **A strategic approach to COVID-19 vaccine R&D.** Corey BL, Mascola JR, Fauci AS, Collins FS. *Science (New York, NY).* 2020.
298. **Mass Air Medical Repatriation of Coronavirus Disease 2019 Patients.** Cornelius B, Cornelius A, Crisafi L, Collins C, McCarthy S, Foster C, et al. *Air Medical Journal.* 2020.
299. **Chloroquine for COVID-19: rationale, facts, hopes.** Cortegiani A, Ippolito M, Ingoglia G, Einav S. *Critical care (London, England).* 2020;24(1):210.
300. **EMCAM (Multiple Sclerosis Autonomous Community of Madrid) document for the management of patients with multiple sclerosis during the SARS-CoV-2 pandemic.** Costa-Frossard L, Moreno-Torres I, Meca-Lallana V, García-Domínguez JM. *Revista de Neurologia.* 2020;70(9):329-40.
301. **The role of cardiovascular imaging for myocardial injury in hospitalized COVID-19 patients.** Cosyns B, Lochy S, Luchian ML, Gimelli A, Pontone G, Allard SD, et al. *European heart journal cardiovascular Imaging.* 2020.
302. **COVID-19 and People with Intellectual Disability: impacts of a pandemic.** Courtenay K, Perera B. *Irish journal of psychological medicine.* 2020:1-21.
303. **COVID-19 pneumonia in lung transplant recipients: report of two cases.** Cozzi E, Faccioli E, Marinello S, Loy M, Congedi S, Calabrese F, et al. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.* 2020.
304. **Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays.** Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, et al. *Viruses.* 2020;12(5).
305. **The Rheumatologist's Role in COVID-19.** Cron RQ, Chatham WW. *The Journal of rheumatology.* 2020;47(5):639-42.
306. **Cardiopulmonary resuscitation in the COVID-19 era – Will the risk-benefit shift in resource-poor settings?** Crook P. *Resuscitation.* 2020;151:118.
307. **SARS-CoV-2 and influenza virus co-infection.** Cuadrado-Payán E, Montagud-Marrahi E, Torres-Elorza M, Bodro M, Blasco M, Poch E, et al. *The Lancet.* 2020;395(10236):e84.
308. **Development of a rapid test kit for SARS-CoV-2: an example of product design.** Cui Z, Chang H, Wang H, Lim B, Hsu CC, Yu Y, et al. *Bio-Design and Manufacturing.* 2020.
309. **Colchicine may not be effective in COVID-19 infection; it may even be harmful?** Cumhuri Cure M, Kucuk A, Cure E. *Clinical Rheumatology.* 2020.
310. **Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection.** Cunningham L, Kimber I, Basketter DA, McFadden JP. *Autoimmunity reviews.* 2020:102563.
311. **Perforin and resistance to SARS coronavirus 2.** Cunningham L, Simmonds P, Kimber I, Basketter DA,

McFadden JP. The Journal of allergy and clinical immunology. 2020.

312. **Comment on 'Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?'**. Cüre E, Cumhur Cüre M. Journal of hypertension. 2020;38(6):1189-98.
313. **Profile of a killer: the complex biology powering the coronavirus pandemic.** Cyranoski D. Nature. 2020;581(7806):22-6.
314. **25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2.** D'Avolio A, Avataneo V, Manca A, Cusato J, De Nicolò A, Lucchini R, et al. Nutrients. 2020;12(5).
315. **COVID-19 Hangover: A Rising Tide of Alcohol Use Disorder and Alcohol-Associated Liver Disease.** Da BL, Im GY, Schiano TD. Hepatology (Baltimore, Md). 2020.
316. **Essential oils as antiviral agents. Potential of essential oils to treat sars-cov-2 infection: An in-silico investigation.** da Silva JKR, Figueiredo PLB, Byler KG, Setzer WN. International Journal of Molecular Sciences. 2020;21(10).
317. **Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19.** Dabaghian F, Khanavi M, Zarshenas MM. Medical Hypotheses. 2020;143.
318. **SARS-CoV-2: Spike glycoprotein structural diversity, phylogeny and potential animal host identification.** Dabravolski SA, Kavalionak YK. Journal of medical virology. 2020.
319. **Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19.** D'Acquarica I, Agranat I. Drug discovery today. 2020.
320. **Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?** Dalamaga M, Karampela I, Mantzoros CS. Metabolism: Clinical and Experimental. 2020;108.
321. **Autonomously replicating RNAs of Bungowannah pestivirus: ERNS is not essential for the generation of infectious particles.** Dalmann A, Reimann I, Wernike K, Beer M. Journal of virology. 2020.
322. **Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during RED-ZONE declaration.** Damiani G, Pacifico A, Bragazzi NL, Malagoli P. Dermatologic therapy. 2020:e13475.
323. **SARS-CoV-2 variants: relevance for symptom granularity, epidemiology, immunity (herd, vaccines), virus origin and containment?** Danchin A, Timmis K. Environmental microbiology. 2020.
324. **The Expression and Polymorphism of Entry Machinery for COVID-19 in Human: Juxtaposing Population Groups, Gender, and Different Tissues.** Darbani B. International journal of environmental research and public health. 2020;17(10). <http://dx.doi.org/10.3390/ijerph17103433>.
325. **Genetic predisposition models to COVID-19 infection.** Darbeheshti F, Rezaei N. Medical Hypotheses. 2020;142.
326. **Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients.** Dariya B, Nagaraju GP. Cytokine and Growth Factor Reviews. 2020.
327. **Keep cystic fibrosis patients out of the hospital.** Dasenbrook E. Cleveland Clinic journal of medicine. 2020.
328. **Endoscopic Skull Base and Transoral Surgery During the COVID-19 Pandemic: Minimizing Droplet Spread with a Negative-Pressure Otolaryngology Viral Isolation Drape (NOVID).** David AP, Jiam NT, Reither JM,

Gurrola JG, Aghi M, El-Sayed IH. Head and Neck. 2020.

329. **COVID-19 and the CRISPR Community Response.** Davies K, Barrangou R. CRISPR Journal. 2020;3(2):66-7.
330. **Letter to the editor regarding "Challenges of Neurosurgery Education During the Coronavirus Disease 2019 (COVID-19) Pandemic: A U.S. Perspective" and a Virtual Neurosurgery Clerkship for Medical Students.** Dawoud RA, Philbrick B, McMahon JT, Douglas JM, Bhatia N, Faraj R, et al. World Neurosurg. 2020. <http://dx.doi.org/10.1016/j.wneu.2020.05.085>.
331. **The ICMR bulletin on targeted hydroxychloroquine prophylaxis for Covid-19: Need to interpret with caution.** D'Cruz M. Indian journal of medical ethics. 2020(2):100-2. <http://dx.doi.org/10.20529/IJME.2020.040>.
332. **Covid-19-The real role of NSAIDs in Italy.** de Girolamo L, Peretti GM, Maffulli N, Brini AT. Journal of orthopaedic surgery and research. 2020;15(1):165.
333. **Mechanism of inflammatory response in associated comorbidities in COVID-19.** de Lucena TMC, da Silva Santos AF, de Lima BR, de Albuquerque Borborema ME, de Azevêdo Silva J. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020;14(4):597-600.
334. **Novel Coronavirus disease (COVID-19) in newborns and infants: What we know so far.** De Rose DU, Piersigilli F, Ronchetti MP, Santisi A, Bersani I, Dotta A, et al. Italian Journal of Pediatrics. 2020;46(1).
335. **Psychological interventions during COVID-19: Challenges for low and middle income countries.** De Sousa A, Mohandas E, Javed A. Asian Journal of Psychiatry. 2020;51.
336. **The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents.** De Spiegeleer A, Bronselaer A, Teo JT, Byttebier G, De Tre G, Belmans L, et al. medRxiv. 2020:2020.05.11.20096347.
337. **Avian coronaviruses.** de Wit JJS, Cook JKA. Avian pathology : journal of the WVPA. 2020:1-7.
338. **Assessing the validity of the Australian Treatment Outcomes Profile for telephone administration in drug health treatment populations.** Deacon RM, Mammen K, Holmes J, Dunlop A, Bruno R, Mills L, et al. Drug and alcohol review. 2020.
339. **Is COVID-19 a New Hematologic Disease?** Debus B, Smadja DM. Stem Cell Reviews and Reports. 2020.
340. **Will environmental changes in temperature affect the course of COVID-19?** Del Rio C, Camacho-Ortiz A. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. 2020.
341. **Translating Science on COVID-19 to Improve Clinical Care and Support the Public Health Response.** del Rio C, Malani P. JAMA. 2020.
342. **Medical treatment options for COVID-19.** Delang L, Neyts J. European Heart Journal: Acute Cardiovascular Care. 2020.
343. **ACE Ins/Del genetic polymorphism and epidemiological findings in COVID-19.** Delanghe JR, Speeckaert MM, De Buyzere ML. Clinical chemistry and laboratory medicine. 2020.
344. **Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels.** Demelo-Rodríguez P, Cervilla-Muñoz E, Ordieres-Ortega L, Parra-Virto A, Toledano-Macías M, Toledo-Samaniego N, et al. Thrombosis Research. 2020;192:23-6.
345. **Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win**

- today's battle against COVID-19?** Derwand R, Scholz M. Medical Hypotheses. 2020;142.
346. **Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?** Derwand R, Scholz M. Med Hypotheses. 2020;142:109815-.
347. **COVID-19 and diabetes mellitus: A need for prudence in elderly patients from a pooled analysis.** Desai R, Singh S, Parekh T, Sachdeva S, Sachdeva R, Kumar G. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020;14(4):683-5.
348. **BCG versus COVID-19: impact on urology.** Desouky E. World journal of urology. 2020.
349. **ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome.** Devaux CA, Rolain JM, Raoult D. Journal of Microbiology, Immunology and Infection. 2020.
350. **Gut microbiota and Covid-19- possible link and implications.** Dhar D, Mohanty A. Virus Research. 2020;285.
351. **Reply: "Biologics for psoriasis during COVID-19 outbreak".** Di Lernia V. Journal of the American Academy of Dermatology. 2020;82(6):e217-e8.
352. **COVID-19 in an elderly patient treated with secukinumab.** Di Lernia V, Bombonato C, Motolese A. Dermatologic therapy. 2020:e13580.
353. **COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature.** Di Lorenzo G, Di Trolio R, Kozlakidis Z, Busto G, Ingenito C, Buonerba L, et al. Critical Reviews in Oncology/Hematology. 2020:102991.
354. **Clotting factors in COVID-19: Epidemiological association and prognostic values in different clinical presentations in an Italian cohort.** Di Micco P, Russo V, Carannante N, Imparato M, Rodolfi S, Cardillo G, et al. Journal of Clinical Medicine. 2020;9(5).
355. **Are probiotics effective adjuvant therapeutic choice in patients with COVID-19?** Di Renzo L, Merra G, Esposito E, De Lorenzo A. European review for medical and pharmacological sciences. 2020;24(8):4062-3.
356. **The Challenges of Vaccine Development against a New Virus during a Pandemic.** Diamond MS, Pierson TC. Cell Host and Microbe. 2020;27(5):699-703.
357. **Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19).** Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Frontiers in Immunology. 2020;11.
358. **Critical review of social, environmental and health risk factors in the Mexican indigenous population and their capacity to respond to the COVID-19.** Díaz de León-Martínez L, de la Sierra-de la Vega L, Palacios-Ramírez A, Rodríguez-Aguilar M, Flores-Ramírez R. Science of the Total Environment. 2020;733.
359. **Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens.** Díez JM, Romero C, Gajardo R. Immunotherapy. 2020.
360. **Challenges in paediatric inflammatory bowel diseases in the COVID-19 time.** Dipasquale V, Cucchiara S, Martinelli M, Miele E, Aloï M, Romano C. Digestive and Liver Disease. 2020;52(5):593-4.
361. **Reduction of coronavirus burden with mass azithromycin distribution.** Doan T, Hinterwirth A, Arzika AM, Worden L, Chen C, Zhong L, et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020.

362. **In vivo antiviral effects of U18666A against type I feline infectious peritonitis virus.** Doki T, Tarusawa T, Hohdatsu T, Takano T. *Pathogens*. 2020;9(1).
363. **ISIDOG recommendations concerning COVID-19 and pregnancy.** Donders F, Lonnée-Hoffmann R, Tsiakalos A, Mendling W, De Oliveira JM, Judlin P, et al. *Diagnostics*. 2020;10(4).
364. **Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity.** Dong J, Huang B, Jia Z, Wang B, Kankanamalage SG, Titong A, et al. *Emerging microbes & infections*. 2020:1-10.
365. **iBioProVis: Interactive Visualization and Analysis of Compound Bioactivity Space.** Donmez A, Rifaioglu AS, Acar A, Dogana T, Cetin-Atalay R, Atalay V. *Bioinformatics (Oxford, England)*. 2020. <http://dx.doi.org/10.1093/bioinformatics/btaa496>.
366. **Novel coronavirus 2019 (COVID-19): A case report and review of treatments.** Douedi S, Miskoff J. *Medicine*. 2020;99(19):e20207.
367. **Dengue fever and severe dengue in Barbados, 2008–2016.** Douglas KO, Dutta SK, Martina B, Anfasa F, Alafia Samuels T, St. Hilaire GM. *Tropical Medicine and Infectious Disease*. 2020;5(2).
368. **Novel coronavirus (COVID-19) infection: What a doctor on the frontline needs to know.** Down B, Kulkarni S, Ahmed Khan AH, Barker B, Tang I. *Annals of medicine and surgery (2012)*. 2020. <http://dx.doi.org/10.1016/j.amsu.2020.05.014>.
369. **Hydroxychloroquine hitting the headlines—retinal considerations.** Downes SM, Leroy BP, Sharma SM, Sivaprasad S, Dollfus H. *Journal*. 2020(Issue).
370. **COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases.** Draghici S, Nguyen T-M, Sonna LA, Ziraldo C, Vanciu RL, Fadel R, et al. *medRxiv*. 2020:2020.05.06.20076687.
371. **Predictors of mortality for patients with COVID-19 pneumonia caused by SARSCoV- 2: A prospective cohort study.** Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. *European Respiratory Journal*. 2020;55(5).
372. **Mathematical Modeling of Interaction between Innate and Adaptive Immune Responses in COVID-19 and Implications for Viral Pathogenesis.** Du SQ, Yuan W. *Journal of Medical Virology*. 2020.
373. **Glucocorticoid for coronavirus disease 2019: a dilemma.** Du X, Yu X. *Zhonghua wei zhong bing ji jiu yi xue*. 2020;32(3):278.
374. **Computation screening of narcissoside a glycosyloxyflavone for potential novel coronavirus 2019 (COVID-19) inhibitor.** Dubey K, Dubey R. *Biomedical journal*. 2020.
375. **Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic.** Dunlop A, Lokuge B, Masters D, Sequeira M, Saul P, Dunlop G, et al. *Harm reduction journal*. 2020;17(1):26.
376. **Appearance of Skin Rash in Pediatric Patients with COVID-19: Three Case Presentations.** Duramaz BB, Yozgat CY, Yozgat Y, Turel O. *Dermatologic therapy*. 2020:e13594.
377. **Early experience with remdesivir in SARS-CoV-2 pneumonia.** Durante-Mangoni E, Andini R, Bertolino L, Mele F, Florio LL, Murino P, et al. *Infection*. 2020. <http://dx.doi.org/10.1007/s15010-020-01448-x>.
378. **Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept.** Duret PM, Sebbag E, Mallick A, Gravier S, Spielmann L, Messer L. *Annals of the Rheumatic Diseases*. 2020.

379. **Ebioenergy crisis in coronavirus diseases?** Dutta A, Das A, Kondziella D, Stachowiak MK. *Brain Sciences*. 2020;10(5).
380. **Perspective: improving vitamin D status in the management of COVID-19.** Ebadi M, Montano-Loza AJ. *European journal of clinical nutrition*. 2020.
381. **Otologic and Audiologic Considerations for COVID-19.** Eby TL, Arteaga AA, Spankovich C. *Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery*. 2020:194599820928989.
382. **Evidence and possible mechanisms of rare maternal-fetal transmission of SARS-CoV-2.** Egloff C, Vauloup-Fellous C, Picone O, Mandelbrot L, Roques P. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2020:104447.
383. **Letter to the editors in response to: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic (Cure et al.).** Ekiz T, Kara M, Özçakar L. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2020;14(4):525-6.
384. **Metformin and COVID-19: A novel deal of an Old Drug.** El-Arabey AA, Abdalla M. *Journal of medical virology*. 2020.
385. **Could patients taking isotretinoin therapy be immune against SARS-COV-2?** Elgarhy LH. *Dermatologic therapy*. 2020.
386. **SARS-CoV-2 infection among patients with systemic autoimmune diseases.** Emmi G, Bettiol A, Mattioli I, Silvestri E, Scala GD, Urban ML, et al. *Autoimmunity reviews*. 2020:102575.
387. **Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.** Encinar JA, Menendez JA. *Viruses*. 2020;12(5). <http://dx.doi.org/10.3390/v12050525>.
388. **Ramping up Delivery of Cardiac Surgery During the COVID-19 Pandemic: A Guidance Statement from The Society of Thoracic Surgeons COVID-19 Task Force.** Engelman DT, Lothar S, George I, Ailawadi G, Atluri P, Grant MC, et al. *The Annals of thoracic surgery*. 2020. <http://dx.doi.org/10.1016/j.athoracsur.2020.05.002>.
389. **Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.** England JT, Abdulla A, Biggs CM, Lee AYY, Hay KA, Hoiland RL, et al. *Blood Reviews*. 2020.
390. **Light as a potential treatment for pandemic coronavirus infections: A perspective.** Enwemeka CS, Bumah VV, Masson-Meyers DS. *Journal of photochemistry and photobiology B, Biology*. 2020;207:111891.
391. **Points to consider in the preparation and transfusion of COVID-19 convalescent plasma.** Epstein J, Burnouf T. *Vox sanguinis*. 2020.
392. **When fear and misinformation go viral: Pharmacists' role in deterring medication misinformation during the 'infodemic' surrounding COVID-19.** Erku DA, Belachew SA, Abrha S, Sinnollareddy M, Thomas J, Steadman KJ, et al. *Research in social & administrative pharmacy : RSAP*. 2020.
393. **Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?** Erre GL, Ferraccioli ES, Piga M, Mangoni A, Passiu G, Gremese E, et al. *Annals of the rheumatic diseases*. 2020.
394. **Chronic myeloid leukemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.** Eşkazan AE. *British journal of clinical pharmacology*. 2020.

395. **Reply: Possible impact of membrane ACE2 expression on COVID-19 infection.** Esler M, Esler D. *Journal of hypertension*. 2020;38(6):1192-4.
396. **Update on treatment of COVID-19: ongoing studies between promising and disappointing results.** Esposito S, Noviello S, Pagliano P. *Infez Med*. 2020;28(2):198-211.
397. **Should Zinc be used in the treatment of COVID-19?** Eubanas GS, Fpds D.
398. **Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure.** Eyal N, Lipsitch M, Smith PG. *The Journal of infectious diseases*. 2020;221(11):1752-6.
399. **Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery.** Eygeris Y, Patel S, Jozic A, Sahay G. *Nano letters*. 2020.
400. **Early Short Course Corticosteroids in Hospitalized Patients with COVID-19.** Fadel R, Morrison AR, Vahia A, Smith ZR, Chaudhry Z, Bhargava P, et al. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
401. **Acute pulmonary embolism in COVID-19 disease: Preliminary report on seven patients.** Faggiano P, Bonelli A, Paris S, Milesi G, Bisegna S, Bernardi N, et al. *International Journal of Cardiology*. 2020.
402. **Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies.** Fagone P, Ciurleo R, Lombardo SD, Iacobello C, Palermo CI, Shoenfeld Y, et al. *Autoimmunity reviews*. 2020:102571.
403. **Nonstructural proteins NS7b and NS8 are likely to be phylogenetically associated with evolution of 2019-nCoV.** Fahmi M, Kubota Y, Ito M. *Infection, Genetics and Evolution*. 2020;81.
404. **Hematologic parameters in patients with COVID-19 infection.** Fan BE, Chong VCL, Chan SSW, Lim GH, Lim KGE, Tan GB, et al. *American Journal of Hematology*. 2020;95(6):E131-E4.
405. **Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model.** Fan HH, Wang LQ, Liu WL, An XP, Liu ZD, He XQ, et al. *Chinese medical journal*. 2020;133(9):1051-6.
406. **Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients.** Fan J, Zhang X, Liu J, Yang Y, Zheng N, Liu Q, et al. *Clinical Infectious Diseases*. 2020.
407. **Analysis of medication characteristics of traditional Chinese medicine in treating COVID-19 based on data mining.** Fan T, Chen Y, Bai Y, Ma F, Wang H, Yang Y, et al. *Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences*. 2020;49(2):260-9.
408. **nSynergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: what molecular dynamics studies of virus-host interactions reveal.** Fantini J, Chahinian H, Yahi N. *International journal of antimicrobial agents*. 2020:106020. <http://dx.doi.org/10.1016/j.ijantimicag.2020.106020>.
409. **The halo sign as a chest computed tomography finding of COVID-19.** Farias LPG, Pereira HAC, Anastacio EPZ, Minenelli FF, Teles GBDS. *Einstein (Sao Paulo, Brazil)*. 2020;18:eAI5742.
410. **Are Iranian Sulfur mustard-exposed survivors more vulnerable to SARS-CoV-2: some similarity in their pathogenesis.** Farnoosh G, Ghanei M, Khorramdelazad H, Alishiri G, Jalali Farahani A, Shahriary A, et al. *Disaster medicine and public health preparedness*. 2020:1-12.

411. **Impact of Online Information on Self-Isolation Intention During the COVID-19 Pandemic: Cross-Sectional Study.** Farooq A, Laato S, Islam A. *Journal of medical Internet research*. 2020;22(5):e19128. <http://dx.doi.org/10.2196/19128>.
412. **Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?** Farsalinos K, Barbouni A, Niaura R. *Internal and emergency medicine*. 2020.
413. **Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID-19 Experience.** Fasano A, Antonini A, Katzenschlager R, Krack P, Odin P, Evans AH, et al. *Movement Disorders Clinical Practice*. 2020;7(4):361-72.
414. **Role of the chronic air pollution levels in the Covid-19 outbreak risk in Italy.** Fattorini D, Regoli F. *Environmental Pollution*. 2020;264.
415. **Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis.** Favalli EG, Agape E, Caporali R. *The Journal of rheumatology*. 2020.
416. **Recommendations for Minimal Laboratory Testing Panels in Patients with COVID-19: Potential for Prognostic Monitoring.** Favalaro EJ, Lippi G. *Seminars in Thrombosis and Hemostasis*. 2020;46(3):379-82.
417. **The pulmonary-proteoliposome as a new therapeutic approach for Coronaviruses.** Feliciello I, Procino A. *Human vaccines & immunotherapeutics*. 2020:1.
418. **Qigong for the Prevention, Treatment, and Rehabilitation of COVID-19 Infection in Older Adults.** Feng F, Tuchman S, Denninger JW, Fricchione GL, Yeung A. *American Journal of Geriatric Psychiatry*. 2020.
419. **COVID-19, hypertension and angiotensin receptor-blocking drugs.** Fernández-Fernández FJ. *Journal of hypertension*. 2020;38(6):1191.
420. **Drug vignettes: Azithromycin.** Ferner RE, Aronson JK. 2020.
421. **COVID-19: Updated Data and its Relation to the Cardiovascular System.** Ferrari F. *Arquivos brasileiros de cardiologia*. 2020.
422. **As a potential treatment of COVID-19: Montelukast.** Fidan C, Aydoğdu A. *Medical Hypotheses*. 2020;142.
423. **Cold Plasma, a New Hope in the Field of Virus Inactivation.** Filipić A, Gutierrez-Aguirre I, Primc G, Mozetič M, Dobnik D. *Trends in Biotechnology*. 2020.
424. **Update on the neurology of COVID-19.** Finsterer J, Stollberger C. *Journal of medical virology*. 2020.
425. **The role of passive immunization in the age of SARS-CoV-2: an update.** Fischer JC, Zanker K, van Griensven M, Schneider M, Kindgen-Milles D, Knoefel WT, et al. *European journal of medical research*. 2020;25(1):16. <http://dx.doi.org/10.1186/s40001-020-00414-5>.
426. **From ground-glass opacities to pulmonary emboli. A snapshot of the evolving role of a radiology unit facing the COVID-19 outbreak.** Flor N, Tonolini M. *Clinical radiology*. 2020.
427. **Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.** Foerch C, Friedauer L, Bauer B, Wolf T, Adam EH. *Multiple Sclerosis and Related Disorders*. 2020;42.
428. **More on COVID-19 Coagulopathy in Caucasian patients.** Fogarty H, Townsend L, Ni Cheallaigh C, Bergin

C, Martin-Loeches I, Browne P, et al. British journal of haematology. 2020.

429. **Clinical display, diagnostics and genetic implication of novel Coronavirus (COVID-19) epidemic.**

Forouzesh M, Rahimi A, Valizadeh R, Dadashzadeh N, Mirzazadeh A. European review for medical and pharmacological sciences. 2020;24(8):4607-15.

430. **Why should we use convalescent plasma for COVID-19?** Franchini M. European journal of internal medicine. 2020.

431. **Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy.** Franchini M, Marano G, Velati C, Pati I, Pupella S, Maria Liembruno G. Vox sanguinis. 2020.

432. **A Veterinary Vaccine Development Process Map to assist in the development of new vaccines.** Francis MJ. Vaccine. 2020.

433. **Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report.** Franzetti M, Pozzetti U, Carugati M, Pandolfo A, Molteni C, Faccioli P, et al. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020.

434. **COVID-19, Negligence and Occupational Health and Safety: Ethical and Legal Issues for Hospitals and Health Centres.** Freckelton I. Journal of law and medicine. 2020;27(3):590-600.

435. **Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.** Freedberg DE, Conigliaro J, Sobieszczyk ME, Markowitz DD, Gupta A, Donnell MR, et al. medRxiv. 2020:2020.05.01.20086694.

436. **What could be the better choice between ACE inhibitors and AT1R antagonists in coronavirus disease 2019 (COVID-19) patients?** Frolidi G. Journal of medical virology. 2020.

437. **The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China.** Fu J, Kong J, Wang W, Wu M, Yao L, Wang Z, et al. Thrombosis Research. 2020;192:3-8.

438. **Letter to the Editor: Three cases of re-detectable positive SARS-CoV-2 RNA in recovered COVID-19 patients with antibodies.** Fu W, Chen Q, Wang T. Journal of medical virology. 2020.

439. **Risk Factors for Viral RNA Shedding in COVID-19 Patients.** Fu Y, Han P, Zhu R, Bai T, Yi J, Zhao X, et al. The European respiratory journal. 2020.

440. **"Water, water, everywhere": a challenge to ventilators in the COVID-19 pandemic.** Fullick J, Oliver M. British journal of anaesthesia. 2020.

441. **Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?** Funck-Brentano C, Salem J-E. The Lancet. 2020.

442. **Evidenced-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19.** Galimberti F, McBride J, Cronin M, Li Y, Fox J, Abrouk M, et al. Clinics in dermatology. 2020.

443. **The CoV-2 outbreak: how hematologists could help to fight Covid-19.** Galimberti S, Baldini C, Baratè C, Ricci F, Balducci S, Grassi S, et al. Pharmacological research. 2020:104866.

444. **Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin.** Gallelli L, Zhang L, Wang T, Fu F. Journal of Clinical Pharmacology. 2020.

445. **Psychiatry in the COVID-19 Era.** Galletly C. Australian and New Zealand Journal of Psychiatry. 2020;54(5):447-8.
446. **Long acting injectable antipsychotic medications: Ensuring care continuity during the COVID-19 pandemic restrictions.** Gannon JM, Conlogue J, Sherwood R, Nichols J, Ballough JR, Fredrick NM, et al. Schizophrenia research. 2020.
447. **A study on infectivity of asymptomatic SARS-CoV-2 carriers.** Gao M, Yang L, Chen X, Deng Y, Yang S, Xu H, et al. Respiratory Medicine. 2020;169.
448. **Rapid and visual detection of porcine deltacoronavirus by recombinase polymerase amplification combined with a lateral flow dipstick.** Gao X, Liu X, Zhang Y, Wei Y, Wang Y. BMC veterinary research. 2020;16(1):130.
449. **Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020.** Garazzino S, Montagnani C, Dona D, Meini A, Felici E, Vergine G, et al. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2020;25(18). <http://dx.doi.org/10.2807/1560-7917.ES.2020.25.18.2000600>.
450. **D-dimer in patients infected with COVID-19 and suspected pulmonary embolism.** Garcia-Olivé I, Sintés H, Radua J, Capa JA, Rosell A. Respiratory medicine. 2020:106023.
451. **Association of Renin Angiotensin System Blockers with Outcomes in Patients with Covid-19: A Systematic Review and Meta-analysis.** Garg A, Rout A, Sharma A, Fiorello B, Kostis JB. medRxiv. 2020:2020.05.23.20111401.
452. **Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North - supports vitamin D as a factor determining severity. Authors' reply.** Garg M, Al-Ani A, Mitchell H, Hendy P, Christensen B. Alimentary pharmacology & therapeutics. 2020.
453. **Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North – supports vitamin D as a factor determining severity. Authors' reply.** Garg M, Al-Ani A, Mitchell H, Hendy P, Christensen B. Alimentary Pharmacology and Therapeutics. 2020.
454. **Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors.** Garg M, Royce SG, Lubel JS. Alimentary pharmacology & therapeutics. 2020.
455. **"Review article: COVID-19 and liver disease - what we know on 1st May 2020".** Garrido I, Liberal R, Macedo G. Alimentary pharmacology & therapeutics. 2020.
456. **Perspectives of Immune Therapy in Coronavirus Disease 2019.** Gasparyan AY, Misra DP, Yessirkepov M, Zimba O. J Korean Med Sci. 2020;35(18):e176. <http://dx.doi.org/10.3346/jkms.2020.35.e176>.
457. **Should azithromycin be used to treat COVID-19? A rapid review.** Gbinigie K, Frie K. BJGP open. 2020. <http://dx.doi.org/10.3399/bjgpopen20X101094>.
458. **Repurposing Existing Medications for Coronavirus Disease 2019: Protocol for a Rapid and Living Systematic Review.** Geisler BP, Zahabi L, Lang AE, Eastwood N, Tennant E, Lukic L, et al. medRxiv. 2020:2020.05.21.20109074.
459. **Are Type 1 Interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?** Gemcioglu E, Davutoglu M, Ozdemir EE, Erden A. Multiple sclerosis and related disorders. 2020:102196.
460. **COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity,**

- Inflammation and Coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?** Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G, Tisato V. *International journal of molecular sciences*. 2020;21(10).
461. **Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis.** Gendelman O, Amital H, Bragazzi NL, Watad A, Chodick G. *Autoimmunity reviews*. 2020:102566.
462. **Patient-Driven Discontinuation of Apremilast During the COVID-19 Pandemic in Two Canadian Academic Hospital Clinics and One Community Practice.** Georgakopoulos JR, Vender R, Yeung J. *Journal of Cutaneous Medicine and Surgery*. 2020.
463. **"Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.** Gerard A, Romani S, Fresse A, Viard D, Parassol N, Granvullemin A, et al. *Therapie*. 2020. <http://dx.doi.org/10.1016/j.therap.2020.05.002>.
464. **Safety considerations of chloroquine and hydroxychloroquine in treatment of COVID-19.** Gevers S, Kwa MSG, Wijnans E, van Nieuwkoop C. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2020.
465. **Angiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection.** Ghafouri-Fard S, Noroozi R, Omrani MD, Branicki W, Pośpiech E, Sayad A, et al. *Vascular Pharmacology*. 2020.
466. **Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2.** Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, et al. *Circulation research*. 2020;126(10):1456-74.
467. **Report of 5 nurses infecting COVID-19 during patient care: case Series.** Gheysarzadeh A, Sadeghifard N, Safari M, Balavandi F, Falahi S, Kenarkoobi A, et al. *New microbes and new infections*. 2020:100694. <http://dx.doi.org/10.1016/j.nmni.2020.100694>.
468. **"ANESTHESIA STAT" TO INTUBATE A COVID-19 PATIENT: IMPLICATIONS FOR THE ANESTHESIOLOGIST.** Ghia S, Lazar M, Epstein J, Bhatt HV. *Journal of cardiothoracic and vascular anesthesia*. 2020.
469. **Acute Thrombosis of an Aortic Prosthetic Graft in a Patient with Severe COVID-19-Related Pneumonia.** Giacomelli E, Dorigo W, Fargion A, Calugi G, Cianchi G, Pratesi C. *Annals of vascular surgery*. 2020.
470. **Cutaneous clinico-pathological findings in three covid-19-positive patients observed in the metropolitan area of Milan, Italy.** Gianotti R, Veraldi S, Recalcati S, Cusini M, Ghislanzoni M, Boggio F, et al. *Acta Dermato-Venereologica*. 2020;100(8).
471. **Expanding our understanding of the role polyprotein conformation plays in the coronavirus life cycle.** Gildenhuis S. *Biochemical Journal*. 2020;477(8):1479-82.
472. **Endocrinology in the time of COVID-19: Management of calcium disorders and osteoporosis.** Gittoes NJ, Criseno S, Appelman-Dijkstra NM, Bollerslev J, Canalis E, Rejnmark L, et al. *European journal of endocrinology*. 2020.
473. **Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing.** Glebov OO. *The FEBS journal*. 2020. <http://dx.doi.org/10.1111/febs.15369>.
474. **Identification of Falsified Chloroquine Tablets in Africa at the Time of the COVID-19 Pandemic.** Gnegel

G, Hauk C, Neci R, Mutombo G, Nyaah F, Wistuba D, et al. The American journal of tropical medicine and hygiene. 2020.

475. **Possible Role of Tetracyclines on COVID-19: Recycling Well-Known Old Drugs from the Shelf.** Gnoni M, Vasquez-Gararatti R, Mena A. The University of Louisville Journal of Respiratory Infections. 2020;4(1):9.

476. **Recommendations for trauma and emergency general surgery practice during COVID-19 pandemic.** Gök AFK, Eryılmaz M, Özmen MM, Alimoğlu O, Ertekin C, Kurtoğlu MH. Ulusal Travma ve Acil Cerrahi Dergisi. 2020;26(3):335-42.

477. **Low-flow Nasal Cannula and Potential Nosocomial Spread of COVID-19.** Goldhaber-Fiebert SN, Greene JA, Garibaldi BT. British journal of anaesthesia. 2020.

478. **Coronavirus disease 2019 in children: Surprising findings in the midst of a global pandemic.** Goldman RD. Canadian family physician Medecin de famille canadien. 2020;66(5):332-4.

479. **Reply: Use of statins in patients with COVID-19.** Goldstein MR, Poland GA, Graeber CW. QJM : monthly journal of the Association of Physicians. 2020.

480. **Lithium for the 2019 novel coronavirus.** Gómez-Bernal G. Medical Hypotheses. 2020;142.

481. **Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORY dlstress syndrome in hospItAlized patieNts with SARS-COV-2 Infection Disease.** Gommans DHF, Nas J, Pinto-Sietsma S-J, Koop Y, Konst RE, Mensink F, et al. American Heart Journal. 2020.

482. **Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old.** Gong Y, Guan L, Jin Z, Chen S, Xiang G, Gao B. Journal of Medical Virology. 2020.

483. **Cancer immunotherapy does not increase the risk of death by COVID-19 in melanoma patients.** Gonzalez-Cao M, Antonazas-Basa M, Puertolas T, Munoz-Couselo E, Manzano JL, Carrera C, et al. medRxiv. 2020:2020.05.19.20106971.

484. **Tocilizumab: From the Rheumatology Practice to the Fight Against COVID-19, a virus infection with multiple faces.** González-Gay MA, Mayo J, Castañeda S, Cifrián JM, Hernández-Rodríguez J. Expert opinion on biological therapy. 2020.

485. **Commentary: COVID in Care Homes-Challenges and Dilemmas in Healthcare Delivery.** Gordon AL, Goodman C, Achterberg W, Barker RO, Burns E, Hanratty B, et al. Age and ageing. 2020.

486. **COVID-19 and Cancer: a Comprehensive Review.** Gosain R, Abdou Y, Singh A, Rana N, Puzanov I, Ernstoff MS. Current Oncology Reports. 2020;22(5).

487. **Corticosteroid use in selected patients with severe Acute Respiratory Distress Syndrome related to Covid-19.** Goursaud S, Descamps R, Daubin C, du Cheyron D, Valette X. The Journal of infection. 2020.

488. **Targeting the dimerization of main protease of coronaviruses: A potential broad-spectrum therapeutic strategy.** Goyal B, Goyal D. ACS combinatorial science. 2020.

489. **Response to: 'Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?' by Erre et al.** Graef ER, Liew JW, Kim AH, Sparks JA. Annals of the rheumatic diseases. 2020.

490. **Rapid COVID-19 vaccine development.** Graham BS. Science (New York, NY). 2020.

491. **Response to "Risks of Hydroxychloroquine use for COVID-19 prophylaxis"**. Grant-Kels JM. *Journal of the American Academy of Dermatology*. 2020.
492. **Chloroquine inhibits the release of inflammatory cytokines by human lung explants**. Grassin-Delye S, Salvator H, Brollo M, Catherinot E, Sage E, Couderc LJ, et al. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
493. **Covid-19 accelerates endothelial dysfunction and nitric oxide deficiency**. Green SJ. *Microbes and infection*. 2020.
494. **Compassionate Use of Remdesivir in Covid-19. Reply**. Grein J, Myers RP, Brainard D. *The New England journal of medicine*. 2020;382.
495. **p38 MAPK inhibition: A promising therapeutic approach for COVID-19**. Grimes JM, Grimes KV. *Journal of Molecular and Cellular Cardiology*. 2020;144:63-5.
496. **Could an endo-lysosomal ion channel be the Achilles heel of SARS-CoV2?** Grimm C, Tang R. *Cell Calcium*. 2020;88.
497. **Dietary Management of Food Protein-Induced Enterocolitis Syndrome during COVID-19 Pandemic**. Groetch M, Durban R, Meyer R, Venter C, Nowak-Wegrzyn A. *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology*. 2020.
498. **COVID-19-associated nephritis: early warning for disease severity and complications?** Gross O, Moerer O, Weber M, Huber TB, Scheithauer S. *The Lancet*. 2020;395(10236):e87-e8.
499. **SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications**. Groß S, Jahn C, Cushman S, Bär C, Thum T. *Journal of Molecular and Cellular Cardiology*. 2020;144:47-53.
500. **Analysis of an improved workflow of endoscope reprocessing for bedside endoscopic diagnosis and treatment on COVID-19 patients**. Gu Q, Wang H-F, Fang Y, Lu Y, Shen Z, Wang Y, et al. *J Zhejiang Univ Sci B*. 2020;21(5):416-22.
501. **Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia**. Guan GW, Gao L, Wang JW, Wen XJ, Mao TH, Peng SW, et al. *Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology*. 2020;28(2):100-6.
502. **Current State of Knowledge About SARS-CoV-2 and COVID-19 Disease in Pregnant Women**. Gujski M, Humeniuk E, Bojar I. *Medical science monitor : international medical journal of experimental and clinical research*. 2020;26:e924725. <http://dx.doi.org/10.12659/MSM.924725>.
503. **Immediate psychological distress in quarantined patients with COVID-19 and its association with peripheral inflammation: a mixed-method study**. Guo Q, Zheng Y, Shi J, Wang J, Li G, Li C, et al. *Brain, behavior, and immunity*. 2020. <http://dx.doi.org/10.1016/j.bbi.2020.05.038>.
504. **Why is SARS-CoV-2 testing not possible in every medical laboratory?** Gupta P. *Indian Journal of Pathology and Microbiology*. 2020;63(2):173-4.
505. **Neurosurgery and Neurology Practices during the Novel COVID-19 Pandemic: A Consensus Statement from India**. Gupta P, Muthukumar N, Rajshekhar V, Tripathi M, Thomas S, Gupta SK, et al. *Neurol India*. 2020;68(2):246-54. <http://dx.doi.org/10.4103/0028-3886.283130>.

506. **Diabetes and COVID-19: evidence, current status and unanswered research questions.** Gupta R, Hussain A, Misra A. *European journal of clinical nutrition*. 2020.
507. **Molecular Docking Studies of N-Acetyl Cysteine, Zinc Acetyl Cysteine and Niclosamide on SARS Cov 2 Protease and Its Comparison with Hydroxychloroquine.** Guthappa R. 2020.
508. **The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.** Habibzadeh P, Moghadami M, Lankarani KB. *Medical Hypotheses*. 2020;143.
509. **COVID-19: Main therapeutic options.** Hachfi W, Ben Lasfar N. *La Tunisie medicale*. 2020;98(4):299-303.
510. **Encephalopathy and seizure activity in a COVID-19 well controlled HIV patient.** Haddad S, Tayyar R, Risch L, Churchill G, Fares E, Choe M, et al. *IDCases*. 2020:e00814. <http://dx.doi.org/10.1016/j.idcr.2020.e00814>.
511. **Coronavirus Disease-19 (COVID-19) associated with severe acute pancreatitis: Case report on three family members.** Hadi A, Werge M, Kristiansen KT, Pedersen UG, Karstensen JG, Novovic S, et al. *Pancreatology : official journal of the International Association of Pancreatology (IAP)* [et al]. 2020.
512. **In Silico discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 using pharmacophore and molecular docking based virtual screening from ZINC database.** Haider Z, Subhani MM, Farooq MA, Ishaq M, Khalid M, Khan RSA, et al. *Journal*. 2020(Issue).
513. **SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant.** Hajifathalian K, Mahadev S, Schwartz RE, Shah S, Sampath K, Schnoll-Sussman F, et al. *World Journal of Gastroenterology*. 2020;26(14):1546-53.
514. **The human ecology of Covid 19: a zinc link?** Hambler C. 2020.
515. **Etoposide-based therapy for severe forms of COVID-19.** Hamizi K, Aouidane S, Belaaloui G. *Medical Hypotheses*. 2020;142.
516. **Clinical Course of COVID-19 in a Liver Transplant Recipient on Hemodialysis and Response to Tocilizumab Therapy: A Case Report.** Hammami MB, Garibaldi B, Shah P, Liu G, Jain T, Chen PH, et al. *American Journal of Transplantation*. 2020.
517. **Procalcitonin for patient stratification and identification of bacterial co-infection in COVID-19.** Han J, Gatheral T, Williams C. *Clinical medicine (London, England)*. 2020;20(3):e47.
518. **Clinical diagnostic value of CT imaging in COVID-19 with multiple negative RT-PCR testing.** Hao W, Li M. *Travel Medicine and Infectious Disease*. 2020;34.
519. **Coronavirus disease 2019 (COVID-19): A literature review.** Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. *Journal of Infection and Public Health*. 2020;13(5):667-73.
520. **COVID-19: progression of disease and intravascular coagulation - present status and future perspectives.** Harenberg J, Favaloro E. *Clinical chemistry and laboratory medicine*. 2020.
521. **Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreak.** Har-Noy M, Or R. *Journal of translational medicine*. 2020;18(1):196.
522. **COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients.** Härter G, Spinner CD, Roeder J, Bickel M, Krznaric I, Grunwald S, et al. *Infection*. 2020.

523. **Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review.** Hashem AM, Alghamdi BS, Algaissi AA, Alshehri FS, Bukhari A, Alfaleh MA, et al. *Travel medicine and infectious disease*. 2020;101735.
524. **Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19.** Hassoun A, Thottacherry ED, Muklewicz J, Aziz QUU, Edwards J. *Journal of Clinical Virology*. 2020;128.
525. **Vitamin D concentrations and COVID-19 infection in UK Biobank.** Hastie CE, Mackay DF, Ho F, Celis-Morales CA, Katikireddi SV, Niedzwiedz CL, et al. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2020;14(4):561-5.
526. **Public activities preceding the onset of acute respiratory infection syndromes in adults in England - implications for the use of social distancing to control pandemic respiratory infections.** Hayward AC, Beale S, Johnson AM, Fragaszy EB. Wellcome open research. 2020;5:54. <http://dx.doi.org/10.12688/wellcomeopenres.15795.1>. eCollection 2020.
527. **Clinical experience of high-flow nasal cannula oxygen therapy in severe COVID-19 patients.** He G, Han Y, Fang Q, Zhou J, Shen J, Li T, et al. *Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences*. 2020;49(2):232-9.
528. **Genomic epidemiology, evolution, and transmission dynamics of porcine deltacoronavirus.** He WT, Ji X, He W, Dellicour S, Wang S, Li G, et al. *Molecular biology and evolution*. 2020.
529. **Exercise as medicine for COVID-19: An ACE in the hole?** Heffernan KS, Young Jae S. *Medical Hypotheses*. 2020;142.
530. **A comparative study of techniques used for the diagnosis of effusive feline infectious peritonitis.** Hellemans A, Acar DD, Stroobants VJE, Theuns S, Desmarests LMB, Nauwynck HJ. *Vlaams Diergeneeskundig Tijdschrift*. 2020;89(1):28-33.
531. **Abdominal presentation of covid-19.** Hellinger JC, Sirous R, Hellinger RL, Krauthamer A. *Applied Radiology*. 2020;49(3):24-6.
532. **COVID-19 and Moral Imperialism in Multinational Clinical Research.** Hellmann F, Williams-Jones B, Garrafa V. *Archives of medical research*. 2020.
533. **High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.** Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. *Intensive care medicine*. 2020.
534. **Remdesivir in the treatment of Coronavirus Disease 2019 (COVID-19): A simplified summary.** Hendaus MA. *Journal of Biomolecular Structure and Dynamics*. 2020:1-10.
535. **Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature.** Hensel A, Bauer R, Heinrich M, Spiegler V, Kayser O, Hempel G, et al. *Planta Med*. 2020. <http://dx.doi.org/10.1055/a-1177-4396>.
536. **Elevated levels of interleukin-6 and CRP predict the need for mechanical ventilation in COVID-19.** Herold T, Jurinovic V, Annreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, et al. *The Journal of allergy and clinical immunology*. 2020.
537. **A clinicopathological study of 8 patients with COVID-19 pneumonia and a late-onset exanthema.** Herrero-Moyano M, Capusan TM, Andreu-Barasoain M, Alcántara-González J, Ruano-Del Salado M, Sánchez-Largo Uceda ME, et al. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2020.

538. **An effective CTL peptide vaccine for Ebola Zaire Based on Survivors' CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design.** Herst CV, Burkholz S, Sidney J, Sette A, Harris PE, Massey S, et al. *Vaccine*. 2020.
539. **COVID-19-Related Stroke.** Hess DC, Eldahshan W, Rutkowski E. *Translational stroke research*. 2020.
540. **Inhaled Nebulized Sodium Pyruvate Use in COVID-19 Patients.** Hidvégi M. *The Israel Medical Association journal : IMAJ*. 2020;22(5):278.
541. **Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs.** Hijikata A, Shionyu-Mitsuyama C, Nakae S, Shionyu M, Ota M, Kanaya S, et al. *FEBS letters*. 2020.
542. **Minimum costs to manufacture new treatments for COVID-19.** Hill A, Wang J, Levi J, Heath K, Fortunak J. *Journal of virus eradication*. 2020;6(2):61-9.
543. **A Call for Vaccine Against COVID-19: Implications for Cardiovascular Morbidity and Healthcare Utilization.** Ho JSY, Tambyah PA, Sia CH. *Cardiovascular drugs and therapy*. 2020.
544. **Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19.** Ho LTF, Chan KKH, Chung VCH, Leung TH. *European Journal of Integrative Medicine*. 2020;36.
545. **Zinc Iodide in combination with Dimethyl Sulfoxide for treatment of SARS-CoV-2 and other viral infections.** Hoang BX, Hoang HQ. *Medical Hypotheses*. 2020:109866.
546. **Compassionate Use of Remdesivir in Covid-19.** Hoffmann C. *The New England journal of medicine*. 2020;382.
547. **Severe COVID-19 infection in pregnancy requiring intubation without preterm delivery: A case report.** Hong L, Smith N, Keerthy M, Lee-Griffith M, Garcia R, Shaman M, et al. *Case Reports in Women's Health*. 2020;27.
548. **Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: we are not sure.** Honore PM, Mugisha A, Kugener L, Redant S, Attou R, Gallerani A, et al. *Crit Care*. 2020;24(1):226. <http://dx.doi.org/10.1186/s13054-020-02943-1>.
549. **Pollen likely seasonal factor in inhibiting flu-like epidemics. A Dutch study into the inverse relation between pollen counts, hay fever and flu-like incidence 2016–2019.** Hoogeveen MJ. *Science of the Total Environment*. 2020;727.
550. **Preventive strategies used by GI physicians during the COVID-19 pandemic.** Hormati A, Ghadir MR, Zamani F, Khodadadi J, Afifian M, Ahmadpour S. *New Microbes and New Infections*. 2020;35.
551. **COVID-19 associated pneumonia despite repeatedly negative PCR-analysis from oropharyngeal swabs.** Hornuss D, Laubner K, Monasterio C, Thimme R, Wagner D. *Deutsche medizinische Wochenschrift (1946)*. 2020.
552. **Three Novel Prevention, Diagnostic and Treatment Options for COVID-19 Urgently Necessitating Controlled Randomized Trials.** Horowitz RI, Freeman PR. *Medical Hypotheses*. 2020:109851.
553. **A Chemographic Audit of anti-Coronavirus Structure-Activity Information from Public Databases (ChEMBL).** Horvath D, Orlov A, Osolodkin DI, Ishmukhametov AA, Marcou G, Varnek A. *Molecular Informatics*. 2020.
554. **CT Scans Obtained for Nonpulmonary Indications: Associated Respiratory Findings of COVID-19.** Hossain R, Lazarus MS, Roudenko A, Dako F, Mehta V, Alis J, et al. *Radiology*. 2020:201743.

555. **Using IL-2R/lymphocyte for predicting the clinical progression of patients with COVID-19.** Hou H, Zhang B, Huang H, Luo Y, Wu S, Tang G, et al. *Clinical and experimental immunology*. 2020.
556. **Potential role of vitamin d in the elderly to resist covid-19 and to slow progression of parkinson's disease.** Hribar CA, Cobbold PH, Church FC. *Brain Sciences*. 2020;10(5).
557. **Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb, in Patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial.** Hu K, Guan WJ, Bi Y, Zhang W, Li L, Zhang B, et al. *Phytomedicine : international journal of phytotherapy and phytopharmacology*. 2020:153242.
558. **Radiological role in the detection, diagnosis and monitoring for the coronavirus disease 2019 (COVID-19).** Hu L, Wang C. *European review for medical and pharmacological sciences*. 2020;24(8):4523-8.
559. **Antimicrobial resistance is a global problem – a UK perspective.** Hu XY, Logue M, Robinson N. *European Journal of Integrative Medicine*. 2020;36.
560. **Positive detection of SARS-CoV-2 combined HSV1 and HHV6B virus nucleic acid in tear and conjunctival secretions of a non-conjunctivitis COVID-19 patient with obstruction of common lacrimal duct.** Hu Y, Chen T, Liu M, Zhang L, Wang F, Zhao S, et al. *Acta ophthalmologica*. 2020. <http://dx.doi.org/10.1111/aos.14456>.
561. **Mining the characteristics of COVID-19 Patients: Based on Social media of China.** Huang C, Xu X, Cai Y, Ge Q, Zeng G, Li X, et al. *Journal of medical Internet research*. 2020.
562. **Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity.** Huang J, Cheng A, Kumar R, Fang Y, Chen G, Zhu Y, et al. *Journal of medical virology*. 2020.
563. **Individualized prediction nomograms for disease progression in mild COVID-19.** Huang J, Cheng A, Lin S, Zhu Y, Chen G. *Journal of medical virology*. 2020.
564. **Obesity hypoventilation syndrome and severe COVID-19.** Huang JF, Wang XB, Zheng KI, Liu WY, Chen JJ, George J, et al. *Metabolism: Clinical and Experimental*. 2020;108.
565. **Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China.** Huang Q, Deng X, Li Y, Sun X, Chen Q, Xie M, et al. *International journal of clinical pharmacy*. 2020:1-9. <http://dx.doi.org/10.1007/s11096-020-01031-2>.
566. **Measures Undertaken in China to Avoid COVID-19 Infection: Internet-Based, Cross-Sectional Survey Study.** Huang Y, Wu Q, Wang P, Xu Y, Wang L, Zhao Y, et al. *Journal of medical Internet research*. 2020;22(5):e18718.
567. **Psychosis in a patient with anxiety related to COVID-19: A case report.** Huarcaya-Victoria J, Herrera D, Castillo C. *Psychiatry Research*. 2020;289.
568. **COVID-19 in persons with multiple sclerosis treated with ocrelizumab - a pharmacovigilance case series.** Hughes R, Pedotti R, Koendgen H. *Multiple sclerosis and related disorders*. 2020:102192.
569. **Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures.** Hui KPY, Cheung MC, Perera RAPM, Ng KC, Bui CHT, Ho JCW, et al. *The Lancet Respiratory Medicine*. 2020.
570. **Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.** Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, et al. *Lancet*. 2020. [http://dx.doi.org/10.1016/S0140-6736\(20\)31042-4](http://dx.doi.org/10.1016/S0140-6736(20)31042-4).

571. **Coronavirus disease (COVID-19) - impact on vaccine preventable diseases.** Hungerford D, Cunliffe NA. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2020;25(18). <http://dx.doi.org/10.2807/1560-7917.ES.2020.25.18.2000756>.
572. **Clinical considerations for patients with diabetes in times of COVID-19 pandemic.** Hussain A, do Vale Moreira NC. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020;14(4):451-3.
573. **Analysis of Codon Usage and Nucleotide Bias in Middle East Respiratory Syndrome Coronavirus Genes.** Hussain S, Shinu P, Islam MM, Chohan MS, Rasool ST. Evolutionary Bioinformatics. 2020;16.
574. **In Silico Exploration of Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2's Main Protease.** Huynh T, Wang H, Luan B. The journal of physical chemistry letters. 2020.
575. **Covid-19: Allow pharmacists to dispense controlled drugs without prescription, urge specialists.** Iacobucci G. BMJ (Clinical research ed). 2020;369:m1868.
576. **Estimating and projecting air passenger traffic during the COVID-19 coronavirus outbreak and its socio-economic impact.** Iacus SM, Natale F, Santamaria C, Spyrtos S, Vespe M. Safety Science. 2020;129.
577. **Pharaonic Bitter Salts for COVID-19; Home Scientific Note.** Ibrahim WA.
578. **Cardiovascular disease as a biomarker for an increased risk of COVID-19 infection and related poor prognosis.** Ielapi N, Licastro N, Provenzano M, Andreucci M, Franciscis S, Serra R. Biomarkers in medicine. 2020.
579. **The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality.** Ilie PC, Stefanescu S, Smith L. Aging Clinical and Experimental Research. 2020.
580. **Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy.** Inciardi RM, Adamo M, Lupi L, Cani DS, Di Pasquale M, Tomasoni D, et al. European heart journal. 2020.
581. **Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: risks and benefits at the time of COVID-19 pandemic.** Infante M, Ricordi C, Fabbri A. Journal of diabetes. 2020.
582. **Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study.** Ip A, Berry DA, Hansen E, Goy AH, Pecora AL, Sinclair BA, et al. medRxiv. 2020:2020.05.21.20109207.
583. **COVID-19 and radiation induced pneumonitis: Overlapping clinical features of different diseases.** Ippolito E, Fiore M, Greco C, D'Angelillo RM, Ramella S. Radiotherapy and Oncology. 2020;148:201-2.
584. **Modeling COVID-19 and Its Impacts on U.S. Immigration and Customs Enforcement (ICE) Detention Facilities, 2020.** Irvine M, Coombs D, Skarha J, Del Pozo B, Rich J, Taxman F, et al. Journal of urban health : bulletin of the New York Academy of Medicine. 2020. <http://dx.doi.org/10.1007/s11524-020-00441-x>.
585. **Virucidal activities of zinc-finger antiviral proteins and zinc-binding domains for virus entry.** Ishida T. DNA/RNA replication and spread. 2020:9-13.
586. **Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples.** Jääskeläinen AJ, Kekäläinen E, Kallio-Kokko H, Mannonen L, Kortela E, Vapalahti O, et al. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2020;25(18).
587. **COVID-19 social distancing and sexual activity in a sample of the British Public.** Jacob L, Smith L, Butler L, Barnett Y, Grabovac I, McDermott D, et al. The journal of sexual medicine. 2020.

588. **COVID-19 and lung pathology.** Jain A. Indian Journal of Pathology and Microbiology. 2020;63(2):171-2.
589. **ENHANCED ECG MONITORING OF COVID-19 PATIENTS.** Jain S, Workman V, Ganeshan R, Obasare ER, Burr A, DeBiasi RM, et al. Heart rhythm. 2020.
590. **Imaging in corona virus disease 2019 (COVID-19)—A Scoping review.** Jajodia A, Ebner L, Heidinger B, Chaturvedi A, Prosch H. European Journal of Radiology Open. 2020;7.
591. **3CL Hydrolase Based Multi Epitope Peptide Vaccine Against Sars-CoV-2 Using Immunoinformatics.** Jakhar R, Kaushik S, Gakhar SK. Journal of medical virology. 2020.
592. **COVID-19: is the ACE2 just a foe?** Jakovac H. American journal of physiology Lung cellular and molecular physiology. 2020;318(5):L1025-L6.
593. **Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.** Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, et al. Autoimmunity reviews. 2020:102567.
594. **Clinical and laboratory findings from patients with COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study.** Javanian M, Bayani M, Shokri M, Sadeghi-Haddad-Zavareh M, Babazadeh A, Yeganeh B, et al. Romanian journal of internal medicine = Revue roumaine de medecine interne. 2020.
595. **Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and Angiotensin II receptor blocker (ARB) Use in COVID-19 prevention or treatment: A Paradox.** Javanmard SH, Heshmat-Ghahdarijani K, Vaseghi G. Infection Control and Hospital Epidemiology. 2020.
596. **Enhancing immunity in viral infections, with special emphasis on COVID-19: A review.** Jayawardena R, Sooriyaarachchi P, Chourdakis M, Jeewandara C, Ranasinghe P. Diabetes & metabolic syndrome. 2020;14(4):367-82.
597. **Old and re-purposed drugs for the treatment of COVID-19.** Jean SS, Hsueh PR. Expert Rev Anti Infect Ther. 2020. <http://dx.doi.org/10.1080/14787210.2020.1771181>.
598. **Guidelines and practice recommendations on Obstetric care of pregnant patients with Covid-19 infection: Scoping review.** Jeldu WG, Tolu LB. 2020.
599. **Identification of Potent Drugs and Antiviral Agents for the Treatment of the SARS-CoV-2 Infection.** Jena N. 2020.
600. **Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs.** Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, et al. Antimicrobial agents and chemotherapy. 2020.
601. **Emerging treatment and prevention strategies against COVID-19: a brief update.** Jha AK, Kumar R, Goenka MK, Dayal VM. Journal of Digestive Endoscopy. 2020;11(1):69-72.
602. **Response to "Comments on "Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human" and "Codon bias analysis alone is uninformative for identifying host(s) of new virus".** Ji W, Li X. J Med Virol. 2020. <http://dx.doi.org/10.1002/jmv.26048>.
603. **Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19).** Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Journal of General Internal Medicine. 2020;35(5):1545-9.
604. **Pharmaceutical care for severe and critically ill patients with COVID-19.** Jiang S, Li L, Ru R, Zhang C, Rao Y, Lin B, et al. Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences. 2020;49(2):158-69.

605. **COVID-19 Dynamic Computed Tomography (CT) Performance and Observation of Some Laboratory Indicators.** Jiang X, Yin Z, Wang T, Zhai N, Lu F, Zhan C, et al. *Medical science monitor : international medical journal of experimental and clinical research.* 2020;26:e924403.
606. **Clinical characteristics of 60 discharged cases of 2019 novel coronavirus-infected pneumonia in Taizhou, China.** Jiang Y, He S, Zhang C, Wang X, Chen X, Jin Y, et al. *Ann Transl Med.* 2020;8(8):547. <http://dx.doi.org/10.21037/atm.2020.04.20>.
607. **Effect of ambient air pollutants and meteorological variables on COVID-19 incidence.** Jiang Y, Wu XJ, Guan YJ. *Infection control and hospital epidemiology.* 2020:1-11.
608. **Erythema multiforme-like eruption in patients with COVID-19 infection: clinical and histological findings.** Jimenez-Cauhe J, Ortega-Quijano D, Carretero-Barrio I, Suarez-Valle A, Saceda-Corralo D, Moreno-Garcia Del Real C, et al. *Clinical and experimental dermatology.* 2020.
609. **Perceived infection transmission routes, infection control practices, psychosocial changes, and management of COVID-19 infected healthcare workers in a tertiary acute care hospital in Wuhan: a cross-sectional survey.** Jin YH, Huang Q, Wang YY, Zeng XT, Luo LS, Pan ZY, et al. *Military Medical Research.* 2020;7(1):24.
610. **Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur.** Jin Z, Zhao Y, Sun Y, Zhang B, Wang H, Wu Y, et al. *Nature structural & molecular biology.* 2020.
611. **Hand sanitizers: A review on formulation aspects, adverse effects, and regulations.** Jing JLJ, Yi TP, Bose RJC, McCarthy JR, Tharmalingam N, Madheswaran T. *International Journal of Environmental Research and Public Health.* 2020;17(9).
612. **Potential influence of COVID-19/ACE2 on the female reproductive system.** Jing Y, Run-Qian L, Hao-Ran W, Hao-Ran C, Ya-Bin L, Yang G, et al. *Molecular human reproduction.* 2020.
613. **The online competition between pro- and anti-vaccination views.** Johnson NF, Velásquez N, Restrepo NJ, Leahy R, Gabriel N, El Oud S, et al. *Nature.* 2020.
614. **Oral Chemotherapy for Treatment of Lung Cancer.** Jonna S, Reuss JE, Kim C, Liu SV. *Frontiers in Oncology.* 2020;10.
615. **Remdesivir: Review of pharmacology, pre-clinical data and emerging clinical experience for COVID-19.** Jorgensen SC, Kebriaei R, Dresser LD. *Pharmacotherapy.* 2020. <http://dx.doi.org/10.1002/phar.2429>.
616. **In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking.** Joshi T, Joshi T, Sharma P, Mathpal S, Pundir H, Bhatt V, et al. *European review for medical and pharmacological sciences.* 2020;24(8):4529-36.
617. **More harm than good?: COVID-19 treatment with chloroquine and hydroxychloroquine hides high risks.** Jungmayr P. *Deutsche Apotheker Zeitung.* 2020;60(17).
618. **Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project).** Juul S, Nielsen N, Bentzer P, Veroniki AA, Thabane L, Linder A, et al. *Systematic reviews.* 2020;9(1):108.
619. **SARS-CoV-2 infection and glucose homeostasis in pregnancy. What about antenatal corticosteroids?** Kakoulidis I, Ilias I, Koukkou E. *Diabetes & metabolic syndrome.* 2020;14(4):519-20.

620. **Highly Conserved Homotrimer Cavity Formed by the SARS-CoV-2 Spike Glycoprotein: A Novel Binding Site.** Kalathiya U, Padariya M, Mayordomo M, Lisowska M, Nicholson J, Singh A, et al. *Journal of clinical medicine*. 2020;9(5). <http://dx.doi.org/10.3390/jcm9051473>.
621. **SARS-CoV-2 Shedding from Asymptomatic Patients: Contribution of Potential Extrapulmonary Tissue Reservoirs.** Kalker R, Goebel S, Sharma GD. *The American journal of tropical medicine and hygiene*. 2020.
622. **COVID 19 in neonates.** Kallem VR, Sharma D. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians*. 2020:1-9.
623. **Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19.** Kandasamy M. *Medicine in Drug Discovery*. 2020;6.
624. **Reply: Introducing special cutaneous "sign" tribute to healthcare workers managing new coronavirus disease (Covid -19) - New additions.** Kannangara AP. *Clinics in dermatology*. 2020.
625. **COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution.** Kansal NK. *Journal of the American Academy of Dermatology*. 2020;82(6):e213. <http://dx.doi.org/10.1016/j.jaad.2020.03.079>. Epub 2020 Apr 1.
626. **'Scientific Strabismus' or Two Related Pandemics: COVID-19 & Vitamin D Deficiency.** Kara M, Ekiz T, Ricci V, Kara Ö, Chang KV, Özçakar L. *The British journal of nutrition*. 2020:1-20.
627. **SARS-CoV-2 immunogenicity at the crossroads.** Karamloo F, König R. *Allergy*. 2020. <http://dx.doi.org/10.1111/all.14360>.
628. **Detection of severe acute respiratory syndrome Coronavirus-2 in the tears of patients with Coronavirus disease 2019.** Karimi S, Arabi A, Shahraki T, Safi S. *Eye (London, England)*. 2020.
629. **18FDG PET/CT Scan Reveals Hypoactive Orbitofrontal Cortex in Anosmia of COVID-19.** Karimi-Galougahi M, Yousefi-Koma A, Bakhshayeshkaram M, Raad N, Haseli S. *Academic radiology*. 2020.
630. **COVID-19 pneumonia and pregnancy; a systematic review and meta-analysis.** Kasraeian M, Zare M, Vafaei H, Asadi N, Faraji A, Bazrafshan K, et al. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. 2020:1-8. <http://dx.doi.org/10.1080/14767058.2020.1763952>.
631. **Refugees besieged: The lurking threat of COVID-19 in Syrian war refugee camps.** Kassem II. *Travel medicine and infectious disease*. 2020:101736.
632. **Clinical course of 2019 novel coronavirus disease (COVID-19) in individuals present during the outbreak on the Diamond Princess cruise ship.** Kato H, Shimizu H, Shibue Y, Hosoda T, Iwabuchi K, Nagamine K, et al. *Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy*. 2020. <http://dx.doi.org/10.1016/j.jiac.2020.05.005>.
633. **Repurposing Interleukin-6 Inhibitors to Combat COVID-19.** Kato S, Kurzrock R. *Journal of Immunotherapy and Precision Oncology*. 2020.
634. **Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection?** Kattan J, Kattan C, Assi T. *Immunotherapy*. 2020;12(6):351-4.
635. **Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature.** Katulanda P, Dissanayake HA, Ranathunga I, Ratnasamy V, Wijewickrama PSA, Yogendranathan N, et al.

Diabetologia. 2020.

636. **Transient cortical blindness in COVID-19 pneumonia; a PRES-like syndrome: Case report.** Kaya Y, Kara S, Akinci C, Kocaman AS. *Journal of the Neurological Sciences*. 2020;413.
637. **Elective, Non-urgent Procedures and Aesthetic Surgery in the Wake of SARS-COVID-19: Considerations Regarding Safety, Feasibility and Impact on Clinical Management.** Kaye K, Paprottka F, Escudero R, Casabona G, Montes J, Fakin R, et al. *Aesthetic plastic surgery*. 2020.
638. **2019 Novel coronavirus disease (COVID-19) in hemodialysis patients: A report of two cases.** Ke C, Wang Y, Zeng X, Yang C, Hu Z. *Clinical Biochemistry*. 2020.
639. **Artificial intelligence approach fighting COVID-19 with repurposing drugs.** Ke YY, Peng TT, Yeh TK, Huang WZ, Chang SE, Wu SH, et al. *Biomedical journal*. 2020.
640. **COVID, resilience, and the built environment.** Keenan JM. *Environment systems & decisions*. 2020:1-6. <http://dx.doi.org/10.1007/s10669-020-09773-0>.
641. **Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management.** Kelleni MT. *Pharmacological research*. 2020;157.
642. **British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic.** Kennedy NA, Jones GR, Lamb CA, Appleby R, Arnott I, Beattie RM, et al. *Gut*. 2020;69(6):984-90. <http://dx.doi.org/10.1136/gutjnl-2020-321244>. Epub 2020 Apr 17.
643. **The role of biomarkers in diagnosis of COVID-19 - A systematic review.** Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. *Life sciences*. 2020:117788.
644. **Get rid of the bad first: Therapeutic plasma exchange with convalescent plasma for severe COVID-19.** Kesici S, Yavuz S, Bayrakci B. *Proceedings of the National Academy of Sciences of the United States of America*. 2020.
645. **Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence.** Khambholja K, Asudani D. *Travel Medicine and Infectious Disease*. 2020.
646. **COVID-2019 associated overexpressed Prevotella proteins mediated host-pathogen interactions and their role in coronavirus outbreak.** Khan AA, Khan Z. *Bioinformatics (Oxford, England)*. 2020.
647. **At the heart of COVID-19.** Khan IH, Zahra SA, Zaim S, Harky A. *Journal of cardiac surgery*. 2020.
648. **Repurposed Drugs Against COVID-19: Safety Concerns and Stockout.** Khan JZ, Ali I, Hassan Z. *Hospital Pharmacy*. 2020:0018578720925387.
649. **Spectroscopy as a tool for detection and monitoring of Corona Virus (COVID-19).** Khan RS, Rehman IU. *Expert review of molecular diagnostics*. 2020.
650. **Emergence of a novel coronavirus, severe acute respiratory syndrome coronavirus 2: Biology and therapeutic options.** Khan S, Siddique R, Shereen MA, Ali A, Liu J, Bai Q, et al. *Journal of Clinical Microbiology*. 2020;58(5).
651. **COVID-19: A Worldwide, Zoonotic, Pandemic Outbreak.** Khan T, Agnihotri K, Tripathi A, Mukherjee S, Agnihotri N, Gupta G. *Alternative therapies in health and medicine*. 2020.
652. **Opioid Use Disorder and COVID-19: Crashing of the Crises.** Khatri UG, Perrone J. *Journal of addiction medicine*. 2020.

653. **Nutrition and Infection with COVID-19.** Khayyatzadeh SS. Journal of Nutrition and Food Security. 2020;5(2):93-6.
654. **Chloroquine and the potential adverse outcome in undiagnosed G6PD-deficient cases infected with COVID-19.** Khneisser I, Farra C. Journal of medical screening. 2020:969141320924452.
655. **Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19).** Khodadadi E, Maroufi P, Khodadadi E, Esposito I, Ganbarov K, Esposito S, et al. Microbial pathogenesis. 2020;146:104241.
656. **Ct diagnosis of coronavirus infection.** Kim EE. Current Medical Imaging. 2020;16(4):273.
657. **Mers-cov spike protein vaccine and inactivated influenza vaccine formulated with single strand rna adjuvant induce t-cell activation through intranasal immunization in mice.** Kim HJ, Kwak HW, Kang KW, Bang YJ, Lee YS, Park HJ, et al. Pharmaceutics. 2020;12(5).
658. **Comparative Efficacy and Safety of Pharmacological Managements for Hospitalized COVID-19 Patients: Protocol for Systematic Review and Trade-Off Network Meta-Analysis.** Kim MS, Kim WJ, An MH. medRxiv. 2020:2020.05.18.20103697.
659. **A Novel Synonymous Mutation of SARS-CoV-2: Is This Possible to Affect Their Antigenicity and Immunogenicity?** Kim SJ, Nguyen VG, Park YH, Park BK, Chung HC. Vaccines. 2020;8(2). <http://dx.doi.org/10.3390/vaccines8020220>.
660. **Characterization of the humoral immune response to porcine epidemic diarrhea virus infection under experimental and field conditions using an AlphaLISA platform.** Kimpston-Burkgren K, Mora-Díaz JC, Roby P, Bjstrom-Kraft J, Main R, Bosse R, et al. Pathogens. 2020;9(3).
661. **Type 2 Inflammation Modulates ACE2 and TMPRSS2 in Airway Epithelial Cells.** Kimura H, Francisco D, Conway M, Martinez FD, Vercelli D, Polverino F, et al. The Journal of allergy and clinical immunology. 2020.
662. **Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2.** Kiyotani K, Toyoshima Y, Nemoto K, Nakamura Y. Journal of human genetics. 2020.
663. **Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection.** Klimke A, Hefner G, Will B, Voss U. Medical hypotheses. 2020;142:109783.
664. **Letter to the Editor about the Article "Excess Mortality Estimation During the COVID-19 Pandemic: Preliminary Data from Portugal <https://doi.org/10.20344/amp.13928>".** Knight A. Acta medica portuguesa. 2020.
665. **COVID-19 Convalescent Plasma; Phase 2.** Knudson CM, Jackson JB. Transfusion. 2020.
666. **Management of ovarian cancer patients in affected areas during covid-19 pandemic: Japan and Korea.** Kobayashi Y, Suh DH, Aoki D, Kim JW. Journal of Gynecologic Oncology. 2020;31(3).
667. **A Case Report of Oligosymptomatic Kidney Transplant Patients with COVID-19: Do They Pose a Risk to Other Recipients?** Kocak B, Arpali E, Akyollu B, Yelken B, Tekin S, Kanbay M, et al. Transplantation proceedings. 2020.
668. **Blood transfusion strategies and ECMO during the COVID-19 pandemic.** Koeckerling D, Pan D, Mudalige NL, Oyefeso O, Barker J. The Lancet Respiratory medicine. 2020;8(5):e40. [http://dx.doi.org/10.1016/S2213-2600\(20\)30173-9](http://dx.doi.org/10.1016/S2213-2600(20)30173-9). Epub 2020 Apr 16.

669. **EAHP launches COVID-19 resource centre for hospital pharmacists.** Kohl S. *European Journal of Hospital Pharmacy.* 2020;27(3):182-3.
670. **Angiotensin II and COVID-19. Secrets of interactions.** Konradi AO, Nedoshivin AO. *Russian Journal of Cardiology.* 2020;25(4):72-4.
671. **SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients.** Korth J, Wilde B, Dolff S, Anastasiou OE, Krawczyk A, Jahn M, et al. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.* 2020:104437. <http://dx.doi.org/10.1016/j.jcv.2020.104437>.
672. **Diabetes and COVID-19 infection.** Kosinski C, Zanchi A, Wojtusciszyn A. *Revue medicale suisse.* 2020;16(692):939-43.
673. **Nanoscale nights of COVID-19.** Kostarelos K. *Nature Nanotechnology.* 2020;15(5):343-4.
674. **Project design of a device for express analysis for Coronaviridae antigens based on Omron industrial programmable logic controller.** Kostarev SN, Kochetova OV, Tatarnikova NA, Sereda TG. *International Journal of Biology and Biomedical Engineering.* 2020;14:21-32.
675. **Use of statins in patients with COVID-19.** Kow CS. *QJM : monthly journal of the Association of Physicians.* 2020.
676. **Glucocorticoid versus immunoglobulin in the treatment of COVID-19-associated fulminant myocarditis.** Kow CS, Hasan SS. *Infection.* 2020.
677. **Effects of 5-alpha reductase inhibitors on lung function: a reason for discontinuation during COVID-19 pandemic?** Kroumpouzou G. *Dermatologic therapy.* 2020:e13535.
678. **Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG.** Krüttgen A, Cornelissen CG, Dreher M, Hornef M, Imöhl M, Kleines M. *Journal of Clinical Virology.* 2020;128.
679. **Should coronavirus disease 2019 concern rheumatologists?** Kucharz EJ. *Polish archives of internal medicine.* 2020.
680. **Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure.** Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. *Annals of internal medicine.* 2020. <http://dx.doi.org/10.7326/M20-1495>.
681. **Urgent reconsideration of lung edema as a preventable outcome in COVID-19: Inhibition of TRPV4 represents a promising and feasible approach.** Kuebler WM, Jordt SE, Liedtke WB. *American journal of physiology Lung cellular and molecular physiology.* 2020.
682. **G6PD deficiency-associated hemolysis and methemoglobinemia in a COVID-19 patient treated with chloroquine.** Kuipers MT, van Zwieten R, Heijmans J, Rutten CE, de Heer K, Kater AP, et al. *American journal of hematology.* 2020.
683. **Treatment of COVID-19 exacerbated asthma: should systemic corticosteroids be used?** Kumar K, Hinks TS, Singanayagam A. *American journal of physiology Lung cellular and molecular physiology.* 2020.
684. **A chronicle of SARS-CoV-2: Part-I - Epidemiology, diagnosis, prognosis, transmission and treatment.** Kumar M, Taki K, Gahlot R, Sharma A, Dhangar K. *Science of the Total Environment.* 2020;734.
685. **Cardiovascular system and COVID-19: perspectives from a developing country.** Kunal S, Gupta K,

Sharma SM, Pathak V, Mittal S, Tarke C. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace. 2020;90(2).

686. **Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target.** Kundu D, Selvaraj C, Singh SK, Dubey VK. J Biomol Struct Dyn. 2020:1-9.

687. **Demand for BCG Vaccine Due to Unproven Claims of its Role in Preventing COVID-19 Is Causing Shortages of Vaccines for Infants in Japan.** Kuroda N. The Pediatric infectious disease journal. 2020.

688. **COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities.** Ky B, Mann DL. JACC: Basic to Translational Science. 2020:501-17.

689. **Arterial Mesenteric Thrombosis as a Complication of SARS-CoV-2 Infection.** L AB, Pacioni C, Ponton S, Francavilla S, Cuzzoli A. European journal of case reports in internal medicine. 2020;7(5):001690. http://dx.doi.org/10.12890/2020_001690. eCollection 2020.

690. **COVID-19: lessons from the Italian reproductive medical experience.** La Marca A, Niederberger C, Pellicer A, Nelson SM. Fertility and Sterility. 2020;113(5):920-2.

691. **Coronavirus in water environments: Occurrence, persistence and concentration methods - A scoping review.** La Rosa G, Bonadonna L, Lucentini L, Kenmoe S, Suffredini E. Water Research. 2020;179.

692. **Chloroquine and hydroxychloroquine during pregnancy: What do we know?** Lacroix I, Bénévent J, Damase-Michel C. Therapie. 2020.

693. **COVID-19 infection also occurs in patients taking hydroxychloroquine.** Lahouati M, Mériçlier E, Martin L, Bouchet S, Desclaux A, Bonnet F. The Journal of antimicrobial chemotherapy. 2020.

694. **CT chest findings in coronavirus disease-19 (COVID-19).** Lal A, Mishra AK, Sahu KK. Journal of the Formosan Medical Association. 2020;119(5):1000-1.

695. **The dark cloud with a silver lining: Assessing the impact of the SARS COVID-19 pandemic on the global environment.** Lal P, Kumar A, Kumar S, Kumari S, Saikia P, Dayanandan A, et al. Science of the Total Environment. 2020;732.

696. **Evaluation of a rapid diagnostic assay for detection of SARS CoV-2 antigen in nasopharyngeal swab.** Lambert-Niclot S, Cuffel A, Le Pape S, Vauloup-Fellous C, Morand-Joubert L, Roque-Afonso AM, et al. Journal of clinical microbiology. 2020.

697. **Sars-cov-2 infection virological diagnosis.** Lamia T, Salma M, Habiba N, Amine JM, Naila H, Lamia FB, et al. Tunisie Medicale. 2020;98(4):304-8.

698. **Expression of the COVID-19 receptor ACE2 in the human conjunctiva.** Lange C, Wolf J, Auw-Haedrich C, Schlecht A, Boneva S, Lapp T, et al. Journal of medical virology. 2020.

699. **Host factors affecting generation of immunity against porcine epidemic diarrhea virus in pregnant and lactating swine and passive protection of neonates.** Langel SN, Wang Q, Vlasova AN, Saif LJ. Pathogens. 2020;9(2).

700. **COVID-19 convalescent plasma transfusion.** Langhi DM, Santis GCD, Bordin JO. Hematology, Transfusion and Cell Therapy. 2020.

701. **COVID-19: beta-thalassemia subjects immunised?** Lansiaux E, Pebay PP, Picard JL, Son-Forget J. Med Hypotheses. 2020;142:109827. <http://dx.doi.org/10.1016/j.mehy.2020.109827>.

702. **Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID -19 infected patients.** Lanza F, Seghatchian J. *British journal of haematology*. 2020.
703. **Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID-19 pandemic.** Larrouquere L, Gabin M, Poingt E, Mouffak A, Hlavaty A, Lepelley M, et al. *Fundamental & clinical pharmacology*. 2020.
704. **COVID-19 and the Cerebro-Cardiovascular Systems: What do we Know so Far?** Larson AS, Savastano L, Kadirvel R, Kallmes DF, Hassan AE, Brinjikji W. *Journal of the American Heart Association*. 2020:e016793.
705. **Use of antimalarial drugs in the treatment of COVID-19: A window of opportunity?** Lasheras I, Santabárbara J. *Medicina clinica*. 2020.
706. **Covid-19 and children with immune thrombocytopenia: Emerging issues.** Lassandro G, Palladino V, Palmieri VV, Amoroso A, Del Vecchio GC, Giordano P. *Mediterranean Journal of Hematology and Infectious Diseases*. 2020;12(1).
707. **Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019.** Latif F, Farr MA, Clerkin KJ, Habal MV, Takeda K, Naka Y, et al. *JAMA cardiology*. 2020.
708. **Fighting COVID-19 with water.** Lauc G, Markotić A, Gornik I, Primorac D. *Journal of global health*. 2020;10(1):010344.
709. **Concomitant acute aortic thrombosis and pulmonary embolism complicating COVID-19 pneumonia.** Le Berre A, Marteau V, Emmerich J, Zins M. *Diagnostic and Interventional Imaging*. 2020;101(5):321-2.
710. **Reply to: "COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution".** Lebowhl M, Rivera-Oyola R, Murrell DF. *Journal of the American Academy of Dermatology*. 2020;82(6):e215.
711. **Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control.** Lee CYP, Lin RTP, Renia L, Ng LFP. *Frontiers in Immunology*. 2020;11.
712. **Effective strategies to prevent coronavirus disease-2019 (COVID-19) outbreak in hospital.** Lee IK, Wang CC, Lin MC, Kung CT, Lan KC, Lee CT. *Journal of Hospital Infection*. 2020;105(1):102-3.
713. **Rapid expansion of temporary, reliable airborne-infection isolation rooms with negative air machines for critical COVID-19 patients.** Lee JK, Jeong HW. *American journal of infection control*. 2020.
714. **Covert COVID-19 complications: Continuing the use of evidence-based drugs to minimize potentially lethal indirect effects of the pandemic in stroke patients.** Lee M, Chen CHS, Ovbiagele B. *Journal of the Neurological Sciences*. 2020;414.
715. **Implementation of an Emergency Use Authorization Test During an Impending National Crisis.** Lefferts JA, Gutmann EJ, Martin IW, Wells WA, Tsongalis GJ. *The Journal of molecular diagnostics : JMD*. 2020.
716. **Longitudinal association between markers of liver injury and mortality in COVID-19 in China.** Lei F, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L, et al. *Hepatology (Baltimore, Md)*. 2020.
717. **Multiple parameters required for diagnosis of COVID-19 in clinical practice.** Lei P, Fan B, Mao J, Wang P. *Journal of Infection*. 2020;80(6):e27-e8.
718. **Does intranasal naloxone administration increase the risk of COVID-19 transmission?** Leong YC,

Verbeek PR. CJEM. 2020:1-3.

719. **COVID-19 and Nicotine as a Mediator of ACE-2.** Leung JM, Yang CX, Sin DD. The European respiratory journal. 2020.
720. **Respiratory virus shedding in exhaled breath and efficacy of face masks.** Leung NHL, Chu DKW, Shiu EYC, Chan KH, McDevitt JJ, Hau BJP, et al. Nature Medicine. 2020.
721. **Presumed COVID-19 Index Case on Diamond Princess cruise ship and Evacuees to Hong Kong.** Leung WS, Chan JMC, Chik TSH, Lau DPL, Choi CYC, Lau AWT, et al. Journal of travel medicine. 2020.
722. **Is the HScore useful in COVID-19?** Leverenz DL, Tarrant TK. The Lancet. 2020;395(10236):e83.
723. **Tocilizumab for severe COVID-19: a promising intervention affecting inflammation and coagulation.** Levi M. European journal of internal medicine. 2020.
724. **Recent progress on the diagnosis of 2019 Novel Coronavirus.** Li C, Ren L. Transboundary and emerging diseases. 2020.
725. **The viral, epidemiologic, clinical characteristics and potential therapy options for COVID-19: a review.** Li C, Xu BH. European review for medical and pharmacological sciences. 2020;24(8):4576-84.
726. **Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: insights from ERS-COVID-19 study.** Li D, Chen Y, Liu H, Jia Y, Li F, Wang W, et al. Signal Transduction and Targeted Therapy. 2020;5(1).
727. **Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis.** Li H, Chen C, Hu F, Wang J, Zhao Q, Gale RP, et al. Leukemia. 2020.
728. **SARS-CoV-2 and viral sepsis: observations and hypotheses.** Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. The Lancet. 2020;395(10235):1517-20.
729. **Transient appearance of EDTA dependent pseudothrombocytopenia in a patient with 2019 novel coronavirus pneumonia.** Li H, Wang B, Ning L, Luo Y, Xiang S. Platelets. 2020:1-2.
730. **An infant with a mild SARS-CoV-2 infection detected only by anal swabs: a case report.** Li J, Feng J, Liu TH, Xu FC, Song GQ. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. 2020.
731. **Air quality changes during the COVID-19 lockdown over the Yangtze River Delta Region: An insight into the impact of human activity pattern changes on air pollution variation.** Li L, Li Q, Huang L, Wang Q, Zhu A, Xu J, et al. Science of the Total Environment. 2020;732.
732. **Digestive system involvement of novel coronavirus infection: Prevention and control infection from a gastroenterology perspective.** Li LY, Wu W, Chen S, Gu JW, Li XL, Song HJ, et al. Journal of Digestive Diseases. 2020;21(4):199-204.
733. **CT imaging features and image evolution characteristics of coronavirus disease 2019.** Li M, Peng W, Chen M, Zhu Q, Zou X, Long X. Zhong nan da xue xue bao Yi xue ban = Journal of Central South University Medical sciences. 2020;45(3):243-9.
734. **Modeling the impact of mass influenza vaccination and public health interventions on COVID-19 epidemics with limited detection capability.** Li Q, Tang B, Bragazzi NL, Xiao Y, Wu J. Mathematical biosciences.

2020:108378.

735. **Therapeutic targets and signaling mechanisms of vitamin C activity against sepsis: a bioinformatics study.** Li R, Guo C, Li Y, Qin Z, Huang W. *Briefings in bioinformatics*. 2020.
736. **COVID-19 receptor ACE2 is expressed in human conjunctival tissue, especially in diseased conjunctival tissue.** li s, li d, fang j, liu q, sun x, xu g, et al. *medRxiv*. 2020:2020.05.21.20109652.
737. **Clinical and CT imaging features between the first nucleic acid-negative and first nucleic acid-positive COVID-19 patients.** Li S, Liu J, Xiong Z, Luo W, Tang H, Pend W, et al. *Zhong nan da xue xue bao Yi xue ban = Journal of Central South University Medical sciences*. 2020;45(3):257-61.
738. **Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019 in Shanghai, China.** Li X, Guo Z, Li B, Zhang X, Tian R, Wu W, et al. *ASAIO Journal*. 2020:475-81.
739. **Acute respiratory failure in COVID-19: is it "typical" ARDS?** Li X, Ma X. *Critical care (London, England)*. 2020;24(1):198.
740. **Organ function support in patients with coronavirus disease 2019: Tongji experience.** Li Y, He F, Zhou N, Wei J, Ding Z, Wang L, et al. *Frontiers of medicine*. 2020;14(2):232-48. <http://dx.doi.org/10.1007/s11684-020-0774-9>. Epub 2020 May 14.
741. **Follow-up testing of viral nucleic acid in discharged patients with moderate type of COVID-19.** Li Y, Hu Y, Zhang X, Yu Y, Li B, Wu J, et al. *Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences*. 2020;49(2):270-4.
742. **The MERS-CoV receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike.** Li Y, Zhang Z, Yang L, Lian X, Xie Y, Li S, et al. *iScience*. 2020:101160. <http://dx.doi.org/10.1016/j.isci.2020.101160>.
743. **Dynamic relationship between D-dimer and COVID-19 severity.** Li Y, Zhao K, Wei H, Chen W, Wang W, Jia L, et al. *British journal of haematology*. 2020.
744. **Epidemiological, clinical, and virological characteristics of 465 hospitalized cases of coronavirus disease 2019 (COVID-19) from Zhejiang province in China.** Lian J, Jin X, Hao S, Jia H, Cai H, Zhang X, et al. *Influenza and other respiratory viruses*. 2020.
745. **Comparison of epidemiological and clinical characteristics of COVID-19 patients with and without Wuhan exposure.** Lian JS, Cai H, Hao SR, Jin X, Zhang XL, Zheng L, et al. *Journal of Zhejiang University: Science B*. 2020.
746. **Liver injury in COVID-19: diagnosis and associated factors - authors' reply.** Lian N, Lin S, Xie H. *Liver international : official journal of the International Association for the Study of the Liver*. 2020.
747. **Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19.** Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. *JAMA internal medicine*. 2020.
748. **Can N95 Respirators Be Reused after Disinfection? How Many Times?** Liao L, Xiao W, Zhao M, Yu X, Wang H, Wang Q, et al. *ACS nano*. 2020.
749. **The Heart in COVID-19: Primary Target or Secondary Bystander?** Libby P. *JACC: Basic to Translational Science*. 2020;5(5):537-42.
750. **Zinc: The Gatekeeper of Immune Function.** Lim E.

751. **Herd immunity and a vaccination game: An experimental study.** Lim W, Zhang P. PLoS One. 2020;15(5):e0232652. <http://dx.doi.org/10.1371/journal.pone.0232652>. eCollection 2020.
752. **COVID-19 and Older People in Asia: AWGS Calls to Actions.** Lim WS, Liang CK, Assantachai P, Auyeung TW, Kang L, Lee WJ, et al. Geriatrics & gerontology international. 2020.
753. **The isolation period should be longer: Lesson from a child infected with SARS-CoV-2 in Chongqing, China.** Lin J, Duan J, Tan T, Fu Z, Dai J. Pediatr Pulmonol. 2020;55(6):E6-e9. <http://dx.doi.org/10.1002/ppul.24763>. Epub 2020 Apr 3.
754. **Impacts of remdesivir on dynamics and efficacy stratified by the severity of COVID- 19: a simulated two-arm controlled study.** Lin T-Y, Chang W-J, Hsu C-Y, Lai C-C, Yen AM-F, Chen SL-S, et al. medRxiv. 2020:2020.05.17.20104711.
755. **Heparin - an old drug with multiple potential targets in Covid-19 therapy.** Lindahl U, Li JP. Journal of thrombosis and haemostasis : JTH. 2020.
756. **Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients.** Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, et al. Chinese medical journal. 2020;133(9):1039-43.
757. **D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis.** Lippi G, Favaloro EJ. Thrombosis and Haemostasis. 2020;120(5):876-7.
758. **Current laboratory diagnostics of coronavirus disease 2019 (COVID-19).** Lippi G, Mattiuzzi C, Bovo C, Plebani M. Acta bio-medica : Atenei Parmensis. 2020;91(2):137-45.
759. **Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine.** Litaïem N, Hajlaoui K, Karray M, Slouma M, Zeglaoui F. Dermatologic therapy. 2020:e13565.
760. **COVID-19 in Older People: A Rapid Clinical Review.** Lithander FE, Neumann S, Tenison E, Lloyd K, Welsh TJ, Rodrigues JCL, et al. Age and ageing. 2020.
761. **Hydroxychloroquine use in the COVID-19 patient.** Littlejohn E. Cleveland Clinic journal of medicine. 2020.
762. **Keeping lupus patients on hydroxychloroquine during the COVID-19 pandemic.** Littlejohn E. Cleveland Clinic journal of medicine. 2020.
763. **Free DNA, a reason for severe COVID-19 infection?** Liu B. Medical Hypotheses. 2020;142.
764. **Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study.** Liu C, Jiang ZC, Shao CX, Zhang HG, Yue HM, Chen ZH, et al. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology. 2020;28(2):107-11.
765. **Pay attention to situation of SARS-CoV-2 and TCM advantages in treatment of novel coronavirus infection.** Liu CX. Chinese Herbal Medicines. 2020;12(2):97-103.
766. **CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients.** Liu F, Zhang Q, Huang C, Shi C, Wang L, Shi N, et al. Theranostics. 2020;10(12):5613-22.
767. **Molecular detection of SARS-CoV-2 in formalin fixed paraffin embedded specimens.** Liu J, Babka AM, Kearney BJ, Radoshitzky SR, Kuhn JH, Zeng X. JCI insight. 2020.
768. **Clinical and radiological changes of hospitalised patients with COVID-19 pneumonia from disease**

- onset to acute exacerbation: a multicentre paired cohort study.** Liu J, Chen T, Yang H, Cai Y, Yu Q, Chen J, et al. *European radiology*. 2020.
769. **Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study.** Liu K, Zhang W, Yang Y, Zhang J, Li Y, Chen Y. *Complementary therapies in clinical practice*. 2020;39:101166.
770. **Traditional Chinese medicine contributes to the treatment of COVID-19 patients.** Liu L. *Chinese Herbal Medicines*. 2020;12(2):95-6.
771. **A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients.** Liu L, Liu W, Zheng Y, Jiang X, Kou G, Ding J, et al. *Microbes and Infection*. 2020.
772. **Efficacy and Safety of Integrated Traditional Chinese and Western Medicine for Corona Virus Disease 2019 (COVID-19): a systematic review and meta-analysis.** Liu M, Gao Y, Yuan Y, Yang K, Shi S, Zhang J, et al. *Pharmacological research*. 2020:104896. <http://dx.doi.org/10.1016/j.phrs.2020.104896>.
773. **Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management.** Liu M, Wang T, Zhou Y, Zhao Y, Zhang Y, Li J. *Journal of Translational Internal Medicine*. 2020;8(1):9.
774. **COVID-19 pneumonia: CT findings of 122 patients and differentiation from influenza pneumonia.** Liu M, Zeng W, Wen Y, Zheng Y, Lv F, Xiao K. *European Radiology*. 2020.
775. **Decreased T cell populations contribute to the increased severity of COVID-19.** Liu R, Wang Y, Li J, Han H, Xia Z, Liu F, et al. *Clinica chimica acta; international journal of clinical chemistry*. 2020.
776. **Providing pharmacy services during the coronavirus pandemic.** Liu S, Luo P, Tang M, Hu Q, Polidoro JP, Sun S, et al. *International Journal of Clinical Pharmacy*. 2020;42(2):299-304.
777. **Convalescent plasma treatment of severe COVID-19: A matched control study.** Liu STH, Lin H-M, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al. *medRxiv*. 2020:2020.05.20.20102236.
778. **COVID-19: the First Documented Coronavirus Pandemic in History.** Liu YC, Kuo RL, Shih SR. *Biomedical journal*. 2020.
779. **Surface-Displayed Porcine IFN- λ 3 in Lactobacillus plantarum Inhibits Porcine Enteric Coronavirus Infection of Porcine Intestinal Epithelial Cells.** Liu YS, Liu Q, Jiang YL, Yang WT, Huang HB, Shi CW, et al. *Journal of Microbiology and Biotechnology*. 2020;30(4):515-25.
780. **Association between Initial Chest CT or Clinical Features and Clinical Course in Patients with Coronavirus Disease 2019 Pneumonia.** Liu Z, Jin C, Wu CC, Liang T, Zhao H, Wang Y, et al. *Korean journal of radiology*. 2020;21(6):736-45.
781. **Thrombotic occlusive vasculopathy in skin biopsy from a livedoid lesion of a COVID-19 patient.** Llamas-Velasco M, Muñoz-Hernández P, Lázaro-González J, Reolid-Pérez A, Abad-Santamaría B, Fraga J, et al. *The British journal of dermatology*. 2020.
782. **COVID-19: The race for a vaccine.** Lockey E. *Journal of the renin-angiotensin-aldosterone system : JRAAS*. 2020;21(2):1470320320926902.
783. **[Inpatient psychosomatics in times of the coronavirus].** Loew TH, Krinninger M, Kettler C. *Psychotherapeut*. 2020:1-6. <http://dx.doi.org/10.1007/s00278-020-00426-w>.
784. **COVID-19 and cardiovascular injury: A role for oxidative stress and antioxidant treatment?** Loffredo L,

Violi F. International Journal of Cardiology. 2020.

785. **Just the Facts: What are the roles of oxygen escalation and non-invasive ventilation in COVID-19?**

Long B, Liang SY, Hicks C, Gottlieb M. CJEM. 2020;1-9.

786. **Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).** Lopes RD, Macedo AVS, de Barros ESPGM, Moll-Bernardes RJ, Feldman A, D'Andréa Saba Arruda G, et al. American heart journal. 2020.

787. **From the handling of an outbreak by an unknown pathogen in wuhan to the preparedness and response in the face of the emergence of covid-19 in mexico.** López-Ortiz E, López-Ortiz G, Mendiola-Pastrana IR, Mazón-Ramírez JJ, Díaz-Quiñonez JA. Gaceta Medica de Mexico. 2020;156(2):132-7.

788. **Almitrine as a non ventilatory strategy to improve intrapulmonary shunt in COVID-19 patients.** Lossler MR, Lapoix C, Champigneulle B, Delannoy M, Payen JF, Payen D. medRxiv. 2020:2020.05.18.20105502.

789. **Prophylaxie post-exposition ou traitement préventif pour le syndrome respiratoire aigu sévère du coronavirus 2 (SARS-CoV-2) : protocole d'étude pour une étude randomisée contrôlée pragmatique.** Lothar SA, Abassi M, Agostinis A, Bangdiwala AS, Cheng MP, Drobot G, et al. Canadian journal of anaesthesia = Journal canadien d'anesthésie. 2020.

790. **Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.** Louapre C, Maillart E, Roux T, Pourcher V, Bussone G, Lubetzki C, et al. Revue Neurologique. 2020.

791. **Features of patients with 2019 novel coronavirus admitted in a pneumology department: The first retrospective Tunisian case series.** Louhaichi S, Allouche A, Baili H, Jrad S, Radhouani A, Greb D, et al. La Tunisie medicale. 2020;98(4):261-5.

792. **Diagnosing herpes simplex-1 encephalitis at the time of COVID-19 pandemic.** Lovati C, Osio M, Pantoni L. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2020.

793. **Detection of low levels of SARS-CoV-2 RNA from nasopharyngeal swabs using three commercial molecular assays.** Lowe CF, Matic N, Ritchie G, Lawson T, Stefanovic A, Champagne S, et al. Journal of Clinical Virology. 2020;128.

794. **Dynamic changes in routine blood parameters of a severe COVID-19 case.** Lu G, Wang J. Clinica Chimica Acta. 2020;508:98-102.

795. **Symptomatic Infection is Associated with Prolonged Duration of Viral Shedding in Mild Coronavirus Disease 2019: A Retrospective Study of 110 Children in Wuhan.** Lu Y, Li Y, Deng W, Liu M, He Y, Huang L, et al. The Pediatric infectious disease journal. 2020.

796. **COVID-19: an unexpected indication for anti-rheumatic therapies?** Lucchino B, Di Franco M, Conti F. Rheumatology (Oxford, England). 2020.

797. **Utility Evaluation of Porcine Enteroids as PDCoV Infection Model in vitro.** Luo H, Zheng J, Chen Y, Wang T, Zhang Z, Shan Y, et al. Frontiers in Microbiology. 2020;11.

798. **Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers.** Luo J, Rizvi H, Egger JV, Preeshagul IR, Wolchok JD, Hellmann MD. Cancer discovery. 2020.

799. **Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab.** Luo

S, Yang L, Wang C, Liu C, Li D. Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences. 2020;49(2):227-31.

800. **A family outbreak of coronavirus disease 2019.** Luo W, Xiong Z, Tang H, Zhou H. Zhong nan da xue xue bao Yi xue ban = Journal of Central South University Medical sciences. 2020;45(3):275-9.

801. **Management of pregnant women infected with COVID-19.** Luo Y, Yin K. The Lancet Infectious Diseases. 2020;20(5):513-4.

802. **Using the diagnostic model based on routine laboratory tests to distinguish patients infected with SARS-CoV-2 from those infected with influenza virus.** Luo Y, Yuan X, Xue Y, Mao L, Lin Q, Tang G, et al. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020.

803. **Using a diagnostic model based on routine laboratory tests to distinguish patients infected with SARS-CoV-2 from those infected with influenza virus.** Luo Y, Yuan X, Xue Y, Mao L, Lin Q, Tang G, et al. International Journal of Infectious Diseases. 2020;95:436-40.

804. **Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.** Lv H, Wu NC, Tak-Yin Tsang O, Yuan M, Perera RAPM, Leung WS, et al. Cell reports. 2020:107725.

805. **Clinical characteristics and co-infections of 354 hospitalized patients with COVID-19 in Wuhan, China: a retrospective cohort study.** Lv Z, Cheng S, Le J, Huang J, Feng L, Zhang B, et al. Microbes and infection. 2020.

806. **Ongoing Clinical Trials for the Management of the COVID-19 Pandemic.** Lythgoe MP, Middleton P. Trends in pharmacological sciences. 2020;41(6):363-82. <http://dx.doi.org/10.1016/j.tips.2020.03.006>. Epub 2020 Apr 9.

807. **Reflection on lower rates of COVID-19 in children: does childhood immunizations offer unexpected protection?** Lyu J, Miao T, Dong J, Cao R, Li Y, Chen Q. Medical hypotheses. 2020:109842.

808. **A single-center, retrospective study of COVID-19 features in children: A descriptive investigation.** Ma H, Hu J, Tian J, Zhou X, Li H, Laws MT, et al. BMC Medicine. 2020;18(1).

809. **Headache medication and the COVID-19 pandemic.** MaassenVanDenBrink A, de Vries T, Danser AHJ. J Headache Pain. 2020;21(1):38-.

810. **Could Patients With Inflammatory Bowel Disease Treated with Immunomodulators or Biologics Be at Lower Risk for Severe Forms of Covid-19?** Macaluso FS, Orlando A. Gastroenterology. 2020.

811. **Relation between BCG coverage rate and COVID-19 infection worldwide.** Macedo A, Febra C. Medical Hypotheses. 2020;142.

812. **Preventing adverse cutaneous reactions from amplified hygiene practices during the COVID-19 pandemic: how dermatologists can help through anticipatory guidance.** MacGibeny MA, Wassef C. Archives of dermatological research. 2020.

813. **Extracorporeal Membrane Oxygenation for Pediatric Patients With Coronavirus Disease 2019-Related Illness.** MacGregor RM, Antiel RM, Najaf T, Said AS, Warner BW, Raval MV, et al. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2020. <http://dx.doi.org/10.1097/PCC.0000000000002432>.

814. **Similar incidence of Coronavirus Disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy.** Macias J, Gonzalez-Moreno P, Sanchez-Garcia E, Morillo-Verdugo R, Dominguez-Quesada C, Pinilla A, et al. medRxiv. 2020:2020.05.16.20104141.

815. **Need of the Hour- COVID-19 for Cardiologists.** Maddury J, Paramjyothi GK. Indian Journal of Cardiovascular Disease in Women - WINCARS. 2020;5(1):04-7.
816. **De første kliniske data fra RASi-behandlede indlagte patienter med COVID-19 kommer nu, og vi skal ikke ændre mediciner.** Madsen PL. Ugeskrift for læger. 2020;182(20).
817. **Prevalence of IgG antibodies to SARS-CoV-2 among emergency department employees.** Madsen T, Levin N, Niehus K, Law K, Mayer J, Chapman M, et al. The American journal of emergency medicine. 2020.
818. **COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?** Maes T, Bracke K, Brusselle GG. American Journal of Respiratory and Critical Care Medicine. 2020.
819. **Vitamin D and coronavirus: A new field of use?** Maestri E, Formoso G, da Cas R, Mammarella F, Guerrizio MA, Trotta F. Recenti progressi in medicina. 2020;111(4):253-6.
820. **A Review: Does Complement or the Contact System Have a Role in Protection or Pathogenesis of COVID-19?** Maglakelidze N, Manto KM, Craig TJ. Pulmonary therapy. 2020. <http://dx.doi.org/10.1007/s41030-020-00118-5>.
821. **Cytokine Storm: Is it the only major death factor in COVID-19 patients? Coagulation role.** Magro G. Medical Hypotheses. 2020;142.
822. **Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an in silico based approach.** Mahanta S, Chowdhury P, Gogoi N, Goswami N, Borah D, Kumar R, et al. J Biomol Struct Dyn. 2020:1-15. <http://dx.doi.org/10.1080/07391102.2020.1768902>.
823. **Covid-19: Remdesivir is helpful but not a wonder drug, say researchers.** Mahase E. BMJ (Clinical research ed). 2020;369:m1798.
824. **Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.** Mahevas M, Tran VT, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Bmj. 2020;369:m1844. <http://dx.doi.org/10.1136/bmj.m1844>.
825. **Emerging Biomolecular Testing to Assess Risk of Mortality from COVID-19 Infection.** Mahmoudi M. Molecular pharmaceutics. 2020.
826. **Falsely low fibrinogen levels in COVID-19 patients on direct thrombin inhibitors.** Maier CL, Barker NA, Sniecinski RM. Anesthesia and analgesia. 2020.
827. **COVID-19 and the Renin-Angiotensin System.** Malha L, Mueller FB, Pecker MS, Mann SJ, August P, Feig PU. Kidney International Reports. 2020;5(5):563-5.
828. **A Viewpoint on Angiotensin-Converting Enzyme 2, Anti-Hypertensives and Coronavirus Disease 2019 (COVID-19).** Mali SN, Thorat BR, Chopade AR. Infectious disorders drug targets. 2020.
829. **Maximising application of the Aerosol Box in protecting healthcare workers during the covid-19 pandemic.** Malik JS, Jenner C, Ward PA. Anaesthesia. 2020.
830. **Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given.** Malviya A. Indian Heart Journal. 2020.
831. **Resuscitation of the patient with suspected/confirmed COVID-19 when wearing personal protective equipment: A randomized multicenter crossover simulation trial.** Malysz M, Dabrowski M, Bottiger BW, Smereka

J, Kulak K, Szarpak A, et al. *Cardiology journal*. 2020. <http://dx.doi.org/10.5603/CJ.a2020.0068>.

832. **Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?** Mamber SW, Krakowka S, Osborn J, Saberski L, Rhodes RG, Dahlberg AE, et al. *mSphere*. 2020;5(3).

833. **COVID-19 pandemic persuaded lockdown effects on environment over stone quarrying and crushing areas.** Mandal I, Pal S. *Science of the Total Environment*. 2020;732.

834. **Evaluation of SARS-CoV-2 neutralizing antibodies using of a CPE-based Colorimetric live virus micro-neutralization assay in human serum samples.** Manenti A, Maggetti M, Casa E, Martinuzzi D, Torelli A, Trombetta CM, et al. *Journal of medical virology*. 2020.

835. **β -Arrestin-Biased Angiotensin II Receptor Agonists for COVID-19.** Manglik A, Wingler LM, Rockman HA, Lefkowitz RJ. *Circulation*. 2020.

836. **Understanding COVID-19: Digit ratio (2D:4D) and sex differences in national case fatality rates.** Manning JT, Fink B. *Early Human Development*. 2020;146.

837. **Letter: low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity.** Mansur J. *Alimentary pharmacology & therapeutics*. 2020.

838. **A child with household transmitted COVID-19.** Mao LJ, Xu J, Xu ZH, Xia XP, Li B, He JG, et al. *BMC infectious diseases*. 2020;20(1):329.

839. **The COVID-19 Pandemic: Consideration for Brain Infection.** Mao XY, Jin WL. *Neuroscience*. 2020;437:130-1.

840. **Biologics for patients affected by Hidradenitis suppurativa in the COVID-19 era: data from a referral centre of Southern Italy.** Marasca C, Ruggiero A, Megna M, Annunziata MC, Fabbrocini G. *The Journal of dermatological treatment*. 2020:1-3.

841. **Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers.** Mareev YV, Mareev VY. *Kardiologiia*. 2020;60(4):4-9.

842. **Diabetes and metabolic syndrome as risk factors for COVID-19.** Marhl M, Grubelnik V, Magdič M, Markovič R. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2020;14(4):671-7.

843. **Organ replacement therapy and life-supporting treatment modalities in critically ill COVID-19 patients.** Mariann B, Ákos F, István L, Tamás V, Csilla M, Béla F, et al. *Orvosi Hetilap*. 2020;161(17):704-9.

844. **Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19.** Marinella MA. *International journal of clinical practice*. 2020:e13535.

845. **What is the role of rheumatologists in the era of COVID-19?** Marotto D, Sarzi-Puttini P. *Autoimmun Rev*. 2020;19(6):102539. <http://dx.doi.org/10.1016/j.autrev.2020.102539>. Epub 2020 Apr 3.

846. **Colorectal cancer care in the age of coronavirus: Strategies to reduce risk and maintain benefit.** Marshall JL, Yarden RI, Weinberg BA. *Colorectal Cancer*. 2020;9(1).

847. **Could nasal nitric oxide help to mitigate the severity of COVID-19?** Martel J, Ko YF, Young JD, Ojcius DM. *Microbes and Infection*. 2020.

848. **Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment.** Martín Giménez VM, Inserra F, Tajer CD, Mariani J, Ferder L,

Reiter RJ, et al. Life sciences. 2020;254.

849. **Hydroxychloroquine in COVID-19 patients: what still needs to be known about the kinetics.** Martin-Blondel G, Ruiz S, Murriss M, Faguer S, Duhalde V, Eyraud F, et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020.
850. **Pulmonary embolism in a young pregnant woman with COVID-19.** Martinelli I, Ferrazzi E, Ciavarella A, Erra R, Iurlaro E, Ossola M, et al. Thrombosis Research. 2020;191:36-7.
851. **Coronavirus (COVID-19): A protocol for prevention, treatment and control.** Marwah A, Marwah P. Journal of Applied and Natural Science. 2020:119-23.
852. **Pathogenesis of COVID-19 from a cell biology perspective.** Mason RJ. European Respiratory Journal. 2020;55(4).
853. **The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.** Mastaglio S, Ruggeri A, Risitano AM, Angelillo P, Yancopoulos D, Mastellos DC, et al. Clinical Immunology. 2020;215.
854. **The first, holistic immunological model of COVID-19: implications for prevention, diagnosis, and public health measures.** Matricardi PM, Dal Negro RW, Nisini R. Pediatric Allergy and Immunology. 2020.
855. **Impact of COVID-19 on the cardiovascular system: A review.** Matsushita K, Marchandot B, Jesel L, Ohlmann P, Morel O. Journal of Clinical Medicine. 2020;9(5).
856. **Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.** Matucci-Cerinic M, Bruni C, Allanore Y, Clementi M, Dagna L, Damjanov NS, et al. Annals of the Rheumatic Diseases. 2020.
857. **A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis.** Mazza S, Sorce A, Peyvandi F, Vecchi M, Caprioli F. Gut. 2020;69(6):1148-9. <http://dx.doi.org/10.1136/gutjnl-2020-321183>. Epub 2020 Apr 3.
858. **Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine.** McCarthy MW. Expert review of anti-infective therapy. 2020:1-7.
859. **Molecular biologists offer “wartime service” in the effort to test for COVID-19.** McDermott A. Proceedings of the National Academy of Sciences of the United States of America. 2020;117(18):9656-9.
860. **Visualizing the invisible: class excursions to ignite children’s enthusiasm for microbes.** McGenity TJ, Gessesse A, Hallsworth JE, Garcia Cela E, Verheecke-Vaessen C, Wang F, et al. Microbial Biotechnology. 2020.
861. **Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia.** McGonagle D, O'Donnell JS, Sharif K, Emery P, Bridgewood C. The Lancet Rheumatology. 2020.
862. **Re: Patiently waiting for the results of anti-IL 6 therapy in severe COVID-19 infection.** McGonagle D, Sharif K, O'Regan A, Bridgewood C. Autoimmunity Reviews. 2020.
863. **Employing Drug Delivery Strategies to Create Safe and Effective Pharmaceuticals for COVID-19.** McHugh KJ. Bioengineering and Translational Medicine. 2020.
864. **Mechanisms of increased morbidity and mortality of SARS-CoV-2 infection in individuals with diabetes: what this means for an effective management strategy.** Means C. Metabolism: Clinical and Experimental. 2020;108.

865. **Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?** Megarbane B, Scherrmann JM. *J Clin Pharmacol*. 2020. <http://dx.doi.org/10.1002/jcph.1646>.
866. **Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.** Mehra MR, Desai SS, Ruschitzka F, Patel AN. *The Lancet*. 2020.
867. **Novel coronavirus-related acute respiratory distress syndrome in a patient with twin pregnancy: A case report.** Mehta H, Ivanovic S, Cronin A, VanBrunt L, Mistry N, Miller R, et al. *Case reports in women's health*. 2020:e00220. <http://dx.doi.org/10.1016/j.crwh.2020.e00220>.
868. **Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Testing Positive for Coronavirus Disease 2019 (COVID-19).** Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, et al. *JAMA Cardiology*. 2020.
869. **Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients.** Menezes-Rodrigues FS, Padrão Tavares JG, Pires de Oliveira M, Guzella de Carvalho R, Ruggero Errante P, Omar Taha M, et al. *Journal of thrombosis and haemostasis : JTH*. 2020.
870. **Providing pharmacy services at cabin hospitals at the coronavirus epicenter in China.** Meng L, Qiu F, Sun S. *International Journal of Clinical Pharmacy*. 2020;42(2):305-8.
871. **SARS-CoV-2 detection by direct rRT-PCR without RNA extraction.** Merindol N, Pépin G, Marchand C, Rheault M, Peterson C, Poirier A, et al. *Journal of Clinical Virology*. 2020;128.
872. **COVID-19 outbreak in Iraqi Kurdistan: The first report characterizing epidemiological, clinical, laboratory, and radiological findings of the disease.** Merza MA, Haleem Al Mezori AA, Mohammed HM, Abdulah DM. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2020;14(4):547-54.
873. **CORONAVIRUS DISEASE 2019 IN NEWBORNS AND VERY YOUNG INFANTS: A SERIES OF SIX PATIENTS IN FRANCE.** Meslin P, Guiomard C, Chouakria M, Porcher J, Duquesne F, Tiprez C, et al. *The Pediatric infectious disease journal*. 2020.
874. **Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection.** Micallef J, Soeiro T, Jonville-Béra AP. *Thérapie*. 2020.
875. **French Association of Urology. COVID-19: Recommendations for functional urology.** Michel F, Gaillet S, Cornu JN, Robert G, Game X, Phé V, et al. *Progres en urologie : journal de l'Association française d'urologie et de la Société française d'urologie*. 2020.
876. **Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.** Michelena X, Borrell H, Lopez-Corbeto M, Lopez-Lasanta M, Moreno E, Pascual-Pastor M, et al. *Seminars in arthritis and rheumatism*. 2020. <http://dx.doi.org/10.1016/j.semarthrit.2020.05.001>.
877. **Clinical presentation and course of COVID-19.** Miller R, Englund K. *Cleveland Clinic journal of medicine*. 2020.
878. **SARS-CoV-2 receptor *ACE2* gene expression and RAAS inhibitors.** Milne S, Yang CX, Timens W, Bossé Y, Sin DD. *The Lancet Respiratory Medicine*. 2020.
879. **Panic of buying toilet papers: A historical memory or a horrible truth? systematic review of gastrointestinal manifestations of COVID-19.** Miri SM, Roozbeh F, Omranirad A, Alavian SM. *Hepatitis Monthly*. 2020;20(3).

880. **Comment on Matricardi PM et al.: The first, holistic immunological model of COVID-19: implications for prevention, diagnosis, and public health measures.** Mirijello A, D'Errico MM, Lamarca A, Piscitelli P, De Cosmo S. *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology*. 2020.
881. **Practice Considerations for Proton Beam Radiation Therapy of Uveal Melanoma During the Coronavirus Disease Pandemic: Particle Therapy Co-Operative Group Ocular Experience.** Mishra KK, Afshar A, Thariat J, Shih HA, Scholey JE, Daftari IK, et al. *Advances in Radiation Oncology*. 2020.
882. **Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach.** Mittal L, Kumari A, Srivastava M, Singh M, Asthana S. *Journal of biomolecular structure & dynamics*. 2020:1-26.
883. **Serum amyloid A is a predictor for prognosis of COVID-19.** Mo XN, Su ZQ, Lei CL, Chen DF, Peng H, Chen RC, et al. *Respirology*. 2020.
884. **The French response to COVID-19: intrinsic difficulties at the interface of science, public health, and policy.** Moatti JP. *The Lancet Public Health*. 2020;5(5):e255.
885. **Newly Diagnosed Glomerulonephritis During COVID-19 Infection Undergoing Immunosuppression Therapy, a Case Report.** Moeinzadeh F, Dezfouli M, Naimi A, Shahidi S, Moradi H. *Iranian journal of kidney diseases*. 2020;14(3):239-42.
886. **Role of increasing the aerobic capacity on improving the function of immune and respiratory systems in patients with coronavirus (COVID-19): A review.** Mohamed AA, Alawna M. *Diabetes & metabolic syndrome*. 2020;14(4):489-96.
887. **Our recommendations for acute management of COVID-19.** Mojoli F, Mongodi S, Orlando A, Arisi E, Pozzi M, Civardi L, et al. *Crit Care*. 2020;24(1):207. <http://dx.doi.org/10.1186/s13054-020-02930-6>.
888. **Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens.** Momekov G, Momekova D. *medRxiv*. 2020:2020.04.11.20061804.
889. **Pharmacological characteristics of patients infected with SARS-Cov-2 admitted to Intensive Care Unit in South of France.** Montastruc F, Romano C, Montastruc JL, Silva S, Seguin T, Minville V, et al. *Therapie*. 2020.
890. **Colchicine: a potential therapeutic tool against COVID-19. Experience of 5 patients.** Montealegre-Gómez G, Garavito E, Gómez-López A, Rojas-Villarraga A, Parra-Medina R. *Reumatología clínica*. 2020.
891. **Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain.** Montero-Escribano P, Matías-Guiu J, Gómez-Iglesias P, Porta-Etessam J, Pytel V, Matias-Guiu JA. *Multiple Sclerosis and Related Disorders*. 2020;42.
892. **Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies.** Montesinos I, Gruson D, Kabamba B, Dahma H, Van den Wijngaert S, Reza S, et al. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2020;128:104413.
893. **Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: 'Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: Lessons from a case with severe pneumonia' by Guilpain et al.** Monti S, Montecucco C. *Annals of the Rheumatic Diseases*. 2020.
894. **Non-steroidal anti-inflammatory treatment during covid-19: Friend or foe? Response to: 'Coronavirus**

disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)' by Giollo et al. Monti S, Montecucco C. *Annals of the Rheumatic Diseases*. 2020.

895. **QTc Evaluation in COVID-19 patients treated with Chloroquine/Hydroxychloroquine.** Monzani A, Genoni G, Scopinaro A, Pistis G, Kozel D, Secco GG. *European Journal of Clinical Investigation*. 2020.

896. **Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.** Morabito CJ, Gangadharan B. *Clinical and translational science*. 2020.

897. **Detecting and Monitoring Porcine Hemagglutinating Encephalomyelitis Virus, an Underresearched Betacoronavirus.** Mora-Díaz JC, Magtoto R, Houston E, Baum D, Carrillo-Ávila JA, Temeeyasen G, et al. *mSphere*. 2020;5(3).

898. **The impact of biosensing in a pandemic outbreak: COVID-19.** Morales-Narváez E, Dincer C. *Biosensors and Bioelectronics*. 2020;163.

899. **Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?** Moreno-Fierros L, García-Silva I, Rosales-Mendoza S. *Expert opinion on biological therapy*. 2020.

900. **Current Evidence Supporting the Use of Orally Administered Zinc in the Treatment of COVID-19.** Moseley H. 2020.

901. **Triage of Acute Ischemic Stroke in Confirmed COVID-19: Large Vessel Occlusion Associated With Coronavirus Infection.** Moshayedi P, Ryan TE, Mejia LLP, Nour M, Liebeskind DS. *Frontiers in Neurology*. 2020;11.

902. **Tuberculosis, COVID-19 and migrants: preliminary analysis of deaths occurring in 69 patients from two cohorts.** Motta I, Centis R, D'Ambrosio L, Garcia-Garcia JM, Goletti D, Gualano G, et al. *Pulmonology*. 2020. <http://dx.doi.org/10.1016/j.pulmoe.2020.05.002>.

903. **Cardiovascular Disease Novel Coronavirus and the Search for Investigational Therapies.** Mousa AY, Broce M, Lucas BD. *Journal of vascular surgery*. 2020.

904. **Anti-inflammatory and SARS-CoV-2 (COVID-19).** Moutaouakkil Y, Tadlaoui Y, Latt EEV, Atbib Y, Cherrah Y, Bennana A, et al. *Douleurs*. 2020.

905. **Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19.** Moutsopoulos HM. *Annals of the Rheumatic Diseases*. 2020.

906. **COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.** Mugheddu C, Pizzatti L, Sanna S, Atzori L, Rongioletti F. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2020.

907. **Global efforts on vaccines for COVID-19: Since, sooner or later, we all will catch the coronavirus.** Mukherjee R. *Journal of biosciences*. 2020;45.

908. **Mental Health and Psychological Distress in People with Diabetes during COVID-19.** Mukhtar S, Mukhtar S. *Metabolism: Clinical and Experimental*. 2020;108.

909. **Novel coronavirus: Current understanding of clinical features, diagnosis, pathogenesis, and treatment options.** Mungroo MR, Khan NA, Siddiqui R. *Pathogens*. 2020;9(4).

910. **β-Glucan extracts from the same edible shiitake mushroom *Lentinus edodes* produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects — Implications for coronavirus disease (COVID-19) immunotherapies.** Murphy EJ, Masterson C, Rezoagli E, O'Toole D, Major I, Stack GD, et al. *Science of*

the Total Environment. 2020;732.

911. **Managing Diabetes in Pregnancy before, during and after COVID-19.** Murphy H. Diabetes technology & therapeutics. 2020.

912. **Nutritional recommendations for CoVID-19 quarantine.** Muscogiuri G, Barrea L, Savastano S, Colao A. European journal of clinical nutrition. 2020;1-2.

913. **Obesity: The "Achilles heel" for COVID-19?** Muscogiuri G, Pugliese G, Barrea L, Savastano S, Colao A. Metabolism: Clinical and Experimental. 2020;108.

914. **Characterisation of COVID-19 Pandemic in Paediatric Age Group: A Systematic Review and Meta-Analysis.** Mustafa NM, L AS. Journal of Clinical Virology. 2020;128.

915. **Identification and Monitoring of International Travelers During the Initial Phase of an Outbreak of COVID-19 - California, February 3-March 17, 2020.** Myers JF, Snyder RE, Porse CC, Teclé S, Lowenthal P, Danforth ME, et al. MMWR Morbidity and mortality weekly report. 2020;69(19):599-602. <http://dx.doi.org/10.15585/mmwr.mm6919e4>.

916. **Has COVID-19 played an unexpected "stroke" on the chain of survival?** Naccarato M, Scali I, Olivo S, Ajcevic M, Buoite Stella A, Furlanis G, et al. J Neurol Sci. 2020;414:116889. <http://dx.doi.org/10.1016/j.jns.2020.116889>.

917. **Molecular Evolution and Structural Mapping of N-Terminal Domain in Spike Gene of Middle East Respiratory Syndrome Coronavirus (MERS-CoV).** Naeem A, Hamed ME, Alghoribi MF, Aljabr W, Al saran H, Enani MA, et al. Viruses. 2020;12(5).

918. **A Case of Coronavirus Disease 2019 Treated With Ciclesonide.** Nakajima K, Ogawa F, Sakai K, Uchiyama M, Oyama Y, Kato H, et al. Mayo Clinic Proceedings. 2020.

919. **Interactions between antihyperglycemic drugs and the renin-angiotensin system: Putative roles in COVID-19. A mini-review.** Nakhleh A, Shehadeh N. Diabetes & metabolic syndrome. 2020;14(4):509-12.

920. **Recommendations for the management of critically ill adult patients with COVID-19.** Ñamendys-Silva SA, Domínguez-Cherit G. Gaceta medica de Mexico. 2020;156(4).

921. **Exploring alternative medicine options for the prevention or treatment of coronavirus disease 2019 (COVID-19)- A systematic scoping review.** Nandan A, Tiwari S, Sharma V. medRxiv. 2020:2020.05.14.20101352.

922. **The ocular surface and the coronavirus disease 2019: Does a dual 'ocular route' exist?** Napoli PE, Nioi M, D'aloja E, Fossarello M. Journal of Clinical Medicine. 2020;9(5).

923. **Safety of dupilumab in atopic patients during COVID-19 outbreak.** Napolitano M, Patruno C, Ruggiero A, Nocerino M, Fabbrocini G. The Journal of dermatological treatment. 2020:1-5.

924. **Impact of sedentarism due to the COVID-19 home confinement on neuromuscular, cardiovascular and metabolic health: Physiological and pathophysiological implications and recommendations for physical and nutritional countermeasures.** Narici M, De Vito G, Franchi M, Paoli A, Moro T, Marcolin G, et al. European journal of sport science. 2020:1-22.

925. **Coronavirus disease (COVID-19): Rheumatological Prospects/Relevance.** Nasonov EL. Nauchno-Prakticheskaya Revmatologiya. 2020;58(2):123-30.

926. **A world of changes: The inheritance of COVID-19.** Negahdaripour M. Iranian Journal of Medical Sciences. 2020;45(3):155-6.

927. **FAKE SCIENCE: XMRV, COVID-19 AND THE TOXIC LEGACY OF DR JUDY MIKOVITS.** Neil S, Campbell EM. AIDS research and human retroviruses. 2020.
928. **The expression level of angiotensin-converting enzyme 2 determine the severity of COVID-19: lung and heart tissue as targets.** Nejadi Babadaei MM, Hasan A, Haj Bloukh S, Edis Z, Sharifi M, Kachooei E, et al. Journal of biomolecular structure & dynamics. 2020:1-13.
929. **Development of Remdesivir Repositioning as a Nucleotide Analog Against COVID-19 RNA Dependent RNA Polymerase.** Nejadi Babadaei MM, Hasan A, Vahdani Y, Haj Bloukh S, Sharifi M, Kachooei E, et al. Journal of Biomolecular Structure and Dynamics. 2020:1-12.
930. **COVID-19 and the eye immunity: lesson learned from the past and possible new therapeutic insights.** Neri P, Pichi F. International Ophthalmology. 2020;40(5):1057-60.
931. **COVID-19 in Neonates and Infants: Progression and Recovery.** Ng KF, Bandi S, Bird PW, Wei-Tze Tang J. The Pediatric infectious disease journal. 2020.
932. **Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!** Nguyen AA, Habiballah SB, Platt CD, Geha RS, Chou JS, McDonald DR. Clinical Immunology. 2020;216.
933. **Cardiovascular Toxicities Associated with Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database.** Nguyen LS, Dolladille C, Drici M-D, Fenioux C, Alexandre J, Mira J-P, et al. Circulation. 2020.
934. **Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.** Nickel RS, Margulies S, Frazer B, Luban NLC, Webb J. Blood. 2020.
935. **First CT characteristic appearance of patients with coronavirus disease 2019.** Nie W, Feng Z, Mao X, Rong P, Wang W, Liang Q. Zhong nan da xue xue bao Yi xue ban = Journal of Central South University Medical sciences. 2020;45(3):262-8.
936. **Sevoflurane, a sigh of relief in COVID-19?** Nieuwenhuijs-Moeke GJ, Jainandunsing JS, Struys MMRF. British Journal of Anaesthesia. 2020.
937. **Application of nanomaterials in treatment, anti-infection and detection of coronaviruses.** Nikaeen G, Abbaszadeh S, Yousefinejad S. Nanomedicine (London, England). 2020.
938. **SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes.** Nikolich-Zugich J, Knox KS, Rios CT, Natt B, Bhattacharya D, Fain MJ. GeroScience. 2020;42(2):505-14.
939. **COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons.** Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G. Cytokine & growth factor reviews. 2020.
940. **Can Zinc Correction in SARS-CoV-2 Patients Improve Treatment Outcomes?** Noeparast A, Verschelden G. 2020.
941. **Social Distancing against COVID-19: Implication for the Control of Influenza.** Noh JY, Seong H, Yoon JG, Song JY, Cheong HJ, Kim WJ. Journal of Korean medical science. 2020;35(19):e182.
942. **Sofosbuvir as a potential option for the treatment of COVID-19.** Nourian A, Khalili H. Acta bio-medica : Atenei Parmensis. 2020;91(2):236-8.

943. **Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19).** Nur E, Gaartman AE, van Tuijn CFJ, Tang MW, Biemond BJ. American Journal of Hematology. 2020;95(6):725-6.
944. **SnapShot: COVID-19.** Oberfeld B, Achanta A, Carpenter K, Chen P, Gilette NM, Langat P, et al. Cell. 2020;181(4):954-.e1.
945. **Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a "Red Zone" Area in Northern Italy.** Occhipinti V, Pastorelli L. Inflammatory bowel diseases. 2020;26(6):793-6. <http://dx.doi.org/10.1093/ibd/izaa084>.
946. **Bacillus Calmette Guérin (BCG) vaccination use in the fight against COVID-19 - what's old is new again?** O'Connor E, Teh J, Kamat AM, Lawrentschuk N. Future oncology (London, England). 2020.
947. **Dramatic improvement after Tocilizumab of a severe COVID-19 in a child with sickle cell disease and acute chest syndrome.** Odièvre MH, de Marcellus C, Ducou Le Pointe H, Allali S, Romain AS, Youn J, et al. American Journal of Hematology. 2020.
948. **Response to the commentary by Alexandra A. Chudnovsky on 'Assessing nitrogen dioxide (NO₂) levels as a contributing factor to coronavirus (COVID-19) fatality'.** Ogen Y. The Science of the total environment. 2020:139239.
949. **Caspase-Mediated Cleavage of Nucleocapsid protein of a Protease-Independent Porcine Epidemic Diarrhea Virus Strain.** Oh C, Kim Y, Chang KO. Virus research. 2020:198026.
950. **Deep Learning COVID-19 Features on CXR using Limited Training Data Sets.** Oh Y, Park S, Ye JC. IEEE transactions on medical imaging. 2020.
951. **High throughput and comprehensive approach to develop multiepitope vaccine against minacious COVID-19.** Ojha R, Gupta N, Naik B, Singh S, Verma VK, Prusty D, et al. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2020:105375.
952. **Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome.** Okour M, Al-Kofahi M, Austin D. Journal of pharmacokinetics and pharmacodynamics. 2020:1-2. <http://dx.doi.org/10.1007/s10928-020-09689-x>.
953. **Mobile phones represent a pathway for microbial transmission: A scoping review.** Olsen M, Campos M, Lohning A, Jones P, Legget J, Bannach-Brown A, et al. Travel Medicine and Infectious Disease. 2020.
954. **Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.** Omarjee L, Janin A, Perrot F, Laviolle B, Meilhac O, Mahe G. Clinical immunology (Orlando, Fla). 2020:108464.
955. **Evaluation of hepatic enzymes changes and association with prognosis in COVID-19 patients.** Omrani-Nava V, Maleki I, Ahmadi A, Moosazadeh M, Hedayatizadeh-Omran A, Roozbeh F, et al. Hepatitis Monthly. 2020;20(4).
956. **Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) from a Symptomatic Patient.** Ong SWX, Tan YK, Chia PY, Lee TH, Ng OT, Wong MSY, et al. JAMA - Journal of the American Medical Association. 2020;323(16):1610-2.
957. **The Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.** Oren O, Yang EH, Gluckman TJ, Michos ED, Blumenthal RS, Gersh BJ. Circulation: Arrhythmia and Electrophysiology. 2020.

958. **Early SARS-CoV-2 outbreak detection by sewage-based epidemiology.** Orive G, Lertxundi U, Barcelo D. *Science of the Total Environment*. 2020;732.
959. **Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target.** Ortega JT, Serrano ML, Pujol FH, Rangel HR. *EXCLI journal*. 2020.
960. **COVID-19: Living through Another Pandemic.** Osman EEA, Toogood PL, Neamati N. *ACS infectious diseases*. 2020.
961. **Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital.** Ottaviani D, Boso F, Tranquillini E, Gapeni I, Pedrotti G, Cozzio S, et al. *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. 2020.
962. **Plasma angiotensin-converting enzyme 2: novel biomarker in heart failure with implications for COVID-19.** Oudit GY, Pfeffer MA. *European heart journal*. 2020.
963. **Nurture to nature via COVID-19, a self-regenerating environmental strategy of environment in global context.** Paital B. *The Science of the total environment*. 2020;729:139088.
964. **Reply to Comment on "Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?".** Pal R, Bhadada SK. *Diabetes research and clinical practice*. 2020:108192.
965. **Do we have enough evidence to use chloroquine/hydroxychloroquine as a public health panacea for COVID-19?** Palmeira VA, Costa LB, Perez LG, Ribeiro VT, Lanza K, Silva ACSE. *Clinics (Sao Paulo, Brazil)*. 2020;75:e1928.
966. **Can graphene take part in the fight against COVID-19?** Palmieri V, Papi M. *Nano Today*. 2020;33.
967. **Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19).** Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. *Radiology*. 2020;295(3):715-21. <http://dx.doi.org/10.1148/radiol.2020200370>. Epub 2020 Feb 13.
968. **Study on transmission dynamic of 15 clusters of coronavirus disease 2019 cases in Ningbo.** Pan XX, Chen Y, Wang AH, Wang JM, Ye LX, Gu SH, et al. *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi*. 2020;41:E066.
969. **COVID-19 Outbreak: an Update on Therapeutic Options.** Panati K, Narala VR. *SN Comprehensive Clinical Medicine*. 2020;2(4):379-80.
970. **Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?** Panigrahy D, Gilligan MM, Huang S, Gartung A, Cortés-Puch I, Sime PJ, et al. *Cancer metastasis reviews*. 2020.
971. **First comprehensive computational analysis of functional consequences of TMPRSS2 SNPs in susceptibility to SARS-CoV-2 among different populations.** Paniri A, Hosseini MM, Akhavan-Niaki H. *Journal of biomolecular structure & dynamics*. 2020:1-18.
972. **Peptide-like and small-molecule inhibitors against Covid-19.** Pant S, Singh M, Ravichandiran V, Murty USN, Srivastava HK. *J Biomol Struct Dyn*. 2020:1-10.
973. **Use of triiodothyronine to treat critically ill COVID-19 patients: a new clinical trial.** Pantos C, Tseti I, Mourouzis I. *Critical care (London, England)*. 2020;24(1):209.
974. **Role of Non-Profit Organization During COVID-19 for Diabetes Care: Healthcare Inequities and Role of Virtual Specialty Clinic.** Panziner D. *Diabetes technology & therapeutics*. 2020.

975. **Systemic Immunobiological, Immunosuppressant and Oncologic Agents for the Treatment of Dermatologic Diseases during the SARS-Cov-2 (COVID19) Pandemic Emergency: a Quick Review for a Quick Consultation.** Paolino G, Mercuri SR, Bearzi P, Mattozzi C. *Dermatologic therapy*. 2020:e13537.
976. **Delivering urgent urological surgery during the COVID-19 pandemic in the United Kingdom: Outcomes from our initial 52 patients.** Paramore L, Yang B, Abdelmotagly Y, Noureldin M, McLean D, Rajkumar G, et al. *BJU international*. 2020.
977. **Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E).** Parang K, El-Sayed NS, Kazeminy AJ, Tiwari RK. *Molecules*. 2020;25(10). <http://dx.doi.org/10.3390/molecules25102343>.
978. **Precision Medicine in COVID-19: IL-1 β a Potential Target.** Parisi V, Leosco D. *JACC: Basic to Translational Science*. 2020;5(5):543-4.
979. **Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.** Park SJ, Yu KM, Kim YI, Kim SM, Kim EH, Kim SG, et al. *mBio*. 2020;11(3). <http://dx.doi.org/10.1128/mBio.01114-20>.
980. **SARS2 modifies spastic paraplegia type 4 age at onset.** Parodi L, Lejeune F, Barbier M, Brice A, Stevanin G, Durr A. *European Journal of Human Genetics*. 2019;27:1486.
981. **COVID-19 diagnosis and management: a comprehensive review.** Pascarella G, Strumia A, Piliengo C, Bruno F, Del Buono R, Costa F, et al. *Journal of internal medicine*. 2020.
982. **Specific EEG Encephalopathy Pattern in SARS-CoV-2 Patients.** Pastor J, Vega-Zelaya L, Martin Abad E. *Journal of clinical medicine*. 2020;9(5). <http://dx.doi.org/10.3390/jcm9051545>.
983. **A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.** Patil VM, Singhal S, Masand N. *Life sciences*. 2020;254.
984. **Dupilumab and COVID-19: what should we expect?** Patruno C, Stingeni L, Fabbrocini G, Hansel K, Napolitano M. *Dermatologic Therapy*. 2020.
985. **Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia.** Pavoni V, Gianesello L, Pazzi M, Stera C, Meconi T, Frigieri FC. *Journal of Thrombosis and Thrombolysis*. 2020.
986. **Recent advances in influenza vaccines.** Pawelec G, McElhaney J. *F1000Research*. 2020;9.
987. **SARS-CoV-2 pandemic : Time to revive the cyclophilin inhibitor alisporivir.** Pawlotsky JM. *Clin Infect Dis*. 2020. <http://dx.doi.org/10.1093/cid/ciaa587>.
988. **Gastrointestinal symptoms as the first, atypical indication of severe acute respiratory syndrome coronavirus 2 infection.** Pazgan-Simon M, Rorat M, Buczyńska I, Zińczuk A, Simon K. *Polish Archives of Internal Medicine*. 2020;130(4):338-9.
989. **Rapid Implementation of Service Delivery Changes to Mitigate COVID-19 and Maintain Access to Methadone Among Persons with and at High-Risk for HIV in an Opioid Treatment Program.** Peavy KM, Darnton J, Grekin P, Russo M, Green CJB, Merrill JO, et al. *AIDS and behavior*. 2020.
990. **A Real-World Evidence Framework for Optimising Dosing in All Patients with COVID-19.** Peck RW, Weiner D, Cook J, Powell JR. *Clin Pharmacol Ther*. 2020. <http://dx.doi.org/10.1002/cpt.1922>.

991. **Initial experiences from patients with covid-19 on ventilatory support in denmark.** Pedersen HP, Hildebrandt T, Poulsen A, Uslu B, Knudsen HH, Roed J, et al. Danish medical journal. 2020;67(5).
992. **Coronavirus disease 2019 in children: Characteristics, antimicrobial treatment, and outcomes.** Peng H, Gao P, Xu Q, Liu M, Peng J, Wang Y, et al. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2020;128:104425. <http://dx.doi.org/10.1016/j.jcv.2020.104425>.
993. **Clinical course of coronavirus disease 2019 in 11 patients after thoracic surgery and challenges in diagnosis.** Peng S, Huang L, Zhao B, Zhou S, Braithwaite I, Zhang N, et al. Journal of Thoracic and Cardiovascular Surgery. 2020.
994. **Conserved High Free Energy Sites in Human Coronavirus Spike Glycoprotein Backbones.** Penner RC. Journal of computational biology : a journal of computational molecular cell biology. 2020.
995. **With soluble ACE2 against COVID-19: New mechanism of action is supposed to intercept viruses and strengthen protective mechanisms.** Penninger J. Deutsche Apotheker Zeitung. 2020;160(11).
996. **Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19.** Pepperrell T, Pilkington V, Owen A, Wang J, Hill AM. Journal of virus eradication. 2020;6(2):52-60.
997. **Validation of SARS-CoV-2 detection across multiple specimen types.** Perchetti GA, Nalla AK, Huang ML, Zhu H, Wei Y, Stensland L, et al. Journal of Clinical Virology. 2020;128.
998. **Long-Term Neurological Threats of COVID-19: A Call to Update the Thinking About the Outcomes of the Coronavirus Pandemic.** Pereira A. Frontiers in Neurology. 2020;11.
999. **The current clinically relevant findings on COVID-19 pandemic.** Pergolizzi JV, Magnusson P, Lequang JA, Breve F, Paladini A, Rekatsina M, et al. Anesthesiology and Pain Medicine. 2020;10(2).
1000. **Acute limb ischaemia in two young, non-atherosclerotic patients with COVID-19.** Perini P, Nabulsi B, Massoni CB, Azzarone M, Freyrie A. The Lancet. 2020;395(10236):1546.
1001. **COVID-19 global pandemic planning: Decontamination and reuse processes for N95 respirators.** Perkins DJ, Villescas S, Wu TH, Muller T, Bradfute S, Hurwitz I, et al. Experimental biology and medicine (Maywood, NJ). 2020:1535370220925768.
1002. **The Silver Lining to COVID-19: Avoiding Diabetic Ketoacidosis Admissions with Telehealth.** Peters AL, Garg S. Diabetes technology & therapeutics. 2020.
1003. **The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).** Peterson D, Damsky W, King B. Journal of the American Academy of Dermatology. 2020;82(6):e223-e6.
1004. **Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19.** Peterson D, Damsky W, King B. Journal of the American Academy of Dermatology. 2020.
1005. **Obesity - a risk factor for increased COVID-19 prevalence, severity and lethality (Review).** Petrakis D, Margină D, Tsarouhas K, Tekos F, Stan M, Nikitovic D, et al. Molecular Medicine Reports. 2020;22(1):9-19.
1006. **Availability of Internationally Controlled Essential Medicines in the COVID-19 Pandemic.** Pettus K, Cleary JF, de Lima L, Ahmed E, Radbruch L. Journal of pain and symptom management. 2020.
1007. **COVID-19 Outbreak: the gold rush and the Responsibilities of the scientific community.** Pezzani MD. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and

Infectious Diseases. 2020.

1008. **Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity.** Picchianti Diamanti A, Rosado MM, Pioli C, Sesti G, Lagana B. *Int J Mol Sci.* 2020;21(9). <http://dx.doi.org/10.3390/ijms21093330>.
1009. **COVID-19 and islet transplantation: different twins.** Piemonti L, Landoni G. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.* 2020. <http://dx.doi.org/10.1111/ajt.16001>.
1010. **COVID alias challenge to onco-rehabilitation and to viable indications and decisions: Cues from an Italian COVID+ oral cancer patient.** Pietrobon G, Tagliabue M, Chu F, De Berardinis R, Ansarin M. *Oral Oncology.* 2020;105.
1011. **A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?** Pilkington V, Pepperrell T, Hill A. *Journal of virus eradication.* 2020;6(2):45-51.
1012. **Recent discovery and development of inhibitors targeting coronaviruses.** Pillaiyar T, Meenakshisundaram S, Manickam M. *Drug Discovery Today.* 2020;25(4):668-88.
1013. **Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.** Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. *Nature.* 2020. <http://dx.doi.org/10.1038/s41586-020-2349-y>.
1014. **Steroid injections for pain management in the COVID-19 era.** Piraccini E, Byrne H, Taddei S. *Minerva anestesologica.* 2020.
1015. **Emergency Approval of Chloroquine and Hydroxychloroquine for Treatment of COVID-19.** Piszczatoski CR, Powell J. *The Annals of pharmacotherapy.* 2020:1060028020925558.
1016. **Our Most Powerful Weapon to Fight COVID-19: Patient Involvement.** Pitts PJ. *Patient.* 2020;13(3):255.
1017. **Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study.** Plaze M, Attali D, Petit AC, Blatzer M, Simon-Loriere E, Vinckier F, et al. *L'Encephale.* 2020.
1018. **Repurposing chlorpromazine to treat COVID-19: the reCoVery study.** Plaze M, Attali D, Petit AC, Blatzer M, Simon-Loriere E, Vinckier F, et al. *L'Encephale.* 2020.
1019. **Ichthyosis vulgaris.** Plesner LL, Dyrberg E, Hansen IV, Abild A, Andersen MB. *Ugeskrift for laeger.* 2020;182(17).
1020. **Tortoises, hares, and vaccines: A cautionary note for SARS-CoV-2 vaccine development.** Poland GA. *Vaccine.* 2020.
1021. **Hydroxychloroquine: A Familiar Agent to Combat the Pandemic of COVID-19.** Polymeropoulos VM. *Frontiers in Medicine.* 2020;7.
1022. **The current understanding and potential therapeutic options to combat COVID-19.** Pooladanda V, Thatikonda S, Godugu C. *Life sciences.* 2020:117765. <http://dx.doi.org/10.1016/j.lfs.2020.117765>.
1023. **Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies.** Porfidia A, Pola R. *Journal of thrombosis and thrombolysis.* 2020.
1024. **Society of Robotic Surgery Review: Recommendations Regarding the Risk of COVID-19 Transmission During Minimally Invasive Surgery.** Porter J, Blau E, Gharagozloo F, Martino M, Cerfolio R, Duvvuri U, et al. *BJU*

international. 2020.

1025. **Genetic variants and source of introduction of SARS-CoV-2 in South America.** Poterico JA, Mestanza O. *J Med Virol.* 2020. <http://dx.doi.org/10.1002/jmv.26001>.
1026. **A Review of Current Interventions for COVID-19 Prevention.** Pradhan D, Biswasroy P, Kumar naik P, Ghosh G, Rath G. *Archives of Medical Research.* 2020.
1027. **Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression.** Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. *Journal of the renin-angiotensin-aldosterone system : JRAAS.* 2020;21(2):1470320320926899. <http://dx.doi.org/10.1177/1470320320926899>.
1028. **The 5% of the Population at High Risk for Severe COVID-19 Infection Is Identifiable and Needs to Be Taken Into Account When Reopening the Economy.** Preskorn SH. *Journal of psychiatric practice.* 2020;26(3):219-27. <http://dx.doi.org/10.1097/PRA.0000000000000475>.
1029. **A Review of Methanol Poisoning: A Crisis Beyond Ocular Toxicology.** Pressman P, Clemens R, Sahu S, Hayes AW. *Cutaneous and ocular toxicology.* 2020:1-19.
1030. **SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.** Prete M, Favoino E, Catacchio G, Racanelli V, Perosa F. *Int J Mol Sci.* 2020;21(9). <http://dx.doi.org/10.3390/ijms21093377>.
1031. **Respiratory management in severe acute respiratory syndrome coronavirus 2 infection.** Price S, Singh S, Ledot S, Bianchi P, Hind M, Tavazzi G, et al. *European heart journal Acute cardiovascular care.* 2020:2048872620924613.
1032. **Ten key points that vascular doctors learned very quickly about COVID-19.** Priollet P, Yannoutsos A, Mourad JJ. *JMV-Journal de Medecine Vasculaire.* 2020;45(3):105-6.
1033. **Letter to the Editor: Kim, S-W., Su, K-P. (2020) Using psychoneuroimmunity against COVID-19, Brain, Behavior, and Immunity (2020), doi: <https://doi.org/10.1016/j.bbi.2020.03.025>.** Psy DL, Bottaccioli AG, Bottaccioli F. *Brain, behavior, and immunity.* 2020. <http://dx.doi.org/10.1016/j.bbi.2020.05.036>.
1034. **ACE2 Activators for the Treatment of Covid 19 Patients.** Puertas RR. *Journal of medical virology.* 2020.
1035. **Influenza virus like particles (VLPs): Opportunities for H7N9 vaccine development.** Pushko P, Tretyakova I. *Viruses.* 2020;12(5).
1036. **COVID-19: a look into the modern age pandemic.** Qamar MA. *Journal of Public Health (Germany).* 2020.
1037. **Catheter-directed thrombolysis in COVID-19 pneumonia with acute PE: Thinking beyond the guidelines.** Qanadli SD, Gudmundsson L, Rotzinger DC. *Thrombosis Research.* 2020;192:9-11.
1038. **Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19?** Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Miller MC, Abraham GM, Obley AJ, et al. *Annals of internal medicine.* 2020. <http://dx.doi.org/10.7326/M20-1998>.
1039. **Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial.** Qin YY, Zhou YH, Lu YQ, Sun F, Yang S, Harypursat V, et al. *Chinese medical journal.* 2020;133(9):1080-6.
1040. **Laboratory testing techniques for SARS-CoV-2.** Qiu F, Wang H, Zhang Z, Cao L, Wang C, Wu J, et al. *Nan*

fang yi ke da xue xue bao = Journal of Southern Medical University. 2020;40(2):164-7.

1041. **Acute on Chronic Liver Failure from Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).** Qiu H, Wander P, Bernstein D, Satopathy SK. *Liver international : official journal of the International Association for the Study of the Liver.* 2020.
1042. **Atypical lung feature on chest CT in a lung adenocarcinoma cancer patient infected with COVID-19.** Qu J, Yang R, Song L, Kamel IR. *Annals of Oncology.* 2020;31(6):825-6.
1043. **Positive result of Sars-Cov-2 in sputum from a cured patient with COVID-19.** Qu YM, Kang EM, Cong HY. *Travel Medicine and Infectious Disease.* 2020;34.
1044. **Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care.** Quartuccio L, Sonaglia A, McGonagle D, Fabris M, Peghin M, Pecori D, et al. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.* 2020:104444.
1045. **Detection of SARS-CoV-2 is comparable in clinical samples preserved in saline or viral transport media.** Radbel J, Jagpal S, Roy J, Brooks A, Tischfield J, Sheldon M, et al. *The Journal of molecular diagnostics : JMD.* 2020. <http://dx.doi.org/10.1016/j.jmoldx.2020.04.209>.
1046. **Three months of COVID-19: A systematic review and meta-analysis.** Rafiq D, Batool A, Bazaz MA. *Reviews in medical virology.* 2020:e2113.
1047. **Is copper beneficial for COVID-19 patients?** Raha S, Mallick R, Basak S, Duttaroy AK. *Medical hypotheses.* 2020;142:109814.
1048. **Convalescent plasma transfusion for the treatment of COVID-19: Systematic review.** Rajendran K, Narayanasamy K, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. *Journal of Medical Virology.* 2020.
1049. **Hypertonic saline nasal irrigation and gargling should be considered as a treatment option for COVID-19.** Ramalingam S, Graham C, Dove J, Morrice L, Sheikh A. *Journal of global health.* 2020;10(1):010332.
1050. **Blood transfusion strategies and ECMO during the COVID-19 pandemic - Authors' reply.** Ramanathan K, MacLaren G, Combes A, Brodie D, Shekar K. *The Lancet Respiratory medicine.* 2020;8(5):e41. [http://dx.doi.org/10.1016/S2213-2600\(20\)30174-0](http://dx.doi.org/10.1016/S2213-2600(20)30174-0). Epub 2020 Apr 16.
1051. **A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).** Rameshrad M, Ghafoori M, Mohammadpour AH, Nayeri MJD, Hosseinzadeh H. *Naunyn-Schmiedeberg's archives of pharmacology.* 2020. <http://dx.doi.org/10.1007/s00210-020-01901-6>.
1052. **Drug-induced vasculitis in a patient with COVID-19.** Ramirez AV, Efe D, Fischer M. *Journal of the European Academy of Dermatology and Venereology : JEADV.* 2020.
1053. **Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemostasia.** Ramírez I, De la Viuda E, Baquedano L, Coronado P, Llana P, Mendoza N, et al. *Maturitas.* 2020;137:57-62.
1054. **Hospital-acquired infective endocarditis during Covid-19 pandemic.** Ramos-Martinez A, Fernandez-Cruz A, Dominguez F, Forteza A, Cobo M, Sanchez-Romero I. *medRxiv.* 2020.
1055. **Therapeutic Application of Chloroquine and Hydroxychloroquine in Clinical Trials for COVID-19: A systematic review.** Rana DR, Dulal S. *medRxiv.* 2020:2020.03.22.20040964.

1056. **RNA genome conservation and secondary structure in SARS-CoV-2 and SARS-related viruses: a first look.** Rangan R, Zheludev IN, Das R. RNA (New York, NY). 2020. <http://dx.doi.org/10.1261/rna.076141.120>.
1057. **Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms.** Raucci F, Mansour AA, Casillo GM, Saviano A, Caso F, Scarpa R, et al. Autoimmunity reviews. 2020:102572.
1058. **Rising Tide: Responding to the Mental Health Impact of the COVID-19 Pandemic.** Rauch SAM, Simon NM, Rothbaum BO. Depression and anxiety. 2020. <http://dx.doi.org/10.1002/da.23058>.
1059. **COVID-19 in Newborns and Infants-Low Risk of Severe Disease: Silver Lining or Dark Cloud?** Rawat M, Chandrasekharan P, Hicar MD, Lakshminrusimha S. American journal of perinatology. 2020.
1060. **COVID-19 Pandemic: Can Maintaining Optimal Zinc Balance Enhance Host Resistance?** Razzaque M. 2020.
1061. **SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment.** Rebeaud ME, Zores F. Frontiers in Medicine. 2020;7.
1062. **Wide complex tachycardia in a COVID-19 patient: What is the mechanism?** Reddy V, Reddy V, Mangat S, Shokr M, Kundumadam S, Laharwani H. Journal of Electrocardiology. 2020;60:200-2.
1063. **Statins and the COVID-19 main protease: in silico evidence on direct interaction.** Reiner Z, Hatamipour M, Banach M, Pirro M, Al-Rasadi K, Jamialahmadi T, et al. Archives of medical science : AMS. 2020;16(3):490-6. <http://dx.doi.org/10.5114/aoms.2020.94655>. eCollection 2020.
1064. **High-flow nasal cannula may be no safer than non-invasive positive pressure ventilation for COVID-19 patients.** Remy KE, Lin JC, Verhoef PA. Critical Care. 2020;24(1).
1065. **Pathogenicity of a QX-like avian infectious bronchitis virus isolated in China.** Ren G, Liu F, Huang M, Li L, Shang H, Liang M, et al. Poultry science. 2020;99(1):111-8.
1066. **Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19.** Ren H, Yang Y, Wang F, Yan Y, Shi X, Dong K, et al. Cardiovascular diabetology. 2020;19(1):58.
1067. **Positive RT-PCR in urine from an asymptomatic patient with novel coronavirus 2019 infection: a case report.** Ren JG, Li DY, Wang CF, Wu JH, Wang Y, Sun YJ, et al. Infectious diseases (London, England). 2020:1-4.
1068. **Stability and infectivity of coronaviruses in inanimate environments.** Ren SY, Wang WB, Hao YG, Zhang HR, Wang ZC, Chen YL, et al. World journal of clinical cases. 2020;8(8):1391-9.
1069. **Identifying potential treatments of COVID-19 from Traditional Chinese Medicine (TCM) by using a data-driven approach.** Ren X, Shao XX, Li XX, Jia XH, Song T, Zhou WY, et al. Journal of Ethnopharmacology. 2020;258.
1070. **[Study on treatment of "cytokine storm" by anti-2019-nCoV prescriptions based on arachidonic acid metabolic pathway].** Ren Y, Yao M-C, Huo X-Q, Gu Y, Zhu W-X, Qiao Y-J, et al. Zhongguo Zhong Yao Za Zhi. 2020;45(6):1225-31.
1071. **A case of postoperative covid-19 infection after cardiac surgery: Lessons learned.** Rescigno G, Firstenberg M, Rudez I, Uddin M, Nagarajan K, Nikolaidis N. Heart Surgery Forum. 2020;23(2):E231-E3.
1072. **Letter: low population mortality from COVID-19 in countries south of latitude 35 degrees North**

- supports vitamin D as a factor determining severity. Authors' reply.** Rhodes JM, Subramanian S, Laird E, Anne Kenny R. *Alimentary pharmacology & therapeutics*. 2020.
1073. **Recommendations for Treatment of Nail Lichen Planus During the COVID-19 Pandemic.** Ricardo JW, Lipner SR. *Dermatologic therapy*. 2020:e13551.
1074. **SARS-CoV-2 infection and air pollutants: Correlation or causation?** Riccò M, Ranzieri S, Balzarini F, Bragazzi NL, Corradi M. *Science of the Total Environment*. 2020;734.
1075. **Remedy for scabies against COVID-19: In vitro efficacy of ivermectin is waiting for clinical confirmation.** Richling AI. *Deutsche Apotheker Zeitung*. 2020;60(17).
1076. **The liver in times of COVID-19: What hepatologists should know.** Ridruejo E, Soza A. *Annals of hepatology*. 2020.
1077. **Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center.** Rimland CA, Morgan CE, Bell GJ, Kim MK, Hedrick T, Marx A, et al. *medRxiv*. 2020:2020.05.13.20100404.
1078. **Early estimates of the indirect effects of the COVID-19 pandemic on maternal and child mortality in low-income and middle-income countries: a modelling study.** Robertson T, Carter ED, Chou VB, Stegmuller AR, Jackson BD, Tam Y, et al. *The Lancet Global health*. 2020.
1079. **Antimicrobial Properties of Gallium-Infused and Zinc-Infused Bioglasses: A Potential Cure for Coronavirus.** Roberts KM. 2020.
1080. **Could CGRP antagonists be helpful in the fight against COVID-19?** Robertson CE. *Headache*. 2020.
1081. **Gastroenterologists, Hepatologists, COVID-19 and the Use of Acetaminophen.** Rodríguez-Morales AJ, Cardona-Ospina JA, Murillo-Muñoz MM. *Clinical Gastroenterology and Hepatology*. 2020.
1082. **The world is upside down; how coronavirus changes the way we care for our patients.** Rogers RG, Swift S. *International Urogynecology Journal*. 2020;31(5):853-4.
1083. **SARS-CoV-2 infection associated with spontaneous pneumothorax.** Rohailla S, Ahmed N, Gough K. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. 2020;192(19):E510.
1084. **The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?** Roldan EQ, Biasiotto G, Magro P, Zanella I. *Pharmacological research*. 2020:104904. <http://dx.doi.org/10.1016/j.phrs.2020.104904>.
1085. **Short Report – Medical nutrition therapy for critically ill patients with COVID-19.** Romano L, Bilotta F, Dauri M, Macheda S, Pujia A, de Santis GL, et al. *European review for medical and pharmacological sciences*. 2020;24(7):4035-9.
1086. **Hydroxychloroquine and ritonavir for COVID-19 infection: a possible synergic toxicity for retinal pigmented epithelium.** Romano MR, Raimondi R, Montericcio A, Allegrini D. *Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie*. 2020.
1087. **No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: response to the comment by Joob and Wiwanitkit.** Romão VC, Cruz-Machado AR, Fonseca JE. *Annals of the rheumatic diseases*. 2020.
1088. **Coronavirus disease 2019 infection and the cardiovascular system.** Romeo F, Calcaterra G, Barilla F,

Mehta JL. *Journal of Cardiovascular Medicine*. 2020;21(6):403-5.

1089. **What about the original antigenic sin of the humans versus SARS-CoV-2?** Roncati L, Palmieri B. *Medical Hypotheses*. 2020;142.

1090. **Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment.** Roncon L, Zuin M, Rigatelli G. *Internal and emergency medicine*. 2020.

1091. **Management of Acute Severe Ulcerative Colitis in a Pregnant Woman With COVID-19 Infection: A Case Report and Review of the Literature.** Rosen MH, Axelrad J, Hudesman D, Rubin DT, Chang S. *Inflammatory bowel diseases*. 2020.

1092. **Early thromboembolic events in hospitalized COVID-19 patients.** Rosen RJ. *Thrombosis Research*. 2020;192:1.

1093. **Angiotensin converting enzyme-2 as therapeutic target in COVID-19.** Roshanravan N, Ghaffari S, Hedayati M. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2020;14(4):637-9.

1094. **COVID-SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults.** Ross SB, Wilson MG, Papillon-Ferland L, Elsayed S, Wu PE, Battu K, et al. *Journal of the American Geriatrics Society*. 2020.

1095. **Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience.** Rossi D. *Lung Cancer*. 2020;145:83-4.

1096. **One proline deletion in the fusion peptide of neurotropic mouse hepatitis virus (MHV) restricts retrograde axonal transport and neurodegeneration.** Rout SS, Singh M, Shindler KS, Sarma JD. *Journal of Biological Chemistry*. 2020;295(20):6926-35.

1097. **Protecting vulnerable patients with inherited anaemias from unnecessary death during the COVID-19 pandemic.** Roy NBA, Telfer P, Eleftheriou P, de la Fuente J, Drasar E, Shah F, et al. *British journal of haematology*. 2020.

1098. **Deep learning for classification and localization of COVID-19 markers in point-of-care lung ultrasound.** Roy S, Menapace W, Oei S, Luijten B, Fini E, Saltori C, et al. *IEEE transactions on medical imaging*. 2020.

1099. **Effects of Micronutrients or Conditional Amino Acids on COVID-19 Related Outcomes: An Evidence Analysis Center Scoping Review.** Rozga M, Cheng FW, Moloney L, Handu D. *Journal of the Academy of Nutrition and Dietetics*. 2020.

1100. **Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.** Ruan Q, Yang K, Wang W, Jiang L, Song J. *Intensive Care Medicine*. 2020;46(5):846-8.

1101. **Audio Interview: Studying Potential Covid-19 Therapies.** Rubin EJ, Baden LR, Morrissey S. *The New England journal of medicine*. 2020;382(19):e72. <http://dx.doi.org/10.1056/NEJMe2015955>.

1102. **Testing an Old Therapy against a New Disease: Convalescent Plasma for COVID-19.** Rubin R. *JAMA - Journal of the American Medical Association*. 2020.

1103. **Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery.** Rubino F, Cohen RV, Mingrone G, le Roux CW, Mechanick JI, Arterburn DE, et al. *The lancet Diabetes & endocrinology*. 2020.

1104. **Cyclosporine therapy during the COVID-19 pandemic is not a reason for concern.** Rudnicka L, Goldust

M, Glowacka P, Sikora M, Sar-Pomian M, Rakowska A, et al. Journal of the American Academy of Dermatology. 2020.

1105. **Hypertension prevalence in human coronavirus disease: the role of ACE system in infection spread and severity.** Ruocco G, Feola M, Palazzuoli A. International Journal of Infectious Diseases. 2020;95:373-5.
1106. **Associations between immune-suppressive and stimulating drugs and novel COVID-19 - A systematic review of current evidence.** Russell B, Moss C, George G, Santaolalla A, Cope A, Papa S, et al. ecanermedscience. 2020;14.
1107. **COVID-19 and treatment with NSAIDs and corticosteroids: Should we be limiting their use in the clinical setting?** Russell B, Moss C, Rigg A, Van Hemelrijck M. ecanermedscience. 2020;14.
1108. **No significant correlation between ACE Ins/Del genetic polymorphism and COVID-19 infection.** Saadat M. Clinical chemistry and laboratory medicine. 2020.
1109. **COVID-19, Angiotensin Receptor Blockers, and the Brain.** Saavedra JM. Cellular and molecular neurobiology. 2020.
1110. **Is COVID Evolution Due to Occurrence of Pulmonary Vascular Thrombosis?** Saba L, Sverzellati N. Journal of thoracic imaging. 2020.
1111. **COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging Beyond Topics.** Saban-Ruiz J, Ly-Pen D. Journal of Nutrition, Health and Aging. 2020.
1112. **The rationale for potential pharmacotherapy of COVID-19.** Saber-Ayad M, Saleh MA, Abu-Gharbieh E. 2020.
1113. **A 63-year-old man treated for coronavirus disease 2019.** Sabri A, Taheri MS, Mahdavi A, Dobranowski J. Polish Archives of Internal Medicine. 2020;130(4):324-5.
1114. **Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.** Saghazadeh A, Rezaei N. International Immunopharmacology. 2020;84.
1115. **A virus that has gone viral: amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus, infectivity.** Saha P, Banerjee AK, Tripathi PP, Srivastava AK, Ray U. Bioscience reports. 2020;40(5). <http://dx.doi.org/10.1042/BSR20201312>.
1116. **Is Fostamatinib a possible drug for COVID-19?—A computational study.** Saha S, Halder AK, Bandyopadhyay SS, Chatterjee P, Nasipuri M, Basu S. 2020.
1117. **Upheaval in cancer care during the COVID-19 outbreak.** Salako O, Okunade K, Allsop M, Habeebu M, Toyé M, Oluyede G, et al. ecanermedscience. 2020;14.
1118. **Platelet functions and activities as potential hematologic parameters related to Coronavirus Disease 2019 (Covid-19).** Salamanna F, Maglio M, Landini MP, Fini M. Platelets. 2020:1-6.
1119. **Chest Computed Tomography Manifestation of Coronavirus Disease 2019 (COVID-19) in Patients With Cardiothoracic Conditions.** Salehi S, Abedi A, Radmard AR, Sorouri M, Gholamrezanezhad A. Journal of thoracic imaging. 2020.
1120. **SARS-CoV-2, Testosterone and frailty in males (PROTEGGIMI): A multidimensional research project.** Salonia A, Corona G, Giwercman A, Maggi M, Minhas S, Nappi RE, et al. Andrology. 2020.

1121. **Emerging pharmacotherapies for COVID-19.** Salvi R, Patankar P. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2020:110267. <http://dx.doi.org/10.1016/j.biopha.2020.110267>.
1122. **Innovation During COVID-19: Improving Addiction Treatment Access.** Samuels EA, Clark SA, Wunsch C, Keeler LAJ, Reddy N, Vanjani R, et al. *Journal of addiction medicine*. 2020.
1123. **Clinical considerations for managing dermatology patients on systemic immunosuppressive and/or biologic therapy during COVID-19 pandemic.** Sanchez DP, Kirsner RS, Lev-Tov H. *Journal of the American Academy of Dermatology*. 2020.
1124. **Why Choose Cyclosporin A as First-line Therapy in COVID-19 Pneumonia.** Sanchez-Pernaute O, Romero-Bueno FI, Selva-O'Callaghan A. *Reumatologia Clinica*. 2020.
1125. **Nasopharyngeal and oropharyngeal swabs, and/or serology for SARS COVID-19: What are we looking for?** Sanduzzi A, Zamparelli SS. *International Journal of Environmental Research and Public Health*. 2020;17(9).
1126. **Evidence for Use or Disuse of Renin-Angiotensin System Modulators in Patients Having COVID-19 With an Underlying Cardiorenal Disorder.** Sankrityayan H, Kale A, Sharma N, Anders HJ, Gaikwad AB. *Journal of cardiovascular pharmacology and therapeutics*. 2020:1074248420921720.
1127. **Evidence for Use or Disuse of Renin–Angiotensin System Modulators in Patients Having COVID-19 With an Underlying Cardiorenal Disorder.** Sankrityayan H, Kale A, Sharma N, Anders HJ, Gaikwad AB. *Journal of Cardiovascular Pharmacology and Therapeutics*. 2020.
1128. **Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration - United States, 2020.** Santoli JM, Lindley MC, DeSilva MB, Kharbanda EO, Daley MF, Galloway L, et al. *MMWR Morbidity and mortality weekly report*. 2020;69(19):591-3. <http://dx.doi.org/10.15585/mmwr.mm6919e2>.
1129. **Hypertension, thrombosis, kidney failure, and diabetes: Is covid-19 an endothelial disease? a comprehensive evaluation of clinical and basic evidence.** Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. *Journal of Clinical Medicine*. 2020;9(5).
1130. **First isolation of SARS-CoV-2 from clinical samples in India.** Sarkale P, Patil S, Yadav PD, Nyayanit DA, Sapkal G, Baradkar S, et al. *Indian Journal of Medical Research*. 2020;151(2):244-50.
1131. **Immunoinformatics-guided designing of epitope-based subunit vaccines against the SARS Coronavirus-2 (SARS-CoV-2).** Sarkar B, Ullah MA, Johora FT, Taniya MA, Araf Y. *Immunobiology*. 2020;225(3).
1132. **How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion.** Sarzi-Puttini P, Marotto D, Antivalle M, Salaffi F, Atzeni F, Maconi G, et al. *Autoimmunity Reviews*. 2020.
1133. **WITHDRAWN: Triaging advanced GI endoscopy procedures during the COVID-19 Pandemic: consensus recommendations using the Delphi method.** Sawhney MS, Bilal M, Pohl H, Kushnir V, Khashab MA, Schulman AR, et al. *Gastrointest Endosc*. 2020. <http://dx.doi.org/10.1016/j.gie.2020.05.014>.
1134. **How to ventilate during CPR in time of Covid-19?** Scapigliati A, Gulli A, Semeraro F, Ristagno G, Arlotta G, Bevilacqua F, et al. *Resuscitation*. 2020;151:148-9.
1135. **Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19).** Schoergenhofer C, Jilma B, Stimpfl T, Karolyi M, Zoufaly A. *Annals of internal medicine*. 2020. <http://dx.doi.org/10.7326/M20-1550>.
1136. **Elective procedures for prostate cancer in the time of Covid-19: a multidisciplinary team experience.**

Sciarra A, Salciccia S, Maggi M, Del Giudice F, Busetto GM, Musio D, et al. Prostate cancer and prostatic diseases. 2020.

1137. **May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?** Scicali R, Di Pino A, Piro S, Rabuazzo AM, Purrello F. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2020.

1138. **Invasive strategy for COVID patients presenting with acute coronary syndrome: The first multicenter Italian experience.** Secco GG, Tarantini G, Mazzarotto P, Garbo R, Parisi R, Maggio S, et al. Catheterization and Cardiovascular Interventions. 2020.

1139. **Methanol toxicity outbreak: when fear of COVID-19 goes viral.** Sefidbakht S, Lotfi M, Jalli R, Moghadami M, Sabetian G, Iranpour P. Emergency medicine journal : EMJ. 2020.

1140. **Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike.** Seghatchian J, Lanza F. Transfusion and Apheresis Science. 2020.

1141. **JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.** Seif F, Aazami H, Khoshmirsafa M, Kamali M, Mohsenzadegan M, Pornour M, et al. International archives of allergy and immunology. 2020:1-9.

1142. **SARS Cov-2 infection in a renal-transplanted patient: A case report.** Seminari E, Colaneri M, Sambo M, Gallazzi I, Di Matteo A, Roda S, et al. American Journal of Transplantation. 2020.

1143. **Within a large healthcare system, the incidence of positive COVID-19 results and mortality are lower in patients on chronic hydroxychloroquine therapy.** Sen S, Werner A, Shekhar A. Drugs Ther Perspect. 2020:1.

1144. **Exosomes Derived From Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19.** Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Stem cells and development. 2020.

1145. **"Toxic erythema" and eosinophilia associated to tocilizumab therapy in a COVID-19 patient.** Sernicola A, Carnicelli G, Di Fraia M, Chello C, Furlan C, Muharremi R, et al. Journal of the European Academy of Dermatology and Venereology : JEADV. 2020.

1146. **The Renin-Angiotensin system and SARS-CoV-2 infection: A role for the ACE2 receptor?** Sever P, Johnston SL. Journal of the renin-angiotensin-aldosterone system : JRAAS. 2020;21(2):1470320320926911.

1147. **Cannabis in the Time of Coronavirus Disease 2019: The Yin and Yang of the Endocannabinoid System in Immunocompetence.** Sexton M. Journal of alternative and complementary medicine (New York, NY). 2020.

1148. **The impact of hydroxychloroquine shortages on patients with dermatological conditions during COVID-19 pandemic.** Shah M, Sachdeva M, Dodiuk-Gad RP. Dermatologic therapy. 2020.

1149. **Cerebellar Scholars' Challenging Time in COVID-19 Pandemia.** Shaikh AG, Mitoma H, Manto M. Cerebellum. 2020;19(3):343-4.

1150. **Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus.** Shaikh K, Shrestha C, Dutta D.

1151. **Treatment considerations for patients with pemphigus during the COVID-19 pandemic.** Shakshouk H, Daneshpazhooch M, Murrell DF, Lehman JS. Journal of the American Academy of Dermatology. 2020;82(6):e235-e6.

1152. **Interferon beta-1b for COVID-19.** Shalhoub S. Lancet (London, England). 2020.

1153. **Hydroxychloroquine Versus COVID-19: A Periodic Systematic Review and Meta-Analysis.** Shamshirian

A, Hessami A, Heydari K, Alizadeh-Navaei R, Ebrahimzadeh MA, Yip GW, et al. medRxiv. 2020:2020.04.14.20065276.

1154. **Dietary management to build adaptive immunity against COVID-19.** Sharma L. Journal of PeerScientist. 2020;2(2):e1000016.

1155. **Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units.** Shekerdemian LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE, McKiernan CA, et al. JAMA pediatrics. 2020.

1156. **Diagnostic efficacy of three test kits for SARS-CoV-2 nucleic acid detection.** Shen L, Huang F, Chen X, Xiong Z, Yang X, Li H, et al. Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences. 2020;49(2):185-90.

1157. **Inhibition of Influenza A virus propagation by benzoselenoxanthenes stabilizing TMPRSS2 Gene G-quadruplex and hence down-regulating TMPRSS2 expression.** Shen LW, Qian MQ, Yu K, Narva S, Yu F, Wu YL, et al. Scientific reports. 2020;10(1):7635.

1158. **Urgent need for evaluating agonists of Angiotensin-(1-7)/ Mas receptor axis for treatment of patients with COVID-19.** Shete A. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020.

1159. **Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019.** Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F, et al. European heart journal. 2020.

1160. **An overview of COVID-19.** Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, et al. Journal of Zhejiang University: Science B. 2020.

1161. **Improving the efficacy of Chloroquine and Hydroxychloroquine against SARS-CoV-2 may require Zinc additives-A better synergy for future COVID-19 clinical trials.** Shittu MO, Afolami OI. Le infezioni in medicina: rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive. 2020;28(2):192-7.

1162. **Potential SARS-CoV-2 Preimmune IgM Epitopes.** Shivarov V, Petrov PK, Pashov AD. Frontiers in Immunology. 2020;11.

1163. **Porcine epidemic diarrhea virus (PEDV) ORF3 enhances viral proliferation by inhibiting apoptosis of infected cells.** Si F, Hu X, Wang C, Chen B, Wang R, Dong S, et al. Viruses. 2020;12(2).

1164. **Pathogenesis and transmission of SARS-CoV-2 in golden hamsters.** Sia SF, Yan LM, Chin AWH, Fung K, Choy KT, Wong AYL, et al. Nature. 2020.

1165. **Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.** Silva J, Figueiredo PLB, Byler KG, Setzer WN. Int J Mol Sci. 2020;21(10). <http://dx.doi.org/10.3390/ijms21103426>.

1166. **Guidelines for the management of diabetes in care homes during the Covid-19 pandemic.** Sinclair A, Dhataria K, Burr O, Nagi D, Higgins K, Hopkins D, et al. Diabetic medicine : a journal of the British Diabetic Association. 2020.

1167. **Editorial: Herd mentality, herds of migrants/people, and COVID-19 in India.** Singh AK, Misra A. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020;14(4):497.

1168. **"Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis."** Singh AK, Singh A, Singh R, Misra A. Diabetes & metabolic syndrome. 2020;14(4):589-96. <http://dx.doi.org/10.1016/j.dsx.2020.05.017>.

1169. **Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies.** Singh AK, Singh A, Singh R, Misra A. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2020;14(4):641-8.
1170. **The research community must meet the coronavirus disease 2019 challenge.** Singh PK. *Indian Journal of Medical Research, Supplement*. 2020;151(2):116-7.
1171. **Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series.** Singh S, Chakravarty T, Chen P, Akhmerov A, Falk J, Friedman O, et al. *Basic research in cardiology*. 2020;115(4):36. <http://dx.doi.org/10.1007/s00395-020-0795-1>.
1172. **Outcomes of Hydroxychloroquine Treatment Among Hospitalized COVID-19 Patients in the United States- Real-World Evidence From a Federated Electronic Medical Record Network.** Singh S, Khan A, Chowdhry M, Chatterjee A. *medRxiv*. 2020:2020.05.12.20099028.
1173. **Lessons from COVID-19 in children: Key hypotheses to guide preventative and therapeutic strategies.** Singh T, Heston SM, Langel SN, Blasi M, Hurst JH, Fouda GG, et al. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
1174. **COVID-19 pandemic perception in adults with celiac disease: an impulse to implement the use of telemedicine: COVID-19 and CeD.** Siniscalchi M, Zingone F, Savarino EV, D'Odorico A, Ciacci C. *Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver*. 2020.
1175. **Systematic and Statistical Review of COVID19 Treatment Trials.** Siordia JA, Bernaba M, Yoshino K, Ulhaque A, Kumar S, Bernaba M, et al. *medRxiv*. 2020:2020.05.16.20102095.
1176. **Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management.** Siripanthong B, Nazarian S, Muser D, Deo R, Santangeli P, Khanji MY, et al. *Heart rhythm*. 2020.
1177. **Monitoring for post-injection delirium/sedation syndrome with long-acting olanzapine during the COVID-19 pandemic.** Siskind D, Northwood K, Berk M, Castle D, Galletly C, Harris A. *The Australian and New Zealand journal of psychiatry*. 2020:4867420927465.
1178. **Elucidating biophysical basis of binding of inhibitors to SARS-CoV-2 main protease by using molecular dynamics simulations and free energy calculations.** Sk MF, Roy R, Jonniya NA, Poddar S, Kar P. *Journal of biomolecular structure & dynamics*. 2020:1-21.
1179. **Zinc and respiratory tract infections: Perspectives for COVID-19.** Skalny AV, Rink L, Ajsuvakova OP, Aschner M, Gritsenko VA, Alekseenko SI, et al. *International Journal of Molecular Medicine*. 2020;46(1):17-26.
1180. **Zinc and respiratory tract infections: Perspectives for COVID-19 (Review).** Skalny AV, Rink L, Ajsuvakova OP, Aschner M, Gritsenko VA, Alekseenko SI, et al. *Int j mol med*. 2020.
1181. **Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract.** Smith JC, Sausville EL, Girish V, Yuan ML, Vasudevan A, John KM, et al. *Developmental cell*. 2020.
1182. **Immunogenicity of a DNA vaccine candidate for COVID-19.** Smith TRF, Patel A, Ramos S, Elwood D, Zhu X, Yan J, et al. *Nat Commun*. 2020;11(1):2601. <http://dx.doi.org/10.1038/s41467-020-16505-0>.
1183. **Therapeutic Potential for Tetracyclines in the Treatment of COVID-19.** Sodhi M, Etminan M. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*. 2020.

1184. **A Systematic Literature Review of Current Therapeutic Approaches for COVID-19 Patients.** Soltani S, Zakeri AM, Karimi MR, Rezayat SA, Anbaji FZ, Tabibzadeh A, et al. *Journal of Pharmaceutical Research International*. 2020;13-25.
1185. **Prevention is better than the cure, but the cure cannot be worse than the disease: fiberoptic tracheal intubation in COVID-19 patients.** Sorbello M, Di Giacinto I, Corso RM, Cataldo R. *British journal of anaesthesia*. 2020.
1186. **COVID-19 Comes 40 Years After AIDS - Any Lesson?** Soriano V, Barreiro P, Ramos JM, Eiros JM, de Mendoza C. *AIDS reviews*. 2020;22(2).
1187. **Emergency preparedness after COVID-19: A review of policy statements for the U.S. water sector.** Sowby RB. *Utilities policy*. 2020:101058. <http://dx.doi.org/10.1016/j.jup.2020.101058>.
1188. **A perfect storm: Root cause analysis of supra-therapeutic anticoagulation with vitamin K antagonists during the COVID-19 pandemic.** Speed V, Patel RK, Byrne R, Roberts LN, Arya R. *Thrombosis research*. 2020.
1189. **Response to 'Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?' by Moiseev et al.** Spinelli FR, Ceccarelli F, Di Franco M, Conti F. *Annals of the Rheumatic Diseases*. 2020.
1190. **HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.** Spinelli FR, Conti F, Gadina M. *Science immunology*. 2020;5(47).
1191. **COVID-19 and Avoiding Ibuprofen. How Good Is the Evidence?** Sridharan GK, Kotagiri R, Chandiramani VH, Mohan BP, Vegunta R, Vegunta R, et al. *American journal of therapeutics*. 2020.
1192. **Antivirals for COVID-19.** Srinivas P, Sacha G, Koval C. *Cleve Clin J Med*. 2020. <http://dx.doi.org/10.3949/ccjm.87a.ccc030>.
1193. **Reviews of Science for Science Librarians: Vitamins and Trace Elements that May Be Preventive or Ameliorating in This Age of Contagion.** Stankus T. *Science & Technology Libraries*. 2020.
1194. **Itch in the era of COVID-19 pandemic: an unfolding scenario.** Stefaniak AA, Białyński-Birula R, Krajewski P, Matusiak Ł, Goldust M, Szepietowski JC. *Dermatologic Therapy*. 2020.
1195. **COVID-19 infection during pregnancy: fetus as a patient deserves more attention.** Stefanovic V. *Journal of perinatal medicine*. 2020.
1196. **COVID-19 and autism.** Steinman G. *Medical Hypotheses*. 2020;142.
1197. **Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.** Sternberg A, McKee DL, Naujokat C. *Curr Top Med Chem*. 2020. <http://dx.doi.org/10.2174/1568026620999200517043137>.
1198. **HMGB1: A Possible Crucial Therapeutic Target for COVID-19?** Street ME. *Hormone research in paediatrics*. 2020:1-3.
1199. **COVID-19: The Uninvited Guest in the Intensive Care Unit - Implications for Pharmacotherapy.** Stringer KA, Puskarich MA, Kenes MT, Dickson RP. *Pharmacotherapy*. 2020;40(5):382-6. <http://dx.doi.org/10.1002/phar.2394>. Epub 2020 May 4.
1200. **Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy).** Stroppa EM, Toscani I, Citterio C, Anselmi E, Zaffignani E, Codeluppi M, et al. *Future oncology (London, England)*. 2020. <http://dx.doi.org/10.2217/fon-2020-0369>.

1201. **The renin-angiotensin system - a therapeutic target in COVID-19?** Sturrock BR, Milne K, Chevassut TJ. *Clinical medicine (London, England)*. 2020.
1202. **The potential application of the traditional Chinese herb *Exocarpium Citri grandis* in the prevention and treatment of COVID-19.** Su WW, Wang YG, Li PB, Wu H, Zeng X, Shi R, et al. *Traditional Medicine Research*. 2020;5(3):160-6.
1203. **Comparison of CRB-65 and quick sepsis-related organ failure assessment for predicting the need for intensive respiratory or vasopressor support in patients with COVID-19.** Su Y, Tu GW, Ju MJ, Yu SJ, Zheng JL, Ma GG, et al. *The Journal of infection*. 2020.
1204. **SARS-CoV-2: A New Song Recalls an Old Melody.** Subbarao K. *Cell Host and Microbe*. 2020;27(5):692-4.
1205. **Prolonged Persistence of SARS-CoV-2 RNA in Body Fluids.** Sun J, Xiao J, Sun R, Tang X, Liang C, Lin H, et al. *Emerging infectious diseases*. 2020;26(8).
1206. **Clinical Features of Patients with Coronavirus Disease 2019 (COVID-19) from a Designated Hospital in Beijing, China.** Sun L, Shen L, Fan J, Gu F, Hu M, An Y, et al. *Journal of medical virology*. 2020.
1207. **Combination of four clinical indicators predicts the severe/critical symptom of patients infected COVID-19.** Sun L, Song F, Shi N, Liu F, Li S, Li P, et al. *Journal of Clinical Virology*. 2020;128.
1208. **Review of Current Evidence of Hydroxychloroquine in Pharmacotherapy of COVID-19.** Suranagi UD, Rehan HS, Goyal N. *medRxiv*. 2020:2020.04.16.20068205.
1209. **Clinical orthodontic management during the COVID-19 pandemic.** Suri S, Vandersluis YR, Kochhar AS, Bhasin R, Abdallah MN. *The Angle orthodontist*. 2020.
1210. **Custom-made 3D-printed face masks in case of pandemic crisis situations with a lack of commercially available FFP2/3 masks.** Swennen GRJ, Pottel L, Haers PE. *International Journal of Oral and Maxillofacial Surgery*. 2020;49(5):673-7.
1211. **The powerful immune system against powerful COVID-19: A hypothesis.** Taghizadeh-Hesary F, Akbari H. *Medical hypotheses*. 2020;140:109762.
1212. **Acute kidney injury in pregnant women following SARS-CoV-2 infection: A case report from Iran.** Taghizadieh A, Mikaeili H, Ahmadi M, Valizadeh H. *Respir Med Case Rep*. 2020:101090. <http://dx.doi.org/10.1016/j.rmcr.2020.101090>.
1213. **Real-time RT-PCR in COVID-19 detection: issues affecting the results.** Tahamtan A, Ardebili A. *Expert Review of Molecular Diagnostics*. 2020;20(5):453-4.
1214. **Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants.** Tahir ul Qamar M, Alqahtani SM, Alamri MA, Chen LL. *Journal of Pharmaceutical Analysis*. 2020.
1215. **Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.** Tai W, Zhang X, He Y, Jiang S, Du L. *Antiviral research*. 2020:104820.
1216. **Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19.** Takami A. *International Journal of Hematology*. 2020.
1217. **COPD at the time of COVID-19: A COPD foundation perspective.** Tal-Singer R, Crapo JD. *Chronic Obstructive Pulmonary Diseases*. 2020;7(2):73-5.

1218. **Associations between Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality among Patients with COVID-19.** Tan ND, Qiu Y, Xing XB, Ghosh S, Chen MH, Mao R. *Gastroenterology*. 2020.
1219. **Ostavimvir is ineffective against COVID-19: in silico assessment, in vitro and retrospective study.** Tan Q, Jin Y. *medRxiv*. 2020:2020.05.15.20102392.
1220. **Clinical Performance of Two SARS-CoV-2 Serologic Assays.** Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, et al. *Clinical chemistry*. 2020.
1221. **Response to "Lupus anticoagulant is frequent in patients with Covid-19".** Tang N. *Journal of thrombosis and haemostasis : JTH*. 2020.
1222. **Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.** Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. *Bmj*. 2020;369:m1849. <http://dx.doi.org/10.1136/bmj.m1849>.
1223. **2019 Novel Coronavirus Disease (COVID-19) in patients with Inflammatory Bowel Diseases.** Taxonera C, Sagastagoitia I, Alba C, Mañas N, Olivares D, Rey E. *Alimentary Pharmacology and Therapeutics*. 2020.
1224. **Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19.** Tchelebi LT, Haustermans K, Scorsetti M, Hosni A, Huguet F, Hawkins MA, et al. *Radiotherapy and Oncology*. 2020;148:194-200.
1225. **Type and dose of heparin in Covid-19: Reply.** Thachil J, Tang N, Gando S, Falanga A, Levi M, Clark C, et al. *Journal of Thrombosis and Haemostasis*. 2020.
1226. **COVID-19: endgames.** The Lancet Infectious D. *The Lancet Infectious Diseases*. 2020;20(5):511.
1227. **The eye as the discrete but defensible portal of coronavirus infection.** Theodore Coroneo M. *The ocular surface*. 2020. <http://dx.doi.org/10.1016/j.jtos.2020.05.011>.
1228. **Protective Role of BTK Inhibitors in Patients with Chronic Lymphocytic Leukemia and COVID-19.** Thibaud S, Tremblay D, Bhalla S, Zimmerman B, Sigel K, Gabrilove J. *British Journal of Haematology*.
1229. **Hyperbaric oxygen therapy in preventing mechanical ventilation in COVID-19 patients: a retrospective case series.** Thibodeaux K, Speyrer M, Raza A, Yaakov R, Serena TE. *Journal of wound care*. 2020;29:S4-s8. <http://dx.doi.org/10.12968/jowc.2020.29.Sup5a.S4>.
1230. **A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2.** Thoguluva Chandrasekar V, Venkatesalu B, Patel HK, Spadaccini M, Manteuffel J, Ramesh MS. *medRxiv*. 2020:2020.05.20.20108365.
1231. **Reply to: "A Dermatologic Manifestation of COVID-19: Transient Livedo Reticularis".** Thomas C. *Journal of the American Academy of Dermatology*. 2020.
1232. **Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom.** Thomas W, Varley J, Johnston A, Symington E, Robinson M, Sheares K, et al. *Thrombosis Research*. 2020;191:76-7.
1233. **Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement.** Thomson DJ, Palma D, Guckenberger M, Balermipas P, Beitler JJ, Blanchard P, et al. *International Journal of Radiation Oncology Biology Physics*. 2020.

1234. **Covid-19 in pregnancy.** Thornton JG. *BJOG : an international journal of obstetrics and gynaecology*. 2020.
1235. **What we do when a COVID-19 patient needs an operation: operating room preparation and guidance.** Ti LK, Ang LS, Foong TW, Ng BSW. *Canadian Journal of Anesthesia*. 2020;67(6):756-8.
1236. **Letter: does vitamin D have a potential role against COVID-19? Authors' reply.** Tian Y, Rong L. *Alimentary pharmacology & therapeutics*. 2020.
1237. **Increased severity of COVID-19 in people with obesity: are we overlooking plausible biological mechanisms?** Tibirićá E, De Lorenzo A. *Obesity (Silver Spring, Md)*. 2020.
1238. **Antihypertensive drugs and risk of COVID-19?** Tignanelli CJ, Ingraham NE, Sparks MA, Reilkoff R, Bezdicek T, Benson B, et al. *The Lancet Respiratory Medicine*. 2020;8(5):e30-e1.
1239. **Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach.** Tilangi P, Desai D, Khan A, Soneja M. *The Lancet Infectious Diseases*. 2020.
1240. **Beyond Smoking Cessation: Investigating Medicinal Nicotine to Prevent and Treat COVID-19.** Tindle HA, Newhouse PA, Freiberg MS. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco*. 2020.
1241. **Investigating the genomic landscape of novel coronavirus (2019-nCoV) to identify non-synonymous mutations for use in diagnosis and drug design.** Tiwari M, Mishra D. *Journal of Clinical Virology*. 2020;128.
1242. **Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: A monocentric survey.** Tomelleri A, Sartorelli S, Campochiaro C, Baldissera EM, Dagna L. *Annals of the Rheumatic Diseases*. 2020.
1243. **Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.** Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. *Autoimmunity reviews*. 2020:102568.
1244. **Pooling of Nasopharyngeal Swab Specimens for SARS-CoV-2 detection by RT-PCR.** Torres I, Albert E, Navarro D. *Journal of medical virology*. 2020.
1245. **Clinical and Chest Radiography Features Determine Patient Outcomes In Young and Middle Age Adults with COVID-19.** Toussie D, Voutsinas N, Finkelstein M, Cedillo MA, Manna S, Maron SZ, et al. *Radiology*. 2020:201754. <http://dx.doi.org/10.1148/radiol.2020201754>.
1246. **COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions.** Triggle CR, Bansal D, Farag EABA, Ding H, Sultan AA. *mSphere*. 2020;5(3).
1247. **A review on possible modes of actions of Chloroquine/Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic.** Tripathy S, Dassarma B, Roy S, Chabalala H, Matsabisa MG. *International Journal of Antimicrobial Agents*. 2020:106028.
1248. **A novel coronavirus (SARS-CoV-2) and COVID-19.** Trojanek M, Grebenyuk V, Herrmannova K, Necas T, Gregorova J, Kucbel M, et al. *Casopis lekaru ceskych*. 2020;159(2):55-66.
1249. **[Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection].** Troldborg A, Bartels LE, Deleuran B. *Ugeskrift for laeger*. 2020;182(20).
1250. **Response to Wen and Li, Anesthesia Procedure of Emergency Operation for Patients with Suspected or Confirmed COVID-19 (DOI: 10.1089/sur.2020.040).** Trujillo A. *Surgical Infections*. 2020;21(4):397.

1251. **Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease.** Tsuji M. FEBS open bio. 2020.
1252. **Current epidemiological and clinical features of COVID-19; a global perspective from China.** Tu H, Tu S, Gao S, Shao A, Sheng J. Journal of Infection. 2020.
1253. **Psychological Outcomes Associated with Stay-at-Home Orders and the Perceived Impact of COVID-19 on Daily Life.** Tull MT, Edmonds KA, Scamaldo KM, Richmond JR, Rose JP, Gratz KL. Psychiatry Res. 2020;289:113098. <http://dx.doi.org/10.1016/j.psychres.2020.113098>.
1254. **Coexistence of COVID-19 and acute ischemic stroke report of four cases.** TunÇ A, ÜNİÜBaŞ Y, Alemdar M, AkyÜ ZE. Journal of Clinical Neuroscience. 2020.
1255. **Cutaneous Side-Effects of the Potential Covid-19 Drugs.** Türsen Ü, Türsen B, Lotti T. Dermatologic Therapy. 2020.
1256. **Anti-TNF- α Agents in Inflammatory Bowel Disease and Course of COVID-19.** Tursi A, Vetrone LM, Papa A. Inflammatory bowel diseases. 2020.
1257. **The Role of Hydroxychloroquine in Coronavirus Disease 2019. A Versatile Tool at the Service of Humanity.** Tzouveleki A, Karampitsakos T, Bouros D. Frontiers in Medicine. 2020;7.
1258. **SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions.** Uddin M, Mustafa F, Rizvi TA, Loney T, Suwaidi HA, Al-Marzouqi AHH, et al. Viruses. 2020;12(5).
1259. **Coronavirus vaccines.** Urbiztondo L, Borrás E, Mirada G. Vacunas. 2020.
1260. **2019-nCoV-SARS-CoV-2 (COVID-19) infection: Cruciality of Furin and relevance with cancer.** Usul Afsar C. Medical Hypotheses. 2020;140.
1261. **Renin-angiotensin-aldosterone system inhibitors in patients with covid-19.** Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. New England Journal of Medicine. 2020;382(17):1653-9.
1262. **Potential mechanisms by which the oxygen-ozone (O₂-O₃) therapy could contribute to the treatment against the coronavirus COVID-19.** Valdenassi L, Franzini M, Ricevuti G, Rinaldi L, Galoforo AC, Tirelli U. European review for medical and pharmacological sciences. 2020;24(8):4059-61.
1263. **Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Ischemic Stroke.** Valderrama EV, Humbert K, Lord A, Frontera J, Yaghi S. Stroke. 2020:STROKEAHA120030153.
1264. **A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.** Valencia-Sanchez C, Wingerchuk DM. Multiple Sclerosis and Related Disorders. 2020;42.
1265. **Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.** Valk SJ, Piechotta V, Chai KL, Doree C, Monsef I, Wood EM, et al. Cochrane Database Syst Rev. 2020;5:CD013600. <http://dx.doi.org/10.1002/14651858.CD013600>.
1266. **Cardiothoracic robotic assisted surgery in times of COVID-19.** Van den Eynde J, De Groote S, Van Lerberghe R, Van den Eynde R, Oosterlinck W. Journal of robotic surgery. 2020.
1267. **Emergence of genomic diversity and recurrent mutations in SARS-CoV-2.** van Dorp L, Acman M, Richard D, Shaw LP, Ford CE, Ormond L, et al. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases. 2020:104351.

1268. **Care for adult non-ICU covid-19 patients: Early experiences from a Belgian tertiary care centre.** Van Halem K, Cox J, Messiaen P, Pat K, Declercq C, Meersman A, et al. *Netherlands Journal of Medicine*. 2020;78(3):111-5.
1269. **Comparison of seven commercial RT-PCR diagnostic kits for COVID-19.** van Kasteren PB, van der Veer B, van den Brink S, Wijsman L, de Jonge J, van den Brandt A, et al. *Journal of Clinical Virology*. 2020;128.
1270. **COVID-19: An Update About the Discovery Clinical Trial.** Vanden Eynde JJ. *Pharmaceuticals (Basel, Switzerland)*. 2020;13(5). <http://dx.doi.org/10.3390/ph13050098>.
1271. **Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein.** Vankadari N. *International Journal of Antimicrobial Agents*. 2020.
1272. **The many faces of the anti-COVID immune response.** Vardhana SA, Wolchok JD. *The Journal of experimental medicine*. 2020;217(6).
1273. **Alcohol withdrawal management during the Covid-19 lockdown in Kerala.** Varma RP. *Indian journal of medical ethics*. 2020(2):105-6.
1274. **Can beta-adrenergic blockers be used in the treatment of COVID-19?** Vasanthakumar N. *Medical hypotheses*. 2020;142:109809.
1275. **Towards effective diagnostic assays for COVID-19: a review.** Venter M, Richter K. *Journal of clinical pathology*. 2020.
1276. **Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus.** Verdecchia P, Angeli F, Reboldi G. *Journal of hypertension*. 2020;38(6):1190-1.
1277. **CE2 Receptor Expression in Testes: Implications in COVID-19 Pathogenesis.** Verma S, Saksena S, Sadri-Ardekani H. *Biology of reproduction*. 2020.
1278. **Time-to-Death approach in revealing Chronicity and Severity of COVID-19 across the World.** Verma V, Vishwakarma RK, Verma A, Nath DC, Khan HTA. *PloS one*. 2020;15(5):e0233074.
1279. **Use of corticosteroids in Coronavirus disease 2019 pneumonia: A systematic review of the literature.** Veronese N, Demurtas J, Yang L, Tonelli R, Barbagallo M, Lopalco P, et al. *Frontiers in Medicine*. 2020;7.
1280. **Angiotensin-converting enzyme-2 in SARS-CoV-2 infection: good or bad?** Versmissen J, Verdonk K, Lafeber M, van den Akker JPC, Hunfeld NGM, Hoorn EJ, et al. *Journal of hypertension*. 2020;38(6):1196-7.
1281. **Lung Ultrasound and the COVID-19 "Pattern": Not All That Glitters Today Is Gold Tomorrow.** Vetrugno L, Bove T, Orso D, Bassi F, Boero E, Ferrari G. *Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine*. 2020.
1282. **Prone positioning and high-flow oxygen improved respiratory function in a 25-week pregnant woman with COVID-19.** Vibert F, Kretz M, Thuet V, Barthel F, De Marcillac F, Deruelle P, et al. *European journal of obstetrics, gynecology, and reproductive biology*. 2020.
1283. **Tocilizumab in COVID-19: beware of risk of intestinal perforation.** Vikse J, Henry BM. *International journal of antimicrobial agents*. 2020:106009.
1284. **Reply To The Article "Bariatric Surgical Practice During the Initial Phase of COVID-19 Outbreak." by Aminian, A., Kermansaravi, M., Azizi, S. et al. Published in Obesity Surgery.** Vilallonga R, Blanco-Colino R, Armengol Carrasco M. *Obes Surg*. 2020:1-2. <http://dx.doi.org/10.1007/s11695-020-04678-y>.

1285. **The healthcare and pharmaceutical vulnerability emerging from the new Coronavirus outbreak.** Vinci DL, Polidori C, Polidori P. *European Journal of Hospital Pharmacy.* 2020;27(3):129-30.
1286. **Sars-CoV-2 and black population: ACE2 as shield or blade?** Vinciguerra M, Greco E. *Infection, Genetics and Evolution.* 2020;84.
1287. **SARS-CoV-2 and myocardial injury: a role for Nox2?** Violi F, Pastori D, Pignatelli P, Cangemi R. *Internal and emergency medicine.* 2020.
1288. **Occurrence of pulmonary embolism in a patient with mild clinical expression of COVID-19.** Vitali C, Minniti A, Caporali R, Del Papa N. *Thrombosis Research.* 2020;192:21-2.
1289. **Neurological manifestations and neuro-invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2.** Vonck K, Garrez I, De Herdt V, Hemelsoet D, Laureys G, Raedt R, et al. *European journal of neurology.* 2020.
1290. **An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic.** Vouri SM, Thai TN, Winterstein AG. *Research in social & administrative pharmacy : RSAP.* 2020. <http://dx.doi.org/10.1016/j.sapharm.2020.04.031>.
1291. **COVID-19 in Correctional and Detention Facilities - United States, February-April 2020.** Wallace M, Hagan L, Curran KG, Williams SP, Handanagic S, Bjork A, et al. *MMWR Morbidity and mortality weekly report.* 2020;69(19):587-90. <http://dx.doi.org/10.15585/mmwr.mm6919e1>.
1292. **Public Health Response to COVID-19 Cases in Correctional and Detention Facilities - Louisiana, March-April 2020.** Wallace M, Marlow M, Simonson S, Walker M, Christophe N, Dominguez O, et al. *MMWR Morbidity and mortality weekly report.* 2020;69(19):594-8. <http://dx.doi.org/10.15585/mmwr.mm6919e3>.
1293. **Androgen sensitivity gateway to COVID-19 disease severity.** Wambier CG, Goren A, Vaño-Galván S, Ramos PM, Ossimetha A, Nau G, et al. *Drug Development Research.* 2020.
1294. **Intravenous Anakinra for Macrophage Activation Syndrome May Hold Lessons for Treatment of Cytokine Storm in the Setting of Coronavirus Disease 2019.** Wampler Muskardin TL. *ACR Open Rheumatology.* 2020.
1295. **Current practice and potential strategy in diagnosing COVID-19.** Wan DY, Luo XY, Dong W, Zhang ZW. *European review for medical and pharmacological sciences.* 2020;24(8):4548-53.
1296. **The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic.** Wan MT, Shin DB, Winthrop KL, Gelfand JM. *Journal of the American Academy of Dermatology.* 2020.
1297. **Evidence from two cases of asymptomatic infection with SARS-CoV-2: Are 14 days of isolation sufficient?** Wan R, Mao ZQ, He LY, Hu YC, Wei C. *International Journal of Infectious Diseases.* 2020;95:174-5.
1298. **Implications of the lack of a unified research project framework: an investigation into the registration of clinical trials of COVID-19.** Wang B, Lai J, Yan X, Jin F, Yao C. *Current medical research and opinion.* 2020:1.
1299. **IL-6 may be a good biomarker for earlier detection of COVID-19 progression.** Wang C, Fei D, Li X, Zhao M, Yu K. *Intensive care medicine.* 2020.
1300. **An evidence based perspective on mRNA-SARScov-2 vaccine development.** Wang F, Kream RM, Stefano

GB. Medical Science Monitor. 2020;26.

1301. **Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia.** Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. The Journal of infectious diseases. 2020;221(11):1762-9.

1302. **Mechanistic insights into ventricular arrhythmogenesis of hydroxychloroquine and azithromycin for the treatment of COVID-19.** Wang G, Tian X, Lu C-J, Flores H, Maj P, Zhang K, et al. bioRxiv. 2020.

1303. **Dynamic changes of chest CT imaging in patients with COVID-19.** Wang J, Liu J, Wang Y, Liu W, Chen X, Sun C, et al. Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences. 2020;49(2):191-7.

1304. **Tracheal intubation in patients with severe and critical COVID-19: analysis of 18 cases.** Wang J, Lu F, Zhou M, Qi Z, Chen Z. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. 2020;40(3):337-41.

1305. **Spontaneous pneumomediastinum: A probable unusual complication of Coronavirus disease 2019 (COVID-19) pneumonia.** Wang J, Su X, Zhang T, Zheng C. Korean Journal of Radiology. 2020;21(5):627-8.

1306. **Recent advances in treatment of viral pneumonia using Chinese patent medicine.** Wang T, Han LF, Wang YF, Miao L, Yang J, Zhang JH, et al. Zhongguo Zhongyao Zazhi. 2020;45(7):1509-14.

1307. **Design, validation, and clinical practice of standardized imaging diagnostic report for COVID-19.** Wang T, Xiong Z, Zhou H, Luo W, Tang H, Liu J. Zhong nan da xue xue bao Yi xue ban = Journal of Central South University Medical sciences. 2020;45(3):229-35.

1308. **The role of cardiac imaging in hospitalized COVID-19-positive patients.** Wang TKM, Tang WHW, Flamm SD, Griffin B, Dugar S, Grimm RA, et al. Cleveland Clinic journal of medicine. 2020.

1309. **Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease-2019.** Wang W, Wei Z, Zhang J, He J, Zhu F. HLA. 2020.

1310. **Nosocomial Outbreak of 2019 Novel Coronavirus Pneumonia in Wuhan, China.** Wang X, Zhou Q, He Y, Liu L, Ma X, Wei X, et al. The European respiratory journal. 2020.

1311. **Asymptomatic Cases with SARS-CoV-2 Infection.** Wang Y, Kang H, Liu X, Tong Z. Journal of medical virology. 2020.

1312. **Retrospective Analysis of Smell and Taste Disturbances Associated with Dermatological Medications Reported to the United States Food and Drug Administration and Relevance to COVID-19 Infections.** Wang Y, Lipner SR. Journal of the American Academy of Dermatology. 2020.

1313. **Clinical Outcomes in 55 Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Who Were Asymptomatic at Hospital Admission in Shenzhen, China.** Wang Y, Liu Y, Liu L, Wang X, Luo N, Li L. The Journal of infectious diseases. 2020;221(11):1770-4. <http://dx.doi.org/10.1093/infdis/jiaa119>.

1314. **Changes in air quality related to the control of coronavirus in China: Implications for traffic and industrial emissions.** Wang Y, Yuan Y, Wang Q, Liu C, Zhi Q, Cao J. The Science of the total environment. 2020;731:139133.

1315. **The pros and cons of traditional Chinese medicines in the treatment of COVID-19.** Wang Y, Zeng X, Zhao Y, Chen W, Chen YZ. Pharmacological research. 2020;157.

1316. **The Risk of Children Hospitalized With Severe COVID-19 in Wuhan.** Wang Y, Zhu F, Wang C, Wu J, Liu J, Chen X, et al. The Pediatric infectious disease journal. 2020.

1317. **Ground-glass opacity on chest computed tomography in a young, athletic man with COVID-19-related pneumonia without hypoxemia.** Wańkiewicz P, Rotter I. Polish archives of internal medicine. 2020.
1318. **Clinical Testing For Covid-19.** Ward S, Lindsley A, Courter J, Assa'ad A. The Journal of allergy and clinical immunology. 2020. <http://dx.doi.org/10.1016/j.jaci.2020.05.012>.
1319. **Analysis of thin-section CT in patients with coronavirus disease (COVID-19) after hospital discharge.** Wei J, Lei P, Yang H, Fan B, Qiu Y, Zeng B, et al. Clinical imaging. 2020.
1320. **Acute myocardial injury is common in patients with covid-19 and impairs their prognosis.** Wei JF, Huang FY, Xiong TY, Liu Q, Chen H, Wang H, et al. Heart. 2020.
1321. **PEDV enters cells through clathrin-, caveolae-, and lipid raft-mediated endocytosis and traffics via the endo-/lysosome pathway.** Wei X, She G, Wu T, Xue C, Cao Y. Veterinary research. 2020;51(1).
1322. **Glycerol monolaurate, an analogue to a factor secreted by lactobacillus, is virucidal against enveloped viruses, including hiv-1.** Welch JL, Xiang J, Okeoma CM, Schlievert PM, Stapleton JT. mBio. 2020;11(3).
1323. **First case of covid-19 in the United States.** Weng L, Jiao Y, Li Y. New England Journal of Medicine. 2020;382(19).
1324. **Some lessons from the COVID-19 pandemic.** Wertheimer A. Journal of Pharmaceutical Health Services Research. 2020;11(2):95.
1325. **COVID-19: Impact on Colorectal Surgery.** Wexner SD, Cortés-Guiral D, Gilshtein H, Kent I, Reymond M. Colorectal Disease. 2020.
1326. **COVID-19: A fast evolving pandemic.** Whitworth J. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2020;114(4):227-8.
1327. **The contribution of diabetic micro-angiopathy to adverse outcomes in COVID-19.** Whyte MB, Vas P, Heiss C, Feher MD. Diabetes research and clinical practice. 2020:108217.
1328. **The time is now: expedited HIV differentiated service delivery during the COVID-19 pandemic.** Wilkinson L, Grimsrud A. Journal of the International AIDS Society. 2020;23(5):e25503.
1329. **The ocular surface, coronaviruses and COVID-19.** Willcox MD, Walsh K, Nichols JJ, Morgan PB, Jones LW. Clinical & experimental optometry. 2020.
1330. **Prioritising access to pandemic influenza vaccine: a review of the ethics literature.** Williams JH, Dawson A. BMC medical ethics. 2020;21(1):40.
1331. **Global Epidemic Of Coronavirus—Covid-19: What Can We Do To Minimize Risks.** Wimalawansa SJ. European Journal of Biomedical. 2020;7(3):432-8.
1332. **Downregulation of COVID-19 hyperinflammation using corticosteroids.** Winkler EA. 2020.
1333. **PRESCIENT: platform for the rapid evaluation of antibody success using integrated microfluidics enabled technology.** Wippold JA, Wang H, Tingling J, Leibowitz JL, de Figueiredo P, Han A. Lab on a Chip. 2020;20(9):1628-38.
1334. **Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank.** Wlodawer A, Dauter Z, Shabalin I, Gilski M, Brzezinski D, Kowiel M, et al. The FEBS journal. 2020.

1335. **COVID-19 and toxicity from potential treatments: panacea or poison.** Wong A. *Emergency medicine Australasia : EMA.* 2020.
1336. **Clinical presentations, laboratory and radiological findings, and treatments for 11,028 COVID-19 patients: a systematic review and meta-analysis.** Wong CK, Wong JY, Tang EH, Au CH, Wai AK. 2020.
1337. **Fibrinolysis Shutdown Correlates to Thromboembolic Events in Severe COVID-19 Infection.** Wright FL, Vogler TO, Moore EE, Moore HB, Wohlaer MV, Urban S, et al. *Journal of the American College of Surgeons.* 2020.
1338. **Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.** Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. 2020.
1339. **Interpretation of CT signs of 2019 novel coronavirus (COVID-19) pneumonia.** Wu J, Pan J, Teng D, Xu X, Feng J, Chen YC. *European radiology.* 2020.
1340. **Recovery from COVID-19 in two patients with coexisted HIV infection.** Wu Q, Chen T, Zhang H. *Journal of medical virology.* 2020.
1341. **An Update on Current Therapeutic Drugs Treating COVID-19.** Wu R, Wang L, Kuo H-CD, Shannar A, Peter R, Chou PJ, et al. *Current Pharmacology Reports.*1.
1342. **Environmental contamination by SARS-CoV-2 in a designated hospital for coronavirus disease 2019.** Wu S, Wang Y, Jin X, Tian J, Liu J, Mao Y. *American journal of infection control.* 2020.
1343. **Identification of Human Single-Domain Antibodies against SARS-CoV-2.** Wu Y, Li C, Xia S, Tian X, Kong Y, Wang Z, et al. *Cell host & microbe.* 2020.
1344. **A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.** Wu Y, Wang F, Shen C, Peng W, Li D, Zhao C, et al. *Science.* 2020. <http://dx.doi.org/10.1126/science.abc2241>.
1345. **Coronavirus disease 2019 and transplantation: The combination of lopinavir/ritonavir and hydroxychloroquine is responsible for excessive tacrolimus trough level and unfavorable outcome.** Xia T, Wang Y. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.* 2020. <http://dx.doi.org/10.1111/ajt.15992>.
1346. **Extreme genomic CpG deficiency in SARS-CoV-2 and evasion of host antiviral defense.** Xia X. *Mol biol evol.* 2020.
1347. **An increased neutrophil/lymphocyte ratio is an early warning signal of severe COVID-19.** Xia X, Wen M, Zhan S, He J, Chen W. *Nan fang yi ke da xue xue bao = Journal of Southern Medical University.* 2020;40(3):333-6.
1348. **Chest CT findings and their dynamic changes in patients with COVID-19.** Xiang Y, Yang Q, Sun H, Qin X, Li X, Zhang Q. *Nan fang yi ke da xue xue bao = Journal of Southern Medical University.* 2020;40(3):327-32.
1349. **Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis.** Xiao Y, Pan H, She Q, Wang F, Chen M. *The Lancet Gastroenterology and Hepatology.* 2020;5(6):528-9.
1350. **Preventive strategy for tumor patients during COVID-19 pandemic.** Xie F, Peng L, Luo X, Ji B. *Journal of Practical Oncology.* 2020;35(2):123-6.
1351. **Mask-induced contact dermatitis in handling COVID-19 outbreak.** Xie Z, Yang YX, Zhang H. *Contact dermatitis.* 2020.

1352. **[Construction and evaluation of a novel diagnosis pathway for 2019-Corona Virus Disease].** Xiong Z, Fu L, Zhou H, Liu JK, Wang AM, Huang Y, et al. *Zhonghua yi xue za zhi*. 2020;100(16):1223-9. <http://dx.doi.org/10.3760/cmaj.cn112137-20200228-00499>.
1353. **Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report.** Xu CY, Lu SD, Ye X, Cao MY, Xu GD, Yu Q, et al. *QJM : monthly journal of the Association of Physicians*. 2020.
1354. **Traditional Chinese Medicine treatment of COVID-19.** Xu J, Zhang Y. *Complementary therapies in clinical practice*. 2020;39:101165.
1355. **Arbidol/IFN- α 2b Therapy for Patients With Corona Virus Disease 2019: A Retrospective Multicenter Cohort Study.** Xu P, Huang J, Fan Z, Huang W, Qi M, Lin X, et al. *Microbes and Infection*. 2020.
1356. **Effect of heat inactivation of blood samples on the efficacy of three detection methods of SARS-CoV-2 antibodies.** Xue X, Zhu C, Huang S, Pan L, Xu J, Li W. *Nan fang yi ke da xue xue bao = Journal of Southern Medical University*. 2020;40(3):316-20.
1357. **Full-genome sequences of the first two SARS-CoV-2 viruses from India.** Yadav PD, Potdar VA, Choudhary ML, Nyayanit DA, Agrawal M, Jadhav SM, et al. *Indian Journal of Medical Research, Supplement*. 2020;151(2):200-9.
1358. **Detection of coronaviruses in Pteropus & Rousettus species of bats from different States of India.** Yadav PD, Shete-Aich A, Nyayanit DA, Pardeshi P, Majumdar T, Balasubramanian R, et al. *Indian Journal of Medical Research*. 2020;151(2):226-35.
1359. **COVID-19 and Cardiovascular diseases. Scoping review study.** Yahia F, Zakhama L, Ben Abdelaziz A. *La Tunisie medicale*. 2020;98(4):283-94.
1360. **Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.** Yan D, Liu XY, Zhu YN, Huang L, Dan BT, Zhang GJ, et al. *The European respiratory journal*. 2020. <http://dx.doi.org/10.1183/13993003.00799-2020>.
1361. **Covert COVID-19 and false-positive dengue serology in Singapore.** Yan G, Lee CK, Lam LTM, Yan B, Chua YX, Lim AYN, et al. *The Lancet Infectious Diseases*. 2020;20(5):536.
1362. **Research Progress of Drug Treatment in Novel Coronavirus Pneumonia.** Yan J, Liu A, Huang J, Wu J, Fan H. *AAPS PharmSciTech*. 2020;21(4).
1363. **Use of Hydroxychloroquine and Interferon alpha-2b for the Prophylaxis of COVID-19.** Yang A, Yang C, Yang B. *Medical Hypotheses*. 2020:109802.
1364. **Clinical characteristics and outcomes of cancer patients with COVID-19.** Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. *Journal of medical virology*. 2020.
1365. **Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study.** Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J, et al. *Hypertension (Dallas, Tex : 1979)*. 2020.
1366. **What do we know about remdesivir drug interactions?** Yang K. *Clinical and translational science*. 2020.
1367. **Network pharmacology studies on the effect of Chai-Ling decoction in coronavirus disease 2019.** Yang L, Li YT, Miao J, Wang L, Fu H, Li Q, et al. *Traditional Medicine Research*. 2020;5(3):145-59.
1368. **Corona Virus Disease 2019, a growing threat to children?** Yang P, Liu P, Li D, Zhao D. *Journal of Infection*.

2020;80(6):671-93.

1369. **Corticosteroids for critically ill COVID-19 patients with cytokine release syndrome: a limited case series.** Yang SS, Lipes J. Canadian Journal of Anaesthesia.1.
1370. **Response to 'What do monitoring platelet counts in COVID-19 teach us?'**. Yang X, Shang Y. Journal of thrombosis and haemostasis : JTH. 2020.
1371. **Use of herbal drugs to treat COVID-19 should be with caution.** Yang Y. Lancet (London, England). 2020.
1372. **Investigation of a cluster epidemic of COVID-19 in Ningbo.** Ye LX, Wang HB, Lu HC, Chen BB, Zhu YY, Gu SH, et al. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2020;41:E065.
1373. **The potential role of TNF α in 2019 novel coronavirus pneumonia.** Ye W, Lu S, xue A. Respiratory Medicine Case Reports. 2020;30.
1374. **Treatment of patients with non-severe and severe COVID-19: an evidence-based guideline.** Ye Z. 2020.
1375. **Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis.** Ye Z, Wang Y, Colunga-Lozano LE, Prasad M, Tangamornsuksan W, Rochweg B, et al. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2020.
1376. **Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab.** Yekedüz E, Dursun B, Aydın GÇ, Yazgan SC, Öztürk HH, Azap A, et al. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2020:1078155220924084.
1377. **APN Expression not IFN Responses Determines the Intestinal Segmental Tropism of Porcine Deltacoronavirus.** Yin L, Chen J, Li L, Guo S, Xue M, Zhang J, et al. Journal of virology. 2020.
1378. **Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2.** Yin S, Huang M, Li D, Tang N. Journal of Thrombosis and Thrombolysis. 2020.
1379. **The implications of preliminary screening and diagnosis: Clinical characteristics of 33 mild patients with SARS-CoV-2 infection in Hunan, China.** Yin S, Peng Y, Ren Y, Hu M, Tang L, Xiang Z, et al. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2020;128:104397.
1380. **The first case of COVID-19 occurring as community-acquired pneumonia in Hokkaido, Japan and our preventive measures against nosocomial infection.** Yokoo K, Sugaya F, Matsuzaka S, Ueda K, Kamimura R, Yokoyama T, et al. Respiratory Medicine Case Reports. 2020;30.
1381. **Molecular Targets for the Testing of COVID-19.** Yong SK, Su PC, Yang YS. Biotechnology journal. 2020:e2000152.
1382. **A global treatments for coronaviruses including COVID-19.** Yousefi B, Valizadeh S, Ghaffari H, Vahedi A, Karbalaeei M, Eslami M. Journal of Cellular Physiology. 2020.
1383. **Osteoporosis Management in the Era of COVID-19.** Yu EW, Tsourdi E, Clarke BL, Bauer DC, Drake MT. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2020. <http://dx.doi.org/10.1002/jbmr.4049>.
1384. **[Genomic analysis of a 2019-novel coronavirus (2019-nCoV) strain in the first COVID-19 patient found in Hangzhou].** Yu H, Wang XC, Li J, Qian X, Yu XF, Sun Z, et al. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]. 2020;54(5):486-90. <http://dx.doi.org/10.3760/cma.j.cn112150-20200217-00128>.

1385. **Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients.** Yu HQ, Sun BQ, Fang ZF, Zhao JC, Liu XY, Li YM, et al. *The European respiratory journal*. 2020.
1386. **DNA vaccine protection against SARS-CoV-2 in rhesus macaques.** Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, et al. *Science*. 2020. <http://dx.doi.org/10.1126/science.abc6284>.
1387. **Exploring the Active Compounds of Traditional Mongolian Medicine in Intervention of Novel Coronavirus (COVID-19) Based on Molecular Docking Method.** Yu JW, Wang L, Bao LD. *Journal of functional foods*. 2020;104016. <http://dx.doi.org/10.1016/j.jff.2020.104016>.
1388. **Prediction of the Development of Pulmonary Fibrosis Using Serial Thin-Section CT and Clinical Features in Patients Discharged after Treatment for COVID-19 Pneumonia.** Yu M, Liu Y, Xu D, Zhang R, Lan L, Xu H. *Korean journal of radiology*. 2020;21(6):746-55. <http://dx.doi.org/10.3348/kjr.2020.0215>.
1389. **Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study.** Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, et al. *The Lancet Infectious Diseases*. 2020;20(5):559-64.
1390. **Multicenter cohort study demonstrates more consolidation in upper lungs on initial CT increases the risk of adverse clinical outcome in COVID-19 patients.** Yu Q, Wang Y, Huang S, Liu S, Zhou Z, Zhang S, et al. *Theranostics*. 2020;10(12):5641-8.
1391. **SARS-CoV-2 viral load in sputum correlates with risk of COVID-19 progression.** Yu X, Sun S, Shi Y, Wang H, Zhao R, Sheng J. *Critical Care*. 2020;24(1).
1392. **Animal Models for Emerging Coronavirus: Progress and New Insights.** Yuan L, Tang Q, Cheng T, Xia N. *Emerging microbes & infections*. 2020:1-26.
1393. **A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV.** Yuan M, Wu NC, Zhu X, Lee CCD, So RTY, Lv H, et al. *Science (New York, NY)*. 2020;368(6491):630-3.
1394. **Treatment of COVID-19 guided by holistic view of traditional Chinese medicine-therapy aimed at both viral and host.** Yuan R, Xin QQ, Tang SH, Cong WH. *Zhongguo Zhongyao Zazhi*. 2020;45(7):1521-5.
1395. **The Impacts of Viral Inactivating Methods On Quantitative RT-PCR for COVID-19.** Yueying W, Song W, Zhao Z, Chen P, Liu J, Li C. *Virus research*. 2020:197988.
1396. **Targeting raised von Willebrand factor levels and macrophage activation in severe COVID-19: Consider low volume plasma exchange and low dose steroid.** Zachariah U, Nair SC, Goel A, Balasubramanian KA, Mackie I, Elias E, et al. *Thrombosis Research*. 2020;192:2.
1397. **Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive IPAH and COVID-19 Infection.** Zamanian RT, Pollack CV, Gentile MA, Rashid M, Fox JC, Mahaffey KW, et al. *American journal of respiratory and critical care medicine*. 2020.
1398. **TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes.** Zang R, Gomez Castro MF, McCune BT, Zeng Q, Rothlauf PW, Sonnek NM, et al. *Science immunology*. 2020;5(47).
1399. **Angiotensin II infusion in COVID-19-associated vasodilatory shock: a case series.** Zangrillo A, Landoni G, Beretta L, Morselli F, Serpa Neto A, Bellomo R. *Critical care (London, England)*. 2020;24(1):227.
1400. **ANNALS EXPRESS: Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: a closer look at angiotensin-converting enzyme 2 (ACE2).** Zemlin AE, Wiese OJ. *Annals of clinical biochemistry*.

2020:4563220928361.

1401. **Convalescent plasma for patients with COVID-19.** Zeng F, Chen X, Deng G. Proceedings of the National Academy of Sciences of the United States of America. 2020.
1402. **A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex.** Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. Journal of medical virology. 2020.
1403. **Association of inflammatory markers with the severity of COVID-19: a meta-analysis.** Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020.
1404. **Biochemical characterization of SARS-CoV-2 nucleocapsid protein.** Zeng W, Liu G, Ma H, Zhao D, Yang Y, Liu M, et al. Biochemical and Biophysical Research Communications. 2020.
1405. **Pulmonary Pathology of Early Phase COVID-19 Pneumonia in a Patient with a Benign Lung Lesion.** Zeng Z, Xu L, Xie XY, Yan HL, Xie BJ, Xu WZ, et al. Histopathology. 2020.
1406. **Dynamic inflammatory response in a critically ill COVID-19 patient treated with corticosteroids.** Zhagn S, Li D, Chen H, Zheng D, Zhou Y, Chen B, et al. Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences. 2020;49(2):220-6.
1407. **Comparison of SARS-CoV-2 spike protein binding to ACE2 receptors from human, pets, farm animals, and putative intermediate hosts.** Zhai X, Sun J, Yan Z, Zhang J, Zhao J, Zhao Z, et al. J Virol. 2020. <http://dx.doi.org/10.1128/JVI.00831-20>.
1408. **COVID-19 epidemic: Skin protection for health care workers must not be ignored.** Zhang B, Zhai R, Ma L. Journal of the European Academy of Dermatology and Venereology. 2020.
1409. **Novel coronavirus disease 2019 (COVID-19): relationship between chest CT scores and laboratory parameters.** Zhang B, Zhang J, Chen H, Chen L, Chen Q, Li M, et al. European journal of nuclear medicine and molecular imaging. 2020.
1410. **The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence.** Zhang D, Zhang B, Lv JT, Sa RN, Zhang XM, Lin ZJ. Pharmacological research. 2020;157.
1411. **Intervention mechanism of Qingwen Baidu Yin on cytokine storm based on network pharmacology.** Zhang FR, Zhu N, Li ZY, Tang SH. Zhongguo Zhongyao Zazhi. 2020;45(7):1499-508.
1412. **Clinical characteristics of 194 cases of COVID-19 in Huanggang and Taian, China.** Zhang H, Shang W, Liu Q, Zhang X, Zheng M, Yue M. Infection. 2020.
1413. **Preliminary evaluation of the safety and efficacy of oral human antimicrobial peptide LL-37 in the treatment of patients of COVID-19, a small-scale, single-arm, exploratory safety study.** Zhang H, Zhao Y, Jiang X, Zhao Y, Li Y, Li C, et al. medRxiv. 2020:2020.05.11.20064584.
1414. **Histopathologic changes and SARS-COV-2 immunostaining in the lung of a patient with covid-19.** Zhang H, Zhou P, Wei Y, Yue H, Wang Y, Hu M, et al. Annals of internal medicine. 2020;172(9):629-32.
1415. **Evaluation of the Adjuvant Efficacy of Natural Herbal Medicine on COVID-19: A Retrospective Matched Case-Control Study.** Zhang HT, Huang MX, Liu X, Zheng XC, Li XH, Chen GQ, et al. The American journal of Chinese medicine. 2020:1-14.

1416. **Risk Factors of Severe Disease and Efficacy of Treatment in Patients Infected with COVID-19: A Systematic Review, Meta-Analysis and Meta-Regression Analysis.** Zhang JJY, Lee KS, Ang LW, Leo YS, Young BE. Clin Infect Dis. 2020. <http://dx.doi.org/10.1093/cid/ciaa576>.
1417. **[Analysis of the pregnancy outcomes in pregnant women with COVID-19 in Hubei Province].** Zhang L, Jiang Y, Wei M, Cheng BH, Zhou XC, Li J, et al. Zhonghua Fu Chan Ke Za Zhi. 2020;55(3):166-71. <http://dx.doi.org/10.3760/cmaj.cn112141-20200218-00111>.
1418. **CT imaging features of 34 patients infected with COVID-19.** Zhang L, Kong X, Li X, Zhu J, Liu S, Li W, et al. Clinical imaging. 2020.
1419. **Potential interventions for novel coronavirus in China: A systematic review.** Zhang L, Liu Y. Journal of medical virology. 2020;92(5):479-90.
1420. **Becoming a Faithful Defender: Traditional Chinese Medicine against Coronavirus Disease 2019 (COVID-19).** Zhang L, Yu J, Zhou Y, Shen M, Sun L. The American journal of Chinese medicine. 2020:1-15.
1421. **Viral Shedding Prolongation in a Kidney Transplant Patient with COVID-19 Pneumonia.** Zhang M, Zhang J, Shi H, Liu B, Zeng F. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2020.
1422. **Current development of COVID-19 diagnostics, vaccines and therapeutics.** Zhang N, Li C, Hu Y, Li K, Liang J, Wang L, et al. Microbes and infection. 2020.
1423. **COVID-19 Prevention and Control Public Health Strategies in Shanghai, China.** Zhang N, Shi T, Zhong H, Guo Y. Journal of public health management and practice : JPHMP. 2020;26(4):334-44. <http://dx.doi.org/10.1097/PHH.0000000000001202>.
1424. **Recent advances of therapeutic targets and potential drugs of COVID-19.** Zhang W, Zhang P, Wang G, Cheng W, Chen J, Zhang X. Die Pharmazie. 2020;75(5):160-2. <http://dx.doi.org/10.1691/ph.2020.0431>.
1425. **Prolonged Viral RNA Shedding Duration in COVID-19.** Zhang WY, Yu LQ, Huang JA, Zeng DX. American journal of therapeutics. 2020.
1426. **Strategies to trace back the origin of COVID-19.** Zhang X, Chen X, Zhang Z, Roy A, Shen Y. Journal of Infection. 2020;80(6):e39-e40.
1427. **ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis.** Zhang X, Yu J, Pan LY, Jiang HY. Pharmacological research. 2020:104927.
1428. **The Clinical Characteristics and Outcomes of Diabetes Mellitus and Secondary Hyperglycaemia Patients with Coronavirus Disease 2019: a Single-center, Retrospective, Observational Study in Wuhan.** Zhang Y, Li H, Zhang J, Cao Y, Zhao X, Yu N, et al. Diabetes, obesity & metabolism. 2020.
1429. **Coagulopathy and antiphospholipid antibodies in patients with covid-19.** Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. New England Journal of Medicine. 2020;382(17):E38.
1430. **Liquid chromatography tandem mass spectrometry for therapeutic drug monitoring of voriconazole in heat-inactivated blood samples: its application during COVID-19 pandemic.** Zhao B, Liu S, Liu Y, Li G, Zhang Q. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. 2020;40(3):342-5.
1431. **A dynamic follow-up of pneumonia caused by coronavirus disease 2019 (COVID-19) on CT Scan.** Zhao L, Chen B, Huang Y, Yang M, Yang J, Zhao Z. Iranian Journal of Radiology. 2020;17(2).

1432. **An update on the status of COVID-19: a comprehensive review.** Zhao N, Zhou ZL, Wu L, Zhang XD, Han SB, Bao HJ, et al. *European review for medical and pharmacological sciences.* 2020;24(8):4597-606.
1433. **Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections.** Zhavoronkov A. *Aging.* 2020;12(8):6492-510.
1434. **Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines.** Zheng Y, Li R, Liu S. *Journal of medical virology.* 2020.
1435. **Clinical characteristics of 34 COVID-19 patients admitted to intensive care unit in Hangzhou, China.** Zheng Y, Sun LJ, Xu M, Pan J, Zhang YT, Fang XL, et al. *Journal of Zhejiang University Science B.* 2020;21(5):378-87.
1436. **The immunology of COVID-19: is immune modulation an option for treatment?** Zhong J, Tang J, Ye C, Dong L. *The Lancet Rheumatology.* 2020.
1437. **CT imaging features of patients with different clinical types of COVID-19.** Zhong Q, Li Z, Shen X, Xu K, Shen Y, Fang Q, et al. *Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences.* 2020;49(2):198-202.
1438. **Multistage CT features of coronavirus disease 2019.** Zhong Z, Hu Y, Yu Q, Li Y, Li P, Huang W, et al. *Zhong nan da xue xue bao Yi xue ban = Journal of Central South University Medical sciences.* 2020;45(3):250-6.
1439. **Chest CT findings and clinical features of coronavirus disease 2019 in children.** Zhong Z, Xie X, Huang W, Zhao W, Yu Q, Liu J. *Zhong nan da xue xue bao Yi xue ban = Journal of Central South University Medical sciences.* 2020;45(3):236-42.
1440. **A Case of Coronavirus Disease 2019 With Concomitant Acute Cerebral Infarction and Deep Vein Thrombosis.** Zhou B, She J, Wang Y, Ma X. *Frontiers in Neurology.* 2020;11.
1441. **Antenatal corticosteroids for pregnant women with COVID-19 infection and preterm prelabor rupture of membranes: a decision analysis.** Zhou CG, Packer CH, Hersh AR, Caughey AB. *The Journal of Maternal-Fetal & Neonatal Medicine.* 2020:1-9.
1442. **A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein.** Zhou H, Chen X, Hu T, Li J, Song H, Liu Y, et al. *Current biology : CB.* 2020. <http://dx.doi.org/10.1016/j.cub.2020.05.023>.
1443. **Infection of bat and human intestinal organoids by SARS-CoV-2.** Zhou J, Li C, Liu X, Chiu MC, Zhao X, Wang D, et al. *Nature Medicine.* 2020.
1444. **From SARS to COVID-19: What we have learned about children infected with COVID-19.** Zhou MY, Xie XL, Peng YG, Wu MJ, Deng XZ, Wu Y, et al. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.* 2020.
1445. **Imaging features and evolution on CT in 100 COVID-19 pneumonia patients in Wuhan, China.** Zhou S, Zhu T, Wang Y, Xia L. *European radiology.* 2020.
1446. **Investigating mechanism of Qingfei Dayuan Granules for treatment of COVID-19 based on network pharmacology and molecular docking.** Zhou SS, Li WN, Ai ZZ, Wang LQ, Ba YM. *Chinese Traditional and Herbal Drugs.* 2020;51(7):1804-13.
1447. **The role of ACEIs/ARBs in COVID-19: Friend or foe?** Zhou Z, Qiu Y, Tao J. *Medical Hypotheses.* 2020;142.
1448. **Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients.** Zhou Z, Ren L,

Zhang L, Zhong J, Xiao Y, Jia Z, et al. Cell Host and Microbe. 2020.

1449. **Prevalence and Influencing Factors of Anxiety and Depression Symptoms in the First-Line Medical Staff Fighting Against COVID-19 in Gansu.** Zhu J, Sun L, Zhang L, Wang H, Fan A, Yang B, et al. Frontiers in psychiatry. 2020;11:386. <http://dx.doi.org/10.3389/fpsy.2020.00386>. eCollection 2020.

1450. **Use of convalescent plasma in COVID-19 patients in China.** Zhu M, Kaiming H, Zhu Z. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine. 2020.

1451. **SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues.** Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, et al. Cell. 2020. <http://dx.doi.org/10.1016/j.cell.2020.04.035>.

1452. **COVID-19 in Children, Pregnancy and Neonates: A Review of Epidemiologic and Clinical Features.** Zimmermann P, Curtis N. The Pediatric infectious disease journal. 2020;39(6):469-77.

1453. **Distinct changes in the real-time PCR detectability of certain SARS-CoV-2 target sequences.** Zóka A, Bekő G. Clinica Chimica Acta. 2020;507:248-9.

1454. **Acute Physiology and Chronic Health Evaluation II Score as a Predictor of Hospital Mortality in Patients of Coronavirus Disease 2019.** Zou X, Li S, Fang M, Hu M, Bian Y, Ling J, et al. Critical care medicine. 2020.

1455. **Immune thrombocytopenic purpura in a patient with covid-19.** Zulfiqar AA, Lorenzo-Villalba N, Hassler P, Andrès E. New England Journal of Medicine. 2020;382(18):E43.

1456. **Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - achieving global consensus and visibility for cellular host-directed therapies.** Zumla A, Wang FS, Ippolito G, Petrosillo N, Agrati C, Azhar EI, et al. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020.

1457. **Coronavirus infection in children.** Zvereva NN, Sayfullin MA, Rtishchev AY, Shamsheva OV, Pshenichnaya NY. Pediatriya - Zhurnal im GN Speranskogo. 2020;99(2):270-8.

Update tot 14-05-2020

1. **COVID-19: France takes vigorous action in the case of off-label prescriptions. Hydroxychloroquine and ritonavir plus lopinavir only in the inpatient sector.** Deutsche Apotheker Zeitung. 2020;160(14).
2. **HIV medicine disappoints: Lopinavir/ritonavir has no benefits in critically ill COVID-19 patients.** Deutsche Apotheker Zeitung. 2020;160(14).
3. **Hirsutism, Amphetamines, COVID-19 Viral Shedding, Hand-Foot-and-Mouth Disease.** American family physician. 2020;101(10):589.
4. **Science in the time of coronavirus.** Nature Methods. 2020;17(4):355.
5. **Covid-19 infection and mortality: a physiologist's perspective enlightening clinical features and plausible interventional strategies.** Abassi ZA, Skorecki K, Heyman SN, Kinaneh S, Armaly Z. American journal of physiology Lung cellular and molecular physiology. 2020;318(5):L1020-L2. <http://dx.doi.org/10.1152/ajplung.00097.2020>. Epub 2020 Mar 24.
6. **In search for effective and safe drugs against SARS-CoV-2: Part III] The electronic factors of Remdesivir and the naturally extracted Spirochlorine drugs.** Abdel-Mottaleb MS, Abdel-Mottaleb Y. 2020.
7. **COVID19 pandemic impacts on anxiety of French urologist in training: Outcomes from a national survey.** Abdessater M, Roupert M, Misrai V, Matillon X, Gondran-Tellier B, Fretton L, et al. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2020. <http://dx.doi.org/10.1016/j.purol.2020.04.015>.
8. **Sacubitril/valsartan in COVID-19 patients: the need for trials.** Acanfora D, Ciccone MM, Scicchitano P, Acanfora C, Casucci G. European heart journal Cardiovascular pharmacotherapy. 2020.
9. **Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency.** Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Science of the Total Environment. 2020;730.
10. **COVID-19 cases are less prevalent in countries where malaria is endemic, suggesting a role for anti-malarial drugs as prophylaxis.** Adams D, Alshaban F. Eye Reports. 2020;6(1):S11-S6.
11. **Cracking the code to the 2019 novel coronavirus (COVID-19): Lessons from the eye.** Adams N. Eye Reports. 2020;6(1):S1-S6.
12. **Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States.** Aggarwal S, Garcia-Telles N, Aggarwal G, Lavie C, Lippi G, Henry BM. Diagnosis (Berlin, Germany). 2020;7(2):91-6.
13. **How the COVID-19 Overcomes the Battle? An Approach to Virus Structure.** Ahmadpour D, Ahmadpour P. Iranian journal of kidney diseases. 2020;14(3):167-72.
14. **First confirmed detection of SARS-CoV-2 in untreated wastewater in Australia: A proof of concept for the wastewater surveillance of COVID-19 in the community.** Ahmed W, Angel N, Edson J, Bibby K, Bivins A, O'Brien JW, et al. Science of the Total Environment. 2020;728.
15. **Treatment of SARS-CoV-2: How far have we reached?** Ahsan W, Javed S, Bratty MA, Alhazmi HA, Najmi A. Drug discoveries & therapeutics. 2020.
16. **COVID-19: treating and managing severe cases.** Ai J, Li Y, Zhou X, Zhang W. Cell research.

2020;30(5):370-1. <http://dx.doi.org/10.1038/s41422-020-0329-2>.

17. **COVID-19 and the Heart.** Akhmerov A, Marban E. *Circ Res.* 2020;126(10):1443-55. <http://dx.doi.org/10.1161/CIRCRESAHA.120.317055>. Epub 2020 Apr 7.

18. **Ticagrelor Can Be an Important Agent in the Treatment of Severe COVID-19 Patients with Myocardial Infarction.** Akşit E, Kırılmaz B, Gazi E, Aydın F. *Balkan medical journal.* 2020.

19. **A Hemodialysis Patient with Severe COVID-19 Pneumonia.** Alalwan AA, Taher A, Alaradi AH. *Cureus.* 2020;12(5):e7995. <http://dx.doi.org/10.7759/cureus.7995>.

20. **The human coronavirus disease covid-19: Its origin, characteristics, and insights into potential drugs and its mechanisms.** Alanagreh L, Alzoughool F, Atoum M. *Pathogens.* 2020;9(5).

21. **Review Article: Prevention, Diagnosis and Management of COVID-19 in the Inflammatory Bowel Disease Patient.** Al-Ani A, Prentice R, Rentsch C, Johnson D, Ardalan Z, Heerasing N, et al. *Alimentary pharmacology & therapeutics.* 2020.

22. **Tocilizumab for the Treatment of Severe COVID-19.** Alattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K, Daghfal JN, et al. *Journal of medical virology.* 2020.

23. **COVID-19 research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine.** Alexander PE, Debono VB, Mammen MJ, Iorio A, Aryal K, Deng D, et al. *Journal of clinical epidemiology.* 2020.

24. **COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine.** Alexander PE, Debono VB, Mammen MJ, Iorio A, Aryal K, Deng D, et al. *Journal of Clinical Epidemiology.* 2020.

25. **Renin-angiotensin-aldosterone system and COVID-19 infection.** Alexandre J, Cracowski JL, Richard V, Bouhanick B. *Annales d'Endocrinologie.* 2020.

26. **Blockade of SARS-CoV-2 infection by recombinant soluble ACE2.** Alhenc-Gelas F, Druke TB. *Kidney international.* 2020.

27. **Delay in OnabotulinumtoxinA Treatment During the COVID-19 Pandemic-Perspectives from a Virus Hotspot.** Ali A. *Headache.* 2020.

28. **SARS-CoV-2 and the Hidden Carriers - Sewage, Feline, and Blood Transfusion.** Ali M, Zaid M, Saqib MAN, Ahmed H, Afzal MS. *Journal of medical virology.* 2020.

29. **HLA studies in the context of coronavirus outbreaks.** Alicia SM. *Swiss Medical Weekly.* 2020;150(15).

30. **Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review.** Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-O'Callaghan A, Pardos-Gea J, Quintana A, et al. *Autoimmun Rev.* 2020:102569. <http://dx.doi.org/10.1016/j.autrev.2020.102569>.

31. **Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness.** Al-Kofahi M, Jacobson P, Boulware DR, Matas A, Kandaswamy R, Jaber MM, et al. *Clinical pharmacology and therapeutics.* 2020.

32. **Are Italy and Iran really suffering from COVID-19 epidemic? A controversial study.** Al-Najjar H, Al-Rousan N. *European review for medical and pharmacological sciences.* 2020;24(8):4519-22.

33. **A recommendation for the use of chloroquine, hydroxychloroquine, primaquine, or tafenoquine for prophylaxis against the 2019 novel coronavirus (COVID-19) with note to the ophthalmic considerations.** Alshaban F. Eye Reports. 2020;6(1):S7-S10.
34. **Novel coronavirus (2019-NCov): Disease briefings.** Al-Tameemi K, Kabakli R. Asian Journal of Pharmaceutical and Clinical Research. 2020;13(5):22-7.
35. **Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS).** Altschuler EL, Kast RE. Medical Hypotheses. 2020;141.
36. **Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review.** Alzghari SK, Acuña VS. Journal of Clinical Virology. 2020;127.
37. **Covid-19, induced activation of hemostasis, and immune reactions: Can an auto-immune reaction contribute to the delayed severe complications observed in some patients?** Amiral J, Vissac AM, Seghatchian J. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 2020;102804. <http://dx.doi.org/10.1016/j.transci.2020.102804>.
38. **Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2.** Anderson DE, Tan CW, Chia WN, Young BE, Linster M, Low JH, et al. Emerging microbes & infections. 2020;9(1):900-2. <http://dx.doi.org/10.1080/22221751.2020.1761267>.
39. **COVID-19: lambda interferon against viral load and hyperinflammation.** Andreakos E, Tsiodras S. EMBO molecular medicine. 2020.
40. **Making waves: Coronavirus detection, presence and persistence in the water environment: State of the art and knowledge needs for public health.** Annalaura C, Federigi I, Dasheng L, Julian RT, Marco V. Water Research. 2020;179.
41. **Application of deep learning technique to manage COVID-19 in routine clinical practice using CT images: Results of 10 convolutional neural networks.** Ardakani AA, Kanafi AR, Acharya UR, Khadem N, Mohammadi A. Computers in Biology and Medicine. 2020;121.
42. **The Importance Of Naturally Attenuated Sars-Cov-2 In The Fight Against Covid-19.** Armengaud J, Delaunay-Moisan A, Thuret JY, van Anken E, Acosta-Alvear D, Aragón T, et al. Environmental microbiology. 2020.
43. **A Marker of Systemic Inflammation or Direct Cardiac Injury: Should Cardiac Troponin Levels be Monitored in COVID-19 Patients?** Atallah B, Mallah SI, AbdelWareth L, AlMahmeed W, Fonarow GC. European heart journal Quality of care & clinical outcomes. 2020.
44. **An Invited Commentary on 'Evidence Based Management Guideline for the COVID-19 pandemic- Review article'.** Atogebania JW, Chen H. International Journal of Surgery. 2020;78:106-7.
45. **Opioid reduction strategies are important for laparotomies during the covid-19 outbreak.** Au Yong PSA, Chan DXH. Regional anesthesia and pain medicine. 2020.
46. **Evidence that high temperatures and intermediate relative humidity might favor the spread of COVID-19 in tropical climate: A case study for the most affected Brazilian cities.** Auler AC, Cássaro FAM, da Silva VO, Pires LF. Science of the Total Environment. 2020;729.
47. **Guide for nuclear medicine applications during the covid-19 outbreak.** Ayan A, Suna Kiraç F. Molecular Imaging and Radionuclide Therapy. 2020;29(2):49-58.
48. **Medical mask or N95 respirator: When and how to use?** Azap A, Erdinç FŞ. Turkish journal of medical

sciences. 2020.

49. **Co-infection with SARS-CoV-2 and influenza A virus.** Azekawa S, Namkoong H, Mitamura K, Kawaoka Y, Saito F. *IDCases*. 2020;20.
50. **Corticosteroids Administration Following COVID-19-induced Acute Respiratory Distress Syndrome. Is it harmful or Life-saving?** Azimi S, Sahebnasagh A, Sharifnia H, Najmeddin F. *Advanced Journal of Emergency Medicine*. 2020;4(2).
51. **Elevated Interleukin-6 and Severe COVID-19: A Meta-Analysis.** Aziz M, Fatima R, Assaly R. *Journal of medical virology*. 2020.
52. **Myocardial injury and COVID-19: Possible mechanisms.** Babapoor-Farrokhran S, Gill D, Walker J, Rasekhi RT, Bozorgnia B, Amanullah A. *Life sciences*. 2020;253.
53. **Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?** Badagliacca R, Sciomer S, Petrosillo N. *Journal of Heart and Lung Transplantation*. 2020.
54. **Covid-19 - The Search for Effective Therapy.** Baden LR, Rubin EJ. *The New England journal of medicine*. 2020;382(19):1851-2. <http://dx.doi.org/10.1056/NEJMe2005477>. Epub 2020 Mar 18.
55. **What dentists need to know about COVID-19.** Baghizadeh Fini M. *Oral Oncology*. 2020;105.
56. **Covid-19 pandemic: A new chapter in the history of infectious diseases.** Balkhair AA. *Oman Medical Journal*. 2020;35(2).
57. **The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.** Ballout RA, Sviridov D, Bukrinsky MI, Remaley AT. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2020.
58. **Selection of viral variants during persistent infection of insectivorous bat cells with Middle East respiratory syndrome coronavirus.** Banerjee A, Subudhi S, Rapin N, Lew J, Jain R, Falzarano D, et al. *Scientific reports*. 2020;10(1):7257.
59. **COVID-19 infection in kidney transplant recipients.** Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M. *Kidney international*. 2020.
60. **What the Diamond Princess taught the world about covid-19.** Baraniuk C. *BMJ (Clinical research ed)*. 2020;369:m1632.
61. **SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria.** Barrasa H, Rello J, Tejada S, Martín A, Balziskueta G, Vinuesa C, et al. *Anaesthesia Critical Care and Pain Medicine*. 2020.
62. **Hypothesized behavioral host manipulation by SARS-CoV2/COVID-19 infection.** Barton MC, Bennett KV, Cook JR, Gallup GG, Platek SM. *Medical Hypotheses*. 2020;141.
63. **Estimating The Infection Fatality Rate Among Symptomatic COVID-19 Cases In The United States.** Basu A. *Health affairs (Project Hope)*. 2020:101377hlthaff202000455. <http://dx.doi.org/10.1377/hlthaff.2020.00455>.
64. **COVID-19 in Piauí: Initial scenario and perspectives for coping.** Batista FMA, Mascarenhas MDM, Marinelli NP, Albuquerque LPA, Rodrigues MTP, Vieira MADCES, et al. *Revista da Sociedade Brasileira de Medicina Tropical*. 2020;53.
65. **Respiratory advice for the non-respiratory physician in the time of COVID-19.** Bennett J, Munavvar M,

Walker P, Phillips G. Clinical medicine (London, England). 2020.

66. **Prediction of severe illness due to COVID-19 based on an analysis of initial Fibrinogen to Albumin Ratio and Platelet count.** Bi X, Su Z, Yan H, Du J, Wang J, Chen L, et al. Platelets. 2020:1-6.

67. **Government advice needed on TB testing during Covid-19 outbreak.** Biggs A. Veterinary Record. 2020;186(14):456.

68. **Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.** Billington J, Deschamps I, Erck SC, Gerberding JL, Hanon E, Ivol S, et al. Health security. 2020.

69. **The Use of Captopril—Angiotensin Converting Enzyme (ACE) Inhibitor for Cystinuria During COVID-19 Pandemic.** Biyani CS, Palit V, Daga S. Urology. 2020.

70. **[First case of COVID-19 treated with tocilizumab in Iceland].** Bjornsson AH, Olafsdottir T, Thormar KM, Kristjansson M, Thorisdottir AS, Ludviksson BR, et al. Laeknabladid. 2020;106(5):247-50. <http://dx.doi.org/10.17992/lbl.2020.05.581>.

71. **IDentif. AI: Artificial Intelligence Pinpoints Remdesivir in Combination with Ritonavir and Lopinavir as an Optimal Regimen Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).** Blasiak A, Lim JJ, Seah SGK, Kee T, Remus A, San Wong P, et al. medRxiv. 2020.

72. **Focus on Middle East respiratory syndrome coronavirus (MERS-CoV).** Bleibtreu A, Bertine M, Bertin C, Houhou-Fidouh N, Visseaux B. Medecine et Maladies Infectieuses. 2020;50(3):243-51.

73. **Natural antiviral compound silvestrol modulates human monocyte-derived macrophages and dendritic cells.** Blum L, Geisslinger G, Parnham MJ, Grünweller A, Schiffmann S. Journal of cellular and molecular medicine. 2020.

74. **Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States.** Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, et al. Journal of diabetes science and technology. 2020:1932296820924469. <http://dx.doi.org/10.1177/1932296820924469>.

75. **Rapid and sensitive detection of SARS-CoV-2 RNA using the Simplexa COVID-19 direct assay.** Bordi L, Piralla A, Lalle E, Giardina F, Colavita F, Tallarita M, et al. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2020;128:104416. <http://dx.doi.org/10.1016/j.jcv.2020.104416>.

76. **Vascular skin symptoms in COVID-19: a french observational study.** Bouaziz JD, Duong T, Jachiet M, Velter C, Lestang P, Cassius C, et al. Journal of the European Academy of Dermatology and Venereology : JEADV. 2020.

77. **Severe Acute Respiratory Syndrome Coronavirus 2 Infection and the Upper Limb Deep Vein Thrombosis Risk.** Bozzani A, Arici V, Franciscone MM, Danesino V, Cascina A, Ticozzelli G, et al. Annals of vascular surgery. 2020.

78. **Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses.** Bray M, Rayner C, Noël F, Jans D, Wagstaff K. Antiviral research. 2020:104805.

79. **Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals.** Breslin N, Baptiste C, Gyamfi-Bannerman C, Miller R, Martinez R, Bernstein K, et al. American Journal of Obstetrics and Gynecology MFM. 2020.

80. **Advanced Preparation Makes Research in Emergencies and Isolation Care Possible: The Case of Novel Coronavirus Disease (COVID-19).** Brett-Major DM, Schnaubelt ER, Creager HM, Lowe A, Cieslak TJ, Dahlke JM, et al. *The American journal of tropical medicine and hygiene*. 2020;102(5):926-31. <http://dx.doi.org/10.4269/ajtmh.20-0205>.
81. **Consensus statement: Safe Airway Society principles of airway management and tracheal intubation specific to the COVID-19 adult patient group.** Brewster DJ, Chrimes N, Do TBT, Fraser K, Groombridge CJ, Higgs A, et al. *Medical Journal of Australia*. 2020.
82. **The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human Receptor.** Brielle ES, Schneidman-Duhovny D, Linial M. *Viruses*. 2020;12(5).
83. **Treatment for emerging viruses: Convalescent plasma and COVID-19.** Brown BL, McCullough J. *Transfusion and Apheresis Science*. 2020.
84. **Successful Treatment of Preterm Labor in Association with Acute COVID-19 Infection.** Browne PC, Linfert JB, Perez-Jorge E. *American journal of perinatology*. 2020.
85. **DC/L-SIGNs of Hope in the COVID-19 Pandemic.** Brufsky A, Lotze MT. *J Med Virol*. 2020. <http://dx.doi.org/10.1002/jmv.25980>.
86. **Experiencing the Surge: Report from a Large New York Radiation Oncology Department During the COVID-19 Pandemic.** Buckstein M, Skubish S, Smith K, Braccia I, Green S, Rosenzweig K. *Advances in radiation oncology*. 2020. <http://dx.doi.org/10.1016/j.adro.2020.04.014>.
87. **SARS-CoV-2 RNA polymerase as target for antiviral therapy.** Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM. *J Transl Med*. 2020;18(1):185. <http://dx.doi.org/10.1186/s12967-020-02355-3>.
88. **Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD.** Burgueño JF, Reich A, Hazime H, Quintero MA, Irina F, Fritsch J, et al. *Inflammatory bowel diseases*. 2020.
89. **RT-QPCR testing of SARS-COV-2: A primer.** Bustin SA, Nolan T. *International Journal of Molecular Sciences*. 2020;21(8).
90. **Structural and evolutionary analysis indicate that the sars-COV-2 mpro is a challenging target for small-molecule inhibitor design.** Bzówka M, Mitusińska K, Raczyńska A, Samol A, Tuszyński JA, Góra A. *International Journal of Molecular Sciences*. 2020;21(9).
91. **Developing a vaccine for covid-19.** Caddy S. *BMJ (Clinical research ed)*. 2020;369:m1790.
92. **SARS-COV2 INFECTION AND LUNG CANCER PATIENTS: the potential role of IL17 target therapy.** Cafarotti S. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2020.
93. **Coding potential and sequence conservation of SARS-CoV-2 and related animal viruses.** Cagliani R, Forni D, Clerici M, Sironi M. *Infection, Genetics and Evolution*. 2020;83.
94. **COVID-19: Abnormal liver function tests.** Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. *Journal of hepatology*. 2020.
95. **Coronavirus Disease 2019 in the Perioperative Period of Lung Resection: A Brief Report From a Single Thoracic Surgery Department in Wuhan, People's Republic of China.** Cai Y, Hao Z, Gao Y, Ping W, Wang Q, Peng S, et al. *Journal of Thoracic Oncology*. 2020.
96. **Otolaryngology Resident Practices and Perceptions in the Initial Phase of the U.S. COVID-19**

- Pandemic.** Cai Y, Jiam NT, Wai KC, Shuman EA, Roland LT, Chang JL. *The Laryngoscope*. 2020. <http://dx.doi.org/10.1002/lary.28733>.
97. **ACE2 and prognosis of COVID-19. Insights from Bartter's and Gitelman's syndromes patients.** Calo LA, Davis PA, Rigato M, Sgarabotto L. *J Med Virol*. 2020. <http://dx.doi.org/10.1002/jmv.25978>.
98. **Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact.** Cantini F, Niccoli L, Matarrese D, Nicastrì E, Stobbione P, Goletti D. *The Journal of infection*. 2020.
99. **A Trial of Lopinavir-Ritonavir in Covid-19. Reply.** Cao B, Zhang D, Wang C. *The New England journal of medicine*. 2020;382(21). <http://dx.doi.org/10.1056/NEJMc2008043>.
100. **Convalescent plasma: possible therapy for novel coronavirus disease 2019.** Cao H, Shi Y. *Transfusion*. 2020.
101. **COVID-19: immunopathology and its implications for therapy.** Cao X. *Nature reviews Immunology*. 2020;20(5):269-70. <http://dx.doi.org/10.1038/s41577-020-0308-3>.
102. **The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene.** Capoluongo ED, Amato F, Castaldo G. *Clinical chemistry and laboratory medicine*. 2020.
103. **Is COVID-19 a proteiform disease inducing also molecular mimicry phenomena?** Cappello F. *Cell Stress and Chaperones*. 2020;25(3):381-2.
104. **Can pioglitazone be potentially useful therapeutically in treating patients with covid-19?** Carboni E, Carta AR, Carboni E. *Medical Hypotheses*. 2020;140.
105. **A Trial of Lopinavir-Ritonavir in Covid-19.** Carmona-Bayonas A, Jimenez-Fonseca P, Castanon E. *The New England journal of medicine*. 2020;382(21). <http://dx.doi.org/10.1056/NEJMc2008043>.
106. **No evidence of increased risk for COVID-19 infection in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy.** Carugno A, Raponi F, Locatelli AG, Vezzoli P, Gambini DM, Di Mercurio M, et al. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2020.
107. **Optical techniques for fast screening – Towards prevention of the coronavirus COVID-19 outbreak.** Carvalho LFDCESD, Nogueira MS. *Photodiagnosis and Photodynamic Therapy*. 2020;30.
108. **Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?** Casillo GM, Mansour AA, Raucci F, Saviano A, Mascolo N, Iqbal AJ, et al. *Pharmacological Research*. 2020;156.
109. **Skull base surgery during the Covid-19 pandemic: The Italian skull base society recommendations.** Castelnuovo P, Turri-Zanoni M, Karligkiotis A, Battaglia P, Pozzi F, Locatelli D, et al. *International forum of allergy & rhinology*. 2020.
110. **Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?** Cattaneo M, Bertinato EM, Bircocchi S, Brizio C, Malavolta D, Manzoni M, et al. *Thrombosis and haemostasis*. 2020.
111. **Reply to: Personal Protective Equipment Recommendations Based on COVID-19 Route of Transmission.** Cavanagh G, Wambier C. *Journal of the American Academy of Dermatology*. 2020.
112. **Herbal drugs having antiviral potency can be used in treatment of corona virus disease.** Chaddha V.

International Journal of Pharmaceutical Sciences Review and Research. 2020;61(2):100-2.

113. **Leveraging open hardware to alleviate the burden of COVID-19 on global health systems.** Chagas AM, Molloy JC, Prieto-Godino LL, Baden T. PLoS Biology. 2020;18(4).
114. **Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis.** Chai P, Yu J, Ge S, Jia R, Fan X. Journal of hematology & oncology. 2020;13(1):43.
115. **COVID-19 and malaria: A symptom screening challenge for malaria endemic countries.** Chanda-Kapata P, Kapata N, Zumla A. International Journal of Infectious Diseases. 2020;94:151-3.
116. **SARS unique domain (SUD) of severe acute respiratory syndrome coronavirus induces NLRP3 inflammasome-dependent CXCL10-mediated pulmonary inflammation.** Chang YS, Ko BH, Ju JC, Chang HH, Huang SH, Lin CW. International Journal of Molecular Sciences. 2020;21(9).
117. **A new era for nuclear medicine.** Chatzipavlidou V. Hellenic journal of nuclear medicine. 2020;23(1):2-3. <http://dx.doi.org/10.1967/s002449912013>.
118. **Systematic review of important viral diseases in africa in light of the 'one health' concept.** Chauhan RP, Dessie ZG, Noreddin A, El Zowalaty ME. Pathogens. 2020;9(4).
119. **Emergency changes in international guidelines on treatment for head and neck cancer patients during the COVID-19 pandemic.** Chaves ALF, Castro AF, Marta GN, Junior GC, Ferris RL, Giglio RE, et al. Oral Oncology. 2020;107.
120. **Role of Dipeptidyl Peptidase 4 Inhibitors in Diabetic Patients with Coronavirus-19 Infection.** Chen CF, Chien CH, Yang YP, Chou SJ, Wang ML, Huo TI, et al. Journal of the Chinese Medical Association : JCMA. 2020.
121. **Containing COVID-19 Among 627,386 Persons in Contact With the Diamond Princess Cruise Ship Passengers Who Disembarked in Taiwan: Big Data Analytics.** Chen CM, Jyan HW, Chien SC, Jen HH, Hsu CY, Lee PC, et al. Journal of medical Internet research. 2020;22(5):e19540.
122. **Donor heart selection during the COVID-19 pandemic: A case study.** Chen CY, Chen SF, Hollander SA, Rosenthal D, Maeda K, Burgart A, et al. Journal of Heart and Lung Transplantation. 2020;39(5):497-8.
123. **Can Chest CT Features Distinguish Patients With Negative From Those With Positive Initial RT-PCR Results for Coronavirus Disease (COVID-19)?** Chen D, Jiang X, Hong Y, Wen Z, Wei S, Peng G, et al. AJR American journal of roentgenology. 2020:1-5.
124. **Clinical and immunological features of severe and moderate coronavirus disease 2019.** Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Journal of Clinical Investigation. 2020;130(5):2620-9.
125. **A novel combination of vitamin c, curcumin and glycyrrhizic acid potentially regulates immune and inflammatory response associated with coronavirus infections: A perspective from system biology analysis.** Chen L, Hu C, Hood M, Zhang X, Zhang L, Kan J, et al. Nutrients. 2020;12(4).
126. **SARS-CoV-2: virus dynamics and host response.** Chen Y, Li L. The Lancet Infectious Diseases. 2020;20(5):515-6.
127. **Spike protein in the detection and treatment of novel coronavirus.** Chen Y, Qiu F. Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi. 2020;37(2):246-50.
128. **Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty.**

Cheng P, Zhu H, Witteles RM, Wu JC, Quertermous T, Wu SM, et al. *Current Cardiology Reports*. 2020;22(5).

129. **Potential pharmacologic treatments for COVID-19 patients: A review study.** Cheraghi Z, Moradi M, Ziai SA. *School of Medicine Students' Journal*.2(2).

130. **Perspectives for repurposing drugs for the coronavirus disease 2019.** Cherian SS, Agrawal M, Basu A, Abraham P, Gangakhedkar RR, Bhargava B. *The Indian journal of medical research*. 2020;151(2):160-71. http://dx.doi.org/10.4103/ijmr.IJMR_585_20.

131. **Is the oncologic patient more susceptible to covid19 but perhaps less likely to undergo severe infection-related complications due to fewer cytokines storm as a consequent of the associated immunodeficiency?** Cherri S, Noventa S, Zaniboni A. *Medical Hypotheses*. 2020;141.

132. **Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus.** Choi JH, Woo HM, Lee TY, Lee SY, Shim SM, Park WJ, et al. *PLoS One*. 2020;15(5):e0232757. <http://dx.doi.org/10.1371/journal.pone.0232757>. eCollection 2020.

133. **BTK inhibitors in cancer patients with COVID19: "The winner will be the one who controls that chaos" (Napoleon Bonaparte).** Chong EA, Roeker LE, Shadman M, Davids MS, Schuster SJ, Mato AR. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2020.

134. **The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.** Chorin E, Dai M, Shulman E, Wadhvani L, Bar-Cohen R, Barbhaiya C, et al. *Nature Medicine*. 2020.

135. **Pharmacological (or Synthetic) and Nutritional Agonists of PPAR- γ as Candidates for Cytokine Storm Modulation in COVID-19 Disease.** Ciavarella C, Motta I, Valente S, Pasquinelli G. *Molecules (Basel, Switzerland)*. 2020;25(9).

136. **The puzzle of sharing bio-molecular targets between coronaviruses and mediators of the cardiovascular system in humans: Looking for plausible hypotheses.** Ciulla MM. *Medical Hypotheses*. 2020;141.

137. **Knowledge and Behaviors toward COVID-19 among U.S. Residents during the Early Days of the Pandemic: Online Questionnaire.** Clements JM. *JMIR public health and surveillance*. 2020. <http://dx.doi.org/10.2196/19161>.

138. **From mice to monkeys, animals studied for coronavirus answers.** Cohen J. *Science*. 2020;368(6488):221-2.

139. **Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020.** Colaneri M, Sacchi P, Zuccaro V, Biscarini S, Sachs M, Roda S, et al. *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin*. 2020;25(16).

140. **Slum Health: Arresting COVID-19 and Improving Well-Being in Urban Informal Settlements.** Corburn J, Vlahov D, Mberu B, Riley L, Caiaffa WT, Rashid SF, et al. *Journal of urban health : bulletin of the New York Academy of Medicine*. 2020.

141. **A Trial of Lopinavir-Ritonavir in Covid-19.** Corrao S, Natoli G, Cacopardo B. *The New England journal of medicine*. 2020;382(21). <http://dx.doi.org/10.1056/NEJMc2008043>.

142. **Use of free CAD design software for 3D printing individualized face masks based on face scans.** Cortes ARG, Galea K, No-Cortes J, Sammut EJ, Alzoubi EE, Attard NJ. *International journal of computerized dentistry*. 2020:1-7.

143. **[Chloroquine as a possible treatment for COVID-19].** Coumou J, de Vries PJ. Nederlands tijdschrift voor geneeskunde. 2020;164.
144. **Covid-19 in Brazil: Advantages of a socialized unified health system and preparation to contain cases.** Croda J, Oliveira WK, Frutuoso RL, Mandetta LH, Baia-Da-silva DC, Brito-Sousa JD, et al. Revista da Sociedade Brasileira de Medicina Tropical. 2020;53.
145. **The Question of Whether to Remain on Therapy for Chronic Rheumatic Diseases in the Setting of the Covid-19 Pandemic.** Cron RQ, Chatham WW. The Journal of rheumatology. 2020.
146. **Predicted success of prophylactic antiviral therapy to block or delay SARS-CoV-2 infection depends on the targeted mechanism.** Czuppon P, Débarre F, Gonçalves A, Tenaillon O, Perelson AS, Guedj J, et al. medRxiv. 2020:2020.05.07.20092965.
147. **COVID-19 and RAS: Unravelling an unclear relationship.** D'ardes D, Boccatonda A, Rossi I, Guagnano MT, Santilli F, Cipollone F, et al. International Journal of Molecular Sciences. 2020;21(8).
148. **COVID-19 Hangover: A Rising Tide of Alcohol Use Disorder and Alcohol-Associated Liver Disease.** Da BL, Im GY, Schiano TD. Hepatology (Baltimore, Md). 2020.
149. **SARS-CoV-2: Spike glycoprotein structural diversity, phylogeny and potential animal host identification.** Dabravolski SA, Kavalionak YK. Journal of medical virology. 2020.
150. **19 treatment regimens?** Dalamaga M, Karampela I, Mantzoros CS. Metabolism. 2020:154260.
151. **The ACE-2 in COVID-19: Foe or Friend?** Dalan R, Bornstein SR, El-Armouche A, Rodionov RN, Markov A, Wielockx B, et al. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme. 2020.
152. **A Trial of Lopinavir-Ritonavir in Covid-19.** Dalerba P, Levin B, Thompson JL. The New England journal of medicine. 2020;382(21). <http://dx.doi.org/10.1056/NEJMc2008043>.
153. **Biologics increase the risk of SARS- CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during RED-ZONE declaration.** Damiani G, Pacifico A, Bragazzi NL, Malagoli P. Dermatologic therapy. 2020:e13475.
154. **SARS-CoV-2 variants: relevance for symptom granularity, epidemiology, immunity (herd, vaccines), virus origin and containment?** Danchin A, Timmis K. Environmental microbiology. 2020.
155. **Management of IBD during the COVID-19 outbreak: resetting clinical priorities.** Danese S, Cecconi M, Spinelli A. Nature Reviews Gastroenterology and Hepatology. 2020;17(5):253-5.
156. **Reply to: Bioactive Lipids and Coronavirus (COVID-19)-further Discussion.** Das UN. Archives of Medical Research. 2020.
157. **Hydroxychloroquine plus azithromycin: a potential interest in reducing in-hospital morbidity due to COVID-19 pneumonia (HI-ZY-COVID)?** Davido B, Lansaman T, Bessis S, Lawrence C, Alvarez J-C, Mascitti H, et al. medRxiv. 2020:2020.05.05.20088757.
158. **COVID-19 and the CRISPR Community Response.** Davies K, Barrangou R. CRISPR Journal. 2020;3(2):66-7.
159. **Remdesivir in treatment of COVID-19: A systematic benefit-risk assessment.** Davies M, Osborne V, Lane S, Roy D, Dhanda S, Evans A, et al. medRxiv. 2020:2020.05.07.20093898.

160. **Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.** de Alwis R, Chen S, Gan ES, Ooi EE. *EBioMedicine*. 2020;55.
161. **Acute hemolysis by hydroxychloroquine was observed in G6PD-deficient patient with severe COVID-19 related lung injury.** De Franceschi L, Costa E, Dima F, Morandi M, Olivieri O. *European Journal of Internal Medicine*. 2020.
162. **Covid-19-The real role of NSAIDs in Italy.** de Girolamo L, Peretti GM, Maffulli N, Brini AT. *Journal of orthopaedic surgery and research*. 2020;15(1):165.
163. **Psychological interventions during COVID-19: Challenges for low and middle income countries.** De Sousa A, Mohandas E, Javed A. *Asian Journal of Psychiatry*. 2020;51.
164. **Avian coronaviruses.** de Wit JJS, Cook JKA. *Avian pathology : journal of the WVPA*. 2020:1-7.
165. **Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients.** Deffune E, Prudenciatti A, Moroz A. *Medical Hypotheses*. 2020;142.
166. **The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19-First, Do No Harm.** DeJong C, Wachter RM. *JAMA internal medicine*. 2020.
167. **Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo.** Deng W, Xu Y, Kong Q, Xue J, Yu P, Liu J, et al. *Signal Transduction and Targeted Therapy*. 2020;5(1):1-3.
168. **Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin.** Derendorf H. *International journal of antimicrobial agents*. 2020:106007. <http://dx.doi.org/10.1016/j.ijantimicag.2020.106007>.
169. **Strategies for daily operating room management of ambulatory surgery centers following resolution of the acute phase of the COVID-19 pandemic.** Dexter F, Elhakim M, Loftus RW, Seering MS, Epstein RH. *Journal of clinical anesthesia*. 2020;64:109854. <http://dx.doi.org/10.1016/j.jclinane.2020.109854>.
170. **Performing the nasopharyngeal and oropharyngeal swab for 2019-Novel Coronavirus (SARS-CoV-2) safely: how to dress, undress, and technical notes.** Di Maio P, Iocca O, Cavallero A, Giudice M. *Head & neck*. 2020.
171. **Clotting factors in COVID-19: Epidemiological association and prognostic values in different clinical presentations in an Italian cohort.** Di Micco P, Russo V, Carannante N, Imperato M, Rodolfi S, Cardillo G, et al. *Journal of Clinical Medicine*. 2020;9(5).
172. **Are probiotics effective adjuvant therapeutic choice in patients with COVID-19?** Di Renzo L, Merra G, Esposito E, De Lorenzo A. *European review for medical and pharmacological sciences*. 2020;24(8):4062-3.
173. **The Challenges of Vaccine Development against a New Virus during a Pandemic.** Diamond MS, Pierson TC. *Cell Host and Microbe*. 2020;27(5):699-703.
174. **Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management.** Diana G, Strollo R, Diana D, Strollo M, Galassi AR, Crea F. *European heart journal Cardiovascular pharmacotherapy*. 2020. <http://dx.doi.org/10.1093/ehjcvp/pvaa049>.
175. **Codon Usage and Phenotypic Divergences of SARS-CoV-2 Genes.** Dilucca M, Forcelloni S, Georgakilas AG, Giansanti A, Pavlopoulou A. *Viruses*. 2020;12(5). <http://dx.doi.org/10.3390/v12050498>.
176. **Managing Close Contacts of COVID-19 Confirmed Cases in Metropolitan Areas in China.** Ding J, Tuan WJ, Temte JL. *Journal of public health management and practice : JPHMP*. 2020.

177. **Correlation analysis of the severity and clinical prognosis of 32 cases of patients with COVID-19.** Ding M, Zhang Q, Li Q, Wu T, Huang YZ. *Respiratory Medicine*. 2020;167.
178. **ISIDOG recommendations concerning COVID-19 and pregnancy.** Donders F, Lonnée-Hoffmann R, Tsiakalos A, Mendling W, De Oliveira JM, Judlin P, et al. *Diagnostics*. 2020;10(4).
179. **SARS-CoV-2 infection in a patient on chronic hydroxychloroquine therapy: Implications for prophylaxis.** Dousa KM, Malavade SS, Furin J, Gripshover B, Hatszegi M, Hojat L, et al. *IDCases*. 2020;20.
180. **Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes.** Doyen D, Mocerri P, Ducreux D, Dellamonica J. *The Lancet*. 2020.
181. **Rheumatology and COVID-19.** Dumusc A, Dan D. *Revue medicale suisse*. 2020;16:831-4.
182. **Ebioenergy crisis in coronavirus diseases?** Dutta A, Das A, Kondziella D, Stachowiak MK. *Brain Sciences*. 2020;10(5).
183. **COVID-19 Among Workers in Meat and Poultry Processing Facilities - 19 States, April 2020.** Dyal JW, Grant MP, Broadwater K, Bjork A, Waltenburg MA, Gibbins JD, et al. *MMWR Morbidity and mortality weekly report*. 2020;69(18). <http://dx.doi.org/10.15585/mmwr.mm6918e3>.
184. **Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome.** Earhart AP, Holliday ZM, Hofmann HV, Schrum AG. *New Microbes and New Infections*. 2020;35.
185. **Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2.** Ebrahimi SA. *Drug Development Research*. 2020.
186. **Letter to the editors in response to: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic (Cure et al.).** Ekiz T, Kara M, Özçakar L. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2020;14(4):525-6.
187. **Metformin and COVID-19: A novel deal of an Old Drug.** El-Arabey AA, Abdalla M. *Journal of medical virology*. 2020.
188. **Natural products may interfere with SARS-CoV-2 attachment to the host cell.** Elfiky AA. *Journal of biomolecular structure & dynamics*. 2020:1-16.
189. **A case of improved oxygenation in SARS-CoV-2 positive patient on nasal cannula undergoing prone positioning.** Elkattawy S, Noori M. *Respiratory medicine case reports*. 2020:101070. <http://dx.doi.org/10.1016/j.rmcr.2020.101070>.
190. **Is GSK3beta a molecular target of chloroquine treatment against COVID-19?** Embi MN, Ganesan N, Sidek HM. *Drug discoveries & therapeutics*. 2020;14(2):107-8. <http://dx.doi.org/10.5582/ddt.2020.03010>. Epub 2020 Apr 21.
191. **Andrographolide As a Potential Inhibitor of SARS-CoV-2 Main Protease: An In Silico Approach.** Enmozhi SK, Raja K, Sebastine I, Joseph J. *Journal of biomolecular structure & dynamics*. 2020:1-10.
192. **Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019.** Fan J, Wang H, Ye G, Cao X, Xu X, Tan W, et al. *Metabolism: Clinical and Experimental*. 2020.
193. **Be aware of misdiagnosis---A 21-Year-Old Primipara with Suspected COVID-19.** Fang H, Xingfei P, Yingwei Q, Dunjin C. *International journal of gynaecology and obstetrics: the official organ of the International*

Federation of Gynaecology and Obstetrics. 2020.

194. **Antihypertensive drugs and risk of COVID-19? – Authors' reply.** Fang L, Karakiulakis G, Roth M. The Lancet Respiratory Medicine. 2020;8(5):e32-e3.
195. **Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID-19 Experience.** Fasano A, Antonini A, Katzenschlager R, Krack P, Odin P, Evans AH, et al. Movement Disorders Clinical Practice. 2020;7(4):361-72.
196. **Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis.** Favalli EG, Agape E, Caporali R. The Journal of rheumatology. 2020.
197. **Photobiomodulation and Antiviral Photodynamic Therapy as a Possible Novel Approach in COVID-19 Management.** Fekrazad R. Photobiomodulation, photomedicine, and laser surgery. 2020.
198. **Widening Disparities Among Patients with Rheumatic Diseases in the COVID-19 Era: An Urgent Call to Action.** Feldman CH, Ramsey-Goldman R. Arthritis & rheumatology (Hoboken, NJ). 2020.
<http://dx.doi.org/10.1002/art.41306>.
199. **Vaginal delivery in SARS-CoV-2 infected pregnant women in Northern Italy: a retrospective analysis.** Ferrazzi E, Frigerio L, Savasi V, Vergani P, Prefumo F, Barresi S, et al. BJOG : an international journal of obstetrics and gynaecology. 2020.
200. **Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports.** Ferrucci S, Romagnuolo M, Angileri L, Berti E, Tavecchio S. Journal of the European Academy of Dermatology and Venereology : JEADV. 2020.
201. **Caution Needed on the Use of Chloroquine and Hydroxychloroquine for Coronavirus Disease 2019.** Fihn SD, Perencevich E, Bradley SM. JAMA network open. 2020;3(423):e209035.
202. **Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs.** Filocamo G, Minoia F, Carbogno S, Costi S, Romano M, Cimaz R. The Journal of rheumatology. 2020.
203. **COVID-19 surface persistence: A recent data summary and its importance for medical and dental settings.** Fiorillo L, Cervino G, Matarese M, D'amico C, Surace G, Paduano V, et al. International Journal of Environmental Research and Public Health. 2020;17(9).
204. **Management of SARS-CoV-2 infection: Recommendations of the Polish Association of Epidemiologists and Infectiologists as of March 31, 2020.** Flisiak R, Horban A, Jaroszewicz J, Kozielowicz D, Pawłowska M, Parczewski M, et al. Polish Archives of Internal Medicine. 2020;130(4):352-7.
205. **Phylogenetic network analysis of SARS-CoV-2 genomes.** Forster P, Forster L, Renfrew C, Forster M. Proceedings of the National Academy of Sciences of the United States of America. 2020;117(17):9241-3.
206. **What could be the better choice between ACE inhibitors and AT1R antagonists in coronavirus disease 2019 (COVID-19) patients?** Frolidi G. Journal of medical virology. 2020.
207. **Letter to the Editor: Three cases of re-detectable positive SARS-CoV-2 RNA in recovered COVID-19 patients with antibodies.** Fu W, Chen Q, Wang T. Journal of medical virology. 2020.
208. **COVID-19 patients presenting with afebrile acute abdominal pain.** Gahide G, Frandon J, Vendrell JF. Clinical medicine (London, England). 2020.

209. **Polish Archives of Internal Medicine in the coronavirus disease 2019 pandemic.** Gajos G, Undas A. Polish Archives of Internal Medicine. 2020;130(4):263.
210. **Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North - supports vitamin D as a factor determining severity. Authors' reply.** Garg M, Al-Ani A, Mitchell H, Hendy P, Christensen B. Alimentary pharmacology & therapeutics. 2020.
211. **COVID-19: Is a paradigm change to be expected in health care and transfusion medicine?** Garraud O. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine. 2020;27(2):59-60. <http://dx.doi.org/10.1016/j.tracli.2020.03.005>. Epub 2020 Mar 31.
212. **Responding to Covid-19 - A Once-in-a-Century Pandemic?** Gates B. The New England journal of medicine. 2020;382(18):1677-9. <http://dx.doi.org/10.1056/NEJMp2003762>. Epub 2020 Feb 28.
213. **Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.** Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. New England Journal of Medicine. 2020.
214. **Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019.** Geng YJ, Wei ZY, Qian HY, Huang J, Lodato R, Castriotta RJ. Cardiovascular Pathology. 2020;47.
215. **Covid-19 tragic pandemic: Concerns over unintentional "directed accelerated evolution" of novel coronavirus (sars-cov-2) and introducing a modified treatment method for ards.** Ghadimi-Moghadam A, Haghani M, Bevelacqua JJ, Jafarzadeh A, Kaveh-Ahangar A, Mortazavi SMJ, et al. Journal of Biomedical Physics and Engineering. 2020;10(2):241-6.
216. **Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries.** Gianfrancesco MA, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Mateus EF, et al. The Lancet Rheumatology. 2020;2(5):e250-e3.
217. **Cutaneous clinico-pathological findings in three covid-19-positive patients observed in the metropolitan area of Milan, Italy.** Gianotti R, Veraldi S, Recalcati S, Cusini M, Ghislanzoni M, Boggio F, et al. Acta Dermato-Venereologica. 2020;100(8).
218. **Emergency Medical Services resource capacity and competency amid COVID-19 in the United States: Preliminary findings from a national survey.** Gibson CV, Ventura CA, Collier GD. Heliyon. 2020:e03900. <http://dx.doi.org/10.1016/j.heliyon.2020.e03900>.
219. **Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).** Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Mayo Clinic Proceedings. 2020.
220. **Outpatient Management of the Kidney Transplant Recipient during the SARS-CoV-2 Virus Pandemic.** Gleeson SE, Formica RN, Marin EP. Clinical journal of the American Society of Nephrology : CJASN. 2020.
221. **Recommendations for trauma and emergency general surgery practice during COVID-19 pandemic.** Gök AFK, Eryılmaz M, Özmen MM, Alimoğlu O, Ertekin C, Kurtoğlu MH. Ulusal Travma ve Acil Cerrahi Dergisi. 2020;26(3):335-42.
222. **Does apolipoprotein E genotype predict COVID-19 severity?** Goldstein MR, Poland GA, Graeber CW. QJM : monthly journal of the Association of Physicians. 2020.
223. **Complete title: Codon bias analysis may be insufficient for identifying host(s) of a novel virus.** Gong Y, Wen G, Jiang J, Feng X. J Med Virol. 2020. <http://dx.doi.org/10.1002/jmv.25977>.

224. **The double burden of disease of COVID-19 in cardiovascular patients: overlapping conditions could lead to overlapping treatments.** Gonzalez-Jaramillo N, Low N, Franco OH. *European journal of epidemiology*. 2020;35(4):335-7.
225. **Truncated IV acetylcysteine treatment duration has potential to safely preserve resources during the COVID-19 pandemic.** Goodnough R, Canseco K. *Clinical toxicology (Philadelphia, Pa)*. 2020:1.
226. **A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.** Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. *Nature*. 2020.
227. **The paramount importance of serological surveys of SARS-CoV-2 infection and immunity.** Goudsmit J. *European journal of epidemiology*. 2020;35(4):331-3.
228. **Response to "Risks of Hydroxychloroquine use for COVID-19 prophylaxis".** Grant-Kels JM. *Journal of the American Academy of Dermatology*. 2020.
229. **Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease.** Griffin DO, Jensen A, Khan M, Chin J, Chin K, Saad J, et al. *Emerging infectious diseases*. 2020;26(8).
230. **Could an endo-lysosomal ion channel be the Achilles heel of SARS-CoV2?** Grimm C, Tang R. *Cell Calcium*. 2020;88.
231. **Uncertainties on the prognostic value of D-dimers in COVID-19 patients.** Gris JC, Quéré I, Pérez-Martin A, Lefrant JY, Sotto A. *Journal of thrombosis and haemostasis : JTH*. 2020.
232. **SARS-CoV-2 infection presenting with hematochezia.** Guotao L, Xingpeng Z, Zhihui D, Huirui W. *Medecine et Maladies Infectieuses*. 2020;50(3):293-6.
233. **Personal Protective Equipment Recommendations Based on COVID-19 Route of Transmission.** Gupta MK, Lipner SR. *Journal of the American Academy of Dermatology*. 2020.
234. **Potential Inhibitors of Coronavirus 3-Chymotrypsin-Like Protease (3CL(pro)): An in silico screening of Alkaloids and Terpenoids from African medicinal plants.** Gyebi GA, Ogunro OB, Adegunloye AP, Ogunyemi OM, Afolabi SO. *Journal of biomolecular structure & dynamics*. 2020:1-19.
<http://dx.doi.org/10.1080/07391102.2020.1764868>.
235. **Should we try the antiinflammatory natural product, celastrol, for COVID-19?** Habtemariam S, Nabavi SF, Berindan-Neagoe I, Cismaru CA, Izadi M, Sureda A, et al. *Phytotherapy Research*. 2020.
236. **Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2.** Habtemariam S, Nabavi SF, Ghavami S, Cismaru CA, Berindan-Neagoe I, Nabavi SM. *Pharmacological Research*. 2020;157.
237. **Bargain with the tooth fairy - the savings accounts for dental stem cells.** Häfner SJ. *Biomedical journal*. 2020.
238. **Bargain with the tooth fairy – The savings accounts for dental stem cells.** Häfner SJ. *Biomedical journal*. 2020.
239. **SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant.** Hajifathalian K, Mahadev S, Schwartz RE, Shah S, Sampath K, Schnoll-Sussman F, et al. *World Journal of Gastroenterology*. 2020;26(14):1546-53.

240. **Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?** Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. *The Lancet Respiratory Medicine*. 2020;8(5):436-8.
241. **Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.** Hamadani M, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra S, et al. *Biology of Blood and Marrow Transplantation*. 2020.
242. **Computational analysis of SARS-CoV-2/COVID-19 surveillance by wastewater-based epidemiology locally and globally: Feasibility, economy, opportunities and challenges.** Hart OE, Halden RU. *Science of the Total Environment*. 2020;730.
243. **A Trial of Lopinavir-Ritonavir in Covid-19.** Havlichek D, Jr. *The New England journal of medicine*. 2020;382(21). <http://dx.doi.org/10.1056/NEJMc2008043>.
244. **Evidence summary: Is it safe to use ibuprofen in the pharmacological treatment of a patient with COVID-19?** Hegarty R, Lee C, Morgan M, Egan S, Leen B.
245. **Abdominal presentation of covid-19.** Hellinger JC, Sirous R, Hellinger RL, Krauthamer A. *Applied Radiology*. 2020;49(3):24-6.
246. **High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.** Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. *Intensive care medicine*. 2020.
247. **Comment on Melatonin as a potential adjuvant treatment for COVID-19.** Herrera EA, González-Candia A. *Life sciences*. 2020;253.
248. **Using effective hand hygiene practice to prevent and control infection.** Hillier MD. *Nursing standard (Royal College of Nursing (Great Britain) : 1987)*. 2020;35(5):45-50.
249. **Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19.** Ho LTF, Chan KKH, Chung VCH, Leung TH. *European Journal of Integrative Medicine*. 2020;36.
250. **Early Experience of COVID-19 in Two Heart Transplant Recipients: Case Reports and Review of Treatment Options.** Holzhauser L, Lourenco L, Sarswat N, Kim G, Chung B, Nguyen AB. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2020. <http://dx.doi.org/10.1111/ajt.15982>.
251. **Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study.** Hong KS, Lee KH, Chung JH, Shin KC, Choi EY, Jin HJ, et al. *Yonsei Med J*. 2020;61(5):431-7. <http://dx.doi.org/10.3349/ymj.2020.61.5.431>.
252. **Pollen likely seasonal factor in inhibiting flu-like epidemics. A Dutch study into the inverse relation between pollen counts, hay fever and flu-like incidence 2016–2019.** Hoogeveen MJ. *Science of the Total Environment*. 2020;727.
253. **Preventive strategies used by GI physicians during the COVID-19 pandemic.** Hormati A, Ghadir MR, Zamani F, Khodadadi J, Afifian M, Ahmadpour S. *New Microbes and New Infections*. 2020;35.
254. **Enabling emergency mass vaccination: Innovations in manufacturing and administration during a pandemic.** Hosangadi D, Warmbrod KL, Martin EK, Adalja A, Cicero A, Inglesby T, et al. *Vaccine*. 2020.
255. **Using IL-2R/lymphocyte for predicting the clinical progression of patients with COVID-19.** Hou H,

Zhang B, Huang H, Luo Y, Wu S, Tang G, et al. *Clinical and experimental immunology*. 2020.

256. **Risk factors for disease progression in hospitalized patients with COVID-19: a retrospective cohort study.** Hou W, Zhang W, Jin R, Liang L, Xu B, Hu Z. *Infectious diseases (London, England)*. 2020:1-8. <http://dx.doi.org/10.1080/23744235.2020.1759817>.

257. **A highly pathogenic GI-19 lineage infectious bronchitis virus originated from multiple recombination events with broad tissue tropism.** Hou Y, Zhang L, Ren M, Han Z, Sun J, Zhao Y, et al. *Virus Res*. 2020:198002. <http://dx.doi.org/10.1016/j.virusres.2020.198002>.

258. **Efficacy of remdesivir in COVID-19 patients with a simulated two-arm controlled study.** Hsu C-Y, Lai C-C, Yen AM-F, Chen SL-S, Chen H-H. *medRxiv*. 2020.

259. **Radiological role in the detection, diagnosis and monitoring for the coronavirus disease 2019 (COVID-19).** Hu L, Wang C. *European review for medical and pharmacological sciences*. 2020;24(8):4523-8.

260. **Early CT features and temporal lung changes in COVID-19 pneumonia in Wuhan, China.** Hu Q, Guan H, Sun Z, Huang L, Chen C, Ai T, et al. *European Journal of Radiology*. 2020;128.

261. **Individualized prediction nomograms for disease progression in mild COVID-19.** Huang J, Cheng A, Lin S, Zhu Y, Chen G. *Journal of medical virology*. 2020.

262. **Obesity hypoventilation syndrome and severe COVID-19.** Huang JF, Wang XB, Zheng KI, Liu WY, Chen JJ, George J, et al. *Metabolism: Clinical and Experimental*. 2020;108.

263. **Lactose Dehydrogenase in Patients with Severe COVID-19: A Meta-Analysis of Retrospective Study.** Huang X, Wei F, Yang Z, Li M, Liu L, Chen K. *Prehospital and disaster medicine*. 2020:1-9.

264. **Occupational exposure to SARS-CoV-2 in burns treatment during the COVID-19 epidemic: Specific diagnosis and treatment protocol.** Huang Z, Zhuang D, Xiong B, Deng DX, Li H, Lai W. *Biomedicine and Pharmacotherapy*. 2020;127.

265. **Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.** Hung IF-N, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, et al. *The Lancet*. 2020.

266. **SARS – CoV-2: Reasons of epidemiology of severe ill disease cases and therapeutic approach using trivalent vaccine (tetanus, diphtheria and Bordetella pertussis).** Ietto G. *Medical Hypotheses*. 2020;141.

267. **Inhaled Nitric Oxide and COVID-19.** Ignarro LJ. *British journal of pharmacology*. 2020.

268. **The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality.** Ilie PC, Stefanescu S, Smith L. *Aging Clinical and Experimental Research*. 2020.

269. **Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19.** Imai K, Tabata S, Ikeda M, Noguchi S, Kitagawa Y, Matuoka M, et al. *Journal of Clinical Virology*. 2020;128.

270. **Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience.** Infantino M, Grossi V, Lari B, Bambi R, Perri A, Manneschi M, et al. *Journal of medical virology*. 2020.

271. **Understanding the Renin-Angiotensin-Aldosterone-SARS-CoV-Axis: A Comprehensive Review.** Ingraham NE, Barakat AG, Reilkoff R, Bezdicek T, Schacker T, Chipman JG, et al. *The European respiratory journal*.

2020.

272. **Immunomodulation in COVID-19.** Ingraham NE, Lotfi-Emran S, Thielen BK, Techar K, Morris RS, Holtan SG, et al. *The Lancet Respiratory Medicine*. 2020.

273. **Gastrointestinal endoscopy in the era of the acute pandemic of COVID-19: Recommendations by Japan Gastroenterological Endoscopy Society (Issued on April 9th , 2020.).** Irisawa A, Furuta T, Matsumoto T, Kawai T, Inaba T, Kanno A, et al. *Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society*. 2020.

274. **A Molecular Modeling Approach to Identify Effective Antiviral Phytochemicals against the Main Protease of SARS-CoV-2.** Islam R, Parves R, Paul AS, Uddin N, Rahman MS, Mamun AA, et al. *Journal of biomolecular structure & dynamics*. 2020:1-20.

275. **Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: Report of three cases.** Iwabuchi K, Yoshie K, Kurakami Y, Takahashi K, Kato Y, Morishima T. *Journal of Infection and Chemotherapy*. 2020.

276. **Safety Considerations in the Laboratory Testing of Specimens Suspected or Known to Contain the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).** Iwen PC, Stiles KL, Pentella MA. *American Journal of Clinical Pathology*. 2020;153(5):567-70.

277. **Association of Respiratory Allergy, Asthma and Expression of the SARS-CoV-2 Receptor, ACE2.** Jackson DJ, Busse WW, Bacharier LB, Kattan M, O'Connor GT, Wood RA, et al. *The Journal of allergy and clinical immunology*. 2020.

278. **Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib.** Jacobs J, Clark-Snustad K, Lee S. *Inflammatory bowel diseases*. 2020.

279. **Acute respiratory distress syndrome and steroids in the shadow of coronavirus disease 2019.** Jaeschke R. *Polish Archives of Internal Medicine*. 2020;130(4):266-7.

280. **COVID-19: A case report from Bangladesh perspective.** Jahan Y, Rahman S, Rahman A. *Respiratory Medicine Case Reports*. 2020;30.

281. **The molecular biology of intracellular events during Coronavirus infection cycle.** Jain J, Gaur S, Chaudhary Y, Kaul R. *Virusdisease*. 2020:1-5. <http://dx.doi.org/10.1007/s13337-020-00591-1>.

282. **The pandemic of COVID-19 and its implications for the purity and authenticity of alcohol-based hand sanitizers: The health risks associated with falsified sanitizers and recommendations for regulatory and public health bodies.** Jairoun AA, Al-Hemyari SS, Shahwan M. *Research in social & administrative pharmacy : RSAP*. 2020.

283. **Standing out from the crowd in treating COVID-19.** Janda KD, Iadarola MJ. *Medicine in Drug Discovery*. 2020;6.

284. **Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic.** Javelot H, Llorca PM, Drapier D, Fakra E, Hingray C, Meyer G, et al. *Encephale*. 2020.

285. **Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs.** Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, et al. *Antimicrobial agents and chemotherapy*. 2020.

286. **COVID-19 Dynamic Computed Tomography (CT) Performance and Observation of Some Laboratory Indicators.** Jiang X, Yin Z, Wang T, Zhai N, Lu F, Zhan C, et al. *Medical science monitor : international medical journal of experimental and clinical research*. 2020;26:e924403.

287. **Potential influence of COVID-19/ACE2 on the female reproductive system.** Jing Y, Run-Qian L, Hao-Ran W, Hao-Ran C, Ya-Bin L, Yang G, et al. *Molecular human reproduction*. 2020.
288. **Bat coronavirus phylogeography in the Western Indian Ocean.** Joffrin L, Goodman SM, Wilkinson DA, Ramasindrazana B, Lagadec E, Gomard Y, et al. *Scientific reports*. 2020;10(1):6873.
289. **Managing COVID-19 in Renal Transplant Recipients: A Review of Recent Literature and Case Supporting Corticosteroid-sparing Immunosuppression.** Johnson KM, Belfer JJ, Peterson GR, Boelkins MR, Dumkow LE. *Pharmacotherapy*. 2020.
290. **¹⁸F-FDG PET/CT and COVID-19.** Joob B, Wiwanitkit V. *European Journal of Nuclear Medicine and Molecular Imaging*. 2020;47(6):1348.
291. **EARLY REPORT ON THE IMPACT OF COVID-19 OUTBREAK IN NEUROSURGICAL PRACTICE AMONG MEMBERS OF THE LATIN AMERICAN FEDERATION OF NEUROSURGICAL SOCIETIES.** Jose Antonio SS, Tito P, Marcelo Z, Alvaro C, Claudio Y, Mauro LV, et al. *World Neurosurg*. 2020. <http://dx.doi.org/10.1016/j.wneu.2020.04.226>.
292. **Discovery of Potential Multi-Target-Directed Ligands by Targeting Host-specific SARS-CoV-2 Structurally Conserved Main Protease.** Joshi RS, Jagdale SS, Bansode SB, Shankar SS, Tellis MB, Pandya VK, et al. *Journal of biomolecular structure & dynamics*. 2020:1-16.
293. **In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking.** Joshi T, Joshi T, Sharma P, Mathpal S, Pundir H, Bhatt V, et al. *European review for medical and pharmacological sciences*. 2020;24(8):4529-36.
294. **Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19.** Kai H, Kai M. *Hypertension Research*. 2020.
295. **Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2.** Kalita P, Padhi AK, Zhang KYJ, Tripathi T. *Microbial Pathogenesis*. 2020;145.
296. **A Pilot Study of the Antiviral Activity of Anionic and Cationic Polyamidoamine Dendrimers Against the Middle East Respiratory Syndrome Coronavirus.** Kandeel M, Al-Taher A, Park BK, Kwon HJ, Al-Nazawi M. *Journal of medical virology*. 2020.
297. **Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.** Kasperkiewicz M, Schmidt E, Fairley JA, Joly P, Payne AS, Yale ML, et al. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2020.
298. **Antibody-based therapies for COVID-19: Can Europe move faster?** Kazatchkine MD, Goldman M, Vincent JL. *PLoS Med*. 2020;17(5):e1003127. <http://dx.doi.org/10.1371/journal.pmed.1003127>. eCollection 2020 May.
299. **Assessing air quality changes in large cities during COVID-19 lockdowns: The impacts of traffic-free urban conditions in Almaty, Kazakhstan.** Kerimray A, Baimatova N, Ibragimova OP, Bukenov B, Kenessov B, Plotitsyn P, et al. *Science of the Total Environment*. 2020;730.
300. **At the heart of COVID-19.** Khan IH, Zahra SA, Zaim S, Harky A. *Journal of cardiac surgery*. 2020.
301. **Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2'-O-ribose methyltransferase.** Khan RJ, Jha RK, Amera GM, Jain M, Singh E, Pathak A, et al. *Journal of Biomolecular Structure and Dynamics*. 2020.
302. **Peripheral nerve blocks in a patient with suspected COVID-19 infection.** Kilicaslan A, Kekec AF, Eren AS,

Uzun ST. *Journal of Clinical Anesthesia*. 2020;65.

303. **COVID-19 vaccines: breaking record times to first-in-human trials.** Kim YC, Dema B, Reyes-Sandoval A. *npj Vaccines*. 2020;5(1).

304. **A tale of two countries. How decentralised organisation and long-term investment build resilient healthcare systems.** Kirchhof P. *European heart journal Quality of care & clinical outcomes*. 2020. <http://dx.doi.org/10.1093/ehjqcco/qcaa036>.

305. **Occurrence, prevention, and management of the psychological effects of emerging virus outbreaks on healthcare workers: rapid review and meta-analysis.** Kisely S, Warren N, McMahon L, Dalais C, Henry I, Siskind D. *Bmj*. 2020;369:m1642. <http://dx.doi.org/10.1136/bmj.m1642>.

306. **Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement.** Klimek L, Jutel M, Akdis C, Bousquet J, Akdis M, Bachert C, et al. *Allergy*. 2020.

307. **Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients.** Klopfenstein T, Zayet S, Lohse A, Balblanc JC, Badie J, Royer PY, et al. *Medecine et maladies infectieuses*. 2020. <http://dx.doi.org/10.1016/j.medmal.2020.05.001>.

308. **COVID-19 Associated Pulmonary Aspergillosis.** Koehler P, Cornely OA, Böttiger BW, Dusse F, Eichenauer DA, Fuchs F, et al. *Mycoses*. 2020.

309. **Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks.** Konda A, Prakash A, Moss GA, Schmoldt M, Grant GD, Guha S. *ACS nano*. 2020.

310. **Applying the ethical principles of resource allocation to drugs in limited supply during a public health crisis.** Kong HE, Grant-Kels JM, Stoff BK. *Journal of the American Academy of Dermatology*. 2020.

311. **Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection.** Kong Q, Xiang Z, Wu Y, Gu Y, Guo J, Geng F. *Molecular cancer*. 2020;19(1):80.

312. **SARS-CoV-2 detection in patients with influenza-like illness.** Kong WH, Li Y, Peng MW, Kong DG, Yang XB, Wang L, et al. *Nature Microbiology*. 2020;5(5):675-8.

313. **COVID-19: ICU delirium management during SARS-CoV-2 pandemic.** Kotfis K, Williams Roberson S, Wilson JE, Dabrowski W, Pun BT, Ely EW. *Critical care (London, England)*. 2020;24(1):176.

314. **Emergence of drift variants that may affect covid-19 vaccine development and antibody treatment.** Koyama T, Weeraratne D, Snowden JL, Parida L. *Pathogens*. 2020;9(5).

315. **FAVPIRAVIR AS A POTENTIAL DRUG IN THE TREATMENT OF COVID-19.** Kramer DG, Da Silva MJL, Da Silva GSE, De Moura AMMA, Junior GBC, De Sousa AM, et al. *International Journal of Research-GRANTHAALAYAH*. 2020;8(4):7-12.

316. **The role of adipocytes and adipocyte-like cells in the severity of COVID-19 infections.** Kruglikov IL, Scherer PE. *Obesity (Silver Spring, Md)*. 2020.

317. **A Trial of Lopinavir-Ritonavir in Covid-19.** Kunz KM. *The New England journal of medicine*. 2020;382(21). <http://dx.doi.org/10.1056/NEJMc2008043>.

318. **Coronavirus in water environments: Occurrence, persistence and concentration methods - A scoping review.** La Rosa G, Bonadonna L, Lucentini L, Kenmoe S, Suffredini E. *Water Research*. 2020;179.

319. **Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients.** Lacour T, Semaan C, Genet T, Ivanec F. *Catheterization and Cardiovascular Interventions*. 2020.
320. **Sars-cov-2 infection virological diagnosis.** Lamia T, Salma M, Habiba N, Amine JM, Naila H, Lamia FB, et al. *Tunisie Medicale*. 2020;98(4):304-8.
321. **Expression of the COVID-19 receptor ACE2 in the human conjunctiva.** Lange C, Wolf J, Auw-Haedrich C, Schlecht A, Boneva S, Lapp T, et al. *Journal of medical virology*. 2020.
322. **Concomitant acute aortic thrombosis and pulmonary embolism complicating COVID-19 pneumonia.** Le Berre A, Marteau V, Emmerich J, Zins M. *Diagnostic and Interventional Imaging*. 2020;101(5):321-2.
323. **Chloroquine hype is derailing the search for coronavirus treatments.** Ledford H. *Nature*. 2020;580(7805):573. <http://dx.doi.org/10.1038/d41586-020-01165-3>.
324. **Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients.** Lee YL, Liao CH, Liu PY, Cheng CY, Chung MY, Liu CE, et al. *Journal of Infection*. 2020.
325. **COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors.** Leonetti A, Facchinetti F, Zielli T, Brianti E, Tiseo M. *European Journal of Cancer*. 2020;132:122-4.
326. **COVID-19 and Nicotine as a Mediator of ACE-2.** Leung JM, Yang CX, Sin DD. *The European respiratory journal*. 2020.
327. **Improper use of germicidal range ultraviolet lamp for household disinfection leading to phototoxicity in COVID-19 suspects.** Leung KCP, Ko TCS. *Cornea*. 2020.
328. **Respiratory virus shedding in exhaled breath and efficacy of face masks.** Leung NHL, Chu DKW, Shiu EYC, Chan KH, McDevitt JJ, Hau BJP, et al. *Nature Medicine*. 2020.
329. **Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: insights from ERS-COVID-19 study.** Li D, Chen Y, Liu H, Jia Y, Li F, Wang W, et al. *Signal Transduction and Targeted Therapy*. 2020;5(1).
330. **First cases of COVID-19 in heart transplantation from China.** Li F, Cai J, Dong N. *Journal of Heart and Lung Transplantation*. 2020;39(5):496-7.
331. **SARS-CoV-2 and viral sepsis: observations and hypotheses.** Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. *The Lancet*. 2020;395(10235):1517-20.
332. **Transient appearance of EDTA dependent pseud thrombocytopenia in a patient with 2019 novel coronavirus pneumonia.** Li H, Wang B, Ning L, Luo Y, Xiang S. *Platelets*. 2020:1-2.
333. **Prolonged SARS-CoV-2 RNA shedding: Not a rare phenomenon.** Li N, Wang X, Lv T. *Journal of medical virology*. 2020.
334. **Can cats become infected with Covid-19?** Li X. *Veterinary Record*. 2020;186(14):457-8.
335. **Retrospective analysis of laboratory testing in 54 patients with severe- or critical-type 2019 novel coronavirus pneumonia.** Li Y, Hu Y, Yu J, Ma T. *Laboratory Investigation*. 2020.
336. **Saliva is a non-negligible factor in the spread of COVID-19.** Li Y, Ren B, Peng X, Hu T, Li J, Gong T, et al. *Molecular oral microbiology*. 2020. <http://dx.doi.org/10.1111/omi.12289>.

337. **Rapid review for the anti-coronavirus effect of remdesivir.** Li Z, Wang X, Cao D, Sun R, Li C, Li G. *Drug discoveries & therapeutics*. 2020;14(2):73-6. <http://dx.doi.org/10.5582/ddt.2020.01015>.
338. **Comparison of epidemiological and clinical characteristics of COVID-19 patients with and without Wuhan exposure.** Lian JS, Cai H, Hao SR, Jin X, Zhang XL, Zheng L, et al. *Journal of Zhejiang University: Science B*. 2020.
339. **There may be virus in conjunctival secretion of patients with COVID-19.** Liang L, Wu P. *Acta Ophthalmologica*. 2020;98(3):223.
340. **Can N95 Respirators Be Reused after Disinfection? How Many Times?** Liao L, Xiao W, Zhao M, Yu X, Wang H, Wang Q, et al. *ACS nano*. 2020.
341. **COVID-19 and Older People in Asia: AWGS Calls to Actions.** Lim WS, Liang CK, Assantachai P, Auyeung TW, Kang L, Lee WJ, et al. *Geriatrics & gerontology international*. 2020.
342. **Early risk factors for the duration of SARS-CoV-2 viral positivity in COVID-19 patients.** Lin A, He ZB, Zhang S, Zhang JG, Zhang X, Yan WH. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
343. **Eosinophil Responses During COVID-19 Infections and Coronavirus Vaccination.** Lindsley AW, Schwartz JT, Rothenberg ME. *The Journal of allergy and clinical immunology*. 2020.
344. **In Silico Design of Antiviral Peptides Targeting the Spike Protein of SARS-CoV-2.** Ling R, Dai Y, Huang B, Huang W, Lu X, Jiang Y. *Peptides*. 2020:170328. <http://dx.doi.org/10.1016/j.peptides.2020.170328>.
345. **18F-FDG PET/CT and Serial Chest CT Findings in a COVID-19 Patient With Dynamic Clinical Characteristics in Different Period.** Liu C, Zhou J, Xia L, Cheng X, Lu D. *Clinical nuclear medicine*. 2020.
346. **Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19.** Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. *Journal of Clinical Virology*. 2020;127.
347. **Mesenchymal stem cells as a potential therapy for COVID-19.** Liu S, Peng D, Qiu H, Yang K, Fu Z, Zou L. *Stem cell research & therapy*. 2020;11(1):169. <http://dx.doi.org/10.1186/s13287-020-01678-8>.
348. **Effective Chemicals against Novel Coronavirus (COVID-19) in China.** Liu W, Zhu HL, Duan Y. *Curr Top Med Chem*. 2020;20(8):603-5. <http://dx.doi.org/10.2174/1568026620999200305145032>.
349. **Plexiglas barrier box to improve ERCP safety during the COVID-19 pandemic.** Ljubicic N, Stojisavljevic-Shapeski S, Virovic-Jukic L, Nikolic M. *Gastrointestinal Endoscopy*. 2020.
350. **Antibody responses to SARS-CoV-2 in patients with COVID-19.** Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. *Nature Medicine*. 2020.
351. **[Respiratory complaints in the time of COVID-19].** Loogman MCM, de Jong N, Platteel TN, Bouma M, Verheij TJM, Opstelten W. *Nederlands tijdschrift voor geneeskunde*. 2020;164.
352. **Simultaneous Onset of COVID-19 and Autoimmune Hemolytic Anemia.** Lopez C, Kim J, Pandey A, Huang T, DeLoughery TG. *Br J Haematol*. 2020. <http://dx.doi.org/10.1111/bjh.16786>.
353. **From the handling of an outbreak by an unknown pathogen in wuhan to the preparedness and response in the face of the emergence of covid-19 in mexico.** López-Ortiz E, López-Ortiz G, Mendiola-Pastrana IR, Mazón-Ramírez JJ, Díaz-Quiñonez JA. *Gaceta Medica de Mexico*. 2020;156(2):132-7.

354. **Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: an Exploratory Randomized, Controlled Trial.** Lou Y, Liu L, Qiu Y. medRxiv. 2020.
355. **SARS-CoV-2 infection in children - Understanding the immune responses and controlling the pandemic.** Lu X, Xiang Y, Du H, Wing-Kin Wong G. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2020.
356. **COVID-19 Lung Injury and High Altitude Pulmonary Edema: A False Equation with Dangerous Implications.** Luks AM, Swenson ER. Annals of the American Thoracic Society. 2020.
357. **Coronavirus Pandemic-Therapy and Vaccines.** Lundstrom K. Biomedicines. 2020;8(5).
<http://dx.doi.org/10.3390/biomedicines8050109>.
358. **Management of pregnant women infected with COVID-19.** Luo Y, Yin K. The Lancet Infectious Diseases. 2020;20(5):513-4.
359. **Headache medication and the COVID-19 pandemic.** MaassenVanDenBrink A, de Vries T, Danser AHJ. The journal of headache and pain. 2020;21(1):38.
360. **Vitamin D and coronavirus: A new field of use?** Maestri E, Formoso G, da Cas R, Mammarella F, Guerrizio MA, Trotta F. Recenti progressi in medicina. 2020;111(4):253-6.
361. **Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection.** Maggio R, Corsini GU. Pharmacological research. 2020:104837.
362. **SARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies?** Magro G. Travel medicine and infectious disease. 2020:101685.
363. **The role of natriuretic peptide estimation in severe COVID-19.** Mahajan K, Negi P. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace. 2020;90(2).
364. **Covid-19: What do we know so far about a vaccine?** Mahase E. BMJ (Clinical research ed). 2020;369:m1679.
365. **Covid-19: Remdesivir is helpful but not a wonder drug, say researchers.** Mahase E. BMJ (Clinical research ed). 2020;369:m1798.
366. **Effect of lockdown amid COVID-19 pandemic on air quality of the megacity Delhi, India.** Mahato S, Pal S, Ghosh KG. Science of the Total Environment. 2020;730.
367. **Natural product-derived phytochemicals as potential agents against coronaviruses: A review.** Mani JS, Johnson JB, Steel JC, Broszczak DA, Neilsen PM, Walsh KB, et al. Virus Research. 2020;284.
368. **COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: "what the bleep do we know?".** Mansoor S, Kelly S, Murphy K, Waters A, Siddiqui NS. Egyptian Journal of Neurology, Psychiatry and Neurosurgery. 2020;56(1).
369. **Antiviral activities of type I interferons to SARS-CoV-2 infection.** Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral Research. 2020;179.
370. **Pulmonary embolism in a young pregnant woman with COVID-19.** Martinelli I, Ferrazzi E, Ciavarella A, Erra R, Iurlaro E, Ossola M, et al. Thrombosis Research. 2020;191:36-7.

371. **COVID-19 and chronic diseases: Current knowledge, future steps and the MaCroScopio project.** Martini N, Piccinni C, Pedrini A, Maggioni A. *Recenti progressi in medicina.* 2020;111(4):198-201.
372. **A Role for Metal-Based Drugs in Fighting Covid-19 Infection? The Case of Auranofin.** Marzo T, Messori L. *ACS Medicinal Chemistry Letters.* 2020.
373. **The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.** Mastaglio S, Ruggeri A, Risitano AM, Angelillo P, Yancopoulou D, Mastellos DC, et al. *Clinical Immunology.* 2020;215.
374. **Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.** Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, et al. *Annals of the Rheumatic Diseases.* 2020.
375. **Should we stop aspirin prophylaxis in pregnant women diagnosed with COVID-19?** Mathilde G, Rolnik DL, Hoffman MK, Panchaud A, Baud D. *Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.* 2020.
376. **Treatment for severe acute respiratory distress syndrome from COVID-19.** Matthay MA, Aldrich JM, Gotts JE. *The Lancet Respiratory Medicine.* 2020;8(5):433-4.
377. **Pharmacy's Call for Authorities to Aggressively Enforce Laws Addressing Price Gouging.** Mattingly TJ, Hogue MD. *Journal of managed care & specialty pharmacy.* 2020:1-4.
378. **Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.** Matucci-Cerinic M, Bruni C, Allanore Y, Clementi M, Dagna L, Damjanov NS, et al. *Annals of the Rheumatic Diseases.* 2020.
379. **Feasibility of Therapeutic Effects of the Cholinergic Anti-Inflammatory Pathway on COVID-19 Symptoms.** Mazloom R. *Journal of Neuroimmune Pharmacology.* 2020:1-2.
380. **Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine.** McCarthy MW. *Expert review of anti-infective therapy.* 2020:1-7.
381. **Racial Variations in COVID-19 Deaths May Be Due to Androgen Receptor Genetic Variants Associated with Prostate Cancer and Androgenetic Alopecia. Are Anti-Androgens a Potential Treatment for COVID-19?** McCoy J, Wambier CG, Vano-Galvan S, Shapiro J, Sinclair R, Müller Ramos P, et al. *Journal of cosmetic dermatology.* 2020.
382. **A Critical Needs Assessment for Research in Companion Animals and Livestock Following the Pandemic of COVID-19 in Humans.** McNamara T, Richt JA, Glickman L. *Vector borne and zoonotic diseases (Larchmont, NY).* 2020. <http://dx.doi.org/10.1089/vbz.2020.2650>.
383. **Biologics for psoriasis in COVID-19 era: what do we know?** Megna M, Napolitano M, Patruno C, Fabbrocini G. *Dermatologic therapy.* 2020:e13467.
384. **Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.** Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. *New England Journal of Medicine.* 2020.
385. **Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Testing Positive for Coronavirus Disease 2019 (COVID-19).** Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, et al. *JAMA Cardiology.* 2020.
386. **Providing pharmacy services at cabin hospitals at the coronavirus epicenter in China.** Meng L, Qiu F,

Sun S. International Journal of Clinical Pharmacy. 2020;42(2):305-8.

387. **Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease M pro.** Mengist HM, Fan X, Jin T. Signal Transduction and Targeted Therapy. 2020;5(1):1-2.

388. **Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.** Meo SA, Klonoff DC, Akram J. European review for medical and pharmacological sciences. 2020;24(8):4539-47. http://dx.doi.org/10.26355/eurrev_202004_21038.

389. **Rethinking the role of hydroxychloroquine in the treatment of COVID-19.** Meyerowitz EA, Vannier AGL, Friesen MGN, Schoenfeld S, Gelfand JA, Callahan MV, et al. FASEB Journal. 2020.

390. **SARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspects.** Michalakis K, Ilias I. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020;14(4):469-71.

391. **Ocular toxicity and Hydroxychloroquine: A Rapid Meta-Analysis.** Michelson M, Minton S, Chow T, Martin N, Ross M, Tee A. medRxiv. 2020:2020.04.28.20083378.

392. **Full-length title: Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.** Million M, Lagier JC, Gautret P, Colson P, Fournier PE, Amrane S, et al. Travel Med Infect Dis. 2020:101738. <http://dx.doi.org/10.1016/j.tmaid.2020.101738>.

393. **To act.....or to wait for the evidence: Ethics in the time of Covid-19!** Misra DP, Agarwal V. Indian Journal of Rheumatology. 2020;15(1):3-4.

394. **Do Patients with Cancer Have a Poorer Prognosis of COVID-19? An Experience in New York City.** Miyashita H, Mikami T, Chopra N, Yamada T, Chernyavsky S, Rizk D, et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2020.

395. **The French response to COVID-19: intrinsic difficulties at the interface of science, public health, and policy.** Moatti JP. The Lancet Public Health. 2020;5(5):e255.

396. **Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532).** Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2020. <http://dx.doi.org/10.1016/j.annonc.2020.04.479>.

397. **Cytokine release syndrome in severe COVID-19.** Moore JB, June CH. Science. 2020;368(6490):473-4. <http://dx.doi.org/10.1126/science.abb8925>. Epub 2020 Apr 17.

398. **Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes.** Moreno-Eutimio MA, López-Macías C, Pastelin-Palacios R. Microbes and Infection. 2020.

399. **Response to COVID-19 and diabetes: Can DPP4 inhibition play a role? – GLP-1 might play one too.** Morin N. Diabetes Research and Clinical Practice. 2020.

400. **Understanding the “Scope” of the Problem: Why Laparoscopy Is Considered Safe during the COVID-19 Pandemic.** Morris SN, Fader AN, Milad MP, Dionisi HJ. Journal of Minimally Invasive Gynecology. 2020;27(4):789-91.

401. **Mental Health and Psychological Distress in People with Diabetes during COVID-19.** Mukhtar S, Mukhtar S. Metabolism: Clinical and Experimental. 2020;108.

402. **COVID-19 pandemic, coronaviruses, and diabetes mellitus.** Muniyappa R, Gubbi S. American Journal of Physiology - Endocrinology and Metabolism. 2020;318(5):E736-E41.
403. **The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections.** Musarrat F, Chouljenko V, Dahal A, Nabi R, Chouljenko T, Jois SD, et al. J Med Virol. 2020. <http://dx.doi.org/10.1002/jmv.25985>.
404. **Obesity: The “Achilles heel” for COVID-19?** Muscogiuri G, Pugliese G, Barrea L, Savastano S, Colao A. Metabolism: Clinical and Experimental. 2020;108.
405. **Anti-inflammatory properties of stingless bee honey may reduce the severity of pulmonary manifestations in COVID-19 infections.** Mustafa MZ, Shamsuddin SH, Sulaiman SA, Abdullah JM. Malaysian Journal of Medical Sciences. 2020;27(2):165-9.
406. **COVID-19 pandemic: Impacts on the air quality during the partial lockdown in São Paulo state, Brazil.** Nakada LYK, Urban RC. Science of the Total Environment. 2020;730.
407. **Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.** Naksuk N, Lazar S, Peeraphatdit TB. European heart journal Acute cardiovascular care. 2020;2048872620922784. <http://dx.doi.org/10.1177/2048872620922784>.
408. **The ocular surface and the coronavirus disease 2019: Does a dual ‘ocular route’ exist?** Napoli PE, Nioi M, D’aloja E, Fossarello M. Journal of Clinical Medicine. 2020;9(5).
409. **Potential role of Janus kinase inhibitors in COVID-19.** Napolitano M, Fabbrocini G, Patrino C. Journal of the American Academy of Dermatology. 2020.
410. **The COVID-19 Pandemic and Mayo Clinic Proceedings.** Nath KA. Mayo Clin Proc. 2020;95(5):835-6. <http://dx.doi.org/10.1016/j.mayocp.2020.04.009>. Epub 2020 Apr 18.
411. **Does SARS-Cov-2 invade the brain? Translational lessons from animal models.** Natoli S, Oliveira V, Calabresi P, Maia LF, Pisani A. European journal of neurology. 2020.
412. **New Data and the Covid-19 Pandemic Mandate a Rethink of Antiplatelet Strategies in Patients With TIA or Minor Stroke Associated With Atherosclerotic Carotid Stenosis.** Naylor AR, McCabe DJH. European Journal of Vascular and Endovascular Surgery. 2020.
413. **A world of changes: The inheritance of COVID-19.** Negahdaripour M. Iranian Journal of Medical Sciences. 2020;45(3):155-6.
414. **Feasibility of known rna polymerase inhibitors as anti-sars-cov-2 drugs.** Neogi U, Hill KJ, Ambikan AT, Heng X, Quinn TP, Byrareddy SN, et al. Pathogens. 2020;9(5).
415. **COVID-19: searching for clues among other respiratory viruses.** Nguyen-Robertson C, Haque A, Mintern J, La Flamme AC. Immunology and Cell Biology. 2020;98(4):247-50.
416. **Anesthesia and intensive care ventilators: differences and usability in COVID-19 patients.** Notz Q, Herrmann J, Stumpner J, Schmid B, Schlesinger T, Kredel M, et al. Der Anaesthesist. 2020.
417. **A COMPARISON ANALYSIS ON REMDESIVIR, FAVIPIRAVIR, HYDROXYCHLOROQUINE, CHLOROQUINE AND AZITHROMYCIN IN THE TREATMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)-A REVIEW.** Nyarko RO, Boateng E, Kahwa I, Boateng PO. 2020.

418. **SARS-CoV-2 will continue to circulate in the human population: an opinion from the point of view of the virus-host relationship.** Oberemok VV, Laikova KV, Yurchenko KA, Fomochkina II, Kubyshekin AV. *Inflammation Research*. 2020.
419. **COVID-19: Present and future challenges for dental practice.** Odeh ND, Babkair H, Abu-Hammad S, Borzangy S, Abu-Hammad A, Abu-Hammad O. *International Journal of Environmental Research and Public Health*. 2020;17(9).
420. **RARE CASE OF PULMONARY NECROTIC RHODOCOCCLUS EQUI INFECTION IN A KIDNEY PANCREAS TRANSPLANT RECIPIENT.** Omar K, Sharfuddin A. *American Journal of Kidney Diseases*. 2020;75(4):614.
421. **Headaches Associated With Personal Protective Equipment – A Cross-Sectional Study Among Frontline Healthcare Workers During COVID-19.** Ong JJY, Bharatendu C, Goh Y, Tang JZY, Sooi KWX, Tan YL, et al. *Headache*. 2020;60(5):864-77.
422. **The COVID-19 pandemic highlights shortcomings in U.S. healthcare informatics infrastructure: a call to action.** O'Reilly-Shah VN, Gentry KR, Van Cleve W, Kendale SM, Jabaley CS, Long DR. *Anesthesia and analgesia*. 2020. <http://dx.doi.org/10.1213/ANE.0000000000004945>.
423. **Systematic benefit-risk assessment for the use of chloroquine or hydroxychloroquine as a treatment for COVID-19: Establishing a framework for rapid decision-making.** Osborne V, Davies M, Dhanda S, Roy D, Lane S, Evans A, et al. *medRxiv*. 2020:2020.05.07.20093989.
424. **COVID-19, hypothalamo-pituitary-adrenal axis and clinical implications.** Pal R. *Endocrine*. 2020.
425. **COVID-19 and diabetes mellitus: An unholy interaction of two pandemics.** Pal R, Bhadada SK. *Diabetes & metabolic syndrome*. 2020;14(4):513-7. <http://dx.doi.org/10.1016/j.dsx.2020.04.049>.
426. **COVID-19 Outbreak: an Update on Therapeutic Options.** Panati K, Narala VR. *SN Comprehensive Clinical Medicine*. 2020;2(4):379-80.
427. **Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?** Park S, Lee HY, Cho EJ, Sung KC, Kim J, Kim D-H, et al. *Clinical Hypertension*. 2020;26(1):1-5.
428. **COVID-19 diagnosis and management: a comprehensive review.** Pascarella G, Strumia A, Piliago C, Bruno F, Del Buono R, Costa F, et al. *Journal of internal medicine*. 2020.
429. **Povidone-iodine gargle as a prophylactic intervention to interrupt the transmission of SARS-CoV-2.** Pattanshetty S, Narayana A, Radhakrishnan R. *Oral diseases*. 2020.
430. **Could host cell receptor alteration prevent SARS-CoV-2 viral entry? - Hype or hope.** Paulpandi M, Kavithaa K, Asaikutty A, Balachandar V, Ayyadurai N, Arul N. *European review for medical and pharmacological sciences*. 2020;24(8):4554-7. http://dx.doi.org/10.26355/eurrev_202004_21040.
431. **Outbreak of COVID-19 infection in children: fear and serenity.** Pavone P, Ceccarelli M, Taibi R, La Rocca G, Nunnari G. *European review for medical and pharmacological sciences*. 2020;24(8):4572-5. http://dx.doi.org/10.26355/eurrev_202004_21043.
432. **Rapid Implementation of Service Delivery Changes to Mitigate COVID-19 and Maintain Access to Methadone Among Persons with and at High-Risk for HIV in an Opioid Treatment Program.** Peavy KM, Darnton J, Grekin P, Russo M, Green CJB, Merrill JO, et al. *AIDS and behavior*. 2020.
433. **SARS-CoV-2 can be detected in urine, blood, anal swabs and oropharyngeal swabs specimens.** Peng L, Liu J, Xu W, Luo Q, Chen D, Lei Z, et al. *Journal of medical virology*. 2020.

434. **With soluble ACE2 against COVID-19: New mechanism of action is supposed to intercept viruses and strengthen protective mechanisms.** Penninger J. *Deutsche Apotheker Zeitung*. 2020;160(11).
435. **Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020.** Perera RA, Mok CK, Tsang OT, Lv H, Ko RL, Wu NC, et al. *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin*. 2020;25(16).
436. **SARS-CoV-2 infection associated with diplopia and anti-acetylcholine receptor antibodies.** Pérez Álvarez Á I, Suárez Cuervo C, Fernández Menéndez S. *Neurologia*. 2020.
437. **Reply to the Comment by Dr. Cure on "Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade".** Perico L, Benigni A, Remuzzi G. *Nephron*. 2020;144(5):253-4.
438. **COVID-19 Related Genes in Sputum Cells in Asthma: Relationship to Demographic Features and Corticosteroids.** Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, et al. *American journal of respiratory and critical care medicine*. 2020.
439. **Calm before the storm: understanding the role of JAK inhibitors in COVID-19.** Peterson D, Damsky W, King B. *Journal of the American Academy of Dermatology*. 2020.
440. **Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations.** Phua J, Weng L, Ling L, Egi M, Lim CM, Divatia JV, et al. *The Lancet Respiratory Medicine*. 2020;8(5):506-17.
441. **Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein.** Pillay TS. *J Clin Pathol*. 2020. <http://dx.doi.org/10.1136/jclinpath-2020-206658>.
442. **Steroid-responsive encephalitis in Covid-19 disease.** Pilotto A, Odolini S, Masciocchi S, Comelli A, Volonghi I, Gazzina S, et al. *medRxiv*. 2020:2020.04.12.20062646.
443. **Pharmacological interventions for COVID-19: Protocol for a Rapid Living Systematic Review with network meta-analysis.** Pinto ACPN, Rocha AP, Milby KMM, Rocha Filho CR, Reis FSA, Carvas Junior N, et al. *medRxiv*. 2020:2020.05.02.20088823.
444. **SARS-CoV-2 virus and liver expression of host receptors: Putative mechanisms of liver involvement in COVID-19.** Piroola CJ, Sookoian S. *Liver international : official journal of the International Association for the Study of the Liver*. 2020.
445. **The psychological impact of sars-cov-2 quarantine: Observations through the lens of the polyvagal theory.** Poli A, Gemignani A, Conversano C. *Clinical Neuropsychiatry*. 2020;17(2):112-4.
446. **Perspectives on Pediatric Appendicitis and Appendectomy During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic.** Polites SF, Azarow KS. *Journal of Laparoendoscopic and Advanced Surgical Techniques*. 2020;30(4):356-7.
447. **Pediatric Microlaryngoscopy and Bronchoscopy in the COVID-19 Era.** Pollaers K, Herbert H, Vijayasekaran S. *JAMA otolaryngology-- head & neck surgery*. 2020.
448. **Fear, anxiety and health-related consequences after the COVID-19 epidemic.** Porcelli P. *Clinical Neuropsychiatry*. 2020;17(2):103-11.
449. **Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic**

- choices, suggestions of medical societies.** Porfidia A, Pola R. *Journal of thrombosis and thrombolysis*. 2020.
450. **Archetype analysis of older adult immunization decision-making and implementation in 34 countries.** Privor-Dumm L, Vasudevan P, Kobayashi K, Gupta J. *Vaccine*. 2020.
451. **Covid-19 and drug therapy, what we learned.** Provenzani A, Polidori P. *International Journal of Clinical Pharmacy*.1.
452. **Multi-Tiered Screening and Diagnosis Strategy for COVID-19: A Model for Sustainable Testing Capacity in Response to Pandemic.** Pulia MS, O'Brien TP, Hou PC, Schuman A, Sambursky R. *Annals of medicine*. 2020:1-20. <http://dx.doi.org/10.1080/07853890.2020.1763449>.
453. **COVID-19 Pandemic: Survey of future use of personal protective equipment in optometric practice.** Pult H. *Contact Lens and Anterior Eye*. 2020.
454. **Acute on Chronic Liver Failure from Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).** Qiu H, Wander P, Bernstein D, Satapathy SK. *Liver international : official journal of the International Association for the Study of the Liver*. 2020.
455. **A Typical Case of Critically Ill Infant of Coronavirus Disease 2019 With Persistent Reduction of T Lymphocytes.** Qiu L, Jiao R, Zhang A, Chen X, Ning Q, Fang F, et al. *The Pediatric infectious disease journal*. 2020. <http://dx.doi.org/10.1097/INF.0000000000002720>.
456. **A possible role for B cells in COVID-19?: Lesson from patients with Agammaglobulinemia.** Quinti I, Lougaris V, Milito C, Cinetto F, Pecoraro A, Mezzaroma I, et al. *The Journal of allergy and clinical immunology*. 2020.
457. **Use of tocilizumab for COVID-19 infection-induced cytokine release syndrome: A cautionary case report.** Radbel J, Narayanan N, Bhatt PJ. *Chest*. 2020.
458. **The key role of palliative care in response to the COVID-19 tsunami of suffering.** Radbruch L, Knaut FM, de Lima L, de Joncheere C, Bhadelia A. *The Lancet*. 2020;395(10235):1467-9.
459. **Supersensitive Multifluorophore RNA-FISH for Early Virus Detection and Flow-FISH by Using Click Chemistry.** Raddaoui N, Croce S, Geiger F, Borodavka A, Möckl L, Stazzoni S, et al. *ChemBioChem*. 2020.
460. **Tackling the COVID-19 Pandemic.** Rahimi F, Talebi Bezman Abadi A. *Archives of Medical Research*. 2020.
461. **Respiratory Distress in Postanesthesia Care Unit: First Presentation of Coronavirus Disease 2019 in a 17-Year-Old Girl: A Case Report.** Rahmzade R, Rahmzadeh R, Hashemian SM. *A&A practice*. 2020;14(7):e01227. <http://dx.doi.org/10.1213/XAA.0000000000001227>.
462. **Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.** Rajoli RKR, Pertinez H, Arshad U, Box H, Tatham L, Curley P, et al. *medRxiv*. 2020:2020.05.01.20087130.
463. **Criminal Justice-Involved Women Navigate COVID-19: Notes From the Field.** Ramaswamy M, Hemberg J, Faust A, Wickliffe J, Comfort M, Lorvick J, et al. *Health education & behavior : the official publication of the Society for Public Health Education*. 2020:1090198120927304. <http://dx.doi.org/10.1177/1090198120927304>.
464. **Coronavirus disease (COVID-19) pandemic.** Rampal L, Seng LB. *Medical Journal of Malaysia*. 2020;75(2):95-7.
465. **Novel Coronavirus 2019 (2019-nCoV) Infection: Part I - Preparedness and Management in the Pediatric Intensive Care Unit in Resource-limited Settings.** Ravikumar N, Nallasamy K, Bansal A, Angurana SK, Basavaraja GV, Sundaram M, et al. *Indian Pediatrics*. 2020;57(4):324-34.

466. **Chloroquine and hydroxychloroquine effectiveness in human subjects during coronavirus: a systematic review.** Rawaf S, Al-Saffar M, Quezada-Yamamoto H, Alshaikh M, Pelly M, Rawaf D, et al. medRxiv. 2020:2020.05.07.20094326.
467. **Clinical phenotypes of SARS-CoV-2: Implications for clinicians and researchers.** Rello J, Storti E, Belliato M, Serrano R. The European respiratory journal. 2020.
468. **Identifying potential treatments of COVID-19 from Traditional Chinese Medicine (TCM) by using a data-driven approach.** Ren X, Shao XX, Li XX, Jia XH, Song T, Zhou WY, et al. Journal of Ethnopharmacology. 2020;258.
469. **Epidemiologic and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China: A descriptive survey report.** Ren ZL, Hu R, Wang ZW, Zhang M, Ruan YL, Wu ZY, et al. Journal of Heart and Lung Transplantation. 2020;39(5):412-7.
470. **COVID-19 patients and the radiology department – advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI).** Revel MP, Parkar AP, Prosch H, Silva M, Sverzellati N, Gleeson F, et al. European Radiology. 2020.
471. **Accessibility of 'essential' alcohol in the time of COVID-19: Casting light on the blind spots of licensing?** Reynolds J, Wilkinson C. Drug and alcohol review. 2020.
472. **The Covid-19 Infection Control Arms Race.** Rhee C, Baker M, Klompas M. Infect Control Hosp Epidemiol. 2020:1-11. <http://dx.doi.org/10.1017/ice.2020.211>.
473. **Remdesivir under close scrutiny: Practical knowledge for an experimental drug against COVID-19.** Richling I. Deutsche Apotheker Zeitung. 2020;160(14).
474. **Acute Generalized Exanthematous Pustulosis with Erythema Multiforme-Like lesions in a COVID-19 woman.** Robustelli Test E, Vezzoli P, Carugno A, Raponi F, Gianatti A, Rongioletti F, et al. Journal of the European Academy of Dermatology and Venereology : JEADV. 2020. <http://dx.doi.org/10.1111/jdv.16613>.
475. **COVID-19 AND PATIENTS UNDERGOING PHARMACOLOGICAL TREATMENTS FOR IMMUNE-MEDIATED INFLAMMATORY DISEASES: PROTOCOL FOR A RAPID LIVING SYSTEMATIC REVIEW.** Rocha AP, Atallah AN, Pinto ACPN, Rocha Filho CR, Reis FSdA, Milby KMM, et al. medRxiv. 2020:2020.05.01.20087494.
476. **A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications.** Roche JA, Roche R. FASEB Journal. 2020.
477. **Evaluation of Transport Media and Specimen Transport Conditions for the Detection of SARS-CoV-2 Using Real Time Reverse Transcription PCR.** Rogers AA, Baumann RE, Borillo GA, Kagan RM, Batterman HJ, Galdzicka M, et al. Journal of clinical microbiology. 2020.
478. **SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE?** Rojas A, Gonzalez I, Morales MA. Inflammation research : official journal of the European Histamine Research Society [et al]. 2020. <http://dx.doi.org/10.1007/s00011-020-01353-x>.
479. **Convalescent plasma in Covid-19: Possible mechanisms of action.** Rojas M, Rodriguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Autoimmun Rev. 2020:102554. <http://dx.doi.org/10.1016/j.autrev.2020.102554>.
480. **Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.** Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J,

et al. *Jama*. 2020. <http://dx.doi.org/10.1001/jama.2020.8630>.

481. **Drugs that aggravate the course of COVID-19 : really ?** Rothuizen LE, Livio F, Buclin T. *Revue medicale suisse*. 2020;16:852-4.
482. **Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.** Rovina N, Akinosoglou K, Eugen-Olsen J, Hayek S, Reiser J, Giamarellos-Bourboulis EJ. *Critical care (London, England)*. 2020;24(1):187.
483. **Hypertension prevalence in human Coronavirus: The role of ACE system in infection spread and severity.** Ruocco G, Feola M, Palazzuoli A. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2020.
484. **Hypertension prevalence in human coronavirus disease: the role of ACE system in infection spread and severity.** Ruocco G, Feola M, Palazzuoli A. *International Journal of Infectious Diseases*. 2020;95:373-5.
485. **COVID-19 and Smoking. Is Nicotine the Hidden Link?** Russo P, Bonassi S, Giacconi R, Malavolta M, Tomino C, Maggi F. *The European respiratory journal*. 2020.
486. **Geospatial analysis of COVID-19 and otolaryngologists above age 60.** Ruthberg JS, Quereshy HA, Jella TK, Kocharyan A, D'Anza B, Maronian N, et al. *American journal of otolaryngology*. 2020:102514. <http://dx.doi.org/10.1016/j.amjoto.2020.102514>.
487. **Is COVID Evolution Due to Occurrence of Pulmonary Vascular Thrombosis?** Saba L, Sverzellati N. *Journal of thoracic imaging*. 2020.
488. **Risks of Hydroxychloroquine use for COVID-19 prophylaxis.** Sachdeva M, Shah M, Ziv M, Leshem E, Dodiuk-Gad RP. *Journal of the American Academy of Dermatology*. 2020.
489. **Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection.** Sacher F, Fauchier L, Boveda S, de Chillou C, Defaye P, Deharo JC, et al. *Archives of Cardiovascular Diseases*. 2020.
490. **Cancer therapy tool informs COVID-19 vaccines.** Saffern M. *Nature Reviews Immunology*. 2020.
491. **A virus that has gone viral: Amino-acid mutation in S protein of Indian-isolate of Coronavirus COVID-19 might impact receptor-binding, thus infectivity.** Saha P, Banerjee AK, Tripathi PP, Srivastava AK, Ray U. *Bioscience reports*. 2020. <http://dx.doi.org/10.1042/BSR20201312>.
492. **SARS-CoV-2, Testosterone and frailty in males (PROTEGGIMI): A multidimensional research project.** Salonia A, Corona G, Giwercman A, Maggi M, Minhas S, Nappi RE, et al. *Andrology*. 2020.
493. **Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors.** Sama IE, Ravera A, Santema BT, van Goor H, Ter Maaten JM, Cleland JGF, et al. *European heart journal*. 2020. <http://dx.doi.org/10.1093/eurheartj/ehaa373>.
494. **Status of SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN).** Sánchez-Álvarez JE, Fontán MP, Martín CJ, Pelicano MB, Reina CJ, Prieto Á MS, et al. *Nefrologia*. 2020.
495. **SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN).** Sanchez-Alvarez JE, Perez Fontan M, Jimenez Martin C, Blasco Pelicano M, Cabezas Reina CJ, Sevillano Prieto AM, et al. *Nefrologia*. 2020. <http://dx.doi.org/10.1016/j.nefro.2020.04.002>.
496. **Early outcomes of tocilizumab in adults hospitalized with severe COVID19. An initial report from the**

Vall dHebron COVID19 prospective cohort study. Sanchez-Montalva A, Selares-Nadal J, Espinosa-Pereiro J, Fernandez-Hidalgo N, Perez-Hoyos S, Salvador F, et al. medRxiv. 2020:2020.05.07.20094599.

497. **Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019.** Sanchis-Gomar F, Lavie CJ, Perez-Quilis C, Henry BM, Lippi G. Mayo Clinic Proceedings. 2020.

498. **Evidence for Use or Disuse of Renin-Angiotensin System Modulators in Patients Having COVID-19 With an Underlying Cardiorenal Disorder.** Sankrityayan H, Kale A, Sharma N, Anders HJ, Gaikwad AB. Journal of cardiovascular pharmacology and therapeutics. 2020:1074248420921720.

499. **Update on coronavirus disease 2019 (COVID-19).** Santantonio TA, Messina G. Open Neurology Journal. 2020;14(1):4-5.

500. **3D-printed face protective shield in interventional radiology: Evaluation of an immediate solution in the era of COVID-19 pandemic.** Sapoval M, Gaultier AL, Del Giudice C, Pellerin O, Kassis-Chikhani N, Lemarteleur V, et al. Diagnostic and Interventional Imaging. 2020.

501. **Performance Evaluation of UAV-Enabled LoRa Networks for Disaster Management Applications.** Saraereh OA, Alsaraira A, Khan I, Uthansakul P. Sensors (Basel, Switzerland). 2020;20(8).

502. **Patients with lupus are not protected from COVID-19.** Sawalha AH. Annals of the Rheumatic Diseases. 2020.

503. **Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?** Sayad B, Sobhani M, Khodarahmi R. Archives of medical research. 2020. <http://dx.doi.org/10.1016/j.arcmed.2020.04.018>.

504. **Conjunctivitis can be the only presenting sign and symptom of COVID-19.** Scalinci SZ, Trovato Battagliola E. IDCases. 2020;20.

505. **The four horsemen of fear: An integrated model of understanding fear experiences during the COVID-19 pandemic.** Schimmenti A, Billieux J, Starcevic V. Clinical Neuropsychiatry. 2020;17(2):41-5.

506. **Initial COVID-19 closure strategies adopted by a convenience sample of U.S. school districts: directions for future research.** Schlegelmilch J, Douglas C. Disaster medicine and public health preparedness. 2020:1-4. <http://dx.doi.org/10.1017/dmp.2020.147>.

507. **Beware: Gastrointestinal symptoms can be a manifestation of COVID-19.** Schmulson M, Dávalos MF, Berumen J. Revista de Gastroenterología de México. 2020.

508. **Public Health Response to the Initiation and Spread of Pandemic COVID-19 in the United States, February 24-April 21, 2020.** Schuchat A. MMWR Morbidity and mortality weekly report. 2020;69(18):551-6. <http://dx.doi.org/10.15585/mmwr.mm6918e2>.

509. **The ethical challenges of the SARS-CoV-2 pandemic in the global south and the global north - same and different.** Schuklenk U. Developing world bioethics. 2020.

510. **Additional safety consideration for azithromycin in the management of SARS-CoV-2 infection.** Seftel MD. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2020;192(18):E483. <http://dx.doi.org/10.1503/cmaj.75427>.

511. **DIC in COVID-19: Implications for Prognosis and Treatment?** Seitz R, Schramm W. Journal of thrombosis and haemostasis : JTH. 2020.

512. **COVID-19 and Depression.** Shader RI. *Clinical Therapeutics*. 2020.
513. **COVID-19 and Older Adults: What We Know.** Shahid Z, Kalayanamitra R, McClafferty B, Kepko D, Ramgobin D, Patel R, et al. *Journal of the American Geriatrics Society*. 2020.
514. **Cerebellar Scholars' Challenging Time in COVID-19 Pandemia.** Shaikh AG, Mitoma H, Manto M. *Cerebellum*. 2020;19(3):343-4.
515. **Caring for patients with pain during the COVID-19 pandemic: consensus recommendations from an international expert panel.** Shanthanna H, Strand NH, Provenzano DA, Lobo CA, Eldabe S, Bhatia A, et al. *Anaesthesia*. 2020.
516. **Editorial: Androgen hazards with COVID-19.** Sharifi N, Ryan CJ. *Endocrine-Related Cancer*. 2020;27(6):E1-E3.
517. **Metformin in COVID-19: A possible role beyond diabetes.** Sharma S, Ray A, Sadasivam B. *Diabetes Research and Clinical Practice*. 2020;164.
518. **Hookah smoking and COVID-19: Call for action.** Shekhar S, Hannah-Shmouni F. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. 2020;192(17):E462.
519. **Clinical evaluation of a rapid colloidal gold immunochromatography assay for SARS-Cov-2 IgM/IgG.** Shen B, Zheng Y, Zhang X, Zhang W, Wang D, Jin J, et al. *American Journal of Translational Research*. 2020;12(4):1348-54.
520. **Association of viral load with serum biomarkers among COVID-19 cases.** Shi F, Wu T, Zhu X, Ge Y, Zeng X, Chi Y, et al. *Virology*. 2020;546:122-6.
521. **Can melatonin reduce the severity of COVID-19 pandemic?** Shneider A, Kudriavtsev A, Vakhrusheva A. *International reviews of immunology*. 2020:1-10.
522. **Vets would not manage Covid-19 this way.** Sibley D, Brownlie J. *Veterinary Record*. 2020;186(14):462-3.
523. **COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal.** Siddiqi HK, Mehra MR. *Journal of Heart and Lung Transplantation*. 2020;39(5):405-7.
524. **Migraine in the Time of COVID-19.** Silvestro M, Tessitore A, Tedeschi G, Russo A. *Headache*. 2020;60(5):988-9.
525. **Guidelines for the management of diabetes in care homes during the Covid-19 pandemic.** Sinclair A, Dhatariya K, Burr O, Nagi D, Higgins K, Hopkins D, et al. *Diabetic medicine : a journal of the British Diabetic Association*. 2020.
526. **Chest CT imaging of an early Canadian case of COVID-19 in a 28-year-old man.** Singh N, Fratesi J. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. 2020;192(17):E455.
527. **An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets.** Sinha SK, Shakya A, Prasad SK, Singh S, Gurav NS, Prasad RS, et al. *Journal of biomolecular structure & dynamics*. 2020:1-13.
528. **Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment.** Smieszek SP, Przychodzen BP, Polymeropoulos MH. *International Journal of Antimicrobial Agents*. 2020.

529. **Covid-19 and mental health: a transformational opportunity to apply an evidence-based approach to clinical practice and research.** Smith K, Ostinelli E, Cipriani A. Evidence-based mental health. 2020;23(2):45-6.
530. **Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor Alisporivir (Debio 025).** Softic L, Brillat R, Berry F, Ahnou N, Nevers Q, Morin-Dewaele M, et al. Antimicrob Agents Chemother. 2020. <http://dx.doi.org/10.1128/AAC.00876-20>.
531. **Genetic diversity of MERS-CoV spike protein gene in Saudi Arabia.** Sohrab SS, Azhar EI. Journal of Infection and Public Health. 2020;13(5):709-17.
532. **Structural Vulnerability in the United States Revealed in Three Waves of Novel Coronavirus Disease (COVID-19).** Solis J, Franco-Paredes C, Henao-Martinez AF, Krsak M, Zimmer SM. The American journal of tropical medicine and hygiene. 2020. <http://dx.doi.org/10.4269/ajtmh.20-0391>.
533. **Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19.** Song JC, Wang G, Zhang W, Zhang Y, Li WQ, Zhou Z. Military Medical Research. 2020;7(1).
534. **Controversy regarding ACE inhibitors / ARBs in COVID-19.** Soria Arcos F, Romero Puche A, Vicente Vera T. Revista Espanola de Cardiologia. 2020.
535. **ACE2, COVID-19, and ACE Inhibitor and ARB Use during the Pandemic: The Pediatric Perspective.** South AM, Brady TM, Flynn JT. Hypertension. 2020.
536. **Lessons learned from chest CT in COVID-19.** Soyer P. Diagnostic and Interventional Imaging. 2020;101(5):261-2.
537. **Reliability and usefulness of a rapid IgM-IgG antibody test for the diagnosis of SARS-CoV-2 infection: A preliminary report.** Spicuzza L, Montineri A, Manuele R, Crimi C, Pistorio MP, Campisi R, et al. Journal of Infection. 2020.
538. **COVID-19 and Avoiding Ibuprofen. How Good Is the Evidence?** Sridharan GK, Kotagiri R, Chandiramani VH, Mohan BP, Vegunta R, Vegunta R, et al. American journal of therapeutics. 2020.
539. **A hypothesis for pathobiology and treatment of COVID-19: the centrality of ACE1/ACE2 imbalance.** Sriram K, Insel PA. British journal of pharmacology. 2020.
540. **Use of non-invasive vagus nerve stimulation to treat respiratory symptoms associated with COVID-19: A theoretical hypothesis and early clinical experience.** Staats P, Giannakopoulos G, Blake J, Liebler E, Levy RM. Neuromodulation : journal of the International Neuromodulation Society. 2020.
541. **Quantitative clinical pharmacology input to SARS-CoV-2 therapeutics should be based on robust data.** Standing J. Clinical pharmacology and therapeutics. 2020.
542. **Editorial A hundred days into the coronavirus disease (COVID-19) pandemic.** Steffens I. Eurosurveillance. 2020;25(14):1-4.
543. **Urologic surgery and COVID-19: How the pandemic is changing the way we operate.** Steward J, Kitley WR, Schmidt CM, Sundaram CP. Journal of endourology. 2020.
544. **A Novel Plan to Deal with SARS-CoV-2 and COVID-19 Disease.** Stricker RB, Fesler MC. Journal of medical virology. 2020.
545. **DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19?** Strollo R, Pozzilli P. Diabetes/metabolism research and reviews. 2020.

546. **Prevention and therapy of covid-19 via exogenous estrogen treatment for both male and female patients; An opinion paper.** Suba Z. *Journal of Pharmacy and Pharmaceutical Sciences*. 2020;23(1):75-85.
547. **SARS-CoV-2: A New Song Recalls an Old Melody.** Subbarao K. *Cell Host and Microbe*. 2020;27(5):692-4.
548. **Novel coronavirus (Covid-19)-a critical review.** Sudan P, Goswami M, Arockia Babu M. *International Journal of Research in Pharmaceutical Sciences*. 2020;11:43-7.
549. **Smartphone-based multiplex 30-minute nucleic acid test of live virus from nasal swab extract.** Sun F, Ganguli A, Nguyen J, Brisbin R, Shanmugam K, Hirschberg DL, et al. *Lab on a chip*. 2020.
550. **Risk factors for mortality in 244 older adults with COVID-19 in Wuhan, China: a retrospective study.** Sun H, Ning R, Tao Y, Yu C, Deng X, Zhao C, et al. *Journal of the American Geriatrics Society*. 2020. <http://dx.doi.org/10.1111/jgs.16533>.
551. **Isolation of Infectious SARS-CoV-2 from Urine of a COVID-19 Patient.** Sun J, Zhu A, Li H, Zheng K, Zhuang Z, Chen Z, et al. *Emerging microbes & infections*. 2020:1-8.
552. **Clinical Features of Patients with Coronavirus Disease 2019 (COVID-19) from a Designated Hospital in Beijing, China.** Sun L, Shen L, Fan J, Gu F, Hu M, An Y, et al. *Journal of medical virology*. 2020.
553. **Estimating the Effects of Asymptomatic and Imported Patients on COVID-19 Epidemic Using Mathematical Modeling.** Sun T, Weng D. *Journal of medical virology*. 2020.
554. **Rheumatologists' view on the use of hydroxychloroquine to treat COVID-19.** Sun X, Ni Y, Zhang M. *Emerging microbes & infections*. 2020;9(1):830-2. <http://dx.doi.org/10.1080/22221751.2020.1760145>.
555. **[Potential harms associated with 4-aminoquinoline treatment].** Svensson M. *Lakartidningen*. 2020;117.
556. **The emotional impact of over suspicion in the corona virus pandemic.** Syal R, Kumari K, Kumar R, Prasad H, Bhatia P. *Journal of Clinical Anesthesia*. 2020;64.
557. **Migraine Care in the Era of COVID-19: Clinical Pearls and Plea to Insurers.** Szperka CL, Ailani J, Barmherzig R, Klein BC, Minen MT, Halker Singh RB, et al. *Headache*. 2020;60(5):833-42.
558. **Will the antimalarial drug take over to combat COVID-19?** T.K S, G S. *Journal of Public Health (Germany)*. 2020.
559. **A Quantitative Framework for Modeling COVID-19 Risk During Adjuvant Therapy Using Published Randomized Trials of Glioblastoma in the Elderly.** Tabrizi S, Trippa L, Cagney D, Tanguturi S, Vents S, Fell G, et al. *Neuro-oncology*. 2020.
560. **Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome.** Tammaro A, Adebajo GAR, Parisella FR, Pezzuto A, Rello J. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2020.
561. **Anesthesia and COVID-19: What We Should Know and What We Should Do.** Tang LY, Wang J. *Seminars in cardiothoracic and vascular anesthesia*. 2020:1089253220921590.
562. **Thrombosis management in times of COVID-19 epidemic; a Dutch perspective.** Ten Cate H. *Thrombosis Journal*. 2020;18(1).
563. **Advances on Antiviral Activity of Morus spp. Plant Extracts: Human Coronavirus and Virus-Related**

Respiratory Tract Infections in the Spotlight. Thabti I, Albert Q, Philippot S, Dupire F, Westerhuis B, Fontanay S, et al. *Molecules* (Basel, Switzerland). 2020;25(8).

564. **What do monitoring platelet counts in COVID-19 teach us?** Thachil J. *Journal of thrombosis and haemostasis* : JTH. 2020.

565. **The versatile heparin in COVID-19.** Thachil J. *Journal of Thrombosis and Haemostasis*. 2020.

566. **Type and dose of heparin in COVID-19.** Thachil J, Tang N, Gando S, Falanga A, Levi M, Clark C, et al. *Journal of thrombosis and haemostasis* : JTH. 2020.

567. **COVID-19: endgames.** The Lancet Infectious D. *The Lancet Infectious Diseases*. 2020;20(5):511.

568. **Nutritional care at hospital during the Covid-19 viral epidemic: Expert opinion from the French-speaking Society for Clinical Nutrition and Metabolism (SFNCM).** Thibault R, Quilliot D, Seguin P, Tamion F, Schneider S, Déchelotte P. *Nutrition Clinique et Metabolisme*. 2020.

569. **Antihypertensive drugs and risk of COVID-19?** Tignanelli CJ, Ingraham NE, Sparks MA, Reilkoff R, Bezdicek T, Benson B, et al. *The Lancet Respiratory Medicine*. 2020;8(5):e30-e1.

570. **Pooling of Nasopharyngeal Swab Specimens for SARS-CoV-2 detection by RT-PCR.** Torres I, Albert E, Navarro D. *Journal of medical virology*. 2020.

571. **Management of CO2 absorbent while using the anesthesia machine as a mechanical ventilator on patients with COVID-19.** Torres MLA, Canhisares FAT, Quintão VC. *Brazilian Journal of Anesthesiology*. 2020.

572. **The role of 18F-FDG PET for COVID-19 infection: myth versus reality.** Treglia G. *Clinical and Translational Imaging*. 2020.

573. **Does pandemic justify the use of Hydroxychloroquine for treatment and prevention of COVID-19 in India?** Tripathy JP. *Journal of medical virology*. 2020.

574. **The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses.** Tse LV, Meganck RM, Graham RL, Baric RS. *Front Microbiol*. 2020;11:658. <http://dx.doi.org/10.3389/fmicb.2020.00658>. eCollection 2020.

575. **Coronavirus in Hematologic Malignancies: Targeting Molecules Beyond the Angiotensin-Converting Enzyme 2 (ACE2) Wall in COVID-19.** Tsiambas E, Papanikolaou V, Chrysovergis A, Mastronikolis N, Ragos V, Kavantzias N, et al. *Pathology oncology research* : POR. 2020.

576. **Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease.** Tsuji M. *FEBS open bio*. 2020.

577. **Mechano-genomic regulation of coronaviruses and its interplay with ageing.** Uhler C, Shivashankar GV. *Nature Reviews Molecular Cell Biology*. 2020;21(5):247-8.

578. **Camostat mesilate therapy for COVID-19.** Uno Y. *Internal and emergency medicine*. 2020.

579. **COVID-19 and diabetes: is metformin a friend or foe?** Ursini F, Ciaffi J, Paola Landini M, Meliconi R. *Diabetes research and clinical practice*. 2020:108167.

580. **2019-nCoV-SARS-CoV-2 (COVID-19) infection: Cruciality of Furin and relevance with cancer.** Usul Afsar C. *Medical Hypotheses*. 2020;140.

581. **The Risks of Prescribing Hydroxychloroquine in COVID-19-Infected Patients With Schizophrenia.** Uvais NA. The primary care companion for CNS disorders. 2020;22(3). <http://dx.doi.org/10.4088/PCC.20com02635>.
582. **A Postpartum Death Due to Coronavirus Disease 2019 (COVID-19) in the United States.** Vallejo V, Ilagan JG. Obstetrics and gynecology. 2020. <http://dx.doi.org/10.1097/AOG.0000000000003950>.
583. **Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.** van de Veerdonk FL, Netea MG, van Deuren M, van der Meer JW, de Mast Q, Brüggemann RJ, et al. eLife. 2020;9.
584. **Chloroquine-induced QTc prolongation in COVID-19 patients.** van den Broek MPH, Möhlmann JE, Abeln BGS, Liebrechts M, van Dijk VF, van de Garde EMW. Netherlands Heart Journal. 2020.
585. **Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1.** Van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. New England Journal of Medicine. 2020;382(16):1564-7.
586. **Care for adult non-ICU covid-19 patients: Early experiences from a Belgian tertiary care centre.** Van Halem K, Cox J, Messiaen P, Pat K, Declercq C, Meersman A, et al. Netherlands Journal of Medicine. 2020;78(3):111-5.
587. **COVID19 pandemic and people with opioid use disorder: innovation to reduce risk.** Vecchio S, Ramella R, Drago A, Carraro D, Littlewood R, Somaini L. Psychiatry Research. 2020;289.
588. **The care of patients with Duchenne, Becker and other muscular dystrophies in the COVID-19 pandemic.** Veerapandiyan A, Wagner KR, Apkon S, McDonald CM, Mathews KD, Parsons JA, et al. Muscle & nerve. 2020.
589. **Mild versus severe COVID-19: laboratory markers.** Velavan TP, Meyer CG. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020.
590. **Patients with advanced basal cell carcinomas in treatment with sonic hedgehog inhibitors during the coronavirus disease 2019 (COVID-19) period: Management and adherence to treatment.** Villani A, Fabbrocini G, Costa C, Scalvenzi M. Journal of the American Academy of Dermatology. 2020.
591. **Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge.** Violi F, Pastori D, Cangemi R, Pignatelli P, Loffredo L. Thrombosis and haemostasis. 2020.
592. **Smoking and sars-cov-2 disease (Covid-19): Dangerous liaisons or confusing relationships?** Volti GL, Caruso M, Polosa R. Journal of Clinical Medicine. 2020;9(5).
593. **An Extensive Meta-Metagenomic Search Identifies SARS-CoV-2-Homologous Sequences in Pangolin Lung Viromes.** Wahba L, Jain N, Fire AZ, Shoura MJ, Artiles KL, McCoy MJ, et al. mSphere. 2020;5(3). <http://dx.doi.org/10.1128/mSphere.00160-20>.
594. **Evidence from two cases of asymptomatic infection with SARS-CoV-2: Are 14 days of isolation sufficient?** Wan R, Mao ZQ, He LY, Hu YC, Wei C. International Journal of Infectious Diseases. 2020;95:174-5.
595. **Long-term Coexistence of SARS-CoV-2 with Antibody Response in COVID-19 Patients.** Wang B, Wang L, Kong X, Geng J, Xiao D, Ma C, et al. Journal of medical virology. 2020.
596. **A human monoclonal antibody blocking SARS-CoV-2 infection.** Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus A, et al. Nat Commun. 2020;11(1):2251. <http://dx.doi.org/10.1038/s41467-020-16256-y>.
597. **COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statement.** Wang C, Rademaker M, Baker C, Foley P. Australasian Journal of

Dermatology. 2020.

598. **Does infection of 2019 novel coronavirus cause acute and/or chronic sialadenitis?** Wang C, Wu H, Ding X, Ji H, Jiao P, Song H, et al. *Medical Hypotheses*. 2020;140.
599. **An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development.** Wang F, Kream RM, Stefano GB. *Medical science monitor : international medical journal of experimental and clinical research*. 2020;26:e924700. <http://dx.doi.org/10.12659/MSM.924700>.
600. **CLINICAL CHARACTERISTICS OF 28 PATIENTS WITH DIABETES AND COVID-19 IN WUHAN, CHINA.** Wang F, Yang Y, Dong K, Yan Y, Zhang S, Ren H, et al. *Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists*. 2020.
601. **The genetic sequence, origin, and diagnosis of SARS-CoV-2.** Wang H, Li X, Li T, Zhang S, Wang L, Wu X, et al. *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology*. 2020.
602. **Spontaneous pneumomediastinum: A probable unusual complication of Coronavirus disease 2019 (COVID-19) pneumonia.** Wang J, Su X, Zhang T, Zheng C. *Korean Journal of Radiology*. 2020;21(5):627-8.
603. **Science in the fight against the novel coronavirus disease 2019 (COVID-19).** Wang JW, Cao B, Wang C. *Chinese medical journal*. 2020;133(9):1009-11.
604. **The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China.** Wang L, Gao YH, Lou LL, Zhang GJ. *The European respiratory journal*. 2020;55(4).
605. **The nucleic acid test of induced sputum should be used for estimation of patients cure with 2019-nCov.** Wang QX, Zeng XH, Zheng SL. *European review for medical and pharmacological sciences*. 2020;24(7):3437.
606. **Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19.** Wang T, Chen R, Liu C, Liang W, Guan W, Tang R, et al. *The Lancet Haematology*. 2020;7(5):e362-e3.
607. **The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro.** Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H, et al. *Cell Discovery*. 2020;6(1).
608. **Nosocomial Outbreak of 2019 Novel Coronavirus Pneumonia in Wuhan, China.** Wang X, Zhou Q, He Y, Liu L, Ma X, Wei X, et al. *The European respiratory journal*. 2020.
609. **MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment.** Wang XY. *European review for medical and pharmacological sciences*. 2020;24(8):4537-8. http://dx.doi.org/10.26355/eurrev_202004_21037.
610. **Impact of COVID-19 on blood centres in Zhejiang province China.** Wang Y, Han W, Pan L, Wang C, Liu Y, Hu W, et al. *Vox Sanguinis*. 2020.
611. **Site-specific glycan analysis of the SARS-CoV-2 spike.** Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M. *Science*. 2020. <http://dx.doi.org/10.1126/science.abb9983>.
612. **Respiratory surveillance wards as a strategy to reduce nosocomial transmission of COVID-19 through early detection: the experience of a tertiary hospital in Singapore.** Wee LE, Hsieh JYC, Puah GC, Tan Y, Conceicao EP, Wijaya L, et al. *Infect Control Hosp Epidemiol*. 2020:1-16. <http://dx.doi.org/10.1017/ice.2020.207>.
613. **Acute myocardial injury is common in patients with covid-19 and impairs their prognosis.** Wei JF,

Huang FY, Xiong TY, Liu Q, Chen H, Wang H, et al. *Heart*. 2020.

614. **Elevations of serum cancer biomarkers correlate with severity of COVID-19.** Wei X, Su J, Yang K, Wei J, Wan H, Cao X, et al. *Journal of medical virology*. 2020.

615. **Glycerol monolaurate, an analogue to a factor secreted by lactobacillus, is virucidal against enveloped viruses, including hiv-1.** Welch JL, Xiang J, Okeoma CM, Schlievert PM, Stapleton JT. *mBio*. 2020;11(3).

616. **The Value of Headache-Specific Recommendations During COVID-19.** Wells RE, Strauss LD. *Headache*. 2020;60(5):820-3.

617. **[Real-world efficacy and safety of lopinavir/ritonavir and arbidol in treating with COVID-19 : an observational cohort study].** Wen CY, Xie ZW, Li YP, Deng XL, Chen XT, Cao Y, et al. *Zhonghua nei ke za zhi*. 2020;59:E012. <http://dx.doi.org/10.3760/cma.j.cn112138-20200227-00147>.

618. **Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing.** Wen W, Su W, Tang H, Le W, Zhang X, Zheng Y, et al. *Cell Discovery*. 2020;6(1).

619. **Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.** Whyte CS, Morrow GB, Mitchell JL, Chowdary P, Mutch NJ. *Journal of thrombosis and haemostasis : JTH*. 2020.

620. **Virological assessment of hospitalized patients with COVID-2019.** Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. *Nature*. 2020.

621. **Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.** Wrapp D, De Vlieger D, Corbett KS, Torres GM, Wang N, Van Breedam W, et al. *Cell*. 2020.

622. **Interpretation of CT signs of 2019 novel coronavirus (COVID-19) pneumonia.** Wu J, Pan J, Teng D, Xu X, Feng J, Chen YC. *European radiology*. 2020.

623. **Hybridization chain reactions targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).** Wu TH, Chang CC, Yang CH, Lin WY, Ee TJ, Lin CW. *International Journal of Molecular Sciences*. 2020;21(9).

624. **Coronavirus disease 2019 among pregnant Chinese women: Case series data on the safety of vaginal birth and breastfeeding.** Wu Y, Liu C, Dong L, Zhang C, Chen Y, Liu J, et al. *BJOG : an international journal of obstetrics and gynaecology*. 2020. <http://dx.doi.org/10.1111/1471-0528.16276>.

625. **Small solitary ground-glass nodule on ct as an initial manifestation of Coronavirus disease 2019 (COVID-19) pneumonia.** Xia T, Li J, Gao J, Xu X. *Korean Journal of Radiology*. 2020;21(5):545-9.

626. **Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: A descriptive study.** Xiao AT, Tong YX, Gao C, Zhu L, Zhang YJ, Zhang S. *Journal of Clinical Virology*. 2020;127.

627. **Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins.** Xiao K, Zhai J, Feng Y, Zhou N, Zhang X, Zou JJ, et al. *Nature*. 2020. <http://dx.doi.org/10.1038/s41586-020-2313-x>.

628. **ACE2: The key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel?** Xiao L, Sakagami H, Miwa N. *Viruses*. 2020;12(5).

629. **Association Between Hypoxemia and Mortality in Patients With COVID-19.** Xie J, Covassin N, Fan Z, Singh P, Gao W, Li G, et al. *Mayo Clinic Proceedings*. 2020.

630. **Characteristics of Patients with Coronavirus Disease (COVID-19) Confirmed using an IgM-IgG Antibody Test.** Xie J, Ding C, Li J, Wang Y, Guo H, Lu Z, et al. *Journal of medical virology*. 2020.
631. **Family cluster of three recovered cases of pneumonia due to severe acute respiratory syndrome coronavirus 2 infection.** Xiong Y, Song S, Ye G, Wang X. *BMJ Case Rep*. 2020;13(5). <http://dx.doi.org/10.1136/bcr-2020-235302>.
632. **Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report.** Xu CY, Lu SD, Ye X, Cao MY, Xu GD, Yu Q, et al. *QJM : monthly journal of the Association of Physicians*. 2020.
633. **Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.** Xu J, Shi PY, Li H, Zhou J. *ACS infectious diseases*. 2020;6(5):909-15. <http://dx.doi.org/10.1021/acsinfecdis.0c00052>. Epub 2020 Mar 10.
634. **Deep thought of COVID-19 based on Diamond Princess's quarantine and home quarantine.** Xu JW, Wang XY, Qin Z, Song HL, Wang H, Luo HY, et al. *European review for medical and pharmacological sciences*. 2020;24(7):4027-9.
635. **[Management of COVID-19: the Zhejiang experience].** Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. *Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences*. 2020;49(2):147-57.
636. **Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines.** Xu X, Ong YK, Wang Y. *Military Medical Research*. 2020;7(1):22. <http://dx.doi.org/10.1186/s40779-020-00251-x>.
637. **Covert COVID-19 and false-positive dengue serology in Singapore.** Yan G, Lee CK, Lam LTM, Yan B, Chua YX, Lim AYN, et al. *The Lancet Infectious Diseases*. 2020;20(5):536.
638. **Clinical characteristics and outcomes of patients with severe covid-19 with diabetes.** Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, et al. *BMJ open diabetes research & care*. 2020;8(1).
639. **Favipiravir: A Possible Pharmaceutical Treatment for COVID-19.** Yanai H. *Journal of Endocrinology and Metabolism*. 2020;10(2):33-4.
640. **Coronavirus disease 2019: a clinical review.** Yang CL, Qiu X, Zeng YK, Jiang M, Fan HR, Zhang ZM. *European review for medical and pharmacological sciences*. 2020;24(8):4585-96. http://dx.doi.org/10.26355/eurrev_202004_21045.
641. **Clinical characteristics and outcomes of cancer patients with COVID-19.** Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. *Journal of medical virology*. 2020.
642. **Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study.** Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J, et al. *Hypertension (Dallas, Tex : 1979)*. 2020.
643. **ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19.** Yang J, Li H, Hu S, Zhou Y. *Aging*. 2020;12.
644. **Persistent viral RNA positivity during recovery period of a patient with SARS-CoV-2 infection.** Yang JR, Deng DT, Wu N, Yang B, Li HJ, Pan XB. *Journal of medical virology*. 2020.
645. **Systematic Review and Meta-analysis of the Effectiveness and Safety of Hydroxychloroquine in COVID-19.** Yang T-H, Chou C-Y, Yang Y-F, Yang Y-P, Chien C-S, Yarmishyn AA, et al. *medRxiv*. 2020:2020.05.07.20093831.

646. **Bee venom and SARS-CoV-2.** Yang W, Hu FL, Xu XF. *Toxicon*. 2020;181:69-70.
647. **On airborne transmission and control of SARS-Cov-2.** Yao M, Zhang L, Ma J, Zhou L. *The Science of the total environment*. 2020;731:139178. <http://dx.doi.org/10.1016/j.scitotenv.2020.139178>.
648. **Retrospective study of risk factors for severe SARS-Cov-2 infections in hospitalized adult patients.** Yao Q, Wang P, Wang X, Qie G, Meng M, Tong X, et al. *Polish archives of internal medicine*. 2020.
649. **[Visualization analysis on treatment of coronavirus based on knowledge graph].** Yi W, Wang Y, Tang J, Xiong X, Zhang Y, Yan S. *Zhonghua wei zhong bing ji jiu yi xue*. 2020;32(3):279-86. <http://dx.doi.org/10.3760/cmaj.cn121430-20200225-00200>.
650. **Correlation between Heart fatty acid binding protein and severe COVID-19: A case-control study.** Yin L, Mou H, Shao J, Zhu Y, Pang X, Yang J, et al. *PLoS ONE*. 2020;15(4).
651. **Connecting clusters of COVID-19: an epidemiological and serological investigation.** Yong SEF, Anderson DE, Wei WE, Pang J, Chia WN, Tan CW, et al. *The Lancet Infectious diseases*. 2020.
652. **Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study.** Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, et al. *The Lancet Infectious Diseases*. 2020;20(5):559-64.
653. **Computational screening of antagonist against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking.** Yu R, Chen L, Lan R, Shen R, Li P. *International journal of antimicrobial agents*. 2020:106012. <http://dx.doi.org/10.1016/j.ijantimicag.2020.106012>.
654. **Association Between Clinical Manifestations and Prognosis in Patients with COVID-19.** Yu T, Cai S, Zheng Z, Cai X, Liu Y, Yin S, et al. *Clinical Therapeutics*. 2020.
655. **Epidemiological and Clinical Characteristics of 333 Confirmed Cases with Coronavirus Disease 2019 in Shanghai, China.** Yu X, Sun X, Cui P, Pan H, Lin S, Han R, et al. *Transboundary and emerging diseases*. 2020.
656. **COVID-19 and surface water quality: Improved lake water quality during the lockdown.** Yunus AP, Masago Y, Hijioka Y. *Science of the Total Environment*. 2020;731.
657. **Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive IPAH and COVID-19 Infection.** Zamanian RT, Pollack CV, Gentile MA, Rashid M, Fox JC, Mahaffey KW, et al. *American journal of respiratory and critical care medicine*. 2020.
658. **Management of COVID-19: the risks associated with treatment are clear, but the benefits remain uncertain.** Zareifopoulos N, Lagadinou M, Karela A, Platanaki C, Karantzogiannis G, Velissaris D. *Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace*. 2020;90(2). <http://dx.doi.org/10.4081/monaldi.2020.1342>.
659. **ANNALS EXPRESS: Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: a closer look at angiotensin-converting enzyme 2 (ACE2).** Zemlin AE, Wiese OJ. *Annals of clinical biochemistry*. 2020:4563220928361.
660. **Treatment and Outcome of a Patient With Lung Cancer Infected With Severe Acute Respiratory Syndrome Coronavirus-2.** Zhang H, Xie C, Huang Y. *Journal of Thoracic Oncology*. 2020;15(5):e63-e4.
661. **Navigating the Pandemic Response Life Cycle: Molecular Diagnostics and Immunoassays in the Context of COVID-19 Management.** Zhang J, Gharizadeh B, Lu D, Yue J, Yu M, Liu Y, et al. *IEEE Reviews in Biomedical Engineering*. 2020.

662. **The clinical data from 19 critically ill patients with coronavirus disease 2019: a single-centered, retrospective, observational study.** Zhang J, Liu P, Wang M, Wang J, Chen J, Yuan W, et al. *Journal of Public Health (Germany)*. 2020.
663. **Current status of potential therapeutic candidates for the COVID-19 crisis.** Zhang J, Xie B, Hashimoto K. *Brain, behavior, and immunity*. 2020.
664. **Investigation on a cluster epidemic of COVID-19 in a supermarket in Liaocheng, Shandong province.** Zhang JZ, Zhou P, Han DB, Wang WC, Cui C, Zhou R, et al. *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi*. 2020;41:E055.
665. **Becoming a Faithful Defender: Traditional Chinese Medicine against Coronavirus Disease 2019 (COVID-19).** Zhang L, Yu J, Zhou Y, Shen M, Sun L. *The American journal of Chinese medicine*. 2020:1-15.
666. **Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia.** Zhang S, Li L, Shen A, Chen Y, Qi Z. *Clinical Drug Investigation*. 2020.
667. **Novel Coronavirus Polymerase and Nucleotidyl-transferase Structures: Potential to Target New Outbreaks.** Zhang W, Stephen P, Theriault JF, Wang R, Lin SX. *The journal of physical chemistry letters*. 2020. <http://dx.doi.org/10.1021/acs.jpcllett.0c00571>.
668. **The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.** Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. *Clinical immunology (Orlando, Fla)*. 2020;214:108393. <http://dx.doi.org/10.1016/j.clim.2020.108393>. Epub 2020 Mar 25.
669. **Prolonged Viral RNA Shedding Duration in COVID-19.** Zhang WY, Yu LQ, Huang JA, Zeng DX. *American journal of therapeutics*. 2020.
670. **Coagulopathy and antiphospholipid antibodies in patients with covid-19.** Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. *New England Journal of Medicine*. 2020;382(17):E38.
671. **Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China.** Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. *Liver International*. 2020.
672. **Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?** Zhang Y, Zhong Y, Pan L, Dong J. *Drug discoveries & therapeutics*. 2020;14(2):100-2. <http://dx.doi.org/10.5582/ddt.2020.03006>.
673. **Active constituents and mechanisms of Respiratory Detox Shot, a traditional Chinese medicine prescription, for COVID-19 control and prevention: Network-molecular docking-LC-MS(E) analysis.** Zhang ZJ, Wu WY, Hou JJ, Zhang LL, Li FF, Gao L, et al. *Journal of integrative medicine*. 2020;18(3):229-41. <http://dx.doi.org/10.1016/j.joim.2020.03.004>. Epub 2020 Apr 8.
674. **icumonitoring.ch: a platform for short-term forecasting of intensive care unit occupancy during the COVID-19 epidemic in Switzerland.** Zhao C, Tepekule B, Criscuolo NG, Wendel Garcia PD, Hilty MP, Risc-Icu Consortium Investigators In S, et al. *Swiss Med Wkly*. 2020;150:w20277. <http://dx.doi.org/10.4414/smw.2020.20277>. eCollection 2020 May 4.
675. **Early detection of SARS-CoV-2 antibodies in COVID-19 patients as a serologic marker of infection.** Zhao R, Li M, Song H, Chen J, Ren W, Feng Y, et al. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
676. **Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening.** Zhao X, Jiang Y, Zhao Y, Xi H, Liu C, Qu F, et al. *European journal of clinical microbiology & infectious*

diseases : official publication of the European Society of Clinical Microbiology. 2020.

677. **Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study.** Zhao XY, Xu XX, Yin HS, Hu QM, Xiong T, Tang YY, et al. BMC infectious diseases. 2020;20(1):311.
678. **Clinical and transmission dynamics characteristics of 406 children with coronavirus disease 2019 in China: A review.** Zhen-Dong Y, Gao-Jun Z, Run-Ming J, Zhi-Sheng L, Zong-Qi D, Xiong X, et al. Journal of Infection. 2020.
679. **Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV.** Zheng M, Song L. Cellular and Molecular Immunology. 2020;17(5):536-8.
680. **The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study.** Zheng Y, Zhang Y, Chi H, Chen S, Peng M, Luo L, et al. Clinical chemistry and laboratory medicine. 2020.
681. **Reusable and Recyclable Graphene Masks with Outstanding Superhydrophobic and Photothermal Performances.** Zhong H, Zhu Z, Lin J, Cheung CF, Lu VL, Yan F, et al. ACS nano. 2020.
682. **Imaging features and evolution on CT in 100 COVID-19 pneumonia patients in Wuhan, China.** Zhou S, Zhu T, Wang Y, Xia L. European radiology. 2020.
683. **Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity.** Zhu Y, Yu D, Yan H, Chong H, He Y. J Virol. 2020. <http://dx.doi.org/10.1128/JVI.00635-20>.
684. **Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019.** Zhu Z, Cai T, Fan L, Lou K, Hua X, Huang Z, et al. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020.
685. **Evaluation of the emergency response strategies and measures on the epidemic of COVID-19 in Shenzhen, China.** Zou X, Wu YS, Liu XJ, Huang SL, He JF, Zhao J, et al. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2020;41:E056.
686. **Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China.** Zou Y, Guo H, Zhang Y, Zhang Z, Liu Y, Wang J, et al. Bioscience trends. 2020.
687. **Neutrophil extracellular traps in COVID-19.** Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. JCI insight. 2020.

Update tot 07-05-2020

1. **Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York.** Journal of the American Society of Nephrology : JASN. 2020.
2. **Managing COVID-19 symptoms (including at the end of life) in the community: Summary of NICE guidelines.** The BMJ. 2020;369.
3. **Moroccan Medicinal plants as inhibitors of COVID-19: Computational investigations.** Aanouz I, Belhassan A, El Khatabi K, Lakhlifi T, El Idrissi M, Bouachrine M. Journal of biomolecular structure & dynamics. 2020:1-12.
4. **Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.** Abbott TR, Dhamdhare G, Liu Y, Lin X, Goudy L, Zeng L, et al. Cell. 2020.
5. **Knowledge, Perceptions, and Attitude of Egyptians Towards the Novel Coronavirus Disease (COVID-19).** Abdelhafiz AS, Mohammed Z, Ibrahim ME, Ziady HH, Alorabi M, Ayyad M, et al. Journal of community health. 2020.
6. **In silico study the inhibition of Angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from western Algeria.** Abdelli I, Hassani F, Bekkel Brikci S, Ghalem S. Journal of Biomolecular Structure and Dynamics. 2020:1-17.
7. **Epidemiology, genome, and clinical features of the pandemic SARS-CoV-2: a recent view.** Abduljalil JM, Abduljalil BM. New Microbes and New Infections. 2020;35.
8. **Is Low Alveolar Type II Cell SOD3 in the Lungs of Elderly Linked to the Observed Severity of COVID-19?** Abouhashem AS, Singh K, Azzazy HM, Sen CK. Antioxidants & redox signaling. 2020.
9. **Amantadine as a drug to mitigate the effects of COVID-19.** Abreu GEA, Aguilar MEH, Covarrubias DH, Durán FR. Medical Hypotheses. 2020;140.
10. **Massively multiplexed nucleic acid detection using Cas13.** Ackerman CM, Myhrvold C, Thakku SG, Freije CA, Metsky HC, Yang DK, et al. Nature. 2020.
11. **Chest CT findings of early and progressive phase COVID-19 infection from a US patient.** Adair LB, Ledermann EJ. Radiology Case Reports. 2020;15(7):819-24.
12. **May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?** Adamowicz J, Juszcak K, Drewna T. Medical Hypotheses. 2020;140.
13. **Thousands Of Lives Could Be Saved In The US During The COVID-19 Pandemic If States Exchanged Ventilators.** Adelman D. Health affairs (Project Hope). 2020:101377hlthaff202000505. <http://dx.doi.org/10.1377/hlthaff.2020.00505>.
14. **SutteARIMA: Short-term forecasting method, a case: Covid-19 and stock market in Spain.** Ahmar AS, del Val EB. Science of the Total Environment. 2020;729.
15. **Click here for free access to our latest coronavirus/COVID-19 research, commentary, and news.** Airan R. Science Translational Medicine. 2020;12(540).
16. **Narrative review of Middle East respiratory syndrome coronavirus (MERS-CoV) infection: updates and implications for practice.** Al Mutair A, Ambani Z. Journal of International Medical Research. 2019;48(1).

17. **Multiple Myeloma in the Time of COVID-19.** Al Saleh AS, Sher T, Gertz MA. *Acta Haematologica*. 2020.
18. **Repurposing didanosine as a potential treatment for covid-19 using single-cell RNA sequencing data.** Alakwaa FM. *mSystems*. 2020;5(2).
19. **New insights into the seriousness of acute myocardial injury during COVID-19.** Alderighi C, Rasoini R, Ambrosio G, Valente S, Gensini GF. *Giornale italiano di cardiologia* (2006). 2020;21(5):328-31.
20. **On the Pharmacy Radar: COVID-19 and Older People.** Alderman C. *The Senior Care Pharmacist*. 2020;35(5):190-4.
21. **Suggestions for thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19.** Alessandro C, Lorenzo A, Anne AS, Pierre F, Bernhard G, Lukas G, et al. *Swiss Medical Weekly*. 2020;150(15).
22. **COVID-19: Disease, management, treatment, and social impact.** Ali I, Alharbi OML. *The Science of the total environment*. 2020;728:138861. <http://dx.doi.org/10.1016/j.scitotenv.2020.138861>.
23. **Off-Label Therapies for COVID-19—Are We All In This Together?** Alpern JD, Gertner E. *Clinical Pharmacology and Therapeutics*. 2020.
24. **The Impact of the COVID-19 Pandemic on Cancer Patients.** Al-Quteimat OM, Amer AM. *American journal of clinical oncology*. 2020.
25. **Severe COVID-19 during Pregnancy and Possible Vertical Transmission.** Alzamora MC, Paredes T, Caceres D, Webb CM, Valdez LM, La Rosa M. *American journal of perinatology*. 2020.
26. **Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19.** Alzoughool F, Alanagreh L. *The International journal of risk & safety in medicine*. 2020.
27. **COVID-19 and psoriasis : should we fear for patients treated with biologics?** Amerio P, Prignano F, Giuliani F, Gualdi G. *Dermatologic therapy*. 2020.
28. **The proximal origin of SARS-CoV-2.** Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. *Nature Medicine*. 2020;26(4):450-2.
29. **In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.** Andreani J, Le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, et al. *Microbial pathogenesis*. 2020:104228. <http://dx.doi.org/10.1016/j.micpath.2020.104228>.
30. **Can cell therapies halt cytokine storm in severe COVID-19 patients?** Ankrum J. *Science Translational Medicine*. 2020;12(540).
31. **Favipiravir for treating novel coronavirus (COVID-19) patients: protocol for a systematic review and meta-analysis of controlled trials.** Arab-Zozani M, Hassanipour S, Ghoddoosi-Nejad D. *medRxiv*. 2020:2020.04.27.20081471.
32. **Does the pathogenesis of SARS-CoV-2 virus decrease at high-altitude?** Arias-Reyes C, Zubieta-DeUrioste N, Poma-Machicao L, Aliaga-Raduan F, Carvajal-Rodriguez F, Dutschmann M, et al. *Respiratory Physiology and Neurobiology*. 2020;277.
33. **A simple model for COVID-19.** Arino J, Portet S. *Infect Dis Model*. 2020. <http://dx.doi.org/10.1016/j.idm.2020.04.002>.

34. **A new era for the therapeutic management of the ongoing COVID-19 pandemic.** Arsene AL, Dumitrescu IB, Drăgoi CM, Udeanu DI, Lupuliasa D, Jinga V, et al. *Farmacia*. 2020;68(2):185-96.
35. **Potential of Heparin and Nafamostat Combination Therapy for COVID-19.** Asakura H, Ogawa H. *Journal of thrombosis and haemostasis : JTH*. 2020.
36. **Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response.** Astuti I, Ysrafil. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2020;14(4):407-12.
37. **Anticoagulation in COVID-19.** Atallah B, Mallah SI, AlMahmeed W. *European Heart Journal-Cardiovascular Pharmacotherapy*. 2020.
38. **Remdesivir for patients with severe COVID-19.** Augustin M, Hallek M, Nitschmann S. *Internist*. 2020.
39. **Correspondence: Angiotensin-converting enzyme 2 coated nanoparticles containing respiratory masks, chewing gums and nasal filters may be used for protection against COVID-19 infection.** Aydemir D, Ulusu NN. *Travel Medicine and Infectious Disease*. 2020.
40. **Do Not Forget Afghanistan in Times of COVID-19: Telemedicine and the Internet of Things to Strengthen Planetary Health Systems.** Azizy A, Fayaz M, Agirbasli M. *Omics : a journal of integrative biology*. 2020.
41. **Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2.** Baek YH, Um J, Antigua KJC, Park JH, Kim Y, Oh S, et al. *Emerging microbes & infections*. 2020:1-31.
42. **Purposing Saikosaponins for the treatment of COVID-19.** Bahbah EI, Negida A, Nabet MS. *Medical Hypotheses*. 2020;140.
43. **Presumed Asymptomatic Carrier Transmission of COVID-19.** Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. *JAMA - Journal of the American Medical Association*. 2020;323(14):1406-7.
44. **Follow-up studies in COVID-19 recovered patients - is it mandatory?** Balachandar V, Mahalaxmi I, Subramaniam M, Kaavya J, Senthil Kumar N, Laldinmawii G, et al. *Science of the Total Environment*. 2020;729.
45. **The other side of COVID-19: Impact on obsessive compulsive disorder (OCD) and hoarding.** Banerjee DD. *Psychiatry Research*. 2020;288.
46. **How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere.** Banna G, Curioni-Fontecedro A, Friedlaender A, Addeo A. *ESMO Open*. 2020;5(2).
47. **COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications.** Barchetta I, Cavallo MG, Baroni MG. *Diabetes Research and Clinical Practice*. 2020;163.
48. **A meta-analysis of multiple whole blood gene expression data unveils a diagnostic host-response transcript signature for respiratory syncytial virus.** Barral-Arca R, Gómez-Carballea A, Cebey-López M, Bello X, Martínón-Torres F, Salas A. *International Journal of Molecular Sciences*. 2020;21(5).
49. **ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment.** Barrett CD, Moore HB, Yaffe MB, Moore EE. *Journal of thrombosis and haemostasis : JTH*. 2020.
50. **Viruses to fight other viruses: the influenza vaccine case.** Bengoechea JA. *EMBO Molecular Medicine*. 2020.
51. **Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19)**

Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit. Bessiere F, Rocchia H, Deliniere A, Charriere R, Chevalier P, Argaud L, et al. *JAMA cardiology*. 2020. <http://dx.doi.org/10.1001/jamacardio.2020.1787>.

52. **Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2.** Beun R, Kusadasi N, Sikma M, Westerink J, Huisman A. *International journal of laboratory hematology*. 2020.

53. **Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study.** Bezzio C, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, et al. *Gut*. 2020. <http://dx.doi.org/10.1136/gutjnl-2020-321411>.

54. **Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach.** Bhattacharya M, Sharma AR, Patra P, Ghosh P, Sharma G, Patra BC, et al. *Journal of Medical Virology*. 2020;92(6):618-31.

55. **COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up.** Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. *Journal of the American College of Cardiology*. 2020.

56. **Adjunct immunotherapies for the management of severely ill COVID-19 patients.** Bonam SR, Kaveri S, Sakuntabhai A, Gilardin L, Bayry J. *Cell Reports Medicine*. 2020:Epub-ahead.

57. **Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment.** Boopathi S, Poma AB, Kolandaivel P. *Journal of biomolecular structure & dynamics*. 2020:1-14.

58. **Covid-19, TMPRSS2, and whether android regulation affects pandemic virus gender incidence and age distribution of disease.** Brenner SR. *Medical Hypotheses*. 2020;140.

59. **Clinical Implications of SARS-Cov2 Interaction with Renin Angiotensin System.** Brojakowska A, Narula J, Shimony R, Bander J. *Journal of the American College of Cardiology*. 2020.

60. **Managing childhood allergies and immunodeficiencies during respiratory virus epidemics - the 2020 COVID-19 pandemic.** Brough HA, Kalayci O, Sediva A, Untersmayr E, Munblit D, Rodriguez Del Rio P, et al. *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology*. 2020.

61. **Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department.** Brown C, Noble J, Coralic Z. *The western journal of emergency medicine*. 2020.

62. **Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic.** Brufsky A. *Journal of Medical Virology*. 2020.

63. **A Remotely Conducted Pediatric Boot Camp for 4th Year Medical Students.** Burns R, Wenger J. *Medical education*. 2020.

64. **Optimal nutritional status for a well-functioning immune system is an important factor to protect against viral infections.** Calder PC, Carr AC, Gombart AF, Eggersdorfer M. *Nutrients*. 2020;12(4).

65. **Antirheumatic agents in covid-19: Is IL-6 the right target?** Capecchi PL, Lazzerini PE, Volterrani L, Mazzei MA, Rossetti B, Zanelli G, et al. *Annals of the Rheumatic Diseases*. 2020.

66. **NSAIDs in patients with viral infections, including Covid-19: victims or perpetrators?** Capuano A, Scavone C, Racagni G, Scaglione F. *Pharmacological Research*. 2020:104849.

67. **Early Self-Proneing in Awake, Non-intubated Patients in the Emergency Department: A Single ED's Experience during the COVID-19 Pandemic.** Caputo ND, Strayer RJ, Levitan R. *Academic emergency medicine* :

official journal of the Society for Academic Emergency Medicine. 2020.

68. **Optimizing Medication Management In COVID-19 Pandemic.** Carroll M. 2020.
69. **May hydrogen peroxide reduce the hospitalization rate and complications of SARS-CoV-2 infection?** Caruso AA, Del Prete A, Lazzarino AI, Capaldi R, Grumetto L. *Infection Control and Hospital Epidemiology*. 2020.
70. **Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?: This paper is dedicated to Sofia Maione born during COVID-19 outbreak.** Casillo GM, Mansour AA, Raucci F, Saviano A, Mascolo N, Jilani Iqbal A, et al. *Pharmacological research*. 2020;104791.
71. **Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?** Caso F, Costa L, Ruscitti P, Navarini L, Del Puente A, Giacomelli R, et al. *Autoimmunity Reviews*. 2020;19(5).
72. **Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review.** Castagnoli R, Votto M, Licari A, Brambilla I, Bruno R, Perlini S, et al. *JAMA Pediatrics*. 2020.
73. **Statin therapy in COVID-19 infection.** Castiglione V, Chiriaco M, Emdin M, Taddei S, Vergaro G. *European Heart Journal-Cardiovascular Pharmacotherapy*. 2020.
74. **COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil.** Castro R, Luz PM, Wakimoto MD, Veloso VG, Grinsztejn B, Perazzo H. *Brazilian Journal of Infectious Diseases*. 2020.
75. **Investigating hypothiocyanite against SARS-CoV-2.** Cegolon L. *International journal of hygiene and environmental health*. 2020;227:113520.
76. **SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options.** Chakraborty C, Sharma AR, Sharma G, Bhattacharya M, Lee SS. *European review for medical and pharmacological sciences*. 2020;24(7):4016-26. http://dx.doi.org/10.26355/eurrev_202004_20871.
77. **Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/HeI Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens.** Chan JF, Yip CC, To KK, Tang TH, Wong SC, Leung KH, et al. *J Clin Microbiol*. 2020;58(5). <http://dx.doi.org/10.1128/JCM.00310-20>. Print 2020 Apr 23.
78. **Genomic Analysis and Comparative Multiple Sequence of SARS-CoV2.** Chang TJ, Yang DM, Wang ML, Liang KH, Tsai PH, Chiou SH, et al. *Journal of the Chinese Medical Association : JCMA*. 2020. <http://dx.doi.org/10.1097/JCMA.0000000000000335>.
79. **Potential of live pathogen vaccines for defeating the COVID-19 pandemic: history and mechanism.** Chen JW, Chen JM. *Journal of medical virology*. 2020.
80. **Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China.** Chen Q, Zheng Z, Zhang C, Zhang X, Wu H, Wang J, et al. *Infection*. 2020.
81. **Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China.** Chen R, Liang W, Jiang M, Guan W, Zhan C, Wang T, et al. *Chest*. 2020.
82. **COVID-19 with acute cerebral infarction: one case report.** Chen S, Hu B, Li H, Xia Y, Zhang Y, Mao L, et al. *Chinese Journal of Neurology*. 2020;53(4):309-11.

83. **The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients.** Chen Y, Chen L, Deng Q, Zhang G, Wu K, Ni L, et al. *Journal of Medical Virology*. 2020.
84. **Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic.** Cheng MP, Lee TC, Tan DHS, Murthy S. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. 2020;192(15):E405-E7.
85. **Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2.** Chiotos K, Hayes M, Kimberlin DW, Jones SB, James SH, Pinninti SG, et al. *Journal of the Pediatric Infectious Diseases Society*. 2020.
86. **Epidemiology and clinical features of coronavirus disease 2019 in children.** Choi SH, Kim HW, Kang JM, Kim DH, Cho EY. *Korean Journal of Pediatrics*. 2020;63(4):125-32.
87. **Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis.** Choudhury R, Barrett CD, Moore HB, Moore EE, McIntyre RC, Moore PK, et al. *World journal of emergency surgery : WJES*. 2020;15(1):29.
88. **Suggesting Ritonavir against COVID-19/SARS-CoV-2.** Choudhury S, Mazumder MK. *Medical Hypotheses*. 2020;140.
89. **A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19.** Chowdhury MS, Rathod J, Gernsheimer J. *Academic emergency medicine : official journal of the Society for Academic Emergency Medicine*. 2020. <http://dx.doi.org/10.1111/acem.14005>.
90. **Translating IL-6 biology into effective treatments.** Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. *Nature Reviews Rheumatology*. 2020.
91. **Where do we stand with antithrombotic prophylaxis in patients with COVID-19?** Ciavarella A, Peyvandi F, Martinelli I. *Thrombosis Research*. 2020;191:29.
92. **Switching to another antihypertensive effective drug when using ACEIs/ARBs to treat arterial hypertension during COVID-19.** Ciulla MM. *European heart journal*. 2020.
93. **COVID-19 myopericarditis: It should be kept in mind in today's conditions.** Cizgici AY, Zencirkiran Agus H, Yildiz M. *American Journal of Emergency Medicine*. 2020.
94. **Psoriasis and Psoriatic Arthritis: how to manage Immunosuppressants in COVID-19 days.** Coletto LA, Favalli EG, Caporali R. *Dermatologic Therapy*. 2020.
95. **A Feasibility Study of Urgent Implementation of Cystic Fibrosis Multidisciplinary Telemedicine Clinic in the Face of COVID-19 Pandemic: Single-Center Experience.** Compton M, Soper M, Reilly B, Gettle L, List R, Bailey M, et al. *Telemedicine journal and e-health : the official journal of the American Telemedicine Association*. 2020. <http://dx.doi.org/10.1089/tmj.2020.0091>.
96. **Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019.** Confalonieri M. 2020.
97. **Doxycycline, a widely used antibiotic in dermatology with a possible anti-inflammatory action against IL-6 in COVID-19 outbreak.** Conforti C, Giuffrida R, Zalaudek I, Di Meo N. *Dermatologic therapy*. 2020:e13437.
98. **Thromboinflammation and the hypercoagulability of COVID-19.** Connors JM, Levy JH. *Journal of thrombosis and haemostasis : JTH*. 2020.

99. **Phytotherapeutics and SARS-CoV-2 infection: Potential role of bioflavonoids.** Coppola M, Mondola R. *Medical Hypotheses*. 2020;140.
100. **Airborne route and bad use of ventilation systems as non-negligible factors in SARS-CoV-2 transmission.** Correia G, Rodrigues L, Gameiro da Silva M, Gonçalves T. *Medical Hypotheses*. 2020;141.
101. **Comment on "Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade".** Cure E, Cumhur Cure M. *Nephron*. 2020:1-2.
102. **CT Imaging and Differential Diagnosis of COVID-19.** Dai WC, Zhang HW, Yu J, Xu HJ, Chen H, Luo SP, et al. *Canadian Association of Radiologists Journal*. 2020;71(2):195-200.
103. **Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during RED-ZONE declaration.** Damiani G, Pacifico A, Bragazzi NL, Malagoli P. *Dermatologic Therapy*. e13475.
104. **The impact of COVID-19 partial lockdown on the air quality of the city of Rio de Janeiro, Brazil.** Dantas G, Siciliano B, França BB, da Silva CM, Arbilla G. *Science of the Total Environment*. 2020;729.
105. **ACE inhibitors, AT1 receptor blockers and COVID-19: clinical epidemiology evidences for a continuation of treatments. The ACER-COVID study.** Dauchet L, Lambert M, Gauthier V, Poissy J, Faure K, Facon A, et al. *medRxiv*. 2020:2020.04.28.20078071.
106. **Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?** Deftereos S, Giannopoulos G, Vrachatis DA, Siasos G, Giotaki SG, Cleman M, et al. *European Heart Journal-Cardiovascular Pharmacotherapy*. 2020.
107. **The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19—First, Do No Harm.** DeJong C, Wachter RM. *JAMA Internal Medicine*.
108. **COVID-19 - New Insights on a Rapidly Changing Epidemic.** Del Rio C, Malani PN. *JAMA - Journal of the American Medical Association*. 2020;323(14):1339-40.
109. **Serological survey of SARS-CoV-2 for experimental, domestic, companion and wild animals excludes intermediate hosts of 35 different species of animals.** Deng J, Jin Y, Liu Y, Sun J, Hao L, Bai J, et al. *Transboundary and emerging diseases*. 2020.
110. **COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know.** Dhawan R, Gundry RL, Brett-Major DM, Mahr C, Thiele GM, Lindsey ML, et al. *Journal of Molecular and Cellular Cardiology*. 2020;144:12-4.
111. **Re: Silke Gillessen Sommer, Thomas Powles. Advice for Medical Oncology Care of Urological Cancer Patients During the COVID-19 Pandemic. Eur Urol. In press: Is It Always Correct to Continue Androgen Receptor Signaling Inhibitors in the COVID-19 Era?** Di Lorenzo G. *European Urology*. 2020.
112. **Can Nebulised Heparin Reduce Time to Extubation in SARS CoV 2 The CHARTER Study Protocol.** Dixon B, Smith R, Artigas A, Laffey J, McNicholas B, Schmidt E, et al. *medRxiv*. 2020:2020.04.28.20082552.
113. **Considerations for Obstetric Care during the COVID-19 Pandemic.** Dotters-Katz SK, Hughes BL. *American journal of perinatology*. 2020.
114. **Serial CT features in discharged COVID-19 patients with positive RT-PCR re-test.** Dou P, Zhang S, Wang C, Cai L, Liu Z, Xu Q, et al. *European Journal of Radiology*. 2020;127.

115. **Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic.** Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. *Journal of the American College of Cardiology*. 2020;75(18):2352-71.
116. **Response to "Dose rationale for favipiravir use in patients infected with SARS-CoV-2".** Du YX, Chen XP. *Clin Pharmacol Ther*. 2020. <http://dx.doi.org/10.1002/cpt.1878>.
117. **Effectiveness of convalescent plasma therapy in severe COVID-19 patients.** Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. *Proc Natl Acad Sci U S A*. 2020;117(17):9490-6. <http://dx.doi.org/10.1073/pnas.2004168117>. Epub 2020 Apr 6.
118. **COVID-19 Convalescent Plasma: Now Is the Time for Better Science.** Dzik S. *Transfusion Medicine Reviews*. 2020.
119. **Faecal calprotectin indicates intestinal inflammation in COVID-19.** Effenberger M, Grabherr F, Mayr L, Schwaerzler J, Nairz M, Seifert M, et al. *Gut*. 2020.
120. **Inactivation of three emerging viruses – severe acute respiratory syndrome coronavirus, Crimean–Congo haemorrhagic fever virus and Nipah virus – in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light.** Eickmann M, Gravemann U, Handke W, Tolksdorf F, Reichenberg S, Müller TH, et al. *Vox Sanguinis*. 2020;115(3):146-51.
121. **Déjà vu: Stimulating open drug discovery for SARS-CoV-2.** Ekins S, Mottin M, Ramos PRPS, Sousa BKP, Neves BJ, Foil DH, et al. *Drug Discovery Today*. 2020.
122. **Let food be the medicine but not for coronavirus: nutrition and food science telling myths from facts.** El Ghoch M, Valerio A. *Journal of Population Therapeutics and Clinical Pharmacology*. 2020;27(2):e1-e4.
123. **Novel Guanosine Derivatives against MERS CoV polymerase: An in silico perspective.** Elfiky AA, Azzam EB. *Journal of biomolecular structure & dynamics*. 2020:1-12.
124. **Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes.** Elmezayen AD, Al-Obaidi A, Şahin AT, Yelekçi K. *Journal of biomolecular structure & dynamics*. 2020:1-12.
125. **Dose rationale for favipiravir use in patients infected with SARS-CoV-2.** Eloy P, Solas C, Touret F, Mentre F, Malvy D, de Lamballerie X, et al. *Clin Pharmacol Ther*. 2020. <http://dx.doi.org/10.1002/cpt.1877>.
126. **Coronavirus Disease 2019 (COVID-19) and dermatologists: Potential biological hazards of laser surgery in epidemic area.** Emadi SN, Abtahi-Naeini B. *Ecotoxicology and Environmental Safety*. 2020;198.
127. **Combination of biodata mining and computational modelling in identification and characterization of ORF1ab polyprotein of SARS-CoV-2 isolated from oronasopharynx of an Iranian patient.** Emameh RZ, Nosrati H, Taheri RA. *Biological Procedures Online*. 2020;22(1).
128. **Is GSK3β a molecular target of chloroquine treatment against COVID-19?** Embi MN, Ganesan N, Sidek HM. *Drug discoveries & therapeutics*. 2020.
129. **Update on treatment of COVID-19: ongoing studies between promising and disappointing results.** Esposito S, Noviello S, Pagliano P. *Le infezioni in medicina*. 2020;28(2):198-211.
130. **Covid-19: A brief overview of the discovery clinical trial.** Eynde JJV. *Pharmaceuticals*. 2020;13(4).
131. **Being a front-line dentist during the Covid-19 pandemic: a literature review.** Fallahi HR, Keyhan SO,

- Zandian D, Kim SG, Cheshmi B. Maxillofacial and Plastic Reconstructive Surgery. 2020;42(1).
132. **Imaging characteristics of initial chest computed tomography and clinical manifestations of patients with COVID-19 pneumonia.** Fan N, Fan W, Li Z, Shi M, Liang Y. Japanese journal of radiology. 2020.
133. **Acute kidney injury in SARS-CoV-2 infected patients.** Fanelli V, Fiorentino M, Cantaluppi V, Gesualdo L, Stallone G, Ronco C, et al. Critical Care. 2020;24(1).
134. **What is the true incidence of COVID-19 in patients with rheumatic diseases?** Favalli EG, Ingegnoli F, Cimaz R, Caporali R. Annals of the Rheumatic Diseases. 2020.
135. **COVID-19: Immunology and treatment options.** Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. Clinical Immunology. 2020;215.
136. **CT findings in lung parenchyma in COVID-19 - pictorial review.** Ferda J, Mírka H, Baxa J, Rajchman P, Vondráková A, Váchalová J, et al. Ceska Radiologie. 2020;74(1):11-8.
137. **Protect Indigenous peoples from COVID-19.** Ferrante L, Fearnside PM. Science. 2020;368(6488):251.
138. **Critically ill SARS-CoV-2-infected patients are not stratified as sepsis by the qSOFA.** Ferreira M, Blin T, Collercandy N, Szychowiak P, Dequin PF, Jouan Y, et al. Annals of Intensive Care. 2020;10(1).
139. **Causes of hypogeusia/hyposmia in SARS-CoV2 infected patients.** Finsterer J, Stollberger C. Journal of medical virology. 2020.
140. **Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement.** Fleming AB, Raabe V. Journal of Clinical Virology. 2020;127.
141. **Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.** Folegatti PM, Bittaye M, Flaxman A, Lopez FR, Bellamy D, Kupke A, et al. The Lancet Infectious diseases. 2020.
142. **COVID-19 and the clinical hematology laboratory.** Frater JL, Zini G, d'Onofrio G, Rogers HJ. International journal of laboratory hematology. 2020.
143. **Developing guidelines for COVID-19 management: A moving target. An invited commentary on "Evidence based management guideline for the COVID-19 pandemic - Review article".** Gallaher J, Charles A. International Journal of Surgery. 2020;78:42.
144. **The unsynchronized changes of CT image and nucleic acid detection in COVID-19: reports the two cases from Gansu, China.** Gao J, Liu JQ, Wen HJ, Liu H, Hu WD, Han X, et al. Respiratory research. 2020;21(1):96.
145. **Can glycopyrrolate come to the airway rescue in Covid-19 patients?** Garg H. Journal of Clinical Anesthesia. 2020;64.
146. **Managing New-Onset Type 1 Diabetes During the COVID-19 Pandemic: Challenges and Opportunities.** Garg SK, Rodbard D, Hirsch IB, Forlenza GP. Diabetes technology & therapeutics. 2020.
147. **COVID-19 pneumonia: ARDS or not?** Gattinoni L, Chiumello D, Rossi S. Critical Care. 2020;24(1).
148. **Respiratory conditions in coronavirus disease 2019 (COVID-19): Important considerations regarding novel treatment strategies to reduce mortality.** Geier MR, Geier DA. Medical Hypotheses. 2020;140.
149. **Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual**

Screening and Molecular Modeling Study. Gentile D, Patamia V, Scala A, Sciortino MT, Piperno A, Rescifina A. *Marine drugs*. 2020;18(4). <http://dx.doi.org/10.3390/md18040225>.

150. **A Patient with COVID-19 Disease in a Referral Hospital in Iran: A Typical Case.** Ghiasvand F, Miandoab SZ, Harandi H, Golestan FS, Alinaghi SAS. *Infectious disorders drug targets*. 2020. <http://dx.doi.org/10.2174/1871526520666200429115535>.

151. **Reply to letter to the editor regarding article: Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis (Ghosal et al.).** Ghosal S. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2020;14(4):449.

152. **The effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on death and severity of disease in patients with coronavirus disease 2019 (COVID-19): A meta-analysis.** Ghosal S, Mukherjee JJ, Sinha B, Gangopadhyay KK. *medRxiv*. 2020:2020.04.23.20076661.

153. **Drug Development and Medicinal Chemistry Efforts Toward SARS-Coronavirus and Covid-19 Therapeutics.** Ghosh AK, Brindisi M, Shahabi D, Chapman ME, Mesecar AD. *ChemMedChem*. 2020.

154. **Sirna could be a potential therapy for covid-19.** Ghosh S, Firdous SM, Nath A. *EXCLI Journal*. 2020;19:528-31.

155. **Exuberant Plasmocytosis in Bronchoalveolar Lavage Specimen of the First Patient Requiring Extracorporeal Membrane Oxygenation for SARS-CoV-2 in Europe.** Giani M, Seminati D, Lucchini A, Foti G, Pagni F. *Journal of Thoracic Oncology*. 2020;15(5):e65-e6.

156. **Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID).** Giollo A, Adami G, Gatti D, Idolazzi L, Rossini M. *Annals of the Rheumatic Diseases*. 2020.

157. **The COVID-19 pandemic and the use of MS disease-modifying therapies.** Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Waubant E, Gold J. *Multiple Sclerosis and Related Disorders*. 2020;39.

158. **Osteoporosis in the age of COVID-19.** Girgis CM, Clifton-Bligh RJ. *Osteoporosis International*. 2020.

159. **A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain – A potential clue to the role of androgens in COVID-19 severity.** Goren A, Vaño-Galván S, Wambier CG, McCoy J, Gomez-Zubiaur A, Moreno-Arrones OM, et al. *Journal of Cosmetic Dermatology*. 2020.

160. **SLE patients are not immune to covid-19: Importance of sending the right message across.** Goyal M. *Annals of the Rheumatic Diseases*. 2020.

161. **Opioid use disorder and the COVID 19 pandemic: A call to sustain regulatory easements and further expand access to treatment.** Green TC, Bratberg J, Finnell DS. *Substance abuse*. 2020;41(2):147-9.

162. **Inaccurate conclusions by Tang and colleagues.** Greenstein YY. *Journal of thrombosis and haemostasis : JTH*. 2020.

163. **Impaired interferon signature in severe COVID-19.** Gruber C. *Nature Reviews Immunology*. 2020.

164. **COVID-19: Gastrointestinal Manifestations and Potential Fecal–Oral Transmission.** Gu J, Han B, Wang J. *Gastroenterology*. 2020;158(6):1518-9.

165. **CT findings of coronavirus disease (CoVid-19) severe pneumonia.** Guan W, Liu J, Yu C. *American Journal of Roentgenology*. 2020;214(5):W85-W6.

166. **Does the coronavirus a global threat?** Güdücüoğlu H, Korkmaz D. Eastern Journal of Medicine. 2020;25(2):327-9.
167. **Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: Lessons from a case with severe pneumonia.** Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, Maria ATJ, et al. Annals of the Rheumatic Diseases. 2020.
168. **Covid-19: Prevention and control measures in community.** Güner R, Hasanoğlu İ, Aktaş F. Turkish Journal of Medical Sciences. 2020;50:571-7.
169. **An effective screening and management process in the outpatient clinic for patients requiring hospitalization during the COVID-19 pandemic.** Guo F, Du Z, Wang T. Journal of medical virology. 2020.
170. **Management of rheumatic diseases in the time of covid-19 pandemic: Perspectives of rheumatology practitioners from India.** Gupta L, Misra DP, Agarwal V, Balan S, Agarwal V. Annals of the Rheumatic Diseases. 2020.
171. **Letter to the editor in response to article: "Clinical considerations for patients with diabetes in times of COVID-19 epidemic (Gupta et al.).** Gupta R. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020;14(4):365.
172. **COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.** Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. Cardiovascular research. 2020. <http://dx.doi.org/10.1093/cvr/cvaa106>.
173. **COVID-19 update.** Haberal M. Experimental and Clinical Transplantation. 2020;18(2):139.
174. **Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective.** Halpin DMG, Singh D, Hadfield RM. Journal. 2020(Issue).
175. **Prevention of exposure and dispersion of COVID-19 using air purifiers: challenges and concerns.** Ham S. Epidemiology and health. 2020:e2020027.
176. **Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic.** Hanna TP, Evans GA, Booth CM. Nature Reviews Clinical Oncology. 2020;17(5):268-70.
177. **Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry.** Hao F, Tan W, Jiang L, Zhang L, Zhao X, Zou Y, et al. Brain, behavior, and immunity. 2020.
178. **Vaccine confidence in the time of COVID-19.** Harrison EA, Wu JW. European journal of epidemiology. 2020.
179. **COVID-19 Respiratory Failure: Targeting Inflammation on VV-ECMO Support.** Hartman ME, Hernandez RA, Patel K, Wagner TE, Trinh T, Lipke AB, et al. ASAIO journal (American Society for Artificial Internal Organs : 1992). 2020.
180. **Lupus anticoagulant is frequent in patients with Covid-19.** Harzallah I, Debliquis A, Drénou B. Journal of thrombosis and haemostasis : JTH. 2020.
181. **Coronaviruses and sars-cov-2.** Hasöksüz M, Kiliç S, Saraç F. Turkish Journal of Medical Sciences. 2020;50:549-56.
182. **Shedding Light on the Effect of Natural Anti-Herpesvirus Alkaloids on SARS-CoV-2: A Treatment**

Option for COVID-19. Hassan STS. *Viruses*. 2020;12(4). <http://dx.doi.org/10.3390/v12040476>.

183. **The relative transmissibility of asymptomatic COVID-19 infections among close contacts.** He D, Zhao S, Lin Q, Zhuang Z, Cao P, Wang MH, et al. *International Journal of Infectious Diseases*. 2020;94:145-7.

184. **Etiology and genetic evolution of canine coronavirus circulating in five provinces of China, during 2018–2019.** He HJ, Zhang W, Liang J, Lu M, Wang R, Li G, et al. *Microbial Pathogenesis*. 2020;145.

185. **Anosmia as a prominent symptom of COVID-19 infection.** Heidari F, Karimi E, Firouzifar M, Khamushian P, Ansari R, Mohammadi Ardehali M. *Rhinology*. 2020.

186. **The Impact of the COVID-19 Pandemic on Parkinson's Disease: Hidden Sorrows and Emerging Opportunities.** Helmich RC, Bloem BR. *Journal of Parkinson's Disease*. 2020;10(2):351-4.

187. **The COVID-19 pandemic: A comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control.** Helmy YA, Fawzy M, Elasad A, Sobieh A, Kenney SP, Shehata AA. *Journal of Clinical Medicine*. 2020;9(4).

188. **Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis.** Henry BM, Vikse J, Benoit S, Favaloro EJ, Lippi G. *Clinica Chimica Acta*. 2020;507:167-73.

189. **Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19.** Hernández A, Papadakos PJ, Torres A, González DA, Vives M, Ferrando C, et al. *Revista española de anestesiología y reanimación*. 2020.

190. **Health Insurance Status and Risk Factors for Poor Outcomes With COVID-19 Among U.S. Health Care Workers: A Cross-sectional Study.** Himmelstein DU, Woolhandler S. *Annals of internal medicine*. 2020. <http://dx.doi.org/10.7326/M20-1874>.

191. **Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2.** Hoffman T, Nissen K, Krambrich J, Rönnberg B, Akaberi D, Esmaeilzadeh M, et al. *Infection Ecology and Epidemiology*. 2020;10(1).

192. **A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells.** Hoffmann M, Kleine-Weber H, Pöhlmann S. *Molecular Cell*. 2020.

193. **Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19.** Hoffmann M, Schroeder S, Kleine-Weber H, Müller MA, Drosten C, Pöhlmann S. *Antimicrobial agents and chemotherapy*. 2020.

194. **Biological plausibility for interactions between dietary fat, resveratrol, ACE2 and SARS-CoV illness severity.** Horne JR, Vohl MC. *American journal of physiology Endocrinology and metabolism*. 2020.

195. **Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases.** Horowitz RI, Freeman PR, Bruzzese J. *Respiratory Medicine Case Reports*. 2020;30.

196. **The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement.** Hotez PJ, Bottazzi ME, Corry DB. *Microbes and Infection*. 2020.

197. **COVID-19 vaccine design: the Janus face of immune enhancement.** Hotez PJ, Corry DB, Bottazzi ME. *Nature Reviews Immunology*. 2020.

198. **Detection of bovine viral diarrhoea virus genotype 1 in aerosol by a real time RT-PCR assay.** Hou P, Xu

Y, Wang H, He H. BMC Veterinary Research. 2020;16(1).

199. **Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment.** Hrusak O, Kalina T, Wolf J, Balduzzi A, Provenzi M, Rizzari C, et al. European Journal of Cancer. 2020;132:11-6.

200. **MiR-10a-5p-Mediated Syndecan 1 Suppression Restricts Porcine Hemagglutinating Encephalomyelitis Virus Replication.** Hu S, Li Z, Lan Y, Guan J, Zhao K, Chu D, et al. Frontiers in Microbiology. 2020;11.

201. **Analysis of Characteristics in Death Patients with COVID-19 Pneumonia without Underlying Diseases.** Hu Y, Deng H, Huang L, Xia L, Zhou X. Academic Radiology. 2020;27(5):752.

202. **A report of three COVID-19 cases with prolonged viral RNA detection in anal swabs.** Hu Y, Shen L, Yao Y, Xu Z, Zhou J, Zhou H. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2020.

203. **COVID19-nuclear medicine departments, be prepared!** Huang HL, Allie R, Gnanasegaran G, Bomanji J. Nuclear Medicine Communications. 2020;41(4):297-9.

204. **How to perform tracheal intubation for COVID-19 patients safely and effectively: Experience AND tips from Sichuan, China.** Huang J, Zeng J, Xie M, Huang X, Wei X, Pan L. Journal of Clinical Anesthesia. 2020;64.

205. **Initial CT imaging characters of an imported family cluster of COVID-19.** Huang L, Jiang J, Li X, Zhou Y, Xu M, Zhou J. Clinical Imaging. 2020;65:78-81.

206. **Implications of COVID-19 for uveitis patients: perspectives from Hong Kong.** Hung JCH, Li KKW. Eye. 2020:1-2.

207. **Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension.** Iaccarino G, Borghi C, Cicero AFG, Ferri C, Minuz P, Muiesan ML, et al. High Blood Pressure and Cardiovascular Prevention. 2020;27(2):105-8.

208. **Long-acting injectable antipsychotics treatment during COVID-19 pandemic – A new challenge.** Ifteni P, Dima L, Teodorescu A. Schizophrenia Research. 2020.

209. **Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey.** Indini A, Aschele C, Cavanna L, Clerico M, Daniele B, Fiorentini G, et al. European Journal of Cancer. 2020;132:17-23.

210. **Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives.** Infantino M, Damiani A, Gobbi FL, Grossi V, Lari B, Macchia D, et al. The Israel Medical Association journal : IMAJ. 2020;22(4):203-10.

211. **Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2.** Ingraham NE, Boulware D, Sparks MA, Schacker T, Benson B, Sparks JA, et al. Crit Care. 2020;24(1):182.
<http://dx.doi.org/10.1186/s13054-020-02894-7>.

212. **An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19.** Intson K, Kumar S, Botta A, Neckles R, Leung C, Jawaid A. Swiss Medical Weekly. 2020;150(1718).

213. **Coronavirus disease 2019: The harms of exaggerated information and non-evidence-based measures.** Ioannidis JPA. European Journal of Clinical Investigation. 2020;50(4).

214. **Methanol Poisoning Emerging as the Result of COVID-19 Outbreak; Radiologic Perspective.** Iranpour P, Firoozi H, Haseli S. *Academic Radiology*. 2020;27(5):755-6.
215. **COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency.** Isidori AM, Arnaldi G, Boscaro M, Falorni A, Giordano C, Giordano R, et al. *Journal of Endocrinological Investigation*. 2020:1.
216. **Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection.** Isidori AM, Pofi R, Hasenmajer V, Lenzi A, Pivonello R. *The Lancet Diabetes & Endocrinology*. 2020.
217. **COVID-19: an update on diagnostic and therapeutic approaches.** Iyer M, Jayaramayya K, Subramaniam MD, Lee SB, Dayem AA, Cho SG, et al. *BMB reports*. 2020;53(4):191-205.
218. **Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in COVID-19: Experience with 32 patients.** Jacobs JP, Stammers AH, St Louis J, Hayanga JWA, Firstenberg MS, Mongero LB, et al. *ASAIO journal (American Society for Artificial Internal Organs : 1992)*. 2020.
219. **Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop.** Jaimes JA, André NM, Chappie JS, Millet JK, Whittaker GR. *Journal of Molecular Biology*. 2020.
220. **COVID-19 Pandemia and Public and Global Mental Health from the Perspective of Global Health Securit.** Jakovljevic M, Bjedov S, Jaksic N, Jakovljevic I. *Psychiatria Danubina*. 2020;32(1):6-14.
221. **A fourteen-day experience with coronavirus disease 2019 (COVID-19) induced acute respiratory distress syndrome (ARDS): An Iranian treatment protocol.** Jamaati H, Dastan F, Tabarsi P, Marjani M, Saffaei A, Hashemian SM. *Iranian Journal of Pharmaceutical Research*. 2020;19(1):31-6.
222. **COVID-19 and (hydroxy)chloroquine-Azithromycin combination: Should we take the risk for our patients?** Javelot H, El-Hage W, Meyer G, Becker G, Michel B, Hingray C. *British journal of clinical pharmacology*. 2020. <http://dx.doi.org/10.1111/bcp.14335>.
223. **Challenges for psychotropics in the context of the SARS-Cov-2 pandemic.** Javelot H, Llorca PM, Meyer G, Fossati P, Haffen E. *Encephale*. 2020.
224. **Why not consider an endothelin receptor antagonist against SARS-CoV-2?** Javor S, Salsano A. *Medical Hypotheses*. 2020;141.
225. **Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety.** Jeevaratnam K. *European Heart Journal-Cardiovascular Pharmacotherapy*. 2020.
226. **COVID-19 in children: Current status.** Jeng MJ. *Journal of the Chinese Medical Association : JCMSA*. 2020.
227. **COVID-19: an FY1 on the frontline.** Jeyabaladevan P. *Medical education online*. 2020;25(1):1759869. <http://dx.doi.org/10.1080/10872981.2020.1759869>.
228. **Structure of Mpro from COVID-19 virus and discovery of its inhibitors.** Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. *Nature*. 2020.
229. **Pulmonary Pathology of Early Phase 2019 Novel Coronavirus Pneumonia.** Joob B, Wiwanitkit V. *Journal of Thoracic Oncology*. 2020;15(5):e67.
230. **Epitope based vaccine prediction for SARS-COV-2 by deploying immuno-informatics approach.** Joshi A, Joshi BC, Mannan MAU, Kaushik V. *Informatics in Medicine Unlocked*. 2020;19.

231. **The role of Nuclear Medicine for COVID-19 - Time to act now.** Juengling FD, Maldonado A, Wuest F, Schindler TH. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine.* 2020.
232. **COVID-19 pandemic in India: Challenges and silver linings.** Kamath S, Kamath R, Salins P. *Postgraduate Medical Journal.* 2020.
233. **On the molecular determinants of the SARS-CoV-2 attack.** Kanduc D, Shoenfeld Y. *Clinical Immunology.* 2020;215.
234. **Potential effect of natural and anabolizan steroids in elderly patient with COVID-19.** Karaahmet F, Karaahmet OZ. *Medical Hypotheses.* 2020;140.
235. **COVID-19 and viral hepatitis elimination programs: Are we stepping backward?** Karimi-Sari H, Rezaee-Zavareh MS. *Liver international : official journal of the International Association for the Study of the Liver.* 2020.
236. **Loop mediated isothermal amplification (LAMP) assays as a rapid diagnostic for COVID-19.** Kashir J, Yaqinuddin A. *Medical Hypotheses.* 2020;141.
237. **Understanding evolution of SARS-CoV-2: a perspective from analysis of genetic diversity of RdRp gene.** Kasibhatla SM, Kinikar M, Limaye S, Kale MM, Kulkarni-Kale U. *Journal of medical virology.* 2020.
238. **Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment.** Keil SD, Ragan I, Yonemura S, Hartson L, Dart NK, Bowen R. *Vox Sanguinis.* 2020.
239. **If a coronavirus vaccine arrives, can the world make enough?** Khamsi R. *Nature.* 2020;580(7805):578-80. <http://dx.doi.org/10.1038/d41586-020-01063-8>.
240. **Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action.** Khan Z, Karatas Y, Rahman H. *Adv Ther.* 2020. <http://dx.doi.org/10.1007/s12325-020-01351-9>.
241. **ACE inhibitors and COVID-19: We don't know yet.** Khashkhusa TR, Chan JSK, Harky A. *Journal of Cardiac Surgery.* 2020.
242. **Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.** Koch T, Dahlke C, Fathi A, Kupke A, Krähling V, Okba NMA, et al. *The Lancet Infectious diseases.* 2020.
243. **Letter to the editor in response to the article "COVID-19 and diabetes: Can DPP4 inhibition play a role?".** Kokic Males V. *Diabetes Research and Clinical Practice.* 2020;163.
244. **Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action.** Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K. *British Journal of Haematology.* 2020.
245. **Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic.** Korobelnik JF, Loewenstein A, Eldem B, Jousen AM, Koh A, Lambrou GN, et al. *Graefes's Archive for Clinical and Experimental Ophthalmology.* 2020.
246. **The post-lockdown period should be used to acquire effective therapies for future resurgence in SARS-Cov-2 infections.** Krause KL, Furneaux R, Benjes P, Brimble M, Davidson T, Denny W, et al. *The New Zealand medical journal.* 2020;133(1513):107-11.

247. **Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States.** Kujawski SA, Wong KK, Collins JP, Epstein L, Killerby ME, Midgley CM, et al. *Nature Medicine*. 2020.
248. **To Tweet or Not to Tweet—a Review of the Viral Power of Twitter for Infectious Diseases.** Kullar R, Goff DA, Gauthier TP, Smith TC. *Current Infectious Disease Reports*. 2020;22(6).
249. **Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19.** Kumar S, Zhi K, Mukherji A, Gerth K. *Viruses*. 2020;12(5). <http://dx.doi.org/10.3390/v12050486>.
250. **Why we should not stop giving aspirin to pregnant women during the COVID-19 pandemic.** Kwiatkowski S, Borowski D, Kajdy A, Poon LC, Rokita W, Wielgoś M. *Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology*. 2020.
251. **Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards.** La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, et al. *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology*. 2020. <http://dx.doi.org/10.1007/s10096-020-03913-9>.
252. **Sex-specific SARS-CoV2 mortality: Among hormone-modulated ace2 expression, risk of venous thromboembolism and hypovitaminosis D.** La Vignera S, Cannarella R, Condorelli RA, Torre F, Aversa A, Calogero AE. *International Journal of Molecular Sciences*. 2020;21(8).
253. **Positive RT-PCR Test Results in Patients Recovered from COVID-19.** Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, et al. *JAMA - Journal of the American Medical Association*. 2020;323(15):1502-3.
254. **Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment.** Lara PC, Burgos J, Macias D. *Clinical and Translational Radiation Oncology*. 2020;23:27-9.
255. **Pandemic of the new coronavirus SARSCoV-2 in Venezuela.** Larreal Y. *Investigacion Clinica (Venezuela)*. 2020;61(1):1-3.
256. **Public health literacy in the face of the Covid-19 pandemic emergency.** Lazcano-Ponce E, Alpuche-Aranda C. *Salud publica de Mexico*. 2020.
257. **The first infant case of COVID-19 acquired from a secondary transmission in Vietnam.** Le HT, Nguyen LV, Tran DM, Do HT, Tran HT, Le YT, et al. *The Lancet Child and Adolescent Health*. 2020;4(5):405-6.
258. **COVID-19 and ENT Pediatric otolaryngology during the COVID-19 pandemic. Guidelines of the French Association of Pediatric Otorhinolaryngology (AFOP) and French Society of Otorhinolaryngology (SFORL).** Leboulanger N, Sagardoy T, Akkari M, Ayari-Khalfallah S, Celerier C, Fayoux P, et al. *European Annals of Otorhinolaryngology, Head and Neck Diseases*. 2020.
259. **Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?** Lee SH, Son H, Peck KR. *International Journal of Antimicrobial Agents*. 2020.
260. **Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig.** Lei C, Qian K, Li T, Zhang S, Fu W, Ding M, et al. *Nature Communications*. 2020;11(1).
261. **The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia.** Li H, Chen K, Liu M, Xu H, Xu Q. *The Journal of infection*. 2020.

262. **The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis.** Li JW, Han TW, Woodward M, Anderson CS, Zhou H, Chen YD, et al. *Progress in Cardiovascular Diseases*. 2020.
263. **Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues.** Li MY, Li L, Zhang Y, Wang XS. *Infectious diseases of poverty*. 2020;9(1):45. <http://dx.doi.org/10.1186/s40249-020-00662-x>.
264. **Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China.** Li T, Zhang Y, Gong C, Wang J, Liu B, Shi L, et al. *European Journal of Clinical Nutrition*. 2020.
265. **Molecular immune pathogenesis and diagnosis of COVID-19.** Li X, Geng M, Peng Y, Meng L, Lu S. *Journal of Pharmaceutical Analysis*. 2020;10(2):102-8.
266. **Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2.** Li X, Zai J, Zhao Q, Nie Q, Li Y, Foley BT, et al. *Journal of Medical Virology*. 2020;92(6):602-11.
267. **A case of a readmitted patient who recovered from COVID-19 in Chengdu, China.** Li XJ, Zhang ZW, Zong ZY. *Critical Care*. 2020;24(1).
268. **Host AAA+ ATPase TER94 plays critical roles in building the baculovirus viral replication factory and virion morphogenesis.** Li Y, Hu L, Chen T, Chang M, Deng F, Hu Z, et al. *Journal of Virology*. 2020;94(6).
269. **Positive result of Sars-Cov-2 in faeces and sputum from discharged patient with COVID-19 in Yiwu, China.** Li Y, Hu Y, Yu Y, Zhang X, Li B, Wu J, et al. *Journal of medical virology*. 2020.
270. **The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients.** Li YC, Bai WZ, Hashikawa T. *Journal of Medical Virology*. 2020;92(6):552-5.
271. **Variable computed tomography appearances of COVID-19.** Lim ZY, Khoo HW, Hui TCH, Kok SSX, Kwan KEL, Young BE, et al. *Singapore medical journal*. 2020.
272. **COVID-19 pneumonia patient without clear epidemiological history outside Wuhan: An analysis of the radiographic and clinical features.** Lin C, Chen Z, Xie B, Sun Z, Ding Y, Li X, et al. *Clinical Imaging*. 2020;65:82-4.
273. **Does the direct renin inhibitor have a role to play in attenuating severity of the outbreak coronavirus disease 2019 (COVID-19)?** Lin CW, Huang YY. *Therapeutic Advances in Endocrinology and Metabolism*. 2020;11.
274. **COVID-19: A critical care perspective informed by lessons learnt from other viral epidemics.** Ling L, Joynt GM, Lipman J, Constantin JM, Joannes-Boyau O. *Anaesthesia Critical Care and Pain Medicine*. 2020;39(2):163-6.
275. **Characteristics and Treatment Strategies of Different Clinical Types in Patients with Corona Virus Disease 2019.** Liu F, Ji C, Luo J, Wu W, Zhang J, Zhong Z, et al. 2020.
276. **Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.** Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. *EBioMedicine*. 2020;55.
277. **Awareness of mental health problems in patients with coronavirus disease 19 (COVID-19): A lesson from an adult man attempting suicide.** Liu Y, Cao L, Li X, Jia Y, Xia H. *Asian Journal of Psychiatry*. 2020;51.
278. **Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals.** Liu Y, Ning Z, Chen Y, Guo M, Liu Y, Gali NK, et al. *Nature*. 2020.
279. **Plexiglass barrier box to improve ERCP safety during the COVID-19 pandemic.** Ljubicic N, Stojisavljevic-Shapeski S, Virovic-Jukic L, Nikolic M. *Gastrointestinal endoscopy*. 2020.

280. **Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy.** Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. *Thrombosis Research*. 2020;191:9-14.
281. **Contributory Role of Positron Emission Tomography in a Left Ventricular Assist Device Recipient at the time of COVID-19 pandemic.** Loforte A, Gliozzi G, Martin Suarez S, Pacini D. *ASAIO journal (American Society for Artificial Internal Organs : 1992)*. 2020.
282. **Characteristics, symptom management and outcomes of 101 patients with COVID-19 referred for hospital palliative care.** Lovell N, Maddocks M, Etkind SN, Taylor K, Carey I, Vora V, et al. *Journal of pain and symptom management*. 2020.
283. **The Wuhan SARS-CoV-2—What's next for China.** Lu H, Stratton CW, Tang YW. *Journal of Medical Virology*. 2020;92(6):546-7.
284. **Coronavirus disease (COVID-19) and neonate: What neonatologist need to know.** Lu Q, Shi Y. *Journal of Medical Virology*. 2020;92(6):564-7.
285. **A novel reverse transcription loop-mediated isothermal amplification method for rapid detection of sars-cov-2.** Lu R, Wu X, Wan Z, Li Y, Jin X, Zhang C. *International Journal of Molecular Sciences*. 2020;21(8).
286. **ACE2 and coronavirus - a question of balance and dynamics?** Lundström A, Sandén P. *Lakartidningen*. 2020;117.
287. **Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): An empirical study from Wuhan, Hubei Province, China.** Luo E, Zhang D, Luo H, Liu B, Zhao K, Zhao Y, et al. *Chinese Medicine (United Kingdom)*. 2020;15(1).
288. **Surveillance of COVID-19 in the General Population Using an Online Questionnaire: Report From 18,161 Respondents in China.** Luo H, Lie Y, Prinzen FW. *JMIR public health and surveillance*. 2020;6(2):e18576. <http://dx.doi.org/10.2196/18576>.
289. **Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19.** Luo P, Liu D, Li J. *International Journal of Antimicrobial Agents*. 2020.
290. **Association between chest CT features and clinical course of Coronavirus Disease 2019.** Luo Z, Wang N, Liu P, Guo Q, Ran L, Wang F, et al. *Respiratory Medicine*. 2020;168.
291. **Clinical consideration and management of coronavirus disease 2019.** Ma K, Chen T, Han MF, Guo W, Ning Q. *Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology*. 2020;28(3):222-8.
292. **Decontamination of face masks with steam for mask reuse in fighting the pandemic COVID-19: experimental supports.** Ma QX, Shan H, Zhang CM, Zhang HL, Li GM, Yang RM, et al. *Journal of medical virology*. 2020.
293. **Clinical features of children with SARS-CoV-2 infection: an analysis of 115 cases.** Ma YL, Xia SY, Wang M, Zhang SM, Du WH, Chen Q. *Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics*. 2020;22(4):290-3.
294. **Focus on Receptors for Coronaviruses with Special Reference to Angiotensin-converting Enzyme 2 as a Potential Drug Target - A Perspective.** Magrone T, Magrone M, Jirillo E. *Endocr Metab Immune Disord Drug Targets*. 2020.

295. **Reducing antibiotic prescribing and addressing the global problem of antibiotic resistance by targeted hygiene in the home and everyday life settings: A Position Paper.** Maillard JY, Bloomfield SF, Courvalin P, Essack SY, Gandra S, Gerba CP, et al. American journal of infection control. 2020.
296. **Probiotics and COVID-19: one size does not fit all.** Mak JWY, Chan FKL, Ng SC. The Lancet Gastroenterology and Hepatology. 2020.
297. **Properties of Coronavirus and SARS-CoV-2.** Malik YA. The Malaysian journal of pathology. 2020;42(1):3-11.
298. **Serum albumin-mediated strategy for the effective targeting of SARS-CoV-2.** Mani Mishra P, Uversky VN, Nandi CK. Medical Hypotheses. 2020;140.
299. **Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis.** Mantovani A, Beatrice G, Dalbeni A. Liver International. 2020.
300. **Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save lives—current situation and perspectives.** Marando M, Tamburello A. Swiss Medical Weekly. 2020;150(1718).
301. **Application of a portable instrument for rapid and reliable detection of SARS-CoV-2 infection in any environment.** Martinelli F, Perrone A, Della Noce I, Colombo L, Lo Priore S, Romano S. Immunological Reviews. 2020.
302. **Potential for Lung Recruitment and Ventilation-Perfusion Mismatch in Patients With the Acute Respiratory Distress Syndrome From Coronavirus Disease 2019.** Mauri T, Spinelli E, Scotti E, Colussi G, Basile MC, Crotti S, et al. Critical care medicine. 2020.
303. **COVID-19 and rheumatology: First steps towards a different future?** McInnes IB. Annals of the Rheumatic Diseases. 2020;79(5):551-2.
304. **Candidate drugs against SARS-CoV-2 and COVID-19.** McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C. Pharmacological Research. 2020:104859.
305. **COVID-19 in pregnancy: risk of adverse neonatal outcomes.** Mehan A, Venkatesh A, Girish M. J Med Virol. 2020. <http://dx.doi.org/10.1002/jmv.25959>.
306. **A crisis for elderly with mental disorders: Relapse of symptoms due to heightened anxiety due to COVID-19.** Mehra A, Rani S, Sahoo S, Parveen S, Singh AP, Chakrabarti S, et al. Asian Journal of Psychiatry. 2020;51.
307. **COVID-19 Illness and Heart Failure: A Missing Link?** Mehra MR, Ruschitzka F. JACC: Heart Failure. 2020.
308. **Protective immunity after COVID-19 has been questioned: What can we do without SARS-CoV-2-IgG detection?** Melgaço JG, Azamor T, Ano Bom APD. Cellular Immunology. 2020;353.
309. **Medical Students Are Not Essential Workers: Examining Institutional Responsibility During the COVID-19 Pandemic.** Menon A, Klein EJ, Kollars K, Kleinhenz ALW. Academic medicine : journal of the Association of American Medical Colleges. 2020. <http://dx.doi.org/10.1097/ACM.0000000000003478>.
310. **Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).** Mercurio NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. JAMA cardiology. 2020. <http://dx.doi.org/10.1001/jamacardio.2020.1834>.
311. **Functional role of dietary intervention to improve the outcome of COVID-19: A hypothesis of work.** Messina G, Polito R, Monda V, Cipolloni L, Di Nunno N, Di Mizio G, et al. International Journal of Molecular Sciences.

2020;21(9).

312. **Experiences of Patients with Rheumatic Diseases in the US During Early Days of the COVID-19 Pandemic.** Michaud K, Wipfler K, Shaw Y, Simon TA, Cornish A, England BR, et al. *ACR Open Rheumatology*. 2020.
313. **Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin.** Millan-Onate J, Millan W, Mendoza LA, Sanchez CG, Fernandez-Suarez H, Bonilla-Aldana DK, et al. *Annals of clinical microbiology and antimicrobials*. 2020;19(1):16. <http://dx.doi.org/10.1186/s12941-020-00358-y>.
314. **Crisis Psychodrama in the Era of COVID-19.** Mindoljević Drakulić A, Radman V. *Psychiatria Danubina*. 2020;32(1):22-4.
315. **Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?** Moiseev S, Avdeev S, Brovko M, Novikov P, Fomin V. *Annals of the Rheumatic Diseases*. 2020.
316. **Covid-19, Coronavirus, SARS-CoV-2 and the small bowel.** Monkemuller K, Fry L, Rickes S. *Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva*. 2020. <http://dx.doi.org/10.17235/reed.2020.7137/2020>.
317. **Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome.** Monteagudo LA, Boothby A, Gertner E. *ACR Open Rheumatology*. 2020.
318. **Preventing COVID-19-induced pneumonia with anticytokine therapy.** Monteleone G, Sarzi-Puttini PC, Ardizzone S. *The Lancet Rheumatology*. 2020;2(5):e255-e6.
319. **A review of initial data on pregnancy during the COVID-19 out-break: Implications for assisted reproductive treatments.** Monteleone PAA, Nakano M, Lazar V, Gomes AP, de Martin H, Bonetti TCS. *Jornal Brasileiro de Reproducao Assistida*. 2020;24(2):219-25.
320. **Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and SLE, hydroxychloroquine and no SLE patients with COVID-19: A comment' by Joob and Wiwanitkit.** Monti S, Montecucco C. *Annals of the Rheumatic Diseases*. 2020.
321. **Letter to the Editor: Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab.** Morrison AR, Johnson JM, Ramesh M, Bradley P, Jennings J, Smith ZR. *Journal of medical virology*. 2020.
322. **Assessment of SARS-CoV-2 Infection Prevalence in Homeless Shelters - Four U.S. Cities, March 27-April 15, 2020.** Mosites E, Parker EM, Clarke KEN, Gaeta JM, Baggett TP, Imbert E, et al. *MMWR Morbidity and mortality weekly report*. 2020;69(17):521-2. <http://dx.doi.org/10.15585/mmwr.mm6917e1>.
323. **The role of Neutrophil Extracellular Traps in Covid-19: Only an hypothesis or a potential new field of research?** Mozzini C, Girelli D. *Thrombosis Research*. 2020;191:26-7.
324. **Successful Guselkumab treatment in a psoriatic patient affected with Cornelia de Lange Syndrome, and prosecution during the COVID-19 pandemic.** Mugheddu C, Dell'Antonia M, Sanna S, Agosta D, Atzori L, Rongioletti F. *Dermatologic therapy*. 2020.
325. **The effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on death and severity of disease in patients with coronavirus disease 2019 (COVID-19): A meta-analysis.** Mukherjee JJ, Sinha B, Gangopadhyay KK. 2020.
326. **Flooded by the torrent: the COVID-19 drug pipeline.** Mullard A. *Lancet*. 2020;395(10232):1245-6. [http://dx.doi.org/10.1016/S0140-6736\(20\)30894-1](http://dx.doi.org/10.1016/S0140-6736(20)30894-1).

327. **Analysis of complement deposition and viral RNA in placentas of COVID-19 patients.** Mulvey JJ, Magro CM, Ma LX, Nuovo GJ, Baergen RN. *Annals of Diagnostic Pathology*. 2020;46.
328. **Care for Critically Ill Patients with COVID-19.** Murthy S, Gomersall CD, Fowler RA. *JAMA - Journal of the American Medical Association*. 2020;323(15):1499-500.
329. **COVID-19 type III hypersensitivity reaction.** Mutar Mahdi B. *Medical Hypotheses*. 2020;140.
330. **Origin, potential therapeutic targets and treatment for coronavirus disease (COVID-19).** Nadeem MS, Zamzami MA, Choudhry H, Murtaza BN, Kazmi I, Ahmad H, et al. *Pathogens*. 2020;9(4).
331. **Global spread of coronavirus disease 2019 and malaria: An epidemiological paradox in the early stage of a pandemic.** Napoli PE, Nioi M. *Journal of Clinical Medicine*. 2020;9(4).
332. **Corticosteroid use for 2019-nCoV infection: A double-edged sword.** Nasim S, Kumar S, Azim D, Ashraf Z, Azeem Q. *Infection control and hospital epidemiology*. 2020:1-6.
333. **COVID-19 disrupts vaccine delivery.** Nelson R. *The Lancet Infectious diseases*. 2020.
334. **Medical Toxicology and COVID-19: Our Role in a Pandemic.** Neumann NR, Chai PR, Wood DM, Greller HA, Mycyk MB. *Journal of Medical Toxicology*.1.
335. **Severe Thrombocytopenia in a Patient with COVID-19.** Nham E, Ko JH, Jeong BH, Huh K, Cho SY, Kang CI, et al. *Infection & chemotherapy*. 2020.
336. **Overview of Covid-19; its prevention and management in the light of Unani medicine.** Nikhat S, Fazil M. *Science of the Total Environment*. 2020;728.
337. **Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child.** Nilsson A, Edner N, Albert J, Ternhag A. *Infectious Diseases*. 2020;52(6):419-22.
338. **Remdesivir for COVID-19: challenges of underpowered studies.** Norrie JD. *The Lancet*. 2020.
339. **Preliminary therapeutic drug monitoring data of β -lactams in critically ill patients with SARS-CoV-2 infection.** Novy E, Scala-Bertola J, Roger C, Guerzi P. *Anaesthesia, critical care & pain medicine*. 2020.
340. **Practical diagnosis and treatment of suspected venous thromboembolism during COVID-19 Pandemic.** Obi AT, Barnes GD, Wakefield TW, Brown Rvt S, Eliason JL, Arndt E, et al. *Journal of vascular surgery Venous and lymphatic disorders*. 2020.
341. **Economic Recovery After the COVID-19 Pandemic: Resuming Elective Orthopedic Surgery and Total Joint Arthroplasty.** O'Connor CM, Anoushiravani AA, DiCaprio MR, Healy WL, Iorio R. *The Journal of arthroplasty*. 2020. <http://dx.doi.org/10.1016/j.arth.2020.04.038>.
342. **An assessment of real-time RT-PCR kits for SARS-CoV-2 detection.** Okamaoto K, Shirato K, Nao N, Saito S, Kageyama T, Hasegawa H, et al. *Jpn J Infect Dis*. 2020. <http://dx.doi.org/10.7883/yoken.JJID.2020.108>.
343. **Coronavirus disease 2019 (COVID-19) outbreak: Could pigs be vectors for human infections?** Opriessnig T, Huang YW. *Xenotransplantation*. 2020;27(2).
344. **Tocilizumab: A new opportunity in the possible therapeutic arsenal against COVID-19.** Ortiz-Martínez Y. *Travel Medicine and Infectious Disease*. 2020.

345. **Down-regulated gene expression spectrum and immune responses changed during the disease progression in COVID-19 patients.** Ouyang Y, Yin J, Wang W, Shi H, Shi Y, Xu B, et al. *Clinical infectious diseases* : an official publication of the Infectious Diseases Society of America. 2020.
346. **Clinically suspected myocarditis in the course of coronavirus infection.** Ozieranski K, Tyminska A, Caforio ALP. *European Heart Journal*. 2020.
347. **Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant.** Pachetti M, Marini B, Benedetti F, Giudici F, Mauro E, Storici P, et al. *Journal of translational medicine*. 2020;18(1):179.
348. **IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study.** Padoan A, Sciacovelli L, Basso D, Negrini D, Zuin S, Cosma C, et al. *Clinica Chimica Acta*. 2020;507:164-6.
349. **Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains.** Padron-Regalado E. *Infectious Diseases and Therapy*. 2020.
350. **Bilirubin levels in patients with mild and severe Covid-19: a pooled analysis.** Paliogiannis P, Zinellu A. *Liver international* : official journal of the International Association for the Study of the Liver. 2020.
351. **Topical preparations to reduce SARS-CoV-2 aerosolization in head and neck mucosal surgery.** Parhar HS, Tasche K, Brody RM, Weinstein GS, O'Malley BW, Shanti RM, et al. *Head and Neck*. 2020.
352. **Epidemiology, virology, and clinical features of severe acute respiratory syndrome-coronavirus-2 (SARS-COV-2; Coronavirus Disease-19).** Park SE. *Korean Journal of Pediatrics*. 2020;63(4):119-24.
353. **COVID-19: New paradigms for disease management.** Patravale VB. *Indian Drugs*. 2020;57(3):5-6.
354. **Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?** Patri A, Fabbrocini G. *Journal of the American Academy of Dermatology*. 2020.
355. **Can an effective sars-cov-2 vaccine be developed for the older population?** Pawelec G, Weng NP. *Immunity and Ageing*. 2020;17(1).
356. **Mental Health Services in Lombardy during COVID-19 outbreak.** Percudani M, Corradin M, Moreno M, Indelicato A, Vita A. *Psychiatry Research*. 2020;288.
357. **Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?** Perrotta F, Matera MG, Cazzola M, Bianco A. *Respiratory Medicine*. 2020;168.
358. **COVID-19 travel restrictions and the International Health Regulations – Call for an open debate on easing of travel restrictions.** Petersen E, McCloskey B, Hui DS, Kock R, Ntoumi F, Memish ZA, et al. *International Journal of Infectious Diseases*. 2020;94:88-90.
359. **Response to: Nephilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan).** Petramala L, Letizia C. *European Heart Journal-Cardiovascular Pharmacotherapy*. 2020.
360. **Nipah virus: Past outbreaks and future containment.** Pillai VS, Krishna G, Veetil MV. *Viruses*. 2020;12(4).
361. **Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19.** Pindiprolu SKSS, Pindiprolu SH. *Medical Hypotheses*. 2020;140.
362. **SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?** Pitocco D, Tartaglione L, Viti L, Di Leo M, Pontecorvi A, Caputo S. *Diabetes Research and Clinical Practice*. 2020;163.

363. **[Options for controlling new Corona virus infection - 2019-nCoV]**. Plusa T. *Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego*. 2020;48(284):112-9.
364. **COVID-19 Deaths: Are We Sure It Is Pneumonia? Please, Autopsy, Autopsy, Autopsy!** Pomara C, Li Volti G, Cappello F. *Journal of clinical medicine*. 2020;9(5). <http://dx.doi.org/10.3390/jcm9051259>.
365. **What Does the COVID-19 Pandemic Mean for Rheumatology Patients?** Pope JE. *Current treatment options in rheumatology*. 2020:1-4. <http://dx.doi.org/10.1007/s40674-020-00145-y>.
366. **Is low sodium intake a risk factor for severe and fatal COVID-19 infection?** Post A, Dullaart RPF, Bakker SJL. *European Journal of Internal Medicine*. 2020;75:109.
367. **Testosterone, a key hormone in the context of COVID-19 pandemic.** Pozzilli P, Lenzi A. *Metabolism: Clinical and Experimental*. 2020;108.
368. **Development of real-time RT-PCR assay for diagnosis of viral enteritis in neonatal goat kids.** Prajapati S, Gururaj K, Andani D, Pachori A, Kumar A, Pawaiya RVS. *Indian Journal of Animal Sciences*. 2020;90(2):147-51.
369. **Yttrium-90 Radioembolization: Telemedicine during COVID-19 outbreak, opportunity for prime time.** Quek LHH, Kannivelu A, Pua U. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2020.
370. **Helmet cpap to treat acute hypoxemic respiratory failure in patients with covid-19: A management strategy proposal.** Radovanovic D, Rizzi M, Pini S, Saad M, Chiumello DA, Santus P. *Journal of Clinical Medicine*. 2020;9(4).
371. **Interpret with caution: An evaluation of the commercial AusDiagnostics versus in-house developed assays for the detection of SARS-CoV-2 virus.** Rahman H, Carter I, Basile K, Donovan L, Kumar S, Tran T, et al. *Journal of Clinical Virology*. 2020;127.
372. **Management challenges for chronic dysimmune neuropathies during the COVID-19 pandemic.** Rajabally YA, Goedee HS, Attarian S, Hartung HP. *Muscle & nerve*. 2020.
373. **Targeting SARS-CoV-2 Spike Protein of COVID-19 with Naturally Occurring Phytochemicals: An in Silico Study for Drug Development.** Rane JS, Chatterjee A, Kumar A, Ray S. 2020.
374. **The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome.** Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M, et al. *Journal of thrombosis and haemostasis : JTH*. 2020.
375. **Coronavirus Disease 2019 (COVID-19) and pregnancy: what obstetricians need to know.** Rasmussen SA, Smulian JC, Lednický JA, Wen TS, Jamieson DJ. *American Journal of Obstetrics and Gynecology*. 2020;222(5):415-26.
376. **The active role of a blood center in outpacing the transfusion transmission of COVID-19.** Raturi M, Kusum A. *Transfusion Clinique et Biologique*. 2020;27(2):96-7.
377. **Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing.** Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. *Clinical Infectious Diseases*.
378. **Commentary: No-test medication abortion: A sample protocol for increasing access during a pandemic and beyond.** Raymond EG, Grossman D, Mark A, Upadhyay UD, Dean G, Creinin MD, et al. *Contraception*. 2020.
379. **COVID-19 patients and the radiology department - advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI).** Revel MP, Parkar AP, Prosch H, Silva M, Sverzellati N,

Gleeson F, et al. European radiology. 2020.

380. **Systemic Immunosuppressive Therapy for Inflammatory Skin Diseases in Children: Expert-Consensus-Based Guidance for Clinical Decision Making During the COVID-19 Pandemic.** Reynolds SD, Mathur AN, Chiu YE, Brandling-Bennett HA, Pope E, Siegel MP, et al. Pediatric dermatology. 2020.
381. **Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North - supports vitamin D as a factor determining severity.** Rhodes JM, Subramanian S, Laird E, Anne Kenny R. Alimentary pharmacology & therapeutics. 2020.
382. **Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North – supports vitamin D as a factor determining severity.** Rhodes JM, Subramanian S, Laird E, Anne Kenny R. Alimentary Pharmacology and Therapeutics. 2020.
383. **Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.** Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. JAMA. 2020.
384. **Inactivated vaccine for SARS-CoV-2.** Risson E. Nature Reviews Immunology. 2020.
385. **Darunavir does not prevent SARS-CoV-2 infection in HIV patients.** Riva A, Conti F, Bernacchia D, Pezzati L, Sollima S, Merli S, et al. Pharmacological Research. 2020;157.
386. **Co-Infection with SARS-COV-2 and Parainfluenza in a young adult patient with pneumonia: Case Report.** Rodriguez JA, Rubio-Gomez H, Roa AA, Miller N, Eckardt PA. IDCases. 2020;20.
387. **Alopecia areata not due by isotretinoin. A thought in COVID-19 time.** Rodríguez-Jiménez P, Ramirez-Bellver JL, Ruiz-Rodríguez R. Dermatologic therapy. 2020.
388. **Covid-19, an emerging coronavirus infection: Current scenario and recent developments - An overview.** Rodriguez-Morales AJ, Katterine Bonilla-Aldana D, Tiwari R, Sah R, Rabaan AA, Dhama K. Journal of Pure and Applied Microbiology. 2020;14(1):5-12.
389. **Explanation for COVID-19 infection neurological damage and reactivations.** Roe K. Transboundary and emerging diseases. 2020.
390. **Age-adjusted D-dimer cut-off levels to rule out venous thromboembolism in COVID-19 patients.** Roncon L, Zuin M, Zonzin P. Thrombosis Research. 2020;190:102.
391. **Use of Disinfectant Wipes to Sanitize Milk's Containers of Human Milk Bank During COVID-19 Pandemic.** Rose DU, Reposi MP, Amadio P, Auriti C, Dall'Oglio I, Corsetti T, et al. Journal of human lactation : official journal of International Lactation Consultant Association. 2020:890334420924639.
392. **Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19.** Rothlin RP, Vetulli HM, Duarte M, Pelorosso FG. Drug development research. 2020. <http://dx.doi.org/10.1002/ddr.21679>.
393. **Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19.** Ruamviboonsuk P, Lai TYY, Chang A, Lai CC, Mieler WF, Lam DSC. Asia-Pacific journal of ophthalmology (Philadelphia, Pa). 2020;9(2):85-7. <http://dx.doi.org/10.1097/APO.0000000000000289>.
394. **Letter to the Editor: Lipemic serum in patients with COVID-19 undergoing treatment.** Rubel AR, Chong PL, Abdullah MS, Asli R, Momin RN, Mani BI, et al. J Med Virol. 2020. <http://dx.doi.org/10.1002/jmv.25942>.
395. **Coronavirus SARS-CoV-2: filtering fact from fiction in the infodemic: Q&A with virologist Professor**

Urs Greber. Ruffell D. FEBS Letters. 2020;594(7):1127-31.

396. **Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation and Cytokine Amplification in COVID-19.** Ryan PM, Caplice NM. Obesity (Silver Spring, Md). 2020.

397. **Cardiac patients and COVID-19: What the general practitioner should know.** Ryczek R, Krzesiński P. *Pediatrics i Medycyna Rodzinna*. 2019;15(4):C6-C9.

398. **Self-harm and COVID-19 Pandemic: An emerging concern – A report of 2 cases from India.** Sahoo S, Rani S, Parveen S, Pal Singh A, Mehra A, Chakrabarti S, et al. *Asian Journal of Psychiatry*. 2020;51.

399. **Facing COVID-19 in the hematopoietic cell transplant setting: A new challenge for transplantation physicians.** Sahu KK, Jindal V, Siddiqui AD, Cerny J. *Blood Cells, Molecules, and Diseases*. 2020;83.

400. **The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection.** Saleh M, Gabriels J, Chang D, Kim BS, Mansoor A, Mahmood E, et al. *Circulation Arrhythmia and electrophysiology*. 2020. <http://dx.doi.org/10.1161/CIRCEP.120.008662>.

401. **The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of COVID-19.** Salem ML, El-Hennawy D. *Medical Hypotheses*. 2020;140.

402. **Correspondence COVID-19: Melatonin as a potential adjuvant treatment.** Salles C. *Life sciences*. 2020;253.

403. **In the search of potential epitopes for Wuhan seafood market pneumonia virus using high order nullomers.** Santoni D, Vergni D. *Journal of Immunological Methods*. 2020.

404. **Is Coronavirus Disease 2019 (COVID-19) seen less in countries more exposed to Malaria?** Sargin G, Yavaşoğlu Sİ, Yavasoglu I. *Medical Hypotheses*. 2020;140.

405. **Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.** Sato K, Mano T, Iwata A, Toda T. *Bioscience trends*. 2020.

406. **Addressing Problems With Alcohol and Other Substances Among Older Adults During the COVID-19 Pandemic.** Satre DD, Hirschtritt ME, Silverberg MJ, Sterling SA. *American Journal of Geriatric Psychiatry*. 2020.

407. **Covid-19: Round and oval areas of ground-glass opacity.** Schmitt W, Marchiori E. *Pulmonology*. 2020.

408. **Changes in care of home artificial nutrition patients during the COVID-19 epidemics in France: position of the French-speaking Society for Clinical Nutrition and Metabolism (SFNCM)'s Home Artificial Nutrition Committee.** Schneider SM, Albert V, Barbier N, Barnoud D, Bouteloup C, Chambrier C, et al. *Nutrition Clinique et Metabolisme*. 2020.

409. **Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in severe patients with COVID-19.** Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, et al. *Clinical and Experimental Rheumatology*. 2020;38:00-.

410. **COVID-19: Four Paediatric Cases in Malaysia.** See KC, Liew SM, Ng DCE, Chew EL, Khoo EM, Sam CH, et al. *International Journal of Infectious Diseases*. 2020;94:125-7.

411. **Coronavirus and diabetes: an update.** Seewoodhary J, Oozageer R. *Practical Diabetes*. 2020;37(2):41-2.

412. **Hispidin and Lepidine E: two Natural Compounds and Folic acid as Potential Inhibitors of 2019-novel coronavirus Main Protease (2019-nCoVMPpro), molecular docking and SAR study.** Serseg T, Benarous K, Yousfi M.

Current computer-aided drug design. 2020.

413. **FDG-PET/CT findings highly suspicious for COVID-19 in an Italian case series of asymptomatic patients.** Setti L, Kirienko M, Dalto SC, Bonacina M, Bombardieri E. *European Journal of Nuclear Medicine and Molecular Imaging*. 2020.
414. **Searching for SARS-COV-2 on Particulate Matter: A Possible Early Indicator of COVID-19 Epidemic Recurrence.** Setti L, Passarini F, De Gennaro G, Barbieri P, Pallavicini A, Ruscio M, et al. *International journal of environmental research and public health*. 2020;17(9). <http://dx.doi.org/10.3390/ijerph17092986>.
415. **Airborne transmission route of covid-19: Why 2 meters/6 feet of inter-personal distance could not be enough.** Setti L, Passarini F, De Gennaro G, Barbieri P, Perrone MG, Borelli M, et al. *International Journal of Environmental Research and Public Health*. 2020;17(8).
416. **Myocardial injury is associated with higher mortality in patients with coronavirus disease 2019: a meta-analysis.** Shao M-J, Shang L-X, Luo J-Y, Shi J, Zhao Y, Li X-M, et al. *Journal of Geriatric Cardiology: JGC*. 2020;17(4):224.
417. **Androgen hazards with COVID-19.** Sharifi N, Ryan C. *Endocrine-related cancer*. 2020.
418. **The Contact Activation System as a Potential Therapeutic Target in Patients with COVID-19.** Shatzel JJ, DeLoughery EP, Lorentz CU, Tucker EI, Aslan JE, Hinds MT, et al. *Research and Practice in Thrombosis and Haemostasis*. 2020.
419. **Recent advances and perspectives of nucleic acid detection for coronavirus.** Shen M, Zhou Y, Ye J, Abdullah ALmAA, Kang Y, Zeng S, et al. *Journal of Pharmaceutical Analysis*. 2020;10(2):97-101.
420. **COVID-19 infection: the perspectives on immune responses.** Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. *Cell Death and Differentiation*. 2020;27(5):1451-4.
421. **Improving the efficacy of Chloroquine and Hydroxychloroquine against SARS-CoV-2 may require Zinc additives - A better synergy for future COVID-19 clinical trials.** Shittu MO, Afolami OI. *Le infezioni in medicina*. 2020;28(2):192-7.
422. **Vitamin D: A simpler alternative to tocilizumab for trial in COVID-19?** Silberstein M. *Medical Hypotheses*. 2020;140.
423. **Antiviral treatment of covid-19.** Şimşek Yavuz S, Ünal S. *Turkish Journal of Medical Sciences*. 2020;50:611-9.
424. **Navigating the impact of COVID-19 on palliative care for head and neck cancer.** Singh AG, Deodhar J, Chaturvedi P. *Head and Neck*. 2020.
425. **COVID-19 transmission through host cell directed network of GPCR.** Singh Y, Gupta G, Satija S, Pabreja K, Chellappan DK, Dua K. *Drug Development Research*. 2020.
426. **3CLpro inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials.** Sisay M. *Pharmacological Research*. 2020;156.
427. **Bocaparvovirus infection in children in the republic of Belarus: Molecular and epidemiological aspects.** Sivets NV, Shmeleva NP, Lapo TP. *Jurnal Infektologii*. 2019;11(4):113-21.
428. **Zinc and respiratory tract infections: Perspectives for COVID-19 (Review).** Skalny AV, Rink L, Ajsuvakova OP, Aschner M, Gritsenko VA, Alekseenko SI, et al. *International journal of molecular medicine*. 2020.

429. **What should a cardiologist know about coronavirus disease 2019?** Slawinski G, Lewicka E. *Kardiologia polska*. 2020;78(4):278-83. <http://dx.doi.org/10.33963/KP.15302>. Epub 2020 Apr 24.
430. **Association between climate variables and global transmission of SARS-CoV-2.** Sobral MFF, Duarte GB, da Penha Sobral AIG, Marinho MLM, de Souza Melo A. *Science of the Total Environment*. 2020;729.
431. **American Geriatrics Society (AGS) Policy Brief: COVID-19 and Assisted Living Facilities.** Society AG. *Journal of the American Geriatrics Society*. 2020. <http://dx.doi.org/10.1111/jgs.16510>.
432. **Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.** Sole G, Salort-Campana E, Pereon Y, Stojkovic T, Wahbi K, Cintas P, et al. *Rev Neurol (Paris)*. 2020. <http://dx.doi.org/10.1016/j.neurol.2020.04.004>.
433. **Clinical features of pediatric patients with coronavirus disease (COVID-19).** Song W, Li J, Zou N, Guan W, Pan J, Xu W. *Journal of Clinical Virology*. 2020;127.
434. **[Epidemic characteristics and trend analysis of the COVID-19 in Hubei province].** Song Y, Liu M, Jia WP, Wang SS, Cao WZ, Han K, et al. *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi*. 2020;41:E053. <http://dx.doi.org/10.3760/cma.j.cn112338-20200321-00409>.
435. **Benefits of exercise on influenza or pneumonia in older adults: A systematic review.** Song Y, Ren F, Sun D, Wang M, Baker JS, István B, et al. *International Journal of Environmental Research and Public Health*. 2020;17(8).
436. **Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover.** Soresina A, Moratto D, Chiarini M, Paolillo C, Baresi G, Focà E, et al. *Pediatric allergy and immunology* : official publication of the European Society of Pediatric Allergy and Immunology. 2020.
437. **Oxytocin as a potential defence against Covid-19?** Soumier A, Sirigu A. *Medical Hypotheses*. 2020;140.
438. **COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure.** Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, et al. *Thrombosis and haemostasis*. 2020.
439. **Hospital-based use of thromboprophylaxis in patients with COVID-19.** Spyropoulos AC, Ageno W, Barnathan ES. *The Lancet*. 2020;395(10234):e75.
440. **Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence.** Sriram K, Insel PA. *Clinical pharmacology and therapeutics*. 2020.
441. **Medication for COVID-19-an Overview of Approaches Currently Under Study.** Stahlmann R, Lode H. *Deutsches Arzteblatt international*. 2020;117(13):213-9. <http://dx.doi.org/10.3238/arztebl.2020.0213>.
442. **Medication for COVID-19-an Overview of Approaches Currently Under Study.** Stahlmann R, Lode H. *Deutsches Arzteblatt international*. 2020;117(13):213.
443. **Navigating the Clean Energy Transition in the COVID-19 Crisis.** Steffen B, Egli F, Pahle M, Schmidt TS. *Joule*. 2020. <http://dx.doi.org/10.1016/j.joule.2020.04.011>.
444. **Using Biosecurity Measures to Combat Respiratory Disease in Cattle: The Norwegian Control Program for Bovine Respiratory Syncytial Virus and Bovine Coronavirus.** Stokstad M, Klem TB, Myrmet M, Oma VS, Toftaker I, Østerås O, et al. *Frontiers in Veterinary Science*. 2020;7.
445. **Virological assessment of SARS-CoV-2.** Stower H. *Nature Medicine*. 2020;26(4):465.

446. **Functionally assessing coronavirus entry.** Stower H. *Nature Medicine*. 2020;26(4):465.
447. **COVID-19: How has the scientific community risen to the challenge?** Straiton J. *BioTechniques*. 2020.
448. **Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients.** Suba Z. *Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques*. 2020;23(1):75-85.
449. **Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic.** Sullivan HC, Roback JD. *Transfusion Medicine Reviews*. 2020.
450. **Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients.** Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, et al. *Emerging microbes & infections*. 2020:1-36.
<http://dx.doi.org/10.1080/22221751.2020.1762515>.
451. **Understanding of COVID-19 based on current evidence.** Sun P, Lu X, Xu C, Sun W, Pan B. *Journal of Medical Virology*. 2020;92(6):548-51.
452. **Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China.** Sun S, Cai X, Wang H, He G, Lin Y, Lu B, et al. *Clinica Chimica Acta*. 2020;507:174-80.
453. **Cytokine storm intervention in the early stages of COVID-19 pneumonia.** Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H, et al. *Cytokine and Growth Factor Reviews*. 2020.
454. **COVID-19: Herd Immunity and Convalescent Plasma Transfer Therapy.** Syal K. *Journal of Medical Virology*. 2020.
455. **Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save lives - current situation and perspectives.** Tamburello A, Marando M. *Swiss medical weekly*. 2020;150:w20264.
<http://dx.doi.org/10.4414/smw.2020.20264>. eCollection 2020 Apr 20.
456. **C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early.** Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, et al. *Journal of Medical Virology*. 2020.
457. **Clinical features of children with SARS-CoV-2 infection: an analysis of 13 cases from Changsha, China.** Tan X, Huang J, Zhao F, Zhou Y, Li JQ, Wang XY. *Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics*. 2020;22(4):294-8.
458. **Clinical Characteristics of 20,662 Patients with COVID-19 in mainland China: A Systemic Review and Meta-analysis.** Tang C, Zhang K, Wang W, Pei Z, Liu Z, Yuan P, et al. *medRxiv*. 2020.
459. **Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak.** Tanriverdi O. *Medical Oncology*. 2020;37(6).
460. **Atypical presentation of COVID-19 in a frail older person.** Tay HS, Harwood R. *Age and ageing*. 2020.
461. **Convalescent plasma: A possible treatment of COVID-19 in India.** Teixeira da Silva JA. *Medical Journal Armed Forces India*. 2020.
462. **Elevated Troponin in Patients With Coronavirus Disease 2019: Possible Mechanisms.** Tersalvi G, Vicenzi M, Calabretta D, Biasco L, Pedrazzini G, Winterton D. *Journal of Cardiac Failure*. 2020.

463. **Novel coronavirus disease (Covid-19) in children.** Tezer H, Bedir Demirdağ T. Turkish Journal of Medical Sciences. 2020;50:592-603.
464. **Laboratory haemostasis monitoring in COVID-19.** Thachil J, Tang N, Gando S, Falanga A, Levi M, Clark C, et al. Journal of thrombosis and haemostasis : JTH. 2020.
465. **Unity amidst uncertainty: COVID-19 pandemic fosters collaboration in rheumatology community.** The Lancet R. The Lancet Rheumatology. 2020;2(5):e245.
466. **COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.** Theoharides TC. BioFactors. 2020.
467. **Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19.** Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al. Nature Medicine. 2020;26(4):453-5.
468. **Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: an ASTRO-ESTRO consensus statement.** Thomson DJ, Palma D, Guckenberger M, Balerspås P, Beitler JJ, Blanchard P, et al. International journal of radiation oncology, biology, physics. 2020.
469. **[Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors].** Tian L, Liu W, Sun L. Sheng wu gong cheng xue bao = Chinese journal of biotechnology. 2020;36(4):605-11. <http://dx.doi.org/10.13345/j.cjb.200049>.
470. **Letter: Covid-19, and vitamin D. Authors' reply.** Tian Y, Rong L. Alimentary Pharmacology and Therapeutics. 2020;51(10):995-6.
471. **What can Parkinson's disease teach us about COVID-19?** Tipton PW, Wszolek ZK. Neurologia i neurochirurgia polska. 2020.
472. **Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear.** Torjesen I. BMJ (Clinical research ed). 2020;369:m1555.
473. **Comment on 'Two cases of COVID-19 presenting with a clinical picture resembling chilblains: first report from the Middle East': pernio unrelated to COVID-19.** Torres-Navarro I, Abril-Perez C, Roca-Gines J, Sanchez-Arreaez J, Botella-Estrada R, Evole-Buselli M. Clinical and experimental dermatology. 2020. <http://dx.doi.org/10.1111/ced.14255>.
474. **Natural compounds as potential inhibitors of novel coronavirus (COVID-19) main protease: An in silico study.** Tripathi V, Mishra A, Pathak Y. 2020.
475. **The epidemiological and clinical features of COVID-19 and lessons from this global infectious public health event.** Tu H, Tu S, Gao S, Shao A, Sheng J. The Journal of infection. 2020.
476. **Covid-19, immune system response, hyperinflammation and repurposing antirheumatic drugs.** Tufan A, Avanoğlu Güler A, Matucci-Cerinic M. Turkish Journal of Medical Sciences. 2020;50:620-32.
477. **Cutaneous Side-Effects of the Potential Covid-19 Drugs.** Tursen U, Tursen B, Lotti T. Dermatologic therapy. 2020:e13476. <http://dx.doi.org/10.1111/dth.13476>.
478. **Covid-19 infection in Crohn's disease under treatment with adalimumab.** Tursi A, Angarano G, Monno L, Saracino A, Signorile F, Ricciardi A, et al. Gut. 2020.
479. **Impact of anti-tnf α antibodies on the risk of Covid-19 and its severity in patients with inflammatory**

Bowel Diseases. Tursi A, Papa A. Journal of Crohn's & colitis. 2020.

480. **Benign COVID-19 in an immunocompromised cancer patient - The case of a married couple.** Valentina S, Alessio P, Hans-Ulrich I. Swiss Medical Weekly. 2020;150(15).
481. **Neutralizing antibody response in mild COVID-19.** van der Heide V. Nature Reviews Immunology. 2020.
482. **Preparedness for COVID-19 in the oncology community in Africa.** Vanderpuye V, Elhassan MMA, Simonds H. The Lancet Oncology. 2020;21(5):621-2.
483. **A data-driven hypothesis on the epigenetic dysregulation of host metabolism by SARS coronavirus infection: Potential implications for the SARS-CoV-2 modus operandi.** Vavougiou GD. Medical Hypotheses. 2020;140.
484. **ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus.** Verdecchia P, Reboldi G, Cavallini C, Mazzotta G, Angeli F. Giornale italiano di cardiologia (2006). 2020;21(5):321-7.
485. **Chloroquine dosing recommendations for pediatric COVID-19 supported by modeling and simulation.** Verscheijden LFM, van der Zanden TM, van Bussel LPM, de Hoop-Sommen M, Russel FGM, Johnson TN, et al. Clinical pharmacology and therapeutics. 2020.
486. **Guillain-Barré Syndrome associated with SARS-CoV-2 infection.** Virani A, Rabold E, Hanson T, Haag A, Elrufay R, Cheema T, et al. IDCases. 2020;20.
487. **Determination of host proteins composing the microenvironment of coronavirus replicase complexes by proximity-labeling.** V'Kovski P, Gerber M, Kelly J, Pfaender S, Ebert N, Braga Lagache S, et al. eLife. 2019;8.
488. **Focal status epilepticus as unique clinical feature of COVID-19: A case report.** Vollono C, Rollo E, Romozzi M, Frisullo G, Servidei S, Borghetti A, et al. Seizure. 2020;78:109-12.
489. **Stilbene-based Natural Compounds as Promising Drug Candidates against COVID-19.** Wahedi HM, Ahmad S, Abbasi SW. Journal of Biomolecular Structure and Dynamics. 2020:1-16.
490. **Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated.** Wambier CG, Goren A. Journal of the American Academy of Dermatology. 2020.
491. **Two cases report of epidemic stress disorder to novel coronavirus pneumonia.** Wang C, Zhou J, Zong C. Asian Journal of Psychiatry. 2020;51.
492. **The laboratory tests and host immunity of COVID-19 patients with different severity of illness.** Wang F, Hou H, Luo Y, Tang G, Wu S, Huang M, et al. JCI insight. 2020.
493. **Characteristic CT findings distinguishing 2019 novel coronavirus disease (COVID-19) from influenza pneumonia.** Wang H, Wei R, Rao G, Zhu J, Song B. European Radiology. 2020.
494. **Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study.** Wang J. Journal of chemical information and modeling. 2020.
495. **Tissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series.** Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, et al. Journal of Thrombosis and Haemostasis. 2020.
496. **Epidemiologic and clinical characteristics of 26 cases of covid-19 arising from patient-to-patient**

- transmission in liaocheng, china.** Wang L, Duan Y, Zhang W, Liang J, Xu J, Zhang Y, et al. *Clinical Epidemiology*. 2020;12:387-91.
497. **A precision medicine approach to managing 2019 novel coronavirus pneumonia.** Wang M, Zhou Y, Zong Z, Liang Z, Cao Y, Tang H, et al. *Precision Clinical Medicine*. 2020;3(1):14-21.
498. **A preliminary assessment of the impact of COVID-19 on environment – A case study of China.** Wang Q, Su M. *Science of the Total Environment*. 2020;728.
499. **COVID-19 in Hemodialysis Patients: A Report of 5 Cases.** Wang R, Liao C, He H, Hu C, Wei Z, Hong Z, et al. *American Journal of Kidney Diseases*. 2020.
500. **A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia.** Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P, et al. *Signal Transduction and Targeted Therapy*. 2020;5(1):1-3.
501. **Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak.** Wang Y, Kang H, Liu X, Tong Z. *Journal of Medical Virology*. 2020;92(6):538-9.
502. **Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures.** Wang Y, Wang Y, Chen Y, Qin Q. *Journal of Medical Virology*. 2020;92(6):568-76.
503. **Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.** Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. *The Lancet*. 2020.
504. **Updating the diagnostic criteria of COVID-19 "suspected case" and "confirmed case" is necessary.** Wang YY, Jin YH, Ren XQ, Li YR, Zhang XC, Zeng XT, et al. *Military Medical Research*. 2020;7(1).
505. **2019_nCoV/SARS-CoV-2: rapid classification of betacoronaviruses and identification of Traditional Chinese Medicine as potential origin of zoonotic coronaviruses.** Wassenaar TM, Zou Y. *Letters in Applied Microbiology*. 2020;70(5):342-8.
506. **Obesity and SARS-CoV-2: a population to safeguard.** Watanabe M, Risi R, Tuccinardi D, Baquero CJ, Manfrini S, Gnassi L. *Diabetes/metabolism research and reviews*. 2020:e3325.
507. **Corticosteroids for Urological Cancer Care During Coronavirus Disease 2019. Treat or Not to Treat?** Waterhouse JV, Hull JH, Linch M. *European Urology*. 2020.
508. **Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients.** Wax RS, Christian MD. *Canadian Journal of Anesthesia*. 2020;67(5):568-76.
509. **Diarrhea is associated with prolonged symptoms and viral carriage in COVID-19.** Wei XS, Wang X, Niu YR, Ye LL, Peng WB, Wang ZH, et al. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. 2020.
510. **A cluster of health care workers with COVID-19 pneumonia caused by SARS-CoV-2.** Wei XS, Wang XR, Zhang JC, Yang WB, Ma WL, Yang BH, et al. *Journal of Microbiology, Immunology and Infection*. 2020.
511. **COVID-19 and Calcineurin Inhibitors: Should They Get Left Out in the Storm?** Willicombe M, Thomas D, McAdoo S. *Journal of the American Society of Nephrology : JASN*. 2020.
512. **Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus,**

COVID-19/SARS-CoV-2. Willis MD, Robertson NP. *J Neurol.* 2020;267(5):1567-9.
<http://dx.doi.org/10.1007/s00415-020-09822-3>.

513. **Modulation of Hb-O₂ affinity to improve hypoxemia in COVID-19 patients.** Woyke S, Rauch S, Ströhle M, Gatterer H. *Clinical Nutrition.* 2020.

514. **Discontinuation of antiviral drugs may be the reason for recovered COVID-19 patients testing positive again.** Wu F, Zhang W, Zhang L, Wang D, Wan Y. *British journal of hospital medicine (London, England : 2005).* 2020;81(4):1-2. <http://dx.doi.org/10.12968/hmed.2020.0156>. Epub 2020 Apr 21.

515. **Detection and analysis of nucleic acid in various biological samples of COVID-19 patients.** Wu J, Liu J, Li S, Peng Z, Xiao Z, Wang X, et al. *Travel medicine and infectious disease.* 2020:101673.

516. **Progress and Concept for COVID-19 Vaccine Development.** Wu SC. *Biotechnology journal.* 2020:e2000147.

517. **Serological tests facilitate identification of asymptomatic SARS-CoV-2 infection in Wuhan, China.** Wu X, Fu B, Chen L, Feng Y. *Journal of medical virology.* 2020.

518. **Clinical features and outcome of treatment for novel coronavirus pneumonia: a meta-analysis.** Wu YY, Li HY, Xu XB, Zheng KX, Qi XS, Guo XZ. *Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.* 2020;28(3):240-6.

519. **Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults.** Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. *Pediatric Pulmonology.* 2020;55(5):1169-74.

520. **Antibody Detection and Dynamic Characteristics in Patients with COVID-19.** Xiang F, Wang X, He X, Peng Z, Yang B, Zhang J, et al. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2020.

521. **Evidence for Gastrointestinal Infection of SARS-CoV-2.** Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. *Gastroenterology.* 2020;158(6):1831-3.e3.

522. **Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: Myth or reality?** Xie W, Wang Y, Zhang Z. *Annals of the Rheumatic Diseases.* 2020.

523. **Clinical Pathway for Early Diagnosis of COVID-19: Updates from Experience to Evidence-Based Practice.** Xu G, Yang Y, Du Y, Peng F, Hu P, Wang R, et al. *Clinical Reviews in Allergy and Immunology.* 2020.

524. **Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19.** Xu T, Chen C, Zhu Z, Cui M, Chen C, Dai H, et al. *International Journal of Infectious Diseases.* 2020;94:68-71.

525. **Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding.** Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, et al. *Nature Medicine.* 2020;26(4):502-5.

526. **Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells.** Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, et al. *Respiratory Investigation.* 2020;58(3):155-68.

527. **Ensuring global access to COVID-19 vaccines.** Yamey G, Schäferhoff M, Hatchett R, Pate M, Zhao F, McDade KK. *The Lancet.* 2020;395(10234):1405-6.

528. **Role of Drugs Affecting the Renin-Angiotensin-Aldosterone System on Susceptibility and Severity of COVID-19: A Large Case-Control Study from Zhejiang Province, China.** Yan H, Valdes AM, Vijay A, Wang S, Liang

L, Yang S, et al. medRxiv. 2020.

529. **Coronavirus disease 2019: reassembly attack of coronavirus.** Yang C, Qiu X, Fan H, Jiang M, Lao X, Zeng Y, et al. *International Journal of Environmental Health Research*. 2020.
530. **The role of essential organ-based comorbidities in the prognosis of COVID-19 infection patients.** Yang R, Gui X, Zhang Y, Xiong Y. *Expert review of respiratory medicine*. 2020:1-4.
<http://dx.doi.org/10.1080/17476348.2020.1761791>.
531. **Combining point-of-care diagnostics and internet of medical things (IOMT) to combat the Covid-19 pandemic.** Yang T, Gentile M, Shen CF, Cheng CM. *Diagnostics*. 2020;10(4).
532. **Facing the COVID-19 outbreak: What should we know and what could we do?** Yang Y, Shang W, Rao X. *Journal of Medical Virology*. 2020;92(6):536-7.
533. **The effects and management of viral pneumonia on lung cancer patients.** Yao Y, Lu M, Liu Y, Cao B. *Chinese Journal of Lung Cancer*. 2020;23(4):255-60.
534. **Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents.** Yaqinuddin A, Kashir J. *Medical Hypotheses*. 2020;140.
535. **[Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].** Ye ZW, Jin DY. *Sheng wu gong cheng xue bao = Chinese journal of biotechnology*. 2020;36(4):571-92.
<http://dx.doi.org/10.13345/j.cjb.200115>.
536. **Vytr hypothesis for the prophylactic and therapeutic efficacy of GS-5734 treatment in humans with COVID-19.** Yethindra V, Dzhangazieva A, Kurzhunbaeva Z, Tagaev T, Nazami F. *International Journal of Research in Pharmaceutical Sciences*. 2020;11:19-22.
537. **Genotyping coronavirus SARS-CoV-2: methods and implications.** Yin C. *Genomics*. 2020.
538. **Evaluation of the auxiliary diagnostic value of antibody assays for the detection of novel coronavirus (SARS-CoV-2).** Yong G, Yi Y, Tuantuan L, Xiaowu W, Xiuyong L, Ang L, et al. *Journal of medical virology*. 2020.
539. **Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients.** Yongchen Z, Shen H, Wang X, Shi X, Li Y, Yan J, et al. *Emerging microbes & infections*. 2020:1-14.
540. **Lessons unfolding from pediatric cases of COVID-19 disease caused by SARS-CoV-2 infection.** Yonker LM, Shen K, Kinane TB. *Pediatric Pulmonology*. 2020;55(5):1085-6.
541. **Caution should be exercised for the detection of SARS-CoV-2, especially in the elderly.** Yuan Y, Wang N, Ou X. *Journal of Medical Virology*. 2020.
542. **Maternal and perinatal outcomes with COVID-19: A systematic review of 108 pregnancies.** Zaigham M, Andersson O. *Acta Obstetrica et Gynecologica Scandinavica*. 2020.
543. **Diagnostic performance of COVID-19 serology assays.** Zainol Rashid Z, Othman SN, Abdul Samat MN, Ali UK, Wong KK. *The Malaysian journal of pathology*. 2020;42(1):13-21.
544. **Delirium and sleep disturbances in COVID-19: a possible role for melatonin in hospitalized patients?** Zambrelli E, Canevini M, Gambini O, D'Agostino A. *Sleep Medicine*. 2020;70:111.
545. **Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with**

- COVID-19 ARDS in Milan, Italy.** Zangrillo A, Beretta L, Scandroglio AM, Monti G, Fominskiy E, Colombo S, et al. *Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.* 2020.
546. **Presepsin in risk stratification of SARS-CoV-2 patients.** Zaninotto M, Mion MM, Cosma C, Rinaldi D, Plebani M. *Clinica Chimica Acta.* 2020;507:161-3.
547. **Does high cardiorespiratory fitness confer some protection against pro-inflammatory responses after infection by SARS-CoV-2?** Zbinden-Foncea H, Francaux M, Deldicque L, Hawley JA. *Obesity (Silver Spring, Md).* 2020.
548. **Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines.** Zhai Z, Li C, Chen Y, Gerotziafas G, Zhang Z, Wan J, et al. *Thrombosis and haemostasis.* 2020.
549. **Reply to “The use of traditional Chinese medicines to treat SARS-CoV-2 may cause more harm than good”.** Zhang AH, Ren JL, Wang XJ. *Pharmacological Research.* 2020;157.
550. **Asymptomatic carriers of COVID-19 as a concern for disease prevention and control: more testing, more follow-up.** Zhang J, Wu S, Xu L. *Bioscience trends.* 2020.
551. **Predictive factors for disease progression in hospitalized patients with coronavirus disease 2019 in Wuhan, China.** Zhang J, Yu M, Tong S, Liu LY, Tang LV. *Journal of Clinical Virology.* 2020;127.
552. **Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors.** Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. *Science.* 2020;368(6489):409-12. <http://dx.doi.org/10.1126/science.abb3405>. Epub 2020 Mar 20.
553. **Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors.** Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. *Science.* 2020;368(6489):409-12.
554. **Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19.** Zhang L, Pang R, Xue X, Bao J, Ye S, Dai Y, et al. *Aging.* 2020;12.
555. **D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19.** Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. *Journal of thrombosis and haemostasis : JTH.* 2020.
556. **Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.** Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. *Annals of Oncology.* 2020.
557. **The novel coronavirus (COVID-19) pneumonia with negative detection of viral ribonucleic acid from nasopharyngeal swabs: a case report.** Zhang P, Cai Z, Wu W, Peng L, Li Y, Chen C, et al. *BMC Infect Dis.* 2020;20(1):317. <http://dx.doi.org/10.1186/s12879-020-05045-z>.
558. **The evidence of SARS-CoV-2 infection on ocular surface.** Zhang X, Chen X, Chen L, Deng C, Zou X, Liu W, et al. *Ocular Surface.* 2020;18(3):360-2.
559. **Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?** Zhao H, Shen D, Zhou H, Liu J, Chen S. *The Lancet Neurology.* 2020;19(5):383-4.
560. **Management strategy for the resumption of regular diagnosis and treatment in gastrointestinal surgery department during the outbreak of coronavirus disease 2019 (COVID-19).** Zhen L, Lin T, Zhao ML, Chen H, Chen T, Guo WH, et al. *Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery.* 2020;23(4):321-6.
561. **Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province,**

- China, January-March 2020: retrospective cohort study.** Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. *BMJ* (Clinical research ed). 2020;369:m1443.
562. **Reply to: 'Interaction between RAAS inhibitors and ACE2 in the context of COVID-19'.** Zheng YY, Ma YT, Zhang JY, Xie X. *Nature Reviews Cardiology*. 2020;17(5):313-4.
563. **Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis.** Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. *Journal of Infection*. 2020.
564. **Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies.** Zhou G, Chen S, Chen Z. *Frontiers of medicine*. 2020.
565. **Clinical and Autoimmune Characteristics of Severe and Critical Cases with COVID-19.** Zhou Y, Han T, Chen J, Hou C, Hua L, He S, et al. *Clinical and translational science*. 2020.
566. **CT imaging features of 4,121 patients with COVID-19: a meta-analysis.** Zhu J, Zhong Z, Li H, Ji P, Pang J, Li B, et al. *Journal of medical virology*. 2020.
567. **Analysis of selective endoscopy results during the epidemic of coronavirus disease 2019 (COVID-19).** Zhu L, Cai MY, Shi Q, Wang P, Li QL, Zhong YS, et al. *Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery*. 2020;23(4):327-31.
568. **Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak.** Zingone F, Buda A, Savarino EV. *Digestive and Liver Disease*. 2020.
569. **The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic.** Zuniga JM, Cortes A. *Expert review of medical devices*. 2020.

Update tot 30-04-2020

1. **The race against COVID-19.** Nature nanotechnology. 2020;15(4):239-40.
<http://dx.doi.org/10.1038/s41565-020-0680-y>.
2. **Some drugs for COVID-19.** The Medical letter on drugs and therapeutics. 2020;62(1595):49-50.
3. **Comment on "COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action".** Abdelmaksoud A, Goldust M, Vestita M. Dermatologic Therapy. 2020.
4. **A critical appraisal of COVID-19 in Malaysia and beyond.** Abdullah JM, Wan Ismail WFN, Mohamad I, Ab Razak A, Harun A, Musa KI, et al. Malaysian Journal of Medical Sciences. 2020;27(2):1-9.
5. **Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients.** Acanfora D, Ciccone MM, Scicchitano P, Acanfora C, Casucci G. European heart journal Cardiovascular pharmacotherapy. 2020.
6. **Grand Challenge in Human/Animal Virology: Unseen, Smallest Replicative Entities Shape the Whole Globe.** Adachi A. Frontiers in Microbiology. 2020;11.
7. **Covid-19 outbreak and perspective in morocco.** Addi RA, Benksim A, Amine M, Cherkaoui M. Electronic Journal of General Medicine. 2020;17(4).
8. **Cardiac involvement in COVID-19 patients: Risk factors, predictors, and complications: A review.** Aghagoli G, Gallo Marin B, Soliman LB, Sellke FW. Journal of Cardiac Surgery. 2020.
9. **Small-molecule antiviral β -d-n4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance.** Agostini ML, Puijssers AJ, Chappell JD, Gribble J, Lu X, Andres EL, et al. Journal of Virology. 2019;93(24).
10. **An alternative approach to minimize the risk of coronavirus (Covid-19) and similar infections.** Ahmad A, Rehman MU, Alkharfy KM. European review for medical and pharmacological sciences. 2020;24(7):4030-4.
http://dx.doi.org/10.26355/eurrev_202004_20873.
11. **Amiodarone as a possible therapy for coronavirus infection.** Aimo A, Baritussio A, Emdin M, Tascini C. European Journal of Preventive Cardiology. 2020.
12. **Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy.** Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. Kidney International Reports. 2020.
13. **Acute respiratory distress syndrome secondary to radiotherapy for breast cancer: A case report.** Alhaddad JB, Bleibel JZ, Hoteit M, Harb SB, Haddad YB. American Journal of Case Reports. 2020;21.
14. **Non-cutaneous considerations of COVID19 for dermatology practices.** Ali FR, Al-Niaimi F. Journal of cosmetic dermatology. 2020.
15. **Chloroquine and COVID-19: A light at the end of the tunnel, or is it another train?** Aljofan M, Gaipov A. Electronic Journal of General Medicine. 2020;17(4).
16. **Can companion animals become infected with Covid-19?** Almendros A, Gascoigne E. Veterinary Record. 2020;186(13):419-20.
17. **Cocirculation of Four Infectious Bronchitis Virus Lineages in Broiler Chickens in the Eastern Region of**

Saudi Arabia from 2012 to 2014. Al-Mubarak AIA, Al-Kubati AAG. *Veterinary Medicine International*. 2020;2020.

18. **Spectrum of histopathological findings in coronavirus disease-19, Middle East respiratory syndrome and severe acute respiratory syndrome.** Alsaad K, Arabi Y, Hajeer A. *Annals of Thoracic Medicine*. 2020;15(2):52-3.
19. **Covid-19 - Knowledge, attitude and practice among medical and non-medical university students in Jordan.** Alzoubi H, Alnawaiseh N, Al-Mnayyis A, Abu-Lubad M, Aqel A, Al-Shagahin H. *Journal of Pure and Applied Microbiology*. 2020;14(1):17-24.
20. **Bariatric Surgical Practice During the Initial Phase of COVID-19 Outbreak.** Aminian A, Kermansaravi M, Azizi S, Alibeigi P, Safamanesh S, Mousavimaleki A, et al. *Obesity Surgery*. 2020.
21. **Melatonin: Roles in influenza, Covid-19, and other viral infections.** Anderson G, Reiter RJ. *Reviews in Medical Virology*. 2020.
22. **Clinical trials for coronavirus disease 2019: What is being evaluated and what is not.** Arabi Y, Asseri A, Webb S, Marshall J, Al Moamary M. *Annals of Thoracic Medicine*. 2020;15(2):49-51.
23. **The outbreak of Coronavirus Disease 2019 (COVID-19)—An emerging global health threat.** Arshad Ali S, Baloch M, Ahmed N, Arshad Ali A, Iqbal A. *Journal of Infection and Public Health*. 2020;13(4):644-6.
24. **COVID-19 outbreak: Challenges for Addiction services in India.** Arya S, Gupta R. *Asian Journal of Psychiatry*. 2020;51.
25. **COVID-19 Drug Discovery Using Intensive Approaches.** Asai A, Konno M, Ozaki M, Otsuka C, Vecchione A, Arai T, et al. *International journal of molecular sciences*. 2020;21(8). <http://dx.doi.org/10.3390/ijms21082839>.
26. **Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.** Ascierto PA, Fox B, Urba W, Anderson AC, Atkins MB, Borden EC, et al. *Journal for immunotherapy of cancer*. 2020;8(1).
27. **Thoughts on COVID-19 and autoimmune diseases.** Askanase AD, Khalili L, Buyon JP. *Lupus Science and Medicine*. 2020;7(1).
28. **N-acetyl-cysteine may prevent COVID-19-associated cytokine storm and acute respiratory distress syndrome.** Assimakopoulos SF, Marangos M. *Medical Hypotheses*. 2020;140.
29. **Is glucose-6-phosphate dehydrogenase enzyme deficiency a factor in Coronavirus-19 (COVID-19) infections and deaths?** Aydemir D, Ulusu NN. *Pathogens and global health*. 2020:1-2.
30. **Saliva is a reliable tool to detect SARS-CoV-2.** Azzi L, Carcano G, Gianfagna F, Grossi P, Gasperina DD, Genoni A, et al. *Journal of Infection*. 2020.
31. **Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.** Bachanova V, Bishop MR, Dahi P, Dholaria B, Grupp SA, Hayes-Lattin B, et al. *Biology of Blood and Marrow Transplantation*. 2020.
32. **Understanding SARS-CoV-2: Genetic Diversity, Transmission and Cure in Human.** Bajaj A, Purohit HJ. *Indian Journal of Microbiology*. 2020.
33. **Peri-operative and critical care concerns in coronavirus pandemic.** Bajwa S, Sarna R, Bawa C, Mehdiratta L. *Indian Journal of Anaesthesia*. 2020;64(4):267-74.
34. **Novel Insights Into Immune Systems of Bats.** Banerjee A, Baker ML, Kulcsar K, Misra V, Plowright R, Mossman K. *Frontiers in Immunology*. 2020;11.

35. **Coronavirus Disease 2019 (COVID-19) CT Findings: A Systematic Review and Meta-analysis.** Bao C, Liu X, Zhang H, Li Y, Liu J. *Journal of the American College of Radiology : JACR.* 2020.
36. **Mesenchymal stromal cell secretome for severe covid-19 infections: Premises for the therapeutic use.** Bari E, Ferrarotti I, Saracino L, Perteghella S, Torre ML, Corsico AG. *Cells.* 2020;9(4).
37. **SARS-Cov-2 in Spanish Intensive Care: Early Experience with 15-day Survival In Vitoria.** Barrasa H, Rello J, Tejada S, Martín A, Balziskueta G, Vinuesa C, et al. *Anaesthesia, critical care & pain medicine.* 2020.
38. **Deciphering the innate immune response elicited by viral vaccine vectors against emerging infectious diseases.** Bartels E, Dahlke C, Fiozzi Assagba G, Zinser ME, Fathi A, Lassen S, et al. *European Journal of Immunology.* 2019;49:132-3.
39. **The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States.** Bartsch SM, Ferguson MC, McKinnell JA, O'Shea KJ, Wedlock PT, Siegmund SS, et al. *Health affairs (Project Hope).* 2020:101377hlthaff202000426. <http://dx.doi.org/10.1377/hlthaff.2020.00426>.
40. **Correlation between climate indicators and COVID-19 pandemic in New York, USA.** Bashir MF, Ma B, Bilal, Komal B, Bashir MA, Tan D, et al. *Science of the Total Environment.* 2020;728.
41. **The Royal College of Pathologists of Australasia (RCPA) position statement on COVID-19.** Bastian I, Waring L. *Australian journal of general practice.* 2020;49.
42. **Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity.** Bauman JL, Tisdale JE. *Pharmacotherapy.* 2020.
43. **Chloroquine and Hydroxychloroquine in the Era of SARS – CoV2: Caution on Their Cardiac Toxicity.** Bauman JL, Tisdale JE. *Pharmacotherapy.* 2020.
44. **Covid-19: Testing times.** Beeching NJ, Fletcher TE, Beadsworth MBJ. *The BMJ.* 2020;369.
45. **The old but new: Can unfractionated heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?** Belen-Apak FB, Sarialioglu F. *Med Hypotheses.* 2020;142:109743. <http://dx.doi.org/10.1016/j.mehy.2020.109743>.
46. **Clozapine prescription in the wake of the coronavirus (SARS CoV-2) outbreak: What measures? Why?** Ben Dhia A, Hamzaoui S, Mouaffak F. *Encephale.* 2020.
47. **Good IgA bad IgG in SARS-CoV-2 infection?** Béné MC, de Carvalho M, Eveillard M, Lebri Y. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2020.
48. **Old and new antirheumatic drugs for the treatment of COVID-19.** Benucci M, Damiani A, Infantino M, Manfredi M, Quartuccio L. *Joint Bone Spine.* 2020;87(3):195-7.
49. **Interim Guidance for the use of Tocilizumab in the Management of Patients who have Severe COVID-19 with Suspected Hyperinflammation [v3. 0].** Bergin C, Browne P, Murray P, O'Dwyer M, Conlon N, Kane D, et al. 2020.
50. **Recent apprise on coronavirus and its terrible insinuations.** Bhattacharya S, Sharma P, Mathur H, Rasheed H, Singh S, Rajput G, et al. *VirusDisease.* 2020.
51. **HLA allele repertoire in Russian CLL patients with an unfavorable prognosis.** Biderman BV, Likold EB, Abdrakhimova AR, Leonov EA, Khamaganova EG, Sudarikov AB. *HLA.* 2020;95(4):409.

52. **2019-NCOV/COVID-19 - Approaches to viral vaccine development and preventive measures.** Bilal M, Nazir MS, Parra-Saldivar R, Iqbal HMN. *Journal of Pure and Applied Microbiology*. 2020;14(1):25-9.
53. **Adalimumab for Treatment of Hidradenitis Suppurativa During the COVID-19 Pandemic: Safety Considerations.** Blaszcak A, Trinidad JCL, Cartron AM. *Journal of the American Academy of Dermatology*. 2020.
54. **Angiotensin-Converting Enzyme 2 as the Molecular Bridge Between Epidemiologic and Clinical Features of COVID-19.** Bombardini T, Picano E. *The Canadian journal of cardiology*. 2020.
55. **Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.** Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. *JAMA network open*. 2020;3(4):e208857. <http://dx.doi.org/10.1001/jamanetworkopen.2020.8857>.
56. **Intravenous Vitamin C for reduction of cytokines storm in Acute Respiratory Distress Syndrome.** Boretti A, Banik BK. *PharmaNutrition*. 2020:100190. <http://dx.doi.org/10.1016/j.phanu.2020.100190>.
57. **Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.** Brownstone ND, Thibodeaux QG, Reddy VD, Myers BA, Chan SY, Bhutani T, et al. *Dermatology and Therapy*. 2020.
58. **Political Intrusions into the International Health Regulations Treaty and Its Impact on Management of Rapidly Emerging Zoonotic Pandemics: What History Tells Us.** Burkle FM. *Prehospital and disaster medicine*. 2020:1-18.
59. **The impact of nutrition on COVID-19 susceptibility and long-term consequences.** Butler MJ, Barrientos RM. *Brain, Behavior, and Immunity*. 2020.
60. **Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?** Cadejani FA. *American journal of physiology Endocrinology and metabolism*. 2020;318(5):E587-E8.
61. **COVID-19 in a designated infectious diseases hospital outside Hubei Province, China.** Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. *Allergy: European Journal of Allergy and Clinical Immunology*. 2020.
62. **COVID-19 in the perioperative period of lung resection: a brief report from a single thoracic surgery department in Wuhan, China.** Cai Y, Hao Z, Gao Y, Ping W, Wang Q, Peng S, et al. *Journal of thoracic oncology* : official publication of the International Association for the Study of Lung Cancer. 2020.
63. **Molecular investigation of SARS-COV-2 proteins and their interactions with antiviral drugs.** Calligari P, Bobone S, Ricci G, Bocedi A. *Viruses*. 2020;12(4).
64. **Coronavirus disease 2019 (COVID-19) pandemic burst and its relevant consequences in dental practice.** Cantore S, Ballini A. *Open Dentistry Journal*. 2020;14(1):111-2.
65. **Clinical and imaging manifestations of familial clustering corona virus disease 2019.** Cao L, Li W, Yu H, An W, Li H, Dong J. *Chinese Journal of Medical Imaging Technology*. 2020;36(3):415-9.
66. **High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019.** Cao W, Liu X, Bai T, Fan H, Hong K, Song H, et al. *Open Forum Infectious Diseases*. 2020;7(3):1-6.
67. **Management of orthodontic emergencies during 2019-NCOV.** Caprioglio A, Pizzetti GB, Zecca PA,

Fastuca R, Maino G, Nanda R. Progress in Orthodontics. 2020;21(1).

68. **COVID-19: A recommendation to examine the effect of mouthrinses with β -cyclodextrin combined with citrox in preventing infection and progression.** Carrouel F, Conte MP, Fisher J, Gonçalves LS, Dussart C, Llodra JC, et al. Journal of Clinical Medicine. 2020;9(4).

69. **Considerations for obesity, vitamin D, and physical activity amidst the COVID-19 pandemic.** Carter SJ, Baranauskas MN, Fly AD. Obesity (Silver Spring, Md). 2020.

70. **Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab.** Cellina M, Orsi M, Bombaci F, Sala M, Marino P, Oliva G. Diagnostic and Interventional Imaging. 2020.

71. **COVID-19 and diabetes management: What should be considered?** Ceriello A, Stoian AP, Rizzo M. Diabetes Research and Clinical Practice. 2020;163.

72. **Electrochemical biosensors for pathogen detection.** Cesewski E, Johnson BN. Biosensors and Bioelectronics. 2020;159.

73. **COVID-19 outbreak: Migration, effects on society, global environment and prevention.** Chakraborty I, Maity P. Science of the Total Environment. 2020;728.

74. **Cleaning and Disinfectant Chemical Exposures and Temporal Associations with COVID-19 - National Poison Data System, United States, January 1, 2020-March 31, 2020.** Chang A, Schnall AH, Law R, Bronstein AC, Marraffa JM, Spiller HA, et al. MMWR Morbidity and mortality weekly report. 2020;69(16):496-8. <http://dx.doi.org/10.15585/mmwr.mm6916e1>.

75. **Middle East respiratory syndrome coronavirus nucleocapsid protein suppresses type I and type III interferon induction by targeting RIG-I signaling.** Chang CY, Liu HM, Chang MF, Chang SC. Journal of virology. 2020.

76. **Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated with Hydroxychloroquine and/or Azithromycin.** Chang D, Saleh M, Gabriels J, Ismail H, Goldner B, Willner J, et al. Journal of the American College of Cardiology. 2020. <http://dx.doi.org/10.1016/j.jacc.2020.04.032>.

77. **Clinical characteristics and diagnostic challenges of pediatric COVID-19: A systematic review and meta-analysis.** Chang TH, Wu JL, Chang LY. Journal of the Formosan Medical Association. 2020.

78. **Porcine epidemic diarrhea virus infection activates proinflammatory responses via the NOD2 signaling pathway.** Chen J, Yan M, Liu G, Jin L. European Journal of Immunology. 2019;49:60-1.

79. **The clinical and immunological features of pediatric COVID-19 patients in China.** Chen J, Zhang ZZ, Chen YK, Long QX, Tian WG, Deng HJ, et al. Genes and Diseases. 2020.

80. **Genomics functional analysis and drug screening of SARS-CoV-2.** Chen L, Zhong L. Genes and Diseases. 2020.

81. **A familial cluster, including a kidney transplant recipient, of Coronavirus Disease 2019 (COVID-19) in Wuhan, China.** Chen S, Yin Q, Shi H, Du D, Chang S, Ni L, et al. American Journal of Transplantation. 2020.

82. **Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study.** Chen T, Dai Z, Mo P, Li X, Ma Z, Song S, et al. The journals of gerontology Series A, Biological sciences and medical sciences. 2020.

83. **Computational Identification of Small Interfering RNA Targets in SARS-CoV-2.** Chen W, Feng P, Liu K,

Wu M, Lin H. *Virologica Sinica*. 2020.

84. **Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19.** Chen WH, Hotez PJ, Bottazzi ME. *Human Vaccines and Immunotherapeutics*. 2020.
85. **A diagnostic model for coronavirus disease 2019 (COVID-19) based on radiological semantic and clinical features: a multi-center study.** Chen X, Tang Y, Mo Y, Li S, Lin D, Yang Z, et al. *European Radiology*. 2020.
86. **Detectable serum SARS-CoV-2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients.** Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
87. **Infants Born to Mothers With a New Coronavirus (COVID-19).** Chen Y, Peng H, Wang L, Zhao Y, Zeng L, Gao H, et al. *Frontiers in Pediatrics*. 2020;8.
88. **Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.** Cheng CY, Lee YL, Chen CP, Lin YC, Liu CE, Liao CH, et al. *Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi*. 2020. <http://dx.doi.org/10.1016/j.jmii.2020.03.032>.
89. **Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)?** Cheng RZ. *Medicine in Drug Discovery*. 2020;5.
90. **The role of community-wide wearing of face mask for control of coronavirus disease 2019 (COVID-19) epidemic due to SARS-CoV-2.** Cheng VCC, Wong SC, Chuang VWM, So SYC, Chen JHK, Sridhar S, et al. *J Infect*. 2020. <http://dx.doi.org/10.1016/j.jinf.2020.04.024>.
91. **Disinfection of N95 respirators by ionized hydrogen peroxide during pandemic coronavirus disease 2019 (COVID-19) due to SARS-CoV-2.** Cheng VCC, Wong SC, Kwan GSW, Hui WT, Yuen KY. *Journal of Hospital Infection*. 2020.
92. **Harnessing the immune system via FcγR function in immune therapy: a pathway to next-gen mAbs.** Chenoweth AM, Wines BD, Anania JC, Mark Hogarth P. *Immunology and cell biology*. 2020;98(4):287-304. <http://dx.doi.org/10.1111/imcb.12326>. Epub 2020 Apr 12.
93. **Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance.** Choudhary R, Sharma AK, Choudhary R. *New microbes and new infections*. 2020:100684. <http://dx.doi.org/10.1016/j.nmni.2020.100684>.
94. **One month of the novel coronavirus 2019 outbreak: Is it still a threat?** Chowdhury A, Jahan N, Wang S. *VirusDisease*. 2020.
95. **Defining Protective Epitopes for COVID-19 Vaccination Models.** Cimolai N. *Journal of medical virology*. 2020.
96. **Psoriasis and Psoriatic Arthritis: how to manage Immunosuppressants in COVID-19 days.** Coletto LA, Favalli EG, Caporali R. *Dermatologic therapy*. 2020:e13415.
97. **Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic.** Cure E, Cumhuri Cure M. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2020;14(4):349-50.
98. **Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis.** Cure E, Cumhuri Cure M. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2020;14(4):405-6.

99. **Cytosine drives evolution of SARS-CoV-2.** Danchin A, Marlière P. *Environmental microbiology*. 2020.
100. **Rapid and Severe Covid-19 Pneumonia with Severe Acute Chest Syndrome in a Sickle Cell Patient Successfully Treated with Tocilizumab.** De Luna G, Habibi A, Deux JF, Colard M, d'Alexandry d'Orengiani ALPH, Schlemmer F, et al. *American journal of hematology*. 2020.
101. **Covid-19, the pandemic war: Implication for neurologists.** de Seze J, Lebrun-Frenay C. *Revue Neurologique*. 2020;176(4):223-4.
102. **COVID-19 infections are also affected by human ACE1 D/I polymorphism.** Delanghe JR, Speeckaert MM, De Buyzere ML. *Clinical chemistry and laboratory medicine*. 2020.
103. **Personal safety during the covid-19 pandemic: Realities and perspectives of healthcare workers in latin America.** Delgado D, Quintana FW, Perez G, Liprandi AS, Ponte-Negretti C, Mendoza I, et al. *International Journal of Environmental Research and Public Health*. 2020;17(8).
104. **Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China.** Deng Q, Hu B, Zhang Y, Wang H, Zhou X, Hu W, et al. *International Journal of Cardiology*. 2020.
105. **Coronavirus diseases (COVID-19) current status and future perspectives: A narrative review.** Di Gennaro F, Pizzol D, Marotta C, Antunes M, Racalbutto V, Veronese N, et al. *International Journal of Environmental Research and Public Health*. 2020;17(8).
106. **Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection.** Di Giambenedetto S, Ciccullo A, Borghetti A, Gambassi G, Landi F, Visconti E, et al. *Journal of medical virology*. 2020.
107. **Biologics for psoriasis during COVID-19 outbreak.** Di Lernia V. *Journal of the American Academy of Dermatology*. 2020.
108. **SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment.** di Mauro G, Cristina S, Concetta R, Francesco R, Annalisa C. *International Immunopharmacology*. 2020;84.
109. **HRCT imaging features in representative imported cases of 2019 novel coronavirus pneumonia.** Diao K, Han P, Pang T, Li Y, Yang Z. *Precision Clinical Medicine*. 2020;3(1):9-13.
110. **Chest CT findings of COVID-19 pneumonia by duration of symptoms.** Ding X, Xu J, Zhou J, Long Q. *European Journal of Radiology*. 2020;127.
111. **Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience.** Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, et al. *European review for medical and pharmacological sciences*. 2020;24(7):4040-7. http://dx.doi.org/10.26355/eurrev_202004_20875.
112. **Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience.** Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, et al. *Eur Rev Med Pharmacol Sci*. 2020;24(7):4040-7.
113. **A new threat from an old enemy: Re-emergence of coronavirus (Review).** Docea AO, Tsatsakis A, Albulescu D, Cristea O, Zlatian O, Vinceti M, et al. *International Journal of Molecular Medicine*. 2020;45(6):1631-43.
114. **Rapid point-of-care testing for SARS-CoV-2 in a community screening setting shows low sensitivity.** Döhla M, Boesecke C, Schulte B, Diegmann C, Sib E, Richter E, et al. *Public Health*. 2020;182:170-2.

115. **Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19.** Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, Ferraz da Silva LF, Pierre de Oliveira E, Nascimento Saldiva PH, et al. *Journal of thrombosis and haemostasis : JTH.* 2020.
116. **Panton-Valentine Leukocidin-Secreting Staphylococcus aureus Pneumonia Complicating COVID-19.** Duployez C, Le Guern R, Tinez C, Lejeune AL, Robriquet L, Six S, et al. *Emerging infectious diseases.* 2020;26(8).
117. **COVID-19 as a factor influencing air pollution?** Dutheil F, Baker JS, Navel V. *Environmental Pollution.* 2020;263.
118. **Remdesivir: A Review of Its Discovery and Development Leading to Human Clinical Trials for Treatment of COVID-19.** Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. 2020.
119. **First COVID-19 infections in the Philippines: A case report.** Edrada EM, Lopez EB, Villarama JB, Salva Villarama EP, Dagoc BF, Smith C, et al. *Tropical Medicine and Health.* 2020;48(1).
120. **Ad hoc laboratory-based surveillance of SARS-CoV-2 by real-time RT-PCR using minipools of RNA prepared from routine respiratory samples.** Eis-Hübinger AM, Hönemann M, Wenzel JJ, Berger A, Widera M, Schmidt B, et al. *Journal of Clinical Virology.* 2020;127.
121. **Palliation in patients with severe COVID-19.** Ekström M, Dahlander B. *Lakartidningen.* 2020;117.
122. **SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: An in silico perspective.** Elfiky AA. *Journal of biomolecular structure & dynamics.* 2020:1-15. <http://dx.doi.org/10.1080/07391102.2020.1761882>.
123. **Coronavirus Vaccines: Light at the End of the Tunnel.** Ella KM, Mohan VK. *Indian pediatrics.* 2020.
124. **Occupational skin disease among health care workers during the coronavirus (COVID-19) epidemic.** Elston DM. *Journal of the American Academy of Dermatology.* 2020;82(5):1085-6.
125. **Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study.** Enayatkhani M, Hasaniazad M, Faezi S, Guklani H, Davoodian P, Ahmadi N, et al. *Journal of biomolecular structure & dynamics.* 2020:1-19.
126. **Severe COVID-19 infection associated with endothelial activation.** Escher R, Breakey N, Lämmle B. *Thrombosis Research.* 2020;190:62.
127. **Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19.** Fang X, Mei Q, Yang T, Li L, Wang Y, Tong F, et al. *The Journal of infection.* 2020.
128. **Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19.** Fang X, Mei Q, Yang T, Li L, Wang Y, Tong F, et al. *Journal of Infection.* 2020.
129. **The Impact of Online Information on Self-isolation Intention during the COVID-19 Pandemic: A cross-sectional study.** Farooq A, Laato S, Islam A. *Journal of medical Internet research.* 2020. <http://dx.doi.org/10.2196/19128>.
130. **Dapsone and doxycycline could be potential treatment modalities for COVID-19.** Farouk A, Salman S. *Medical Hypotheses.* 2020;140.
131. **Remdesivir in covid-19.** Ferner RE, Aronson JK. *Journal.* 2020(Issue).
132. **Routine blood tests as a potential diagnostic tool for COVID-19.** Ferrari D, Motta A, Strollo M, Banfi G, Locatelli M. *Clinical Chemistry and Laboratory Medicine.* 2020.

133. **New challenges in the COVID-19 pandemic.** Fiedorowicz JG. *Journal of Psychosomatic Research*. 2020;133.
134. **COVID-19 paranoia in a patient suffering from schizophrenic psychosis – a case report.** Fischer M, Coogan AN, Faltraco F, Thome J. *Psychiatry Research*. 2020;288.
135. **Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment.** Ford N, Vitoria M, Rangaraj A, Norris SL, Calmy A, Doherty M. *Journal of the International AIDS Society*. 2020;23(4):e25489.
136. **Management of Infantile Hemangiomas during the COVID Pandemic.** Frieden IJ, Püttgen KB, Drolet BA, Garzon MC, Chamlin SL, Pope E, et al. *Pediatric dermatology*. 2020.
137. **Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis.** Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. *Journal of Infection*. 2020.
138. **Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.** Funck-Brentano C, Salem JE, Nguyen LS, Drici MD, Roden DM. *Arch Cardiovasc Dis*. 2020. <http://dx.doi.org/10.1016/j.acvd.2020.04.001>.
139. **Increased expression of CD8 marker on T-cells in COVID-19 patients.** Ganji A, Farahani I, Khansarinejad B, Ghazavi A, Mosayebi G. *Blood Cells, Molecules, and Diseases*. 2020;83.
140. **Prognostic value of NT-proBNP in patients with severe COVID-19.** Gao L, Jiang D, Wen XS, Cheng XC, Sun M, He B, et al. *Respiratory research*. 2020;21(1):83.
141. **Acute leukemia in the time of COVID-19.** Gavillet M, Carr Klappert J, Spertini O, Blum S. *Leukemia Research*. 2020;92.
142. **Efficacy of remdesivir versus placebo for the treatment of COVID-19: A protocol for systematic review and meta-analysis of randomized controlled trials.** Gebrie D, Getnet D, Manyazewal T. *medRxiv*. 2020.
143. **Chloroquine as a prophylactic agent against COVID-19?** Gendrot M, Javelle E, Le Dault E, Clerc A, Savini H, Pradines B. *International Journal of Antimicrobial Agents*. 2020.
144. **Sinonasal pathophysiology of SARS-CoV-2 and COVID-19: A systematic review of the current evidence.** Gengler I, Wang JC, Speth MM, Sedaghat AR. *Laryngoscope Investigative Otolaryngology*. 2020.
145. **COVID-19 infection in Italian people with diabetes: Lessons learned for our future (an experience to be used).** Gentile S, Strollo F, Ceriello A. *Diabetes Research and Clinical Practice*. 2020;162.
146. **Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19.** Ghaffari S, Roshanravan N, Tutunchi H, Ostadrahimi A, Pouraghaei M, Kafil B. *Archives of Medical Research*. 2020.
147. **Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure.** Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al. *Cell Host and Microbe*. 2020.
148. **Advice Regarding Systemic Therapy in Patients with Urological Cancers During the COVID-19 Pandemic.** Gillessen S, Powles T. *European Urology*. 2020.
149. **Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy.**

Giordano G, Blanchini F, Bruno R, Colaneri P, Di Filippo A, Di Matteo A, et al. *Nature medicine*. 2020. <http://dx.doi.org/10.1038/s41591-020-0883-7>.

150. **Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19.** Giovannoni G. *Multiple Sclerosis and Related Disorders*. 2020;41.

151. **Covid-19: Weathering the storm.** Godlee F. *The BMJ*. 2020;368.

152. **Cardiac drugs and outcome in COVID-19: Reply.** Goldstein MR, Poland GA, Graeber CW. *QJM : monthly journal of the Association of Physicians*. 2020.

153. **A Tool to Early Predict Severe Corona Virus Disease 2019 (COVID-19) : A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China.** Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L, et al. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.

154. **Development of C-based single domain antibodies as therapeutic candidates against emerging viruses.** Gong R. *European Journal of Immunology*. 2019;49:1750.

155. **A preliminary observation: male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity.** Goren A, Vano-Galvan S, Wambier CG, McCoy J, Gomez-Zubiaur A, Moreno-Arrones OM, et al. *Journal of cosmetic dermatology*. 2020.

156. **The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm than good.** Gray PE, Belessis Y. *Pharmacological Research*. 2020;156.

157. **Managing ACS during COVID-19 infection: Do not follow the traditional route.** Guha S, Mukhopadhyay S, Karak A, Choudhury B, Kapoor A, Yadav R. *Indian Heart Journal*. 2020.

158. **Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India.** Gupta N, Agrawal S, Ish P, Mishra S, Gaiind R, Usha G, et al. *Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace*. 2020;90(1).

159. **Combating 2019-nCoV Amidst the Pandemic Scare.** Haider KH, Hyder Q. *Open Journal of Regenerative Medicine*. 2020;9(2):15.

160. **Graft cryopreservation does not impact overall survival allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide for GVHD prophylaxis.** Hamadani M, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra S, et al. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2020.

161. **CT morphology of COVID-19: Case report and review of literature.** Hamer OW, Salzberger B, Gebauer J, Stroszczyński C, Pfeifer M. *RoFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin*. 2020;192(5):386-92. <http://dx.doi.org/10.1055/a-1142-4094>. Epub 2020 Mar 26.

162. **Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China.** Han H, Xie L, Liu R, Yang J, Liu F, Wu K, et al. *Journal of Medical Virology*. 2020.

163. **Sequential analysis of viral load in a neonate and her mother infected with SARS-CoV-2.** Han MS, Seong MW, Heo EY, Park JH, Kim N, Shin S, et al. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.

164. **A Diabetic Patient With 2019-nCoV (COVID-19) Infection Who Recovered and Was Discharged From Hospital.** Han X, Fan Y, Wan YL, Shi H. *Journal of thoracic imaging*. 2020;35(3):W94-w5. <http://dx.doi.org/10.1097/RTI.0000000000000506>.

165. **Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2.** Han Y, Král P. ACS nano. 2020.
166. **Inappropriate Antibiotic Consumption as a Possible Cause of Inflammatory Storm and Septic Shock in Patients Diagnosed with Coronavirus Disease 2019 (COVID-19).** Hantoushzadeh S, Norooznezhad AH. Archives of Medical Research. 2020.
167. **Europe's migrant containment policies threaten the response to covid-19.** Hargreaves S, Kumar BN, McKee M, Jones L, Veizis A. The BMJ. 2020;368.
168. **Main Protease Inhibitors and Drug Surface Hotspot for the Treatment of COVID-19: Drug Repurposing and Molecular Docking Approach.** Hasan M, Parvez MSA, Azim KF, Imran AS, Raihan T, Gulshan A, et al. 2020.
169. **The clinical course and its correlated immune status in COVID-19 pneumonia.** He R, Lu Z, Zhang L, Fan T, Xiong R, Shen X, et al. Journal of Clinical Virology. 2020;127.
170. **COVID-19 in persons with haematological cancers.** He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. Leukemia. 2020. <http://dx.doi.org/10.1038/s41375-020-0836-7>.
171. **Mycophenolate Mofetil Is Active Against SARS-CoV-2 in Vero E6 Cells.** He Y, Pei R, Xu Z, Chen Z, Xiao S, Xia H, et al. 2020.
172. **On the alert for cytokine storm: Immunopathology in COVID-19.** Henderson LA, Canna SW, Schuler GS, Volpi S, Lee PY, Kernan KF, et al. Arthritis & rheumatology (Hoboken, NJ). 2020.
173. **Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis.** Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Clinical chemistry and laboratory medicine. 2020.
174. **Impact of the COVID-19 pandemic on therapeutic choices in Thrombosis-Hemostasis.** Hermans C, Lambert C. Journal of thrombosis and haemostasis : JTH. 2020.
175. **COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome.** Hirano T, Murakami M. Immunity. 2020.
176. **Environmental cleaning is effective for the eradication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in contaminated hospital rooms: A patient from the Diamond Princess cruise ship.** Hirotsu Y, Maejima M, Nakajima M, Mochizuki H, Omata M. Infection control and hospital epidemiology. 2020:1-8.
177. **New paths for sustainable solutions to tackle global and emerging infectious threats.** Holm A. Biologicals. 2020.
178. **Analysis and comparison of the tongue picture of 34 patients with severe acute respiratory syndrome.** Hong-jin W, Fan W, Bin W, Sheng-qi W, Xi-yin Z, Jun Y, et al. Chinese Journal of Integrative Medicine. 2004;10(2):112-6.
179. **Evaluation of the Efficacy and Safety of Intravenous Remdesivir in Adult Patients with Severe Pneumonia caused by COVID-19 virus Infection: study protocol for a Phase 3 Randomized, Double-blind, Placebo-controlled, Multicentre trial.** Horby PW, Cao B, Wang Y, Wang C. 2020.
180. **Chest low-dose CT in auxiliary diagnosis of corona virus disease 2019.** Hou Q, Shi N, Song F, Shi Y, Hua X, Shan F. Chinese Journal of Medical Imaging Technology. 2020;36(3):411-4.

181. **Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19.** Hu X, Xing Y, Jia J, Ni W, Liang J, Zhao D, et al. *Science of the Total Environment*. 2020;728.
182. **COVID-19 in posttransplant patients—report of 2 cases.** Huang J, Lin H, Wu Y, Fang Y, Kumar R, Chen G, et al. *American Journal of Transplantation*. 2020.
183. **A correlation study of CT and clinical features of different clinical types of COVID-19.** Huang L, Han R, Yu P, Wang S, Xia L. *Chinese Journal of Radiology (China)*. 2020;54(4):300-4.
184. **RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-2.** Huang WE, Lim B, Hsu CC, Xiong D, Wu W, Yu Y, et al. *Microbial biotechnology*. 2020. <http://dx.doi.org/10.1111/1751-7915.13586>.
185. **Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19.** Huang Z, Jiang Y, Chen J, Zhou Y. *Cardiology journal*. 2020.
186. **The emergence of novel-coronavirus and its replication cycle - An overview.** Iqbal HMN, Romero-Castillo KD, Bilal M, Parra-Saldivar R. *Journal of Pure and Applied Microbiology*. 2020;14(1):13-6.
187. **Emergence of deadly severe acute respiratory syndrome coronavirus-2 during 2019–2020.** Islam A, Ahmed A, Naqvi IH, Parveen S. *VirusDisease*. 2020.
188. **National Consumption of Antimalarial Drugs and COVID-19 Deaths Dynamics : an Ecological Study.** Izoulet M. *medRxiv*. 2020:2020.04.18.20063875.
189. **COVID-19 and vitamin D-Is there a link and an opportunity for intervention?** Jakovac H. *American journal of physiology Endocrinology and metabolism*. 2020;318(5):E589.
190. **Enhancing immunity in viral infections, with special emphasis on COVID-19: A review.** Jayawardena R, Sooriyaarachchi P, Chourdakis M, Jeewandara C, Ranasinghe P. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2020;14(4):367-82.
191. **Geospatial Mapping of Orthopaedic Surgeons Age 60 and Over and Confirmed Cases of COVID-19.** Jella TK, Acuna AJ, Samuel LT, Jella TK, Mroz TE, Kamath AF. *J Bone Joint Surg Am*. 2020. <http://dx.doi.org/10.2106/JBJS.20.00577>.
192. **Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy.** Jensen JD, Lynch M. *Heredity*. 2020;124(5):619-20. <http://dx.doi.org/10.1038/s41437-020-0314-z>. Epub 2020 Apr 6.
193. **Porcine deltacoronavirus activates the Raf/MEK/ERK pathway to promote its replication.** Jeon JH, Lee YJ, Lee C. *Virus Research*. 2020;283.
194. **Echoes of 2009 H1N1 Influenza Pandemic in the COVID Pandemic.** Jhaveri R. *Clinical Therapeutics*. 2020.
195. **CT appearances and short-term changes of COVID-19 in subclinical period.** Jiang N, Zheng C, Fan Y, Han X, Chen Y, Cheng Q, et al. *Chinese Journal of Radiology (China)*. 2020;54(4):305-9.
196. **Clinical and Dynamic Computed Tomography Features of 24 Patients With Coronavirus Disease 2019.** Jie B, Liu X, Suo H, Qiao G, Zheng Q, Xu W, et al. *Canadian Association of Radiologists Journal*. 2020.
197. **Novel coronavirus pneumonia emergency in Zhuhai: impact and challenges.** Jin H, Liu J, Cui M, Lu L. *Journal of Hospital Infection*. 2020;104(4):452-3.
198. **Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions.** Jogalekar MP, Veerabathini A, Gangadaran P. *Experimental Biology and Medicine*. 2020.

199. **What Is the Role of Angiotensin-Converting Enzyme 2 (ACE2) in COVID-19 Infection in Hypertensive Patients With Diabetes?** John TJ, John K. *The Canadian journal of cardiology*. 2020.
200. **Does COVID-19 Disprove the Obesity Paradox in ARDS?** Jose RJ, Manuel A. *Obesity (Silver Spring, Md)*. 2020.
201. **Two cases of coronavirus 2019–related cardiomyopathy in pregnancy.** Juusela A, Nazir M, Gimovsky M. *American Journal of Obstetrics and Gynecology MFM*. 2020.
202. **COVID-19: an Immunopathological View.** Kadkhoda K. *mSphere*. 2020;5(2). <http://dx.doi.org/10.1128/mSphere.00344-20>.
203. **Cell-Mediated Immunity Induced by two Recombinant Modified Vaccinia Virus Ankara Vaccines Delivering the G Antigen of Nipah Virus.** Kalodimou G, Veit S, Jany S, Lülfi-Averhoff AT, Sutter G, Volz A. *European Journal of Immunology*. 2019;49:129.
204. **Behavioral considerations and impact on personal protective equipment use: Early lessons from the coronavirus (COVID-19) pandemic.** Kantor J. *Journal of the American Academy of Dermatology*. 2020;82(5):1087-8.
205. **Risk of COVID-19 for patients with obesity.** Kassir R. *Obesity Reviews*. 2020.
206. **A systematic review of Anakinra, Tocilizumab, Sarilumab and Siltuximab for coronavirus-related infections.** Khan F, Fabbri L, Stewart I, Robinson K, Smyth AR, Jenkins G. *medRxiv*. 2020:2020.04.23.20076612.
207. **Ensemble Technique for Prediction of T-cell Mycobacterium tuberculosis Epitopes.** Khanna D, Rana PS. *Interdisciplinary sciences, computational life sciences*. 2019;11(4):611-27.
208. **Perceived risk of COVID-19 pandemic: The role of public worry and trust.** Khosravi M. *Electronic Journal of General Medicine*. 2020;17(4):1-2.
209. **COVID-19 outbreak: An elusive enemy.** Kikuchi T. *Respiratory Investigation*. 2020.
210. **The Architecture of SARS-CoV-2 Transcriptome.** Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H. *Cell*. 2020.
211. **Walk-Through Screening Center for COVID-19: an Accessible and Efficient Screening System in a Pandemic Situation.** Kim SI, Lee JY. *Journal of Korean medical science*. 2020;35(15):e154.
212. **Two distinct cases with COVID-19 in kidney transplant recipients.** Kim Y, Kwon O, Paek JH, Park WY, Jin K, Hyun M, et al. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2020. <http://dx.doi.org/10.1111/ajt.15947>.
213. **Middle East respiratory syndrome coronavirus (MERS-CoV) seropositive camel handlers in Kenya.** Kiyong'a AN, Cook EAJ, Okba NMA, Kivali V, Reusken C, Haagmans BL, et al. *Viruses*. 2020;12(4).
214. **Cardiac and arrhythmic complications in patients with COVID-19.** Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. *Journal of Cardiovascular Electrophysiology*. 2020.
215. **Position statement of expert panel of the Polish Allergology Society on the management of patients with bronchial asthma and allergic diseases during SARS-Cov-2 pandemics.** Kowalski ML, Bartuzi Z, Bręborowicz A, Czarnecka-Operacz M, Kruszewski J, Kulus M, et al. *Alergia Astma Immunologia*. 2020;25(1):2-7.
216. **Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 by WHO-Recommended Hand Rub**

Formulations and Alcohols. Kratzel A, Todt D, V'Kovski P, Steiner S, Gultom M, Thao TTN, et al. Emerging infectious diseases. 2020;26(7).

217. **Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19.** Kreutz R, Algharably EAEH, Azizi M, Dobrowolski P, Guzik T, Januszewicz A, et al. Cardiovascular research. 2020.

218. **Mast cells contribute to coronavirus-induced inflammation: New anti-inflammatory strategy.** Kritas SK, Ronconi G, Caraffa A, Gallenga CE, Ross R, Conti P. Journal of Biological Regulators and Homeostatic Agents. 2020;34(1):9-14.

219. **Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China [version 1; peer review: awaiting peer review].** Kruse RL. F1000Research. 2020;9.

220. **The 2019 novel coronavirus (COVID-19) outbreak in China and world: A new lesson for public health system.** Kuca K. Letters in Drug Design and Discovery. 2020;17(4):364-5.

221. **Letter to the editor regarding article: Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis (Ghoshal et al.).** Kumar A, Arora A, Sharma P. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020;14(4):383.

222. **Dealing with Corona virus anxiety and OCD.** Kumar A, Somani A. Asian Journal of Psychiatry. 2020;51.

223. **Geographical accessibility to glucose-6-phosphate dioxxygenase deficiency point-of-care testing for antenatal care in Ghana.** Kuupiel D, Adu KM, Bawontuo V, Adogboba DA, Drain PK, Moshabela M, et al. Diagnostics. 2020;10(4).

224. **More questions than answers, but a way ahead.** La Manna G. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia. 2020;37(2).

225. **High IL-6/IFN- γ ratio could be associated with severe disease in COVID-19 patients.** Lagunas-Rangel FA, Chávez-Valencia V. Journal of medical virology. 2020.

226. **Origin and transmission of Feline coronavirus type I in domestic cats from Northern Italy: a phylogeographic approach.** Lauzi S, Stranieri A, Giordano A, Luzzago C, Zehender G, Paltrinieri S, et al. Veterinary Microbiology. 2020;244.

227. **At least 68 vaccine candidates under development.** Leach S. Lakartidningen. 2020;117.

228. **Early preemptive immunomodulators (Corticosteroids) for severe pneumonia patients infected with SARS-COV-2.** Lee KY, Rhim JW, Kang JH. Korean Journal of Pediatrics. 2020;63(4):117-8.

229. **Coronavirus anxiety scale: A brief mental health screener for COVID-19 related anxiety.** Lee SA. Death studies. 2020:1-9.

230. **Clinical and computed tomographic (CT) images characteristics in the patients with COVID-19 infection: What should radiologists need to know?** Lei P, Huang Z, Liu G, Wang P, Song W, Mao J, et al. Journal of X-ray science and technology. 2020.

231. **Molecular mechanism of action of repurposed drugs and traditional Chinese medicine used for the treatment of patients infected with COVID-19: A systematic review.** Lem FF, Opook F, Herng DLJ, Tyng CF, Lawson FP, Na CS. medRxiv. 2020:2020.04.10.20060376.

232. **[Medication and comedication in COVID-19 patients].** Lenkens M, de Wit H, Danser AH, Esselink AC, Horikx A, Ten Oever J, et al. *Nederlands tijdschrift voor geneeskunde*. 2020;164.
233. **COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.** Lentini G, Cavalluzzi MM, Habtemariam S. *Molecules (Basel, Switzerland)*. 2020;25(8).
<http://dx.doi.org/10.3390/molecules25081834>.
234. **Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis.** Li H, Xiang X, Ren H, Xu L, Zhao L, Chen X, et al. *Journal of Infection*. 2020.
235. **Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.** Li J, Wang X, Chen J, Zhang H, Deng A. *JAMA cardiology*. 2020.
236. **Therapeutic strategies for critically ill patients with COVID-19.** Li L, Li R, Wu Z, Yang X, Zhao M, Liu J, et al. *Annals of Intensive Care*. 2020;10(1).
237. **Clinical characteristics of 225 patients with COVID-19 in a tertiary Hospital near Wuhan, China.** Li R, Tian J, Yang F, Lv L, Yu J, Sun G, et al. *Journal of Clinical Virology*. 2020;127.
238. **Porcine epidemic diarrhea virus membrane protein suppresses the activation of IRF7 to decrease type I interferon production.** Li S, Ma J, Zhu Z, Zheng H. *European Journal of Immunology*. 2019;49:1095-6.
239. **Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan.** Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. *The Journal of allergy and clinical immunology*. 2020.
240. **Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis.** Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. *Journal of Medical Virology*. 2020.
241. **Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study.** Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q. *Clinical Microbiology and Infection*. 2020.
242. **Whole genome sequencing of SARS-CoV-2 isolated in Guangdong Province and factors influencing the sequencing.** Liang L, Li B, Liu Z, Li Z, Guo Q, Song Y, et al. *Chinese Journal of Microbiology and Immunology (China)*. 2020;40(3):174-7.
243. **Evolution of CT findings in patients with mild COVID-19 pneumonia.** Liang T, Liu Z, Wu CC, Jin C, Zhao H, Wang Y, et al. *European Radiology*. 2020.
244. **COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.** Licciardi F, Giani T, Baldini L, Favalli EG, Caporali R, Cimaz R. *Pediatric rheumatology online journal*. 2020;18(1):35.
<http://dx.doi.org/10.1186/s12969-020-00422-z>.
245. **Novel coronavirus disease (Covid-19): The first two patients in the UK with person to person transmission.** Lillie PJ, Samson A, Li A, Adams K, Capstick R, Barlow GD, et al. *Journal of Infection*. 2020;80(5):578-606.
246. **Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19).** Lin C, Xiang J, Yan M, Li H, Huang S, Shen C. *Clinical Chemistry and Laboratory Medicine*. 2020.
247. **Nonstructural protein 6 of porcine epidemic diarrhea virus induces autophagy to promote viral replication via the PI3K/Akt/mTOR axis.** Lin H, Li B, Liu M, Zhou H, He K, Fan H. *Veterinary Microbiology*. 2020;244.
248. **SARS-CoV-2: at the crossroad between aging and neurodegeneration.** Lippi A, Domingues R, Setz C,

Outeiro TF, Krisko A. Movement disorders : official journal of the Movement Disorder Society. 2020.

249. **Hemoglobin value may be decreased in patients with severe coronavirus disease 2019.** Lippi G, Mattiuzzi C. Hematology, Transfusion and Cell Therapy. 2020.
250. **Assessment of immune response to SARS-CoV-2 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays.** Lippi G, Salvagno GL, Pegoraro M, Militello V, Caloi C, Peretti A, et al. Clinical Chemistry and Laboratory Medicine. 2020.
251. **Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient.** Liu B, Wang Y, Zhao Y, Shi H, Zeng F, Chen Z. American Journal of Transplantation. 2020.
252. **Analysis of the initial chest high resolution CT manifestations of COVID-19.** Liu H, Zhang D, Yang Y, Long B, Yin L, Zhao M, et al. Chinese Journal of Radiology (China). 2020;54(4):292-5.
253. **Anti-spike IgG causes severe acute lung injury during acute SARS-CoV infection.** Liu L, Wei Q, Lin Q, Fang J, Peng J, Tang H, et al. European Journal of Immunology. 2019;49:1022.
254. **The value of urine biochemical parameters in the prediction of the severity of coronavirus disease 2019.** Liu R, Ma Q, Han H, Su H, Liu F, Wu K, et al. Clinical chemistry and laboratory medicine. 2020.
255. **CT imaging analysis of 33 cases with the 2019 novel coronavirus infection.** Liu RR, Zhu Y, Wu MY, Liu J, Ren R, Cao QL, et al. Zhonghua yi xue za zhi. 2020;100(13):1007-11.
256. **Antigen-specific T-cell immunity to emerging and re-emerging viruses in human.** Liu W. European Journal of Immunology. 2019;49:1048.
257. **Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19.** Liu Z, Long W, Tu M, Chen S, Huang Y, Wang S, et al. The Journal of infection. 2020.
258. **Cardiovascular complications in COVID-19.** Long B, Brady WJ, Koyfman A, Gottlieb M. American Journal of Emergency Medicine. 2020.
259. **Lack of association between genetic variants at *ACE2* and *TMPRSS2* genes involved in SARS-CoV-2 infection and human quantitative phenotypes.** Lopera E, van der Graaf A, Lanting P, van der Geest M, Fu J, Swertz M, et al. medRxiv. 2020:2020.04.22.20074963.
260. **Chest high resolution CT manifestations of early stage corona virus disease 2019.** Lou J, Fu F, Bai Y, Wang M. Chinese Journal of Medical Imaging Technology. 2020;36(3):396-9.
261. **Clinical Presentation of COVID-19: A Systematic Review Focusing on Upper Airway Symptoms.** Lovato A, de Filippis C. Ear, nose, & throat journal. 2020:145561320920762.
262. **Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19.** Lu C, Li S, Liu Y. Annals of the Rheumatic Diseases. 2020.
263. **Peptide presentation by bat MHC class I provides new insight into the antiviral immunity of bats.** Lu D, Liu K, Gao GF, Liu WJ. European Journal of Immunology. 2019;49:1004-5.
264. **Clinical features and high resolution CT imaging findings of preliminary COVID-19.** Lu X, Gong W, Wang L, Li L, Xie B, Peng Z, et al. Chinese Journal of Radiology (China). 2020;54(4):296-9.

265. **A potential inhibitory role for integrin in the receptor targeting of SARS-CoV-2.** Luan J, Lu Y, Gao S, Zhang L. *The Journal of infection*. 2020.
266. **Fibreoptic tracheal intubation in COVID-19: not so fast.** Lyons C. *British Journal of Anaesthesia*. 2020.
267. **The use of high-flow nasal oxygen in COVID-19.** Lyons C, Callaghan M. *Anaesthesia*. 2020.
268. **Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity.** Lyons-Weiler J. *Journal of Translational Autoimmunity*. 2020;3.
269. **High resolution CT features of COVID-19 in children.** Ma H, Shao J, Wang Y, Zhai A, Zheng N, Li Q, et al. *Chinese Journal of Radiology (China)*. 2020;54(4):310-3.
270. **Consideration of povidone-iodine as a public health intervention for COVID-19: Utilization as "Personal Protective Equipment" for frontline providers exposed in high-risk head and neck and skull base oncology care.** Mady LJ, Kubik MW, Baddour K, Snyderman CH, Rowan NR. *Oral Oncology*. 2020.
271. **Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases.** Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. *Translational research : the journal of laboratory and clinical medicine*. 2020.
272. **Focus on Receptors for Coronaviruses with Special Reference to Angiotensin-converting Enzyme 2 as a Potential Drug Target - A Perspective.** Magrone T, Magrone M, Jirillo E. *Endocrine, metabolic & immune disorders drug targets*. 2020. <http://dx.doi.org/10.2174/1871530320666200427112902>.
273. **The mechanistic target of rapamycin (mTOR): Novel Considerations as an Antiviral Treatment and Possibilities for COVID-19.** Maiese K. *Current neurovascular research*. 2020. <http://dx.doi.org/10.2174/1567202617666200425205122>.
274. **Indian society of anaesthesiologists (ISA national) advisory and position statement regarding COVID-19.** Malhotra N, Joshi M, Datta R, Bajwa S, Mehdiratta L. *Indian Journal of Anaesthesia*. 2020;64(4):259-63.
275. **Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals.** Manning TJ, Thomas-Richardson J, Cowan M, Beard T. *Drug Discov Today*. 2020. <http://dx.doi.org/10.1016/j.drudis.2020.04.010>.
276. **Pulmonary thrombosis in 2019-nCoV pneumonia?** Marongiu F, Grandone E, Barcellona D. *Journal of Thrombosis and Haemostasis*. 2020.
277. **First case of COVID-19 in a kidney transplant recipient treated with belatacept.** Marx D, Moulin B, Fafi-Kremer S, Benotmane I, Gautier G, Perrin P, et al. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2020.
278. **Could HIV infection alter the clinical course of SARS-CoV-2 infection? When less is better.** Mascolo S, Romanelli A, Carleo MA, Esposito V. *Journal of medical virology*. 2020.
279. **Pediatric Airway Management in COVID-19 patients - Consensus Guidelines from the Society for Pediatric Anesthesia's Pediatric Difficult Intubation Collaborative and the Canadian Pediatric Anesthesia Society.** Matava CT, Kovatsis PG, Summers JL, Castro P, Denning S, Yu J, et al. *Anesthesia and analgesia*. 2020.
280. **Ventilator Triage Policies During the COVID-19 Pandemic at U.S. Hospitals Associated With Members of the Association of Bioethics Program Directors.** Matheny Antommara AH, Gibb TS, McGuire AL, Wolpe PR, Wynia MK, Applewhite MK, et al. *Annals of internal medicine*. 2020. <http://dx.doi.org/10.7326/M20-1738>.

281. **The VACCINES Act, Deciphering Vaccine Hesitancy in the Time of COVID19.** McAteer J, Yildirim I, Chahroudi A. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2020.
282. **May IL-17 have a role in COVID-19 infection?** Megna M, Napolitano M, Fabbrocini G. *Medical Hypotheses.* 2020;140.
283. **Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears.** Megna M, Ruggiero A, Marasca C, Fabbrocini G. *The Journal of dermatological treatment.* 2020:1-5.
284. **Pharmacotherapy in COVID-19; A narrative review for emergency providers.** Mehta N, Mazer-Amirshahi M, Alkindi N, Ali P. *American Journal of Emergency Medicine.* 2020.
285. **Therapeutic and prophylactic potential of anti-microbial peptides against coronaviruses.** Memariani H, Memariani M. *Irish Journal of Medical Science.* 2020.
286. **Could enhanced influenza and pneumococcal vaccination programs help limit the potential damage from SARS-CoV-2 to fragile health systems of southern hemisphere countries this winter?** Mendelson M. *International Journal of Infectious Diseases.* 2020;94:32-3.
287. **CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China.** Meng H, Xiong R, He R, Lin W, Hao B, Zhang L, et al. *Journal of Infection.* 2020.
288. **SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.** Messina F, Piaserico S. *Journal of the European Academy of Dermatology and Venereology : JEADV.* 2020.
289. **Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics.** Meziyerh S, Zwart TC, van Etten RW, Janson JA, van Gelder T, Alwayn IPJ, et al. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.* 2020. <http://dx.doi.org/10.1111/ajt.15943>.
290. **Early chest computed tomography to diagnose COVID-19 from suspected patients: A multicenter retrospective study.** Miao C, Jin M, Miao L, Yang X, Huang P, Xiong H, et al. *American Journal of Emergency Medicine.* 2020.
291. **A new emerging zoonotic virus of concern: The 2019 novel Coronavirus (COVID-19).** Millán-Oñate J, Rodríguez-Morales AJ, Camacho-Moreno G, Mendoza-Ramírez H, Rodríguez-Sabogal IA, Álvarez-Moreno C. *Infectio.* 2020;24(3).
292. **Safe bronchodilator treatment in mechanically ventilated COVID-19 patients: A single center experience.** Miller A, Epstein D. *Journal of Critical Care.* 2020;58:56-7.
293. **Cardiac drugs and outcome in COVID - 19.** Mishra AK, Sahu KK, Sargent J. *QJM : monthly journal of the Association of Physicians.* 2020.
294. **To Act.....or to wait for the evidence: Ethics in the time of covid-19!** Misra D, Agarwal V. *Indian Journal of Rheumatology.* 2020;15(1):3-4.
295. **Affective temperament, attachment style, and the psychological impact of the COVID-19 outbreak: an early report on the Italian general population.** Moccia L, Janiri D, Pepe M, Dattoli L, Molinaro M, De Martin V, et al. *Brain, behavior, and immunity.* 2020. <http://dx.doi.org/10.1016/j.bbi.2020.04.048>.
296. **Two Middle East respiratory syndrome vaccines: first step for other coronavirus vaccines?** Modjarrad K, Kim JH. *The Lancet Infectious Diseases.* 2020.

297. **Smell dysfunction: a biomarker for COVID-19.** Moein ST, Hashemian SMR, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. International forum of allergy & rhinology. 2020.
298. **Is There a Role for Tissue Plasminogen Activator (tPA) as a Novel Treatment for Refractory COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS)?** Moore HB, Barrett CD, Moore EE, McIntyre RC, Moore PK, Talmor DS, et al. The journal of trauma and acute care surgery. 2020.
299. **Chest radiography and computed tomography findings from a brazilian patient with covid-19 pneumonia.** Moreira BL, D'Almeida Brotto MP, Marchiori E. Revista da Sociedade Brasileira de Medicina Tropical. 2020;53.
300. **COVID-19 and Older Adult.** Morley JE, Vellas B. Journal of Nutrition, Health and Aging. 2020;24(4):364-5.
301. **SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells.** Mu J, Xu J, Zhang L, Shu T, Wu D, Huang M, et al. Science China Life sciences. 2020.
302. **Covid-19 nephropathy; an emerging condition caused by novel coronavirus infection.** Mubarak M, Nasri H. Journal of Nephropathology. 2020;9(3).
303. **COVID-19 pandemic and environmental pollution: A blessing in disguise?** Muhammad S, Long X, Salman M. Science of the Total Environment. 2020;728.
304. **SARS-CoV-2: Is it the newest spark in the TORCH?** Muldoon KM, Fowler KB, Pesch MH, Schleiss MR. Journal of Clinical Virology. 2020;127.
305. **Covid-19: The Pandemic of Our Time.** Murphy JFA. Irish medical journal. 2020;113(4):46.
306. **Binding of SARS-CoV-2 and angiotensin-converting enzyme 2: clinical implications.** Murray E, Tomaszewski M, Guzik TJ. Cardiovascular research. 2020.
307. **Reply to: "Biologics for psoriasis during COVID-19 outbreak".** Murrell DF, Rivera-Oyola R, Lebwohl M. Journal of the American Academy of Dermatology. 2020.
308. **The role of afferent pulmonary innervation in ARDS associated with COVID-19 and potential use of resiniferatoxin to improve prognosis: A review.** Nahama A, Ramachandran R, Cisternas AF, Ji H. Medicine in Drug Discovery. 2020;5.
309. **A sporadic COVID-19 pneumonia treated with extracorporeal membrane oxygenation in Tokyo, Japan: A case report.** Nakamura K, Hikone M, Shimizu H, Kuwahara Y, Tanabe M, Kobayashi M, et al. Journal of Infection and Chemotherapy. 2020.
310. **All about COVID-19 in brief.** Naserghandi A, Allameh SF, Saffarpour R. New Microbes and New Infections. 2020;35.
311. **Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?** Negro F. Swiss medical weekly. 2020;150:w20249. <http://dx.doi.org/10.4414/smw.2020.20249>. eCollection 2020 Apr 6.
312. **Mimics and chameleons of COVID-19.** Nickel Christian H, Bingisser R. Swiss Medical Weekly. 2020;150(13).
313. **Coronavirus Disease 2019-related dyspnea cases difficult to interpret using chest computed tomography.** Nie S, Han S, Ouyang H, Zhang Z. Respiratory Medicine. 2020.
314. **COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?** Novi G, Mikulska M, Briano F, Toscanini F, Tazza F, Uccelli A, et al. Multiple Sclerosis and Related Disorders. 2020;42.

315. **What do we know about the SARS-CoV-2 coronavirus in the environment?** Núñez-Delgado A. *Science of the Total Environment*. 2020;727.
316. **Weak Induction of Interferon Expression by SARS-CoV-2 Supports Clinical Trials of Interferon Lambda to Treat Early COVID-19.** O'Brien TR, Thomas DL, Jackson SS, Prokunina-Olsson L, Donnelly RP, Hartmann R. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
317. **Mild Encephalitis/Encephalopathy with reversible splenic lesion syndrome: An unusual presentation of anti-GFAP astrocytopathy.** Oger V, Bost C, Salah L, Yazbeck E, Maurey H, Bellesme C, et al. *European Journal of Paediatric Neurology*. 2020.
318. **Covid-19 and the angiotensin-converting enzyme (ACE2): Areas for research.** Omar MB. *Heart and Lung*. 2020.
319. **Sedating ventilated COVID-19 patients with inhalational anesthetic drugs.** Orser BA, Wang DS, Lu WY. *EBioMedicine*. 2020;55.
320. **Perioperative Considerations During Emergency General Surgery in the Era of COVID-19: A U.S. Experience.** Orthopoulos G, Fernandez GL, Dahle JL, Casey E, Jabbour N. *Journal of laparoendoscopic & advanced surgical techniques Part A*. 2020. <http://dx.doi.org/10.1089/lap.2020.0266>.
321. **Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics.** Padoan A, Cosma C, Sciacovelli L, Faggian D, Plebani M. *Clinical Chemistry and Laboratory Medicine*. 2020.
322. **Inter nation social lockdown versus medical care against COVID-19, a mild environmental insight with special reference to India.** Paital B, Das K, Parida SK. *Science of the Total Environment*. 2020;728.
323. **Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?** Pal R, Bhadada SK. *Diabetes research and clinical practice*. 2020:108146.
324. **ADAM17 inhibition may exert a protective effect on COVID-19.** Palau V, Riera M, Soler MJ. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2020.
325. **Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients.** Pan Y, Li X, Yang G, Fan J, Tang Y, Zhao J, et al. *Journal of Infection*. 2020.
326. **Letter: Covid-19, and vitamin D.** Panarese A, Shahini E. *Alimentary Pharmacology and Therapeutics*. 2020.
327. **Study of SARS-CoV-2 in semen and urine samples of a volunteer with positive naso-pharyngeal swab.** Paoli D, Pallotti F, Colangelo S, Basilico F, Mazzuti L, Turriziani O, et al. *Journal of endocrinological investigation*. 2020. <http://dx.doi.org/10.1007/s40618-020-01261-1>.
328. **A review novel coronavirus.** Parameshwar K, Pamu S, Sandeep K, Suresh C. *Asian Journal of Pharmaceutical and Clinical Research*. 2020;13(4):12-7.
329. **Back to the Basics: Diluted Bleach for COVID-19.** Patel P, Sanghvi S, Malik K, Khachemoune A. *Journal of the American Academy of Dermatology*. 2020.
330. **Report from the american society for microbiology covid-19 international summit, 23 march 2020: Value of diagnostic testing for sars-cov-2/covid-19.** Patel R, Babady E, Theel ES, Storch GA, Pinsky BA, George KS, et al. *mBio*. 2020;11(2).

331. **New insights into the evolutionary features of viral overlapping genes by discriminant analysis.** Pavese A. *Virology*. 2020;546:51-66.
332. **Managing patients with cancer in the COVID-19 era.** Peng L, Zagorac S, Stebbing J. *European Journal of Cancer*. 2020;132:5-7.
333. **COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter.** Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, et al. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2020. <http://dx.doi.org/10.1111/ajt.15941>.
334. **Recognition of potential Covid-19 drug treatments through study of existing protein-drug structures: an analysis of thermodynamically active residues.** Perišić O. *arXiv preprint arXiv:200410233*. 2020.
335. **The use of Janus kinase inhibitors in the time of SARS-CoV-2.** Peterson D, Damsky W, King B. *Journal of the American Academy of Dermatology*. 2020.
336. **The management of biologics in dermatologic patients in the 2019-nCoV era.** Plachouri KM, Georgiou S. *The Journal of dermatological treatment*. 2020;1.
337. **18F-Fluorodeoxyglucose Uptake in Patient With Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus Disease 2019) Referred to Positron Emission Tomography/Computed Tomography for NSCLC Restaging.** Polverari G, Arena V, Ceci F, Pelosi E, Ianniello A, Poli E, et al. *Journal of Thoracic Oncology*. 2020.
338. **Venous thromboembolism in COVID-19 patients.** Porfidia A, Pola R. *Journal of thrombosis and haemostasis : JTH*. 2020.
339. **Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.** Praveen D, Puvvada RC, M VA. *International Journal of Antimicrobial Agents*. 2020.
340. **Mental Health Care Providers Dealing with Coronavirus Disease 2019 (COVID-19): What Is the Definition of a Case, How Is That Changing, and What Kinds of Tests Are Available?** Preskorn SH. *Journal of Psychiatric Practice*. 2020.
341. **Health-Related Quality of Life in Common Variable Immunodeficiency Italian Patients Switched to Remote Assistance During the COVID-19 Pandemic.** Pulvirenti F, Cinetto F, Milito C, Bonanni L, Pesce AM, Leodori G, et al. *Journal of Allergy and Clinical Immunology: In Practice*. 2020.
342. **Disrupting the LC3 Interaction Region (LIR) Binding of Selective Autophagy Receptors Sensitizes AML Cell Lines to Cytarabine.** Putyrski M, Vakhrusheva O, Bonn F, Guntur S, Vorobyov A, Brandts C, et al. *Frontiers in Cell and Developmental Biology*. 2020;8.
343. **Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate Severe Acute Respiratory Syndrome Coronavirus 2 Detection.** Qiu G, Gai Z, Tao Y, Schmitt J, Kullak-Ublick GA, Wang J. *ACS nano*. 2020.
344. **Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).** Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X, et al. *Clin Infect Dis*. 2020. <http://dx.doi.org/10.1093/cid/ciaa489>.
345. **Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome.** Quartuccio L, Semerano L, Benucci M, Boissier MC, De Vita S. *Joint Bone Spine*. 2020;87(3):191-3.

346. **Severe cerebral involvement in adult-onset hemophagocytic lymphohistiocytosis.** Radmanesh F, Rodriguez-Pla A, Pincus MD, Burns JD. *Journal of Clinical Neuroscience*. 2020.
347. **Coronavirus as silent killer: recent advancement to pathogenesis, therapeutic strategy and future perspectives.** Raj K, Rohit, Ghosh A, Singh S. *VirusDisease*. 2020.
348. **Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring.** Ramireddy A, Chugh HS, Reinier K, Ebinger J, Park E, Thompson M, et al. *medRxiv*. 2020:2020.04.22.20075671.
349. **Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia.** Rauch B. *European Journal of Preventive Cardiology*. 2020.
350. **Letter to the Editor Re: Coronavirus disease 2019: The harms of exaggerated information and non-evidence-based measures.** Reichmann JP. *European journal of clinical investigation*. 2020:e13224.
351. **Study on treatment of "cytokine storm" by anti-2019-nCoV prescriptions based on arachidonic acid metabolic pathway.** Ren Y, Yao MC, Huo XQ, Gu Y, Zhu WX, Qiao YJ, et al. *Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica*. 2020;45(6):1225-31.
352. **Thoughts on What Chemists Can Contribute to Fighting SARS-CoV-2 - A Short Note on Hand Sanitizers, Drug Candidates and Outreach.** Richert C, Opatz T, Senn-Bilfinger J. *Angewandte Chemie (International ed in English)*. 2020. <http://dx.doi.org/10.1002/anie.202004721>.
353. **Pandemic brings mass vaccinations to a halt.** Roberts L. *Science*. 2020;368(6487):116-7.
354. **COVID-19 pandemic: Palliative care for elderly and frail patients at home and in residential and nursing homes.** Roland K, Markus M. *Swiss Medical Weekly*. 2020;150(13).
355. **What does plant-based vaccine technology offer to the fight against COVID-19?** Rosales-Mendoza S, Márquez-Escobar VA, González-Ortega O, Nieto-Gómez R, Arévalo-Villalobos JI. *Vaccines*. 2020;8(2).
356. **Oligonucleotides and the COVID-19 Pandemic: A Perspective.** Rossi JJ, Rossi D. *Nucleic acid therapeutics*. 2020.
357. **Audio Interview: Approaches to Covid-19 Vaccines and Antivirals.** Rubin EJ, Baden LR, Morrissey S. *The New England journal of medicine*. 2020;382(16):e58. <http://dx.doi.org/10.1056/NEJMe2012889>.
358. **Routine Early Antibiotic use in Symptomatic preterm Neonates (REASON): a prospective randomized controlled trial.** Ruoss JL, Bazacliu C, Russell JT, de la Cruz D, Li N, Gurka MJ, et al. *medRxiv*. 2020:2020.04.17.20069617.
359. **Environmental perspective of COVID-19.** Saadat S, Rawtani D, Hussain CM. *Science of the Total Environment*. 2020;728.
360. **Angiotensin receptor blockers and COVID-19.** Saavedra JM. *Pharmacological Research*. 2020;156.
361. **Corona, COVID and kidney transplantation.** Sahay M, Kute V, Prasad N. *Indian Journal of Transplantation*. 2020;14(1):1-4.
362. **Remdesivir as a potential therapy against COVID-19.** Saiz LC. 2020.

363. **Routine childhood immunization may protect against COVID-19.** Salman S, Salem ML. *Medical Hypotheses*. 2020;140.
364. **Novel ionophores active against La Crosse virus identified through rapid antiviral screening.** Sandler ZJ, Firpo MR, Omoba OS, Vu MN, Menachery VD, Mounce BC. *Antimicrobial agents and chemotherapy*. 2020.
365. **COVID-19 in Children: Clinical Approach and Management.** Sankar J, Dhochak N, Kabra SK, Lodha R. *Indian J Pediatr*. 2020. <http://dx.doi.org/10.1007/s12098-020-03292-1>.
366. **Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: A meta-analysis.** Santoso A, Pranata R, Wibowo A, Al-Farabi MJ, Huang I, Antariksa B. *The American journal of emergency medicine*. 2020. <http://dx.doi.org/10.1016/j.ajem.2020.04.052>.
367. **Can hepatitis a vaccine provide protection against COVID-19?** Sarialioglu F, Apak FBB, Haberal M. *Experimental and Clinical Transplantation*. 2020;18(2):141-3.
368. **Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers.** Sarzani R, Giulietti F, Pentima CD, Giordano P, Spannella F. *European journal of preventive cardiology*. 2020:2047487320918421.
369. **Field trials evaluating the efficacy of porcine epidemic diarrhea vaccine, RNA (Harrisvaccine) in the Philippines.** Sawattrakool K, Stott CJ, Bandalaria-Marca RD, Srijangwad A, Palabrica DJ, Nilubol D. *Tropical animal health and production*. 2020.
370. **COVID-19 outbreak and steroids administration: are patients treated for Sars-Cov-2 at risk of adrenal insufficiency?** Scaroni C, Armigliato M, Cannavò S. *Journal of Endocrinological Investigation*. 2020.
371. **Current pharmacological treatments for COVID-19: what's next?** Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, et al. *British journal of pharmacology*. 2020. <http://dx.doi.org/10.1111/bph.15072>.
372. **COVID-19: risk for cytokine targeting in chronic inflammatory diseases?** Schett G, Sticherling M, Neurath MF. *Nature Reviews Immunology*. 2020.
373. **A cross sectional study on patients with inflammatory rheumatic diseases in terms of their compliance to their immunosuppressive medication during COVID-19 pandemic.** Schmeiser T, Broll M, Dormann A, Fräbel C, Hermann W, Hudowenz O, et al. *Zeitschrift fur Rheumatologie*. 2020.
374. **The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19.** Schmith VD, Zhou J, Lohmer LRL. *medRxiv*. 2020:2020.04.21.20073262.
375. **Guillain Barre syndrome associated with COVID-19 infection: A case report.** Sedaghat Z, Karimi N. *Journal of Clinical Neuroscience*. 2020.
376. **In ovo delivered toll-like receptor 7 ligand, resiquimod enhances host responses against infectious bronchitis corona virus (IBV) infection.** Senapathi UDS, Aboelkhair M, Puro K, Ali M, Amarasinghe A, Sarjoon Abdul-Cader M, et al. *Vaccines*. 2020;8(2).
377. **Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor.** Seo G, Lee G, Kim MJ, Baek SH, Choi M, Ku KB, et al. *ACS nano*. 2020.
378. **COVID-19 and intracerebral haemorrhage: causative or coincidental?** Sharifi-Razavi A, Karimi N, Rouhani N. *New Microbes and New Infections*. 2020;35.

379. **Searching an Effective Therapy for the Coronavirus Pandemic: Do We See Light at the End of the Tunnel?** Sharma M, Surani S. *Cureus*. 2020;12(3):e7415. <http://dx.doi.org/10.7759/cureus.7415>.
380. **Effect of restricted emissions during COVID-19 on air quality in India.** Sharma S, Zhang M, Anshika, Gao J, Zhang H, Kota SH. *Science of the Total Environment*. 2020;728.
381. **Successful treatment of plasma exchange followed by intravenous immunoglobulin in a critically ill patient with 2019 novel coronavirus infection.** Shi H, Zhou C, He P, Huang S, Duan Y, Wang X, et al. *International journal of antimicrobial agents*. 2020:105974.
382. **Evaluation of Antiviral Therapies for Coronavirus Disease 2019 (COVID-19) Pneumonia in Shanghai, China.** Shi X, Lu Y, Li R, Tang Y, Shi N, Song F, et al. *Journal of medical virology*. 2020.
383. **Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs.** Song J, Kang S, Choi SW, Seo KW, Lee S, So MW, et al. *Rheumatology International*. 2020.
384. **Caution of coronavirus transmission through ocular surface.** Song JX, Xing YX, Wu J, Zhang HB. *International Eye Science*. 2020;20(4):726-8.
385. **Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections.** Speth RC. *Drug Development Research*. 2020.
386. **SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup.** Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et al. *Current protocols in microbiology*. 2020;57(1):e100.
387. **Lessons from covid-19: Visiting patients at home and assessing comorbidities.** Stevens AMH. *The BMJ*. 2020;369.
388. **Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China.** Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. *Kidney International*. 2020.
389. **Mechanism research on type I IFN production suppression through m6A modification induced by MERS-CoV NS4b in the nucleus.** Sujuan H, Zhao Z. *European Journal of Immunology*. 2019;49:1079-80.
390. **Incidence of Adverse Drug Reactions in COVID-19 patients in China: an active monitoring study by Hospital Pharmacovigilance System.** Sun J, Deng X, Chen X, Huang J, Huang S, Li Y, et al. *Clin Pharmacol Ther*. 2020. <http://dx.doi.org/10.1002/cpt.1866>.
391. **Editorial: Challenges to Opioid Use Disorders During COVID-19.** Sun Y, Bao Y, Kosten T, Strang J, Shi J, Lu L. *American Journal on Addictions*. 2020.
392. **Hydroxychloroquine for the management of COVID-19: Hope or Hype? A Systematic review of the current evidence.** Suranagi UD, Rehan HS, Goyal N. *medRxiv*. 2020:2020.04.16.20068205.
393. **Natural Bioactive Compounds from Fungi as Potential Candidates for Protease Inhibitors and Immunomodulators to Apply for Coronaviruses.** Suwannarach N, Kumla J, Sujarit K, Pattananandecha T, Saenjum C, Lumyong S. *Molecules (Basel, Switzerland)*. 2020;25(8).
394. **C-reactive protein correlates with CT findings and predicts severe COVID-19 early.** Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, et al. *Journal of medical virology*. 2020.

395. **Coronavirus membrane fusion mechanism offers a potential target for antiviral development.** Tang T, Bidon M, Jaimes JA, Whittaker GR, Daniel S. *Antiviral Research*. 2020;178.
396. **Hematological findings and complications of COVID-19.** Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. *American journal of hematology*. 2020.
397. **Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients.** Testa S, Paoletti O, Giorgi-Pierfranceschi M, Pan A. *Internal and emergency medicine*. 2020.
398. **Direct oral anticoagulant plasma levels striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents. The Cremona experience.** Testa S, Prandoni P, Paoletti O, Morandini R, Tala M, Dellanoce C, et al. *Journal of thrombosis and haemostasis : JTH*. 2020. <http://dx.doi.org/10.1111/jth.14871>.
399. **DOACs and 'newer' haemophilia therapies in COVID-19.** Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. *Journal of thrombosis and haemostasis : JTH*. 2020.
400. **A real-time dashboard of clinical trials for COVID-19.** Thorlund K. *The Lancet Digital Health*. 2020.
401. **Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies.** Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, et al. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. 2020.
402. **Letter: Covid-19 and vitamin D-authors' reply.** Tian Y, Rong L. *Alimentary pharmacology & therapeutics*. 2020.
403. **Therapeutic Management of COVID-19 Patients: A systematic review.** Tobaiqy M, Qashqary M, Al-Dahery S, Mujallad A, Hershan AA, Kamal MA, et al. *medRxiv*. 2020:2020.04.02.20051029.
404. **[Hazard of acquired long QT syndrome during coronavirus pandemic. Focus on hydroxychloroquine].** Tomcsanyi J, Tomcsanyi K. *Orvosi hetilap*. 2020;161(17):689-91. <http://dx.doi.org/10.1556/650.2020.31817>.
405. **Public health emergency of international concern: Coronavirus disease 2019 (COVID-19).** Topcuoglu N. *Open Dentistry Journal*. 2020;14(1):71-2.
406. **A comprehensive analysis of genome composition and codon usage patterns of emerging coronaviruses.** Tort FL, Castells M, Cristina J. *Virus Research*. 2020;283.
407. **Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?** Trifirò G, Crisafulli S, Andò G, Racagni G, Drago F, Berrino L, et al. *Drug Safety*. 2020.
408. **Natural compounds as potential inhibitors of novel coronavirus (COVID-19) main protease: An in silico study.** Tripathi V, Mishra A, Pathak Y. 2020.
409. **Tomatidine, a natural steroidal alkaloid shows antiviral activity towards chikungunya virus in vitro.** Troost B, Mulder LM, Diosa-Toro M, van de Pol D, Rodenhuis-Zybert IA, Smit JM. *Scientific reports*. 2020;10(1):6364.
410. **Risk of drug-induced Long QT Syndrome associated with the use of repurposed COVID-19 drugs: a systematic review.** Turgeon J, Michaud V, Dow P, Al Rihani SR, Deodhar M, Arwood M, et al. *medRxiv*. 2020:2020.04.21.20066761.
411. **Interleukin-6 as a potential biomarker of COVID-19 progression.** Ulhaq ZS, Soraya GV. *Medecine et Maladies Infectieuses*. 2020.

412. **Spotlight of Remdesivir in Comparison with Ribavirin, Favipiravir, Oseltamivir and Umifenovir in Coronavirus Disease 2019 (COVID-19) Pandemic.** Vafaei S, Razmi M, Mansoori M, Asadi-Lari M, Madjd Z. Favipiravir, Oseltamivir and Umifenovir in Coronavirus Disease. 2019.
413. **A short review on antibody therapy for COVID-19.** Venkat Kumar G, Jeyanthi V, Ramakrishnan S. New Microbes and New Infections. 2020;35.
414. **Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff.** Verbeek JH, Rajamaki B, Ijaz S, Sauni R, Toomey E, Blackwood B, et al. The Cochrane database of systematic reviews. 2020;4:CD011621.
415. **The pivotal link between ACE2 deficiency and SARS-CoV-2 infection.** Verdecchia P, Cavallini C, Spanevello A, Angeli F. European Journal of Internal Medicine. 2020.
416. **Three unsuspected CT diagnoses of COVID-19.** Vu D, Ruggiero M, Choi WS, Masri D, Flyer M, Shyknevsky I, et al. Emergency radiology. 2020.
417. **SARS-COV-2 infection is likely to be androgen mediated.** Wambier CG, Goren A. Journal of the American Academy of Dermatology. 2020.
418. **Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients.** Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. British Journal of Haematology. 2020.
419. **Porcine deltacoronavirus engages the transmissible gastroenteritis virus functional receptor porcine aminopeptidase N for infectious cellular entry.** Wang B, Huang Y. European Journal of Immunology. 2019;49:1633.
420. **No Clear Benefit to the Use of Corticosteroid as Treatment in Adult Patients with Coronavirus Disease 2019 : A Retrospective Cohort Study.** Wang D, Wang J, Jiang Q, Yang J, Li J, Gao C, et al. medRxiv. 2020:2020.04.21.20066258.
421. **SARS-CoV-2 RNA detection of hospital isolation wards hygiene monitoring during the Coronavirus Disease 2019 outbreak in a Chinese hospital.** Wang J, Feng H, Zhang S, Ni Z, Ni L, Chen Y, et al. International Journal of Infectious Diseases. 2020;94:103-6.
422. **CT characteristics of patients infected with 2019 novel coronavirus: association with clinical type.** Wang J, Xu Z, Feng R, An Y, Ao W, Gao Y, et al. Clinical Radiology. 2020.
423. **An anti-oxidative therapy for ameliorating cardiac injuries of critically ill COVID-19-infected patients.** Wang JZ, Zhang RY, Bai J. International Journal of Cardiology. 2020.
424. **Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China.** Wang R, Pan M, Zhang X, Fan X, Han M, Zhao F, et al. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020.
425. **Application value of chest multi-detector spiral CT in diagnosis and follow-up of corona virus disease 2019.** Wang X, Liu B, Yu Y, Wu X, Gu J, Du Y, et al. Chinese Journal of Medical Imaging Technology. 2020;36(3):400-4.
426. **Anesthesia procedure of emergency operation for patients with suspected or confirmed COVID-19.** Wen X, Li Y. Surgical Infections. 2020;21(3):299.
427. **The 4 D's of Pellagra and Progress.** Williams AC, Hill LJ. International Journal of Tryptophan Research. 2020;13.

428. **An Interactive Online Dashboard for Tracking COVID-19 in U.S. Counties, Cities, and States in Real Time.** Wissel BD, Van Camp PJ, Kouril M, Weis C, Glauser TA, White PS, et al. Journal of the American Medical Informatics Association : JAMIA. 2020. <http://dx.doi.org/10.1093/jamia/ocaa071>.
429. **Suppression of type I IFN production by Middle-East respiratory syndrome coronavirus ORF8b accessory protein through inhibition of HSP70-dependent activation of IKK ϵ .** Wong LYR, Ye ZW, Lui PY, Fung SY, Yuen KS, Cai Z, et al. European Journal of Immunology. 2019;49:1071.
430. **Clinical Manifestation and Laboratory Characteristics of SARS-CoV-2 Infection in Pregnant Women.** Wu C, Yang W, Wu X, Zhang T, Zhao Y, Ren W, et al. Virologica Sinica. 2020.
431. **Emergency Caesarean delivery in a patient with confirmed COVID-19 under spinal anaesthesia.** Xia H, Zhao S, Wu Z, Luo H, Zhou C, Chen X. British Journal of Anaesthesia. 2020;124(5):e216-e8.
432. **Extreme genomic CpG deficiency in SARS-CoV-2 and evasion of host antiviral defense.** Xia X. Molecular biology and evolution. 2020.
433. **Antiviral role of IFITM proteins in pseudorabies virus Bartha-61 infection.** Xie J, Zhang H, Li X, Feng R. European Journal of Immunology. 2019;49:1040.
434. **Insight into 2019 novel coronavirus — An updated interim review and lessons from SARS-CoV and MERS-CoV.** Xie M, Chen Q. International Journal of Infectious Diseases. 2020;94:119-24.
435. **An Infectious cDNA Clone of SARS-CoV-2.** Xie X, Muruato A, Lokugamage KG, Narayanan K, Zhang X, Zou J, et al. Cell host & microbe. 2020.
436. **Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19.** Xie Y, Cao S, Li Q, Chen E, Dong H, Zhang W, et al. The Journal of infection. 2020.
437. **Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China.** Xu B, Fan CY, Wang AL, Zou YL, Yu YH, He C, et al. Journal of Infection. 2020.
438. **Significance of Serology Testing to Assist Timely Diagnosis of SARS-CoV-2 infections: Implication from a Family Cluster.** Xu Y, Xiao M, Liu X, Xu S, Du T, Xu J, et al. Emerging microbes & infections. 2020:1-12.
439. **Establishment and preliminary application of an indirect elisa for detecting antibody based on N protein of porcine epidemic diarrhea variant virulent strain.** Yan R, Yang P, Ban F, Wang H, Ma Z. European Journal of Immunology. 2019;49:1639-40.
440. **Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures.** Yan Y, Chang L, Wang L. Reviews in Medical Virology. 2020.
441. **Clinical features and outcomes of pregnant women suspected of coronavirus disease 2019.** yang H, Sun G, Tang F, Peng M, Gao Y, Peng J, et al. Journal of Infection. 2020.
442. **Imaging auxiliary diagnosis of corona virus disease 2019.** Yang L, Sun G, Chen H, Shen B, Zhang Y. Chinese Journal of Medical Imaging Technology. 2020;36(3):468-70.
443. **Clinical characteristics and risk assessment of newborns born to mothers with COVID-19.** Yang P, Wang X, Liu P, Wei C, He B, Zheng J, et al. Journal of Clinical Virology. 2020;127.
444. **Imaging of coronavirus disease 2019: A Chinese expert consensus statement.** Yang Q, Liu Q, Xu H, Lu H, Liu S, Li H. European Journal of Radiology. 2020;127.

445. **The role of imaging in 2019 novel coronavirus pneumonia (COVID-19).** Yang W, Sirajuddin A, Zhang X, Liu G, Teng Z, Zhao S, et al. *European Radiology*. 2020.
446. **A broad species tropism in vitro and a mouse model for swine acute severe diarrhea syndrome coronavirus infection.** Yang Y, Huang Y. *European Journal of Immunology*. 2019;49:1634-5.
447. **Broad cross-species infection of cultured cells by bat HKU2- related swine acute diarrhea syndrome coronavirus and identification of its replication in murine dendritic cells in vivo highlight its potential for diverse interspecies transmission.** Yang YL, Qin P, Wang B, Liu Y, Xu GH, Peng L, et al. *Journal of Virology*. 2019;93(24).
448. **The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis.** Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. *Journal of Infection*. 2020.
449. **Bioactive Lipids and Coronavirus (COVID-19).** Yasri S, Wiwanitkit V. *Archives of Medical Research*. 2020.
450. **Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.** Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. *Journal of medical virology*. 2020.
451. **High resolution CT findings and clinical features of COVID-19 in Guangzhou.** Yu C, Qu J, Zhang L, Jiang S, Chen B, Guan W, et al. *Chinese Journal of Radiology (China)*. 2020;54(4):314-7.
452. **Nucleic acid-unextracted, isothermal and discriminative detection of classical swine fever virus virulent and vaccine vtrain by CRISPR/Cas13a.** Yuhang Z, Junqing G, Qingmei L, Ruiguang D, Gaiping Z. *European Journal of Immunology*. 2019;49:1957.
453. **Laboratory data analysis of novel coronavirus (COVID-19) screening in 2510 patients.** Yun H, Sun Z, Wu J, Tang A, Hu M, Xiang Z. *Clinica Chimica Acta*. 2020;507:94-7.
454. **Indirect effects of COVID-19 on the environment.** Zambrano-Monserrate MA, Ruano MA, Sanchez-Alcalde L. *Science of the Total Environment*. 2020;728.
455. **Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19.** Zaorsky NG, Yu JB, McBride SM, Dess RT, Jackson WC, Mahal BA, et al. *Advances in Radiation Oncology*. 2020.
456. **CT imaging of the COVID-19.** Zhang FY, Qiao Y, Zhang H. *Journal of the Formosan Medical Association*. 2020.
457. **Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China.** Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, et al. *Journal of Clinical Virology*. 2020;127.
458. **Bioinformatics prediction of molecular mechanism and intervention drugs of SARS-related immune injury and their significance for COVID-19 treatment.** Zhang H, Chen H, Yang Y, Chen X, Zhang J, Guo B, et al. *Chinese Journal of Microbiology and Immunology (China)*. 2020;40(3):165-73.
459. **Digestive system is a potential route of COVID-19: An analysis of single-cell coexpression pattern of key proteins in viral entry process.** Zhang H, Kang Z, Gong H, Xu D, Wang J, Li Z, et al. *Gut*. 2020.
460. **Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China.** Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. *Clinical Microbiology and Infection*. 2020.
461. **IFIT5 inhibit PEDV replication via phosphorylation of the STAT1.** Zhang N, Liu G. *European Journal of Immunology*. 2019;49:1065.

462. **Active constituents and mechanisms of Respiratory Detox Shot, a traditional Chinese medicine prescription, for COVID-19 control and prevention: Network-molecular docking-LC-MSE analysis.** Zhang ZJ, Wu WY, Hou JJ, Zhang LL, Li FF, Gao L, et al. *Journal of Integrative Medicine*. 2020.
463. **Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.** Zhao M. *International Journal of Antimicrobial Agents*. 2020.
464. **Challenges of Convalescent Plasma Therapy on COVID-19.** Zhao Q, He Y. *Journal of Clinical Virology*. 2020;127.
465. **Stem cell-based therapy for coronavirus disease 2019.** Zhao RC. *Stem cells and development*. 2020.
466. **Risk-adapted Treatment Strategy For COVID-19 Patients.** Zheng C, Wang J, Guo H, Lu Z, Ma Y, Zhu Y, et al. *International Journal of Infectious Diseases*. 2020;94:74-7.
467. **A Case Series of Recurrent Viral RNA Positivity in Recovered COVID-19 Chinese Patients.** Zheng KI, Wang XB, Jin XH, Liu WY, Gao F, Chen YP, et al. *Journal of General Internal Medicine*. 2020.
468. **Clinical characteristics and immunosuppressants management of coronavirus disease 2019 in solid organ transplant recipients.** Zhong Z, Zhang Q, Xia H, Wang A, Liang W, Zhou W, et al. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2020.
469. **Chloroquine, arbidol (umifenovir) or lopinavir/ritonavir as the antiviral monotherapy for COVID-19 patients: a retrospective cohort study.** Zhou L, Huang W, Huang H, Guan L, Yang Y, Grange JML, et al. *Journal*. 2020(Issue).
470. **Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response.** Zhu H, Rhee JW, Cheng P, Waliyan S, Chang A, Witteles RM, et al. *Current Cardiology Reports*. 2020;22(5).
471. **Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis.** Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, et al. *Journal of medical virology*. 2020.
472. **Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China.** Zhu L, Gong N, Liu B, Lu X, Chen D, Chen S, et al. *European Urology*. 2020.
473. **Association between short-term exposure to air pollution and COVID-19 infection: Evidence from China.** Zhu Y, Xie J, Huang F, Cao L. *Science of the Total Environment*. 2020;727.
474. **Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children.** Zimmermann P, Curtis N. *The Pediatric infectious disease journal*. 2020;39(5):355-68. <http://dx.doi.org/10.1097/INF.0000000000002660>.

Literatuuroverzicht tot 23-04-2020

1. **The Novel Coronavirus Outbreak: What We Know and What We Don't.** Cell. 2020;180(6):1034-6.
2. **Coronavirus papers: Viral proteins point to potential treatments.** Nature. 2020.
3. **Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020.** MMWR Morbidity and mortality weekly report. 2020;69(13):382-6. <http://dx.doi.org/10.15585/mmwr.mm6913e2>.
4. **EMA advice on the use of NSAIDs for Covid-19.** Drug and Therapeutics Bulletin. 2020.
5. **AMPA Position Statement on COVID-19.** Air Medical Journal. 2020.
6. **[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].** Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases. 2020;43(3):185-8. <http://dx.doi.org/10.3760/cmaj.issn.1001-0939.2020.03.009>.
7. **Geographic Differences in COVID-19 Cases, Deaths, and Incidence - United States, February 12-April 7, 2020.** MMWR Morbidity and mortality weekly report. 2020;69(15):465-71. <http://dx.doi.org/10.15585/mmwr.mm6915e4>.
8. **Angiotensin converting enzyme 2 - An ally or a Trojan horse? Implications to SARS-CoV-2 -related cardiovascular complications.** Abassi ZA, Assady S, Khoury EE, Heyman SN. American journal of physiology Heart and circulatory physiology. 2020.
9. **Covid-19 infection and mortality - A physiologist's perspective enlightening clinical features and plausible interventional strategies.** Abassi ZA, Skorecki K, Heyman SN, Kinaneh S, Armaly Z. American journal of physiology Lung cellular and molecular physiology. 2020.
10. **Middle East respiratory syndrome coronavirus (MERS-CoV) neutralising antibodies in a high-risk human population, Morocco, November 2017 to January 2018.** Abbad A, Perera RAPM, Anga L, Faouzi A, Minh NNT, Malik SMMR, et al. Eurosurveillance. 2019;24(48):1-8.
11. **Project IDentif.AI: Harnessing Artificial Intelligence to Rapidly Optimize Combination Therapy Development for Infectious Disease Intervention.** Abdulla A, Wang B, Qian F, Kee T, Blasiak A, Ong YH, et al. Advanced Therapeutics. 2020:2000034.
12. **Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19).** Abedi F, Rezaee R, Karimi G. Pharmacological Research. 2020;156.
13. **Re: Letter to the Editor of Public Health in response to 'Nipah virus infection: gaps in evidence and its public health importance'.** Acharya Y. Public Health. 2020;181:204.
14. **Antiviral Agents: Discovery to Resistance.** Adamson CS. Viruses. 2020;12(4). <http://dx.doi.org/10.3390/v12040406>.
15. **Inside the heart of COVID-19.** Adão R. Cardiovascular research. 2020.
16. **Oral Mutian® X stopped faecal feline coronavirus shedding by naturally infected cats.** Addie DD, Curran S, Bellini F, Crowe B, Sheehan E, Ukrainchuk L, et al. Research in Veterinary Science. 2020;130:222-9.
17. **Gastrointestinal and Liver Manifestations of COVID-19.** Agarwal A, Chen A, Ravindran N, To C, Thuluvath PJ. Journal of Clinical and Experimental Hepatology. 2020.

18. **Proposal of a low-dose, long-pitch, dual-source chest CT protocol on third-generation dual-source CT using a tin filter for spectral shaping at 100 kVp for CoronaVirus Disease 2019 (COVID-19) patients: a feasibility study.** Agostini A, Floridi C, Borgheresi A, Badaloni M, Esposito Pirani P, Terilli F, et al. *La Radiologia medica*. 2020. <http://dx.doi.org/10.1007/s11547-020-01179-x>.
19. **Emerging prophylaxis strategies against COVID-19.** Agrawal S, Goel AD, Gupta N. *Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace*. 2020;90(1). <http://dx.doi.org/10.4081/monaldi.2020.1289>.
20. **Why the immune system fails to mount an adaptive immune response to a Covid -19 infection.** Ahmadpoor P, Rostaing L. *Transplant international : official journal of the European Society for Organ Transplantation*. 2020.
21. **Limited transmissibility of coronavirus (SARS-1, MERS, and SARS-2) in certain regions of Africa.** Ahmed AE. *Journal of medical virology*. 2020.
22. **Global challenges to urology practice during COVID-19 pandemic.** Ahmed K, Hayat S, Dasgupta P. *BJU international*. 2020. <http://dx.doi.org/10.1111/bju.15082>
23. **Preliminary identification of potential vaccine targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies.** Ahmed SF, Quadeer AA, McKay MR. *Viruses*. 2020;12(3).
24. **Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19).** Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. *Journal of Microbiology and Biotechnology*. 2020;30(3):313-24.
25. **Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea.** Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, et al. *Journal of Korean medical science*. 2020;35(14):e149. <http://dx.doi.org/10.3346/jkms.2020.35.e149>.
26. **Era of molecular diagnosis for pathogen identification of unexplained pneumonia, lessons to be learned.** Ai JW, Zhang Y, Zhang HC, Xu T, Zhang WH. *Emerging Microbes and Infections*. 2020;9(1):597-600.
27. **A novel coronavirus outbreak from Wuhan City in China, rapid need for emergency departments preparedness and response; a letter to editor.** Alavi-Moghaddam M. *Archives of Academic Emergency Medicine*. 2020;8(1).
28. **Synthesis and evaluation of some new 1,3,4-oxadiazoles bearing thiophene, thiazole, coumarin, pyridine and pyridazine derivatives as antiviral agents.** Albratty M, El-Sharkawy KA, Alhazmi HA. *Acta Pharmaceutica*. 2019;69(2):261-76.
29. **Circulation of pantropic canine coronavirus in autochthonous and imported dogs, Italy.** Alfano F, Fusco G, Mari V, Occhiogrosso L, Miletti G, Brunetti R, et al. *Transboundary and Emerging Diseases*. 2020.
30. **The Viral Macrodomain Counters Host Antiviral ADP-Ribosylation.** Alhammad YMO, Fehr AR. *Viruses*. 2020;12(4).
31. **Artificial intelligence and machine learning to fight COVID-19.** Alimadadi A, Aryal S, Manandhar I, Munroe PB, Joe B, Cheng X. *Physiological genomics*. 2020;52(4):200-2.
32. **COVID-19 Treatment: The Race Against Time. Electron J Gen Med. 2020; 17 (6): em227.** Aljofan M, Gaipov A. *Journal*. 2020(Issue).
33. **Coronavirus disease 2019 outbreak: Preparedness and readiness of countries in the eastern**

- mediterranean region.** Al-Mandhari A, Samhouri D, Abubakar A, Brennan R. Eastern Mediterranean Health Journal. 2020;26(2):136-7.
34. **Off-Label Therapies for COVID-19-Are We All In This Together?** Alpern JD, Gertner E. Clin Pharmacol Ther. 2020. <http://dx.doi.org/10.1002/cpt.1862>
35. **Inquiring into Benefits of Independent Activation of Non-Classical Renin-Angiotensin System in the Clinical Prognosis and Reduction of COVID-19 mortality.** Álvarez-Aragón LM, Cuesta-Muñoz AL, Álvarez-López I. Clinical Infectious Diseases. 2020.
36. **SARS-CoV-2 Vaccines: Status Report.** Amanat F, Krammer F. Immunity. 2020;52(4):583-9.
37. **How to link patients with suspicious COVID-19 to health system from the community pharmacies? A route proposal.** Amariles P, Ledezma-Morales M, Salazar-Ospina A, Hincapié-García JA. Research in social & administrative pharmacy : RSAP. 2020.
38. **The possible of immunotherapy for COVID-19: A systematic review.** AminJafari A, Ghasemi S. International Immunopharmacology. 2020;83.
39. **Lidocaine during intubation and extubation in patients with coronavirus disease (COVID-19).** Aminnejad R, Salimi A, Saeidi M. Canadian Journal of Anesthesia. 2020.
40. **Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses.** Amirian ES, Levy JK. One Health. 2020;9:100128. <http://dx.doi.org/10.1016/j.onehlt.2020.100128>. eCollection 2020 Jun.
41. **CT Manifestations of Novel Coronavirus Pneumonia: A Case Report.** An P, Song P, Lian K, Wang Y. Balkan medical journal. 2020.
42. **Discovery and development of safe-in-man broad-spectrum antiviral agents.** Andersen PI, Ianevski A, Lysvand H, Vitkauskienė A, Oksenysh V, Bjørås M, et al. International Journal of Infectious Diseases. 2020;93:268-76.
43. **Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines.** Ang L, Lee HW, Choi JY, Zhang J, Soo Lee M. Integrative Medicine Research. 2020;9(2).
44. **COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis.** Angeletti S, Benvenuto D, Bianchi M, Giovanetti M, Pascarella S, Ciccozzi M. Journal of Medical Virology. 2020.
45. **The Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP-CAP) Study: Rationale and Design.** Angus DC, Berry S, Lewis RJ, Al-Beidh F, Arabi Y, van Bentum-Puijk W, et al. Annals of the American Thoracic Society. 2020.
46. **Use of recombinant cytokines for optimized induction of antiviral immunity against SIV in the nonhuman primate model of human AIDS.** Ansari AA, Mayne AE, Onlamoon N, Pattanapanyasat K, Mori K, Villinger F. Immunologic Research. 2004;29(1).
47. **Immunosuppression drug-related and clinical manifestation of Coronavirus disease 2019: a therapeutic hypothesis.** Antonio R, Silvia M. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2020.
48. **Critical care management of adults with community-acquired severe respiratory viral infection.** Arabi YM, Fowler R, Hayden FG. Intensive Care Medicine. 2020;46(2):315-28.
49. **Hydroxychloroquine for treatment of SARS-CoV-2 infection? Improving our confidence in a**

- model-based approach to dose selection.** Arnold SL, Buckner F. *Clinical and translational science*. 2020.
50. **Drugs and the renin-angiotensin system in covid-19.** Aronson JK, Ferner RE. *BMJ (Clinical research ed)*. 2020;369:m1313.
 51. **Lung Involvement Found on Chest CT Scan in a Pre-Symptomatic Person with SARS-CoV-2 Infection: A Case Report.** Asadollahi-Amin A, Hasibi M, Ghadimi F, Rezaei H, SeyedAlinaghi S. *Tropical medicine and infectious disease*. 2020;5(2). <http://dx.doi.org/10.3390/tropicalmed5020056>.
 52. **How health anxiety influences responses to viral outbreaks like COVID-19: What all decision-makers, health authorities, and health care professionals need to know.** Asmundson GJG, Taylor S. *Journal of Anxiety Disorders*. 2020;71.
 53. **Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.** Atluri S, Manchikanti L, Hirsch JA. *Pain physician*. 2020;23(2):E71-e83.
 54. **COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies.** Atri D, Siddiqi HK, Lang J, Nauffal V, Morrow DA, Bohula EA. *JACC Basic to translational science*. 2020. <http://dx.doi.org/10.1016/j.jacbts.2020.04.002>.
 55. **Adoption of COVID-19 triage strategies for low-income settings.** Ayebare RR, Flick R, Okware S, Bodo B, Lamorde M. *The Lancet Respiratory Medicine*. 2020;8(4):e22.
 56. **COVID-19 vaccination clinical trials should consider multiple doses of BCG.** Ayoub BM. *Die Pharmazie*. 2020;75(4):159. <http://dx.doi.org/10.1691/ph.2020.0444>
 57. **Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity?** Baglivo M, Baronio M, Natalini G, Beccari T, Chiurazzi P, Fulcheri E, et al. *Acta Biomed*. 2020;91(1):161-4. <http://dx.doi.org/10.23750/abm.v91i1.9402>.
 58. **Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT.** Bai HX, Hsieh B, Xiong Z, Halsey K, Choi JW, Tran TML, et al. *Radiology*. 2020:200823.
 59. **Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms.** Baig AM, Khaleeq A, Ali U, Syeda H. *ACS Chemical Neuroscience*. 2020.
 60. **Persons Evaluated for 2019 Novel Coronavirus - United States, January 2020.** Bajema KL, Oster AM, McGovern OL, Lindstrom S, Stenger MR, Anderson TC, et al. *MMWR Morbidity and mortality weekly report*. 2020;69(6):166-70. <http://dx.doi.org/10.15585/mmwr.mm6906e1>.
 61. **Visualizing an unseen enemy; mobilizing structural biology to counter COVID-19.** Baker EN. *Acta crystallographica Section F, Structural biology communications*. 2020;76:158-9.
 62. **COVID-19: Emerging protective measures.** Balachandar V, Mahalaxmi I, Kaavya J, Vivekanandhan G, Ajithkumar S, Arul N, et al. *European Review for Medical and Pharmacological Sciences*. 2020;24(6):3422-5.
 63. **Screening of FDA Approved Drugs Against COVID-19 Main Protease: Coronavirus Disease.** Balakrishnan V, Lakshminarayanan K. 2020.
 64. **Coronavirus Disease (COVID-19) in Children - What We Know So Far and What We Do Not?** Balasubramanian S, Rao NM, Goenka A, Roderick M, Ramanan AV. *Indian pediatrics*. 2020.
 65. **Cardiovascular disease and COVID-19.** Bansal M. *Diabetes & metabolic syndrome*. 2020;14(3):247-50.

66. **Effects of integrative Chinese and Western medicine on arterial oxygen saturation in patients with severe acute respiratory syndrome.** Bao-yan L, Jing-qing H, Yan-ming X, Wei-liang W, Rong-bing W, Yan-ping Z, et al. Chinese Journal of Integrative Medicine. 2004;10(2):117-22.
67. **Case report of chloroquine therapy and hypoglycaemia in type 1 diabetes: What should we have in mind during the COVID-19 pandemic?** Baretic M. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020;14(4):355-6. <http://dx.doi.org/10.1016/j.dsx.2020.04.014>
68. **Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2.** Barker H, Parkkila S. bioRxiv. 2020:2020.04.13.038752.
69. **Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.** Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ, Claassen CW, et al. Pharmacotherapy. 2020. <http://dx.doi.org/10.1002/phar.2398>.
70. **Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?** Baron SA, Devaux C, Colson P, Raoult D, Rolain JM. International journal of antimicrobial agents. 2020:105944.
71. **Teicoplanin: an alternative drug for the treatment of COVID-19?** Baron SA, Devaux C, Colson P, Raoult D, Rolain JM. International journal of antimicrobial agents. 2020.
72. **Sars-cov-2 (Covid-19) by the numbers.** Bar-On YM, Flamholz A, Phillips R, Milo R. eLife. 2020;9.
73. **Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19).** Bartiromo M, Borch B, Botta A, Bagala A, Lugli G, Tilli M, et al. Transplant infectious disease : an official journal of the Transplantation Society. 2020. <http://dx.doi.org/10.1111/tid.13286>.
74. **Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV.** Baruah V, Bose S. Journal of Medical Virology. 2020;92(5):495-500.
75. **The Role of YouTube and the Entertainment Industry in Saving Lives by Educating and Mobilizing the Public to Adopt Behaviors for Community Mitigation of COVID-19: A Successive Sampling Design.** Basch CE, Basch CH, Hillyer GC, Jaime C. JMIR public health and surveillance. 2020. <http://dx.doi.org/10.2196/19145>.
76. **Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres.** Basile C, Combe C, Pizzarelli F, Covic A, Davenport A, Kanbay M, et al. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2020.
77. **The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm.** Bassetti M, Vena A, Giacobbe DR. European Journal of Clinical Investigation. 2020;50(3). <http://dx.doi.org/10.1111/eci.13209>
78. **COVID-19 Related Misinformation on Social Media: A Qualitative Study from Iran.** Bastani P, Bahrami MA. Journal of medical Internet research. 2020.
79. **The differential expression of the ACE2 receptor across ages and gender explains the differential lethality of SARS-Cov-2 and suggests possible therapy.** Bastolla U. arXiv preprint arXiv:200407224. 2020.
80. **Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?** Battle D, Wysocki J, Satchell K. Clinical science (London, England : 1979). 2020;134(5):543-5.
81. **Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute Hospital Trust.** Bean D, Kraljevic Z, Searle T, Bendayan R, Pickles A, Folarin A, et al. medRxiv.

2020:2020.04.07.20056788.

82. **Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model.** Beck BR, Shin B, Choi Y, Park S, Kang K. Computational and Structural Biotechnology Journal. 2020;18:784-90.
83. **Off-label prescribing in the midst of a pandemic: The case of hydroxychloroquine.** Bell JS, Bell JA, Creek DJ. Australian journal of general practice. 2020;49. <http://dx.doi.org/10.31128/AJGP-COVID-06>
84. **New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws.** Bennardo F, Buffone C, Giudice A. Oral oncology. 2020:104659.
85. **The 2019-new coronavirus epidemic: Evidence for virus evolution.** Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M. Journal of Medical Virology. 2020;92(4):455-9.
86. **Global epidemiology, pathogenesis, immune response, diagnosis, treatment, economic and psychological impact, challenges, and future prevention of COVID-19: A scoping review.** Berhe B, Legese H, Degefa H, Adhanom G, Gebrewahd A, Mardu F, et al. medRxiv. 2020:2020.04.02.20051052.
87. **COVID-19 needs a Manhattan Project.** Berkley S. Science. 2020;367(6485):1407.
88. **Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.** Bersanelli M. Immunotherapy. 2020.
89. **Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.** Bhatnagar T, Murhekar MV, Soneja M, Gupta N, Giri S, Wig N, et al. The Indian journal of medical research. 2020. http://dx.doi.org/10.4103/ijmr.IJMR_502_20.
90. **Is A Problem Shared, A Problem Halved? Not Always! The Novel Coronavirus COVID-19 Outbreak.** Bhosale S, Kulkarni AP. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine. 2020;24(2):88-9. <http://dx.doi.org/10.5005/jp-journals-10071-23365>.
91. **Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial.** Bian H, Zheng Z-H, Wei D, Zhang Z, Kang W-Z, Hao C-Q, et al. medRxiv. 2020:2020.03.21.20040691.
92. **Statins in coronavirus outbreak: It's time for experimental and clinical studies.** Bifulco M, Gazzo P. Pharmacological Research. 2020;156. <http://dx.doi.org/10.1016/j.phrs.2020.104803>
93. **The next big threat to global health? 2019 novel coronavirus (2019-nCoV): What advice can we give to travellers? – Interim recommendations January 2020, from the Latin-American society for Travel Medicine (SLAMVI).** Biscayart C, Angeleri P, Lloveras S, Chaves TDSS, Schlagenhauf P, Rodríguez-Morales AJ. Travel Medicine and Infectious Disease. 2020;33.
94. **COVID-19: The Role of Angiotensin-2 Receptor in Transmission Process.** Bittmann S. J Regen Biol Med. 2020;2(1):1-2.
95. **Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?** Bizzarri M, Laganà AS, Aragona D, Unfer V. European Review for Medical and Pharmacological Sciences. 2020;24(6):3426-32.
96. **COVID-19 challenge: Feverish search for vaccines and antiviral treatments.** Blasius H. Deutsche Apotheker Zeitung. 2020;160(10).

97. **Emetine, ipecac, ipecac alkaloids and analogues as potential antiviral agents for coronaviruses.** Bleasel MD, Peterson GM. *Pharmaceuticals*. 2020;13(3).
98. **Short, terminally modified 2'-OMe RNAs as inhibitors of microRNA.** Blechinger J, Pieper H, Marzenell P, Kovbasyuk L, Serva A, Starkuviene V, et al. *Chemical Communications*. 2013;49(67):7397-9. <http://dx.doi.org/10.1039/c3cc43174f>
99. **Diabetes and COVID-19.** Bloomgarden ZT. *Journal of Diabetes*. 2020;12(4):347-8.
100. **Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper.** Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, et al. *JHEP Reports*. 2020;2(3).
101. **Stability study of common clinical chemistry tests in heparinized plasma samples stored in the refrigerated module of flexlab total laboratory automation system.** Bonetti G, Alzini A, Bellini C, Bellintani S, Bianchini E, Brugnani D, et al. *Biochimica Clinica*. 2018;42:S161.
102. **Choice of the right sample type for plasma glucose determination in oral glucose tolerance test: An important pre-analytical tool for a correct classification of gestational diabetes mellitus.** Bonetti G, Gavarina D, Urbani D, Marchetti C, Marini M, Carta M. *Biochimica Clinica*. 2018;42:S10-S1.
103. **A rapid fatal evolution of Coronavirus Disease-19 (COVID-19) in an advanced lung cancer patient with a long time response to nivolumab.** Bonomi L, Ghilardi L, Arnoldi E, Tondini CA, Bettini AC. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2020.
104. **Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study).** Borba MGS, Val FdA, Sampaio VS, Alexandre MAA, et al. *medRxiv*. 2020:2020.04.07.20056424.
105. **Microbial burden and viral exacerbations in a longitudinal multicenter COPD cohort.** Bouquet J, Tabor DE, Silver JS, Nair V, Tovchigrechko A, Griffin MP, et al. *Respiratory Research*. 2020;21(1).
106. **Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement.** Bousquet J, Akdis C, Jutel M, Bachert C, Klimek L, Agache I, et al. *Allergy*. 2020.
107. **N-glycosylation of infectious bronchitis virus M41 spike determines receptor specificity.** Bouwman KM, Habraeken N, Laconi A, Berends AJ, Groenewoud L, Alders M, et al. *The Journal of general virology*. 2020.
108. **Early Impact of COVID-19 on Transplant Center Practices and Policies in the United States.** Boyarsky BJ, Chiang TP, Werbel WA, Durand CM, Avery RK, Getsin SN, et al. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2020. <http://dx.doi.org/10.1111/ajt.15915>.
109. **Smoking upregulates angiotensin-converting Enzyme-2 receptor: A potential adhesion site for novel coronavirus SARS-CoV-2 (COVID-19).** Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. *Journal of Clinical Medicine*. 2020;9(3). <http://dx.doi.org/10.3390/jcm9030841>
110. **Chloroquine and hydroxychloroquine for the treatment of COVID-19: A living systematic review protocol.** Bravo Jeria R, Rojas Reyes MX, Franco JV, Acuna MP, Torres Lopez LA, Rada Gr. *medRxiv*. 2020:2020.04.03.20052530.
111. **Coronavirus pandemic and HIV infection.** Brichacek B, Bukrinsky M. *Open AIDS Journal*. 2020;14(1):10.
112. **Assessment of the Antiviral Properties of Zeolites Containing Metal Ions.** Bright KR, Sicairos-Ruelas EE,

- Gundy PM, Gerba CP. Food and Environmental Virology. 2009;1(1):37-41.
113. **Why is COVID-19 so mild in children?** Brodin P. Acta paediatrica (Oslo, Norway : 1992). 2020.
114. **Antihypertensive drugs and risk of COVID-19?** Brown JD. The Lancet Respiratory medicine. 2020.
115. **Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic.** Brown JD. Research in social & administrative pharmacy : RSAP. 2020. <http://dx.doi.org/10.1016/j.sapharm.2020.03.020>
116. **Studying COVID-19 in light of critical approaches to risk and uncertainty: research pathways, conceptual tools, and some magic from Mary Douglas.** Brown P. Health, Risk and Society. 2020;22(1):1-14.
117. **Distinct Viral Clades of SARS-CoV-2: Implications for Modeling of Viral Spread.** Brufsky A. J Med Virol. 2020. <http://dx.doi.org/10.1002/jmv.25902>
118. **Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.** Buckley LF, Cheng JWM, Desai A. Journal of Cardiovascular Pharmacology. 9000.
119. **Anti-IL6R role in treatment of COVID-19-related ARDS.** Buonaguro FM, Puzanov I, Ascierto PA. J Transl Med. 2020;18(1):165. <http://dx.doi.org/10.1186/s12967-020-02333-9>.
120. **Point-of-Care Lung Ultrasound findings in novel coronavirus disease-19 pneumoniae: A case report and potential applications during COVID-19 outbreak.** Buonsenso D, Piano A, Raffaelli F, Bonadia N, de Gaetano Donati K, Franceschi F. European Review for Medical and Pharmacological Sciences. 2020;24(5):2776-80.
121. **Renin-Angiotensin-Aldosterone System: Double-Edged Sword in COVID-19 Infection.** burchfield.
122. **COVID-19 and the RAAS—a potential role for angiotensin II?** Busse LW, Chow JH, McCurdy MT, Khanna AK. Critical Care. 2020;24(1):136.
123. **COVID-19 and the RAAS-a potential role for angiotensin II?** Busse LW, Chow JH, McCurdy MT, Khanna AK. Critical care (London, England). 2020;24(1):136.
124. **Early nutritional supplementation in non-critically ill patients hospitalized for the 2019 novel coronavirus disease (COVID-19): Rationale and feasibility of a shared pragmatic protocol.** Caccialanza R, Laviano A, Lobascio F, Montagna E, Bruno R, Ludovisi S, et al. Nutrition. 2020.
125. **Computational inference of selection underlying the evolution of the novel coronavirus, SARS-CoV-2.** Cagliani R, Forni D, Clerici M, Sironi M. J Virol. 2020. <http://dx.doi.org/10.1128/JVI.00411-20>.
126. **Sex difference and smoking predisposition in patients with COVID-19.** Cai H. The Lancet Respiratory Medicine. 2020;8(4):e20.
127. **Theoretical basis and effect characteristics of andrographolide against COVID-19.** Cai N, Li YJ, Zhou GR, Xin C, Xie J, Zhou HH, et al. Chinese Traditional and Herbal Drugs. 2020;51(5):1159-66.
128. **Characteristics of Liver Tests in COVID-19 Patients.** Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. Journal of hepatology. 2020. <http://dx.doi.org/10.1016/j.jhep.2020.04.006>.
129. **Bimetallic catalyzed N-arylation used in synthesis of novel β -carboline derivatives.** Cai R, Zhu L, Wang P, Zhao Y. Letters in Drug Design and Discovery. 2020;17(5):520-5.
130. **Blood transfusion during the COVID-19 outbreak.** Cai X, Ren M, Chen F, Li L, Lei H, Wang X. Blood

Transfus. 2020;18(2):79-82. <http://dx.doi.org/10.2450/2020.0076-20>.

131. **Coronavirus vaccines: five key questions as trials begin.** Callaway E. Nature. 2020;579(7800):481.

132. **Should scientists infect healthy people with the coronavirus to test vaccines?** Callaway E. Nature. 2020.

133. **China coronavirus: Six questions scientists are asking.** Callaway E, Cyranoski D. Nature. 2020;577(7792):605-7.

134. **Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions with Antiviral Drugs.** Calligari P, Bobone S, Ricci G, Bocedi A. Viruses. 2020;12(4). <http://dx.doi.org/10.3390/v12040445>

135. **Isolation and rapid sharing of the 2019 novel coronavirus (SAR-CoV-2) from the first patient diagnosed with COVID-19 in Australia.** Caly L, Druce J, Roberts J, Bond K, Tran T, Kostecki R, et al. Medical Journal of Australia. 2020.

136. **The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.** Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. Antiviral research. 2020:104787.

137. **Understanding Mechanism of Infection and outlining definitive therapy for Corona Virus (COVID-19).** Camm. Journal Of Pharmacy And Biological Sciences. 2020.

138. **Evaluation of the Efficacy and Safety of Intravenous Remdesivir in Adult Patients with Severe Pneumonia caused by COVID-19 virus infection: study protocol for a Phase 3 Randomized, Double-blind, Placebo-controlled, Multicentre trial.** Cao B, Wang C, Wang Y, Zhou F, Zhang D, Zhao J, et al. 2020.

139. **A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.** Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. The New England journal of medicine. 2020.

140. **SARS-CoV-2 infection in children: Transmission dynamics and clinical characteristics.** Cao Q, Chen YC, Chen CL, Chiu CH. Journal of the Formosan Medical Association. 2020;119(3):670-3.

141. **Imaging and Clinical Features of Patients With 2019 Novel Coronavirus SARS-CoV-2: A systematic review and meta-analysis.** Cao Y, Liu X, Xiong L, Cai K. Journal of medical virology. 2020.

142. **Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence.** Cao YC, Deng QX, Dai SX. Travel Medicine and Infectious Disease. 2020.

143. **An exclusive 42 amino acid signature in pp1ab protein provides insights into the evolutive history of the 2019 novel human-pathogenic coronavirus (SARS-CoV2).** Cárdenas-Conejo Y, Liñan-Rico A, García-Rodríguez DA, Centeno-Leija S, Serrano-Posada H. Journal of medical virology. 2020.

144. **An exclusive 42 amino acid signature in pp1ab protein provides insights into the evolutive history of the 2019 novel human-pathogenic coronavirus (SARS-CoV-2).** Cárdenas-Conejo Y, Liñan-Rico A, García-Rodríguez DA, Centeno-Leija S, Serrano-Posada H. Journal of Medical Virology. 2020.

145. **Hospital surge capacity in a tertiary emergency referral centre during the COVID-19 outbreak in Italy.** Carena L, Costantini E, Greco M, Barra FL, Rendiniello V, Mainetti M, et al. Anaesthesia. 2020. <http://dx.doi.org/10.1111/anae.15072>.

146. **Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge.** Carnero Contentti E, Correa J. Multiple Sclerosis and Related Disorders. 2020;41. <http://dx.doi.org/10.1016/j.msard.2020.102097>

147. **A new clinical trial to test high-dose vitamin C in patients with COVID-19.** Carr AC. *Critical care* (London, England). 2020;24(1):133.
148. **Double Jeopardy: Methamphetamine Use and HIV as Risk Factors for COVID-19.** Carrico AW, Horvath KJ, Grov C, Moskowitz JT, Pahwa S, Pallikkuth S, et al. *AIDS and behavior*. 2020.
149. **Personality differences and COVID-19: are extroversion and conscientiousness personality traits associated with engagement with containment measures?** Carvalho LF, Pianowski G, Goncalves AP. *Trends in psychiatry and psychotherapy*. 2020. <http://dx.doi.org/10.1590/2237-6089-2020-0029>.
150. **The convalescent sera option for containing COVID-19.** Casadevall A, Pirofski LA. *The Journal of clinical investigation*. 2020;130(4):1545-8. <http://dx.doi.org/10.1172/JCI138003>.
151. **Antiplasmodial Activity of p-Substituted Benzyl Thiazinoquinone Derivatives and Their Potential against Parasitic Infections.** Casertano M, Menna M, Fattorusso C, Basilico N, Parapini S, Persico M, et al. *Molecules* (Basel, Switzerland). 2020;25(7).
152. **Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department.** Cassaniti I, Novazzi F, Giardina F, Salinaro F, Sachs M, Perlini S, et al. *Journal of Medical Virology*. 2020. <http://dx.doi.org/10.1002/jmv.25800>
153. **In Silico Discovery of Candidate Drugs against Covid-19.** Cava. 2020.
154. **Editorial – Differences and similarities between Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet?** Ceccarelli M, Berretta M, Rullo EV, Nunnari G, Cacopardo B. *European Review for Medical and Pharmacological Sciences*. 2020;24(5):2781-3.
155. **Genomic variance of the 2019-nCoV coronavirus.** Ceraolo C, Giorgi FM. *Journal of Medical Virology*. 2020;92(5):522-8.
156. **Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.** Ceribelli A, Motta F, De Santis M, Ansari AA, Ridgway WM, Gershwin ME, et al. *Journal of autoimmunity*. 2020:102442. <http://dx.doi.org/10.1016/j.jaut.2020.102442>.
157. **Coronavirus ORF1ab Polyprotein Associated Nsp16 Protein is a RlmE Methyltransferase and May Methylate 21S Mitochondrial rRNA of Host Cells Inhibiting Protein Synthesis.** Chakraborty AK. 2020.
158. **Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan.** Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. *Emerg Microbes Infect.* 2020;9(1):221-36. <http://dx.doi.org/10.1080/22221751.2020.1719902>. eCollection 2020.
159. **Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/HeI real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens.** Chan JF, Yip CC, To KK, Tang TH, Wong SC, Leung KH, et al. *J Clin Microbiol*. 2020. <http://dx.doi.org/10.1128/JCM.00310-20>.
160. **A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.** Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. *The Lancet*. 2020;395(10223):514-23.
161. **Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility.** Chan JFW, Zhang AJ, Yuan S, Poon VKM, Chan CCS, Lee ACY, et al. *Clinical infectious diseases : an official publication of the Infectious*

Diseases Society of America. 2020.

162. **COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease.** Chan KW, Wong VT, Tang SCW. *The American journal of Chinese medicine*. 2020:1-26.
163. **Severe influenza a cases requiring extra-corporeal membrane oxygenation (ECMO) therapy, 2018–2019.** Charlton M, Dunn C, Dashey S, Lai FY, Tang JW. *Journal of Infection*. 2020;80(4):469-96.
164. **Indian pharma threatened by COVID-19 shutdowns in China.** Chatterjee P. *Lancet (London, England)*. 2020;395(10225):675.
165. **Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial.** Chen C, Huang J, Yin P, Zhang Y, Cheng Z, Wu J, et al. *medRxiv*. 2020:2020.03.17.20037432.
166. **Clinical and immunologic features in severe and moderate Coronavirus Disease 2019.** Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. *The Journal of clinical investigation*. 2020.
167. **Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records.** Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. *The Lancet*. 2020;395(10226):809-15.
168. **Pathogenicity and transmissibility of 2019-nCoV—A quick overview and comparison with other emerging viruses.** Chen J. *Microbes and Infection*. 2020;22(2):69-71.
169. **Clinical progression of patients with COVID-19 in Shanghai, China.** Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. *J Infect*. 2020. <http://dx.doi.org/10.1016/j.jinf.2020.03.004>.
170. **Thoughts on prevention and treatment of coronavirus disease 2019 (COVID-19) by traditional Chinese medicine.** Chen J, Wang WQ, Shi CY, Fang JG. *Chinese Traditional and Herbal Drugs*. 2020;51(5):1106-12.
171. **Effects of sample processing modes on high-throughput sequencing of coronavirus whole genome.** Chen J, Zhang Y, Niu P, Lu R, Zhu N, Fan H, et al. *Chinese Journal of Microbiology and Immunology (China)*. 2020;40(2):103-9.
172. **The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease.** Chen L, Hao G. *Cardiovascular research*. 2020.
173. **The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2.** Chen L, Li X, Chen M, Feng Y, Xiong C. *Cardiovascular research*. 2020.
174. **Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease.** Chen L, Liu M, Zhang Z, Qiao K, Huang T, Chen M, et al. *British Journal of Ophthalmology*. 2020.
175. **RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak.** Chen L, Liu W, Zhang Q, Xu K, Ye G, Wu W, et al. *Emerging Microbes and Infections*. 2020;9(1):313-9.
176. **Convalescent plasma as a potential therapy for COVID-19.** Chen L, Xiong J, Bao L, Shi Y. *The Lancet Infectious Diseases*. 2020;20(4):398-400.
177. **Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.** Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. *BMJ (Clinical research ed)*. 2020;368:m1091.

178. **Buffer areas in emergency department to handle potential COVID-19 community infection in Taiwan.** Chen TY, Lai HW, Hou IL, Lin CH, Chen MK, Chou CC, et al. *Travel medicine and infectious disease*. 2020:101635.
179. **Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity.** Chen W, Lan Y, Yuan X, Deng X, Li Y, Cai X, et al. *Emerging Microbes and Infections*. 2020;9(1):469-73. <http://dx.doi.org/10.1080/22221751.2020.1732837>
180. **Dynamic Chest CT Evaluation in Three Cases of 2019 Novel Coronavirus Pneumonia.** Chen X, Liu S, Zhang C, Pu G, Sun J, Shen J, et al. *Archives of Iranian medicine*. 2020;23(4):277-80.
181. **Perioperative Management of Patients Infected with the Novel Coronavirus: Recommendation from the Joint Task Force of the Chinese Society of Anesthesiology and the Chinese Association of Anesthesiologists.** Chen X, Liu Y, Gong Y, Guo X, Zuo M, Li J, et al. *Anesthesiology*. 2020.
182. **The Presence of SARS-CoV-2 RNA in Feces of COVID-19 Patients.** Chen Y, Chen L, Deng Q, Zhang G, Wu K, Ni L, et al. *Journal of medical virology*. 2020.
183. **Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis.** Chen Y, Gong X, Wang L, Guo J. *medRxiv*. 2020:2020.03.25.20043133.
184. **Emerging coronaviruses: Genome structure, replication, and pathogenesis.** Chen Y, Liu Q, Guo D. *Journal of Medical Virology*. 2020;92(4):418-23.
185. **Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates.** Chen YW, Yiu CB, Wong KY. *F1000Research*. 2020;9:129. <http://dx.doi.org/10.12688/f1000research.22457.1>. eCollection 2020.
186. **High-resolution computed tomography manifestations of COVID-19 infections in patients of different ages.** Chen Z, Fan H, Cai J, Li Y, Wu B, Hou Y, et al. *European Journal of Radiology*. 2020;126.
187. **Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial.** Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. *medRxiv*. 2020:2020.03.22.20040758.
188. **Organ-protective Effect of Angiotensin-converting Enzyme 2 and its Effect on the Prognosis of COVID-19.** Cheng H, Wang Y, Wang GQ. *Journal of medical virology*. 2020.
189. **First case of Coronavirus Disease 2019 (COVID-19) pneumonia in Taiwan.** Cheng SC, Chang YC, Fan Chiang YL, Chien YC, Cheng M, Yang CH, et al. *Journal of the Formosan Medical Association*. 2020;119(3):747-51. <http://dx.doi.org/10.1016/j.jfma.2020.02.007>
190. **Disinfection of N95 respirators by ionized hydrogen peroxide in pandemic coronavirus disease 2019 (COVID-19) due to SARS-CoV-2.** Cheng VCC, Wong SC, Kwan GSW, Hui WT, Yuen KY. *The Journal of hospital infection*. 2020. <http://dx.doi.org/10.1016/j.jhin.2020.04.003>
191. **Kidney disease is associated with in-hospital death of patients with COVID-19.** Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. *Kidney International*. 2020;97(5):829-38.
192. **Clinical Features and Chest CT Manifestations of Coronavirus Disease 2019 (COVID-19) in a Single-Center Study in Shanghai, China.** Cheng Z, Lu Y, Cao Q, Qin L, Pan Z, Yan F, et al. *AJR American journal of roentgenology*. 2020:1-6.
193. **Harnessing the immune system via FcγR function in immune therapy: A pathway to next-gen mAbs.** Chenoweth AM, Wines BD, Anania JC, Mark Hogarth P. *Immunology and cell biology*. 2020.

194. **Staff safety during emergency airway management for COVID-19 in Hong Kong.** Cheung JCH, Ho LT, Cheng JV, Cham EYK, Lam KN. *The Lancet Respiratory Medicine*. 2020;8(4):e19.
195. **COVID-19 virus outbreak forecasting of registered and recovered cases after sixty day lockdown in Italy: A data driven model approach.** Chintalapudi N, Battineni G, Amenta F. *Journal of Microbiology, Immunology and Infection*. 2020. <http://dx.doi.org/10.1016/j.jmii.2020.04.004>
196. **How Should U.S. Hospitals Prepare for Coronavirus Disease 2019 (COVID-19)?** Chopra V, Toner E, Waldhorn R, Washer L. *Annals of internal medicine*. 2020. <http://dx.doi.org/10.7326/M20-0907>.
197. **Angiotensin II for the Treatment of COVID-19–Related Vasodilatory Shock.** Chow AL. *Anesthesia and analgesia*. 2020.
198. **Angiotensin II for the Treatment of COVID-19-Related Vasodilatory Shock.** Chow JH, Mazzeffi MA, McCurdy MT. *Anesthesia and analgesia*. 2020.
199. **Biophysical characterization of the SARS-CoV-2 spike protein binding with the ACE2 receptor explains increased COVID-19 pathogenesis.** Chowdhury R, Maranas CD. *bioRxiv*. 2020:2020.03.30.015891.
200. **Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.** Choy KT, Wong AYL, Kaewpreedee P, Sia SF, Chen D, Hui KPY, et al. *Antiviral Research*. 2020;178.
201. **A RANDOMIZED TRIAL OF INSTRUCTOR-LED TRAINING VERSUS VIDEO LESSON IN TRAINING HEALTH CARE PROVIDERS IN PROPER DRESSING AND DOFFING OF PERSONAL PROTECTIVE EQUIPMENT.** Christensen L, Rasmussen CS, Benfield T, Franc JM. *Disaster medicine and public health preparedness*. 2020:1-15. <http://dx.doi.org/10.1017/dmp.2020.56>.
202. **Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19.** Chu H, Chan JFW, Wang Y, Yuen TTT, Chai Y, Hou Y, et al. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
203. **Clinical Characteristics of 54 medical staff with COVID-19: A retrospective study in a single center in Wuhan, China.** Chu J, Yang N, Wei Y, Yue H, Zhang F, Zhao J, et al. *Journal of medical virology*. 2020.
204. **The Restructuring of Structural Heart Disease Practice During The Covid-19 Pandemic.** Chung CJ, Nazif TM, Wolbinski M, Hakemi E, Lebehn M, Brandwein R, et al. *Journal of the American College of Cardiology*. 2020. <http://dx.doi.org/10.1016/j.jacc.2020.04.009>.
205. **CT imaging features of 2019 novel coronavirus (2019-nCoV).** Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, et al. *Radiology*. 2020;295(1):202-7.
206. **Novel coronavirus infection: Covid-19.** Çiftçi E, Çoksüer F. *Flora*. 2020;25(1):9-18.
207. **Infection of cultured intestinal epithelial cells with severe acute respiratory syndrome coronavirus.** Cinatl Jr J, Hoever G, Morgenstern B, Preiser W, Vogel JU, Hofmann WK, et al. *Cellular and Molecular Life Sciences*. 2004;61(16):2100-12.
208. **COVID-19 Outbreak: An Overview.** Ciotti M, Angeletti S, Minieri M, Giovannetti M, Benvenuto D, Pascarella S, et al. *Chemotherapy*. 2020:1-9.
209. **Coronavirus uses as binding site in humans angiotensin-converting enzyme 2 functional receptor that is involved in arterial blood pressure control and fibrotic response to damage and is a drug target in cardiovascular disease. Is this just a phylogenetic coincidence?** Ciulla MM. *Journal of Medical Virology*. 2020.

210. **Genome Detective Coronavirus Typing Tool for rapid identification and characterization of novel coronavirus genomes.** Cleemput S, Dumon W, Fonseca V, Karim WA, Giovanetti M, Alcantara LC, et al. *Bioinformatics* (Oxford, England). 2020.
211. **Platelet-derived HMGB1: Critical mediator of SARs related to transfusion.** Cognasse F, Sut C, Hamzeh-Cognasse H, Garraud O. *Annals of Translational Medicine*. 2020;8(4).
212. **New coronavirus threat galvanizes scientists.** Cohen J. *Science*. 2020;367(6477):492-3. <http://dx.doi.org/10.1126/science.367.6477.492>.
213. **Vaccine designers take first shots at COVID-19: Two candidate vaccines start trials while dozens more are rushed into development.** Cohen J, Kupferschmidt K. *Science*. 2020;368(6486):14-6.
214. **International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic.** Coles CE, Aristei C, Bliss J, Boersma L, Brunt AM, Chatterjee S, et al. *Clinical Oncology*. 2020;32(5):279-81.
215. **Well-aerated Lung on Admitting Chest CT to Predict Adverse Outcome in COVID-19 Pneumonia.** Colombi D, Bodini FC, Petrini M, Maffi G, Morelli N, Milanese G, et al. *Radiology*. 2020:201433. <http://dx.doi.org/10.1148/radiol.2020201433>.
216. **Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.** Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. *International journal of antimicrobial agents*. 2020.
217. **Chloroquine for the 2019 novel coronavirus SARS-CoV-2.** Colson P, Rolain JM, Raoult D. *International journal of antimicrobial agents*. 2020;55(3).
218. **Letter to the editor: Plenty of coronaviruses but no SARS-CoV-2.** Colson P, Scola BL, Esteves-Vieira V, Ninove L, Zandotti C, Jimeno MT, et al. *Eurosurveillance*. 2020;25(8).
219. **COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action.** Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I. *Dermatologic therapy*. 2020:e13298.
220. **Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies.** Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. *Journal of biological regulators and homeostatic agents*. 2020;34(2).
221. **Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection.** Conti P, Younes A. *Journal of biological regulators and homeostatic agents*. 2020;34(2).
222. **The novel zoonotic COVID-19 pandemic: An expected global health concern.** Contini C, Nuzzo MD, Barp N, Bonazza A, de Giorgio R, Tognon M, et al. *Journal of Infection in Developing Countries*. 2020;14(3):254-64.
223. **Identification of Coronavirus Sequences in Carp cDNA from Wuhan, China.** Conway MJ. *Journal of medical virology*. 2020.
224. **On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2.** Corrêa Giron C, Laaksonen A, Barroso da Silva F. *Journal*. 2020(Issue).
225. **SARS-CoV-2, the Virus that Causes COVID-19: Cytometry and the New Challenge for Global Health.** Cossarizza A, De Biasi S, Guaraldi G, Girardis M, Mussini C. *Cytometry Part A : the journal of the International Society for Analytical Cytology*. 2020.

226. **Handling and Processing of Blood Specimens from Patients with COVID-19 for Safe Studies on Cell Phenotype and Cytokine Storm.** Cossarizza A, Gibellini L, De Biasi S, Lo Tartaro D, Mattioli M, Paolini A, et al. *Cytometry Part A : the journal of the International Society for Analytical Cytology*. 2020.
227. **SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus.** Costanzo M, De Giglio MAR, Roviello GN. *Curr Med Chem*. 2020. <http://dx.doi.org/10.2174/0929867327666200416131117>.
228. **The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade.** Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. *Antiviral Res*. 2020;176:104742. <http://dx.doi.org/10.1016/j.antiviral.2020.104742>. Epub 2020 Feb 10.
229. **WHO declares COVID-19 a pandemic.** Cucinotta D, Vanelli M. *Acta Biomedica*. 2020;91(1):157-60.
230. **Traditional Chinese medicine for treatment of coronavirus disease 2019: A review.** Cui HT, Li YT, Guo LY, Liu XG, Wang LS, Jia JW, et al. *Traditional Medicine Research*. 2020;5(2):65-73.
231. **Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia.** Cui S, Chen S, Li X, Liu S, Wang F. *Journal of thrombosis and haemostasis : JTH*. 2020. <http://dx.doi.org/10.1111/jth.14830>
232. **Role of Porcine Aminopeptidase N and Sialic Acids in Porcine Coronavirus Infections in Primary Porcine Enterocytes.** Cui T, Theuns S, Xie J, Van den Broeck W, Nauwynck HJ. *Viruses*. 2020;12(4).
233. **Treatment of COVID-19: old tricks for new challenges.** Cunningham AC, Goh HP, Koh D. *Critical care (London, England)*. 2020;24(1):91.
234. **Comment on "Organ-protective Effect of Angiotensin-converting Enzyme 2 and its Effect on the Prognosis of COVID-19".** Cure E, Cumhuri Cure M. *Journal of medical virology*. 2020.
235. **This scientist hopes to test coronavirus drugs on animals in locked-down Wuhan.** Cyranoski D. *Nature*. 2020;577(7792):607. <http://dx.doi.org/10.1038/d41586-020-00190-6>.
236. **Coronavirus (Covid-19) outbreak on the cruise ship Diamond Princess.** Dahl E. *International maritime health*. 2020;71(1):5-8.
237. **High-resolution Chest CT Features and Clinical Characteristics of Patients Infected with COVID-19 in Jiangsu, China.** Dai H, Zhang X, Xia J, Zhang T, Shang Y, Huang R, et al. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2020.
238. **Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology.** Dal Moro F, Livi U. *Clinical Immunology*. 2020;214.
239. **Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention and management.** D'Amico F, Baumgart DC, Danese S, Peyrin-Biroulet L. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. 2020. <http://dx.doi.org/10.1016/j.cgh.2020.04.001>.
240. **Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19.** Damle B, Vourvahis M, Wang E, Leaney J, Corrigan B. *Clin Pharmacol Ther*. 2020. <http://dx.doi.org/10.1002/cpt.1857>.
241. **Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.** Danser AHJ, Epstein M, Batlle D. *Hypertension (Dallas, Tex : 1979)*. 2020:HYPERTENSIONAHA12015082.

242. **Renin-Angiotensin System Blockers and the COVID-19 Pandemic.** Danser AHJ, Epstein M, Battlle D. Hypertension. 2020:HYPERTENSIONAHA.120.15082.
243. **From Endothelium to Lipids, Through microRNAs and PCSK9: A Fascinating Travel Across Atherosclerosis.** D'Ardes D, Santilli F, Guagnano MT, Bucci M, Cipollone F. High Blood Press Cardiovasc Prev. 2020;27(1):1-8.
244. **Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?** Das UN. Archives of Medical Research. 2020.
245. **Coronavirus Disease 2019 (COVID-19) Pandemic and Pregnancy.** Dashraath P, Jing Lin Jeslyn W, Mei Xian Karen L, Li Min L, Sarah L, Biswas A, et al. American journal of obstetrics and gynecology. 2020.
246. **Considerations for statin therapy in patients with COVID-19.** Dashti-Khavidaki S, Khalili H. Pharmacotherapy. 2020.
247. **Thalidomide against coronavirus disease 2019 (Covid-19): A medicine with a thousand faces.** Dastan F, Tabarsi P, Marjani M, Moniri A, Hashemian SM, Tavakoli-Ardakani M, et al. Iranian Journal of Pharmaceutical Research. 2020;19(1):1-2.
248. **Mutated COVID-19 may foretell a great risk for mankind in the future.** Dawood AA. New Microbes and New Infections. 2020;35.
249. **Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists.** Day M. BMJ (Clinical research ed). 2020;368:m1086.
250. **Covid-19: European drugs agency to review safety of ibuprofen.** Day M. BMJ (Clinical research ed). 2020;368:m1168.
251. **Managing neonates with respiratory failure due to SARS-CoV-2.** De Luca D. The Lancet Child and Adolescent Health. 2020;4(4):e8.
252. **Lack of Antiviral Activity of Darunavir against SARS-CoV-2.** De Meyer S, Bojkova D, Cinati J, Van Damme E, Buyck C, Van Loock M, et al. medRxiv. 2020:2020.04.03.20052548.
253. **Speculation is not evidence: antihypertensive therapy and COVID-19.** de Simone G, Mancusi C. European Heart Journal - Cardiovascular Pharmacotherapy. 2020.
254. **Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.** de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, et al. Proc Natl Acad Sci U S A. 2020;117(12):6771-6. <http://dx.doi.org/10.1073/pnas.1922083117>. Epub 2020 Feb 13.
255. **A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology.** de Leon J, Ruan CJ, Schoretsanitis G, De las Cuevas C. Psychotherapy and Psychosomatics. 2020.
256. **COVID-19 from veterinary medicine and one health perspectives: What animal coronaviruses have taught us.** Decaro N, Martella V, Saif LJ, Buonavoglia C. Research in Veterinary Science. 2020;131:21-3.
257. **The GReek study in the Effects of Colchicine in COvid-19 complications prevention (GRECCO-19 study): rationale and study design.** Deftereos SG, Siasos G, Giannopoulos G, Vrachatis DA, Angelidis C, Giotaki SG, et al. Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese. 2020.
258. **2019 Novel Coronavirus - Important Information for Clinicians.** Del Rio C, Malani PN. JAMA - Journal of the American Medical Association. 2020;323(11):1039-40.

259. **The host's angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections.** Delanghe JR, Speeckaert MM, De Buyzere ML. *Clinica chimica acta; international journal of clinical chemistry*. 2020.
260. **The global battle against SARS-CoV-2 and COVID-19.** Deng CX. *International journal of biological sciences*. 2020;16(10):1676-7.
261. **Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019:a retrospective cohort study.** Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. *The Journal of infection*. 2020.
262. **Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study.** Deng Y, Liu W, Liu K, Fang YY, Shang J, Zhou L, et al. *Chinese medical journal*. 2020.
263. **Study on active compounds from Huoxiang Zhengqi Oral Liquid for prevention of coronavirus disease 2019 (COVID-19) based on network pharmacology and molecular docking.** Deng YJ, Liu BW, He ZX, Liu T, Zheng RL, Yang AD, et al. *Chinese Traditional and Herbal Drugs*. 2020;51(5):1113-22.
264. **Discussing the ABCs of Health Security - Antibiotic Resistance, Biothreats, and Coronavirus.** Desai AN. *JAMA - Journal of the American Medical Association*. 2020;323(10):912-4.
265. **Rapid surveillance of COVID-19 in the United States using a prospective space-time scan statistic: Detecting and evaluating emerging clusters.** Desjardins MR, Hohl A, Delmelle EM. *Applied geography (Sevenoaks, England)*. 2020;118:102202. <http://dx.doi.org/10.1016/j.apgeog.2020.102202>. Epub 2020 Apr 8.
266. **New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?** Devaux CA, Rolain JM, Colson P, Raoult D. *International journal of antimicrobial agents*. 2020:105938.
267. **Perioperative COVID-19 Defense: An Evidence-Based Approach for Optimization of Infection Control and Operating Room Management.** Dexter F, Parra MC, Brown JR, Loftus RW. *Anesthesia and analgesia*. 2020.
268. **COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics.** Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, et al. *Human vaccines & immunotherapeutics*. 2020:1-7.
269. **How do we plan hematopoietic cell transplant and cellular therapy with the looming COVID-19 threat?** Dholaria B, Savani BN. *Br J Haematol*. 2020;189(2):239-40. <http://dx.doi.org/10.1111/bjh.16597>. Epub 2020 Mar 16.
270. **Antipsoriatic treatments during COVID-19 outbreak.** Di Lernia V. *Dermatologic therapy*. 2020:e13345.
271. **A possible probiotic (*S. salivarius* K12) approach to improve oral and lung microbiotas and raise defenses against SARS-CoV-2.** Di Pierro F. *Minerva medica*. 2020. <http://dx.doi.org/10.23736/S0026-4806.20.06570-2>.
272. **Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured *Lentinula edodes* mycelia (AHCC) in patients infected with 2019 novel coronavirus.** Di Pierro F, Bertuccioli A, Cavecchia I. *Minerva gastroenterologica e dietologica*. 2020.
273. **Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.** Diaz JH. *Journal of travel medicine*. 2020.
274. **Currently available intravenous immunoglobulin (Gamunex©-C and Flebogamma© DIF) contains antibodies reacting against SARS-CoV-2 antigens.** Díez J-M, Romero C, Gajardo R. *bioRxiv*. 2020.

275. **The clinical characteristics of pneumonia patients co-infected with 2019 novel coronavirus and influenza virus in Wuhan, China.** Ding Q, Lu P, Fan Y, Xia Y, Liu M. *Journal of medical virology*. 2020.
276. **The clinical characteristics of pneumonia patients coinfecting with 2019 novel coronavirus and influenza virus in Wuhan, China.** Ding Q, Lu P, Fan Y, Xia Y, Liu M. *Journal of Medical Virology*. 2020.
277. **Host factor prioritization for pan-viral genetic perturbation screens using random intercept models and network propagation.** Dirmeier S, Dächert C, van Hemert M, Tas A, Ogando NS, van Kuppeveld F, et al. *PLoS Computational Biology*. 2020;16(2).
278. **Novel coronavirus infection (Covid-19) in humans: A scoping review and meta-analysis.** Do Nascimento IJB, Cacic N, Abdulazeem HM, von Groote TC, Jayarajah U, Weerasekara I, et al. *Journal of Clinical Medicine*. 2020;9(4).
279. **Corona virus: A novel outbreak.** Dogra A, Goyal B, Sharma AM. *Biomedical and Pharmacology Journal*. 2020;13(1):8-10.
280. **New PA/1220/98-like variant of infectious bronchitis virus in Poland.** Domanska-Blicharz K, Sajewicz-Krukowska J, Lisowska A. *Avian pathology : journal of the WVPA*. 2020:1-25.
281. **Discovering drugs to treat coronavirus disease 2019 (COVID-19).** Dong L, Hu S, Gao J. *Drug discoveries & therapeutics*. 2020;14(1):58-60.
282. **A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV).** Dong S, Sun J, Mao Z, Wang L, Lu YL, Li J. *Journal of medical virology*. 2020.
283. **Eleven Faces of Coronavirus Disease 2019.** Dong X, Cao YY, Lu XX, Zhang JJ, Du H, Yan YQ, et al. *Allergy*. 2020.
284. **Infectious diseases in children and adolescents in China: analysis of national surveillance data from 2008 to 2017.** Dong Y, Wang L, Burgner DP, Miller JE, Song Y, Ren X, et al. *Bmj*. 2020;369:m1043. <http://dx.doi.org/10.1136/bmj.m1043>.
285. **[Pharmacotherapeutics for the new coronavirus pneumonia].** Du B, Qiu HB, Zhan X, Wang YS, Kang HYJ, Li XY, et al. *Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases*. 2020;43(3):173-6. <http://dx.doi.org/10.3760/cma.j.issn.1001-0939.2020.03.005>.
286. **[Investigation on demands for antenatal care services among 2 002 pregnant women during the epidemic of COVID-19 in Shanghai].** Du L, Gu YB, Cui MQ, Li WX, Wang J, Zhu LP, et al. *Zhonghua Fu Chan Ke Za Zhi*. 2020;55(3):160-5. <http://dx.doi.org/10.3760/cma.j.cn112141-20200218-00112>.
287. **Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study.** Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. *The European respiratory journal*. 2020.
288. **Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study.** Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. *American journal of respiratory and critical care medicine*. 2020.
289. **Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection.** Du YX, Chen XP. *Clin Pharmacol Ther*. 2020. <http://dx.doi.org/10.1002/cpt.1844>.
290. **Detection of antibodies against SARS-CoV-2 in patients with COVID-19.** Du Z, Zhu F, Guo F, Yang B, Wang T. *Journal of medical virology*. 2020.

291. **The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study.** Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. medRxiv. 2020:2020.03.16.20036145.
292. **The Trial of Chloroquine in the Treatment of Corona Virus Disease 2019 (COVID-19) and Its Research Progress in Forensic Toxicology.** Duan YJ, Liu Q, Zhao SQ, Huang F, Ren L, Liu L, et al. Fa yi xue za zhi. 2020;36(2).
293. **Pre- and Posttreatment Chest CT Findings: 2019 Novel Coronavirus (2019-nCoV) Pneumonia.** Duan YN, Qin J. Radiology. 2020;295(1):21.
294. **The 2019 novel Coronavirus (2019-NCov): Novel virus, old challenges.** Duarte R, Furtado I, Sousa L, Carvalho C. Acta Medica Portuguesa. 2020;33(3):155-7.
295. **Covid-19: Trump sought to buy vaccine developer exclusively for US, say German officials.** Dyer O. BMJ (Clinical research ed). 2020;368:m1100.
296. **Saudi Arabia`s measures to curb the COVID-19 outbreak: temporary suspension of the Umrah pilgrimage.** Ebrahim SH, Memish ZA. J Travel Med. 2020. <http://dx.doi.org/10.1093/jtm/taaa029>.
297. **Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond.** Ekins S, Lane TR, Madrid PB. Pharmaceutical research. 2020;37(4):71. <http://dx.doi.org/10.1007/s11095-020-02799-8>.
298. **Tilorone: A Broad-Spectrum Antiviral For Emerging Viruses.** Ekins S, Madrid PB. Antimicrobial agents and chemotherapy. 2020.
299. **COVID-19 pandemia: Impact on the cardiovascular system. Data of 1st April 2020.** El Boussadani B, Benajiba C, Aajal A, Ait Brik A, Ammour O, El Hangouch J, et al. Annales de Cardiologie et d'Angéiologie. 2020. <http://dx.doi.org/10.1016/j.ancard.2020.04.001>
300. **From SARS to COVID-19: A previously unknown SARS- related coronavirus (SARS-CoV-2) of pandemic potential infecting humans – Call for a One Health approach.** El Zowalaty ME, Järhult JD. One Health. 2020;9.
301. **Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.** Elens L, Langman LJ, Hesselink DA, Bergan S, Moes D, Molinaro M, et al. Ther Drug Monit. 2020. <http://dx.doi.org/10.1097/FTD.0000000000000761>.
302. **Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.** Elfiky AA. Life Sciences. 2020;248.
303. **Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.** Elfiky AA. Life sciences. 2020:117592. <http://dx.doi.org/10.1016/j.lfs.2020.117592>.
304. **Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?** Esler M, Esler D. Journal of hypertension. 2020.
305. **Coronavirus pandemic and worries during pregnancy; a letter to editor.** Fakari FR, Simbar M. Archives of Academic Emergency Medicine. 2020;8(1).
306. **Anal swab findings in an infant with COVID-19.** Fan Q, Pan Y, Wu Q, Liu S, Song X, Xie Z, et al. Pediatric Investigation. 2020;4(1):48-50.
307. **Analysis of medication characteristics of traditional Chinese medicine in treating coronavirus disease-19 based on data mining.** Fan T, Chen Y, Bai Y, Ma F, Wang H, Yang Y, et al. Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences. 2020;49(1):0.

308. **Clinical Features of COVID-19-Related Liver Damage.** Fan Z, Chen L, Li J, Cheng X, Jingmao Y, Tian C, et al. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. 2020. <http://dx.doi.org/10.1016/j.cgh.2020.04.002>.
309. **Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?** Fang L, Karakiulakis G, Roth M. *The Lancet Respiratory Medicine*. 2020;8(4):e21.
310. **Changes of CT findings in a 2019 novel coronavirus (2019-nCoV) pneumonia patient.** Fang X, Zhao M, Li S, Yang L, Wu B. *Qjm*. 2020;113(4):271-2. <http://dx.doi.org/10.1093/qjmed/hcaa038>.
311. **CT manifestations of two cases of 2019 novel coronavirus (2019-NCoV) pneumonia.** Fang Y, Zhang H, Xu Y, Xie J, Pang P, Ji W. *Radiology*. 2020;295(1):208-9.
312. **Comparisons of nucleic acid conversion time of SARS-CoV-2 of different samples in ICU and non-ICU patients.** Fang Z, Zhang Y, Hang C, Zhang W, Ai J, Li S. *The Journal of infection*. 2020.
313. **Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection.** Fantini J, Di Scala C, Chahinian H, Yahi N. *International journal of antimicrobial agents*. 2020.
314. **A field indoor air measurement of SARS-CoV-2 in the patient rooms of the largest hospital in Iran.** Faridi S, Niazi S, Sadeghi K, Naddafi K, Yavarian J, Shamsipour M, et al. *Science of the Total Environment*. 2020;725.
315. **DNA sequence symmetries from randomness: the origin of the Chargaff's second parity rule.** Fariselli P, Taccioli C, Pagani L, Maritan A. *Briefings in bioinformatics*. 2020.
316. **Middle East respiratory syndrome coronavirus (MERS-CoV) — Surveillance and testing in North England from 2012 to 2019.** Farooq HZ, Davies E, Ahmad S, Machin N, Hesketh L, Guiver M, et al. *International Journal of Infectious Diseases*. 2020;93:237-44.
317. **Covid-19 - Navigating the uncharted.** Fauci AS, Lane HC, Redfield RR. *New England Journal of Medicine*. 2020;382(13):1268-9.
318. **Baricitinib for COVID-19: a suitable treatment?** Favalli EG, Biggioggero M, Maioli G, Caporali R. *The Lancet Infectious diseases*. 2020.
319. **COVID-19 infection and rheumatoid arthritis: Faraway, so close!** Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. *Autoimmunity reviews*. 2020:102523.
320. **Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection.** Fedson DS, Opal SM, Rordam OM. *mBio*. 2020;11(2).
321. **Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.** Feldmann M, Maini RN, Woody JN, Holgate ST, Winter G, Rowland M, et al. *The Lancet*. 2020. [http://dx.doi.org/10.1016/S0140-6736\(20\)30858-8](http://dx.doi.org/10.1016/S0140-6736(20)30858-8)
322. **A case report of COVID-19 with false negative RT-PCR test: necessity of chest CT.** Feng H, Liu Y, Lv M, Zhong J. *Japanese journal of radiology*. 2020.
323. **COVID-19 with Different Severity: A Multi-center Study of Clinical Features.** Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. *American Journal of Respiratory and Critical Care Medicine*. 2020.
324. **Protecting healthcare workers from sars-cov-2 infection: Practical indications.** Ferioli M, Cisternino C,

Leo V, Pisani L, Palange P, Nava S. *European Respiratory Review*. 2020;29(155):1-10.

325. **Comment on: Cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies.** Fernandez-Nieto D, Ortega-Quijano D, Segurado-Miravalles G, Pindado-Ortega C, Prieto-Barrios M, Jimenez-Cauhe J. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2020. <http://dx.doi.org/10.1111/jdv.16470>.

326. **COVID-19 in solid organ transplant recipients: a single-center case series from Spain.** Fernandez-Ruiz M, Andres A, Loinaz C, Delgado JF, Lopez-Medrano F, San Juan R, et al. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2020. <http://dx.doi.org/10.1111/ajt.15929>.

327. **Chloroquine and hydroxychloroquine in covid-19.** Ferner RE, Aronson JK. *Bmj*. 2020;369:m1432. <http://dx.doi.org/10.1136/bmj.m1432>.

328. **A Case of Novel Coronavirus Disease 19 in a Chronic Hemodialysis Patient Presenting with Gastroenteritis and Developing Severe Pulmonary Disease.** Ferrey AJ, Choi G, Hanna RM, Chang Y, Tantisattamo E, Ivaturi K, et al. *American journal of nephrology*. 2020:1-6.

329. **COVID-19: the new challenge for rheumatologists.** Ferro F, Elefante E, Baldini C, Bartoloni E, Puxeddu I, Talarico R, et al. *Clinical and experimental rheumatology*. 2020;38(2):175-80.

330. **Are my patients with rheumatic diseases at higher risk of COVID-19?** Figueroa-Parra G, Aguirre-Garcia GM, Gamboa-Alonso CM, Camacho-Ortiz A, Galarza-Delgado DA. *Annals of the rheumatic diseases*. 2020.

331. **Introduction to the special issue: Tumor antigens in the time of the coronavirus pandemic.** Finn OJ. *Seminars in Immunology*. 2020.

332. **Inflammatory bowel disease care in the COVID-19 pandemic era: the Humanitas, Milan experience.** Fiorino G, Allocca M, Furfaro F, Gilardi D, Zilli A, Radice S, et al. *Journal of Crohn's & colitis*. 2020.

333. **Q&A: The novel coronavirus outbreak causing COVID-19.** Fisher D, Heymann D. *BMC medicine*. 2020;18(1):57. <http://dx.doi.org/10.1186/s12916-020-01533-w>.

334. **Novel Coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve.** Fishman JA, Grossi PA. *American Journal of Transplantation*. 2020.

335. **Misguided drug advice for COVID-19.** FitzGerald GA. *Science*. 2020;367(6485):1434.

336. **Has China faced only a herald wave of SARS-CoV-2?** Flahault A. *The Lancet*. 2020;395(10228):947.

337. **Synthesis and Biological Evaluation of Novel (thio)semicarbazone-Based Benzimidazoles as Antiviral Agents against Human Respiratory Viruses.** Francesconi V, Cichero E, Schenone S, Naesens L, Tonelli M. *Molecules (Basel, Switzerland)*. 2020;25(7).

338. **Identifying and Interrupting Superspreading Events-Implications for Control of Severe Acute Respiratory Syndrome Coronavirus 2.** Frieden TR, Lee CT. *Emerging infectious diseases*. 2020;26(6).

339. **Why tocilizumab could be an effective treatment for severe COVID-19?** Fu B, Xu X, Wei H. *Journal of Translational Medicine*. 2020;18(1):164.

340. **COVID-19 Infection in a Patient with End-Stage Kidney Disease.** Fu D, Yang B, Xu J, Mao Z, Zhou C, Xue C. *Nephron*. 2020.

341. **A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses.** Fung SY, Yuen KS, Ye ZW, Chan CP, Jin DY. *Emerging Microbes and Infections.* 2020;9(1):558-70.
342. **Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin.** Gabriels J, Saleh M, Chang D, Epstein LM. *HeartRhythm Case Reports.* 2020.
343. **Clinical laboratory and SARS-CoV-2 infection: where do we stand?** Galli C, Plebani M. *Clinical chemistry and laboratory medicine.* 2020.
344. **COVID-19 in kidney transplant recipients.** Gandolfini I, Delsante M, Fiaccadori E, Zaza G, Manenti L, Degli Antoni A, et al. *American Journal of Transplantation.* 2020.
345. **Detection of serum immunoglobulin M and immunoglobulin G antibodies in 2019-novel coronavirus infected cases from different stages.** Gao HX, Li YN, Xu ZG, Wang YL, Wang HB, Cao JF, et al. *Chinese medical journal.* 2020.
346. **Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).** Gao J, Hu S. *BioScience Trends.* 2020.
347. **Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.** Gao J, Tian Z, Yang X. *Bioscience trends.* 2020;14(1):72-3.
348. **2019 Novel coronavirus infection and gastrointestinal tract.** Gao QY, Chen YX, Fang JY. *Journal of Digestive Diseases.* 2020;21(3):125-6.
349. **A family cluster of severe acute respiratory syndrome coronavirus 2 infections.** Gao X, Yuan Z, Yang D, Li H, Zhang Y, Gao P, et al. *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.* 2020.
350. **Characterization, Pathogenicity and Protective efficacy of a Cell Culture-Derived Porcine Deltacoronavirus.** Gao X, Zhao D, Zhou P, Zhang L, Li M, Li W, et al. *Virus research.* 2020:197955.
351. **Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19.** Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. *Journal of medical virology.* 2020.
352. **Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modeling approach for effective drug repurposing.** Garcia-Cremades M, Solans BP, Hughes E, Ernest JP, Wallender E, Aweeka F, et al. *Clin Pharmacol Ther.* 2020. <http://dx.doi.org/10.1002/cpt.1856>.
353. **Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modeling approach for effective drug repurposing.** Garcia-Cremades M, Solans BP, Hughes E, Ernest JP, Wallender E, Aweeka F, et al. *Clinical Pharmacology & Therapeutics.*
354. **Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020.** Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, et al. *MMWR Morbidity and mortality weekly report.* 2020;69(15):458-64. <http://dx.doi.org/10.15585/mmwr.mm6915e3>.
355. **Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic.** Gasmi A, Noor S, Tippairote T, Dadar M, Menzel A, Bjørklund G. *Clinical immunology (Orlando, Fla).* 2020:108409. <http://dx.doi.org/10.1016/j.clim.2020.108409>
356. **Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label**

non-randomized clinical trial. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. International journal of antimicrobial agents. 2020:105949. <http://dx.doi.org/10.1016/j.ijantimicag.2020.105949>.

357. **Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.** Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, et al. Travel Med Infect Dis. 2020:101663. <http://dx.doi.org/10.1016/j.tmaid.2020.101663>.

358. **ANNALS EXPRESS: On the Clinical Utility of Cardiac Troponin measurement in COVID-19 Infection.** Gaze DC. Annals of clinical biochemistry. 2020:4563220921888.

359. **BIANCA for an automatic detection of multiple sclerosis lesions using machine learning.** Gentile G, Battaglini M, Luchetti L, Giorgio A, Griffanti L, Sundaresan V, et al. Multiple Sclerosis Journal. 2019;25:681.

360. **Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs.** Georgiev T. Rheumatology international. 2020.

361. **Angiotensin Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System.** Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong J-C, Turner Anthony J, et al. Circulation Research. 2020.

362. **Community Transmission of SARS-CoV-2 at Two Family Gatherings - Chicago, Illinois, February-March 2020.** Ghinai I, Woods S, Ritger KA, McPherson TD, Black SR, Sparrow L, et al. MMWR Morbidity and mortality weekly report. 2020;69(15):446-50. <http://dx.doi.org/10.15585/mmwr.mm6915e1>.

363. **Rapid sputum testing and not thermal screening alone should be the first-line screening test at airports: A Bayesian analysis.** Ghosal S, Sinha B. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020;14(4):317-8.

364. **Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis.** Ghosal S, Sinha B, Majumder M, Misra A. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020;14(4):319-23.

365. **Telemedicine for diabetes care in India during COVID19 pandemic and national lockdown period: Guidelines for physicians.** Ghosh A, Gupta R, Misra A. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020;14(4):273-6.

366. **Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past.** Giannis D, Ziogas IA, Gianni P. Journal of Clinical Virology. 2020;127. <http://dx.doi.org/10.1016/j.jcv.2020.104362>

367. **Novel 2019 coronavirus SARS-CoV-2 (COVID-19): An updated overview for emergency clinicians.** Giwa AL, Desai A, Duca A. Emergency medicine practice. 2020;22(5):1-28.

368. **Shell disorder analysis predicts greater resilience of the SARS-CoV-2 (COVID-19) outside the body and in body fluids.** Goh GKM, Dunker AK, Foster JA, Uversky VN. Microbial Pathogenesis. 2020;144.

369. **Rigidity of the outer shell predicted by a protein intrinsic disorder model sheds light on the COVID-19 (Wuhan-2019-nCoV) infectivity.** Goh GKM, Keith Dunker A, Foster JA, Uversky VN. Biomolecules. 2020;10(2).

370. **Harnessing Innate Immunity to Eliminate SARS-CoV-2 and Ameliorate COVID-19 Disease.** Golonka RM, Saha P, Yeoh BS, Chattopadhyay S, Gewirtz AT, Joe B, et al. Physiological genomics. 2020.

371. **Timing of antiviral treatment initiation is critical to reduce SARS-Cov-2 viral load.** Gonçalves A,

Bertrand J, Ke R, Comets E, de Lamballerie X, Malvy D, et al. medRxiv. 2020:2020.04.04.20047886.

372. **Internet Hospitals Help Prevent and Control the Epidemic of COVID-19 in China: Multicenter User Profiling Study.** Gong K, Xu Z, Cai Z, Chen Y, Wang Z. Journal of medical Internet research. 2020;22(4):e18908. <http://dx.doi.org/10.2196/18908>.

373. **Novel findings from a beta coronavirus outbreak on an American Miniature Horse breeding farm in upstate New York.** Goodrich EL, Mittel LD, Glaser A, Ness SL, Radcliffe RM, Divers TJ. Equine Veterinary Education. 2020;32(3):150-4.

374. **A 25-year-old sample contributes the complete genome sequence of avian coronavirus vaccine strain ARKDPI, reisolated from commercial broilers in the United States.** Goraichuk IV, Davis JF, Kulkarni AB, Afonso CL, Suarez DL. Microbiology Resource Announcements. 2020;9(9).

375. **The antiviral compound remdesivir potently inhibits RNAdependent RNA polymerase from Middle East respiratory syndrome coronavirus.** Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. Journal of Biological Chemistry. 2020;295(15):4773-9.

376. **Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.** Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, et al. The Journal of biological chemistry. 2020. <http://dx.doi.org/10.1074/jbc.RA120.013679>.

377. **Perspective: cardiovascular disease and the Covid-19 pandemic.** Gori T, Lelieveld J, Münzel T. Basic Research in Cardiology. 2020;115(3).

378. **Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses.** Gorse GJ, Donovan MM, Patel GB. Journal of Medical Virology. 2020;92(5):512-7.

379. **Treatment of pancreatic diseases and prevention of infection during outbreak of 2019 coronavirus disease.** Gou SM, Yin T, Xiong JX, Peng T, Li Y, Wu HS. Zhonghua wai ke za zhi [Chinese journal of surgery]. 2020;58:E006.

380. **[Editorial] Possibility of transmission through dogs being a contributing factor to the extreme Covid19 outbreak in North Italy.** Goumenou M, Spandidos DA, Tsatsakis A. Molecular medicine reports. 2020. <http://dx.doi.org/10.3892/mmr.2020.11037>.

381. **Possibility of transmission through dogs being a contributing factor to the extreme Covid-19 outbreak in North Italy.** Goumenou M, Spandidos DA, Tsatsakis A. Molecular Medicine Reports. 2020;21(6):2293-5. <http://dx.doi.org/10.3892/mmr.2020.11037>

382. **Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection?** Gracia-Ramos AE. Archives of Medical Research. 2020.

383. **Immune Predictors of Mortality after Ribonucleic Acid Virus Infection.** Graham JB, Swarts JL, Menachery VD, Gralinski LE, Schäfer A, Plante KS, et al. Journal of Infectious Diseases. 2020;221(6):882-9.

384. **Return of the coronavirus: 2019-nCoV.** Gralinski LE, Menachery VD. Viruses. 2020;12(2).

385. **Semisynthesis and biological evaluation of amidochelocardin derivatives as broad-spectrum antibiotics.** Grandclaude C, Birudukota NVS, Elgaher WAM, Jumde RP, Yahiaoui S, Arisetti N, et al. European Journal of Medicinal Chemistry. 2020;188.

386. **Evidence that vitamin d supplementation could reduce risk of influenza and covid-19 infections and**

- deaths.** Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, et al. *Nutrients*. 2020;12(4).
387. **Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.** Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. *JAMA*. 2020.
388. **A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2.** Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. *Cell host & microbe*. 2020.
389. **Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support.** Gritti G, Raimondi F, Ripamonti D, Riva I, Landi F, Alborghetti L, et al. *medRxiv*. 2020:2020.04.01.20048561.
390. **Imaging Features of Coronavirus disease 2019 (COVID-19): Evaluation on Thin-Section CT.** Guan CS, Lv ZB, Yan S, Du YN, Chen H, Wei LG, et al. *Academic Radiology*. 2020.
391. **Clinical Characteristics of Coronavirus Disease 2019 in China.** Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. *The New England journal of medicine*. 2020.
392. **Hypertonic saline stimulates vagal afferents that respond to lung deflation.** Guardiola J, Saad M, Yu J. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*. 2019;317(6):R814-R7.
393. **Could chloroquine /hydroxychloroquine be harmful in Coronavirus Disease 2019 (COVID-19) treatment?** Guastalegname M, Vallone A. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
394. **Survival of Coronaviruses in Water and Wastewater.** Gundy PM, Gerba CP, Pepper IL. *Food and Environmental Virology*. 2009;1(1):10-4.
395. **Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.** Guo J, Huang Z, Lin L, Lv J. *Journal of the American Heart Association*. 2020;9(7):e016219.
396. **Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.** Guo J, Huang Z, Lin L, Lv J. *Journal of the American Heart Association*. 2020;9(7):e016219.
397. **Single-cell RNA Analysis on ACE2 Expression Provides Insight into SARS-CoV-2 Blood Entry and Heart Injury.** Guo J, Wei X, Li Q, Li L, Yang Z, Shi Y, et al. *medRxiv*. 2020:2020.03.31.20047621.
398. **Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19).** Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, et al. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
399. **Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19).** Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. *JAMA Cardiology*. 2020.
400. **Diabetes is a risk factor for the progression and prognosis of COVID-19.** Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. *Diabetes/Metabolism Research and Reviews*. 2020.
401. **The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.** Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. *Military Medical Research*. 2020;7(1):11.

402. **In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel.** Gupta MK, Vemula S, Donde R, Gouda G, Behera L, Vadde R. *Journal of biomolecular structure & dynamics*. 2020:1-17.
403. **Chloroquine in COVID-19: the evidence.** Gupta N, Agrawal S, Ish P. *Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace*. 2020;90(1). <http://dx.doi.org/10.4081/monaldi.2020.1290>.
404. **Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infection with reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc).** Gupta R, Misra A. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2020;14(3):251-4.
405. **Master regulator analysis of the sars-cov-2/human interactome.** Guzzi PH, Mercatelli D, Ceraolo C, Giorgi FM. *Journal of Clinical Medicine*. 2020;9(4):1-16.
406. **Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors.** Hackbart M, Deng X, Baker SC. *Proceedings of the National Academy of Sciences of the United States of America*. 2020;117(14):8094-103.
407. **Does recombinant human Erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?** Hadadi A, Mortezaadeh M, Kolahdouzan K, Alavian G. *Journal of medical virology*. 2020.
408. **Angiotensin-Converting Enzyme inhibitors (ACE inhibitors) and Angiotensin II Receptor Blockers (ARBs) role in SARS-CoV-2 infection: A Rapid Systematic Review.** Hadji J, Matuoka JY, PdCs P, Gvd B, Marra LP, Fcd M, et al. 2020.
409. **Thinking Globally, Acting Locally - The U.S. Response to Covid-19.** Haffajee RL, Mello MM. *The New England journal of medicine*. 2020. <http://dx.doi.org/10.1056/NEJMp2006740>.
410. **Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics).** Hamid S, Mir MY, Rohela GK. *New Microbes and New Infections*. 2020;35.
411. **Developments of isoCombretastatin A-4 derivatives as highly cytotoxic agents.** Hamze A, Alami M, Provot O. *European Journal of Medicinal Chemistry*. 2020;190.
412. **Noninvasive Positive Pressure Ventilation Treatment for Acute Respiratory Failure in SARS.** Han F, Jiang YY, Zheng JH, Gao ZC, He QY. *Sleep and Breathing*. 2004;8(2):97-106.
413. **Prominent changes in blood coagulation of patients with SARS-CoV-2 infection.** Han H, Yang L, Liu R, Liu F, Wu KL, Li J, et al. *Clinical chemistry and laboratory medicine*. 2020.
414. **Coronavirus 2019-nCoV: A brief perspective from the front line.** Han Q, Lin Q, Jin S, You L. *J Infect*. 2020;80(4):373-7. <http://dx.doi.org/10.1016/j.jinf.2020.02.010>. Epub 2020 Feb 25.
415. **Early Clinical and CT Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia.** Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D. *AJR American journal of roentgenology*. 2020:1-6.
416. **The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019.** Han W, Quan B, Guo Y, Zhang J, Lu Y, Feng G, et al. *J Med Virol*. 2020;92(5):461-3. <http://dx.doi.org/10.1002/jmv.25711>. Epub 2020 Mar 1.
417. **Novel Coronavirus Pneumonia (COVID-19) Progression Course in 17 Discharged Patients: Comparison**

of Clinical and Thin-Section CT Features During Recovery. Han X, Cao Y, Jiang N, Chen Y, Alwalid O, Zhang X, et al. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2020.

418. **A Diabetic Patient With 2019-nCoV Infection Who Recovered and Was Discharged From Hospital.** Han X, Fan Y, Wan YL, Shi H. *Journal of thoracic imaging.* 2020.

419. **COVID-19 in a patient with long-term use of glucocorticoids: A study of a familial cluster.** Han Y, Jiang M, Xia D, He L, Lv X, Liao X, et al. *Clinical Immunology.* 2020;214.

420. **Computational design of ACE2-based short peptide inhibitors of SARS-CoV-2.** Han Y, Kral P. 2020.

421. **A comparative-descriptive analysis of clinical characteristics in 2019-Coronavirus-infected children and adults.** Han YN, Feng ZW, Sun LN, Ren XX, Wang H, Xue YM, et al. *Journal of medical virology.* 2020.

422. **Application of integrative medicine protocols in treatment of coronavirus disease 2019.** Han YY, Zhao MR, Shi Y, Song ZH, Zhou SP, He Y. *Chinese Traditional and Herbal Drugs.* 2020;51(4):878-82.

423. **Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System—a Call for Epidemiologic Investigations.** Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2020.

424. **Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System—a Call for Epidemiologic Investigations.** Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. *Clinical Infectious Diseases.* 2020.

425. **Coronavirus 2019-nCoV: Is the genie already out of the bottle?** Hanscheid T, Valadas E, Grobusch MP. *Travel Medicine and Infectious Disease.* 2020.

426. **Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with 2019 Novel Coronavirus Disease, United States.** Harcourt J, Tamin A, Lu X, Kamili S, Sakthivel SK, Murray J, et al. *Emerging infectious diseases.* 2020;26(6).

427. **A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin.** Hasan A, Paray BA, Hussain A, Qadir FA, Attar F, Aziz FM, et al. *Journal of biomolecular structure & dynamics.* 2020:1-13.

428. **Childhood Rheumatic Diseases and COVID-19 Pandemic: An Intriguing Linkage and a New Horizon.** Haşlak F, Yıldız M, Adrovic A, Barut K, Kasapçopur Ö. *Balkan medical journal.* 2020.

429. **Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020.** Haveri A, Smura T, Kuivanen S, Österlund P, Hepojoki J, Ikonen N, et al. *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.* 2020;25(11).

430. **Research strategy of drugs against 2019-novel coronavirus based on supramolecular “qi chromatography” theory of TCM.** He FY, Deng KW, Pan X, Zhou YQ. *Chinese Traditional and Herbal Drugs.* 2020;51(3):557-62.

431. **Clinical experience of high-flow nasal cannula oxygen therapy in severe corona virus disease 2019 (COVID-19) patients.** He G, Han Y, Fang Q, Zhou J, Shen J, Li T, et al. *Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences.* 2020;49(1):0.

432. **Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients.** He XW, Lai JS, Cheng J, Wang MW, Liu YJ, Xiao ZC, et al. *Zhonghua xin xue guan bing za zhi.* 2020;48:E011.

433. **[Replication and transmission mechanisms of highly pathogenic human coronaviruses]**. He Y, Zheng C. Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences. 2020;49(1):0.
434. **COVID-19 – Considerations for the paediatric rheumatologist**. Hedrich CM. Clinical Immunology. 2020;214.
435. **Transmission of COVID-19 to Health Care Personnel During Exposures to a Hospitalized Patient - Solano County, California, February 2020**. Heinzerling A, Stuckey MJ, Scheuer T, Xu K, Perkins KM, Resseger H, et al. MMWR Morbidity and mortality weekly report. 2020;69(15):472-6. <http://dx.doi.org/10.15585/mmwr.mm6915e5>.
436. **Exploiting the Therapeutic Potential of MicroRNAs in Viral Diseases: Expectations and Limitations**. Hemida MG, Ye X, Thair S, Yang D. Molecular Diagnosis and Therapy. 2010;14(5):271-82.
437. **Learning from our immunological history: What can SARS-CoV teach us about SARS-CoV-2?** Henrickson SE. Science immunology. 2020;5(46).
438. **COVID-19, ECMO, and lymphopenia: a word of caution**. Henry BM. The Lancet Respiratory Medicine. 2020;8(4):e24.
439. **The COVID-19 Pandemic: New Global Challenges for the Hemophilia Community**. Hermans C, Weill A, Pierce GF. Haemophilia : the official journal of the World Federation of Hemophilia. 2020.
440. **Delayed Initiation of Remdesivir in a COVID-19 Positive Patient**. Hillaker E, Belfer JJ, Bondici A, Murad H, Dumkow LE. Pharmacotherapy. 2020. <http://dx.doi.org/10.1002/phar.2403>.
441. **Diagnostic performance of chest CT to differentiate COVID-19 pneumonia in non-high-epidemic area in Japan**. Himoto Y, Sakata A, Kirita M, Hiroi T, Kobayashi KI, Kubo K, et al. Japanese journal of radiology. 2020.
442. **What do urologists need to know: Diagnosis, treatment, and follow-up during COVID-19 pandemic**. Ho HC, Hughes T, Bozlu M, Kadioglu A, Somani BK. Turkish journal of urology. 2020. <http://dx.doi.org/10.5152/tud.2020.20119>.
443. **Thiol-Ene Networks from Sequence-Defined Polyurethane Macromers**. Hoff EA, De Hoe GX, Mulvaney CM, Hillmyer MA, Alabi CA. Journal of the American Chemical Society. 2020.
444. **SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor**. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. Cell. 2020.
445. **Time to pull together**. Holden Thorp H. Science. 2020;367(6484):1282.
446. **First case of 2019 novel coronavirus in the United States**. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. New England Journal of Medicine. 2020;382(10):929-36.
447. **Cerebrospinal fluid MinION sequencing of 16S rRNA gene for rapid and accurate diagnosis of bacterial meningitis**. Hong NTT, Nghia HDT, Thanh TT, Lan NPH, Ny NTH, Ngoc NM, et al. Journal of Infection. 2020;80(4):469-96.
448. **Insights from nanomedicine into chloroquine efficacy against COVID-19**. Hu TY, Frieman M, Wolfram J. Nature nanotechnology. 2020.
449. **Review of historical evaluation and modern application of Chinese materia medica fumigation in prevention of epidemic disease**. Hu WS, Wu QF. Chinese Traditional and Herbal Drugs. 2020;51(4):895-901.
450. **CT imaging of two cases of one family cluster 2019 novel coronavirus (2019-nCoV) pneumonia:**

Inconsistency between clinical symptoms amelioration and imaging sign progression. Hu X, Chen J, Jiang X, Tao S, Zhen Z, Zhou C, et al. *Quantitative Imaging in Medicine and Surgery*. 2020;10(2):508-10.

451. **SwiftOrtho: A fast, memory-efficient, multiple genome orthology classifier.** Hu X, Friedberg I. *GigaScience*. 2019;8(10).

452. **Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China.** Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. *Science China Life sciences*. 2020.

453. **Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.** Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. *The Lancet*. 2020;395(10223):497-506.

454. **[Dynamic basic reproduction number based evaluation for current prevention and control of COVID-19 outbreak in China].** Huang LL, Shen SP, Yu P, Wei YY. *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi*. 2020;41(4):466-9. <http://dx.doi.org/10.3760/cma.j.cn112338-20200209-00080>.

455. **Treating COVID-19 with Chloroquine.** Huang M, Tang T, Pang P, Li M, Ma R, Lu J, et al. *Journal of Molecular Cell Biology*. 2020.

456. **Coronavirus: from common cold to severe pulmonary failure: Chronology of a pandemia.** Hufert F, Spiegel M. *Monatsschrift fur Kinderheilkunde*. 2020.

457. **Emergent strategies for the next phase of covid-19.** Huh K, Shin HS, Peck KR. *Infection and Chemotherapy*. 2020;52(1):105-9.

458. **The spread of the COVID-19 coronavirus: Health agencies worldwide prepare for the seemingly inevitability of the COVID-19 coronavirus becoming endemic.** Hunter P. *EMBO reports*. 2020;21(4):e50334. <http://dx.doi.org/10.15252/embr.202050334>. Epub 2020 Mar 17.

459. **COVID-19 and diabetes: Knowledge in progress.** Hussain A, Bhowmik B, do Vale Moreira NC. *Diabetes Research and Clinical Practice*. 2020;162.

460. **COVID-19: What implications for sexual and reproductive health and rights globally?** Hussein J. *Sexual and Reproductive Health Matters*. 2020;28(1).

461. **Multimeric conformation of type III intermediate filaments but not the filamentous conformation exhibits high affinity to lipid bilayers.** Hwang B, Ise H. *Genes to cells : devoted to molecular & cellular mechanisms*. 2020.

462. **In silico identification of vaccine targets for 2019-nCoV.** Hyun-Jung Lee C, Koohy H. *F1000Research*. 2020;9:145.

463. **COVID-19 and diabetes: Can DPP4 inhibition play a role?** Iacobellis G. *Diabetes Research and Clinical Practice*. 2020;162.

464. **Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel.** Ianiro G, Mullish BH, Kelly CR, Sokol H, Kassam Z, Ng S, et al. *The lancet Gastroenterology & hepatology*. 2020;5(5):430-2. [http://dx.doi.org/10.1016/S2468-1253\(20\)30082-0](http://dx.doi.org/10.1016/S2468-1253(20)30082-0). Epub 2020 Mar 17.

465. **A Computational Vaccine Designing Approach for MERS-CoV Infections.** Ibrahim HS, Kafi SK. *Methods in molecular biology (Clifton, NJ)*. 2020;2131:39-145.

466. **COVID-19 spike-host cell receptor GRP78 binding site prediction.** Ibrahim IM, Abdelmalek DH, Elshahat

ME, Elfiky AA. Journal of Infection. 2020.

467. **Hyperglycemia and the novel Covid-19 infection: Possible pathophysiological mechanisms.** Ilias I, Zabuliene L. Medical Hypotheses. 2020;139.

468. **Cardiac Involvement in a Patient with Coronavirus Disease 2019 (COVID-19).** Inciardi RM, Lupi L, Zacccone G, Italia L, Raffo M, Tomasoni D, et al. JAMA Cardiology. 2020.

469. **Natural products and their derivatives against coronavirus: A review of the non-clinical and pre-clinical data.** Islam MT, Sarkar C, El-Kersh DM, Jamaddar S, Uddin SJ, Shilpi JA, et al. Phytotherapy research : PTR. 2020.

470. **Ultra-high-resolution computed tomography can demonstrate alveolar collapse in novel coronavirus (COVID-19) pneumonia.** Iwasawa T, Sato M, Yamaya T, Sato Y, Uchida Y, Kitamura H, et al. Japanese Journal of Radiology. 2020.

471. **Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.** Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard JF, et al. Journal of the Neurological Sciences. 2020;412.

472. **Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus.** Jakhar D, Kaur I. Nature medicine. 2020.

473. **COVID-19 - is the ACE2 just a foe?** Jakovac H. American journal of physiology Lung cellular and molecular physiology. 2020.

474. **Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?** Jawhara S. International journal of molecular sciences. 2020;21(7).

475. **Managing oncology services during a major coronavirus outbreak: Lessons from the Saudi Arabia experience.** Jazieh AR, Al Hadab A, Al Olayan A, AlHejazi A, Al Safi F, Al Qarni A, et al. Journal of Global Oncology. 2020;6:518-24.

476. **Treatment options for COVID-19: The reality and challenges.** Jean SS, Lee PI, Hsueh PR. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2020.
<http://dx.doi.org/10.1016/j.jmii.2020.03.034>

477. **2019 novel coronavirus disease outbreak and molecular genetic characteristics of severe acute respiratory syndrome-coronavirus-2.** Jeong YS. Journal of Bacteriology and Virology. 2020;50(1):1-8.

478. **Update: Public Health Response to the Coronavirus Disease 2019 Outbreak - United States, February 24, 2020.** Jernigan DB. MMWR Morbidity and mortality weekly report. 2020;69(8):216-9.
<http://dx.doi.org/10.15585/mmwr.mm6908e1>.

479. **Prediction for Progression Risk in Patients with COVID-19 Pneumonia: the CALL Score.** Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020.

480. **Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.** Ji H, Yan Y, Ding B, Guo W, Brunswick M, Niethammer A, et al. Medicine in drug discovery. 2020;5:100026. <http://dx.doi.org/10.1016/j.medidd.2020.100026>.
Epub 2020 Mar 25.

481. **Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility.** Ji HL, Zhao R, Matalon S, Matthay MA. *Physiological reviews*. 2020.
482. **Cross-species transmission of the newly identified coronavirus 2019-nCoV.** Ji W, Wang W, Zhao X, Zai J, Li X. *Journal of Medical Virology*. 2020;92(4):433-40.
483. **Flavonoids isolated from loquat (*Eriobotrya japonica*) leaves inhibit oxidative stress and inflammation induced by cigarette smoke in COPD mice: the role of TRPV1 signaling pathways.** Jian T, Chen J, Ding X, Lv H, Li J, Wu Y, et al. *Food & function*. 2020.
484. **[Treatment experience of burn patients combined with inhalation injury during epidemic period of Corona Virus Disease 2019].** Jiang NN, Wang DY, Chen L, Xie WG. *Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns*. 2020;36:E007.
<http://dx.doi.org/10.3760/cma.j.cn501120-20200308-00135>.
485. **Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees.** Jiang S. *Nature*. 2020;579(7799):321.
486. **An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies.** Jiang S, Du L, Shi Z. *Emerg Microbes Infect*. 2020;9(1):275-7.
<http://dx.doi.org/10.1080/22221751.2020.1723441>. eCollection 2020.
487. **Creation of Al-Enriched Mesoporous ZSM-5 Nanoboxes with High Catalytic Activity: Converting Tetrahedral Extra-Framework Al into Framework Sites via Post Treatment.** Jiao Y, Forster L, Xu S, Chen H, Han J, Liu X, et al. *Angewandte Chemie (International ed in English)*. 2020.
488. **Higher immune response induced by vaccination in Houhai acupoint relates to the lymphatic drainage of the injection site.** Jin H, Wu Y, Bi S, Xu Y, Shi F, Li X, et al. *Research in Veterinary Science*. 2020;130:230-6.
489. **Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms.** Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. *Gut*. 2020.
490. **COVID-19 in a patient with chronic lymphocytic leukaemia.** Jin XH, Zheng KI, Pan KH, Xie YP, Zheng MH. *The Lancet Haematology*. 2020;7(4):e351-e2.
491. **Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019.** Jin Y, Wang M, Zuo Z, Fan C, Ye F, Cai Z, et al. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2020.
492. **Virology, epidemiology, pathogenesis, and control of covid-19.** Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. *Viruses*. 2020;12(4).
493. **A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version).** Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. *Military Medical Research*. 2020;7(1).
494. **Clinical characteristics of 42 SARS patients and their treatment of integrative Chinese and western medicine.** Jin-pan Z, Bao-jin H, Chang-huai C, Gui-cheng X, Hao S, Yin W, et al. *Chinese Journal of Integrative Medicine*. 2003;9(3):169-74.
495. **The COVID-19 pandemic: Important considerations for contact lens practitioners.** Jones L, Walsh K, Willcox M, Morgan P, Nichols J. *Contact Lens and Anterior Eye*. 2020.
496. **COVID-19 , School Closings and Weight Gain.** Joob B, Wiwanitkit V. *Obesity (Silver Spring, Md)*. 2020.

<http://dx.doi.org/10.1002/oby.22825>.

497. **Epitope finding in 2019 novel coronavirus (2019-nCoV): The first world report.** Joob B, Wiwanitkit V. *Asian Pacific Journal of Tropical Medicine*. 2020;13(4):187-8.
498. **Understanding COVID-19: what does viral RNA load really mean?** Joynt GM, Wu WK. *The Lancet Infectious diseases*. 2020.
499. **Replicative capacity of porcine deltacoronavirus and porcine epidemic diarrhea virus in primary bovine mesenchymal cells.** Jung K, Vasquez-Lee M, Saif LJ. *Veterinary Microbiology*. 2020;244.
500. **Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.** Juurlink DN. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. 2020. <http://dx.doi.org/10.1503/cmaj.200528>.
501. **Does COVID19 infect the brain? If so, smokers might be at a higher risk.** Kabbani N, Olds JL. *Molecular pharmacology*. 2020.
502. **Pharmacologic Treatments and Supportive Care for Middle East Respiratory Syndrome.** Kain T, Lindsay PJ, Adhikari NKJ, Arabi YM, Van Kerkhove MD, Fowler RA. *Emerging infectious diseases*. 2020;26(6).
503. **A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19).** Kakodkar P, Kaka N, Baig MN. *Cureus*. 2020;12(4):e7560. <http://dx.doi.org/10.7759/cureus.7560>.
504. **Can chlorine dioxide prevent the spreading of coronavirus or other viral infections? Medical hypotheses.** Kály-Kullai K, Wittmann M, Noszticzus Z, Rosivall L. *Physiology international*. 2020:1-11.
505. **Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report.** Kamali Aghdam M, Jafari N, Eftekhari K. *Infectious Diseases*. 2020.
506. **Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents.** Kampf G, Todt D, Pfaender S, Steinmann E. *Journal of Hospital Infection*. 2020;104(3):246-51.
507. **Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.** Kandeel M, Al-Nazawi M. *Life Sciences*. 2020;251.
508. **From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes.** Kandeel M, Ibrahim A, Fayez M, Al-Nazawi M. *J Med Virol*. 2020. <http://dx.doi.org/10.1002/jmv.25754>.
509. **COVID-19 (Novel Coronavirus 2019) - recent trends.** Kannan S, Shaik Syed Ali P, Sheeza A, Hemalatha K. *European Review for Medical and Pharmacological Sciences*. 2020;24(4):2006-11.
510. **Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society.** Kapoor A, Pandurangi U, Arora V, Gupta A, Jaswal A, Nabar A, et al. *Indian Pacing and Electrophysiology Journal*. 2020.
511. **Mortality of a pregnant patient diagnosed with COVID-19: A case report with clinical, radiological, and histopathological findings.** Karami P, Naghavi M, Feyzi A, Aghamohammadi M, Novin MS, Mobaïen A, et al. *Travel Medicine and Infectious Disease*. 2020.
512. **To control the covid-19 outbreak, young, healthy patients should avoid the emergency department.** Karan A. *The BMJ*. 2020;368.

513. **G6PD and chloroquine: selecting the treatment against SARS-CoV-2?** Kassi EN, Papavassiliou KA, Papavassiliou AG. *Journal of Cellular and Molecular Medicine*. 2020.
514. **An overview of coronaviruses including the SARS-2 coronavirus – Molecular biology, epidemiology and clinical implications.** Kaul D. *Current Medicine Research and Practice*. 2020. <http://dx.doi.org/10.1016/j.cmrp.2020.04.001>
515. **A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19.** Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. *Crit Care*. 2020;24(1):128. <http://dx.doi.org/10.1186/s13054-020-2836-4>.
516. **Fear of the novel coronavirus.** Kelvin DJ, Rubino S. *Journal of Infection in Developing Countries*. 2020;14(1):1-2. <http://dx.doi.org/10.3855/jidc.12496>
517. **miRNA repertoire and host immune factor regulation upon avian coronavirus infection in eggs.** Kemp V, Laconi A, Cocciolo G, Berends AJ, Breit TM, Verheije MH. *Archives of virology*. 2020;165(4):835-43.
518. **Dysosmia and dysgeusia due to the 2019 Novel Coronavirus; a hypothesis that needs further investigation.** Keyhan SO, Fallahi HR, Cheshmi B. *Maxillofacial and Plastic Reconstructive Surgery*. 2020;42(1).
519. **Novel coronavirus treatment with ribavirin: Groundwork for evaluation concerning COVID-19.** Khalili JS, Zhu H, Mak A, Yan Y, Zhu Y. *J Med Virol*. 2020. <http://dx.doi.org/10.1002/jmv.25798>.
520. **Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19.** Khalili JS, Zhu H, Mak NSA, Yan Y, Zhu Y. *J Med Virol*. 2020. <http://dx.doi.org/10.1002/jmv.25798>.
521. **Targeting SARS-CoV-2: A Systematic Drug Repurposing Approach to Identify Promising Inhibitors Against 3C-like Proteinase and 2'-O-RiboseMethyltransferase.** Khan RJ, Jha RK, Amara G, Jain M, Singh E, Pathak A, et al. *Journal of biomolecular structure & dynamics*. 2020:1-40.
522. **Novel coronavirus: how things are in Wuhan.** Khan S, Nabi G, Han G, Siddique R, Lian S, Shi H, et al. *Clinical Microbiology and Infection*. 2020;26(4):399-400.
523. **The 2019 Novel Coronavirus Outbreak - A Global Threat.** Khot WY, Nadkar MY. *The Journal of the Association of Physicians of India*. 2020;68(3):67-71.
524. **Human Saliva: Non-Invasive Fluid for Detecting Novel Coronavirus (2019-nCoV).** Khurshid Z, Asiri FYI, Al Wadaani H. *International journal of environmental research and public health*. 2020;17(7).
525. **Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors.** Kilianski A, Baker SC. *Antiviral Research*. 2014;101:105-12.
526. **Eating related epilepsy in a 5-month-old baby.** Kim DU, Lim SM, Moon JH. *Epilepsia*. 2019;60:238.
527. **Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.** Kim E, Erdos G, Huang S, Kenniston TW, Balmert SC, Carey CD, et al. *EBioMedicine*. 2020:102743. <http://dx.doi.org/10.1016/j.ebiom.2020.102743>.
528. **Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19.** Kim ES, Chin BS, Kang CK, Kim NJ, Kang YM, Choi JP, et al. *Journal of Korean medical science*. 2020;35(13):e142.
529. **Middle East respiratory syndrome-coronavirus infection into established HDPP4-transgenic mice**

accelerates lung damage via activation of the pro-inflammatory response and pulmonary fibrosis. Kim J, Yang YL, Jeong Y, Jang YS. *Journal of Microbiology and Biotechnology*. 2020;30(3):427-38.

530. **Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR.** Kim JY. *Journal of Korean medical science*. 2020;35(7):e88.

531. **Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2.** Kim Y, Jedrzejczak R, Maltseva NI, Wilamowski M, Endres M, Godzik A, et al. *Protein science : a publication of the Protein Society*. 2020. <http://dx.doi.org/10.1002/pro.3873>.

532. **Infection and Rapid Transmission of SARS-CoV-2 in Ferrets.** Kim YI, Kim SG, Kim SM, Kim EH, Park SJ, Yu KM, et al. *Cell host & microbe*. 2020.

533. **Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020.** Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, et al. *MMWR Morbidity and mortality weekly report*. 2020;69(13):377-81.

534. **Halting coronavirus polymerase.** Kirchdoerfer RN. *Journal of Biological Chemistry*. 2020;295(15):4780-1.

535. **Incidence of thrombotic complications in critically ill ICU patients with COVID-19.** Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. *Thromb Res*. 2020. <http://dx.doi.org/10.1016/j.thromres.2020.04.013>.

536. **Arguments in favor of remdesivir for treating SARS-CoV-2 infections.** Ko WC, Rolain JM, Lee NY, Chen PL, Huang CT, Lee PI, et al. *International journal of antimicrobial agents*. 2020:105933.

537. **Arguments in favour of remdesivir for treating SARS-CoV-2 infections.** Ko WC, Rolain JM, Lee NY, Chen PL, Huang CT, Lee PI, et al. *International journal of antimicrobial agents*. 2020.

538. **How Should the Rehabilitation Community Prepare for 2019-nCoV?** Koh GCH, Hoenig H. *Archives of physical medicine and rehabilitation*. 2020.

539. **The novel coronavirus - Should we be worried?** Kohnen W. *Zentralsterilisation - Central Service*. 2020;28(1):38.

540. **Design, synthesis, and biological evaluation of novel C5-modified pyrimidine ribofuranonucleosides as potential antitumor or/and antiviral agents.** Kollatos N, Mitsos C, Manta S, Tzioumaki N, Giannakas C, Alexouli T, et al. *Medicinal Chemistry*. 2020;16(3):368-84.

541. **Cold exposure-induced up-regulation of HSP70 positively regulates PEDV mRNA synthesis and protein expression in vitro.** Kong F, Xu Y, Ran W, Yin B, Feng L, Sun D. *Pathogens*. 2020;9(4).

542. **Early epidemiological and clinical characteristics of 28 cases of coronavirus disease in South Korea.** Kong I, Park Y, Woo Y, Lee J, Cha J, Choi J, et al. *Osong Public Health and Research Perspectives*. 2020(1):8-14.

543. **Identification of a novel B-cell epitope in the spike protein of porcine epidemic diarrhea virus.** Kong N, Meng Q, Jiao Y, Wu Y, Zuo Y, Wang H, et al. *Virology journal*. 2020;17(1):46.

544. **Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020.** Konrad R, Eberle U, Dangel A, Treis B, Berger A, Bengs K, et al. *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin*. 2020;25(9).

545. **Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study.** Koo JR, Cook

AR, Park M, Sun Y, Sun H, Lim JT, et al. *The Lancet Infectious diseases*. 2020.

546. **2019 novel coronavirus: A mysterious threat from Wuhan, China—A current review.** Kothai R, Arul B. *International Journal of Research in Pharmaceutical Sciences*. 2020;11:7-15.

547. **Processing of the SARS-CoV pp1a/ab nsp7-10 region.** Krichel B, Falke S, Hilgenfeld R, Redecke L, Uetrecht C. *Biochemical Journal*. 2020;477(5):1009-19.

548. **Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.** Kruse RL. *F1000Research*. 2020;9:72.

549. **Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV).** Kumar S, Maurya VK, Prasad AK, Bhatt MLB, Saxena SK. *Virusdisease*. 2020;31(1):13-21. <http://dx.doi.org/10.1007/s13337-020-00571-5>. Epub 2020 Mar 5.

550. **Race to find COVID-19 treatments accelerates.** Kupferschmidt K, Cohen J. *Science*. 2020;367(6485):1412-3. <http://dx.doi.org/10.1126/science.367.6485.1412>.

551. **SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?** Kuster GM, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P, et al. *European Heart Journal*. 2020.

552. **A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic?** Kutlu O, Metin A. *Dermatologic therapy*. 2020:e13383. <http://dx.doi.org/10.1111/dth.13383>.

553. **Testing the repatriated for SARS-Cov2: Should laboratory-based quarantine replace traditional quarantine?** Lagier JC, Colson P, Tissot Dupont H, Salomon J, Doudier B, Aubry C, et al. *Travel Medicine and Infectious Disease*. 2020.

554. **Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis.** Lagunas-Rangel FA. *Journal of Medical Virology*. 2020.

555. **Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.** Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. *Journal of Microbiology, Immunology and Infection*. 2020.

556. **Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.** Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. *International journal of antimicrobial agents*. 2020;55(3).

557. **What we know so far: COVID-19 current clinical knowledge and research.** Lake MA. *Clinical Medicine, Journal of the Royal College of Physicians of London*. 2020;20(2):124-7.

558. **Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution.** Land WG. *Molecular diagnosis & therapy*. 2020.

559. **Sarah Gilbert: carving a path towards a COVID-19 vaccine.** Lane R. *The Lancet*. 2020;395(10232):1247.

560. **Timing of Community Mitigation and Changes in Reported COVID-19 and Community Mobility - Four U.S. Metropolitan Areas, February 26-April 1, 2020.** Lasry A, Kidder D, Hast M, Poovey J, Sunshine G, Winglee K, et al. *MMWR Morbidity and mortality weekly report*. 2020;69(15):451-7. <http://dx.doi.org/10.15585/mmwr.mm6915e2>.

561. **Middle east respiratory syndrome coronavirus antibodies in bactrian and hybrid camels from Dubai.** Lau SKP, Li KSM, Luk HKH, He Z, Teng JLL, Yuen KY, et al. *mSphere*. 2020;5(1).

562. **Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction.** Lau SY, Wang P, Mok BW, Zhang AJ, Chu H, Lee AC, et al. *Emerg Microbes Infect.* 2020;1-15. <http://dx.doi.org/10.1080/22221751.2020.1756700>.
563. **Biomarkers of biological age as predictors of COVID-19 disease severity.** Lauc G, Sinclair D. *Aging.* 2020.
564. **The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application.** Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. *Annals of internal medicine.* 2020. <http://dx.doi.org/10.7326/M20-0504>.
565. **Should biologics for psoriasis be interrupted in the era of COVID-19?** Lebwohl M, Rivera-Oyola R, Murrell DF. *Journal of the American Academy of Dermatology.* 2020.
566. **How does COVID-19 kill? Uncertainty is hampering doctors' ability to choose treatments.** Ledford H. *Nature.* 2020;580(7803):311-2. <http://dx.doi.org/10.1038/d41586-020-01056-7>
567. **Quarantined.** Lee M. *Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.* 2020. <http://dx.doi.org/10.1111/acem.13975>.
568. **A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic.** Lee NY, Li CW, Tsai HP, Chen PL, Syue LS, Li MC, et al. *Journal of Microbiology, Immunology and Infection.* 2020.
569. **CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia.** Lei J, Li J, Li X, Qi X. *Radiology.* 2020;295(1):18.
570. **Transplantation of ACE2- Mesenchymal stem cells improves the outcome of patients with covid-19 pneumonia.** Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. *Aging and Disease.* 2020;11(2):216-28.
571. **Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence.** Lenzer J. *BMJ (Clinical research ed).* 2020;369:m1335.
572. **Silent circulation of coronaviruses in pigs.** Leopardi S, Terregino C, Paola DB. *Veterinary Record.* 2020;186(10):323.
573. **ACE-2 Expression in the Small Airway Epithelia of Smokers and COPD Patients: Implications for COVID-19.** Leung JM, Yang CX, Tam A, Shaipanich T, Hackett TL, Singhera GK, et al. *The European respiratory journal.* 2020.
574. **Diagnostic Value and Key Features of Computed Tomography in Coronavirus Disease 2019.** Li B, Li X, Wang Y, Han Y, Wang Y, Wang C, et al. *Emerging microbes & infections.* 2020:1-14.
575. **Radiographic and Clinical Features of Children with 2019 Novel Coronavirus (COVID-19) Pneumonia.** Li B, Shen J, Li L, Yu C. *Indian pediatrics.* 2020.
576. **Genetic evolution analysis of 2019 novel coronavirus and coronavirus from other species.** Li C, Yang Y, Ren L. *Infection, Genetics and Evolution.* 2020;82.
577. **Clinical Study and CT Findings of a Familial Cluster of Pneumonia with Coronavirus Disease 2019 (COVID-19).** Li CX, Wu B, Luo F, Zhang N. *Sichuan da xue xue bao Yi xue ban = Journal of Sichuan University Medical science edition.* 2020;51(2):155-8.
578. **False-negative results of real-time reverse-transcriptase polymerase chain reaction for severe acute respiratory syndrome coronavirus 2: Role of deep-learning-based ct diagnosis and insights from two cases.** Li

- D, Wang D, Dong J, Wang N, Huang H, Xu H, et al. *Korean Journal of Radiology*. 2020;21(4):505-8.
579. **Therapeutic options for the 2019 novel coronavirus (2019-nCoV).** Li G, De Clercq E. *Nature reviews Drug discovery*. 2020;19(3):149-50. <http://dx.doi.org/10.1038/d41573-020-00016-0>.
580. **Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19.** Li G, He X, Zhang L, Ran Q, Wang J, Xiong A, et al. *Journal of Autoimmunity*. 2020:102463.
581. **Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension.** Li G, Hu R, Zhang X. *Hypertension Research*. 2020.
582. **[Potential antiviral therapeutics for 2019 Novel Coronavirus].** Li H, Wang YM, Xu JY, Cao B. *Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases*. 2020;43(3):170-2. <http://dx.doi.org/10.3760/cma.j.issn.1001-0939.2020.03.004>.
583. **SAA is a biomarker to distinguish the severity and prognosis of Coronavirus Disease 2019 (COVID-19).** Li H, Xiang X, Ren H, Xu L, Zhao L, Chen X, et al. *The Journal of infection*. 2020. <http://dx.doi.org/10.1016/j.jinf.2020.03.035>
584. **Puzzle of highly pathogenic human coronaviruses (2019-nCoV).** Li J, Liu W. *Protein & cell*. 2020;11(4):235-8. <http://dx.doi.org/10.1007/s13238-020-00693-y>.
585. **Screening of active components from Chinese materia medica against SARS-CoV-2 based on literature mining and molecular docking.** Li J, Ma XB, Shen J, Zhang ZF. *Chinese Traditional and Herbal Drugs*. 2020;51(4):845-50.
586. **The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future.** Li JY, You Z, Wang Q, Zhou ZJ, Qiu Y, Luo R, et al. *Microbes and Infection*. 2020;22(2):80-5.
587. **Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection.** Li K, Li Z, Wohlford-Lenane C, Meyerholz DK, Channappanavar R, An D, et al. *mBio*. 2020;11(2). <http://dx.doi.org/10.1128/mBio.00554-20>.
588. **2019 novel coronavirus patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis.** Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. *Journal of Medical Virology*. 2020.
589. **Maternal and neonatal outcomes of pregnant women with COVID-19 pneumonia: a case-control study.** Li N, Han L, Peng M, Lv Y, Ouyang Y, Liu K, et al. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
590. **Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV.** Li R, Qiao S, Zhang G. *Journal of Infection*. 2020;80(4):469-96.
591. **Atypical presentation of SARS-CoV-2 infection: A case report.** Li RL, Chu SG, Luo Y, Huang ZH, Hao Y, Fan CH. *World Journal of Clinical Cases*. 2020;8(7):1265-70.
592. **Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0): Working Group of 2019 Novel Coronavirus, Peking Union Medical College Hospital.** Li T. *Emerging Microbes and Infections*. 2020;9(1):582-5.

593. **Clinical observation and management of COVID-19 patients.** Li T, Lu H, Zhang W. *Emerging microbes & infections.* 2020;9(1):687-90.
594. **Chest computed tomography in children with COVID-19 respiratory infection.** Li W, Cui H, Li K, Fang Y, Li S. *Pediatric Radiology.* 2020.
595. **Clinical characteristics of 25 death cases with COVID-19: a retrospective review of medical records in a single medical center, Wuhan, China.** Li X, Wang L, Yan S, Yang F, Xiang L, Zhu J, et al. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.* 2020.
596. **CT imaging changes of corona virus disease 2019(COVID-19): a multi-center study in Southwest China.** Li X, Zeng W, Li X, Chen H, Shi L, Li X, et al. *Journal of translational medicine.* 2020;18(1):154.
597. **Pharmacovigilance and protective medication for drug-induced liver injury in treatment of COVID-19.** Li XJY, Li YJ, Ge JD, Wu KY, Sun R. *Chinese Traditional and Herbal Drugs.* 2020;51(4):851-9.
598. **[The keypoints in treatment of the critical coronavirus disease 2019 patient(2)].** Li XY, Du B, Wang YS, Kang HYJ, Wang F, Sun B, et al. *Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.* 2020;43(4):277-81. <http://dx.doi.org/10.3760/cmaj.cn112147-20200224-00159>.
599. **Follow-up testing of viral nucleic acid in discharged patients with moderate type of 2019 coronavirus disease (COVID-19).** Li Y, Hu Y, Zhang X, Yu Y, Li B, Wu J, et al. *Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences.* 2020;49(1):0.
600. **EZH2-mediated H3K27me3 inhibits ACE2 expression.** Li Y, Li H, Zhou L. *Biochemical and Biophysical Research Communications.* 2020.
601. **An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI).** Li Y, Xie Z, Lin W, Cai W, Wen C, Guan Y, et al. *medRxiv.* 2020:2020.03.19.20038984.
602. **Analysis of TCM in prevention and treatment of post-traumatic stress disorder induced by COVID-19.** Li YF, Zhang YG, Niu JT, Si XL, Yan XK. *Chinese Traditional and Herbal Drugs.* 2020;51(5):1130-8.
603. **Chemotherapy strategy for colorectal cancer under the outbreak of corona virus disease 2019.** Li YH, Shen L, Li J. *Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery.* 2020;23(3):217-9.
604. **From the insight of glucose metabolism disorder: Oxygen therapy and blood glucose monitoring are crucial for quarantined COVID-19 patients.** Li Z, Liu G, Wang L, Liang Y, Zhou Q, Wu F, et al. *Ecotoxicology and Environmental Safety.* 2020;197.
605. **Exploration on mechanism of anti-coronavirus of Sophora flavescens through multi-pathway.** Li Z, Yu KX. *Chinese Traditional and Herbal Drugs.* 2020;51(4):888-94.
606. **Analysis of Epidemiological and Clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan.** Lian J, Jin X, Hao S, Cai H, Zhang S, Zheng L, et al. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2020.
607. **Mathematical model of infection kinetics and its analysis for COVID-19, SARS and MERS.** Liang K. *Infection, Genetics and Evolution.* 2020;82.
608. **Clinics in Diagnostic Imaging: COVID-19 atypical pneumonia.** Liew JRP, Lim YRD, Liew JYC, Poh CCA. *Singapore medical journal.* 2020.

609. **The Author's Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR.** Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Journal of Korean medical science. 2020;35(7):e89.
610. **Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR.** Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Journal of Korean medical science. 2020;35(6):e79.
611. **Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection.** Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z, et al. Gut. 2020.
612. **Hypothesis for potential pathogenesis of SARS-CoV-2 infection--a review of immune changes in patients with viral pneumonia.** Lin L, Lu L, Cao W, Li T. Emerging microbes & infections. 2020:1-14.
613. **Applying integrative Chinese and western medicine in fighting SARS.** Lin L, Rong-bing W, Yong-tao Z, Guang-hua T. Chinese Journal of Integrative Medicine. 2003;9(3):162-8.
614. **Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection.** Lin Q, Zhu L, Ni Z, Meng H, You L. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2020.
615. **Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design.** Lin SM, Lin SC, Hsu JN, Chang CK, Chien CM, Wang YS, et al. Journal of Medicinal Chemistry. 2020.
616. **Novel coronavirus pneumonia outbreak in 2019: Computed tomographic findings in two cases.** Lin X, Gong Z, Xiao Z, Xiong J, Fan B, Liu J. Korean Journal of Radiology. 2020;21(3):365-8.
617. **Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2).** Ling CQ. Journal of Integrative Medicine. 2020;18(2):87-8.
618. **Critically ill patients with COVID-19 in Hong Kong: a multicentre retrospective observational cohort study.** Ling L, So C, Shum HP, Chan PKS, Lai KKC, Kandamby DH, et al. Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine. 2020.
619. **C-reactive protein levels in the early stage of COVID-19.** Ling W. Medecine et maladies infectieuses. 2020.
620. **Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis.** Lippi G, Lavie CJ, Sanchis-Gomar F. Progress in cardiovascular diseases. 2020.
621. **Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19).** Lippi G, Simundic AM, Plebani M. Clin Chem Lab Med. 2020. <http://dx.doi.org/10.1515/cclm-2020-0285>.
622. **Non-steroidal anti-inflammatory drugs and covid-19.** Little P. BMJ (Clinical research ed). 2020;368:m1185.
623. **Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?** Liu B, Li M, Zhou Z, Guan X, Xiang Y. Journal of Autoimmunity. 2020.
624. **Pregnancy and Perinatal Outcomes of Women With Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis.** Liu D, Li L, Wu X, Zheng D, Wang J, Yang L, et al. AJR American journal of roentgenology. 2020:1-6.

625. **Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression.** Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K, et al. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2020.
626. **Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation.** Liu H, He X, Wang Y, Zhou S, Zhang D, Zhu J, et al. *Hepatology international*. 2020. <http://dx.doi.org/10.1007/s12072-020-10043-z>
627. **Clinical and CT Imaging Features of the COVID-19 Pneumonia: Focus on Pregnant Women and Children.** Liu H, Liu F, Li J, Zhang T, Wang D, Lan W. *The Journal of infection*. 2020.
628. **Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.** Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. *Cell Discovery*. 2020;6(1).
629. **Application of traditional Chinese medicine in prevention and treatment of COVID-19.** Liu J, Cui Y, Bai MX, Zhang HW, Jin YL, Lv P. *Chinese Traditional and Herbal Drugs*. 2020;51(4):860-5.
630. **Development of a rapid immunochromatographic strip test for the detection of porcine epidemic diarrhea virus specific SIgA in colostrum.** Liu J, Gao R, Shi H, Cong G, Chen J, Zhang X, et al. *Journal of Virological Methods*. 2020;279.
631. **Design, synthesis and biological evaluation of novel N-[4-(2-fluorophenoxy)pyridin-2-yl]cyclopropanecarboxamide derivatives as potential c-Met kinase inhibitors.** Liu J, Gong Y, Shi J, Hao X, Wang Y, Zhou Y, et al. *European Journal of Medicinal Chemistry*. 2020;194.
632. **Clinical feature of COVID-19 in elderly patients: a comparison with young and middle-aged patients.** Liu K, Chen Y, Lin R, Han K. *The Journal of infection*. 2020.
633. **Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients.** Liu K, Chen Y, Lin R, Han K. *Journal of Infection*. 2020.
634. **CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity.** Liu KC, Xu P, Lv WF, Qiu XH, Yao JL, Gu JF, et al. *European Journal of Radiology*. 2020;126.
635. **High-Resolution Computed Tomography Manifestations of 5 Pediatric Patients With 2019 Novel Coronavirus.** Liu M, Song Z, Xiao K. *Journal of computer assisted tomography*. 2020.
636. **[Analysis on epidemic situation and spatiotemporal changes of COVID-19 in Anhui].** Liu M, Xu HL, Yuan M, Liu ZR, Wu XY, Zhang Y, et al. *Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]*. 2020;54:E019. <http://dx.doi.org/10.3760/cma.j.cn112150-20200221-00150>.
637. **The Science Underlying COVID-19: Implications for the Cardiovascular System.** Liu PP, Blet A, Smyth D, Li H. *Circulation*. 2020. <http://dx.doi.org/10.1161/CIRCULATIONAHA.120.047549>.
638. **Traditional Chinese medicine for treatment of COVID-19 based on literature mining of targeting cytokine storm.** Liu RP, Ge JD, Zhong Y, Zheng Q, Sun R. *Chinese Traditional and Herbal Drugs*. 2020;51(5):1096-105.
639. **Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2.** Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. *Journal of clinical microbiology*. 2020.
640. **Detection of Covid-19 in Children in Early January 2020 in Wuhan, China.** Liu W, Zhang Q, Chen J, Xiang R, Song H, Shu S, et al. *The New England journal of medicine*. 2020;382(14):1370-1. <http://dx.doi.org/10.1056/NEJMc2003717>. Epub 2020 Mar 12.

641. **Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction.** Liu X, Li Z, Liu S, Chen Z, Zhao Z, Huang Y-y, et al. medRxiv. 2020:2020.02.27.20027557.
642. **Challenges to prevent and control the outbreak of Novel Coronavirus Pneumonia (COVID-19).** Liu X, Na RS, Bi ZQ. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2020;41:E029.
643. **Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines.** Liu X, Wang XJ. Journal of genetics and genomics = Yi chuan xue bao. 2020.
644. **Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients.** Liu Y, Huang F, Xu J, Yang P, Qin Y, Cao M, et al. medRxiv. 2020:2020.03.20.20039586.
645. **Critical care response to a hospital outbreak of the 2019-nCoV infection in Shenzhen, China.** Liu Y, Li J, Feng Y. Critical Care. 2020;24(1). <http://dx.doi.org/10.1186/s13054-020-2786-x>
646. **Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19.** Liu Y, Liao W, Wan L, Xiang T, Zhang W. Viral immunology. 2020. <http://dx.doi.org/10.1089/vim.2020.0062>.
647. **Thrombin/PAR-1 activation induces endothelial damages via NLRP1 inflammasome in gestational diabetes.** Liu Y, Tang ZZ, Zhang YM, Kong L, Xiao WF, Ma TF, et al. Biochemical Pharmacology. 2020;175.
648. **Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury.** Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Science China Life sciences. 2020;63(3):364-74.
649. **A locally transmitted case of SARS-CoV-2 infection in Taiwan.** Liu YC, Liao CH, Chang CF, Chou CC, Lin YR. New England Journal of Medicine. 2020;382(11).
650. **[What we learned from SARS may provide important insights into understanding and management of coronavirus disease 2019].** Liu YJ, Yang YL, Xu Y. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases. 2020;43(4):339-44. <http://dx.doi.org/10.3760/cma.j.cn112147-20200218-00119>.
651. **Conjunctiva is not a preferred gateway of entry for SARS-CoV-2 to infect respiratory tract.** Liu Z, Sun CB. Journal of medical virology. 2020.
652. **Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2.** Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H, et al. Journal of Medical Virology. 2020.
653. **Coronavirus Disease 2019 and Influenza 2019-2020.** Livingston E, Bucher K, Rekito A. JAMA - Journal of the American Medical Association. 2020;323(12):1122.
654. **Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau.** Lo IL, Lio CF, Cheong HH, Lei CI, Cheong TH, Zhong X, et al. Int J Biol Sci. 2020;16(10):1698-707. <http://dx.doi.org/10.7150/ijbs.45357>. eCollection 2020.
655. **Importance of oral and nasal decontamination for patients undergoing anesthetics during the COVID-19 era.** Loftus RW, Dexter F, Parra MC, Brown JR. Anesthesia and analgesia. 2020.
656. **Vademecum for the treatment of people with COVID-19. Edition 2.0, 13 March 2020.** Lombardy Section Italian Society I, Tropical D. Le infezioni in medicina. 2020;28(2):143-52.
657. **COVID-19 pneumonia manifestations at the admission on chest ultrasound, radiographs, and CT:**

- single-center study and comprehensive radiologic literature review.** Lomoro P, Verde F, Zerboni F, Simonetti I, Borghi C, Fachinetti C, et al. *European Journal of Radiology Open*. 2020;7.
658. **Potential therapeutic agents against COVID-19: What we know so far.** Lu CC, Chen MY, Chang YL. *Journal of the Chinese Medical Association : JCMA*. 2020. <http://dx.doi.org/10.1097/JCMA.0000000000000318>.
659. **Drug treatment options for the 2019-new coronavirus (2019-nCoV).** Lu H. *Bioscience trends*. 2020;14(1):69-71.
660. **Development of an indirect ELISA for detecting porcine deltacoronavirus IgA antibodies.** Lu M, Liu Q, Wang X, Zhang J, Zhang X, Shi D, et al. *Archives of virology*. 2020;165(4):845-51.
661. **Timely development of vaccines against SARS-CoV-2.** Lu S. *Emerging Microbes and Infections*. 2020;9(1):542-4.
662. **Computed Tomography Manifestations of 5 Cases of the Novel Coronavirus Disease 2019 (COVID-19) Pneumonia From Patients Outside Wuhan.** Lu T, Pu H. *Journal of thoracic imaging*. 2020.
663. **SARS-CoV-2 spike protein favors ACE2 from Bovidae and Cricetidae.** Luan J, Jin X, Lu Y, Zhang L. *J Med Virol*. 2020. <http://dx.doi.org/10.1002/jmv.25817>.
664. **Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection.** Luan J, Lu Y, Jin X, Zhang L. *Biochem Biophys Res Commun*. 2020. <http://dx.doi.org/10.1016/j.bbrc.2020.03.047>.
665. **Epidemiology, Treatment, and Epidemic Prevention and Control of the Coronavirus Disease 2019: a Review.** Luan RS, Wang X, Sun X, Chen XS, Zhou T, Liu QH, et al. *Sichuan da xue xue bao Yi xue ban = Journal of Sichuan University Medical science edition*. 2020;51(2):131-8.
666. **SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells.** Lukassen S, Lorenz Chua R, Trefzer T, Kahn NC, Schneider MA, Muley T, et al. *The EMBO journal*. 2020.
667. **The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase.** Lung J, Lin YS, Yang YH, Chou YL, Shu LH, Cheng YC, et al. *Journal of Medical Virology*. 2020.
668. **Positive SARS-Cov-2 test in a woman with COVID-19 at 22 days after hospital discharge: A case report.** Luo A. *Journal of Traditional Chinese Medical Sciences*. 2020.
669. **Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs.** Luo H, Tang QL, Shang YX, Liang SB, Yang M, Robinson N, et al. *Chinese Journal of Integrative Medicine*. 2020;26(4):243-50.
670. **Tocilizumab treatment in COVID-19: a single center experience.** Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. *Journal of medical virology*. 2020.
671. **2019 novel coronavirus (2019-nCoV) outbreak: A new challenge.** Lupia T, Scabini S, Mornese Pinna S, Di Perri G, De Rosa FG, Corcione S. *Journal of Global Antimicrobial Resistance*. 2020;21:22-7.
672. **2019-novel coronavirus outbreak: A new challenge.** Lupia T, Scabini S, Pinna SM, Di Perri G, De Rosa FG, Corcione S. *Journal of global antimicrobial resistance*. 2020.
673. **Perspective on the COVID-19 Coronavirus Outbreak.** Lushington GH. *Combinatorial chemistry & high throughput screening*. 2020;23(2):90-1. <http://dx.doi.org/10.2174/138620732302200406130010>.

674. **Nuklearmedizin zu Zeiten der SARS-CoV-2 Pandemie: 18F-FDG-PET/CT zur Visualisierung von COVID-19.** Lütje S, Marinova M, Kütting D, Attenberger U, Essler M, Bundschuh RA. Nuklearmedizin Nuclear medicine. 2020.
675. **Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic.** Luzi L, Radaelli MG. Acta diabetologica. 2020.
676. **Dynamic change process of target genes by RT-PCR testing of SARS-Cov-2 during the course of a Coronavirus Disease 2019 patient.** Lv DF, Ying QM, Weng YS, Shen CB, Chu JG, Kong JP, et al. Clinica Chimica Acta. 2020;506:172-5.
677. **Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19.** Ma J, Xia P, Zhou Y, Liu Z, Zhou X, Wang J, et al. Clinical Immunology. 2020;214.
678. **Potential utilities of mask wearing and instant hand hygiene for fighting SARS-CoV-2.** Ma QX, Shan H, Zhang HL, Li GM, Yang RM, Chen JM. Journal of medical virology. 2020.
679. **Potential utilities of mask-wearing and instant hand hygiene for fighting SARS-CoV-2.** Ma QX, Shan H, Zhang HL, Li GM, Yang RM, Chen JM. Journal of Medical Virology. 2020.
680. **The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19.** Ma WX, Ran XW. Sichuan da xue xue bao Yi xue ban = Journal of Sichuan University Medical science edition. 2020;51(2):146-50.
681. **COVID-19: A novel zoonotic disease caused by a coronavirus from China: What we know and what we don't.** MacKenzie JS, Smith DW. Microbiology Australia. 2020;41(1):45-50.
682. **Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics.** Maddaloni E, Buzzetti R. Diabetes/metabolism research and reviews. 2020:e33213321.
683. **Potential Effects of Coronaviruses on the Cardiovascular System: A Review.** Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. JAMA Cardiology. 2020.
684. **The daily impact of COVID-19 in gastroenterology.** Magro F, Abreu C, Rahier JF. United European Gastroenterology Journal. 2020.
685. **Covid-19: six million doses of hydroxychloroquine donated to US despite lack of evidence.** Mahase E. BMJ (Clinical research ed). 2020;368:m1166.
686. **Covid-19: Gilead withdraws orphan drug designation from potential treatment after criticism.** Mahase E. BMJ (Clinical research ed). 2020;368:m1259.
687. **Covid-19: Increased demand for steroid inhalers causes "distressing" shortages.** Mahase E. BMJ (Clinical research ed). 2020;369:m1393.
688. **Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats.** Malavolta M, Giacconi R, Brunetti D, Provinciali M, Maggi F. Cells. 2020;9(4). <http://dx.doi.org/10.3390/cells9040909>.
689. **Emerging novel coronavirus (2019-nCoV)—current scenario, evolutionary perspective based on genome analysis and recent developments.** Malik YS, Sircar S, Bhat S, Sharun K, Dhama K, Dadar M, et al. Veterinary Quarterly. 2020;40(1):68-76.
690. **What the cruise-ship outbreaks reveal about COVID-19.** Mallapaty S. Nature. 2020.

691. **View: "Scorched Earth" strategy: The RAS as possible target for treating COVID-19 patients with a combination of three approved pharmaceutical agents.** Mancini M. 2020.
692. **Facts and reflections on COVID-19 and anti-hypertensives drugs.** Marin GH. Drug discoveries & therapeutics. 2020.
693. **Influence of early use of antimicrobial on the health and performance of Holstein calves in the first month of life.** Martin CC, Basqueira NS, Ramos JS, Silva KN, Baccili CC, Brandão PE, et al. Pesquisa Veterinaria Brasileira. 2020;40(1):17-28.
694. **Compounds with therapeutic potential against novel respiratory 2019 coronavirus.** Martinez MA. Antimicrob Agents Chemother. 2020. <http://dx.doi.org/10.1128/AAC.00399-20>.
695. **Primary care management of the coronavirus (Covid-19).** Mash B. South African Family Practice. 2020;62(1).
696. **Enhanced isolation of SARS-CoV-2 by TMPRSS2- expressing cells.** Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I, et al. Proceedings of the National Academy of Sciences of the United States of America. 2020;117(13):7001-3.
697. **Equine Coronavirus-Associated Colitis in Horses: A Retrospective Study.** Mattei DN, Kopper JJ, Sanz MG. Journal of Equine Veterinary Science. 2020;87.
698. **Coronavirus Disease (COVID-19) and the Gastrointestinal System in Children.** Matthai J, Shanmugam N, Sobhan P. Indian pediatrics. 2020.
699. **Efficient conversion of N6-threonylcarbamoyladenine (t6A) into a tRNA native hydantoin cyclic form (ct6A) performed at nucleoside and oligoribonucleotide levels.** Matuszewski M, Debiec K, Sochacka E. Chemical Communications. 2017;53(56):7945-8. <http://dx.doi.org/10.1039/c7cc03560h>
700. **A biscoumarin scaffold as an efficient anti-Zika virus lead with NS3-helicase inhibitory potential: In vitro and in silico investigations.** Mayank, Kumar D, Kaur N, Giri R, Singh N. New Journal of Chemistry. 2020;44(5):1872-80.
701. **Optimisation of Vitamin D Status for Enhanced Immuno-protection Against Covid-19.** McCartney DM, Byrne DG. Irish medical journal. 2020;113(4):58.
702. **Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options.** McCreary EK, Pogue JM. Open Forum Infect Dis. 2020;7(4):ofaa105. <http://dx.doi.org/10.1093/ofid/ofaa105>. eCollection 2020 Apr.
703. **Urgent need for individual mobile phone and institutional reporting of at home, hospitalized, and intensive care unit cases of SARS-CoV-2 (COVID-19) infection.** McCullough PA, Eidt J, Rangaswami J, Lerma E, Tumlin J, Wheelan K, et al. Reviews in cardiovascular medicine. 2020;21(1):1-7.
704. **The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease.** McGonagle D, Sharif K, O'Regan A, Bridgwood C. Autoimmunity Reviews. 2020.
705. **Corticosteroid Guidance for Pregnancy during COVID-19 Pandemic.** McIntosh JJ. American journal of perinatology. 2020.
706. **Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution.** Mégarbane B. Clinical Toxicology. 2020.
707. **COVID-19: consider cytokine storm syndromes and immunosuppression.** Mehta P, McAuley DF, Brown

- M, Sanchez E, Tattersall RS, Manson JJ. *The Lancet*. 2020;395(10229):1033-4.
708. **Middle East respiratory syndrome.** Memish ZA, Perlman S, Van Kerkhove MD, Zumla A. *The Lancet*. 2020;395(10229):1063-77.
709. **Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.** Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. *Emerging microbes & infections*. 2020;9(1):757-60.
710. **Intubation and Ventilation amid the COVID-19 Outbreak: Wuhan's Experience.** Meng L, Qiu H, Wan L, Ai Y, Xue Z, Guo Q, et al. *Anesthesiology*. 2020.
711. **COVID-19 and Renin Angiotensin Blockers: Current Evidence and Recommendations.** Messerli FH, Siontis GCM, Rexhaj E. *Circulation*. 2020.
712. **Mesenchymal stem cells and management of COVID-19 pneumonia.** Metcalfe SM. *Medicine in Drug Discovery*. 2020;5.
713. **Drug repurposing of approved drugs Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir, Antrafenine and Ergotamine for combating COVID19.** Mevada V, Dudhagara P, Gandhi H, Vaghamshi N, Beladiya U, Patel R. 2020.
714. **Imported Infections in Rural Mid-West United States - A Report from a Tertiary Care Center.** Meyer A, Regunath H, Rojas-Moreno C, Salzer W, Christensen G. *Missouri medicine*. 2020;117(2):89-94.
715. **Red light-controlled polymerase chain reaction.** Meyer A, Schikora M, Mokhir A. *Chemical Communications*. 2015;51(68):13324-6. <http://dx.doi.org/10.1039/c5cc01805f>
716. **Angiotensin converting enzyme 2 activation: a novel potential Covid-19 therapeutic strategy.** Michel HE. 2020.
717. **Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report.** Michot JM, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F, et al. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2020.
718. **COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD.** Mihai C, Dobrota R, Schröder M, Garaiman A, Jordan S, Becker MO, et al. *Annals of the Rheumatic Diseases*. 2020. <http://dx.doi.org/10.1136/annrheumdis-2020-217442>
719. **Reporting of all cardiac medications and their outcome in COVID - 19.** Mishra AK, Sahu KK, Lal A. *Journal of medical virology*. 2020.
720. **Patterns of heart Injury in COVID - 19 and relation to outcome.** Mishra AK, Sahu KK, Lal A, Sargent J. *Journal of medical virology*. 2020.
721. **Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.** Misra DP, Agarwal V, Gasparyan AY, Zimba O. *Clin Rheumatol*. 2020. <http://dx.doi.org/10.1007/s10067-020-05073-9>.
722. **Use of antiviral drugs to reduce COVID-19 transmission.** Mitjà O, Clotet B. *The Lancet Global health*. 2020.
723. **An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine.** Mitra RL, Greenstein SA, Epstein LM. *HeartRhythm Case Reports*. 2020.

724. **Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020.** Mizumoto K, Kagaya K, Zarebski A, Chowell G. *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.* 2020;25(10).
725. **Discovery of Potent Covid-19 Main Protease Inhibitors Using Machine Learning Based Virtual Screening Strategy.** Mk T, James N, Karuppasamy R. 2020.
726. **Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China.** Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2020.
727. **Vitamin D, Covid-19 and Children.** Molloy EJ, Murphy N. *Irish medical journal.* 2020;113(4):64.
728. **Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes.** Monteiro WM, Brito-Sousa JD, Baia-da-Silva D, Melo GC, Siqueira AM, Val F, et al. *Rev Soc Bras Med Trop.* 2020;53:e20200155. <http://dx.doi.org/10.1590/0037-8682-0155-2020>. eCollection 2020.
729. **Are patients with inflammatory bowel disease at increased risk for Covid-19 infection?** Monteleone G, Ardizzone S. *Journal of Crohn's & colitis.* 2020.
730. **Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.** Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. *Annals of the Rheumatic Diseases.* 2020. <http://dx.doi.org/10.1136/annrheumdis-2020-217424>
731. **Chloroquine for COVID-19 Infection.** Moore N. *Drug Safety.* 2020.
732. **COVID-19 virus and children: What do we know?** Morand A, Fabre A, Minodier P, Boutin A, Vanel N, Bosdure E, et al. *Archives de Pediatrie.* 2020;27(3):117-8.
733. **Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus.** Morel CM, Lindahl O, Harbarth S, de Kraker MEA, Edwards S, Hollis A. *The Journal of antibiotics.* 2020.
734. **A first case of meningitis/encephalitis associated with SARS-Coronavirus-2.** Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. *International Journal of Infectious Diseases.* 2020;94:55-8. <http://dx.doi.org/10.1016/j.ijid.2020.03.062>
735. **Annual review of virology seasonality of respiratory viral infections.** Moriyama M, Hugentobler WJ, Iwasaki A. *Annual Review of Virology.* 2020;7.
736. **Resource Allocation and Decision Making for Pediatric and Congenital Cardiac Catheterization During the Novel Coronavirus SARS-CoV-2 (COVID-19) Pandemic: A U.S. Multi-Institutional Perspective.** Morray BH, Gordon BM, Crystal MA, Goldstein BH, Qureshi AM, Torres AJ, et al. *The Journal of invasive cardiology.* 2020.
737. **Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV.** Morse JS, Lalonde T, Xu S, Liu WR. *ChemBioChem.* 2020;21(5):730-8.
738. **Role of Zidovudine and Candesartan in the Novel SARS-CoV-2 Treatment Trials: Theoretical Study.** Mostafa M. *AIJR Preprints.* 2020.
739. **Interaction between RAAS inhibitors and ACE2 in the context of COVID-19.** Mourad JJ, Levy BI. *Nature Reviews Cardiology.* 2020.
740. **Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir**

binding with SARS-CoV-2 protease against COVID-19. Muralidharan N, Sakthivel R, Velmurugan D, Gromiha MM. *Journal of biomolecular structure & dynamics*. 2020:1-6. <http://dx.doi.org/10.1080/07391102.2020.1752802>.

741. **Possible method for the production of a Covid-19 vaccine.** Myint A, Jones T. *The Veterinary record*. 2020;186(12):388.

742. **Possible treatment of Covid-19 with a therapeutic vaccine.** Myint A, Jones T. *Veterinary Record*. 2020;186(13):419.

743. **Chronology of COVID-19 cases on the Diamond Princess cruise ship and ethical considerations: a report from Japan.** Nakazawa E, Ino H, Akabayashi A. *Disaster medicine and public health preparedness*. 2020:1-27.

744. **Indian Sarsaparilla (Hemidesmus indicus): Recent progress in research on ethnobotany, phytochemistry and pharmacology.** Nandy S, Mukherjee A, Pandey DK, Ray P, Dey A. *Journal of Ethnopharmacology*. 2020;254.

745. **An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19.** Nataf S. *Journal of medical virology*. 2020.

746. **The battle against covid-19: Where do we stand now?** Negahdaripour M. *Iranian Journal of Medical Sciences*. 2020;45(2):81-2.

747. **COVID-19: time for WHO to reconsider its stance towards Taiwan.** Nelson CW. *Nature*. 2020;579(7798):193.

748. **COVID-19 and risks to the supply and quality of tests, drugs, and vaccines.** Newton PN, Bond KC. *The Lancet Global health*. 2020. [http://dx.doi.org/10.1016/S2214-109X\(20\)30136-4](http://dx.doi.org/10.1016/S2214-109X(20)30136-4)

749. **Coronaviruses in animals and humans.** Ng LFP, Hiscox JA. *The BMJ*. 2020;368.

750. **Human leukocyte antigen susceptibility map for SARS-CoV-2.** Nguyen A, David JK, Maden SK, Wood MA, Weeder BR, Nellore A, et al. *J Virol*. 2020. <http://dx.doi.org/10.1128/JVI.00510-20>.

751. **People with Suspected COVID-19 Symptoms Were More Likely Depressed and Had Lower Health-Related Quality of Life: The Potential Benefit of Health Literacy.** Nguyen HC, Nguyen MH, Do BN, Tran CQ, Nguyen TTP, Pham KM, et al. *Journal of clinical medicine*. 2020;9(4). <http://dx.doi.org/10.3390/jcm9040965>.

752. **Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses.** Nguyen TM, Zhang Y, Pandolfi PP. *Cell research*. 2020;30(3):189-90.

753. **Coronavirus disease (COVID-19) in a paucisymptomatic patient: Epidemiological and clinical challenge in settings with limited community transmission, Italy, February 2020.** Nicastrì E, D'Abramo A, Faggioni G, De Santis R, Mariano A, Lepore L, et al. *Eurosurveillance*. 2020;25(11).

754. **Evidence Based Management Guideline for the COVID-19 Pandemic - Review article.** Nicola M, O'Neill N, Sohrabi C, Khan M, Agha M, Agha R. *International journal of surgery (London, England)*. 2020. <http://dx.doi.org/10.1016/j.ijsu.2020.04.001>.

755. **Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.** Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. *Emerging microbes & infections*. 2020;9(1):680-6.

756. **Hydroxychloroquine Use in the United States and the Potential Impact of Critical Shortages from SARS-CoV-2.** Niforatos JD, Johansen ME. 2020.

757. **Novel Coronavirus (SARS-CoV-2) Infection in A Renal Transplant Recipient: Case Report.** Ning L, Liu L, Li W, Liu H, Wang J, Yao Z, et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2020. <http://dx.doi.org/10.1111/ajt.15897>.
758. **[Rapid establishment of traditional Chinese medicine prevention and treatment of 2019-nCoV based on clinical experience and molecular docking].** Niu M, Wang RL, Wang ZX, Zhang P, Bai ZF, Jing J, et al. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. 2020;45(6):1213-8. <http://dx.doi.org/10.19540/j.cnki.cjcmm.20200206.501>.
759. **Why are lopinavir and ritonavir effective against the newly emerged Coronavirus 2019?: Atomistic insights into the inhibitory mechanisms.** Nutho B, Mahalapbutr P, Hengphasatporn K, Pattarangoon NC, Simanon N, Shigeta Y, et al. Biochemistry. 2020. <http://dx.doi.org/10.1021/acs.biochem.0c00160>.
760. **Assessing nitrogen dioxide (NO₂) levels as a contributing factor to coronavirus (COVID-19) fatality.** Ogen Y. Science of the Total Environment. 2020;726.
761. **Multidrug treatment with nelfinavir and cepharanthine against COVID-19.** Ohashi H, Watashi K, Saso W, Shionoya K, Iwanami S, Hirokawa T, et al. bioRxiv. 2020:2020.04.14.039925.
762. **Macrolide treatment for COVID-19: Will this be the way forward?** Ohe M, Shida H, Jodo S, Kusunoki Y, Seki M, Furuya K, et al. Bioscience trends. 2020.
763. **Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients.** Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. Emerging infectious diseases. 2020;26(7).
764. **Is nicotine exposure linked to cardiopulmonary vulnerability to COVID-19 in the general population?** Olds JL, Kabbani N. The FEBS journal. 2020.
765. **Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis.** Ortega JT, Serrano ML, Pujol FH, Rangel HR. EXCLI Journal. 2020;19:410-7.
766. **Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target.** Ortega JT, Serrano ML, Pujol FH, Rangel HR. EXCLI Journal. 2020;19:400-9.
767. **Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.** Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Nat Commun. 2020;11(1):1620. <http://dx.doi.org/10.1038/s41467-020-15562-9>.
768. **Conducting Clinical Research During the COVID-19 Pandemic: Investigator and Participant Perspectives.** Padala PR, Jendro AM, Padala KP. JMIR public health and surveillance. 2020;6(2):e18887. <http://dx.doi.org/10.2196/18887>.
769. **Undocumented U.S. Immigrants and Covid-19.** Page KR, Venkataramani M, Beyrer C, Polk S. The New England journal of medicine. 2020. <http://dx.doi.org/10.1056/NEJMp2005953>.
770. **Is Hydroxychloroquine a possible post-exposure prophylaxis drug to limit the transmission to health care workers exposed to COVID19?** Pagliano P, Piazza O, De Caro F, Ascione T, Filippelli A. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020.
771. **COVID-19, diabetes mellitus and ACE2: The conundrum.** Pal R, Bhansali A. Diabetes Research and Clinical Practice. 2020;162.
772. **Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus**

(COVID-19) Pneumonia. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. *Radiology*. 2020:200370. <http://dx.doi.org/10.1148/radiol.2020200370>.

773. **Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis.** Pan XW, Xu D, Zhang H, Zhou W, Wang LH, Cui XG. *Intensive Care Medicine*. 2020.

774. **Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): A systematic review.** Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JIP, et al. *Journal of Clinical Medicine*. 2020;9(3).

775. **Synthesis, in vitro and in vivo biological evaluation of novel lappaconitine derivatives as potential anti-inflammatory agents.** Pang L, Liu CY, Gong GH, Quan ZS. *Acta Pharmaceutica Sinica B*. 2020;10(4):628-45.

776. **Analysis on pattern of prescriptions and syndromes of traditional Chinese medicine for prevention and treatment of COVID-19.** Pang WT, Jin XY, Pang B, Yang FW, Wang H, Liu CX, et al. *Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica*. 2020;45(6):1242-7. <http://dx.doi.org/10.19540/j.cnki.cjcmm.20200218.502>

777. **Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis.** Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al. *Journal of thrombosis and haemostasis : JTH*. 2020. <http://dx.doi.org/10.1111/jth.14850>.

778. **Peptide-like and small-molecule inhibitors against Covid-19.** Pant S, Singh M, Ravichandiran V, Murty USN, Srivastava HK. *Journal of biomolecular structure & dynamics*. 2020:1-15. <http://dx.doi.org/10.1080/07391102.2020.1757510>

779. **Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event.** Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G, Tsiodras S. *Infection, Genetics and Evolution*. 2020;79.

780. **Delivery in pregnant women infected with SARS-CoV-2: A fast review.** Parazzini F, Bortolus R, Mauri PA, Favilli A, Gerli S, Ferrazzi E. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*. 2020. <http://dx.doi.org/10.1002/ijgo.13166>

781. **Collaborative Multi-Disciplinary Incident Command at Seattle Children's Hospital for Rapid Preparatory Pediatric Surgery Countermeasures to the COVID-19 Pandemic.** Parikh SR, Avansino JR, Dick AA, Enriquez BK, Geiduschek JM, Martin LD, et al. *Journal of the American College of Surgeons*. 2020. <http://dx.doi.org/10.1016/j.jamcollsurg.2020.04.012>.

782. **Development of Reverse Transcription Loop-mediated Isothermal Amplification (RT-LAMP) Assays Targeting SARS-CoV-2.** Park GS, Ku K, Baek SH, Kim SJ, Kim SI, Kim BT, et al. *The Journal of molecular diagnostics : JMD*. 2020. <http://dx.doi.org/10.1016/j.jmoldx.2020.03.006>

783. **Active virological surveillance in backyard ducks in Bangladesh: Detection of avian influenza and gamma-coronaviruses.** Parvin R, Kabiraj CK, Mumu TT, Chowdhury EH, Islam MR, Beer M, et al. *Avian pathology : journal of the WVPA*. 2020:1-29.

784. **Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020.** Patel A, Jernigan DB. *MMWR Morbidity and mortality weekly report*. 2020;69(5):140-6. <http://dx.doi.org/10.15585/mmwr.mm6905e1>.

785. **COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?** Patel AB, Verma A. *JAMA*. 2020.

786. **Report from the American Society for Microbiology COVID-19 International Summit, 23 March 2020: Value of Diagnostic Testing for SARS-CoV-2/COVID-19.** Patel R, Babady E, Theel ES, Storch GA, Pinsky BA, St George K, et al. *mBio*. 2020;11(2).
787. **SARS-CoV-2: A Storm is Raging.** Pedersen SF, Ho YC. *The Journal of clinical investigation*. 2020.
788. **Avoiding pitfalls in the pursuit of a COVID-19 vaccine.** Peeples L. *Proceedings of the National Academy of Sciences of the United States of America*. 2020;117(15):8218-21.
789. **A validated UPLC–MS/MS method for quantitative determination of a potent neuroprotective agent Sarsasapogenin-AA13 in rat plasma: Application to pharmacokinetic studies.** Pei L, Ye Y, Zhao W, Ye Q, Ge S, Jiang ZW, et al. *Biomedical Chromatography*. 2020;34(3).
790. **Substituting Angiotensin-(1-7) to Prevent Lung Damage in SARSCoV2 Infection?** Peiró C, Moncada S. *Circulation*. 2020.
791. **Improved Early Recognition of Coronavirus Disease-2019 (COVID-19): Single-Center Data from a Shanghai Screening Hospital.** Peng L, Liu KY, Xue F, Miao YF, Tu PA, Zhou C. *Archives of Iranian medicine*. 2020;23(4):272-6.
792. **Transmission routes of 2019-nCoV and controls in dental practice.** Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. *International journal of oral science*. 2020;12(1):9.
793. **Unlikely SARS-CoV-2 vertical transmission from mother to child: A case report.** Peng Z, Wang J, Mo Y, Duan W, Xiang G, Yi M, et al. *Journal of Infection and Public Health*. 2020. <http://dx.doi.org/10.1016/j.jiph.2020.04.004>
794. **Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.** Pereira BB. *Journal of Toxicology and Environmental health Part B, Critical Reviews*. 2020:1-5.
795. **Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade.** Perico L, Benigni A, Remuzzi G. *Nephron*. 2020:1-9.
796. **Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients.** Perinel S, Launay M, Botelho-Nevers É, Diconne É, Louf-Durier A, Lachand R, et al. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
797. **Another decade, another coronavirus.** Perlman S. *New England Journal of Medicine*. 2020;382(8):760-2. <http://dx.doi.org/10.1056/NEJMe2001126>
798. **Possible Consequences of a Shortage of Hydroxychloroquine for Lupus Patients Amid the COVID-19 Pandemic.** Peschken CA. *The Journal of rheumatology*. 2020.
799. **Structure–activity relationships and molecular docking analysis of Mcl-1 targeting renieramycin T analogues in patient-derived lung cancer cells.** Petsri K, Yokoya M, Tungsukruthai S, Rungrotmongkol T, Nutho B, Vinayanuwattikun C, et al. *Cancers*. 2020;12(4). <http://dx.doi.org/10.3390/cancers12040875>
800. **COVID-19 treatment by repurposing drugs until the vaccine is in sight.** Phadke M, Saunik S. *Drug Development Research*. 2020.
801. **Importation and human-to-human transmission of a novel coronavirus in Vietnam.** Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, et al. *New England Journal of Medicine*. 2020;382(9):872-4.

802. **Novel coronavirus: From discovery to clinical diagnostics.** Phan T. *Infection, Genetics and Evolution.* 2020;79.
803. **Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19.** Picot S, Marty A, Bienvenu AL, Blumberg LH, Dupouy-Camet J, Carnevale P, et al. *One Health.* 2020.
804. **ACE2 Expression is Increased in the Lungs of Patients with Comorbidities Associated with Severe COVID-19.** Pinto BGG, Oliveira AER, Singh Y, Jimenez L, Goncalves ANA, Ogawa RLT, et al. *medRxiv.* 2020:2020.03.21.20040261.
805. **The New Coronavirus, the Current King of China.** Plotkin SA. *Journal of the Pediatric Infectious Diseases Society.* 2019;9(1):1-2.
806. **Multiplex Screening Assay for Identifying Cytotoxic CD8+ T Cell Epitopes.** Poh CM, Zheng J, Channappanavar R, Chang ZW, Nguyen THO, Rénia L, et al. *Frontiers in immunology.* 2020;11:400.
807. **Interacting Temperature, Nutrients and Zooplankton Grazing Control Phytoplankton Size-Abundance Relationships in Eight Swiss Lakes.** Pomati F, Shurin JB, Andersen KH, Tellenbach C, Barton AD. *Frontiers in Microbiology.* 2020;10.
808. **Clinical Characteristics of Patients Hospitalized with Coronavirus Disease, Thailand.** Pongpirul WA, Mott JA, Woodring JV, Uyeki TM, MacArthur JR, Vachiraphan A, et al. *Emerging infectious diseases.* 2020;26(7).
809. **Emergence of a novel human coronavirus threatening human health.** Poon LLM, Peiris M. *Nature Medicine.* 2020;26(3):317-9.
810. **Roadblocks to Infection Prevention Efforts in Healthcare SARS-CoV-2/COVID-19 Response.** Popescu S. *Disaster medicine and public health preparedness.* 2020:1-7. <http://dx.doi.org/10.1017/dmp.2020.55>.
811. **The Use of Nonsteroidal Anti-inflammatory Drugs in Urological Practice in the COVID-19 Era: Is “Safe Better than Sorry”?** Pradère B, Ploussard G, Catto JWF, Rouprêt M, Misrai V. *European Urology.* 2020.
812. **Drug targets for corona virus: A systematic review.** Prajapat M, Sarma P, Shekhar N, Avti P, Sinha S, Kaur H, et al. *Indian Journal of Pharmacology.* 2020;52(1):56-65.
813. **BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF COVID 19.** Praveen D, Chowdary PR, Aanandhi MV. *International journal of antimicrobial agents.* 2020:105967.
814. **COVID-19 and Immunomodulator/Immunosuppressant Use in Dermatology.** Price KN, Frew JW, Hsiao JL, Shi VY. *Journal of the American Academy of Dermatology.* 2020.
815. **COVID-19 and emerging viral infections: The case for interferon lambda.** Prokunina-Olsson L, Alphonse N, Dickenson RE, Durbin JE, Glenn JS, Hartmann R, et al. *The Journal of experimental medicine.* 2020;217(5). <http://dx.doi.org/10.1084/jem.20200653>.
816. **Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic.** Prompetchara E, Ketloy C, Palaga T. *Asian Pacific journal of allergy and immunology.* 2020;38(1):1-9.
817. **Evaluate Severe Acute Respiratory Syndrome Coronavirus 2 Infectivity by Pseudoviral Particles.** Pu T, Ding C, Li Y, Liu X, Li H, Duan J, et al. *Journal of medical virology.* 2020.
818. **Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures.** Pung R, Chiew CJ, Young BE, Chin S, Chen MIC, Clapham HE, et al. *The Lancet.* 2020;395(10229):1039-46.

819. **Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses.** Qi F, Qian S, Zhang S, Zhang Z. *Biochemical and biophysical research communications*. 2020.
820. **CT imaging of coronavirus disease 2019 (COVID-19): From the qualitative to quantitative.** Qi X, Lei J, Yu Q, Xi Y, Wang Y, Ju S. *Annals of Translational Medicine*. 2020;8(5).
821. **Transmissible Gastroenteritis Virus Infection Up-Regulates FcRn Expression via Nucleocapsid Protein and Secretion of TGF- β in Porcine Intestinal Epithelial Cells.** Qian S, Gao Z, Cao R, Yang K, Cui Y, Li S, et al. *Frontiers in Microbiology*. 2020;10.
822. **Fighting against the common enemy of COVID-19: A practice of building a community with a shared future for mankind.** Qian X, Ren R, Wang Y, Guo Y, Fang J, Wu ZD, et al. *Infectious Diseases of Poverty*. 2020;9(1).
823. **Analysis of baseline liver biochemical parameters in 324 cases with novel coronavirus pneumonia in Shanghai area.** Qian ZP, Mei X, Zhang YY, Zou Y, Zhang ZG, Zhu H, et al. *Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology*. 2020;28:E005.
824. **Using the spike protein feature to predict infection risk and monitor the evolutionary dynamic of coronavirus.** Qiang XL, Xu P, Fang G, Liu WB, Kou Z. *Infectious diseases of poverty*. 2020;9(1):33.
825. **18F-FDG PET/CT findings of COVID-19: a series of four highly suspected cases.** Qin C, Liu F, Yen TC, Lan X. *European Journal of Nuclear Medicine and Molecular Imaging*. 2020;47(5):1281-6.
826. **Dysregulation of immune response in patients with COVID-19 in Wuhan, China.** Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
827. **Intensive care during the coronavirus epidemic.** Qiu H, Tong Z, Ma P, Hu M, Peng Z, Wu W, et al. *Intensive Care Medicine*. 2020;46(4):576-8.
828. **Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study.** Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. *Lancet Infect Dis*. 2020. [http://dx.doi.org/10.1016/S1473-3099\(20\)30198-5](http://dx.doi.org/10.1016/S1473-3099(20)30198-5).
829. **Identification of potential cross-protective epitope between a new type of coronavirus (2019-nCoV) and severe acute respiratory syndrome virus.** Qiu T, Mao T, Wang Y, Zhou M, Qiu J, Wang J, et al. *Journal of genetics and genomics = Yi chuan xue bao*. 2020.
830. **Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2.** Qiu Y, Zhao YB, Wang Q, Li JY, Zhou ZJ, Liao CH, et al. *Microbes and infection*. 2020.
831. **Observation on clinical effect of Shufeng Jiedu Capsule combined with Arbidol Hydrochloride Capsule in treatment of COVID-19.** Qu XK, Hao SL, Ma JH, Wei GY, Song KY, Tang C, et al. *Chinese Traditional and Herbal Drugs*. 2020;51(5):1167-70.
832. **SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview.** Rabaan AA, Al-Ahmed SH, Haque S, Sah R, Tiwari R, Malik YS, et al. *Le infezioni in medicina*. 2020;28(2):174-84.
833. **Current drugs with potential for treatment of covid-19: A literature review.** Rabby MII. *Journal of Pharmacy and Pharmaceutical Sciences*. 2020;23(1):58-64.
834. **Sars-cov-2 and coronavirus disease 2019: What we know so far.** Rabi FA, Al Zoubi MS, Al-Nasser AD, Kasasbeh GA, Salameh DM. *Pathogens*. 2020;9(3).

835. **A Consensus Statement on the Use of Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors in relation to COVID-19 (Corona Virus Disease 2019).** Rabindranath. 2020.
836. **Advice regarding COVID-19 and use of immunomodulators, in patients with severe dermatological diseases.** Rademaker M, Baker C, Foley P, Sullivan J, Wang C. The Australasian journal of dermatology. 2020.
837. **Practical Strategies Against the Novel Coronavirus and COVID-19—the Imminent Global Threat.** Rahimi F, Talebi Bezmin Abadi A. Archives of Medical Research. 2020.
838. **2019-nCoV (Wuhan virus), a novel Coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness.** Ralph R, Lew J, Zeng T, Francis M, Xue B, Roux M, et al. J Infect Dev Ctries. 2020;14(1):3-17. <http://dx.doi.org/10.3855/jidc.12425>.
839. **Tackling corona virus disease 2019 (COVID 19) in workplaces.** Ramesh N, Siddaiah A, Joseph B. Indian Journal of Occupational and Environmental Medicine. 2020;24(1):16-8.
840. **Optimizing COVID-19 candidate therapeutics: Thinking Without Borders.** Rayner CR, Smith PF, Hershberger K, Wesche D. Clinical and translational science. 2020.
841. **Evolutionary trajectory for the emergence of novel coronavirus SARS-CoV-2.** Rehman SU, Shafique L, Ihsan A, Liu Q. Pathogens. 2020;9(3).
842. **Remdesivir, the antiviral hope against SARS-CoV-2.** Reina J. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia. 2020.
843. **The SARS-CoV-2, a new pandemic zoonosis that threatens the world.** Reina J. Vacunas. 2020.
844. **Traditional Chinese medicine for COVID-19 treatment.** Ren JL, Zhang AH, Wang XJ. Pharmacological Research. 2020;155.
845. **Analysis on diagnosis and treatment scheme of traditional Chinese medicine in treatment of COVID-19 in Chinese provinces and regions.** Ren WY, Su J, Liu YQ, Hou WQ, Zheng YJ, Wei BJ, et al. Chinese Traditional and Herbal Drugs. 2020;51(5):1139-46.
846. **Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020.** Reusken CBEM, Broberg EK, Haagmans B, Meijer A, Corman VM, Papa A, et al. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2020;25(6).
847. **Comparison of Abbott ID Now, Diasorin Simplexa, and CDC FDA EUA methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19.** Rhoads DD, Cherian SS, Roman K, Stempak LM, Schmotzer CL, Sadri N. J Clin Microbiol. 2020. <http://dx.doi.org/10.1128/JCM.00760-20>.
848. **Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.** Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. The Lancet. 2020;395(10223):e30-e1.
849. **Baricitinib for COVID-19: a suitable treatment? - Authors' reply.** Richardson PJ, Corbellino M, Stebbing J. The Lancet Infectious diseases. 2020.
850. **COVID-19 tsunami: the first case of a spinal cord injury patient in Italy.** Righi G, Del Popolo G. Spinal cord series and cases. 2020;6(1):22. <http://dx.doi.org/10.1038/s41394-020-0274-9>.
851. **Covid-19: junior doctor calls on colleagues to gather supplies for staff working long hours.** Rimmer A.

Bmj. 2020;368:m1072. <http://dx.doi.org/10.1136/bmj.m1072>.

852. **Liver and kidney injuries in COVID-19 and their effects on drug therapy; a letter to editor.** Rismanbaf A, Zarei S. Archives of Academic Emergency Medicine. 2020;8(1).

853. **Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?** Ritchie AI, Singanayagam A. Lancet. 2020;395(10230):1111. [http://dx.doi.org/10.1016/S0140-6736\(20\)30691-7](http://dx.doi.org/10.1016/S0140-6736(20)30691-7). Epub 2020 Mar 24.

854. **The Impact of COVID-19 on Radiation Oncology Clinics and Cancer Patients in the U.S.** Rivera A, Ohri N, Thomas E, Miller R, Knoll MA. Advances in radiation oncology. 2020. <http://dx.doi.org/10.1016/j.adro.2020.03.006>.

855. **COVID-19 in the heart and the lungs: could we "Notch" the inflammatory storm?** Rizzo P, Vieceli Dalla Sega F, Fortini F, Marracino L, Rapezzi C, Ferrari R. Basic research in cardiology. 2020;115(3):31.

856. **Convalescent Plasma to Treat COVID-19: Possibilities and Challenges.** Roback JD, Guarner J. JAMA - Journal of the American Medical Association. 2020:E1-E2.

857. **Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus.** Robson B. Computers in Biology and Medicine. 2020;119.

858. **Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS.** Rokni M, Ghasemi V, Tavakoli Z. Reviews in Medical Virology. 2020.

859. **Renin-angiotensin system: The unexpected flaw inside the human immune system revealed by SARS-CoV-2.** Roncati L, Gallo G, Manenti A, Palmieri B. Medical Hypotheses. 2020;140.

860. **Therapeutic effects of integrated traditional Chinese medicine and western medicine in treating severe acute respiratory syndrome.** Rong-bing W, Jun-min L, Yu-yong J, Yun-zhong W, Xiao-jing W, Pin-pin C, et al. Chinese Journal of Integrative Medicine. 2003;9(4):259-62.

861. **Clinical trials on drug repositioning for COVID-19 treatment.** Rosa SGV, Santos WC. Revista panamericana de salud publica = Pan American journal of public health. 2020;44:e40. <http://dx.doi.org/10.26633/RPSP.2020.40>. eCollection 2020.

862. **Will plant-made biopharmaceuticals play a role in the fight against COVID-19?** Rosales-Mendoza S. Expert opinion on biological therapy. 2020.

863. **Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.** Rossi GP, Sanga V, Barton M. eLife. 2020;9.

864. **Challenges and solutions for addressing critical shortage of supply chain for personal and protective equipment (PPE) arising from Coronavirus disease (COVID19) pandemic – Case study from the Republic of Ireland.** Rowan NJ, Laffey JG. Science of the Total Environment. 2020;725.

865. **Audio Interview: New Research on Possible Treatments for Covid-19.** Rubin EJ, Baden LR, Morrissey S. The New England journal of medicine. 2020;382(12):e30. <http://dx.doi.org/10.1056/NEJMe2005759>.

866. **Audio Interview: Lessons from Covid-19 Hotspots.** Rubin EJ, Baden LR, Morrissey S. The New England journal of medicine. 2020;382(14):e35. <http://dx.doi.org/10.1056/NEJMe2007783>.

867. **Audio Interview: Caring for Patients with Covid-19.** Rubin EJ, Baden LR, Morrissey S. The New England journal of medicine. 2020;382(16):e50. <http://dx.doi.org/10.1056/NEJMe2011242>

868. **As COVID-19 cases, deaths and fatality rates surge in Italy, underlying causes require investigation.** Rubino S, Kelvin N, Bermejo-Martin JF, Kelvin DJ. *Journal of Infection in Developing Countries*. 2020;14(3):265-7.
869. **COVID-19 Related School Closings and Risk of Weight Gain Among Children.** Rundle AG, Park Y, Herbstman JB, Kinsey EW, Wang YC. *Obesity (Silver Spring, Md)*. 2020. <http://dx.doi.org/10.1002/oby.22813>.
870. **Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2).** Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qin Hai M, Yongxia S, et al. *Pharmacological research*. 2020:104761.
871. **Immune-epidemiological parameters of the novel coronavirus—a perspective.** Saghadzadeh A, Rezaei N. *Expert Review of Clinical Immunology*. 2020.
872. **Complete genome sequence of a 2019 novel coronavirus (SARS-COV-2) strain isolated in Nepal.** Sah R, Rodriguez-Morales AJ, Jha R, Chu DKW, Gu H, Peiris M, et al. *Microbiology Resource Announcements*. 2020;9(11).
873. **Aminoquinolines Against Coronavirus Disease 2019 (COVID-19): Chloroquine or Hydroxychloroquine.** Sahraei Z, Shabani M, Shokouhi S, Saffaei A. *International journal of antimicrobial agents*. 2020:105945.
874. **COVID-2019: update on epidemiology, disease spread and management.** Sahu KK, Mishra AK, Lal A. *Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace*. 2020;90(1). <http://dx.doi.org/10.4081/monaldi.2020.1292>
875. **Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients.** Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. *AJR American journal of roentgenology*. 2020:1-7.
876. **Helen Salisbury: Coronavirus diaries.** Salisbury H. *The BMJ*. 2020;368.
877. **Type 1 interferons as a potential treatment against COVID-19.** Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. *Antiviral Research*. 2020;178.
878. **Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.** Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. *Jama*. 2020. <http://dx.doi.org/10.1001/jama.2020.6019>.
879. **Recent Trends of 2019 New Coronavirus Disease.** Santel. 2020.
880. **Guidance On Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society.** Sapp JL, Alqarawi W, MacIntyre CJ, Tadros R, Steinberg C, Roberts JD, et al. *The Canadian journal of cardiology*. 2020. <http://dx.doi.org/10.1016/j.cjca.2020.04.003>.
881. **Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19.** Saqrane S, El Mhammedi MA. *New Microbes and New Infections*. 2020;35.
882. **COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?** Sargiacomo C, Sotgia F, Lisanti MP. *Aging (Albany NY)*. 2020. <http://dx.doi.org/10.18632/aging.103001>.
883. **Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.** Sarkar R, Banerjee S, Amin SA, Adhikari N, Jha T. *European Journal of Medicinal Chemistry*. 2020;192.
884. **Virological and Clinical Cure in Covid-19 Patients Treated with Hydroxychloroquine: A Systematic Review and Meta-Analysis.** Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A, et al. *J Med Virol*. 2020.

<http://dx.doi.org/10.1002/jmv.25898>.

885. **Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach.** Sarma P, Prajapat M, Avti P, Kaur H, Kumar S, Medhi B. *Indian Journal of Pharmacology*. 2020;52(1):1-5.
886. **In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain).** Sarma P, Sekhar N, Prajapat M, Avti P, Kaur H, Kumar S, et al. *Journal of biomolecular structure & dynamics*. 2020:1-11.
887. **Detection of porcine epidemic diarrhea virus–neutralizing antibody using high-throughput imaging cytometry.** Sarmiento LV, Poonsuk K, Tian L, Mora-Díaz JC, Main RG, Baum DH, et al. *Journal of Veterinary Diagnostic Investigation*. 2020;32(2):324-8.
888. **COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?** Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, et al. *Clinical and experimental rheumatology*. 2020.
889. **Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients.** Sawalha AH, Zhao M, Coit P, Lu Q. *Clinical Immunology*. 2020;215. <http://dx.doi.org/10.1016/j.clim.2020.108410>
890. **Seroprevalence of Middle East Respiratory Syndrome Corona Virus in dromedaries and their traders in upper Egypt.** Sayed AS, Malek SS, Abushahba MF. *Journal of infection in developing countries*. 2020;14(2):191-8.
891. **Susceptibility of the Elderly to SARS-CoV-2 Infection: ACE-2 Overexpression, Shedding and Antibody-dependent Enhancement (ADE).** Schatzmann Peron JP, Nakaya H. *Journal*. 2020(Issue).
892. **Advances in Discovering Deubiquitinating Enzyme (DUB) Inhibitors.** Schauer NJ, Magin RS, Liu X, Doherty LM, Buhrlage SJ. *Journal of Medicinal Chemistry*. 2020;63(6):2731-50.
893. **Hypertension and COVID-19.** Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. *American Journal of Hypertension*. 2020.
894. **Repurposing antimalarials and other drugs for COVID-19.** Schlagenhaut P, Grobusch MP, Maier JD, Gautret P. *Travel Medicine and Infectious Disease*. 2020.
895. **Generalized Pustular Figurate Erythema A Newly Delineated Severe Cutaneous Drug Reaction Linked with Hydroxychloroquine.** Schwartz RA, Janniger CK. *Dermatologic therapy*. 2020.
896. **First Mildly Ill, Non-Hospitalized Case of Coronavirus Disease 2019 (COVID-19) Without Viral Transmission in the United States - Maricopa County, Arizona, 2020.** Scott SE, Zabel K, Collins J, Hobbs KC, Kretschmer MJ, Lach M, et al. *Clin Infect Dis*. 2020. <http://dx.doi.org/10.1093/cid/ciaa374>.
897. **Hydroxychloroquine: a potential ethical dilemma for rheumatologists during the COVID-19 pandemic.** Scuccimarrì R, Sutton E, Fitzcharles MA. *The Journal of rheumatology*. 2020.
898. **In silico studies on therapeutic agents for COVID-19: Drug repurposing approach.** Shah B, Modi P, Sagar SR. *Life Sciences*. 2020:117652.
899. **COVID-19 pandemic through the lens of a gastroenterology fellow: looking for the silver lining.** Shah R, Satyavada S, Ismail M, Kurin M, Smith ZL, Cooper GS, et al. *Gastrointestinal Endoscopy*. 2020.
900. **A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19).** Shah S, Das S, Jain A, Misra DP, Negi VS. *International Journal of Rheumatic Diseases*. 2020.

901. **COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic.** Shaker MS, Oppenheimer J, Grayson M, Stukus D, Hartog N, Hsieh EWY, et al. *The journal of allergy and clinical immunology In practice.* 2020.
902. **Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry.** Shang J, Wan Y, Liu C, Yount B, Gully K, Yang Y, et al. *PLoS pathogens.* 2020;16(3):e1008392.
903. **On the use of corticosteroids for 2019-nCoV pneumonia.** Shang L, Zhao J, Hu Y, Du R, Cao B. *The Lancet.* 2020;395(10225):683-4.
904. **The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines.** Shang W, Yang Y, Rao Y, Rao X. *npj Vaccines.* 2020;5(1).
905. **Cancer Care Delivery Challenges Amidst Coronavirus Disease - 19 (COVID-19) Outbreak: Specific Precautions for Cancer Patients and Cancer Care Providers to Prevent Spread.** Shankar A, Saini D, Roy S, Mosavi Jarrahi A, Chakraborty A, Bharti SJ, et al. *Asian Pacific journal of cancer prevention : APJCP.* 2020;21(3):569-73. <http://dx.doi.org/10.31557/APJCP.2020.21.3.569>.
906. **Measles Immunization: Worth Considering Containment Strategy for SARS-CoV-2 Global Outbreak.** Shanker V. *Indian Pediatr.* 2020;57(4):380.
907. **Emergence of novel coronavirus 2019-nCoV: Need for rapid vaccine and biologics development.** Shanmugaraj B, Malla A, Phoolcharoen W. *Pathogens.* 2020;9(2).
908. **Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).** Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. *Asian Pacific journal of allergy and immunology.* 2020;38(1):10-8. <http://dx.doi.org/10.12932/AP-200220-0773>.
909. **Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.** Shannon A, Tuyet Le NT, Selisko B, Eydoux C, Alvarez K, Guillemot JC, et al. *Antiviral Res.* 2020:104793. <http://dx.doi.org/10.1016/j.antiviral.2020.104793>.
910. **Biological treatment use amid the COVID-19 era, a close look at the unresolved perplexity.** Shanshal M. *The Journal of dermatological treatment.* 2020:1-9.
911. **A review on clinical application of high frequency traditional Chinese medicine in treatment of coronavirus pneumonia 2019.** Shao ZB, Zhu YX, Liu SH, Jiang KJ, Wu Q, Shen JY, et al. *Chinese Traditional and Herbal Drugs.* 2020;51(5):1153-8.
912. **An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.** Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, et al. *Science translational medicine.* 2020.
913. **Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma.** Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. *JAMA - Journal of the American Medical Association.* 2020.
914. **Quantitative computed tomography analysis for stratifying the severity of Coronavirus Disease 2019.** Shen C, Yu N, Cai S, Zhou J, Sheng J, Liu K, et al. *Journal of Pharmaceutical Analysis.* 2020.
915. **Novel coronavirus infection in children outside of Wuhan, China.** Shen Q, Guo W, Guo T, Li J, He W, Ni S, et al. *Pediatric Pulmonology.* 2020.
916. **Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)-induced**

pneumonia. Shetty AK. Aging and Disease. 2020;11(2):462-4.

917. **The potential of low molecular weight heparin to mitigate cytokine storm in severe covid-19 patients: a retrospective clinical study.** Shi C, Wang C, Wang H, Yang C, Cai FEI, Zeng F, et al. medRxiv. 2020:2020.03.28.20046144.

918. **Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study.** Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. The Lancet Infectious Diseases. 2020;20(4):425-34.

919. **Evolution of CT Manifestations in a Patient Recovered from 2019 Novel Coronavirus (2019-nCoV) Pneumonia in Wuhan, China.** Shi H, Han X, Zheng C. Radiology. 2020;295(1):20.

920. **2019 novel coronavirus, angiotensin converting enzyme 2 and cardiovascular drugs.** Shi HZ, Ma P, Gao FY, Chen GL, Yu YH, Wang XD, et al. Zhonghua xin xue guan bing za zhi. 2020;48:E010.

921. **Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.** Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. JAMA cardiology. 2020.

922. **Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV).** Shi Y, Wang N, Zou QM. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]. 2020;54:E029.

923. **The Burden of COVID-19 in People Living with HIV: A Syndemic Perspective.** Shiao S, Krause KD, Valera P, Swaminathan S, Halkitis PN. AIDS and behavior. 2020. <http://dx.doi.org/10.1007/s10461-020-02871-9>.

924. **Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning.** Shoenfeld Y. Autoimmunity Reviews. 2020.

925. **Covid-19: The outbreak caused by a new coronavirus.** Sifuentes-Rodríguez E, Palacios-Reyes D. Boletín Médico del Hospital Infantil de México. 2020;77(2):47-53.

926. **A potential role for integrins in host cell entry by SARS-CoV-2.** Sigrist CJ, Bridge A, Le Mercier P. Antiviral Research. 2020;177.

927. **Revision of the elegans-group of Alona s. lato and its status as a subgenus of Coronatella Dybowski amp; Grochowski, 1894 (Cladocera: Anomopoda: Chydoridae).** Sinev AY. Zootaxa. 2020;4732(4):zootaxa.4732.4.1.

928. **COVID-19: From bench to bed side.** Singh A, Shaikh A, Singh R, Singh AK. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020;14(4):277-81.

929. **Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations.** Singh AK, Gupta R, Ghosh A, Misra A. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020;14(4):303-10.

930. **Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers.** Singh AK, Gupta R, Misra A. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020;14(4):283-7.

931. **Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries.** Singh AK, Singh A, Shaikh A, Singh R, Misra A. Diabetes & metabolic syndrome. 2020;14(3):241-6.

932. **A Review of Coronavirus Disease-2019 (COVID-19).** Singhal T. Indian Journal of Pediatrics. 2020.

933. **Consensus statement on the use of clozapine during the COVID-19 pandemic.** Siskind D, Honer WG, Clark S, Correll CU, Hasan A, Howes O, et al. Journal of psychiatry & neuroscience : JPN. 2020;45(3):2.

934. **Current strategies and approaches in combating SARS-CoV-2 virus that causes COVID-19.** Sivaraman D, Pradeep PS, Sundar Manoharan S, Ramachandra Bhat C, Leela KV, Venugopal V. *Letters in Drug Design and Discovery.* 2020;17(5):670-2.
935. **ACE2, COVID19 and serum ACE as a possible biomarker to predict severity of disease.** Skarstein Kolberg E. *Journal of Clinical Virology.* 2020;126.
936. **Dosing will be a key success factor in repurposing antivirals for COVID-19.** Smith PF, Dodds M, Bentley D, Yeo K, Rayner C. *British journal of clinical pharmacology.* 2020. <http://dx.doi.org/10.1111/bcp.14314>.
937. **Possible cause of outbreak of prolific vomiting in dogs.** Smith SL, Singleton DA, Noble PJ, Radford AD, Brant B, Pinchbeck GL, et al. *Veterinary Record.* 2020;186(10):324.
938. **Safety of Ibuprofen in Patients with COVID-19; Causal or Confounded?** Sodhi M, Etminan M. *Chest.* 2020.
939. **Therapeutic Potential for Tetracyclines in the Treatment of COVID-19.** Sodhi M, Etminan M. *Pharmacotherapy.* 2020.
940. **Rabies encephalitis and extra-neural manifestations in a patient bitten by a domestic cat.** Soler-Rangel S, Jiménez-Restrepo N, Nariño D, Rosselli D. *Revista do Instituto de Medicina Tropical de Sao Paulo.* 2020;62.
941. **Scarcity in the Covid-19 Pandemic.** Solomon MZ, Wynia M, Gostin LO. *The Hastings Center report.* 2020;50(2):3. <http://dx.doi.org/10.1002/hast.1093>
942. **Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?** Sommerstein R, Kochen MM, Messerli FH, Gräni C. *Journal of the American Heart Association.* 2020;9(7):e016509.
943. **Emerging 2019 novel coronavirus (2019-NCov) pneumonia.** Song F, Shi N, Shan F, Zhang Z, Shen J, Lu H, et al. *Radiology.* 2020;295(1):210-7.
944. **Design, Synthesis, Biological Evaluation and Inhibition Mechanism of 3-/4-Alkoxy Phenylethylidenethiosemicarbazides as New, Potent and Safe Tyrosinase Inhibitors.** Song S, Mai Y, Shi H, Liao B, Wang F. *Chemical & pharmaceutical bulletin.* 2020;68(4):369-79.
945. **Covid-19, a clinical syndrome manifesting as hypersensitivity pneumonitis.** Song YG, Shin HS. *Infection and Chemotherapy.* 2020;52(1):110-2.
946. **Hospital pharmacists' pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience.** Song Z, Hu Y, Zheng S, Yang L, Zhao R. *Research in social & administrative pharmacy : RSAP.* 2020. <http://dx.doi.org/10.1016/j.sapharm.2020.03.027>
947. **Impact of new coronavirus epidemics on HIV-infected patients.** Soriano V, Barreiro P. *AIDS Reviews.* 2020;22(1):57-8.
948. **ACE-2 in the highlight of COVID-19, A proposed pathology and potential correlations.** Sorour K. 2020.
949. **COVID-19 outbreak: An overview on dentistry.** Spagnuolo G, De Vito D, Rengo S, Tatullo M. *International Journal of Environmental Research and Public Health.* 2020;17(6).
950. **Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19.** Sparks MA, South A, Welling P, Luther JM, Cohen J, Byrd JB, et al. *Clinical journal of the American Society of Nephrology : CJASN.* 2020.

951. **Keep Taking Your ACE Inhibitors and ARBs During the COVID 19 Pandemic.** Speth RC. Journal of travel medicine. 2020.
952. **Benign COVID-19 in an immunocompromised cancer patient - the case of a married couple.** Spezzani V, Piuino A, Iselin HU. Swiss medical weekly. 2020;150:w20246. <http://dx.doi.org/10.4414/smw.2020.20246>. eCollection 2020 Apr 6.
953. **To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic.** Spinelli FR, Ceccarelli F, Di Franco M, Conti F. Annals of the Rheumatic Diseases. 2020. <http://dx.doi.org/10.1136/annrheumdis-2020-217367>
954. **First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020.** Spiteri G, Fielding J, Diercke M, Campese C, Enouf V, Gaymard A, et al. Euro surveillance : bulletin European sur les maladies transmissibles = European communicable disease bulletin. 2020;25(9).
955. **Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved Functional Regions of Viral Proteins.** Srinivasan S, Cui H, Gao Z, Liu M, Lu S, Mkandawire W, et al. Viruses. 2020;12(4).
956. **Dangers of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence.** Sriram K, Insel PA. medRxiv. 2020:2020.03.25.20043927.
957. **COVID-19: combining antiviral and anti-inflammatory treatments.** Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. The Lancet Infectious Diseases. 2020;20(4):400-2.
958. **The 2019 coronavirus: Learning curves, lessons, and the weakest link.** Stein RA. International Journal of Clinical Practice. 2020;74(4).
959. **TMPRSS2 and COVID-19: Serendipity or opportunity for intervention?** Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. Cancer discovery. 2020. <http://dx.doi.org/10.1158/2159-8290.CD-20-0451>
960. **Lopinavir-ritonavir in severe COVID-19.** Stower H. Nature medicine. 2020. <http://dx.doi.org/10.1038/s41591-020-0849-9>.
961. **Lopinavir-ritonavir in severe COVID-19.** Stower H. Nature Medicine. 2020. <http://dx.doi.org/10.1038/s41591-020-0849-9>
962. **COVID-19: Not a Simple Public Health Emergency.** Stratton SJ. Prehospital and disaster medicine. 2020;35(2):119.
963. **Ca(2+) ions promote fusion of Middle East respiratory syndrome coronavirus with host cells and increase infectivity.** Straus MR, Tang T, Lai AL, Flegel A, Bidon M, Freed JH, et al. J Virol. 2020. <http://dx.doi.org/10.1128/JVI.00426-20>.
964. **The different clinical characteristics of corona virus disease cases between children and their families in China - the character of children with COVID-19.** Su L, Ma X, Yu H, Zhang Z, Bian P, Han Y, et al. Emerging microbes & infections. 2020;9(1):707-13.
965. **The different clinical characteristics of corona virus disease cases between children and their families in China—the character of children with COVID-19.** Su L, Ma X, Yu H, Zhang Z, Bian P, Han Y, et al. Emerging Microbes and Infections. 2020;9(1):707-13.
966. **SARS-CoV ORF1b-encoded nonstructural proteins 12-16: Replicative enzymes as antiviral targets.** Subissi L, Imbert I, Ferron F, Collet A, Coutard B, Decroly E, et al. Antiviral Research. 2014;101(1):122-30.

967. **Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study.** Sun D, Li H, Lu XX, Xiao H, Ren J, Zhang FR, et al. *World journal of pediatrics : WJP.* 2020.
968. **CD-sACE2 Inclusion Compounds: An Effective Treatment for Corona Virus Disease 2019 (COVID-19).** Sun P, Lu X, Xu C, Wang Y, Sun W, Xi J. *Journal of Medical Virology.* 2020.
969. **Pharmaceutical care of chloroquine phosphate in elderly patients with coronavirus pneumonia (COVID-19).** Sun X, Li S, Li K, Hu X. *Aging Medicine.* 2020.
970. **Potential Factors Influencing Repeated SARS Outbreaks in China.** Sun Z, Thilakavathy K, Kumar SS, He G, Liu SV. *International journal of environmental research and public health.* 2020;17(5).
<http://dx.doi.org/10.3390/ijerph17051633>.
971. **Chronic Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Is High Among Intensive Care Unit Patients With Non-COVID-19 Sepsis but Carry a Moderately Increased Risk of Death.** Sunden-Cullberg J. *Hypertension (Dallas, Tex: 1979).* 2020:HYPERTENSIONAHA12015178.
972. **The 2019 novel corona virus outbreak - An institutional guideline.** Suresh V. *Indian Journal of Anaesthesia.* 2020;64(3):242-3.
973. **Cell-Type-Specific Expression of Renin-Angiotensin-System Components in the Human Body and Its Relevance to SARS-CoV-2 Infection.** Suryawanshi H, Morozov P, Muthukumar T, tenOever BR, Yamaji M, Williams Z, et al. *bioRxiv.* 2020:2020.04.11.034603.
974. **COVID-19: Herd Immunity and Convalescent Plasma Transfer Therapy.** Syal K. *Journal of Medical Virology.* 2020.
975. **Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.** Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. *Cellular & molecular immunology.* 2020. <http://dx.doi.org/10.1038/s41423-020-0400-4>.
976. **Epidemic and genetic characterization of porcine epidemic diarrhea virus strains circulating in the regions around Hunan, China, during 2017-2018.** Tan L, Li Y, He J, Hu Y, Cai X, Liu W, et al. *Archives of virology.* 2020;165(4):877-89.
977. **Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study.** Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. *Signal Transduction and Targeted Therapy.* 2020;5(1).
978. **Epidemiologic and clinical characteristics of 10 children with coronavirus disease 2019 in Changsha, China.** Tan YP, Tan BY, Pan J, Wu J, Zeng SZ, Wei HY. *Journal of Clinical Virology.* 2020;127.
979. **Coronavirus Disease 2019 (COVID-19) Pneumonia in a Hemodialysis Patient.** Tang B, Li S, Xiong Y, Tian M, Yu J, Xu L, et al. *Kidney medicine.* 2020. <http://dx.doi.org/10.1016/j.xkme.2020.03.001>.
980. **Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.** Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. *Journal of thrombosis and haemostasis : JTH.* 2020.
981. **Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.** Tang N, Li D, Wang X, Sun Z. *Journal of Thrombosis and Haemostasis.* 2020.
982. **Coronavirus membrane fusion mechanism offers as a potential target for antiviral development.** Tang T, Bidon M, Jaimes JA, Whittaker GR, Daniel S. *Antiviral research.* 2020:104792.

983. **Comparison of Hospitalized Patients with Acute Respiratory Distress Syndrome Caused by COVID-19 and H1N1.** Tang X, Du R, Wang R, Cao T, Guan L, Yang C, et al. *Chest*. 2020.
984. **Covid-19: FDA approves use of convalescent plasma to treat critically ill patients.** Tanne JH. *BMJ* (Clinical research ed). 2020;368:m1256.
985. **Structurally novel PI3K δ / γ dual inhibitors characterized by a seven-membered spirocyclic spacer: The SARs investigation and PK evaluation.** Tao Q, Chen Y, Liang X, Hu Y, Li J, Fang F, et al. *European Journal of Medicinal Chemistry*. 2020;191.
986. **The Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks.** Tataru AM. *Tissue engineering Part A*. 2020. <http://dx.doi.org/10.1089/ten.TEA.2020.0094>
987. **Is COVID-19 receiving ADE from other coronaviruses?** Tetro JA. *Microbes and Infection*. 2020;22(2):72-3.
988. **The COVID-19 vaccine development landscape.** Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. *Nature reviews Drug discovery*. 2020.
989. **COVID-19: social distancing, ACE 2 receptors, protease inhibitors and beyond?** Thomson G. *International journal of clinical practice*. 2020:e13503.
990. **Underpromise, overdeliver.** Thorp HH. *Science*. 2020;367(6485):1405.
991. **2019-nCoV: new challenges from coronavirus.** Tian HY. *Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]*. 2020;54(3):235-8.
992. **Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer.** Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. *Journal of Thoracic Oncology*. 2020.
993. **Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.** Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. *Emerging Microbes and Infections*. 2020;9(1):382-5.
994. **Review article: Gastrointestinal features in COVID-19 and the possibility of faecal transmission.** Tian Y, Rong L, Nian W, He Y. *Alimentary pharmacology & therapeutics*. 2020.
995. **Molecular basis of COVID-19 relationships in different species: a one health perspective.** Tilocca B, Soggiu A, Musella V, Britti D, Sanguinetti M, Urbani A, et al. *Microbes and infection*. 2020.
996. **Comparative computational analysis of SARS-CoV-2 nucleocapsid protein epitopes in taxonomically related coronaviruses.** Tilocca B, Soggiu A, Sanguinetti M, Musella V, Britti D, Bonizzi L, et al. *Microbes and Infection*. 2020.
997. **Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.** To KKW, Tsang OTY, Leung WS, Tam AR, Wu TC, Lung DC, et al. *The Lancet Infectious diseases*. 2020.
998. **Therapeutic Management of COVID-19 Patients: A systematic review.** Tobaigy M, Qashqary M, Al-Dahery S, Mujallad A, Hershman AA, Kamal MA, et al. *medRxiv*. 2020:2020.04.02.20051029.
999. **Changes in air quality during the lockdown in Barcelona (Spain) one month into the SARS-CoV-2 epidemic.** Tobías A, Carnerero C, Reche C, Massagué J, Via M, Minguillón MC, et al. *Science of the Total Environment*. 2020;726.

1000. **COVID-19 interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; looking at a potential treatment.** Tolouian R, Vahed SZ, Ghiyasvand S, Tolouian A, Ardalan M. *Journal of Renal Injury Prevention*. 2020;9(2).
1001. **Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds.** Ton AT, Gentile F, Hsing M, Ban F, Cherkasov A. *Molecular informatics*. 2020.
1002. **Covid-19: NICE advises against using NSAIDs for fever in patients with suspected cases.** Torjesen I. *BMJ (Clinical research ed)*. 2020;369:m1409.
1003. **Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic.** Torres T, Puig L. *American journal of clinical dermatology*. 2020. <http://dx.doi.org/10.1007/s40257-020-00514-2>
1004. **Correlation between weather and Covid-19 pandemic in Jakarta, Indonesia.** Tosepu R, Gunawan J, Effendy DS, Ahmad LOAI, Lestari H, Bahar H, et al. *Science of the Total Environment*. 2020;725.
1005. **ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19.** Touyz RM, Li H, Delles C. *Clinical science (London, England : 1979)*. 2020;134(7):747-50.
1006. **Leading on the Edge of Insanity.** Trepanier S. *Nurse leader*. 2020. <http://dx.doi.org/10.1016/j.mnl.2020.03.021>.
1007. **SARS-COV-2 and infectivity: Possible increase in infectivity associated to integrin motif expression.** Tresoldi I, Sangiuolo CF, Manzari V, Modesti A. *Journal of Medical Virology*. 2020.
1008. **Antiviral action of tryptanthrin isolated from strobilanthes cusia leaf against human coronavirus nl63.** Tsai YC, Lee CL, Yen HR, Chang YS, Lin YP, Huang SH, et al. *Biomolecules*. 2020;10(3).
1009. **A Review of SARS-CoV-2 and the Ongoing Clinical Trials.** Tu YF, Chien CS, Yarmishyn AA, Lin YY, Luo YH, Lin YT, et al. *Int J Mol Sci*. 2020;21(7). <http://dx.doi.org/10.3390/ijms21072657>.
1010. Ulhaq ZS, Soraya GV. *Medecine et maladies infectieuses*. 2020.
1011. **CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement.** Ulrich H, Pillat MM. *Stem cell reviews and reports*. 2020. <http://dx.doi.org/10.1007/s12015-020-09976-7>
1012. **Artificial Intelligence (AI) applications for COVID-19 pandemic.** Vaishya R, Javaid M, Khan IH, Haleem A. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2020;14(4):337-9. <http://dx.doi.org/10.1016/j.dsx.2020.04.012>
1013. **Detection of novel coronaviruses in bats in Myanmar.** Valitutto MT, Aung O, Tun KYN, Vodzak ME, Zimmerman D, Yu JH, et al. *PLoS ONE*. 2020;15(4).
1014. **The first Vietnamese case of COVID-19 acquired from China.** Van Cuong L, Giang HTN, Linh LK, Shah J, Van Sy L, Hung TH, et al. *The Lancet Infectious Diseases*. 2020;20(4):408-9.
1015. **COVID-19: A Brief Overview of the Discovery Clinical Trial.** Vanden Eynde JJ. *Pharmaceuticals (Basel, Switzerland)*. 2020;13(4). <http://dx.doi.org/10.3390/ph13040065>.
1016. **Fast nosocomial spread of SARS-CoV2 in a French geriatric unit Lyon Study Group on Covid-19 infection.** Vanhems P. *Infect Control Hosp Epidemiol*. 2020:1-4. <http://dx.doi.org/10.1017/ice.2020.99>.

1017. **Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26.** Vankadari N, Wilce JA. *Emerging Microbes and Infections.* 2020;9(1):601-4.
1018. **Warning Against the Use of Anti-Inflammatory Medicines to Cure COVID-19: Building Castles in the Air.** Varrassi G. *Advances in Therapy.* 2020.
1019. **Withanone from *Withania somnifera* May Inhibit Novel Coronavirus (COVID-19) Entry by Disrupting Interactions between Viral S-Protein Receptor Binding Domain and Host ACE2 Receptor.** Varshney A, Balkrishna A, Pokhrel S, Singh J. *Journal.* 2020(Issue).
1020. **In vitro diagnostic assays for COVID-19: Recent advances and emerging trends.** Vashist SK. *Diagnostics.* 2020;10(4). <http://dx.doi.org/10.3390/diagnostics10040202>
1021. **COVID-19: A promising cure for the global panic.** Vellingiri B, Jayaramayya K, Iyer M, Narayanasamy A, Govindasamy V, Giridharan B, et al. *Science of the Total Environment.* 2020;725.
1022. **COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence.** Venerito V, Lopalco G, Iannone F. *Rheumatology International.* 2020.
1023. **Comparison of Copan Eswab and FLOQswab for COVID-19 PCR diagnosis: working around a supply shortage.** Vermeiren C, Marchand-Senecal X, Sheldrake E, Bulir D, Smieja M, Chong S, et al. *J Clin Microbiol.* 2020. <http://dx.doi.org/10.1128/JCM.00669-20>.
1024. **Covid-19: A puzzle with many missing pieces.** Vetter P, Eckerle I, Kaiser L. *The BMJ.* 2020;368.
1025. **Commentary: COVID-19 and diabetes.** Villabona CV. *Diabetes Research and Clinical Practice.* 2020;162.
1026. **Early consensus management for non-ICU ARF SARS-CoV-2 emergency in Italy: from ward to trenches.** Vitacca M, Nava S, Santus P, Harari S. *The European respiratory journal.* 2020.
1027. **Familial hypercholesterolemia and COVID-19: triggering of increased sustained cardiovascular risk.** Vuorio A, Watts GF, Kovanen PT. *Journal of internal medicine.* 2020.
1028. **Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.** Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. *Cell.* 2020.
1029. **Effect of Nilavembu kudineer in the Prevention and Management of COVID-19 by inhibiting ACE2 Receptor.** Walter TM, Justinraj CS, Nandini VS.
1030. **Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing.** Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. *Journal of medical virology.* 2020.
1031. **Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.** Wan Y, Shang J, Graham R, Baric RS, Li F. *Journal of virology.* 2020;94(7).
1032. **Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed.** Wang A, Zhao W, Xu Z, Gu J. *Diabetes Research and Clinical Practice.* 2020;162.
1033. **Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis.** Wang B, Li R, Lu Z, Huang Y. *Aging (Albany NY).* 2020;12. <http://dx.doi.org/10.18632/aging.103000>.
1034. **A novel coronavirus outbreak of global health concern.** Wang C, Horby PW, Hayden FG, Gao GF. *The Lancet.* 2020;395(10223):470-3. [http://dx.doi.org/10.1016/S0140-6736\(20\)30185-9](http://dx.doi.org/10.1016/S0140-6736(20)30185-9)

1035. **The establishment of reference sequence for SARS-CoV-2 and variation analysis.** Wang C, Liu Z, Chen Z, Huang X, Xu M, He T, et al. *Journal of medical virology*. 2020.
1036. **COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australia/New Zealand consensus statement.** Wang C, Rademaker M, Baker C, Foley P. *The Australasian journal of dermatology*. 2020.
1037. **Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.** Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. *JAMA - Journal of the American Medical Association*. 2020;323(11):1061-9.
1038. **What to do next to control the 2019-nCoV epidemic?** Wang FS, Zhang C. *The Lancet*. 2020;395(10222):391-3.
1039. **Potential neurological symptoms of COVID-19.** Wang HY, Li XL, Yan ZR, Sun XP, Han J, Zhang BW. *Therapeutic Advances in Neurological Disorders*. 2020;13.
1040. **Managing neonates with respiratory failure due to SARS-CoV-2 – Authors' reply.** Wang J, Shi Y. *The Lancet Child and Adolescent Health*. 2020;4(4):e9.
1041. **Advances in the research of mechanism of pulmonary fibrosis induced by Corona Virus Disease 2019 and the corresponding therapeutic measures.** Wang J, Wang BJ, Yang JC, Wang MY, Chen C, Luo GX, et al. *Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns*. 2020;36:E006.
1042. **Strengths, Weaknesses, Opportunities and Threats (SWOT) Analysis of China's Prevention and Control Strategy for the COVID-19 Epidemic.** Wang J, Wang Z. *International journal of environmental research and public health*. 2020;17(7). <http://dx.doi.org/10.3390/ijerph17072235>.
1043. **Imaging manifestations and diagnostic value of chest CT of coronavirus disease 2019 (COVID-19) in the Xiaogan area.** Wang K, Kang S, Tian R, Zhang X, Wang Y. *Clinical Radiology*. 2020.
1044. **The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China.** Wang K, Zhao W, Li J, Shu W, Duan J. *Annals of Intensive Care*. 2020;10(1).
1045. **Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up.** Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. *Journal of Infection*. 2020.
1046. **Structural and biochemical characterization of SARS-CoV Papain Like protease 2.** Wang L, Hu W, Fan C. *Protein science : a publication of the Protein Society*. 2020.
1047. **Structural and biochemical characterization of SARS-CoV papain-like protease 2.** Wang L, Hu W, Fan C. *Protein Science*. 2020.
1048. **Genetic Profiles in Pharmacogenes Indicate Personalized Drug Therapy for COVID-19.** Wang L-Y, Cui J-J, OuYang Q-Y, Zhan Y, Wang Y-M, Xu X-Y, et al. *medRxiv*. 2020:2020.03.23.20041350.
1049. **Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.** Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. *Cell Res*. 2020;30(3):269-71. <http://dx.doi.org/10.1038/s41422-020-0282-0>. Epub 2020 Feb 4.
1050. **Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses.** Wang N, Shang J, Jiang S, Du L. *Frontiers in Microbiology*. 2020;11.

1051. **A method to prevent SARS-CoV-2 IgM false positives in gold immunochromatography and enzyme-linked immunosorbent assays.** Wang Q, Du Q, Guo B, Mu D, Lu X, Ma Q, et al. *Journal of clinical microbiology*. 2020. <http://dx.doi.org/10.1128/JCM.00375-20>
1052. **A Unique Protease Cleavage Site Predicted in the Spike Protein of the Novel Pneumonia Coronavirus (2019-nCoV) Potentially Related to Viral Transmissibility.** Wang Q, Qiu Y, Li JY, Zhou ZJ, Liao CH, Ge XY. *Virologica Sinica*. 2020.
1053. **Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.** Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. *Cell*. 2020. <http://dx.doi.org/10.1016/j.cell.2020.03.045>.
1054. **Comorbidities and multi-organ injuries in the treatment of COVID-19.** Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, et al. *The Lancet*. 2020;395(10228):e52.
1055. **Design, Synthesis and Evaluation of 3-Substituted Coumarin Derivatives as Anti-Inflammatory Agents.** Wang T, Peng T, Wen X, Wang G, Liu S, Sun Y, et al. *Chemical & pharmaceutical bulletin*. 2020.
1056. **Design, Synthesis and Preliminary Biological Evaluation of Benzylsulfone Coumarin Derivatives as Anti-Cancer Agents.** Wang T, Peng T, Wen X, Wang G, Sun Y, Liu S, et al. *Molecules (Basel, Switzerland)*. 2019;24(22).
1057. **Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital.** Wang X, Fang J, Zhu Y, Chen L, Ding F, Zhou R, et al. *Clinical Microbiology and Infection*. 2020.
1058. **Cloning, Prokaryotic Soluble Expression, and Analysis of Antiviral Activity of Two Novel Feline IFN- ω Proteins.** Wang X, Li F, Han M, Jia S, Wang L, Qiao X, et al. *Viruses*. 2020;12(3).
1059. **[Retracted: Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen].** Wang XF, Yuan J, Zheng YJ, Chen J, Bao YM, Wang YR, et al. *Zhonghua Er Ke Za Zhi*. 2020;58:E008. <http://dx.doi.org/10.3760/cma.j.issn.0578-1310.2020.0008>.
1060. **The role of CT for Covid-19 patient's management remains poorly Defined.** Wang XYJ, Hong Liu W, Yang M, Chen W. *Annals of Translational Medicine*. 2020;8(4).
1061. **Discovery and SARs of 5-Chloro- N4-phenyl- N2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity.** Wang Y, Chen X, Yan Y, Zhu X, Liu M, Liu X. *Journal of Medicinal Chemistry*. 2020;63(6):3327-47.
1062. **Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study.** Wang Y, Dong C, Hu Y, Li C, Ren Q, Zhang X, et al. *Radiology*. 2020:200843.
1063. **Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen, China.** Wang Y, Liu Y, Liu L, Wang X, Luo N, Ling L. *The Journal of infectious diseases*. 2020.
1064. **Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19.** Wang YX, Ma JR, Wang SQ, Zeng YQ, Zhou CY, Ru YH, et al. *European Review for Medical and Pharmacological Sciences*. 2020;24(6):3360-84.
1065. **Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.** Wang Z, Chen X, Lu Y, Chen F, Zhang W. *Bioscience trends*. 2020;14(1):64-8.
1066. **Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China.** Wang Z, Yang B, Li Q,

- Wen L, Zhang R. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
1067. **2019 novel coronavirus (Covid-19) pneumonia: Serial computed tomography findings.** Wei J, Xu H, Xiong J, Shen Q, Fan B, Ye C, et al. *Korean Journal of Radiology*. 2020;21(4):494-7.
1068. **Expression of prothrombinase/fibroleukin gene fg12 in lung impairment in a murine severe acute respiratory syndrome model.** Wei-ming Y, Jia-quan H, Xiao-ping L, Qin N. *Virologica Sinica*. 2007;22(3):181-92.
1069. **COVID-19: Knowns, unknowns, and questions.** Weston S, Frieman MB. *mSphere*. 2020;5(2).
1070. **Visit to singapore medical journal during covid-19 outbreak: Learning “beyond” the expectation.** Widjaja FF, Suryaningrat WCHN. *Medical Journal of Indonesia*. 2020;29(1):3-5.
1071. **A Primary Care Response to COVID-19 for Patients with an Opioid Use Disorder.** Wilson CG, Ramage M, Fagan EB. *The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association*. 2020. <http://dx.doi.org/10.1111/jrh.12438>
1072. **What goes on board aircraft? Passengers include Aedes, Anopheles, 2019-nCoV, dengue, Salmonella, Zika, et al.** Wilson ME. *Travel Medicine and Infectious Disease*. 2020;33.
1073. **Awareness, Attitudes, and Actions Related to COVID-19 Among Adults With Chronic Conditions at the Onset of the U.S. Outbreak: A Cross-sectional Survey.** Wolf MS, Serper M, Opsasnick L, O’Conor RM, Curtis LM, Benavente JY, et al. *Annals of internal medicine*. 2020. <http://dx.doi.org/10.7326/M20-1239>.
1074. **European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis.** Wollenberg A, Flohr C, Simon D, Cork MJ, Thyssen JP, Bieber T, et al. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2020.
1075. **Covid-19 and the Digestive System.** Wong SH, Lui RN, Sung JJ. *Journal of gastroenterology and hepatology*. 2020.
1076. **Sequence variation of SARS-CoV-2 spike protein may facilitate stronger interaction with ACE2 promoting high infectivity.** Woo HG, Shah M, Ahmad B, Choi S. *Journal*. 2020(Issue).
1077. **Intersecting U.S. Epidemics: COVID-19 and Lack of Health Insurance.** Woolhandler S, Himmelstein DU. *Annals of internal medicine*. 2020. <http://dx.doi.org/10.7326/M20-1491>.
1078. **Endonasal instrumentation and aerosolization risk in the era of COVID-19: simulation, literature review, and proposed mitigation strategies.** Workman AD, Welling DB, Carter BS, Curry WT, Holbrook EH, Gray ST, et al. *International forum of allergy & rhinology*. 2020.
1079. **Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.** Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. *Science*. 2020;367(6483):1260-3.
1080. **Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China.** Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. *JAMA Internal Medicine*. 2020.
1081. **Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.** Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. *Acta pharmaceutica Sinica B*. 2020. <http://dx.doi.org/10.1016/j.apsb.2020.02.008>.
1082. **TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.** Wu

D, Yang XO. *Journal of Microbiology, Immunology and Infection*. 2020.

1083. **A new coronavirus associated with human respiratory disease in China.** Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. *Nature*. 2020;579(7798):265-9.

1084. **Important roles of dietary taurine, creatine, carnosine, anserine and 4-hydroxyproline in human nutrition and health.** Wu G. *Amino Acids*. 2020;52(3):329-60.

1085. **Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19).** Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, et al. *Journal of internal medicine*. 2020.

1086. **Quantitative Proteomic Analysis Reveals Antiviral and Anti-inflammatory Effects of Puerarin in Piglets Infected With Porcine Epidemic Diarrhea Virus.** Wu M, Zhang Q, Yi D, Wu T, Chen H, Guo S, et al. *Frontiers in Immunology*. 2020;11.

1087. **Radiological findings and clinical characteristics of pregnant women with COVID-19 pneumonia.** Wu X, Sun R, Chen J, Xie Y, Zhang S, Wang X. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*. 2020.

1088. **Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury.** Wu Y. *Virologica Sinica*. 2020.

1089. **Prolonged presence of SARS-CoV-2 viral RNA in faecal samples.** Wu Y, Guo C, Tang L, Hong Z, Zhou J, Dong X, et al. *The lancet Gastroenterology & hepatology*. 2020.

1090. **Plasminogen improves lung lesions and hypoxemia in patients with COVID-19.** Wu Y, Wang T, Guo C, Zhang D, Ge X, Huang Z, et al. *QJM : monthly journal of the Association of Physicians*. 2020.
<http://dx.doi.org/10.1093/qjmed/hcaa121>

1091. **The outbreak of COVID-19: An overview.** Wu YC, Chen CS, Chan YJ. *Journal of the Chinese Medical Association*. 2020;83(3):217-20.

1092. **Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal.** Wynants L, Van Calster B, Bonten MMJ, Collins GS, Debray TPA, De Vos M, et al. *BMJ (Clinical research ed)*. 2020;369:m1328.

1093. **Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.** Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, et al. *Cell Res*. 2020. <http://dx.doi.org/10.1038/s41422-020-0305-x>.

1094. **Epidemiological and initial clinical characteristics of patients with family aggregation of COVID-19.** Xia XY, Wu J, Liu HL, Xia H, Jia B, Huang WX. *Journal of Clinical Virology*. 2020;127.
<http://dx.doi.org/10.1016/j.jcv.2020.104360>

1095. **Risk of COVID-19 for patients with cancer.** Xia Y, Jin R, Zhao J, Li W, Shen H. *The Lancet Oncology*. 2020;21(4):e180.

1096. **False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence.** Xiao AT, Tong YX, Zhang S. *Journal of medical virology*. 2020.

1097. **HIV-1 did not contribute to the 2019-nCoV genome.** Xiao C, Li X, Liu S, Sang Y, Gao SJ, Gao F. *Emerging Microbes and Infections*. 2020;9(1):378-81.

1098. **Evolving status of the 2019 novel coronavirus infection: Proposal of conventional serologic assays for disease diagnosis and infection monitoring.** Xiao SY, Wu Y, Liu H. *Journal of Medical Virology*. 2020;92(5):464-7.
1099. **Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests.** Xie C, Jiang L, Huang G, Pu H, Gong B, Lin H, et al. *International Journal of Infectious Diseases*. 2020;93:264-7.
1100. **Detection of influenza and other respiratory viruses in air sampled from a university campus: A longitudinal study.** Xie C, Lau EHY, Yoshida T, Yu H, Wang X, Wu H, et al. *Clinical Infectious Diseases*. 2020;70(5):850-8.
1101. **Clinical characteristics of Non-ICU hospitalized patients with coronavirus disease 2019 and liver injury : A Retrospective study.** Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. *Liver international : official journal of the International Association for the Study of the Liver*. 2020.
1102. **Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study.** Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. *Liver International*. 2020.
1103. **Insight into 2019 novel coronavirus - an updated interim review and lessons from SARS-CoV and MERS-CoV.** Xie M, Chen Q. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2020.
1104. **Euphoresulanes A–M, structurally diverse jatrophone diterpenoids from Euphorbia esula.** Xie XL, Fan RZ, Hu R, Luo SY, Tang GH, Yin S. *Bioorganic Chemistry*. 2020;98.
1105. **Pay attention to SARS-CoV-2 infection in children.** Xie Z. *Pediatric Investigation*. 2020;4(1):1-4.
1106. **Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019.** Xing YH, Ni W, Wu Q, Li WJ, Li GJ, Wang WD, et al. *Journal of Microbiology, Immunology and Infection*. 2020.
1107. **Design, synthesis and biological evaluation of 4-(pyridin-4-yloxy)benzamide derivatives bearing a 5-methylpyridazin-3(2H)-one fragment.** Xiong H, Zhang J, Zhang Q, Duan Y, Zhang H, Zheng P, et al. *Bioorganic and Medicinal Chemistry Letters*. 2020.
1108. **Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells.** Xiong H-L, Wu Y-T, Cao J-L, Yang R, Ma J, Qiao X-Y, et al. *bioRxiv*. 2020:2020.04.08.026948.
1109. **Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients.** Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, et al. *Emerging Microbes and Infections*. 2020;9(1):761-70.
1110. **Construction and evaluation of a novel diagnosis process for 2019-Corona Virus Disease.** Xiong Z, Fu L, Zhou H, Liu JK, Wang AM, Huang Y, et al. *Zhonghua yi xue za zhi*. 2020;100:E019.
1111. **Therapeutic effect of integrative traditional Chinese and western medicine on 51 SARS patients and its influence on their T lymphocyte subsets.** Xiu-hui L, Jian-hua H, Ke Z, Jun Y, Chun-yan G. *Chinese Journal of Integrative Medicine*. 2003;9(4):263-5.
1112. **EuNPs-mAb fluorescent probe based immunochromatographic strip for rapid and sensitive detection of porcine epidemic diarrhea virus.** Xu F, Jin Z, Zou S, Chen C, Song Q, Deng S, et al. *Talanta*. 2020;214:120865. <http://dx.doi.org/10.1016/j.talanta.2020.120865>
1113. **Natural Product-Based Fungicides Discovery: Design, Synthesis and Antifungal Activities of Some Sarisan Analogs Containing 1,3,4-Oxadiazole Moieties.** Xu H, Jia A, Hou E, Liu Z, Yang R, Yang R, et al. *Chemistry*

and Biodiversity. 2020;17(2).

1114. **High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa.** Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. International journal of oral science. 2020;12(1):8.

1115. **Salivary Glands: Potential Reservoirs for COVID-19 Asymptomatic Infection.** Xu J, Li Y, Gan F, Du Y, Yao Y. Journal of dental research. 2020:22034520918518. <http://dx.doi.org/10.1177/0022034520918518>.

1116. **Management of corona virus disease-19 (COVID-19): the Zhejiang experience.** Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences. 2020;49(1):0.

1117. **Factors associated with prolonged viral RNA shedding in patients with COVID-19.** Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W, et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020.

1118. **Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission.** Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Science China Life sciences. 2020;63(3):457-60.

1119. **A flagellin-adjuvanted inactivated porcine epidemic diarrhea virus (PEDV) vaccine provides enhanced immune protection against PEDV challenge in piglets.** Xu X, Du L, Fan B, Sun B, Zhou J, Guo R, et al. Archives of virology. 2020.

1120. **Imaging features of 2019 novel coronavirus pneumonia.** Xu X, Yu C, Zhang L, Luo L, Liu J. European Journal of Nuclear Medicine and Molecular Imaging. 2020;47(5):1022-3.

1121. **Analysis on prevention plan of coronavirus disease 2019 (COVID-19) by traditional Chinese medicine in various regions.** Xu X, Zhang Y, Li X, Li XX. Chinese Traditional and Herbal Drugs. 2020;51(4):866-72.

1122. **Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: Retrospective case series.** Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. The BMJ. 2020;368.

1123. **Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2.** Xu YH, Dong JH, An WM, Lv XY, Yin XP, Zhang JZ, et al. Journal of Infection. 2020;80(4):394-400.

1124. **CT manifestations of lung changes and complications in patients with severe acute respiratory syndrome.** Xue-zhe Z, Wu W, Yan L, Zhen-guo H, Wen H, Yan-ning S, et al. Chinese Journal of Integrative Medicine. 2003;9(4):254-8.

1125. **Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay.** Yan C, Cui J, Huang L, Du B, Chen L, Xue G, et al. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2020. <http://dx.doi.org/10.1016/j.cmi.2020.04.001>.

1126. **Biological Product Development Strategies for Prevention and Treatment of Coronavirus Disease 2019.** Yan CX, Li J, Shen X, Luo L, Li Y, Li MY. Sichuan da xue xue bao Yi xue ban = Journal of Sichuan University Medical science edition. 2020;51(2):139-45.

1127. **Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.** Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Science. 2020;367(6485):1444-8. <http://dx.doi.org/10.1126/science.abb2762>. Epub 2020 Mar 4.

1128. **The first 75 days of novel coronavirus (SARS-CoV-2) outbreak: Recent advances, prevention, and**

treatment. Yan Y, Shin WI, Pang YX, Meng Y, Lai J, You C, et al. International Journal of Environmental Research and Public Health. 2020;17(7).

1129. **The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients.** Yang AP, Liu JP, Tao WQ, Li HM. International Immunopharmacology. 2020;84. <http://dx.doi.org/10.1016/j.intimp.2020.106504>

1130. **Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension.** Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J, et al. medRxiv. 2020:2020.03.31.20038935.

1131. **Challenges and Countermeasures of Integrative Cancer Therapy in the Epidemic of COVID-19.** Yang G, Zhang H, Yang Y. Integrative cancer therapies. 2020;19:1534735420912811.

1132. **ACE2 in the context of 2019-nCoV infection: friend or foe?** Yang JM, Meng X, Xue F, Zhang Y, Zhang C. Zhonghua xin xue guan bing za zhi. 2020;48:E012.

1133. **Discovery of potential drugs for COVID-19 based on the connectivity map.** Yang L, Li Z, Bai T, Hou X. Journal. 2020(Issue).

1134. **Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19.** Yang N, Shen HM. International journal of biological sciences. 2020;16(10):1724-31.

1135. **COVID-19: a new challenge for human beings.** Yang P, Wang X. Cellular & Molecular Immunology. 2020.

1136. **More evidence is urgently needed to confirm the relation between angiotensin-converting enzyme inhibitors and COVID-19.** Yang S, Meng G. Journal of molecular and cellular cardiology. 2020. <http://dx.doi.org/10.1016/j.yjmcc.2020.04.003>

1137. **Point-of-care RNA-based diagnostic device for Covid-19.** Yang T, Wang YC, Shen CF, Cheng CM. Diagnostics. 2020;10(3).

1138. **Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China.** Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, et al. Journal of Infection. 2020;80(4):388-93.

1139. **Generation, identification, and functional analysis of monoclonal antibodies against porcine epidemic diarrhea virus nucleocapsid.** Yang W, Chen W, Huang J, Jin L, Zhou Y, Chen J, et al. Applied Microbiology and Biotechnology. 2019;103(9):3705-14.

1140. **A case of COVID-19 patient with the diarrhea as initial symptom and literature review.** Yang X, Zhao J, Yan Q, Zhang S, Wang Y, Li Y. Clinics and Research in Hepatology and Gastroenterology. 2020. <http://dx.doi.org/10.1016/j.clinre.2020.03.013>

1141. **Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective.** Yang Y, Islam MS, Wang J, Li Y, Chen X. International journal of biological sciences. 2020;16(10):1708-17.

1142. **Trypsin promotes porcine deltacoronavirus mediating cell-to-cell fusion in a cell type-dependent manner.** Yang YL, Meng F, Qin P, Herrler G, Huang YW, Tang YD. Emerging Microbes and Infections. 2020;9(1):457-68.

1143. **Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients.** Yang Z, Shi J, He Z, Lü Y, Xu Q, Ye C, et al. Aging. 2020;12. <http://dx.doi.org/10.18632/aging.102999>

1144. **Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia**

combined with liver injury in Shaanxi region. Yao N, Wang SN, Lian JQ, Sun YT, Zhang GF, Kang WZ, et al. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology. 2020;28:E003.

1145. **A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease-19 treatment option.** Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. Journal of Medical Virology. 2020.

1146. **In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).** Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020.

1147. **[A pathological report of three COVID-19 cases by minimally invasive autopsies].** Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. Zhonghua bing li xue za zhi = Chinese journal of pathology. 2020;49:E009. <http://dx.doi.org/10.3760/cmaj.cn112151-20200312-00193>.

1148. **How could artificial intelligence aid in the fight against coronavirus?: An interview with Dr Hadi M Yassine and Dr Zubair Shah by Felicity Poole, Commissioning Editor.** Yassine HM, Shah Z. Expert Review of Anti-Infective Therapy. 2020.

1149. **ANTIVIRAL TREATMENT OF COVID-19.** Yavuz S, Unal S. Turkish journal of medical sciences. 2020. <http://dx.doi.org/10.3906/sag-2004-145>.

1150. **Delivery of infection from asymptomatic carriers of COVID-19 in a familial cluster.** Ye F, Xu S, Rong Z, Xu R, Liu X, Deng P, et al. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020.

1151. **Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation.** Ye G, Pan Z, Pan Y, Deng Q, Chen L, Li J, et al. Journal of Infection. 2020.

1152. **Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor.** Ye L, Chen X, Li R, Pan Z, Qian C, Yang Y, et al. medRxiv. 2020:2020.04.06.20055475.

1153. **Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019.** Ye XT, Luo YL, Xia SC, Sun QF, Ding JG, Zhou Y, et al. European review for medical and pharmacological sciences. 2020;24(6):3390-6. http://dx.doi.org/10.26355/eurrev_202003_20706.

1154. **Novel coronavirus pneumonia combined with conjunctivitis: three cases report.** Ye Y, Song Y, Yan M, Hu C, Chen X, Yu J, et al. Zhonghua Shiy Yanke Zazhi/Chinese Journal of Experimental Ophthalmology. 2020;38(3):242-4.

1155. **[Management of a colon cancer patient infected with corona virus disease 2019].** Ye Z, Hong Y, Wu X, Hong D, Zhang Y, Dong X, et al. Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences. 2020;49(1):0.

1156. **Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review.** Ye Z, Zhang Y, Wang Y, Huang Z, Song B. European radiology. 2020.

1157. **Interrupting COVID-19 transmission by implementing enhanced traffic control bundling: Implications for global prevention and control efforts.** Yen MY, Schwartz J, Chen SY, King CC, Yang GY, Hsueh PR. Journal of Microbiology, Immunology and Infection. 2020.

1158. **Enteric involvement of coronaviruses: is faecal–oral transmission of SARS-CoV-2 possible?** Yeo C, Kaushal S, Yeo D. The Lancet Gastroenterology and Hepatology. 2020;5(4):335-7.

[http://dx.doi.org/10.1016/S2468-1253\(20\)30048-0](http://dx.doi.org/10.1016/S2468-1253(20)30048-0)

1159. **Role of GS-5734 (Remdesivir) in inhibiting SARS-CoV and MERS-CoV: The expected role of GS-5734 (remdesivir) in COVID-19 (2019-nCoV)-VYTR hypothesis.** Yethindra V. International Journal of Research in Pharmaceutical Sciences. 2020;11:1-6.
1160. **COVID-19: what has been learned and to be learned about the novel coronavirus disease.** Yi Y, Lagniton PNP, Ye S, Li E, Xu RH. Int J Biol Sci. 2020;16(10):1753-66. <http://dx.doi.org/10.7150/ijbs.45134>. eCollection 2020.
1161. **Research progress on prevention and treatment of cytokine storm with traditional Chinese medicine.** Yin MX, Cao Y, Shi CY, Wang WQ, Fang JG. Chinese Traditional and Herbal Drugs. 2020;51(5):1089-95.
1162. **Advance in research of beta coronavirus receptors on ocular surface.** Yin X, Zhang J. Zhonghua Shiyan Yanke Zazhi/Chinese Journal of Experimental Ophthalmology. 2020;38(3):254-6.
1163. **Development of a Novel, Genome Subtraction-Derived, SARS-CoV-2-Specific COVID-19-nsp2 Real-Time RT-PCR Assay and Its Evaluation Using Clinical Specimens.** Yip CCY, Ho CC, Chan JFW, To KKW, Chan HSY, Wong SCY, et al. International journal of molecular sciences. 2020;21(7). <http://dx.doi.org/10.3390/ijms21072574>
1164. **Chest radiographic and ct findings of the 2019 novel coronavirus disease (Covid-19): Analysis of nine patients treated in korea.** Yoon SH, Lee KH, Kim JY, Lee YK, Ko H, Kim KH, et al. Korean Journal of Radiology. 2020;21(4):498-504.
1165. **Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.** Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Jama. 2020. <http://dx.doi.org/10.1001/jama.2020.3204>.
1166. **Anti-Corona's Drug Virtual Screening.** Yousef F, Mansou O. 2020.
1167. **The exogenous human recombinant ACE2 has therapeutic potential against covid-19.** Yousefi R.
1168. **Antiviral therapy in management of COVID-19: a systematic review on current evidence.** Yousefifard M, Zali A, Mohamed Ali K, Madani Neishaboori A, Zarghi A, Hosseini M, et al. Arch Acad Emerg Med. 2020;8(1):e45.
1169. **Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China.** Yu F, Du L, Ojcius DM, Pan C, Jiang S. Microbes and Infection. 2020;22(2):74-9.
1170. **Genomic analysis of a 2019-nCoV strain in the first COVID-19 patient found in Hangzhou, Zhejiang, China.** Yu H, Wang XC, Li J, Qian X, Yu XF, Sun Z, et al. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]. 2020;54:E026.
1171. **Network pharmacology-based analysis of the role of traditional Chinese herbal medicines in the treatment of COVID-19.** Yu S, Wang J, Shen H. Annals of palliative medicine. 2020.
1172. **COVID-19 transmission through asymptomatic carriers is a challenge to containment.** Yu X, Yang R. Influenza and other respiratory viruses. 2020.
1173. **PCR Assays Turned Positive in 25 Discharged COVID-19 Patients.** Yuan J, Kou S, Liang Y, Zeng J, Pan Y, Liu L. Clin Infect Dis. 2020. <http://dx.doi.org/10.1093/cid/ciaa398>.
1174. **The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients.** Yuan J, Zou R, Zeng L, Kou S, Lan J, Li X, et al. Inflammation research : official journal of the European Histamine Research Society [et al]. 2020. <http://dx.doi.org/10.1007/s00011-020-01342-0>.

1175. **A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV.** Yuan M, Wu NC, Zhu X, Lee CD, So RTY, Lv H, et al. *Science*. 2020. <http://dx.doi.org/10.1126/science.abb7269>.
1176. **Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China.** Yuan M, Yin W, Tao Z, Tan W, Hu Y. *PLoS one*. 2020;15(3):e0230548.
1177. **Molecular basis of binding between Middle East respiratory syndrome coronavirus and CD26 from seven bat species.** Yuan Y, Qi J, Peng R, Li C, Lu G, Yan J, et al. *Journal of Virology*. 2020;94(5).
1178. **A broad-spectrum virus-and host-targeting antiviral peptide against SARS-CoV-2 and other respiratory viruses.** Yuen K, Zhao H, To KKW, Sze K, Yung TT, Bian M, et al. 2020.
1179. **SARS-CoV-2 and COVID-19: The most important research questions.** Yuen KS, Ye ZW, Fung SY, Chan CP, Jin DY. *Cell and Bioscience*. 2020;10(1).
1180. **Genotyping and phylogenetic analysis of canine parvovirus circulating in Egypt.** Zaher KS, El-Dabae WH, El-Sebelgy MM, Aly NI, Salama ZT. *Veterinary World*. 2020;13(2):326-33.
1181. **The possible risk for Angiotensin-converting enzyme 2-coded protein (ACE2) overexpression - prediction for Coronavirus (COVID-19) postinfectious complications.** Zborowska. 2020.
1182. **Infectious Bronchitis Virus Immune Responses in the Harderian Gland upon Initial Vaccination.** Zegpi RA, Breedlove C, Gulley S, Toro H. *Avian diseases*. 2020;64(1):92-5.
1183. **Limited Protection Conferred by Recombinant Newcastle Disease Virus Expressing Infectious Bronchitis Spike Protein.** Zegpi RA, He L, Yu Q, Joiner KS, van Santen VL, Toro H. *Avian diseases*. 2020;64(1):53-9.
1184. **Infectious Bronchitis Virus Population Structure Defines Immune Response and Protection.** Zegpi RA, Joiner KS, van Santen VL, Toro H. *Avian diseases*. 2020;64(1):60-8.
1185. **A potential protective role of losartan against coronavirus-induced lung damage.** Zeinalian M, Salari-Jazi A, Jannesari A, Khanahmad H. *Infection control and hospital epidemiology*. 2020:1-2.
1186. **First case of COVID-19 complicated with fulminant myocarditis: a case report and insights.** Zeng JH, Liu YX, Yuan J, Wang FX, Wu WB, Li JX, et al. *Infection*. 2020.
1187. **Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19).** Zha L, Li S, Pan L, Tefsen B, Li Y, French N, et al. *Medical Journal of Australia*. 2020.
1188. **Public's early response to the novel coronavirus-infected pneumonia.** Zhan S, Yang YY, Fu C. *Emerging Microbes and Infections*. 2020;9(1):534.
1189. **Successful treatment of COVID-19 using extracorporeal membrane oxygenation, a case report.** Zhan WQ, Li MD, Xu M, Lu YB. *European Review for Medical and Pharmacological Sciences*. 2020;24(6):3385-9.
1190. **Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection.** Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, et al. *Chest*. 2020.
1191. **Controversial treatments: an updated understanding of the Coronavirus Disease 2019.** Zhang C, Huang S, Zheng F, Dai Y. *Journal of medical virology*. 2020.
1192. **The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality.** Zhang C, Wu Z, Li JW, Zhao H, Wang GQ.

International journal of antimicrobial agents. 2020.

1193. **Protein structure and sequence re-analysis of 2019-nCoV genome refutes snakes as its intermediate host or the unique similarity between its spike protein insertions and HIV-1.** Zhang C, Zheng W, Huang X, Bell EW, Zhou X, Zhang Y. *Journal of proteome research*. 2020.
1194. **Protein Structure and Sequence Reanalysis of 2019-nCoV Genome Refutes Snakes as Its Intermediate Host and the Unique Similarity between Its Spike Protein Insertions and HIV-1.** Zhang C, Zheng W, Huang X, Bell EW, Zhou X, Zhang Y. *Journal of proteome research*. 2020;19(4):1351-60.
1195. **Immune responses and histopathological changes in rabbits immunized with inactivated SARS coronavirus.** Zhang CH, Liu XJ, Wang YF, Lu JH, Zheng HY, Xiong S, et al. *Virologica Sinica*. 2007;22(5):360-5.
1196. **In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus.** Zhang DH, Wu KL, Zhang X, Deng SQ, Peng B. *Journal of Integrative Medicine*. 2020;18(2):152-8. <http://dx.doi.org/10.1016/j.joim.2020.02.005>
1197. **Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis.** Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S. *Respiratory research*. 2020;21(1):74.
1198. **Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.** Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. *Intensive Care Medicine*. 2020;46(4):586-90.
1199. **Swine acute diarrhea syndrome coronavirus-induced apoptosis is caspase- and cyclophilin D-dependent.** Zhang J, Han Y, Shi H, Chen J, Zhang X, Wang X, et al. *Emerging Microbes and Infections*. 2020;9(1):439-56.
1200. **Progress and prospects on vaccine development against sars-cov-2.** Zhang J, Zeng H, Gu J, Li H, Zheng L, Zou Q. *Vaccines*. 2020;8(2).
1201. **Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics.** Zhang J, Zhou L, Yang Y, Peng W, Wang W, Chen X. *The Lancet Respiratory Medicine*. 2020;8(3):e11-e2.
1202. **Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α -ketoamide inhibitors.** Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. *Science (New York, NY)*. 2020.
1203. **Potential interventions for novel coronavirus in China: A systematic review.** Zhang L, Liu Y. *J Med Virol*. 2020;92(5):479-90. <http://dx.doi.org/10.1002/jmv.25707>. Epub 2020 Mar 3.
1204. **Quarantine vehicle scheduling for transferring high-risk individuals in epidemic areas.** Zhang MX, Yan HF, Wu JY, Zheng YJ. *International Journal of Environmental Research and Public Health*. 2020;17(7).
1205. **Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study.** Zhang P, Li J, Liu H, Han N, Ju J, Kou Y, et al. *Bone Research*. 2020;8(1).
1206. **CT features of SARS-CoV-2 pneumonia according to clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan city.** Zhang R, Ouyang H, Fu L, Wang S, Han J, Huang K, et al. *European radiology*. 2020. <http://dx.doi.org/10.1007/s00330-020-06854-1>
1207. **COVID-19: Melatonin as a potential adjuvant treatment.** Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. *Life sciences*. 2020:117583.

1208. **Detectable SARS-CoV-2 Viral RNA in Feces of Three Children during Recovery Period of COVID-19 Pneumonia.** Zhang T, Cui X, Zhao X, Wang J, Zheng J, Zheng G, et al. *Journal of medical virology*. 2020.
1209. **Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak.** Zhang T, Wu Q, Zhang Z. *Current biology : CB*. 2020.
1210. **Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes.** Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, et al. *Emerging Microbes and Infections*. 2020;9(1):386-9.
1211. **The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China.** Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. *Clinical immunology (Orlando, Fla)*. 2020:108393. <http://dx.doi.org/10.1016/j.clim.2020.108393>.
1212. **Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings.** Zhang X, Cai H, Hu J, Lian J, Gu J, Zhang S, et al. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2020.
1213. **Competing endogenous RNA network profiling reveals novel host dependency factors required for MERS-CoV propagation.** Zhang X, Chu H, Wen L, Shuai H, Yang D, Wang Y, et al. *Emerging microbes & infections*. 2020;9(1):733-46.
1214. **First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab.** Zhang X, Song K, Tong F, Fei M, Guo H, Lu Z, et al. *Blood advances*. 2020;4(7):1307-10.
1215. **CT image of novel coronavirus pneumonia: a case report.** Zhang X, Song W, Liu X, Lyu L. *Japanese journal of radiology*. 2020.
1216. **Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia.** Zhang Y, Cao W, Xiao M, Li YJ, Yang Y, Zhao J, et al. *Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi*. 2020;41:E006.
1217. **The functional motif of SARS-CoV S protein involved in the interaction with ACE2.** Zhang Y, Wang W, Gao JR, Ye L, Fang XN, Zeng YC, et al. *Virologica Sinica*. 2007;22(1).
1218. **A Novel Coronavirus (COVID-19) Outbreak: A Call for Action.** Zhang Y, Xu J, Li H, Cao B. *Chest*. 2020;157(4):e99-e101.
1219. **Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan city, China.** Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. *Liver international : official journal of the International Association for the Study of the Liver*. 2020.
1220. **Research progress of intervention of Chinese herbal medicine and its active components on human coronavirus.** Zhang YS, Cong WH, Zhang JJ, Guo FF, Li HM. *Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica*. 2020;45(6):1263-71. <http://dx.doi.org/10.19540/j.cnki.cjcmm.20200219.501>
1221. **A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias.** Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J, et al. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
1222. **COVID-19 drives new threat to bats in China.** Zhao H. *Science*. 2020;367(6485):1436.
1223. **Investigating mechanism of Qing-Fei-Pai-Du-Tang for treatment of COVID-19 by network**

- pharmacology.** Zhao J, Tian SS, Yang J, Liu JF, Zhang WD. *Chinese Traditional and Herbal Drugs*. 2020;51(4):829-35.
1224. **Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019.** Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
1225. **Successive passage in vitro led to lower virulence and higher titer of a variant porcine epidemic diarrhea virus.** Zhao P, Wang S, Chen Z, Yu J, Tang R, Qiu W, et al. *Viruses*. 2020;12(4).
1226. **Anesthetic Management of Patients With Suspected or Confirmed 2019 Novel Coronavirus Infection During Emergency Procedures.** Zhao S, Ling K, Yan H, Zhong L, Peng X, Yao S, et al. *Journal of Cardiothoracic and Vascular Anesthesia*. 2020.
1227. **Activation of C-Type Lectin Receptor and (RIG)-I-Like Receptors Contributes to Proinflammatory Response in Middle East Respiratory Syndrome Coronavirus-Infected Macrophages.** Zhao X, Chu H, Wong BHY, Chiu MC, Wang D, Li C, et al. *Journal of Infectious Diseases*. 2020;221(4):647-59.
1228. **The characteristics and clinical value of chest CT images of novel coronavirus pneumonia.** Zhao X, Liu B, Yu Y, Wang X, Du Y, Gu J, et al. *Clinical Radiology*. 2020.
1229. **Preliminary study of traditional Chinese medicine for preventing COVID-19 based on data mining.** Zhao X, Zhang LX, Lu XJ. *Chinese Traditional and Herbal Drugs*. 2020;51(5):1147-52.
1230. **Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China.** Zheng F, Liao C, Fan QH, Chen HB, Zhao XG, Xie ZG, et al. *Current medical science*. 2020.
1231. **Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha.** Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. *European Review for Medical and Pharmacological Sciences*. 2020;24(6):3404-10.
1232. **Development of a duplex SYBR Green I based real-time PCR assay for detection of porcine epidemic diarrhea virus and porcine bocavirus3/4/5.** Zheng LL, Cui JT, Han HY, Hou HL, Wang L, Liu F, et al. *Molecular and Cellular Probes*. 2020.
1233. **Functional exhaustion of antiviral lymphocytes in COVID-19 patients.** Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. *Cellular & molecular immunology*. 2020.
1234. **Necessity and feasibility of viral RNA detection in specialist ophthalmic institute during the COVID-19 epidemic.** Zheng M, Wu W, Chen W, Yu X, Shi Y, Qu J. *Zhonghua Shiyan Yanke Zazhi/Chinese Journal of Experimental Ophthalmology*. 2020;38(3):257-60.
1235. **Single-cell RNA expression profiling of ACE2 and AXL in the human maternal-Fetal interface.** Zheng QL, Duan T, Jin LP. *Reproductive and Developmental Medicine*. 2020;4(1):7-10.
<http://dx.doi.org/10.4103/2096-2924.278679>
1236. **[Drug interaction monitoring of lopinavir / ritonavir in COVID-19 patients with cancer].** Zheng XW, Tao G, Zhang YW, Yang GN, Huang P. *Zhonghua nei ke za zhi*. 2020;59:E004.
<http://dx.doi.org/10.3760/cma.j.cn112138-20200219-00097>.
1237. **Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu.** Zheng Y, Xu H, Yang M, Zeng Y, Chen H, Liu R, et al. *Journal of Clinical Virology*. 2020;127.
<http://dx.doi.org/10.1016/j.jcv.2020.104366>
1238. **Consistency analysis of COVID-19 nucleic acid tests and the changes of lung CT.** Zhifeng J, Feng A, Li T.

Journal of Clinical Virology. 2020;127. <http://dx.doi.org/10.1016/j.jcv.2020.104359>

1239. **Detection of serum IgM and IgG for COVID-19 diagnosis.** Zhong L, Chuan J, Gong BO, Shuai P, Zhou Y, Zhang Y, et al. *Science China Life sciences*. 2020.
1240. **CT imaging features of patients with different clinical types of coronavirus disease 2019 (COVID-19).** Zhong Q, Li Z, Shen X, Xu K, Shen Y, Fang Q, et al. *Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences*. 2020;49(1):0.
1241. **Spinal anaesthesia for patients with coronavirus disease 2019 and possible transmission rates in anaesthetists: retrospective, single-centre, observational cohort study.** Zhong Q, Liu YY, Luo Q, Zou YF, Jiang HX, Li H, et al. *British Journal of Anaesthesia*. 2020.
1242. **The Abnormal ACE2 Expression Correlated with Immune Infiltration May Worsen Progression After SARS-CoV-2 Infection in UCEC and KIRP.** Zhou AP. 2020.
1243. **COVID-19 with spontaneous pneumomediastinum.** Zhou C, Gao C, Xie Y, Xu M. *The Lancet Infectious Diseases*. 2020;20(4):510.
1244. **COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.** Zhou D, Dai SM, Tong Q. *The Journal of antimicrobial chemotherapy*. 2020.
1245. **Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.** Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. *The Lancet*. 2020.
1246. **Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2.** Zhou G, Zhao Q. *Int J Biol Sci*. 2020;16(10):1718-23. <http://dx.doi.org/10.7150/ijbs.45123>. eCollection 2020.
1247. **Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China.** Zhou J, Tan J. *Metabolism: Clinical and Experimental*. 2020;107.
1248. **Coronavirus disease 2019 (COVID-19): a clinical update.** Zhou M, Zhang X, Qu J. *Frontiers of medicine*. 2020. <http://dx.doi.org/10.1007/s11684-020-0767-8>.
1249. **A pneumonia outbreak associated with a new coronavirus of probable bat origin.** Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. *Nature*. 2020;579(7798):270-3.
1250. **Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia.** Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, et al. *Signal Transduction and Targeted Therapy*. 2020;5(1).
1251. **Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.** Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. *Cell Discovery*. 2020;6(1).
1252. **Clinical features and chest CT findings of coronavirus disease 2019 in infants and young children.** Zhou Y, Yang GD, Feng K, Huang H, Yun YX, Mou XY, et al. *Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics*. 2020;22(3):215-20.
1253. **Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus.** Zhou Y, Zhang Z, Tian J, Xiong S. *Annals of palliative medicine*. 2020.
1254. **Coronavirus disease 2019: initial chest CT findings.** Zhou Z, Guo D, Li C, Fang Z, Chen L, Yang R, et al. *European radiology*. 2020.
1255. **New Borrelidins from Onchidium sp. Associated Streptomyces olivaceus SCSIO LO13.** Zhou Z, Wu Q,

Xie Q, Ling C, Zhang H, Sun C, et al. *Chemistry and Biodiversity*. 2020;17(1).

1256. **Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia.** Zhu H, Wang L, Fang C, Peng S, Zhang L, Chang G, et al. *Translational Pediatrics*. 2020;9(1):51-60.

1257. **Possible causes for decreased susceptibility of children to coronavirus.** Zhu L, Lu X, Chen L. *Pediatric research*. 2020.

1258. **Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression.** Zhu L, Xu X, Ma K, Yang J, Guan H, Chen S, et al. *American Journal of Transplantation*. 2020.

1259. **Emerging Therapeutic Strategies for COVID-19 patients.** Zhu S, Guo X, Geary K, Zhang D. *Discoveries (Craiova, Romania)*. 2020;8(1):e105. <http://dx.doi.org/10.15190/d.2020.2>

1260. **Initial clinical features of suspected Coronavirus Disease 2019 in two emergency departments outside of Hubei, China.** Zhu W, Xie K, Lu H, Xu L, Zhou S, Fang S. *Journal of medical virology*. 2020.

1261. **Arbidol Monotherapy is Superior to Lopinavir/ritonavir in Treating COVID-19.** Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T, et al. *J Infect*. 2020. <http://dx.doi.org/10.1016/j.jinf.2020.03.060>.

1262. **Surveillance and taxonomic analysis of the coronavirus dominant in pigeons in China.** Zhuang Q, Liu S, Zhang X, Jiang W, Wang K, Wang S, et al. *Transboundary and Emerging Diseases*. 2020.

1263. **Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak.** Zingone F, Savarino EV. *The Lancet Gastroenterology & hepatology*. 2020.

1264. **Exploring active compounds of Da-Yuan-Yin in treatment of COVID-19 based on network pharmacology and molecular docking method.** Zong Y, Ding ML, Jia KK, Ma ST, Ju WZ. *Chinese Traditional and Herbal Drugs*. 2020;51(4):836-44.

1265. **Investigation of potential Chinese materia medica and its monomers in treatment of coronavirus disease 2019 (COVID-19) based on angiotensin converting enzyme II (ACE2) receptor.** Zong Y, Ding ML, Ma ST, Ju WZ. *Chinese Traditional and Herbal Drugs*. 2020;51(5):1123-9.

1266. **Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection.** Zou X, Chen K, Zou J, Han P, Hao J, Han Z. *Frontiers of medicine*. 2020.

1267. **Reducing mortality from 2019-nCoV: host-directed therapies should be an option.** Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. *The Lancet*. 2020;395(10224):e35-e6.